Feverish illness in children: assessment and initial management in children younger than 5 years

Appendices A – L

National Collaborating Centre for Women's and Children's Health

Commissioned by the National Institute for Health and Care Excellence

| Published by the Royal College Park, London NW1 4RG | of Obstetricians | and Gynaecologists, | 27 Sussex | Place, Regent's |
|--|------------------|---------------------|-----------|-----------------|
| www.rcog.org.uk | | | | |

First published May 2013

Registered charity no. 213280

2nd edition © 2013 National Collaborating Centre for Women's and Children's Health 1st edition published in 2007

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

While every effort has been made to ensure the accuracy of the information contained within this publication, the publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check current indications and accuracy by consulting other pharmaceutical literature and following the guidelines laid down by the manufacturers of specific products and the relevant authorities in the country in which they are practising.

This guideline has been fully funded by NICE. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient.

Implementation of this guidance is the responsibility of local commissioners and/or providers

NCC-WCH Editor: Karen Packham

Contents

| Scope | 1 |
|--|--|
| Stakeholders | 9 |
| Declarations of interest | 18 |
| Review protocols | 20 |
| Search strategies | 30 |
| Summary of identified studies | 366 |
| Excluded studies | 369 |
| Evidence tables | 392 |
| GRADE profiles | 393 |
| Deleted material from 2007 version | 582 |
| Proposed changes to original recommendations | 599 |
| The formal consensus survey | 614 |
| | Stakeholders Declarations of interest Review protocols Search strategies Summary of identified studies Excluded studies Evidence tables GRADE profiles Deleted material from 2007 version Proposed changes to original recommendations |

Appendix A Scope

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

SCOPE

1.1 Guideline title

Feverish illness in children: assessment and initial management in children younger than 5 years

1.2 Short title

Feverish illness in children

2 The remit

This is a partial update of 'Feverish illness in children', NICE clinical guideline 47 (2007), available from www.nice.org.uk/guidance/CG47. See section 4.3.1 for details of which sections will be updated. We will also carry out an editorial review of all recommendations to ensure that they comply with NICE's duties under equalities legislation.

This update is being undertaken as part of the guideline review cycle.

3 Clinical need for the guideline

3.1 Epidemiology

a) Feverish illness in young children is most frequently caused by self-limiting viral infections. However, some viral infections do lead to more serious illnesses that need support and treatment in hospital. In addition, fever may be a presenting feature of bacterial illnesses such as meningitis, septicaemia, urinary tract infections and pneumonia. Feverish

illness may be associated with a variety of more severe symptoms and signs, such as cough, breathlessness, vomiting, diarrhoea, rash and/or convulsions. Many symptoms and signs are non-specific and may offer no specific clue to the cause of the fever.

- b) Feverish illness in young children is a great concern for parents and carers. It has been reported that 60% of children younger than 12 months in England and Wales have a GP consultation for infection, as do 36% of children aged between 1 and 4 years, and 20% of those aged between 5 and 15 years. It is one of the most common medical complaints presenting to accident and emergency departments.
- type B, meningococcal C and pneumococcal conjugate are likely to have significantly reduced the level of admissions to hospital resulting from associated diseases. For example, early analysis of the pneumococcal vaccination programme in England showed that the incidence of pneumococcal related disease has fallen 38% in children younger than 2 years since vaccination was introduced. However, evidence suggests an increase in the prevalence of disease caused by sub-types of bacteria not covered by vaccination programmes.
- d) Potentially serious cases of feverish illness are likely to be rare, so it is important that information is in place to help healthcare professionals distinguish these from mild cases.

3.2 Current practice

- a) Feverish illness in young children is a diagnostic challenge for healthcare professionals because it is often difficult to identify the cause, and to distinguish between mild or moderate illness and more severe illness. To further complicate assessment and diagnosis, the clinical picture often changes rapidly in young children.
- b) The aim of this guideline update is to revise recommendations on the topics listed in section 4.3.1 in the light of new evidence.

4 The guideline

The guideline development process is described in detail on the NICE website (see section 6, 'Further information').

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider. The scope is based on the referral from the Department of Health.

The areas that will be addressed by the guideline are described in the following sections.

4.1 Population

4.1.1 Groups that will be covered

- a) Children from birth up to their 5th birthday presenting with a fever that has not been previously diagnosed.
- b) No patient subgroups have been identified as needing specific consideration.

4.1.2 Groups that will not be covered

- a) Children already admitted to hospital.
- b) Children with a pre-existing comorbidity for which fever is already covered by an established management plan by their specialist team; for example, cystic fibrosis, immunosuppression, sickle cell disease and cerebral shunts.
- c) Children with recurring fever.
- d) Children diagnosed with tropical diseases.

4.2 Healthcare setting

a) All settings in which care is funded by the NHS.

4.3 Clinical management

4.3.1 Key clinical issues that will be covered

- a) The predictive value of the following symptoms and signs, alone or in combination, as initial indications of serious illness:
 - abnormal skin or mucosal colour (for example, pallor or cyanosis)
 - appearing ill to a healthcare professional or parent/carer
 - altered responsiveness or cry
 - altered breathing (for example, nasal flaring, grunting, chest indrawing)
 - abnormal respiratory rate, pulmonary (lung) crackles and other sounds
 - oxygen desaturation
 - dehydration
 - prolonged capillary refill time, cold hands and feet
 - poor feeding
 - persistent fever (5 days or more)
 - height of fever
 - limb or joint swelling
 - unwillingness to bear weight or use a limb
 - bulging fontanelle
 - rash (blanching or non-blanching)
 - focal neurological signs
 - focal seizures
 - new lumps
 - neck stiffness
 - vomiting
 - status epilepticus (prolonged or continuous fits).

If evidence is found on additional signs and symptoms they will added to the above list.

- b) The predictive value of heart rate, including:
 - how heart rate changes with temperature
 - whether heart rate outside the normal range is a sign of serious illness.

- c) The predictive value of pro-calcitonin and/or C-reactive protein markers.
- d) Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease.
- e) The predictive value of the clinical response to paracetamol or NSAIDs.
- f) Effect on fever and associated symptoms of treatment with:
 - paracetamol alone or NSAIDs alone, compared with placebo and with one another
 - alternating paracetamol and NSAIDs strategies, compared with placebo, either drug alone, and taking both at the same time
 - paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone.
- g) Note that guideline recommendations will normally fall within licensed indications; exceptionally, and only if clearly supported by evidence, use outside a licensed indication may be recommended. The guideline will assume that prescribers will use a drug's summary of product characteristics to inform decisions made with individual patients.

4.3.2 Clinical issues that will not be covered

The following areas will not be updated, except for specific parts that relate to the topics in section 4.3.1 and alterations to wording to comply with equalities issues or maintain consistency with areas that have been updated.

- a) Types of thermometers and the site of temperature measurement.
- b) Format of the 'traffic light' system for diagnosis.
- c) Diagnosis of specific illness (outside initial risk assessment as part of the 'traffic light' system).
- d) Management of specific illnesses.
- e) Imported infections.

- f) Tests, management and the use of antibiotics by a non-paediatric practitioner.
- g) Management by remote assessment.
- h) Management by a paediatric specialist.
- i) Advice for home care.

4.4 Main outcomes

- a) Mortality.
- b) Morbidity, including symptomatic relief of fever and associated symptoms such as discomfort.
- c) Appropriate disposition (for example, home management or referral to hospital).
- d) Accuracy of diagnosis of serious illness.
- e) Appropriate use of antibiotics.
- f) Parents and carer satisfaction.

4.5 Economic aspects

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between alternative interventions. In this guideline, the cost-effectiveness of alternative NSAID and paracetamol regimens will be examined, considering both the effect on immediate outcomes (reduction in fever) and longer term outcomes (morbidity and mortality), if data are available. A review of the economic evidence will be conducted and new economic analyses will be carried out. If data are not available, a 'what if' model may be developed to support GDG recommendations on the cost-effectiveness of different scenarios.

The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the costs considered will usually be only from an NHS and personal social services (PSS) perspective. Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

4.6 Status

4.6.1 Scope

This is the final scope.

4.6.2 Timing

The development of the guideline recommendations will begin in December 2011.

5 Related NICE guidance

5.1 Published guidance

5.1.1 NICE guidance to be updated

This guideline will update and replace the following NICE guidance:

 Feverish illness in children. NICE clinical guideline 47 (2007). Available from www.nice.org.uk/guidance/CG47

5.1.2 Other related NICE guidance

- Bacterial meningitis and meningococcal septicaemia. NICE clinical guideline 102 (2010). Available from www.nice.org.uk/guidance/CG102
- Diarrhoea and vomiting in children under 5. NICE clinical guideline 84 (2009).
 Available from www.nice.org.uk/guidance/CG84
- Amantadine, oseltamivir and zanamivir for the treatment of influenza. NICE technology appraisal guidance 168 (2009). Available from www.nice.org.uk/guidance/TA168
- Medicines adherence. NICE clinical guideline 76 (2009). Available from <u>www.nice.org.uk/guidance/CG76</u>
- Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza. NICE technology appraisal guidance 158 (2008). Available from www.nice.org.uk/guidance/TA158
- Urinary tract infection in children. NICE clinical guideline 54 (2007). Available from <u>www.nice.org.uk/guidance/CG54</u>

5.1.3 Guidance under development

NICE is currently developing the following related guidance (details available from the NICE website):

 Antibiotics for neonatal infection. NICE clinical guideline. Publication expected September 2012.

6 Further information

Information on the guideline development process is provided in:

- 'How NICE clinical guidelines are developed: an overview for stakeholders the public and the NHS'
- 'The guidelines manual'.

These are available from the NICE website (www.nice.org.uk/GuidelinesManual). Information on the progress of the guideline will also be available from the NICE website (www.nice.org.uk).

Appendix B Stakeholders

2013 Stakeholder organisations

3M Health Care UK

Action for Sick Children

Airedale NHS Trust

Alder Hey Children's NHS Foundation Trust

Anglesey Local Health Board

Arrowe Park Hospital

Aspirin Foundation

Association of Anaesthetists of Great Britain and Ireland

Association of Child Psychotherapists, The

Association of Paediatric Emergency Medicine

Barking, Havering and Redbridge Hospitals NHS Trust

Barnet Primary Care Trust

Barnsley Hospital NHS Foundation Trust

Barnsley Primary Care Trust

Barts and the London NHS Trust

Birmingham Children's Hospital NHS Foundation Trust

Bolton Hospitals NHS Trust

Boots

Bradford District Care Trust

Bristol-Myers Squibb Pharmaceuticals Ltd

British Association for Counselling and Psychotherapy

British Infection Association

British Medical Association

British Medical Journal

British National Formulary

British Paediatric Allergy, Immunology & Infection Group

British Psychological Society

British Society for Antimicrobial Chemotherapy

British Society for Immunology

British Society of Paediatric Gastroenterology Hepatology and Nutrition

Broomfield Hospital

Calderdale and Huddersfield NHS Trust

Calderdale Primary Care Trust

Cambridge University Hospitals NHS Foundation Trust

Camden Link

Care Quality Commission (CQC)

Central & North West London NHS Foundation Trust

Children living with Inherited Metabolic Diseases

Church Grange Surgery

College of Emergency Medicine

Commission for Social Care Inspection

Confidential Enquiry into Maternal and Child Health

Co-operative Pharmacy Association

County Durham Primary Care Trust

Crookes Healthcare Limited

Croydon Primary Care Trust

David Lewis Centre, The

Department for Communities and Local Government

Department of Health

Department of Health, Social Services and Public Safety - Northern Ireland

Division of Public Health & Primary Health Care

Dorset Primary Care Trust

Eaton Foundation

Encephalitis Society

Epilepsy Action

Faculty of Public Health

George Eliot Hospital NHS Trust

Great Western Hospitals NHS Foundation Trust

Greater Manchester Ambulance Service NHS Trust

Hampshire Partnership NHS Trust

Health Protection Agency

Health Quality Improvement Partnership

Healthcare Improvement Scotland

Healthcare Infection Society

Heart of England NHS Foundation Trust

Herpes Viruses Association

Hertfordshire Partnership NHS Trust

Hindu Council UK

Huddersfield Central Primary Care Trust

Humber NHS Foundation Trust

Independent Healthcare Advisory Services

Infection Control Nurses Association

Infection Prevention Society

Institute of Biomedical Science

Lancashire Care NHS Foundation Trust

Leeds Teaching Hospitals NHS Trust

Leukemia Research Fund

Lewisham University Hospital

Liverpool Primary Care Trust

London Ambulance Service NHS Trust

Luton and Dunstable Hospital NHS Trust

Maidstone and Tunbridge Wells NHS Trust

McNeil Products

Medicines and Healthcare products Regulatory Agency

Medicines for Children Research Network

Medway NHS Foundation Trust

Meningitis Research Foundation

Meningitis Trust

Meningitis UK

Mid Staffordshire NHS Foundation Trust

Ministry of Defence

National Clinical Guideline Centre

National Collaborating Centre for Cancer

National Collaborating Centre for Mental Health

National Collaborating Centre for Women's and Children's Health

National Institute for Health Research Health Technology Assessment Programme

National Patient Safety Agency

National Pharmacy Association

National Public Health Service for Wales

National Reyes Syndrome Foundation of the UK

National Treatment Agency for Substance Misuse

National Youth Advocacy Service

Neonatal & Paediatric Pharmacists Group

NHS Cambridgeshire

NHS Clinical Knowledge Summaries

NHS Confederation

NHS Connecting for Health

NHS Derbyshire county

NHS Direct

NHS Milton Keynes

NHS Newcastle

NHS Pathways

NHS Plus

NHS Sefton

NHS Sheffield

NHS Sickle Cell & Thalassaemia Screening Programme

NHS South Birmingham

NHS Warwickshire Primary Care Trust

North East London Foundation Trust

North Somerset Primary Care Trust

North Tees and Hartlepool NHS Foundation Trust

North Yorkshire & York Primary Care Trust

Northwick Park and St Mark's Hospitals

Nottingham City Hospital

Paracetamol Information Centre

PERIGON Healthcare Ltd

Pfizer

Public Health Wales NHS Trust

Queen Mary's Hospital NHS Trust

Reckitt-Benckiser

Rotherham Primary Care Trust

Royal Berkshire NHS Foundation Trust

Royal Brompton Hospital & Harefield NHS Trust

Royal College of Anaesthetists

Royal College of General Practitioners

Royal College of General Practitioners in Wales

Royal College of Midwives

Royal College of Nursing

Royal College of Obstetricians and Gynaecologists

Royal College of Paediatrics and Child Health

Royal College of Paediatrics and Child Health, Gastroenetrology, Hepatology and Nutrition

Royal College of Pathologists

Royal College of Physicians

Royal College of Psychiatrists

Royal College of Radiologists

Royal College of Surgeons of England

Royal Pharmaceutical Society

Royal Society of Medicine

Royal United Hospital Bath NHS Trust

Royal West Sussex NHS Trust

Scottish Intercollegiate Guidelines Network

SEE BETSI CADWALADR - North Wales NHS Trust

Sheffield Children's Hospital

Sheffield Primary Care Trust

Sheffield Teaching Hospitals NHS Foundation Trust

Social Care Institute for Excellence

Society for Academic Primary Care

Society for General Microbiology

Solent Healthcare

South Asian Health Foundation

South East Coast Ambulance Service

South London Cardiac and Stroke Network

South Staffordshire and Shropshire Healthcare NHS Foundation Trust

South Western Ambulance Service NHS Foundation Trust

Staffordshire Ambulance Service NHS Trust

Stockport Primary Care Trust

Sunfield

Sussex Ambulance Services NHS Trust

Tameside Hospital NHS Foundation Trust

The Association of the British Pharmaceutical Industry

The British In Vitro Diagnostics Association

The Princess Alexandra Hospital NHS Trust

The Rotherham NHS Foundation Trust

Thermo Fisher Scientific

UK Clinical Pharmacy Association

UK Specialised Services Public Health Network

University College London Hospital NHS Foundation Trust

University of Bristol

University of Southampton

Welsh Government

Welsh Scientific Advisory Committee

Western Cheshire Primary Care Trust

Wirral Community NHS Trust

Wirral University Teaching Hospital NHS Foundation Trust

Wishaw General Hospital

Wyre Forest Primary Care Trust

York Hospitals NHS Foundation Trust

Yorkshire Ambulance Service NHS Trust

2007 Stakeholder organisations

Action for Sick Children

Acute Care Collaborating Centre

Addenbrookes NHS Trust

Airedale General Hospital - Acute Trust

Anglesey Local Health Board

Aspirin Foundation

Association of Child Psychotherapists

Association of Medical Microbiologists

Association of Paediatric Emergency Medicine

Association of the British Pharmaceuticals Industry (ABPI)

Barking Havering & Redbridge Acute Trust

Barnet PCT

Barnsley PCT

Barts and the London NHS Trust - London

Bedfordshire & Hertfordshire NHS Strategic Health Authority

Birmingham Children's Hospital

Bolton Hospitals NHS Trust

Boots Healthcare International

Bristol-Myers Squibb Pharmaceuticals Ltd

British National Formulary (BNF)

British Psychological Society

British Society for Antimicrobial Chemotherapy

Calderdale and Huddersfield Acute Trust

CASPE

CEMACH

Chronic Conditions Collaborating Centre

Church Grange Surgery

CIS'ters

CLIMB - Children Living with Inherited Metabolic Disorders

Clinovia Ltd

College of Emergency Medicine

Coloplast Limited

Commission for Social Care Inspection

Connecting for Health

Conwy & Denbighshire Acute Trust

Co-operative Pharmacy Association

Craven Harrogate and Rural District PCT

Crookes Healthcare Limited

Croydon PCT

David Lewis Centre

Department of Health

Department of Primary Care

East Cambridgeshire and Fenland PCT

Eaton Foundation

Encephalitis Society

Faculty of Public Health

Good Hope Hospitals NHS Trust

Great Ormond Street Hospital for Children NHS Trust

Greater Manchester Ambulance Service NHS Trust

Hampshire Partnership NHS Trust

Health Protection Agency

Healthcare Commission

Heart of England NHS Foundation Trust

Herpes Viruses Association

Hertfordshire Partnership NHS Trust

Hospital Infection Society

Infection Control Nurses Association of the British Isles

Institute of Biomedical Science

King's College Acute Trust

Leeds Teaching Hospitals NHS Trust

Leukaemia Research Fund

Liverpool PCT

Luton and Dunstable Hospital NHS Trust

Maidstone and Tunbridge Wells NHS Trust

Medicines and Healthcare products Regulatory Agency (MHRA)

Medway NHS Trust

Meningitis Research Foundation

Meningitis Trust

Mental Health Collaborating Centre

Mid Essex Hospitals NHS Trust

Mid Staffordshire General Hospitals NHS Trust

Milton Keynes PCT

National Childbirth Trust

National Collaborating Centre for Cancer

National Collaborating Centre for Nursing and Supportive Care (NCC-NSC)

National Collaborating Centre for Primary Care

National Collaborating Centre for Women's and Children's Health (NCC-WCH)

National Coordinating Centre for Health Technology Assessment (NCCHTA)

National Patient Safety Agency

National Public Health Service - Wales

National Reyes Syndrome Foundation of the UK

National Youth Advocacy Service

Neonatal & Paediatric Pharmacists Group (NPPG)

Newcastle PCT

NHS Direct

NHS Pathways

NHS Quality Improvement Scotland

NICE – Guidelines Health Economists for information

NICE - Implementation Consultant - Region East

NICE - Implementation Consultant - Region London/SE

NICE - Implementation Consultant - Region NW & NE

NICE - Implementation Consultant - Region SW

NICE - Implementation Consultant - Region West Midlands

NICE - R&D for information

North Eastern Derbyshire PCT

North Lincolnshire PCT

North Tees and Hartlepool Acute Trust

North West London Hospitals NHS Trust

Northwick Park and St Mark's Hospitals NHS Trust

Paracetamol Information Centre

Patient and Public Involvement Programme (PPIP) for NICE

PERIGON (formerly the NHS Modernisation Agency)

Princess Alexandra Hospital NHS Trust

Prodigy

Queen Mary's Hospital NHS Trust (Sidcup)

Reckitt Benckiser Healthcare (UK) Ltd

Regional Public Health Group – London

Rotherham PCT

Royal Bolton Hospitals NHS Trust

Royal College of General Practitioners

Royal College of General Practitioners Wales

Royal College of Nursing

Royal College of Paediatrics and Child Health

Royal College of Pathologists

Royal College of Physicians of London

Royal College of Surgeons of England

Royal Liverpool Children's Hospital

Royal Pharmaceutical Society of Great Britain

Royal Society of Medicine

Royal United Hospital Bath NHS Trust

Royal West Sussex Trust

Sandwell & West Birmingham NHS Trust

Scottish Intercollegiate Guidelines Network (SIGN)

Sedgefield PCT

Sheffield Children's Hospital Trust

Sheffield PCT

Society for Academic Primary Care

South Birmingham PCT

South East Sheffield PCT

South Huddersfield and Central Huddersfield PCTs

South Yorkshire Ambulance Service NHS Trust

Specialist Advisory Committee on Antimicrobial Resistance (SACAR)

Staffordshire Ambulance HQ

Staffordshire Moorlans PCT

Stockport PCT

Sussex Ambulance Services NHS Trust

Tameside and Glossop Acute Trust

Tameside and Glossop PCT

UK Specialised Services Public Health Network

UKCPA - Infection Management Group

University College London Hospitals (UCLH) Acute Trust

University Hospital Lewisham NHS Trust

University of Bristol

University of Southampton

Welsh Assembly Government

Welsh Scientific Advisory Committee (WSAC)

Wirral Hospital Acute Trust

Wyre Forest Primary Care Trust

Appendix C Declarations of interest

All GDG members' interests were recorded on declaration forms provided by NICE. The form covered consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare industry. GDG members' interests are listed in this section. No material conflicts of interest were identified.

This appendix includes all interests declared on or before 15 March 2013.

Table C.1 GDG members' declarations of interest

| GDG member | Interest |
|-------------------|--|
| Leah Bowen | Non-personal pecuniary |
| | PhD studentship funded by National Institute of Health Care Research School of Primary Care at University of Bristol. |
| Richard Bowker | No interests declared |
| John Crimmins | No interests declared |
| Penny McDougall | No interests declared |
| Edward Purssell | Personal pecuniary interests |
| | Attended educational meeting sponsored by Berlin Chemi/Abbot in November 2012. |
| | Taught at a workshop about systematic reviwing in May 2011. The workshop was fund by Abbott. |
| | Presented at a symposium in September 2012. The symposium was funded by Berlin Chemi. |
| | Currently writing a paper for Wyeth about infant feeding. |
| Debra Quantrill | No interests declared |
| Martin Richardson | No interests declared |
| Andrew Riordan | Non-personal pecuniary |
| | Undertaking a retrospective study on the use of Zanamivir in children aged under 2. This work is funded by Glaxo Smith Kline. |
| | Personal non-pecuniary |
| | Research on diagnostic usefulness of procalcitonin is undertaken at the institute where he is working, the Alder Hey Children's NHS Foundation Trust. |
| | Has published studies on bio-markers in meningococcal dieses (Pediatric Critica Care Medicine) and on how to use C-reactive protein (Arch Dis Child Educ Prace Ed 2010). |

Damian Roland Personal pecuniary interests Director and co-founder of The Paediatric Emergency Medicine Leicester Academic Group (PEMLA) a non-profit making social enterprise. Funded by NIHR to undertake a Doctoral Research Fellowship. Personal non-pecuniary interest Recipient of HIEC grant looking at POPS (The Paediatric Observation Priority Score) a scoring system based on the NICE table. Guideline member of BTS oxygen guideline update. Council member and trustee of RCPCH Advisor on Map of Medicine as paediatric emergency medicine specialist. Speaker at the Children and Young People Urgent Care – launch of high volume pathway event. Talk entitled "Implementing NICE guidelines", Chiltern Clinical Commissioning Group, September 2012.

Table C.2 NCC staff members' declarations of interest

| NCC-WCH staff | Interest |
|--------------------------|-----------------------|
| Zosia Beckles | No interests declared |
| Jiri Chard | No interests declared |
| Hannah-Rose Douglas | No interests declared |
| Ella Fields | No interests declared |
| M Stephen Murphy | No interests declared |
| Nitara Prasannan | No interests declared |
| Cristina Visintin | No interests declared |
| Zipporah Iheozor-Ejiofor | No interests declared |

Appendix D Review protocols

Chapter 5

Review question

What is the value (as shown by likelihood ratios, sensitivity, specificity, positive predictive value and negative predictive value) of the following symptoms and signs, alone or in combination, as initial indications of serious illness?:

- abnormal skin or mucosal colour (for example, pallor or cyanosis)
- appearing ill to a healthcare professional or parent/carer
- · altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing)
- abnormal respiratory rate, pulmonary (lung) crackles and othersounds
- oxygen desaturation
- dehydration
- prolonged capillary refill time, cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- limb or joint swelling
- · unwillingness to bear weight or use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- status epilepticus (prolonged or continuous fits).

Details

Review question

The predictive value of the following symptoms and signs, alone or in combination, as initial indications of serious illness:

- abnormal skin or mucosal colour (for example, pallor or, cyanosis)
- · appearing ill to a healthcare professional or parent
- altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing,)
- respiratory rate

Details

- pulmonary (lung) crackles and other sounds
- · oxygen desaturation
- dehydration
- · capillary refill time
- cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- · limb or joint swelling
- · unwillingness to weight bear or to use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- · status epilepticus (prolonged or continuous fits).

If evidence is found on additional signs and symptoms they will be added to the above list.

Objectives

- To assess and up-date the evidence base on which the current traffic light system for non-specific symptoms of serious illness is based.
- Symptoms for specific serious conditions will not be examined as these are covered elsewhere in the guideline.

Language

English

Study design

Diagnostic accuracy/prognostic studies:

- · randomised controlled trials (RCTs)
- cohort studies/case-series
- · case-control studies

Status

Published papers

Population

Children aged 5 or under presenting with fever

Intervention

- abnormal skin or mucosal colour (for example pallor or, cyanosis),
- appearing ill to a healthcare professional or parent
- · altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing,)
- respiratory rate
- pulmonary (lung) crackles and other sounds
- oxygen desaturation
- dehydration
- · capillary refill time
- cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- · limb or joint swelling
- · unwillingness to weight bear or to use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- · focal neurological signs
- focal seizures
- new lumps
- neck stiffness

| | Details |
|--|--|
| | vomitingstatus epilepticus (prolonged or continuous fits). |
| | Other factors identified in literature (unknown number). |
| Comparator or reference standard | |
| Outcomes | Detecting serious illness (Sensitivity, specificity, PPV, NPV, ROC, calibration). |
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |
| Equality | Issues relating to race (different signs and symptoms) and religion (physical assessment) may impact on the interpretation of evidence |

Chapter 5

Heart rate

Review question

The predictive value of heart rate, including:

- how heart rate changes with temperature?
- whether heart rate outside the normal range detects serious illness?
- whether heart rate and temperature outside normal range detects serious illness?

| | Details |
|--|--|
| Review question | The predictive value of heart rate, including: |
| | how heart rate changes with temperaturewhether heart rate outside the normal range detects serious illness. |
| Objectives | New evidence has become available since the 2007 guideline. |
| | To ascertain how heart rate changes with temperature, and if this differs between benign and serious bacterial causes. This will improve precision and accuracy of diagnosis. |
| Language | English |
| Study design | Diagnostic accuracy/prognostic studies evaluating clinical outcomes: |
| | cohort studies |
| Status | Published papers |
| Population | Children aged 5 or under |
| Intervention | Heart rate with fever with serious causeHeart rate with serious cause |
| Comparator or | Heart rate with fever with benign cause |
| reference standard | Normal heart rate |
| Outcomes | Detecting serious illness (Sensitivity, specificity, PPV, NPV, ROC, calibration). |
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (January 2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |
| Equality | Issues of race (differences in physiology) and religion (use of tests) may impact on the interpretation of evidence |

Chapter 8

Children 3 months and older

Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

| | Details |
|--|--|
| Review question | As outlined in the scope: |
| | "The predictive value of pro-calcitonin and/or C reactive protein markers." |
| | The review question examines: |
| | "What is the predictive value of the following markers for identifying serious illness in children with fever who are aged 5 years or less: |
| | Procalcitonin C-reactive protein Procalcitonin and C-reactive protein" |
| Objectives | New evidence has become available since the 2007 guideline. |
| | The main aim is to ascertain if PCT should now be recommended. |
| Language | English |
| Study design | Diagnostic accuracy/prognostic studies evaluating clinical outcomes: |
| | randomised controlled trials (RCTs)prospective cohort studies |
| Status | Published papers |
| Population | Children aged 5 or under presenting with fever |
| Intervention | Pro-calcitonin levels C reactive protein levels PCT & CRP |
| Reference | One or any combination of the following: |
| standard | Blood culture Urine culture Cerebrospinal fluid culture Synovial fluid culture Chest X-ray Scintigraphy Full blood count Signs and symptoms |
| Outcomes | Detecting serious illness (Sensitivity, specificity, PPV, NPV, AUC, calibration). |
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (January 2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |

| | Details |
|----------|---|
| Equality | Issues of race (differences in physiology) and religion (use of tests) may impact on the interpretation of evidence |

Chapter 8

Response to antipyretic medication

Review question

What is the predictive value of the clinical response to paracetamol or NSAIDs?

| | Details |
|--|--|
| Review question | The predictive value of the clinical response to paracetamol or NSAIDs. |
| Objectives | To assess if clinical response of a child to paracetamol or NSAIDs can be used to predict the course of the illness |
| Language | English |
| Study design | Effectiveness and efficacy: |
| | randomised controlled trials (RCTs)cohort studies |
| Status | Published full papers |
| Population | Children aged 5 or under presenting with fever |
| Intervention | Paracetamol alone Ibuprofen alone Alternating paracetamol and Ibuprofen Combining paracetamol and Ibuprofen |
| Comparator or reference standard | Final diagnosis: serious infectious disease – from gold standard test or follow-up |
| Outcomes | Detecting serious illness (Sensitivity, specificity, PPV, NPV, ROC, calibration). |
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (January 2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |
| Equality | Issues relating to religion (use of pharmaceuticals) may impact on the interpretation of evidence |

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

| | Details |
|--|--|
| Review question | Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the illness. |
| Objectives | New evidence has become available since the last guideline was published. |
| | To assess if use of paracetamol or NSAIDs prevents diagnosis of potentially serious illness. This can be via masking an illness or slowing immune response. |
| Language | English |
| Study design | Effectiveness and efficacy: |
| | randomised controlled trials (RCTs)cohort studies (n > 1000 and long-term follow-up) |
| Status | Published full papers |
| Population | Children aged 5 or under presenting with fever |
| Intervention | Paracetamol alone Ibuprofen alone Alternating paracetamol and Ibuprofen Combined paracetamol and Ibuprofen |
| Comparator or reference standard | No treatment |
| Outcomes | MortalityMorbidity of underlying condition |
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (January 2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |
| Equality | Issues relating to religion (use of pharmaceuticals) may impact on the interpretation of evidence |

9.3 Physical and drug interventions

Review question

Effect on fever and associated symptoms of treatment with:

- Paracetamol alone or NSAIDs alone, compared with placebo and with one another
- Alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- Paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone.

Details

Review question as stated in scope

Effect on fever and associated symptoms of treatment with:

- paracetamol alone or NSAIDs alone, compared with placebo and with one another
- alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone

This question can be unpackaged to these comparisons:

- · Paracetamol vs. placebo
- Ibuprofen vs. placebo
- Paracetamol and ibuprofen combined vs. placebo
- Paracetamol and ibuprofen alternating vs. placebo
- · Paracetamol vs. ibuprofen
- · Paracetamol vs. paracetamol and ibuprofen combined
- · Paracetamol vs. paracetamol and ibuprofen alternating
- Ibuprofen vs. paracetamol and ibuprofen combined
- Ibuprofen vs. paracetamol and ibuprofen alternating
- · Paracetamol and ibuprofen combined vs. paracetamol and ibuprofen alternating

Objectives

To ascertain if paracetamol or ibuprofen is more effective at treating specific symptoms of fever in children age 5 years or less

Language Englis

Study design randomised controlled trials (RCTs)

Status Published full papers only

Population Children aged 5 or under with fever

Intervention

- Paracetamol
- Ibuporfen
- Alternating paracetamol or ibuprofen
- Combined paracetamol or ibuprofen

Comparator or reference standard

- Ibuprofen (see note no other NSAIDs being used)
- Paracetamol
- Alternating paracetamol or ibuprofen
- · Combined paracetamol or ibuprofen
- Placebo

Outcomes

- Change in physical signs and symptoms
 - Fever (temperature mean change, AUC, proportion without fever by 3 hours and 8 hours)
 - Discomfort (PRIMARY OUTCOME)
- Quality of life
- · Adverse events of the intervention

| | Details |
|--|--|
| Other criteria for inclusion/ exclusion of studies | Exclude non-human studies |
| Search strategies | See separate document |
| Review strategies | Evidence will be assessed for quality according to the process described in the NICE guidelines manual (January 2009) A list of excluded studies will be provided following weeding Evidence tables and an evidence profile will be used to summarise the evidence |
| Equality | Issues relating to religion (use of pharmaceuticals) may impact on the interpretation of evidence |

Appendix E Search strategies

2013 Search strategies

Chapter 5

Review question

What is the value (as shown by likelihood ratios, sensitivity, specificity, positive predictive value and negative predictive value) of the following symptoms and signs, alone or in combination, as initial indications of serious illness?

- abnormal skin or mucosal colour (for example, pallor or cyanosis)
- appearing ill to a healthcare professional or parent/carer
- · altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing)
- abnormal respiratory rate, pulmonary (lung) crackles and othersounds
- oxygen desaturation
- dehydration
- · prolonged capillary refill time, cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- · height of fever
- limb or joint swelling
- unwillingness to bear weight or use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- status epilepticus (prolonged or continuous fits).

2013 Update

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q2_traffic_light_dx_combined_medline_rerun2_011012

| | d_dz_trainc_iignt_dx_combined_mediine_refunz_011012 |
|----|---|
| # | Searches |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| | |

| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
|----|--|
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp "SIGNS AND SYMPTOMS"/ |
| 54 | (sign? adj2 symptom\$).tw. |
| 55 | or/53-54 |
| 56 | (sign? or symptom\$ or complain\$).ti,ab. |
| 57 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).ti,ab. |
| 58 | (presenting adj3 (feature? or finding? or factor?)).ti,ab. |
| 59 | presentation?.ti,ab. |

| 60 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).ti,ab. |
|----|--|
| 61 | or/55-60 |
| 62 | ((ill or sick) adj3 (look\$ or appear\$)).ti,ab. |
| 63 | unwell.ti,ab. |
| 64 | CYANOSIS/ |
| 65 | cyano\$.ti,ab. |
| 66 | exp SKIN/ |
| 67 | (skin\$ or pallor).ti,ab. |
| 68 | exp PURPURA/ |
| 69 | (purpura\$ or petechia\$ or rash or mottled).ti,ab. |
| 70 | exp BEHAVIOR/ or IRRITABLE MOOD/ |
| 71 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).ti,ab. |
| 72 | VOMITING/ |
| 73 | (vomit\$ or emes\$).ti,ab. |
| 74 | RESPIRATION DISORDERS/ |
| 75 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).ti,ab. |
| 76 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).ti,ab. |
| 77 | NOSE/ |
| 78 | ((nose or nasal or nostril? or alar) adj3 flar\$).ti,ab. |
| 79 | RESPIRATORY RATE/ or TACHYPNEA/ |
| 80 | ((respirat\$ or breath\$) adj3 rate?).ti,ab. |
| 81 | tachypn\$.ti,ab. |
| 82 | RESPIRATORY SOUNDS/ |
| 83 | ((respirat\$ or breath\$) adj3 sound?).ti,ab. |
| 84 | (crackl\$ or grunt\$).ti,ab. |
| 85 | CRANIAL FONTANELLES/ |
| 86 | (fontanel\$ adj3 (bulg\$ or tens\$)).ti,ab. |
| 87 | FEEDING BEHAVIOR/ or SUCKING BEHAVIOR/ |
| 88 | BOTTLE FEEDING/ or BREAST FEEDING/ |
| 89 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).ti,ab. |
| 90 | DEHYDRATION/ |

| 91 | dehydrat\$.ti,ab. |
|-----|--|
| 92 | OLIGURIA/ |
| 93 | oliguri\$.ti,ab. |
| 94 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).ti,ab. |
| 95 | OXYGEN/bl [blood] |
| 96 | exp OXIMETRY/ |
| 97 | (oxygen adj2 (desaturat\$ or saturat\$)).ti,ab. |
| 98 | CAPILLARIES/ |
| 99 | REGIONAL BLOOD FLOW/ |
| 100 | MICROCIRCULATION/ |
| 101 | (capill?ary refill time? or CRT).ti,ab. |
| 102 | CHILLS/ or SHIVERING/ |
| 103 | ((cold or chill\$) adj3 (hand? or feet or foot)).ti,ab. |
| 104 | (shiver\$ or rigor? or chill?).ti,ab. |
| 105 | EDEMA/ |
| 106 | (edem\$ or oedem\$ or sw#II\$ or lump? or bump?).ti,ab. |
| 107 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).ti,ab. |
| 108 | (limb? adj3 tender\$).ti,ab. |
| 109 | exp NEUROLOGICAL MANIFESTATIONS/ |
| 110 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).ti,ab. |
| 111 | SEIZURES/ |
| 112 | ((focal or partial or local\$) adj3 seiz\$).ti,ab. |
| 113 | NECK PAIN/ |
| 114 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).ti,ab. |
| 115 | STATUS EPILEPTICUS/ |
| 116 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).ti,ab. |
| 117 | (fit? or seiz\$ or convuls\$).ti,ab. |
| 118 | or/62-117 |
| 119 | and/5,8,52,61,118 |
| 120 | exp COHORT STUDIES/ |
| 121 | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or |
| | |

| | analys\$)).tw. |
|-----|--|
| 122 | retrospective\$.ti. |
| 123 | or/120-122 |
| 124 | and/5,52,55,123 |
| 125 | limit 124 to yr="2006 -Current" |
| 126 | or/119,125 |
| 127 | limit 126 to english language |
| 128 | LETTER/ |
| 129 | EDITORIAL/ |
| 130 | NEWS/ |
| 131 | exp HISTORICAL ARTICLE/ |
| 132 | ANECDOTES AS TOPIC/ |
| 133 | COMMENT/ |
| 134 | (letter or comment* or abstracts).ti. |
| 135 | or/128-134 |
| 136 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 137 | 135 not 136 |
| 138 | ANIMALS/ not HUMANS/ |
| 139 | exp ANIMALS, LABORATORY/ |
| 140 | exp ANIMAL EXPERIMENTATION/ |
| 141 | exp MODELS, ANIMAL/ |
| 142 | exp RODENTIA/ |
| 143 | (rat or rats or mouse or mice).ti. |
| 144 | or/137-143 |
| 145 | 127 not 144 |
| | |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_Q2_traffic_light_dx_combined_mip_rerun2_011012

| # | Searches |
|---|---|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |

| disease?), ti, ab. mening\$.ti, ab. (sepsis or septic?emi\$, ti, ab. bacter?emi\$.ti, ab. pneumon\$.ti, ab. (encephalit\$ adj5 (herpe\$ or HSV)), ti, ab. (garthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)), ti, ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)), ti, ab. or/12-13 bosteomyelit\$.ti, ab. ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$), ti, ab. ((upper or lower) adj5 urin\$), ti, ab. UTI.ti, ab. ((pyelonephr\$ or pyonephr\$), ti, ab. ((pyelonephr\$ or pyonephr\$), ti, ab. ((pyelonephr\$ or pyonephr\$), ti, ab. ((upper or lower) adj3 lymph\$), ti, ab. ((pyelonephr\$ or pyonephr\$), ti, ab. | | |
|--|----|--|
| ((thacteriis or streptococcs or staphylococcs or seriouss or severes or criticals or acutes) adj (infects or ills or disease?)).ti.ab. (sepsis or septic?emi\$).ti,ab. (sepsis or septic?emi\$).ti,ab. or/7-8 poeumon\$.ti,ab. (encephalits adj5 (herpe\$ or HSV/)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. (urins or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. ((pyelonephr\$ or pyocystif\$ or pyelocystif\$ or cystopyelit\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((kawasaki\$ adj (disease? or syndrome?)).ti,ab. or/15-6.9-11.14-15,21.25-26 (sign? or symptom\$).tw. | 3 | or/1-2 |
| disease?)),ti,ab. mening\$.ti,ab. (sepsis or septic?emi\$).ti,ab. bacter?emi\$.ti,ab. pneumon\$.ti,ab. (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. or/12-13 bosteomyelit\$.ti,ab. ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. UTI.ti,ab. ((upper or lower) adj5 urin\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((kawasaki\$ adj (disease? or syndrome?)).ti,ab. (Kawasaki\$ adj (disease? or syndrome?)).ti,ab. or/5-6,9-11,14-15,21,25-26 (sign? or symptom\$ or complain\$).ti,ab. | 4 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| (sepsis or septic?emi\$.ti,ab. bacter?emi\$.ti,ab. or/7-8 pneumon\$.ti,ab. (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. yp?arth\$.ti,ab. or/12-13 steomyelit\$.ti,ab. forurin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. UTI.ti,ab. (pyelonephr\$ or pyonephr\$).ti,ab. (pyelonephr\$ or pyonephr\$).ti,ab. (mucocutaneous adj3 lymph\$).ti,ab. (mucocutaneous adj3 lymph\$).ti,ab. (kawasaki\$ adj (disease? or syndrome?)).ti,ab. or/16-20 (mucocutaneous adj3 lymph\$).ti,ab. or/26-6,9-11,14-15,21,25-26 (sign? adj2 symptom\$).tw. | 5 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| bacter?emi\$.ti,ab. preumon\$.ti,ab. lencephalit\$ adj5 (herpe\$ or HSV)).ti,ab. lencephalit\$ adj5 (herpe\$ or his population or pyogen\$)).ti,ab. lor/12-13 by?arth\$.ti,ab. lift or/12-13 lift or/12-13 lift osteomyelit\$.ti,ab. lift ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. lift ((upper or lower) adj5 urin\$).ti,ab. lift ((upper or lower) adj5 urin\$).ti,ab. lift (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. lor/16-20 lencephalit\$ adj6 (disease? or syndrome?)).ti,ab. lift (kawasaki\$ adj (disease? or syndrome?)).ti,ab. lift or/16-20 lencephalit\$ adj6 (disease? or syndrome?)).ti,ab. lift or/16-20- lencephalit\$ adj6 (disease? or syndrome?)).ti,ab. | 6 | mening\$.ti,ab. |
| or/7-8 or/7-8 preumon\$.ti,ab. (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. py?arth\$.ti,ab. for/12-13 (urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$),ti,ab. ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 urin\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. ((cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. ((pyelonephr\$ or pyonephr\$).ti,ab. MCLS.ti,ab. ((kawasaki\$ adj (disease? or syndrome?)).ti,ab. or/16-6,9-11,14-15,21,25-26 (sign? adj2 symptom\$).tw. | 7 | (sepsis or septic?emi\$).ti,ab. |
| 10 pneumon\$.ti,ab. 11 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 12 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 13 py?arth\$.ti,ab. 14 or/12-13 15 osteomyelit\$.ti,ab. 16 ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. 17 ((upper or lower) adj5 urin\$).ti,ab. 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 8 | bacter?emi\$.ti,ab. |
| 11 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 12 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 13 py?arth\$.ti,ab. 14 or/12-13 15 osteomyelit\$.ti,ab. 16 ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. 17 ((upper or lower) adj5 urin\$).ti,ab. 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 9 | or/7-8 |
| 12 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 13 py?arth\$,ti,ab. 14 or/12-13 15 osteomyelit\$,ti,ab. ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. ((upper or lower) adj5 urin\$).ti,ab. (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. (pyelonephr\$ or pyonephr\$).ti,ab. (uncocutaneous adj3 lymph\$).ti,ab. (uncocutaneous adj3 lymph\$).ti,ab. (kawasaki\$ adj (disease? or syndrome?)).ti,ab. (kawasaki\$ adj (disease? or syndrome?)).ti,ab. (cystit\$ or pyonephr\$) (cystit\$ or p | 10 | pneumon\$.ti,ab. |
| 13 py?arth\$.ti,ab. 14 or/12-13 15 osteomyelit\$.ti,ab. 16 ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. 17 ((upper or lower) adj6 urin\$).ti,ab. 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 11 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 14 or/12-13 15 osteomyelit\$.ti,ab. 16 ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. 17 ((upper or lower) adj5 urin\$).ti,ab. 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 12 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 15 osteomyelit\$.ti,ab. 16 ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. 17 ((upper or lower) adj5 urin\$).ti,ab. 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 13 | py?arth\$.ti,ab. |
| Continue of the continue of | 14 | or/12-13 |
| To or uro?gen\$) adj5 infect\$).ti,ab. | 15 | osteomyelit\$.ti,ab. |
| 18 UTI.ti,ab. 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 16 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 19 (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 17 | ((upper or lower) adj5 urin\$).ti,ab. |
| 20 (pyelonephr\$ or pyonephr\$).ti,ab. 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 18 | UTI.ti,ab. |
| 21 or/16-20 22 (mucocutaneous adj3 lymph\$).ti,ab. 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 19 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| Continue of the complete of | 20 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 23 MCLS.ti,ab. 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 21 | or/16-20 |
| 24 (kawasaki\$ adj (disease? or syndrome?)).ti,ab. | 22 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 25 or/22-24 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 23 | MCLS.ti,ab. |
| 26 pyrogen\$.ti,ab. 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 24 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 27 or/5-6,9-11,14-15,21,25-26 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 25 | or/22-24 |
| 28 (sign? adj2 symptom\$).tw. 29 (sign? or symptom\$ or complain\$).ti,ab. | 26 | pyrogen\$.ti,ab. |
| 29 (sign? or symptom\$ or complain\$).ti,ab. | 27 | or/5-6,9-11,14-15,21,25-26 |
| | 28 | (sign? adj2 symptom\$).tw. |
| 30 (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).ti,ab. | 29 | (sign? or symptom\$ or complain\$).ti,ab. |
| | 30 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).ti,ab. |
| 31 (presenting adj3 (feature? or finding? or factor?)).ti,ab. | 31 | (presenting adj3 (feature? or finding? or factor?)).ti,ab. |
| 32 presentation?.ti,ab. | 32 | presentation?.ti,ab. |

| 33 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).ti,ab. |
|----|--|
| 34 | or/28-33 |
| 35 | ((ill or sick) adj3 (look\$ or appear\$)).ti,ab. |
| 36 | unwell.ti,ab. |
| 37 | cyano\$.ti,ab. |
| 38 | (skin\$ or pallor).ti,ab. |
| 39 | (purpura\$ or petechia\$ or rash or mottled).ti,ab. |
| 40 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).ti,ab. |
| 41 | (vomit\$ or emes\$).ti,ab. |
| 42 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).ti,ab. |
| 43 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).ti,ab. |
| 44 | ((nose or nasal or nostril? or alar) adj3 flar\$).ti,ab. |
| 45 | ((respirat\$ or breath\$) adj3 rate?).ti,ab. |
| 46 | tachypn\$.ti,ab. |
| 47 | ((respirat\$ or breath\$) adj3 sound?).ti,ab. |
| 48 | (crackl\$ or grunt\$).ti,ab. |
| 49 | (fontanel\$ adj3 (bulg\$ or tens\$)).ti,ab. |
| 50 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).ti,ab. |
| 51 | dehydrat\$.ti,ab. |
| | oliguri\$.ti,ab. |
| 53 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).ti,ab. |
| 54 | (oxygen adj2 (desaturat\$ or saturat\$)).ti,ab. |
| 55 | (capill?ary refill time? or CRT).ti,ab. |
| 56 | ((cold or chill\$) adj3 (hand? or feet or foot)).ti,ab. |
| 57 | (shiver\$ or rigor? or chill?).ti,ab. |
| 58 | (edem\$ or oedem\$ or sw#II\$ or lump? or bump?).ti,ab. |
| 59 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).ti,ab. |
| 60 | (limb? adj3 tender\$).ti,ab. |
| 61 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).ti,ab. |
| 62 | ((focal or partial or local\$) adj3 seiz\$).ti,ab. |
| 63 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).ti,ab. |

| 64 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).ti,ab. |
|----|--|
| 65 | (fit? or seiz\$ or convuls\$).ti,ab. |
| 66 | or/35-65 |
| | and/3-4,27,34,66 |
| 68 | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw. |
| 69 | retrospective\$.ti. |
| 70 | or/68-69 |
| 71 | and/3,27-28,70 |
| 72 | limit 71 to yr="2006 -Current" |
| 73 | or/67,72 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q2_traffic_light_dx_combined_cctr_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |

| 17 | SEPSIS/ |
|----|--|
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |

| 48 | or/44-47 |
|----|--|
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp "SIGNS AND SYMPTOMS"/ |
| 54 | (sign? adj2 symptom\$).tw. |
| 55 | or/53-54 |
| 56 | (sign? or symptom\$ or complain\$).ti,ab. |
| 57 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).ti,ab. |
| 58 | (presenting adj3 (feature? or finding? or factor?)).ti,ab. |
| 59 | presentation?.ti,ab. |
| 60 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).ti,ab. |
| 61 | or/55-60 |
| 62 | ((ill or sick) adj3 (look\$ or appear\$)).ti,ab. |
| 63 | unwell.ti,ab. |
| 64 | CYANOSIS/ |
| 65 | cyano\$.ti,ab. |
| 66 | exp SKIN/ |
| 67 | (skin\$ or pallor).ti,ab. |
| 68 | exp PURPURA/ |
| 69 | (purpura\$ or petechia\$ or rash or mottled).ti,ab. |
| 70 | exp BEHAVIOR/ or IRRITABLE MOOD/ |
| 71 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).ti,ab. |
| 72 | VOMITING/ |
| 73 | (vomit\$ or emes\$).ti,ab. |
| 74 | RESPIRATION DISORDERS/ |
| 75 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).ti,ab. |
| 76 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).ti,ab. |
| 77 | NOSE/ |
| 78 | ((nose or nasal or nostril? or alar) adj3 flar\$).ti,ab. |

| 79 | RESPIRATORY RATE/ or TACHYPNEA/ |
|-----|--|
| 80 | ((respirat\$ or breath\$) adj3 rate?).ti,ab. |
| 81 | tachypn\$.ti,ab. |
| 82 | RESPIRATORY SOUNDS/ |
| 83 | ((respirat\$ or breath\$) adj3 sound?).ti,ab. |
| 84 | (crackl\$ or grunt\$).ti,ab. |
| 85 | CRANIAL FONTANELLES/ |
| 86 | (fontanel\$ adj3 (bulg\$ or tens\$)).ti,ab. |
| 87 | FEEDING BEHAVIOR/ or SUCKING BEHAVIOR/ |
| 88 | BOTTLE FEEDING/ or BREAST FEEDING/ |
| 89 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).ti,ab. |
| 90 | DEHYDRATION/ |
| 91 | dehydrat\$.ti,ab. |
| 92 | OLIGURIA/ |
| 93 | oliguri\$.ti,ab. |
| 94 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).ti,ab. |
| 95 | OXYGEN/bl [blood] |
| 96 | exp OXIMETRY/ |
| 97 | (oxygen adj2 (desaturat\$ or saturat\$)).ti,ab. |
| 98 | CAPILLARIES/ |
| 99 | REGIONAL BLOOD FLOW/ |
| 100 | MICROCIRCULATION/ |
| 101 | (capill?ary refill time? or CRT).ti,ab. |
| 102 | CHILLS/ or SHIVERING/ |
| 103 | ((cold or chill\$) adj3 (hand? or feet or foot)).ti,ab. |
| 104 | (shiver\$ or rigor? or chill?).ti,ab. |
| 105 | EDEMA/ |
| 106 | (edem\$ or oedem\$ or sw#ll\$ or lump? or bump?).ti,ab. |
| 107 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).ti,ab. |
| 108 | (limb? adj3 tender\$).ti,ab. |
| 109 | exp NEUROLOGICAL MANIFESTATIONS/ |

| 11 1 1 () 11 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).ti,ab. |
|---------------|--|
| 111 | SEIZURES/ |
| 112 | ((focal or partial or local\$) adj3 seiz\$).ti,ab. |
| 113 | NECK PAIN/ |
| 114 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).ti,ab. |
| 115 | STATUS EPILEPTICUS/ |
| 116 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).ti,ab. |
| 117 | (fit? or seiz\$ or convuls\$).ti,ab. |
| 118 | or/62-117 |
| 119 | and/5,8,52,61,118 |
| | exp COHORT STUDIES/ |
| 121 | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw. |
| 122 | retrospective\$.ti. |
| 123 | or/120-122 |
| 124 | and/5,52,55,123 |
| 125 | limit 124 to yr="2006 -Current" |
| 126 | or/119,125 |

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_Q2_traffic_light_dx_combined_cdsrdare_rerun2_011012

| # | Searches |
|---|---|
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | FEVER.kw. |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw,tx. |
| 8 | or/6-7 |
| 9 | BACTERIAL INFECTIONS.kw. |

| 10 | (CRITICAL ILLNESS or ACUTE DISEASE).kw. |
|----|--|
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw,tx. |
| 12 | or/9-11 |
| 13 | MENINGITIS, BACTERIAL.kw. |
| 14 | MENINGOENCEPHALITIS.kw. |
| 15 | mening\$.tw,tx. |
| 16 | or/13-15 |
| 17 | SEPSIS.kw. |
| 18 | BACTEREMIA.kw. |
| 19 | (sepsis or septic?emi\$).tw,tx. |
| 20 | bacter?emi\$.tw,tx. |
| 21 | or/17-20 |
| 22 | PNEUMONIA.kw. |
| 23 | pneumon\$.tw,tx. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX.kw. |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw,tx. |
| 27 | or/25-26 |
| 28 | ARTHRITIS, INFECTIOUS.kw. |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw,tx. |
| 30 | py?arth\$.tw,tx. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS.kw. |
| 33 | osteomyelit\$.tw,tx. |
| 34 | or/32-33 |
| 35 | URINARY TRACT INFECTIONS.kw. |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw,tx. |
| 37 | ((upper or lower) adj5 urin\$).tw,tx. |
| 38 | UTI.tw,tx. |
| 39 | CYSTITIS.kw. |

| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw,tx. |
|----|---|
| 41 | PYELONEPHRITIS.kw. |
| 42 | (pyelonephr\$ or pyonephr\$).tw,tx. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME.kw. |
| 45 | (mucocutaneous adj3 lymph\$).tw,tx. |
| 46 | MCLS.tw,tx. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw,tx. |
| 48 | or/44-47 |
| 49 | PYROGENS.kw. |
| 50 | pyrogen\$.tw,tx. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | "SIGNS AND SYMPTOMS".kw. |
| 54 | (sign? adj2 symptom\$).tw. |
| 55 | or/53-54 |
| 56 | (sign? or symptom\$ or complain\$).tw,tx. |
| 57 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).tw,tx. |
| 58 | (presenting adj3 (feature? or finding? or factor?)).tw,tx. |
| 59 | presentation?.tw,tx. |
| 60 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).tw,tx. |
| 61 | or/55-60 |
| 62 | ((ill or sick) adj3 (look\$ or appear\$)).tw,tx. |
| 63 | unwell.tw,tx. |
| 64 | CYANOSIS.kw. |
| 65 | cyano\$.tw,tx. |
| 66 | SKIN.kw. |
| 67 | (skin\$ or pallor).tw,tx. |
| 68 | PURPURA.kw. |
| 69 | (purpura\$ or petechia\$ or rash or mottled).tw,tx. |
| 70 | (BEHAVIOR or IRRITABLE MOOD).kw. |

| 72 VOMITING kw. 73 (vomit\$ or emes\$).tw,tx. 74 RESPIRATION DISORDERS.kw. 75 ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).tw,tx. 76 ((chest or sternal or sternum or intercostat) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw,tx. 77 NOSE.kw. 78 ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. 79 (RESPIRATORY RATE or TACHYPNEA).kw. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 tachypn\$:tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((rospirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 ((tontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 71 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).tw,tx. |
|---|-----|--|
| RESPIRATION DISORDERS.kw. 75 ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).tw,tx. 76 ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw,tx. 77 (NOSE.kw. 78 ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. 79 (RESPIRATORY RATE or TACHYPNEA).kw. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 (tachypn\$.tw,tx. 82 (RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 (CRANIAL FONTANELLES.kw. 86 (tontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. | 72 | VOMITING.kw. |
| 75 ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).tw,tx. 76 ((Chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw,tx. 77 (NOSE.kw.) 78 ((Inose or nasal or nostril? or alar) adj3 flar\$).tw,tx. 79 (RESPIRATORY RATE or TACHYPNEA).kw. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 (tachypn\$:tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (cracki\$ or grunt\$).tw,tx. 85 (CRANIAL FONTANELLES.kw. 86 (Inotanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. | 73 | (vomit\$ or emes\$).tw,tx. |
| 76 ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw,tx. 77 NOSE.kw. 78 ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. 79 (RESPIRATORY RATE or TACHYPNEA).kw. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 tachypn\$.tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (cracki\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 (tontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. | 74 | RESPIRATION DISORDERS.kw. |
| 77 NOSE.kw. 78 ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. 79 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 (lachypn\$.tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 75 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).tw,tx. |
| ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. ((respirat\$ or breath\$) adj3 rate?).tw,tx. ((respirat\$ or breath\$) adj3 rate?).tw,tx. ((respirat\$ or breath\$) adj3 sound?).tw,tx. ((rackl\$ or grunt\$).tw,tx. ((rorackl\$ or grunt\$).tw,tx. ((rorackl\$ or grunt\$).tw,tx. ((rotanel\$ adj3 (bulg\$ or tens\$)).tw,tx. ((rotanel\$ adj3 (bulg\$ or tens\$)).tw,tx. ((rotanel\$ adj3 (bulg\$ or fens\$)).tw,tx. ((rotanel\$ adj3 (bulg\$ or fens\$)).tw,tx. ((rotus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. ((rotus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. ((rotus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. ((rotus\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. ((roduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. ((roduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. ((roduc\$ or low\$) adj2 (desaturat\$ or saturat\$)).tw,tx. ((rotygen adj2 (desaturat\$ or saturat\$)).tw,tx. | 76 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw,tx. |
| 79 (RESPIRATORY RATE or TACHYPNEA).kw. 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 tachypn\$.tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 ((fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 ((BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 77 | NOSE.kw. |
| 80 ((respirat\$ or breath\$) adj3 rate?).tw,tx. 81 tachypn\$.tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 ((fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 78 | ((nose or nasal or nostril? or alar) adj3 flar\$).tw,tx. |
| 81 tachypn\$.tw,tx. 82 RESPIRATORY SOUNDS.kw. 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackt\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 (fontanet\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (coxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 79 | (RESPIRATORY RATE or TACHYPNEA).kw. |
| RESPIRATORY SOUNDS.kw. RESPIRATORY SOUNDS.kw. ((respirat\$ or breath\$) adj3 sound?).tw,tx. (crackl\$ or grunt\$).tw,tx. CRANIAL FONTANELLES.kw. (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. (BOTTLE FEEDING or BREAST FEEDING).kw. ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. DEHYDRATION.kw. DEHYDRATION.kw. (Ureduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. COLIGURIA.kw. COLIGURIA.kw. | 80 | ((respirat\$ or breath\$) adj3 rate?).tw,tx. |
| 83 ((respirat\$ or breath\$) adj3 sound?).tw,tx. 84 (crackl\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 81 | tachypn\$.tw,tx. |
| 84 (cracki\$ or grunt\$).tw,tx. 85 CRANIAL FONTANELLES.kw. 86 (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 82 | RESPIRATORY SOUNDS.kw. |
| 85 CRANIAL FONTANELLES.kw. 86 (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 83 | ((respirat\$ or breath\$) adj3 sound?).tw,tx. |
| 86 (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 84 | (crackl\$ or grunt\$).tw,tx. |
| 87 (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 85 | CRANIAL FONTANELLES.kw. |
| 88 (BOTTLE FEEDING or BREAST FEEDING).kw. 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 86 | (fontanel\$ adj3 (bulg\$ or tens\$)).tw,tx. |
| 89 ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 87 | (FEEDING BEHAVIOR or SUCKING BEHAVIOR).kw. |
| 90 DEHYDRATION.kw. 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 88 | (BOTTLE FEEDING or BREAST FEEDING).kw. |
| 91 dehydrat\$.tw,tx. 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. | 89 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw,tx. |
| 92 OLIGURIA.kw. 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 90 | DEHYDRATION.kw. |
| 93 oliguri\$.tw,tx. 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 91 | dehydrat\$.tw,tx. |
| 94 ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 92 | OLIGURIA.kw. |
| 95 OXYGEN.kw. 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 93 | oliguri\$.tw,tx. |
| 96 OXIMETRY.kw. 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 94 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw,tx. |
| 97 (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 95 | OXYGEN.kw. |
| 98 CAPILLARIES.kw. 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 96 | OXIMETRY.kw. |
| 99 REGIONAL BLOOD FLOW.kw. 100 MICROCIRCULATION.kw. | 97 | (oxygen adj2 (desaturat\$ or saturat\$)).tw,tx. |
| 100 MICROCIRCULATION.kw. | 98 | CAPILLARIES.kw. |
| | 99 | REGIONAL BLOOD FLOW.kw. |
| 101 (capill?ary refill time? or CRT).tw,tx. | 100 | MICROCIRCULATION.kw. |
| | 101 | (capill?ary refill time? or CRT).tw,tx. |

| 102 | (CHILLS or SHIVERING).kw. |
|-----|--|
| 103 | ((cold or chill\$) adj3 (hand? or feet or foot)).tw,tx. |
| 104 | (shiver\$ or rigor? or chill?).tw,tx. |
| 105 | EDEMA.kw. |
| 106 | (edem\$ or oedem\$ or sw#ll\$ or lump? or bump?).tw,tx. |
| 107 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).tw,tx. |
| 108 | (limb? adj3 tender\$).tw,tx. |
| | NEUROLOGICAL MANIFESTATIONS.kw. |
| 110 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).tw,tx. |
| 111 | SEIZURES.kw. |
| 112 | ((focal or partial or local\$) adj3 seiz\$).tw,tx. |
| 113 | NECK PAIN.kw. |
| 114 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).tw,tx. |
| 115 | STATUS EPILEPTICUS.kw. |
| 116 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).tw,tx. |
| 117 | (fit? or seiz\$ or convuls\$).tw,tx. |
| 118 | or/62-117 |
| 119 | and/5,8,52,61,118 |
| | COHORT STUDIES.kw. |
| 121 | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw. |
| 122 | retrospective\$.ti. |
| 123 | or/120-122 |
| 124 | and/5,52,55,123 |
| 125 | or/119,124 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012 FICu_Q2_traffic_light_dx_combined_hta_rerun2_011012

| # | Searches |
|---|--|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |

| 4 | (child\$ or toddler\$).tw. |
|----|--|
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.tw. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).tw. |
| 20 | bacter?emi\$.tw. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.tw. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 30 | py?arth\$.tw. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.tw. |
| 34 | or/32-33 |

| 35 | exp URINARY TRACT INFECTIONS/ |
|----------|---|
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw. |
| 37 | ((upper or lower) adj5 urin\$).tw. |
| 38 | UTI.tw. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).tw. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).tw. |
| 46 | MCLS.tw. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.tw. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp "SIGNS AND SYMPTOMS"/ |
| 54 | (sign? adj2 symptom\$).tw. |
| 55 | or/53-54 |
| 56 | (sign? or symptom\$ or complain\$).tw. |
| 57 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).tw. |
| 58 | (presenting adj3 (feature? or finding? or factor?)).tw. |
| 59 | presentation?.tw. |
| 60 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).tw. |
| 61 | or/55-60 |
| 62 | ((ill or sick) adj3 (look\$ or appear\$)).tw. |
| 63 | unwell.tw. |
| 64 | CYANOSIS/ |
| 65 | cyano\$.tw. |
| <u> </u> | |

| 66 | exp SKIN/ |
|----|---|
| 67 | (skin\$ or pallor).tw. |
| 68 | exp PURPURA/ |
| 69 | (purpura\$ or petechia\$ or rash or mottled).tw. |
| 70 | exp BEHAVIOR/ or IRRITABLE MOOD/ |
| 71 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).tw. |
| 72 | VOMITING/ |
| 73 | (vomit\$ or emes\$).tw. |
| 74 | RESPIRATION DISORDERS/ |
| 75 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).tw. |
| 76 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).tw. |
| 77 | NOSE/ |
| 78 | ((nose or nasal or nostril? or alar) adj3 flar\$).tw. |
| 79 | RESPIRATORY RATE/ or TACHYPNEA/ |
| 80 | ((respirat\$ or breath\$) adj3 rate?).tw. |
| 81 | tachypn\$.tw. |
| 82 | RESPIRATORY SOUNDS/ |
| 83 | ((respirat\$ or breath\$) adj3 sound?).tw. |
| 84 | (crackl\$ or grunt\$).tw. |
| 85 | CRANIAL FONTANELLES/ |
| 86 | (fontanel\$ adj3 (bulg\$ or tens\$)).tw. |
| 87 | FEEDING BEHAVIOR/ or SUCKING BEHAVIOR/ |
| 88 | BOTTLE FEEDING/ or BREAST FEEDING/ |
| 89 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).tw. |
| 90 | DEHYDRATION/ |
| 91 | dehydrat\$.tw. |
| 92 | OLIGURIA/ |
| 93 | oliguri\$.tw. |
| 94 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).tw. |
| 95 | OXYGEN/ |
| 96 | exp OXIMETRY/ |

| 97 | (oxygen adj2 (desaturat\$ or saturat\$)).tw. |
|-----|--|
| 98 | CAPILLARIES/ |
| 99 | REGIONAL BLOOD FLOW/ |
| 100 | MICROCIRCULATION/ |
| 101 | (capill?ary refill time? or CRT).tw. |
| 102 | CHILLS/ or SHIVERING/ |
| 103 | ((cold or chill\$) adj3 (hand? or feet or foot)).tw. |
| 104 | (shiver\$ or rigor? or chill?).tw. |
| 105 | EDEMA/ |
| 106 | (edem\$ or oedem\$ or sw#II\$ or lump? or bump?).tw. |
| 107 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).tw. |
| 108 | (limb? adj3 tender\$).tw. |
| 109 | exp NEUROLOGIC MANIFESTATIONS/ |
| 110 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).tw. |
| 111 | SEIZURES/ |
| 112 | ((focal or partial or local\$) adj3 seiz\$).tw. |
| 113 | NECK PAIN/ |
| 114 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).tw. |
| 115 | STATUS EPILEPTICUS/ |
| 116 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).tw. |
| 117 | (fit? or seiz\$ or convuls\$).tw. |
| 118 | or/62-117 |
| 119 | and/5,8,52,61,118 |
| 120 | exp COHORT STUDIES/ |
| | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw. |
| 122 | retrospective\$.ti. |
| 123 | or/120-122 |
| 124 | and/5,52,55,123 |
| 125 | or/119,124 |

2013 Update

Database(s): Embase 1980 to 2012 Week 39

FICu_Q2_traffic_light_dx_combined_embase_rerun2_011012

| | d_dz_tranic_light_dx_combined_embase_refunz_011012 |
|----|---|
| # | Searches |
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | FEVER/ |
| 5 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 6 | PYREXIA IDIOPATHICA/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/4-7 |
| 9 | exp BACTERIAL INFECTION/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | BACTERIAL MENINGITIS/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPTICEMIA/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | HERPES SIMPLEX ENCEPHALITIS/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp INFECTIOUS ARTHRITIS/ |
| | |

| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
|----|--|
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | exp OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTION/ |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGEN/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp SYMPTOMATOLOGY/ |
| 54 | (sign? adj2 symptom\$).tw. |
| 55 | or/53-54 |
| 56 | (sign? or symptom\$ or complain\$).ti,ab. |
| 57 | (clinical adj3 (manifestation? or feature? or finding? or aspect? or marker?)).ti,ab. |
| 58 | (presenting adj3 (feature? or finding? or factor?)).ti,ab. |
| 59 | presentation?.ti,ab. |

| 60 | (physical adj3 (manifestaion? or characteristic? or feature? or finding?)).ti,ab. |
|----|--|
| 61 | or/55-60 |
| 62 | ((ill or sick) adj3 (look\$ or appear\$)).ti,ab. |
| 63 | unwell.ti,ab. |
| 64 | CYANOSIS/ |
| 65 | cyano\$.ti,ab. |
| 66 | exp SKIN/ |
| 67 | (skin\$ or pallor).ti,ab. |
| 68 | exp RASH/ |
| 69 | (purpura\$ or petechia\$ or rash or mottled).ti,ab. |
| 70 | BEHAVIOR CHANGE/ or IRRITABILITY/ |
| 71 | (behav\$ or respon\$ or non?respon\$ or cry\$ or cries or irritab\$).ti,ab. |
| 72 | VOMITING/ |
| 73 | (vomit\$ or emes\$).ti,ab. |
| 74 | BREATHING DISORDER/ or TACHYPNEA/ |
| 75 | ((respirat\$ or breath\$) adj3 (distress\$ or disorder? or alter\$)).ti,ab. |
| 76 | ((chest or sternal or sternum or intercostal) adj3 (in drawing or in?drawing or recess\$ or retract\$)).ti,ab. |
| 77 | NOSE/ |
| 78 | ((nose or nasal or nostril? or alar) adj3 flar\$).ti,ab. |
| 79 | RESPIRATORY RATE/ |
| 80 | ((respirat\$ or breath\$) adj3 rate?).ti,ab. |
| 81 | tachypn\$.ti,ab. |
| 82 | ABNORMAL RESPIRATORY SOUND/ |
| 83 | ((respirat\$ or breath\$) adj3 sound?).ti,ab. |
| 84 | (crackl\$ or grunt\$).ti,ab. |
| 85 | exp FONTANEL/ |
| 86 | (fontanel\$ adj3 (bulg\$ or tens\$)).ti,ab. |
| 87 | FEEDING BEHAVIOR/ or SUCKING/ |
| 88 | exp INFANT FEEDING/ |
| 89 | ((refus\$ or poor) adj3 (feed\$ or fed or suck\$)).ti,ab. |
| 90 | DEHYDRATION/ |

| 91 | dehydrat\$.ti,ab. |
|-----|--|
| | OLIGURIA/ |
| | |
| | oliguri\$.ti,ab. |
| 94 | ((reduc\$ or low\$) adj2 urin\$ adj2 (volume? or output? or level?)).ti,ab. |
| 95 | OXYGEN SATURATION/ |
| 96 | exp OXIMETRY/ |
| 97 | (oxygen adj2 (desaturat\$ or saturat\$)).ti,ab. |
| 98 | CAPILLARY/ |
| 99 | CAPILLARY FLOW/ |
| 100 | (capill?ary refill time? or CRT).ti,ab. |
| 101 | CHILL/ or SHIVERING/ or RIGOR/ |
| 102 | ((cold or chill\$) adj3 (hand? or feet or foot)).ti,ab. |
| 103 | (shiver\$ or rigor? or chill?).ti,ab. |
| 104 | exp EDEMA/ |
| 105 | (edem\$ or oedem\$ or sw#ll\$ or lump? or bump?).ti,ab. |
| 106 | ((unwill\$ or unable or inability) adj3 (weight bear\$ or weight?bear\$ or bear weight or "use limb?")).ti,ab. |
| 107 | (limb? adj3 tender\$).ti,ab. |
| 108 | (focal adj2 (neurologic\$ or CNS) adj2 (sign? or deficit? or manifestation? or symptom? or dysfunction?)).ti,ab. |
| 109 | SEIZURE/ |
| 110 | ((focal or partial or local\$) adj3 seiz\$).ti,ab. |
| 111 | MUSCLE STIFFNESS/ or NECK PAIN/ |
| 112 | ((neck or cervical) adj3 (ache or pain\$ or stiff\$)).ti,ab. |
| 113 | EPILEPTIC STATE/ |
| 114 | (stat\$ adj3 (epileptic\$ or absence or grand mal or petit mal)).ti,ab. |
| 115 | (fit? or seiz\$ or convuls\$).ti,ab. |
| 116 | or/62-115 |
| 117 | and/3,8,52,61,116 |
| 118 | COHORT ANALYSIS/ |
| 119 | LONGITUDINAL STUDY/ |
| 120 | FOLLOW UP/ |
| 121 | PROSPECTIVE STUDY/ |

| 122 | RETROSPECTIVE STUDY/ |
|-----|--|
| 123 | ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw. |
| 124 | retrospective\$.ti. |
| 125 | or/118-124 |
| 126 | and/3,52,55,125 |
| 127 | limit 126 to yr="2006 -Current" |
| 128 | or/117,127 |
| 129 | limit 128 to english language |
| 130 | conference abstract.pt. |
| 131 | letter.pt. or LETTER/ |
| 132 | note.pt. |
| 133 | editorial.pt. |
| 134 | (letter or comment* or abstracts).ti. |
| 135 | or/130-134 |
| 136 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 137 | 135 not 136 |
| 138 | ANIMAL/ not HUMAN/ |
| 139 | NONHUMAN/ |
| 140 | exp ANIMAL EXPERIMENT/ |
| 141 | exp EXPERIMENTAL ANIMAL/ |
| 142 | ANIMAL MODEL/ |
| 143 | exp RODENT/ |
| 144 | (rat or rats or mouse or mice).ti. |
| 145 | or/137-144 |
| 146 | 129 not 145 |

Collated search strategies: Q2 scoring systems Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q2_scoring_systems_medline_rerun2_011012

| # | Searches |
|---|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |

| 1 | 3 | exp CHILD/ |
|--|----|---|
| 6 exp FEVER/ 7 (tevers or febris or hyper therms or hyper?therms or pyrexs or hyper?pyrexs or temperature?).ti,ab. 8 or/6-7 9 exp BACTERIAL INFECTIONS/ 10 CRITICAL ILLNESS/ or ACUTE DISEASE/ 11 (thacteris or streptococcs or staphylococcs or serious or severes or criticals or acutes) adj (infects or ills disease?)).ti,ab. 12 or/9-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 menings.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emis).ti,ab. 20 bacter?emis.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumons.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalits adj5 (herpes or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrits adj3 (bacteris or septics or infects or suppurats or purulens or pyogens)).ti,ab. 30 py?arths.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 4 | (child\$ or toddler\$).ti,ab. |
| [tevers or febris or hyper therms or hyper?therms or pyrexs or hyper?pyrexs or temperature?).ti,ab. or/6-7 | 5 | or/1-4 |
| moriformatical contents of the | 6 | exp FEVER/ |
| exp BACTERIAL INFECTIONS/ 10 CRITICAL ILLNESS/ or ACUTE DISEASE/ 11 (Idcateris or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ disease?)).ti,ab. 12 or/9-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 10 CRITICAL ILLNESS/ or ACUTE DISEASE/ 11 ((bacteris or streptococcs or staphylococcs or seriouss or severes or criticals or acutes) adj (infects or ills disease?)).ti.ab. 12 or/9-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 menings.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emis).ti,ab. 20 bacter?emis.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumons.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalits adj5 (herpes or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrits adj3 (bacteris or septics or infects or suppurats or purulens or pyogens)).ti,ab. 30 py?arths.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 8 | or/6-7 |
| 11 ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ disease?)).ti,ab. 12 or/9-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 9 | exp BACTERIAL INFECTIONS/ |
| 1 | 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 13 | 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| MENINGOENCEPHALITIS/ | 12 | or/9-11 |
| 15 | 13 | exp MENINGITIS, BACTERIAL/ |
| 16 | 14 | MENINGOENCEPHALITIS/ |
| SEPSIS/ SEPSIS or septic?emi\$).ti,ab. SEPSIS or septic?emi\$).ti,ab. SEPSIS or septic?emi\$).ti,ab. SEPSIS or septic?emi\$.ti,ab. SEPSIS or septic* SEPSIS or septic* | 15 | mening\$.ti,ab. |
| 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 16 | or/13-15 |
| 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 22 exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 17 | SEPSIS/ |
| bacter?emi\$.ti,ab. 21 or/17-20 | 18 | exp BACTEREMIA/ |
| 21 or/17-20 22 exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 19 | (sepsis or septic?emi\$).ti,ab. |
| exp PNEUMONIA/ 23 pneumon\$.ti,ab. 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 20 | bacter?emi\$.ti,ab. |
| pneumon\$.ti,ab. Proposition of the property | 21 | or/17-20 |
| 24 or/22-23 25 ENCEPHALITIS, HERPES SIMPLEX/ 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 22 | exp PNEUMONIA/ |
| ENCEPHALITIS, HERPES SIMPLEX/ [26] (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. [27] or/25-26 [28] exp ARTHRITIS, INFECTIOUS/ [29] (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. [30] py?arth\$.ti,ab. [31] or/28-30 [32] OSTEOMYELITIS/ | 23 | pneumon\$.ti,ab. |
| 26 (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 24 | or/22-23 |
| 27 or/25-26 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 28 exp ARTHRITIS, INFECTIOUS/ 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 29 (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. 30 py?arth\$.ti,ab. 31 or/28-30 32 OSTEOMYELITIS/ | 27 | or/25-26 |
| 30 py?arth\$.ti,ab. | 28 | exp ARTHRITIS, INFECTIOUS/ |
| 31 or/28-30 32 OSTEOMYELITIS/ | 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 32 OSTEOMYELITIS/ | 30 | py?arth\$.ti,ab. |
| | 31 | or/28-30 |
| 33 osteomyelit\$.ti.ab. | 32 | OSTEOMYELITIS/ |
| | 33 | osteomyelit\$.ti,ab. |

| 34 | or/32-33 |
|----|--|
| 35 | exp URINARY TRACT INFECTIONS/ |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | SEVERITY OF ILLNESS INDEX/ |
| 55 | (scor\$ adj system\$).ti,ab. |
| 56 | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).ti,ab. |
| 57 | ((logistic or risk or predict\$) adj3 model\$).ti,ab. |
| 58 | (Yale or Rochester).ti,ab. |
| 59 | or/54-58 |
| 60 | and/53,59 |
| 61 | limit 60 to english language |
| 62 | LETTER/ |
| 63 | EDITORIAL/ |
| 64 | NEWS/ |

| 65 | exp HISTORICAL ARTICLE/ |
|----|--|
| 66 | ANECDOTES AS TOPIC/ |
| 67 | COMMENT/ |
| 68 | CASE REPORT/ |
| 69 | (letter or comment* or abstracts).ti. |
| 70 | or/62-69 |
| 71 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 72 | 70 not 71 |
| 73 | ANIMALS/ not HUMANS/ |
| 74 | exp ANIMALS, LABORATORY/ |
| 75 | exp ANIMAL EXPERIMENTATION/ |
| 76 | exp MODELS, ANIMAL/ |
| 77 | exp RODENTIA/ |
| 78 | (rat or rats or mouse or mice).ti. |
| 79 | or/72-78 |
| 80 | 61 not 79 |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_Q2_scoring_systems_mip_rerun2_011012

| # | Searches |
|---------|---|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| ווי כוו | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 6 | mening\$.ti,ab. |
| 7 | (sepsis or septic?emi\$).ti,ab. |
| 8 | bacter?emi\$.ti,ab. |
| 9 | or/7-8 |
| 10 | pneumon\$.ti,ab. |
| 11 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |

| 12 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
|----|--|
| 13 | py?arth\$.ti,ab. |
| 14 | or/12-13 |
| 15 | osteomyelit\$.ti,ab. |
| 16 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 17 | ((upper or lower) adj5 urin\$).ti,ab. |
| 18 | UTI.ti,ab. |
| 19 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 20 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 21 | or/16-20 |
| 22 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 23 | MCLS.ti,ab. |
| 24 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 25 | or/22-24 |
| 26 | pyrogen\$.ti,ab. |
| 27 | or/5-6,9-11,14-15,21,25-26 |
| 28 | and/3-4,27 |
| 29 | (scor\$ adj system\$).ti,ab. |
| 30 | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).ti,ab. |
| 31 | ((logistic or risk or predict\$) adj3 model\$).ti,ab. |
| 32 | (Yale or Rochester).ti,ab. |
| 33 | or/29-32 |
| 34 | and/28,33 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q2_scoring_systems_cctr_rerun2_011012

| _ | |
|---|---|
| # | Searches |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |

| 5 | or/1-4 |
|----|---|
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |

| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
|----|--|
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | SEVERITY OF ILLNESS INDEX/ |
| 55 | (scor\$ adj system\$).ti,ab. |
| 56 | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).ti,ab. |
| 57 | ((logistic or risk or predict\$) adj3 model\$).ti,ab. |
| 58 | (Yale or Rochester).ti,ab. |
| 59 | or/54-58 |
| | |

60 and/53,59

2013 Update

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_Q2_scoring_systems_cdsrdare_rerun2_011012

| 1 1 | Su_Q2_scoring_systems_casrdare_rerun2_011012 |
|-----|---|
| # | Searches |
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | FEVER.kw. |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw,tx. |
| 8 | or/6-7 |
| 9 | BACTERIAL INFECTIONS.kw. |
| 10 | (CRITICAL ILLNESS or ACUTE DISEASE).kw. |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw,tx. |
| 12 | or/9-11 |
| 13 | MENINGITIS, BACTERIAL.kw. |
| 14 | MENINGOENCEPHALITIS.kw. |
| 15 | mening\$.tw,tx. |
| 16 | or/13-15 |
| 17 | SEPSIS.kw. |
| 18 | BACTEREMIA.kw. |
| 19 | (sepsis or septic?emi\$).tw,tx. |
| 20 | bacter?emi\$.tw,tx. |
| 21 | or/17-20 |
| 22 | PNEUMONIA.kw. |
| 23 | pneumon\$.tw,tx. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX.kw. |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw,tx. |
| 27 | or/25-26 |
| _ | |

| 28 | ARTHRITIS, INFECTIOUS.kw. |
|----|--|
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw,tx. |
| 30 | py?arth\$.tw,tx. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS.kw. |
| 33 | osteomyelit\$.tw,tx. |
| 34 | or/32-33 |
| | URINARY TRACT INFECTIONS.kw. |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw,tx. |
| 37 | ((upper or lower) adj5 urin\$).tw,tx. |
| 38 | UTI.tw,tx. |
| 39 | CYSTITIS.kw. |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw,tx. |
| 41 | PYELONEPHRITIS.kw. |
| 42 | (pyelonephr\$ or pyonephr\$).tw,tx. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME.kw. |
| 45 | (mucocutaneous adj3 lymph\$).tw,tx. |
| 46 | MCLS.tw,tx. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw,tx. |
| 48 | or/44-47 |
| 49 | PYROGENS.kw. |
| 50 | pyrogen\$.tw,tx. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | SEVERITY OF ILLNESS INDEX.kw. |
| 55 | (scor\$ adj system\$).ti,ab. |
| 56 | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).ti,ab. |
| 57 | ((logistic or risk or predict\$) adj3 model\$).ti,ab. |
| 58 | (Yale or Rochester).ti,ab. |

| 59 | or/54-58 |
|----|-----------|
| 60 | and/53,59 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012 FICu_Q2_scoring_systems_hta_rerun2_011012

| FIG | U_Q2_scoring_systems_nta_rerun2_011012 |
|-----|--|
| # | Searches |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.tw. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).tw. |
| 20 | bacter?emi\$.tw. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.tw. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| | |

| 27 | or/25-26 |
|----|---|
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 30 | py?arth\$.tw. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.tw. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw. |
| 37 | ((upper or lower) adj5 urin\$).tw. |
| 38 | UTI.tw. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).tw. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| | (mucocutaneous adj3 lymph\$).tw. |
| 46 | MCLS.tw. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.tw. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | SEVERITY OF ILLNESS INDEX/ |
| 55 | (scor\$ adj system\$).tw. |
| 56 | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).tw. |
| 57 | ((logistic or risk or predict\$) adj3 model\$).tw. |
| | |

| 58 | (Yale or Rochester).tw. |
|----|-------------------------|
| 59 | or/54-58 |
| 60 | and/53,59 |

Database(s): Embase 1980 to 2012 Week 39

FICu_Q2_scoring_systems_embase_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | FEVER/ |
| 5 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 6 | PYREXIA IDIOPATHICA/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/4-7 |
| 9 | exp BACTERIAL INFECTION/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | BACTERIAL MENINGITIS/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPTICEMIA/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| | |

| ٥٢ | LIEDDEC CIMPLEY ENCEDITALITIC/ |
|----|--|
| 25 | HERPES SIMPLEX ENCEPHALITIS/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp INFECTIOUS ARTHRITIS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | exp OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTION/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGEN/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/3,8,52 |
| 54 | SCORING SYSTEM/ |
| 55 | (scor\$ adj system\$).ti,ab. |
| | |

| EC | ((illness or poverity or right) adia (alegaith or eritorit or access to a index to a indicate an access and index to a contract or access to a index to a indicate an access t |
|----|--|
| Эb | ((illness or severity or risk) adj3 (classif\$ or criteri\$ or assess\$ or index\$ or indice? or scale? or scor\$)).ti,ab. |
| 57 | ((logistic or risk or predict\$) adj3 model\$).ti,ab. |
| 58 | (Yale or Rochester).ti,ab. |
| 59 | or/54-58 |
| 60 | and/53,59 |
| 61 | limit 60 to english language |
| 62 | conference abstract.pt. |
| 63 | letter.pt. or LETTER/ |
| 64 | note.pt. |
| 65 | editorial.pt. |
| 66 | CASE REPORT/ or CASE STUDY/ |
| 67 | (letter or comment* or abstracts).ti. |
| 68 | or/62-67 |
| 69 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 70 | 68 not 69 |
| 71 | ANIMAL/ not HUMAN/ |
| 72 | NONHUMAN/ |
| 73 | exp ANIMAL EXPERIMENT/ |
| 74 | exp EXPERIMENTAL ANIMAL/ |
| 75 | ANIMAL MODEL/ |
| 76 | exp RODENT/ |
| 77 | (rat or rats or mouse or mice).ti. |
| 78 | or/70-77 |
| 79 | 61 not 78 |

Chapter 5

Heart rate

Review question

The predictive value of heart rate, including:

- how heart rate changes with temperature?
- whether heart rate outside the normal range detects serious illness?
- whether heart rate and temperature outside normal range detects serious illness?

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q6_heart_rate_medline_rerun1_011012

| _ | Searches |
|----|--|
| Щ | |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | HEART RATE/ |
| 7 | PULSE/ |
| 8 | exp TACHYCARDIA/ or BRADYCARDIA/ |
| 9 | (heart adj (rate? or beat?)).ti,ab. |
| | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or bradyarrhythmi\$).ti,ab. |
| 11 | (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).ti,ab. |
| 12 | or/6-11 |
| 13 | exp FEVER/ |
| 14 | exp BODY TEMPERATURE/ |
| 15 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 16 | or/13-15 |
| 17 | and/5,12,16 |
| 18 | REFERENCE STANDARDS/ or REFERENCE VALUES/ |
| 19 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).ti,ab. |
| 20 | or/18-19 |
| 21 | and/17,20 |
| 22 | exp BACTERIAL INFECTIONS/ |

| _ | |
|----|--|
| 23 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 25 | or/22-24 |
| 26 | exp MENINGITIS, BACTERIAL/ |
| 27 | MENINGOENCEPHALITIS/ |
| 28 | mening\$.ti,ab. |
| 29 | or/26-28 |
| 30 | SEPSIS/ |
| 31 | exp BACTEREMIA/ |
| 32 | (sepsis or septic?emi\$).ti,ab. |
| 33 | bacter?emi\$.ti,ab. |
| 34 | or/30-33 |
| 35 | exp PNEUMONIA/ |
| 36 | pneumon\$.ti,ab. |
| 37 | or/35-36 |
| 38 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 39 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 40 | or/38-39 |
| 41 | exp ARTHRITIS, INFECTIOUS/ |
| 42 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 43 | py?arth\$.ti,ab. |
| 44 | or/41-43 |
| 45 | OSTEOMYELITIS/ |
| 46 | osteomyelit\$.ti,ab. |
| 47 | or/45-46 |
| 48 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 50 | ((upper or lower) adj5 urin\$).ti,ab. |
| 51 | UTI.ti,ab. |
| 52 | exp CYSTITIS/ |
| | |

| (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
|---|
| exp PYELONEPHRITIS/ |
| (pyelonephr\$ or pyonephr\$).ti,ab. |
| or/48-55 |
| MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| (mucocutaneous adj3 lymph\$).ti,ab. |
| MCLS.ti,ab. |
| (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| or/57-60 |
| exp PYROGENS/ |
| pyrogen\$.ti,ab. |
| or/62-63 |
| or/25,29,34,37,40,44,47,56,61,64 |
| "PREDICTIVE VALUE OF TESTS"/ |
| DIAGNOSIS, DIFFERENTIAL/ |
| PROGNOSIS/ |
| ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).ti,ab. |
| or/66-69 |
| and/17,65,70 |
| ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or cardiactribute\$ or varie\$ or varie\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).ti,ab. |
| and/5,72 |
| or/21,71,73 |
| limit 74 to english language |
| LETTER/ |
| EDITORIAL/ |
| NEWS/ |
| exp HISTORICAL ARTICLE/ |
| ANECDOTES AS TOPIC/ |
| COMMENT/ |
| CASE REPORT/ |
| |

| 83 | (letter or comment* or abstracts).ti. |
|----|--|
| 84 | or/76-83 |
| 85 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 86 | 84 not 85 |
| 87 | ANIMALS/ not HUMANS/ |
| 88 | exp ANIMALS, LABORATORY/ |
| 89 | exp ANIMAL EXPERIMENTATION/ |
| 90 | exp MODELS, ANIMAL/ |
| 91 | exp RODENTIA/ |
| 92 | (rat or rats or mouse or mice).ti. |
| 93 | or/86-92 |
| 94 | 75 not 93 |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_Q6_heart_rate_mip_rerun2_011012

| # | Searches |
|----|--|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | (heart adj (rate? or beat?)).ti,ab. |
| | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or tachyarrhythmi\$).ti,ab. |
| 6 | (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).ti,ab. |
| 7 | or/4-6 |
| 8 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 9 | and/3,7-8 |
| 10 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).ti,ab. |
| 11 | and/9-10 |
| 12 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 13 | mening\$.ti,ab. |
| 14 | (sepsis or septic?emi\$).ti,ab. |

| 15 | bacter?emi\$.ti,ab. |
|----|---|
| 16 | or/14-15 |
| 17 | pneumon\$.ti,ab. |
| 18 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 19 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 20 | py?arth\$.ti,ab. |
| 21 | or/19-20 |
| 22 | osteomyelit\$.ti,ab. |
| 23 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 24 | ((upper or lower) adj5 urin\$).ti,ab. |
| 25 | UTI.ti,ab. |
| 26 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 27 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 28 | or/23-27 |
| 29 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 30 | MCLS.ti,ab. |
| 31 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 32 | or/29-31 |
| 33 | pyrogen\$.ti,ab. |
| 34 | or/12-13,16-18,21-22,28,32-33 |
| 35 | ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).ti,ab. |
| 36 | and/9,34-35 |
| 37 | ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or correlat\$ or attribute\$ or vary\$ or varies or varia\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).ti,ab. |
| 38 | and/3,37 |
| 39 | or/11,36,38 |
| 1— | |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q6_heart_rate_cctr_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | HEART RATE/ |
| 7 | PULSE/ |
| 8 | exp TACHYCARDIA/ or BRADYCARDIA/ |
| | (heart adj (rate? or beat?)).ti,ab. |
| 10 | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or bradyarrhythmi\$).ti,ab. |
| 11 | (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).ti,ab. |
| 12 | or/6-11 |
| 13 | exp FEVER/ |
| 14 | exp BODY TEMPERATURE/ |
| 15 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 16 | or/13-15 |
| 17 | and/5,12,16 |
| 18 | REFERENCE STANDARDS/ or REFERENCE VALUES/ |
| 19 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).ti,ab. |
| 20 | or/18-19 |
| 21 | and/17,20 |
| 22 | exp BACTERIAL INFECTIONS/ |
| 23 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 25 | or/22-24 |
| 26 | exp MENINGITIS, BACTERIAL/ |
| 27 | MENINGOENCEPHALITIS/ |

| 28 | mening\$.ti,ab. |
|----|--|
| 29 | or/26-28 |
| 30 | SEPSIS/ |
| 31 | exp BACTEREMIA/ |
| 32 | (sepsis or septic?emi\$).ti,ab. |
| 33 | bacter?emi\$.ti,ab. |
| 34 | or/30-33 |
| 35 | exp PNEUMONIA/ |
| 36 | pneumon\$.ti,ab. |
| 37 | or/35-36 |
| 38 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 39 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 40 | or/38-39 |
| 41 | exp ARTHRITIS, INFECTIOUS/ |
| 42 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 43 | py?arth\$.ti,ab. |
| 44 | or/41-43 |
| 45 | OSTEOMYELITIS/ |
| 46 | osteomyelit\$.ti,ab. |
| 47 | or/45-46 |
| 48 | exp URINARY TRACT INFECTIONS/ |
| 49 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 50 | ((upper or lower) adj5 urin\$).ti,ab. |
| 51 | UTI.ti,ab. |
| 52 | exp CYSTITIS/ |
| 53 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 54 | exp PYELONEPHRITIS/ |
| 55 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 56 | or/48-55 |
| 57 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 58 | (mucocutaneous adj3 lymph\$).ti,ab. |

| 59 | MCLS.ti,ab. |
|----|---|
| 60 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 61 | or/57-60 |
| 62 | exp PYROGENS/ |
| 63 | pyrogen\$.ti,ab. |
| 64 | or/62-63 |
| 65 | or/25,29,34,37,40,44,47,56,61,64 |
| 66 | "PREDICTIVE VALUE OF TESTS"/ |
| 67 | DIAGNOSIS, DIFFERENTIAL/ |
| 68 | PROGNOSIS/ |
| 69 | ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).ti,ab. |
| 70 | or/66-69 |
| 71 | and/17,65,70 |
| 72 | ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or correlat\$ or attribute\$ or vary\$ or varies or varia\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).ti,ab. |
| 73 | and/5,72 |
| 74 | or/21,71,73 |

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_Q6_heart_rate_cdsrdare_rerun2_011012

| # | Searches |
|----|---|
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | HEART RATE.kw. |
| 7 | PULSE.kw. |
| 8 | (TACHYCARDIA or BRADYCARDIA).kw. |
| 9 | (heart adj (rate? or beat?)).tw,tx. |
| 10 | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or |

| 11 | bradyarrhythmi\$).tw,tx. (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).tw,tx. |
|---------------|---|
| \sqsubseteq | |
| 12 | or/6-11 |
| 13 | FEVER.kw. |
| 14 | BODY TEMPERATURE.kw. |
| 15 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw,tx. |
| 16 | or/13-15 |
| 17 | and/5,12,16 |
| 18 | (REFERENCE STANDARDS or REFERENCE VALUES).kw. |
| 19 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).tw,tx. |
| 20 | or/18-19 |
| 21 | and/17,20 |
| 22 | BACTERIAL INFECTIONS.kw. |
| 23 | (CRITICAL ILLNESS or ACUTE DISEASE).kw. |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw,tx. |
| 25 | or/22-24 |
| 26 | MENINGITIS, BACTERIAL.kw. |
| 27 | MENINGOENCEPHALITIS.kw. |
| 28 | mening\$.tw,tx. |
| 29 | or/26-28 |
| 30 | SEPSIS.kw. |
| 31 | BACTEREMIA.kw. |
| 32 | (sepsis or septic?emi\$).tw,tx. |
| 33 | bacter?emi\$.tw,tx. |
| 34 | or/30-33 |
| 35 | PNEUMONIA.kw. |
| 36 | pneumon\$.tw,tx. |
| 37 | or/35-36 |
| 38 | ENCEPHALITIS, HERPES SIMPLEX.kw. |
| 39 | (encephalit\$ adj5 (herpe\$ or HSV)).tw,tx. |
| 40 | or/38-39 |

| 41 | ARTHRITIS, INFECTIOUS.kw. |
|----|--|
| 42 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw,tx. |
| 43 | py?arth\$.tw,tx. |
| 44 | or/41-43 |
| 45 | OSTEOMYELITIS.kw. |
| 46 | osteomyelit\$.tw,tx. |
| 47 | or/45-46 |
| | URINARY TRACT INFECTIONS.kw. |
| 49 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw,tx. |
| 50 | ((upper or lower) adj5 urin\$).tw,tx. |
| 51 | UTI.tw,tx. |
| 52 | CYSTITIS.kw. |
| 53 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw,tx. |
| 54 | PYELONEPHRITIS.kw. |
| 55 | (pyelonephr\$ or pyonephr\$).tw,tx. |
| 56 | or/48-55 |
| 57 | MUCOCUTANEOUS LYMPH NODE SYNDROME.kw. |
| 58 | (mucocutaneous adj3 lymph\$).tw,tx. |
| | MCLS.tw,tx. |
| 60 | (kawasaki\$ adj (disease? or syndrome?)).tw,tx. |
| 61 | or/57-60 |
| 62 | PYROGENS.kw. |
| 63 | pyrogen\$.tw,tx. |
| 64 | or/62-63 |
| 65 | or/25,29,34,37,40,44,47,56,61,64 |
| 66 | "PREDICTIVE VALUE OF TESTS".kw. |
| 67 | DIAGNOSIS, DIFFERENTIAL.kw. |
| 68 | PROGNOSIS.kw. |
| 69 | ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).tw,tx. |
| 70 | or/66-69 |
| 71 | and/17,65,70 |
| | |

| 11 | ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or correlat\$ or attribute\$ or vary\$ or varies or varia\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).tw,tx. |
|----|---|
| 73 | 3 and/5,72 |
| 74 | 4 or/21,71,73 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012

FICu_Q6_heart_rate_hta_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | HEART RATE/ |
| 7 | PULSE/ |
| 8 | exp TACHYCARDIA/ or BRADYCARDIA/ |
| 9 | (heart adj (rate? or beat?)).tw. |
| 10 | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or bradyarrhythmi\$).tw. |
| 11 | (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).tw. |
| 12 | or/6-11 |
| 13 | exp FEVER/ |
| 14 | exp BODY TEMPERATURE/ |
| 15 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 16 | or/13-15 |
| 17 | and/5,12,16 |
| 18 | REFERENCE STANDARDS/ or REFERENCE VALUES/ |
| 19 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).tw. |
| 20 | or/18-19 |
| 21 | and/17,20 |
| 22 | exp BACTERIAL INFECTIONS/ |
| 23 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |

| | //besterit an atrantace of a atran |
|----|--|
| 24 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 25 | or/22-24 |
| 26 | exp MENINGITIS, BACTERIAL/ |
| 27 | MENINGOENCEPHALITIS/ |
| 28 | mening\$.tw. |
| 29 | or/26-28 |
| 30 | SEPSIS/ |
| 31 | exp BACTEREMIA/ |
| 32 | (sepsis or septic?emi\$).tw. |
| 33 | bacter?emi\$.tw. |
| 34 | or/30-33 |
| 35 | exp PNEUMONIA/ |
| 36 | pneumon\$.tw. |
| 37 | or/35-36 |
| 38 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 39 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| 40 | or/38-39 |
| 41 | exp ARTHRITIS, INFECTIOUS/ |
| 42 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 43 | py?arth\$.tw. |
| 44 | or/41-43 |
| 45 | OSTEOMYELITIS/ |
| 46 | osteomyelit\$.tw. |
| 47 | or/45-46 |
| 48 | exp URINARY TRACT INFECTIONS/ |
| 49 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw. |
| 50 | ((upper or lower) adj5 urin\$).tw. |
| 51 | UTI.tw. |
| 52 | exp CYSTITIS/ |
| 53 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |

| 54 | exp PYELONEPHRITIS/ |
|----|--|
| 55 | (pyelonephr\$ or pyonephr\$).tw. |
| 56 | or/48-55 |
| 57 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 58 | (mucocutaneous adj3 lymph\$).tw. |
| 59 | MCLS.tw. |
| 60 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 61 | or/57-60 |
| 62 | exp PYROGENS/ |
| 63 | pyrogen\$.tw. |
| 64 | or/62-63 |
| 65 | or/25,29,34,37,40,44,47,56,61,64 |
| 66 | "PREDICTIVE VALUE OF TESTS"/ |
| 67 | DIAGNOSIS, DIFFERENTIAL/ |
| 68 | PROGNOSIS/ |
| 69 | ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).tw. |
| 70 | or/66-69 |
| 71 | and/17,65,70 |
| 72 | ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or correlat\$ or attribute\$ or vary\$ or varies or varia\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).tw. |
| 73 | and/5,72 |
| 74 | or/21,71,73 |
| | |

Database(s): Embase 1980 to 2012 Week 39

FICu_Q6_heart_rate_embase_rerun2_011012

| # | Searches |
|---|---|
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | exp "HEART RATE AND RHYTHM"/ |
| 5 | exp TACHYCARDIA/ |
| 6 | exp BRADYCARDIA/ |

| П | |
|----|---|
| 7 | (heart adj (rate? or beat?)).ti,ab. |
| 8 | (heart?rate? or heart?beat? or puls\$ or arrhythmi\$ or tachycardi\$ or tachyarrhythmi\$ or bradycardi\$ or bradyarrhythmi\$).ti,ab. |
| 9 | (cardi\$ adj3 (monitor\$ or observ\$ or rate?)).ti,ab. |
| 10 | or/4-9 |
| 11 | FEVER/ |
| 12 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 13 | PYREXIA IDIOPATHICA/ |
| 14 | exp BODY TEMPERATURE/ or BRAIN TEMPERATURE/ or CORE TEMPERATURE/ or SKIN TEMPERATURE/ |
| 15 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 16 | or/11-15 |
| 17 | and/3,10,16 |
| 18 | REFERENCE VALUE/ or STANDARD/ |
| 19 | ((refer\$ or normal) adj3 (range? or interval? or value? or standard?)).ti,ab. |
| 20 | or/18-19 |
| 21 | and/17,20 |
| 22 | exp BACTERIAL INFECTION/ |
| 23 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 24 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 25 | or/22-24 |
| 26 | BACTERIAL MENINGITIS/ |
| 27 | MENINGOENCEPHALITIS/ |
| 28 | mening\$.ti,ab. |
| 29 | or/26-28 |
| 30 | SEPTICEMIA/ |
| 31 | exp BACTEREMIA/ |
| 32 | (sepsis or septic?emi\$).ti,ab. |
| 33 | bacter?emi\$.ti,ab. |
| 34 | or/30-33 |
| 35 | exp PNEUMONIA/ |
| 36 | pneumon\$.ti,ab. |
| | |

| 37 | or/35-36 |
|----|--|
| | |
| 38 | HERPES SIMPLEX ENCEPHALITIS/ |
| 39 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 40 | or/38-39 |
| 41 | exp INFECTIOUS ARTHRITIS/ |
| 42 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 43 | py?arth\$.ti,ab. |
| 44 | or/41-43 |
| 45 | exp OSTEOMYELITIS/ |
| 46 | osteomyelit\$.ti,ab. |
| 47 | or/45-46 |
| 48 | exp URINARY TRACT INFECTION/ |
| 49 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 50 | ((upper or lower) adj5 urin\$).ti,ab. |
| 51 | UTI.ti,ab. |
| 52 | exp CYSTITIS/ |
| 53 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 54 | exp PYELONEPHRITIS/ |
| 55 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 56 | or/48-55 |
| 57 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 58 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 59 | MCLS.ti,ab. |
| 60 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 61 | or/57-60 |
| 62 | exp PYROGEN/ |
| 63 | pyrogen\$.ti,ab. |
| 64 | or/62-63 |
| 65 | or/25,29,34,37,40,44,47,56,61,64 |
| 66 | PREDICTIVE VALUE/ or DIAGNOSTIC VALUE/ |
| 67 | DIFFERENTIAL DIAGNOSIS/ |
| _ | |

| | |
|---|---|
| 68 | PROGNOSIS/ |
| 69 | ((infect\$ or ill\$) adj3 (identif\$ or diagnos\$ or predict\$ or distinguish\$ or prognos\$)).ti,ab. |
| 70 | or/66-69 |
| 71 | and/17,65,70 |
| 11 1 | ((pulse? or heart\$ or cardiac or tachycardi\$) adj5 (increas\$ or decreas\$ or change\$ or relat\$ or correlat\$ or attribute\$ or vary\$ or varies or varia\$ or centile? or range?) adj5 (temperature? or fever\$ or febri\$ or pyrex\$)).ti,ab. |
| 73 | and/3,72 |
| 74 | or/21,71,73 |
| 75 | limit 74 to english language |
| 76 | conference abstract.pt. |
| 77 | letter.pt. or LETTER/ |
| 78 | note.pt. |
| 79 | editorial.pt. |
| 80 | CASE REPORT/ or CASE STUDY/ |
| 81 | (letter or comment* or abstracts).ti. |
| 82 | or/76-81 |
| 83 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 84 | 82 not 83 |
| 85 | ANIMAL/ not HUMAN/ |
| 86 | NONHUMAN/ |
| 87 | exp ANIMAL EXPERIMENT/ |
| 88 | exp EXPERIMENTAL ANIMAL/ |
| 89 | ANIMAL MODEL/ |
| 90 | exp RODENT/ |
| 91 | (rat or rats or mouse or mice).ti. |
| 92 | or/84-91 |
| 93 | 75 not 92 |
| | |

Chapter 8

Children 3 months and older

Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q1_PCT_CRP_dx_medline_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |

| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
|----|--|
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | CALCITONIN/ |
| 55 | PROTEIN PRECURSOR/ |
| | |

| 57 (pro?calcitonin\$ or calcitonin\$ or PCT).ti.ab. 58 or/54-57 59 C-REACTIVE PROTEIN/ 60 c-reactive protein.m. 61 ((c reactive or c?reactive) adj1 protein\$).ti.ab. 62 CRP.ti.ab. 63 or/59-62 64 or/58,63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti.ab. 77 75 not 76 78 ANIMALS, LABORATORY/ 80 exp ANIMALS, LABORATORY/ 81 exp MODELS, ANIMAL/ 82 exp RODENTIA/ 83 exp RODENTIA/ 84 exp MODELS, ANIMAL/ 85 exp RODENTIA/ 86 exp RODENTIA/ 87 exp RODENTIA/ 88 exp RODENTIA/ 89 exp RODENTIA/ | |
|---|--|
| C-REACTIVE PROTEIN/ 60 c-reactive protein.nm. 61 ((c reactive or c?reactive) adj1 protein\$).ti,ab. 62 CRP.ti,ab. 63 or/59-62 64 or/58.63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 8 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| c-reactive protein.nm. 61 ((c reactive or c?reactive) adj1 protein\$).ti.ab. 62 CRP.ti,ab. 63 or/59-62 64 or/58,63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 61 ((c reactive or c?reactive) adj1 protein\$).ti,ab. 62 CRP.ti,ab. 63 or/59-62 64 or/58.63 65 and/53.64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMALS, LABORATORY/ 81 exp MODELS, ANIMAL/ | |
| 62 CRP.ti,ab. 63 or/59-62 64 or/58,63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 63 or/59-62 64 or/58,63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 64 or/58,63 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 65 and/53,64 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 66 limit 65 to english language 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 67 LETTER/ 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 68 EDITORIAL/ 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 69 NEWS/ 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 70 exp HISTORICAL ARTICLE/ 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 71 ANECDOTES AS TOPIC/ 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 72 COMMENT/ 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 73 CASE REPORT/ 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 74 (letter or comment* or abstracts).ti. 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 75 or/67-74 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 76 RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 77 75 not 76 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 78 ANIMALS/ not HUMANS/ 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 79 exp ANIMALS, LABORATORY/ 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 80 exp ANIMAL EXPERIMENTATION/ 81 exp MODELS, ANIMAL/ | |
| 81 exp MODELS, ANIMAL/ | |
| | |
| 82 exp RODENTIA/ | |
| | |
| 83 (rat or rats or mouse or mice).ti. | |
| 84 or/77-83 | |
| 85 66 not 84 | |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_Q1_PCT_CRP_dx_mip_rerun2_011012

| # | Searches |
|----|--|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 5 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 6 | mening\$.ti,ab. |
| 7 | (sepsis or septic?emi\$).ti,ab. |
| 8 | bacter?emi\$.ti,ab. |
| 9 | or/7-8 |
| 10 | pneumon\$.ti,ab. |
| 11 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 12 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 13 | py?arth\$.ti,ab. |
| 14 | or/12-13 |
| 15 | osteomyelit\$.ti,ab. |
| 16 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 17 | ((upper or lower) adj5 urin\$).ti,ab. |
| 18 | UTI.ti,ab. |
| 19 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 20 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 21 | or/16-20 |
| 22 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 23 | MCLS.ti,ab. |
| 24 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 25 | or/22-24 |
| 26 | pyrogen\$.ti,ab. |
| 27 | or/5-6,9-11,14-15,21,25-26 |

| 28 | and/3-4,27 |
|----|--|
| 29 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 30 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 31 | CRP.ti,ab. |
| 32 | or/29-31 |
| 33 | and/28,32 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q1_PCT_CRP_dx_cctr_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |

| ᆜᆜ | xp PNEUMONIA/ |
|-------|--|
| 23 pr | |
| == | neumon\$.ti,ab. |
| 24 or | r/22-23 |
| 25 EI | NCEPHALITIS, HERPES SIMPLEX/ |
| 26 (e | encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 or | r/25-26 |
| 28 ex | xp ARTHRITIS, INFECTIOUS/ |
| 29 (a | arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 py | y?arth\$.ti,ab. |
| 31 or | r/28-30 |
| 32 O | OSTEOMYELITIS/ |
| 33 os | steomyelit\$.ti,ab. |
| 34 or | r/32-33 |
| 35 ex | xp URINARY TRACT INFECTIONS/ |
| | (urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ r uro?gen\$) adj5 infect\$).ti,ab. |
| 37 ((| (upper or lower) adj5 urin\$).ti,ab. |
| 38 U | ITI.ti,ab. |
| 39 ex | xp CYSTITIS/ |
| | cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 ex | xp PYELONEPHRITIS/ |
| 42 (p | pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 or | r/35-42 |
| 44 M | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 (n | mucocutaneous adj3 lymph\$).ti,ab. |
| 46 M | ICLS.ti,ab. |
| 47 (k | kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 or | r/44-47 |
| 40 0 | xp PYROGENS/ |
| 49 67 | |
| | yrogen\$.ti,ab. |
| 50 py | r/49-50 |

| 53 | and/5,8,52 |
|----|--|
| 54 | CALCITONIN/ |
| 55 | PROTEIN PRECURSOR/ |
| 56 | [procalcitonin.nm.] |
| 57 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 58 | or/54-57 |
| 59 | C-REACTIVE PROTEIN/ |
| 60 | [c-reactive protein.nm.] |
| 61 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 62 | CRP.ti,ab. |
| 63 | or/59-62 |
| 64 | or/58,63 |
| 65 | and/53,64 |

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_Q1_PCT_CRP_dx_cdsrdare_rerun2_011012

| # | Searches |
|----|---|
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | FEVER.kw. |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw,tx. |
| 8 | or/6-7 |
| 9 | BACTERIAL INFECTIONS.kw. |
| 10 | (CRITICAL ILLNESS or ACUTE DISEASE).kw. |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw,tx. |
| 12 | or/9-11 |
| 13 | MENINGITIS, BACTERIAL.kw. |

| 14 | MENINGOENCEPHALITIS.kw. |
|----|--|
| 15 | mening\$.tw,tx. |
| 16 | or/13-15 |
| 17 | SEPSIS.kw. |
| 18 | BACTEREMIA.kw. |
| 19 | (sepsis or septic?emi\$).tw,tx. |
| 20 | bacter?emi\$.tw,tx. |
| 21 | or/17-20 |
| 22 | PNEUMONIA.kw. |
| 23 | pneumon\$.tw,tx. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX.kw. |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw,tx. |
| 27 | or/25-26 |
| 28 | ARTHRITIS, INFECTIOUS.kw. |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw,tx. |
| 30 | py?arth\$.tw,tx. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS.kw. |
| 33 | osteomyelit\$.tw,tx. |
| 34 | or/32-33 |
| | URINARY TRACT INFECTIONS.kw. |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw,tx. |
| 37 | ((upper or lower) adj5 urin\$).tw,tx. |
| 38 | UTI.tw,tx. |
| 39 | CYSTITIS.kw. |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw,tx. |
| 41 | PYELONEPHRITIS.kw. |
| 42 | (pyelonephr\$ or pyonephr\$).tw,tx. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME.kw. |
| | |

| 45 | (mucocutaneous adj3 lymph\$).tw,tx. |
|----|--|
| 46 | MCLS.tw,tx. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw,tx. |
| 48 | or/44-47 |
| 49 | PYROGENS.kw. |
| 50 | pyrogen\$.tw,tx. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | CALCITONIN.kw. |
| 55 | PROTEIN PRECURSOR.kw. |
| 56 | (pro?calcitonin\$ or calcitonin\$ or PCT).tw,tx. |
| 57 | or/54-56 |
| 58 | C-REACTIVE PROTEIN.kw. |
| 59 | ((c reactive or c?reactive) adj1 protein\$).tw,tx. |
| 60 | CRP.tw,tx. |
| 61 | or/58-60 |
| 62 | or/57,61 |
| 63 | and/53,62 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012 FiCu_Q1_PCT_CRP_dx_hta_rerun2_011012

| # | Searches |
|---|--|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 8 | or/6-7 |
| 9 | exp BACTERIAL INFECTIONS/ |

| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
|----|---|
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 12 | or/9-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.tw. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).tw. |
| 20 | bacter?emi\$.tw. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.tw. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 30 | py?arth\$.tw. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.tw. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw. |
| 37 | ((upper or lower) adj5 urin\$).tw. |
| 38 | UTI.tw. |
| 39 | exp CYSTITIS/ |

| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |
|----|---|
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).tw. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).tw. |
| 46 | MCLS.tw. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.tw. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/5,8,52 |
| 54 | CALCITONIN/ |
| 55 | PROTEIN PRECURSOR/ |
| 56 | (pro?calcitonin\$ or calcitonin\$ or PCT).tw. |
| 57 | or/54-56 |
| 58 | C-REACTIVE PROTEIN/ |
| | ((c reactive or c?reactive) adj1 protein\$).tw. |
| 60 | CRP.tw. |
| 61 | or/58-60 |
| 62 | or/57,61 |
| 63 | and/53,62 |

Database(s): Embase 1980 to 2012 Week 39

FICu_Q1_PCT_CRP_dx_embase_rerun2_011012

| # | Searches |
|---|---|
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | FEVER/ |

| 5 | HYPERTHERMIA/ or HYPERPYREXIA/ |
|----|---|
| 6 | PYREXIA IDIOPATHICA/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/4-7 |
| 9 | exp BACTERIAL INFECTION/ |
| 10 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 11 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 12 | or/9-11 |
| 13 | BACTERIAL MENINGITIS/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPTICEMIA/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).ti,ab. |
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | HERPES SIMPLEX ENCEPHALITIS/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp INFECTIOUS ARTHRITIS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | exp OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTION/ |
| | |

| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
|----|--|
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGEN/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | and/3,8,52 |
| 54 | PROCALCITONIN/ |
| 55 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 56 | or/54-55 |
| 57 | C REACTIVE PROTEIN/ |
| 58 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 59 | CRP.ti,ab. |
| 60 | or/57-59 |
| 61 | or/56,60 |
| 62 | and/53,61 |
| 63 | limit 62 to english language |
| 64 | conference abstract.pt. |
| 65 | letter.pt. or LETTER/ |
| 66 | note.pt. |
| | |

| 67 | editorial.pt. |
|----|--|
| 68 | CASE REPORT/ or CASE STUDY/ |
| 69 | (letter or comment* or abstracts).ti. |
| 70 | or/64-69 |
| 71 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 72 | 70 not 71 |
| 73 | ANIMAL/ not HUMAN/ |
| 74 | NONHUMAN/ |
| 75 | exp ANIMAL EXPERIMENT/ |
| 76 | exp EXPERIMENTAL ANIMAL/ |
| 77 | ANIMAL MODEL/ |
| 78 | exp RODENT/ |
| 79 | (rat or rats or mouse or mice).ti. |
| 80 | or/72-79 |
| 81 | 63 not 80 |

Collated search strategies: health economics Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q1_PCT_CRP_dx_economic_medline_rerun2_011012

| # | Searches |
|---|--------------------------------|
| 1 | ECONOMICS/ |
| 2 | VALUE OF LIFE/ |
| 3 | exp "COSTS AND COST ANALYSIS"/ |
| 4 | exp ECONOMICS, HOSPITAL/ |
| 5 | exp ECONOMICS, MEDICAL/ |
| 6 | exp RESOURCE ALLOCATION/ |
| 7 | ECONOMICS, NURSING/ |
| 8 | ECONOMICS, PHARMACEUTICAL/ |
| 9 | exp "FEES AND CHARGES"/ |

| 10 | exp BUDGETS/ |
|----|---|
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |
| 13 | (economic* or pharmaco?economic*).ti,ab. |
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value adj2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | or/1-20 |
| 22 | exp INFANT/ |
| 23 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 24 | exp CHILD/ |
| 25 | (child\$ or toddler\$).ti,ab. |
| 26 | or/22-25 |
| 27 | exp FEVER/ |
| 28 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 29 | or/27-28 |
| 30 | exp BACTERIAL INFECTIONS/ |
| 31 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 33 | or/30-32 |
| 34 | exp MENINGITIS, BACTERIAL/ |
| 35 | MENINGOENCEPHALITIS/ |
| 36 | mening\$.ti,ab. |
| 37 | or/34-36 |
| 38 | SEPSIS/ |
| 39 | exp BACTEREMIA/ |
| 40 | (sepsis or septic?emi\$).ti,ab. |

| 44 | |
|----|--|
| 41 | bacter?emi\$.ti,ab. |
| 42 | or/38-41 |
| 43 | exp PNEUMONIA/ |
| 44 | pneumon\$.ti,ab. |
| 45 | or/43-44 |
| 46 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 47 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 48 | or/46-47 |
| 49 | exp ARTHRITIS, INFECTIOUS/ |
| 50 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 51 | py?arth\$.ti,ab. |
| 52 | or/49-51 |
| 53 | OSTEOMYELITIS/ |
| 54 | osteomyelit\$.ti,ab. |
| 55 | or/53-54 |
| 56 | exp URINARY TRACT INFECTIONS/ |
| 57 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 58 | ((upper or lower) adj5 urin\$).ti,ab. |
| 59 | UTI.ti,ab. |
| 60 | exp CYSTITIS/ |
| 61 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 62 | exp PYELONEPHRITIS/ |
| 63 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 64 | or/56-63 |
| 65 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 66 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 67 | MCLS.ti,ab. |
| 68 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 69 | or/65-68 |
| 70 | exp PYROGENS/ |
| 71 | pyrogen\$.ti,ab. |
| | |

| 72 | or/70-71 |
|-----|--|
| 73 | or/33,37,42,45,48,52,55,64,69,72 |
| 74 | and/26,29,73 |
| 75 | CALCITONIN/ |
| 76 | PROTEIN PRECURSOR/ |
| 77 | procalcitonin.nm. |
| 78 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 79 | or/75-78 |
| 80 | C-REACTIVE PROTEIN/ |
| 81 | c-reactive protein.nm. |
| 82 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 83 | CRP.ti,ab. |
| 84 | or/80-83 |
| 85 | or/79,84 |
| 86 | and/74,85 |
| 87 | limit 86 to english language |
| 88 | LETTER/ |
| 89 | EDITORIAL/ |
| 90 | NEWS/ |
| 91 | exp HISTORICAL ARTICLE/ |
| 92 | ANECDOTES AS TOPIC/ |
| 93 | COMMENT/ |
| 94 | CASE REPORT/ |
| 95 | (letter or comment* or abstracts).ti. |
| 96 | or/88-95 |
| 97 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 98 | 96 not 97 |
| 99 | ANIMALS/ not HUMANS/ |
| 100 | exp ANIMALS, LABORATORY/ |
| 101 | exp ANIMAL EXPERIMENTATION/ |
| 102 | exp MODELS, ANIMAL/ |

| 103 | exp RODENTIA/ |
|-----|------------------------------------|
| 104 | (rat or rats or mouse or mice).ti. |
| 105 | or/98-104 |
| 106 | 87 not 105 |
| 107 | and/21,106 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q1_PCT_CRP_dx_economic_cctr_rerun2_011012

| # | Searches |
|----|--|
| 1 | ECONOMICS/ |
| 2 | VALUE OF LIFE/ |
| 3 | exp "COSTS AND COST ANALYSIS"/ |
| 4 | exp ECONOMICS, HOSPITAL/ |
| 5 | exp ECONOMICS, MEDICAL/ |
| 6 | exp RESOURCE ALLOCATION/ |
| 7 | ECONOMICS, NURSING/ |
| 8 | ECONOMICS, PHARMACEUTICAL/ |
| 9 | exp "FEES AND CHARGES"/ |
| 10 | exp BUDGETS/ |
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |
| 13 | (economic* or pharmaco?economic*).ti,ab. |
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value adj2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | or/1-20 |
| 22 | exp INFANT/ |

| _ | |
|----|---|
| 23 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 24 | exp CHILD/ |
| 25 | (child\$ or toddler\$).ti,ab. |
| 26 | or/22-25 |
| 27 | exp FEVER/ |
| 28 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 29 | or/27-28 |
| 30 | exp BACTERIAL INFECTIONS/ |
| 31 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 33 | or/30-32 |
| 34 | exp MENINGITIS, BACTERIAL/ |
| 35 | MENINGOENCEPHALITIS/ |
| 36 | mening\$.ti,ab. |
| 37 | or/34-36 |
| 38 | SEPSIS/ |
| 39 | exp BACTEREMIA/ |
| 40 | (sepsis or septic?emi\$).ti,ab. |
| 41 | bacter?emi\$.ti,ab. |
| 42 | or/38-41 |
| 43 | exp PNEUMONIA/ |
| 44 | pneumon\$.ti,ab. |
| 45 | or/43-44 |
| 46 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 47 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 48 | or/46-47 |
| 49 | exp ARTHRITIS, INFECTIOUS/ |
| 50 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 51 | py?arth\$.ti,ab. |
| 52 | or/49-51 |
| 53 | OSTEOMYELITIS/ |
| | |

| 54 | osteomyelit\$.ti,ab. |
|----|--|
| 55 | or/53-54 |
| 56 | exp URINARY TRACT INFECTIONS/ |
| 57 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 58 | ((upper or lower) adj5 urin\$).ti,ab. |
| 59 | UTI.ti,ab. |
| 60 | exp CYSTITIS/ |
| 61 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 62 | exp PYELONEPHRITIS/ |
| 63 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 64 | or/56-63 |
| 65 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 66 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 67 | MCLS.ti,ab. |
| 68 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 69 | or/65-68 |
| 70 | exp PYROGENS/ |
| 71 | pyrogen\$.ti,ab. |
| 72 | or/70-71 |
| 73 | or/33,37,42,45,48,52,55,64,69,72 |
| 74 | and/26,29,73 |
| 75 | CALCITONIN/ |
| 76 | PROTEIN PRECURSOR/ |
| 77 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 78 | or/75-77 |
| 79 | C-REACTIVE PROTEIN/ |
| 80 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 81 | CRP.ti,ab. |
| 82 | or/79-81 |
| 83 | or/78,82 |
| 84 | and/74,83 |

85 and/21,84

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012, EBM Reviews - NHS Economic Evaluation Database 3rd Quarter 2012

FICu_Q1_PCT_CRP_dx_economic_nhseedhta_rerun2_011012

| # | Searches |
|----|--|
| 1 | ECONOMICS/ |
| 2 | VALUE OF LIFE/ |
| 3 | exp "COSTS AND COST ANALYSIS"/ |
| 4 | exp ECONOMICS, HOSPITAL/ |
| 5 | exp ECONOMICS, MEDICAL/ |
| 6 | exp RESOURCE ALLOCATION/ |
| 7 | ECONOMICS, NURSING/ |
| 8 | ECONOMICS, PHARMACEUTICAL/ |
| 9 | exp "FEES AND CHARGES"/ |
| 10 | exp BUDGETS/ |
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |
| 13 | (economic* or pharmaco?economic*).ti,ab. |
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value adj2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | or/1-20 |
| 22 | exp INFANT/ |
| 23 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 24 | exp CHILD/ |
| 25 | (child\$ or toddler\$).tw. |
| 26 | or/22-25 |

| 27 | exp FEVER/ |
|----|--|
| 28 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 29 | or/27-28 |
| 30 | exp BACTERIAL INFECTIONS/ |
| 31 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 32 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 33 | or/30-32 |
| 34 | exp MENINGITIS, BACTERIAL/ |
| 35 | MENINGOENCEPHALITIS/ |
| 36 | mening\$.tw. |
| 37 | or/34-36 |
| 38 | SEPSIS/ |
| 39 | exp BACTEREMIA/ |
| 40 | (sepsis or septic?emi\$).tw. |
| 41 | bacter?emi\$.tw. |
| 42 | or/38-41 |
| 43 | exp PNEUMONIA/ |
| 44 | pneumon\$.tw. |
| 45 | or/43-44 |
| 46 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 47 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| 48 | or/46-47 |
| 49 | exp ARTHRITIS, INFECTIOUS/ |
| 50 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 51 | py?arth\$.tw. |
| 52 | or/49-51 |
| 53 | OSTEOMYELITIS/ |
| 54 | osteomyelit\$.tw. |
| 55 | or/53-54 |
| 56 | exp URINARY TRACT INFECTIONS/ |
| 57 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ |
| | |

| | O |
|----|---|
| | or uro?gen\$) adj5 infect\$).tw. |
| 58 | ((upper or lower) adj5 urin\$).tw. |
| 59 | UTI.tw. |
| 60 | exp CYSTITIS/ |
| 61 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |
| 62 | exp PYELONEPHRITIS/ |
| 63 | (pyelonephr\$ or pyonephr\$).tw. |
| 64 | or/56-63 |
| 65 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 66 | (mucocutaneous adj3 lymph\$).tw. |
| 67 | MCLS.tw. |
| 68 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 69 | or/65-68 |
| 70 | exp PYROGENS/ |
| 71 | pyrogen\$.tw. |
| 72 | or/70-71 |
| 73 | or/33,37,42,45,48,52,55,64,69,72 |
| 74 | and/26,29,73 |
| 75 | CALCITONIN/ |
| 76 | PROTEIN PRECURSOR/ |
| 77 | (pro?calcitonin\$ or calcitonin\$ or PCT).tw. |
| 78 | or/75-77 |
| 79 | C-REACTIVE PROTEIN/ |
| 80 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 81 | CRP.ti,ab. |
| 82 | or/79-81 |
| 83 | or/78,82 |
| 84 | and/74,83 |

Database(s): Embase 1980 to 2012 Week 39

FICu_Q1_PCT_CRP_dx_economic_embase_rerun2_011012

| # | Searches |
|----|---|
| 1 | HEALTH ECONOMICS/ |
| 2 | exp ECONOMIC EVALUATION/ |
| 3 | exp HEALTH CARE COST/ |
| 4 | exp FEE/ |
| 5 | BUDGET/ |
| 6 | FUNDING/ |
| 7 | budget*.ti,ab. |
| 8 | cost*.ti. |
| 9 | (economic* or pharmaco?economic*).ti. |
| 10 | (price* or pricing*).ti,ab. |
| 11 | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 12 | (financ* or fee or fees).ti,ab. |
| 13 | (value adj2 (money or monetary)).ti,ab. |
| 14 | resourc* allocat*.ti,ab. |
| 15 | (fund or funds or funding* or funded).ti,ab. |
| 16 | (ration or rations or rationing* or rationed).ti,ab. |
| 17 | or/1-16 |
| 18 | exp CHILD/ |
| 19 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 20 | or/18-19 |
| 21 | FEVER/ |
| 22 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 23 | PYREXIA IDIOPATHICA/ |
| 24 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 25 | or/21-24 |
| 26 | exp BACTERIAL INFECTION/ |
| 27 | CRITICAL CARE/ or ACUTE DISEASE/ |
| 28 | ((bacteri\$ or streptococc\$ or staphylococc\$ or serious\$) adj (infect\$ or ill\$)).ti,ab. |
| 29 | or/26-28 |

| 30 | BACTERIAL MENINGITIS/ |
|----|--|
| 31 | MENINGOENCEPHALITIS/ |
| | |
| 32 | mening\$.ti,ab. |
| 33 | or/30-32 |
| 34 | SEPTICEMIA/ |
| 35 | exp BACTEREMIA/ |
| 36 | (sepsis or septic?emi\$).ti,ab. |
| 37 | bacter?emi\$.ti,ab. |
| 38 | or/34-37 |
| 39 | exp PNEUMONIA/ |
| 40 | pneumon\$.ti,ab. |
| 41 | or/39-40 |
| 42 | HERPES SIMPLEX ENCEPHALITIS/ |
| 43 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 44 | or/42-43 |
| 45 | exp INFECTIOUS ARTHRITIS/ |
| 46 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 47 | py?arth\$.ti,ab. |
| 48 | or/45-47 |
| 49 | exp OSTEOMYELITIS/ |
| 50 | osteomyelit\$.ti,ab. |
| 51 | or/49-50 |
| | exp URINARY TRACT INFECTION/ |
| 53 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 54 | ((upper or lower) adj5 urin\$).ti,ab. |
| 55 | UTI.ti,ab. |
| 56 | exp CYSTITIS/ |
| 57 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 58 | exp PYELONEPHRITIS/ |
| 59 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 60 | or/52-59 |
| | |

| 64 | MUCOCUTANICOUO I VARU NORE OVARROME! |
|----|--|
| Щ | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 62 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 63 | MCLS.ti,ab. |
| 64 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 65 | or/61-64 |
| 66 | exp PYROGEN/ |
| 67 | pyrogen\$.ti,ab. |
| 68 | or/66-67 |
| 69 | or/29,33,38,41,44,48,51,60,65,68 |
| 70 | and/20,25,69 |
| 71 | PROCALCITONIN/ |
| 72 | (pro?calcitonin\$ or calcitonin\$ or PCT).ti,ab. |
| 73 | or/71-72 |
| 74 | C REACTIVE PROTEIN/ |
| 75 | ((c reactive or c?reactive) adj1 protein\$).ti,ab. |
| 76 | CRP.ti,ab. |
| 77 | or/74-76 |
| 78 | or/73,77 |
| 79 | and/70,78 |
| 80 | limit 79 to english language |
| 81 | conference abstract.pt. |
| 82 | letter.pt. or LETTER/ |
| 83 | note.pt. |
| 84 | editorial.pt. |
| 85 | CASE REPORT/ or CASE STUDY/ |
| 86 | (letter or comment* or abstracts).ti. |
| 87 | or/81-86 |
| 88 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 89 | 87 not 88 |
| 90 | ANIMAL/ not HUMAN/ |
| 91 | NONHUMAN/ |
| _ | |

| 92 | exp ANIMAL EXPERIMENT/ |
|----|------------------------------------|
| 93 | exp EXPERIMENTAL ANIMAL/ |
| 94 | ANIMAL MODEL/ |
| 95 | exp RODENT/ |
| 96 | (rat or rats or mouse or mice).ti. |
| 97 | or/89-96 |
| 98 | 80 not 97 |
| 99 | and/17,98 |

Chapter 8

Response to antipyretic medication

Review question

What is the predictive value of the clinical response to paracetamol or NSAIDs?

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

9.3 Physical and drug interventions

Review question

Effect on fever and associated symptoms of treatment with:

- Paracetamol alone or NSAIDs alone, compared with placebo and with one another
- Alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- Paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone.

Collated search strategies for the above review questions on antipyretic interventions

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q3-5_antipyretics_post-2006_medline_rerun2_011012

| _ | | |
|----|---|--|
| # | Searches | |
| 1 | exp INFANT/ | |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. | |
| 3 | exp CHILD/ | |
| 4 | (child\$ or toddler\$).ti,ab. | |
| 5 | or/1-4 | |
| 6 | exp FEVER/ | |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. | |
| 8 | or/6-7 | |
| 9 | exp ANTIPYRETICS/ | |
| 10 | (anti pyretic? or anti?pyretic?).ti,ab. | |
| 11 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ | |
| 12 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. | |
| 13 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or | |

| | anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
|----|--|
| 14 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 15 | ACETAMINOPHEN/ |
| 16 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 17 | IBUPROFEN/ |
| 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 19 | or/9-18 |
| 20 | and/5,8,19 |
| 21 | limit 20 to english language |
| 22 | LETTER/ |
| 23 | EDITORIAL/ |
| 24 | NEWS/ |
| 25 | exp HISTORICAL ARTICLE/ |
| 26 | ANECDOTES AS TOPIC/ |
| 27 | COMMENT/ |
| 28 | CASE REPORT/ |
| 29 | (letter or comment* or abstracts).ti. |
| 30 | or/22-29 |
| 31 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 32 | 30 not 31 |
| 33 | ANIMALS/ not HUMANS/ |
| 34 | exp ANIMALS, LABORATORY/ |
| 35 | exp ANIMAL EXPERIMENTATION/ |
| 36 | exp MODELS, ANIMAL/ |
| 37 | exp RODENTIA/ |
| 38 | (rat or rats or mouse or mice).ti. |
| 39 | or/32-38 |
| 40 | 21 not 39 |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_Q3-5_antipyretics_post-2006_mip_rerun2_011012

| # | Searches |
|-----|--|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 5 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 6 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| - X | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 9 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 10 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 11 | or/5-10 |
| 12 | and/3-4,11 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q3-5_antipyretics_post-2006_cctr_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/6-7 |
| 9 | exp ANTIPYRETICS/ |
| 10 | (anti pyretic? or anti?pyretic?).ti,ab. |

| 11 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ | 12 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. | 13 | (((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. | 15 | ACETAMINOPHEN/ | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. | 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. | 20 | and/5,8,19 |

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_Q3-5_antipyretics_post-2006_cdsrdare_rerun2_011012

| # | Searches |
|----|--|
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | FEVER.kw. |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw,tx. |
| 8 | or/6-7 |
| 9 | ANTIPYRETICS.kw. |
| 10 | (anti pyretic? or anti?pyretic?).tw,tx. |
| 11 | ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL.kw. |
| | (NSAID? or NAID? or NSAIA? or NSAIM?).tw,tx. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw,tx. |
| 14 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw,tx. |

| 15 | ACETAMINOPHEN.kw. |
|----|--|
| 16 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).tw,tx. |
| | IBUPROFEN.kw. |
| 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).tw,tx. |
| 19 | or/9-18 |
| 20 | and/5,8,19 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012 FICu Q3-5 antipyretics post-2006 hta rerun2 011012

| ГΙ | Cu_Q3-5_antipyretics_post-2006_nta_rerun2_011012 |
|----|---|
| # | Searches |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 8 | or/6-7 |
| 9 | exp ANALGESICS, NON-NARCOTIC/ |
| 10 | (anti pyretic? or anti?pyretic?).tw. |
| 11 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| | (NSAID? or NAID? or NSAIA? or NSAIM?).tw. |
| 13 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 14 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 15 | ACETAMINOPHEN/ |
| 16 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).tw. |
| 17 | IBUPROFEN/ |
| 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).tw. |
| 19 | or/9-18 |

20 and/5,8,19

Database(s): Embase 1980 to 2012 Week 39

FICu_Q3-5_antipyretics_post-2006_embase_rerun2_011012

| # | Searches |
|----|--|
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | FEVER/ |
| 5 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 6 | PYREXIA IDIOPATHICA/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 8 | or/4-7 |
| 9 | ANTIPYRETIC AGENT/ |
| 10 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 11 | exp NONSTEROID ANTIINFLAMMATORY AGENT/ |
| 12 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| 13 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 14 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 15 | PARACETAMOL/ |
| 16 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| | IBUPROFEN/ |
| 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 19 | or/9-18 |
| 20 | and/3,8,19 |
| 21 | limit 20 to english language |
| 22 | conference abstract.pt. |
| 23 | letter.pt. or LETTER/ |
| 24 | note.pt. |
| 25 | editorial.pt. |

| 26 | CASE REPORT/ or CASE STUDY/ |
|----|--|
| 27 | (letter or comment* or abstracts).ti. |
| 28 | or/22-27 |
| 29 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 30 | 28 not 29 |
| 31 | ANIMAL/ not HUMAN/ |
| 32 | NONHUMAN/ |
| 33 | exp ANIMAL EXPERIMENT/ |
| 34 | exp EXPERIMENTAL ANIMAL/ |
| 35 | ANIMAL MODEL/ |
| 36 | exp RODENT/ |
| 37 | (rat or rats or mouse or mice).ti. |
| 38 | or/30-37 |
| 39 | 21 not 38 |

Collated search strategies on antipyretic intervention: health economics

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_Q3-5_antipyretics_economic_medline_rerun2_011012

| # | Searches |
|----|--------------------------------|
| 1 | ECONOMICS/ |
| 2 | VALUE OF LIFE/ |
| 3 | exp "COSTS AND COST ANALYSIS"/ |
| 4 | exp ECONOMICS, HOSPITAL/ |
| 5 | exp ECONOMICS, MEDICAL/ |
| 6 | exp RESOURCE ALLOCATION/ |
| 7 | ECONOMICS, NURSING/ |
| 8 | ECONOMICS, PHARMACEUTICAL/ |
| 9 | exp "FEES AND CHARGES"/ |
| 10 | exp BUDGETS/ |
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |

| 13 | (economic* or pharmaco?economic*).ti,ab. |
|----|--|
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value adj2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | or/1-20 |
| 22 | exp INFANT/ |
| 23 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 24 | exp CHILD/ |
| 25 | (child\$ or toddler\$).ti,ab. |
| 26 | or/22-25 |
| 27 | exp FEVER/ |
| 28 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 29 | or/27-28 |
| 30 | exp ANTIPYRETICS/ |
| 31 | (anti pyretic? or anti?pyretic?).ti,ab. |
| | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| 33 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| 34 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 35 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 36 | ACETAMINOPHEN/ |
| 37 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| | IBUPROFEN/ |
| 39 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 40 | or/30-39 |
| 41 | and/26,29,40 |
| | |

| 42 | LETTER/ |
|----|--|
| | |
| 43 | EDITORIAL/ |
| 44 | NEWS/ |
| 45 | exp HISTORICAL ARTICLE/ |
| 46 | ANECDOTES AS TOPIC/ |
| 47 | COMMENT/ |
| 48 | CASE REPORT/ |
| 49 | (letter or comment* or abstracts).ti. |
| 50 | or/42-49 |
| 51 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 52 | 50 not 51 |
| 53 | ANIMALS/ not HUMANS/ |
| 54 | exp ANIMALS, LABORATORY/ |
| 55 | exp ANIMAL EXPERIMENTATION/ |
| 56 | exp MODELS, ANIMAL/ |
| 57 | exp RODENTIA/ |
| 58 | (rat or rats or mouse or mice).ti. |
| 59 | or/52-58 |
| 60 | 41 not 59 |
| 61 | limit 60 to english language |
| 62 | and/21,61 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_Q3-5_antipyretics_economic_cctr_rerun2_011012

| # | Searches |
|---|--------------------------------|
| 1 | ECONOMICS/ |
| 2 | VALUE OF LIFE/ |
| 3 | exp "COSTS AND COST ANALYSIS"/ |
| 4 | exp ECONOMICS, HOSPITAL/ |
| 5 | exp ECONOMICS, MEDICAL/ |
| 6 | exp RESOURCE ALLOCATION/ |

| 7 | ECONOMICS, NURSING/ |
|----|--|
| | |
| 8 | ECONOMICS, PHARMACEUTICAL/ |
| 9 | exp "FEES AND CHARGES"/ |
| 10 | exp BUDGETS/ |
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |
| 13 | (economic* or pharmaco?economic*).ti,ab. |
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value adj2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | or/1-20 |
| 22 | exp INFANT/ |
| 23 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 24 | exp CHILD/ |
| 25 | (child\$ or toddler\$).ti,ab. |
| 26 | or/22-25 |
| 27 | exp FEVER/ |
| 28 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 29 | or/27-28 |
| 30 | exp ANTIPYRETICS/ |
| 31 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 32 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| 33 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| 34 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 35 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 36 | ACETAMINOPHEN/ |

| 37 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
|----|--|
| | IBUPROFEN/ |
| 39 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 40 | or/30-39 |
| 41 | and/26,29,40 |
| 42 | and/21,41 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012, EBM Reviews - NHS Economic Evaluation Database 3rd Quarter 2012

FICu_Q3-5_antipyretics_economic_htanhseed_rerun2_011012

| | ou_qo-o_antipyretico_economic_ntamiseed_refunz_offorz |
|----|---|
| # | Searches |
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | exp FEVER/ |
| 7 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).tw. |
| 8 | or/6-7 |
| 9 | exp ANTIPYRETICS/ |
| 10 | (anti pyretic? or anti?pyretic?).tw. |
| 11 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| | (NSAID? or NAID? or NSAIA? or NSAIM?).tw. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 14 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 15 | ACETAMINOPHEN/ |
| 16 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).tw. |
| 17 | IBUPROFEN/ |
| 18 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).tw. |

| 19 | or/9-18 |
|----|------------|
| 20 | and/5,8,19 |

Database(s): Embase 1980 to 2012 Week 39

FICu_Q3-5_antipyretics_economic_embase_rerun2_011012

| # | Searches |
|----|---|
| 1 | HEALTH ECONOMICS/ |
| 2 | exp ECONOMIC EVALUATION/ |
| 3 | exp HEALTH CARE COST/ |
| 4 | exp FEE/ |
| 5 | BUDGET/ |
| 6 | FUNDING/ |
| 7 | RESOURCE ALLOCATION/ |
| 8 | budget*.ti,ab. |
| 9 | cost*.ti,ab. |
| 10 | (economic* or pharmaco?economic*).ti,ab. |
| 11 | (price* or pricing*).ti,ab. |
| 12 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 13 | (value adj2 (money or monetary)).ti,ab. |
| 14 | resourc* allocat*.ti,ab. |
| 15 | (fund or funds or funding* or funded).ti,ab. |
| 16 | (ration or rations or rationing* or rationed).ti,ab. |
| 17 | or/1-16 |
| 18 | exp CHILD/ |
| 19 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 20 | or/18-19 |
| 21 | FEVER/ |
| 22 | HYPERTHERMIA/ or HYPERPYREXIA/ |
| 23 | PYREXIA IDIOPATHICA/ |
| 24 | (fever\$ or febri\$ or hyper therm\$ or hyper?therm\$ or pyrex\$ or hyper?pyrex\$ or temperature?).ti,ab. |
| 25 | or/21-24 |
| 26 | ANTIPYRETIC AGENT/ |

| _ | |
|----------|--|
| 27 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 28 | exp NONSTEROID ANTIINFLAMMATORY AGENT/ |
| 29 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 31 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 32 | PARACETAMOL/ |
| 33 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 34 | IBUPROFEN/ |
| 35 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 36 | or/26-35 |
| 37 | and/20,25,36 |
| 38 | conference abstract.pt. |
| 39 | letter.pt. or LETTER/ |
| 40 | note.pt. |
| 41 | editorial.pt. |
| 42 | CASE REPORT/ or CASE STUDY/ |
| 43 | (letter or comment* or abstracts).ti. |
| 44 | or/38-43 |
| 45 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 46 | 44 not 45 |
| 47 | ANIMAL/ not HUMAN/ |
| 48 | NONHUMAN/ |
| 49 | exp ANIMAL EXPERIMENT/ |
| 50 | exp EXPERIMENTAL ANIMAL/ |
| 51 | ANIMAL MODEL/ |
| 52 | exp RODENT/ |
| 53 | (rat or rats or mouse or mice).ti. |
| 54 | or/46-53 |
| 55 | 37 not 54 |
| <u> </u> | |

56 and/17,55

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

Database(s): Ovid MEDLINE(R) 1946 to September Week 3 2012

FICu_antipyretics_masking_medline_rerun2_011012

| # Searches exp INFANT/ | _ | |
|--|----|---|
| cinfan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. | # | Searches |
| a exp CHILD/ (child\$ or toddler\$).ti,ab. or/1-4 *INFECTION/ or *COMMUNICABLE DISEASES/ VIRUS DISEASES/ exp BACTERIAL INFECTIONS/ CRITICAL ILLNESS/ or ACUTE DISEASE/ ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) at (infect\$ adj disease?)).ti,ab. (infect\$ adj disease?).ti. or/6-11 sexp MENINGITIS, BACTERIAL/ MENINGOENCEPHALITIS/ mening\$.ti,ab. or/13-15 resp BACTEREMIA/ (sepsis or septic?emi\$).ti,ab. observed sexp BACTEREMIA/ (sepsis or septic?emi\$).ti,ab. | 1 | exp INFANT/ |
| 4 (child\$ or toddler\$).ti,ab. 5 or/1-4 6 'INFECTION/ or "COMMUNICABLE DISEASES/ 7 VIRUS DISEASES/ 8 exp BACTERIAL INFECTIONS/ 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) ac (infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 5 or/1-4 6 *INFECTION/ or *COMMUNICABLE DISEASES/ 7 VIRUS DISEASES/ 8 exp BACTERIAL INFECTIONS/ 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) ac ((infect\$ aci j disease?)).ti,ab. 11 (infect\$ aci j disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. | 3 | exp CHILD/ |
| 6 "INFECTION/ or "COMMUNICABLE DISEASES/ 7 VIRUS DISEASES/ 8 exp BACTERIAL INFECTIONS/ 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) at (infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. | 4 | (child\$ or toddler\$).ti,ab. |
| 7 VIRUS DISEASES/ 8 exp BACTERIAL INFECTIONS/ 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) ac (infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. | 5 | or/1-4 |
| 8 exp BACTERIAL INFECTIONS/ 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) ac (infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 6 | *INFECTION/ or *COMMUNICABLE DISEASES/ |
| 9 CRITICAL ILLNESS/ or ACUTE DISEASE/ 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) acute\$) acute\$ (infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 7 | VIRUS DISEASES/ |
| 10 ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) ac ((infect\$ or ill\$ or disease?).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 8 | exp BACTERIAL INFECTIONS/ |
| [(Infect\$ or ill\$ or disease?)).ti,ab. 11 (infect\$ adj disease?).ti. 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | | |
| 12 or/6-11 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 10 | ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 13 exp MENINGITIS, BACTERIAL/ 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 11 | (infect\$ adj disease?).ti. |
| 14 MENINGOENCEPHALITIS/ 15 mening\$.ti,ab. 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. | 12 | or/6-11 |
| 15 mening\$.ti,ab. | 13 | exp MENINGITIS, BACTERIAL/ |
| 16 or/13-15 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. | 14 | MENINGOENCEPHALITIS/ |
| 17 SEPSIS/ 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 15 | mening\$.ti,ab. |
| 18 exp BACTEREMIA/ 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 16 | or/13-15 |
| 19 (sepsis or septic?emi\$).ti,ab. 20 bacter?emi\$.ti,ab. 21 or/17-20 | 17 | SEPSIS/ |
| 20 bacter?emi\$.ti,ab. 21 or/17-20 | 18 | exp BACTEREMIA/ |
| 21 or/17-20 | 19 | (sepsis or septic?emi\$).ti,ab. |
| | 20 | bacter?emi\$.ti,ab. |
| 22 exp PNEUMONIA/ | 21 | or/17-20 |
| | 22 | exp PNEUMONIA/ |

| _ | |
|----|--|
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.ti,ab. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp ANTIPYRETICS/ |
| | |

| 54 | (anti pyretic? or anti?pyretic?).ti,ab. |
|----|--|
| 55 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| 56 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 58 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 59 | ACETAMINOPHEN/ |
| 60 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 61 | IBUPROFEN/ |
| 62 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 63 | or/53-62 |
| 64 | and/5,52,63 |
| 65 | limit 64 to english language |
| 66 | LETTER/ |
| 67 | EDITORIAL/ |
| 68 | NEWS/ |
| 69 | exp HISTORICAL ARTICLE/ |
| 70 | ANECDOTES AS TOPIC/ |
| 71 | COMMENT/ |
| 72 | CASE REPORT/ |
| 73 | (letter or comment* or abstracts).ti. |
| 74 | or/66-73 |
| 75 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 76 | 74 not 75 |
| 77 | ANIMALS/ not HUMANS/ |
| 78 | exp ANIMALS, LABORATORY/ |
| 79 | exp ANIMAL EXPERIMENTATION/ |
| 80 | exp MODELS, ANIMAL/ |
| 81 | exp RODENTIA/ |
| 82 | (rat or rats or mouse or mice).ti. |

| 83 | or/76-82 |
|----|-----------|
| 84 | 65 not 83 |

Database(s): Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations September 28, 2012

FICu_antipyretics_masking_mip_rerun2_011012

| # | Searches |
|----|---|
| 1 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 2 | (child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 5 | (infect\$ adj disease?).ti. |
| 6 | mening\$.ti,ab. |
| 7 | (sepsis or septic?emi\$).ti,ab. |
| 8 | bacter?emi\$.ti,ab. |
| 9 | pneumon\$.ti,ab. |
| 10 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 11 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 12 | py?arth\$.ti,ab. |
| 13 | osteomyelit\$.ti,ab. |
| 14 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 15 | ((upper or lower) adj5 urin\$).ti,ab. |
| 16 | UTI.ti,ab. |
| 17 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 18 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 19 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 20 | MCLS.ti,ab. |
| 21 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 22 | pyrogen\$.ti,ab. |
| 23 | or/4-22 |
| 24 | (anti pyretic? or anti?pyretic?).ti,ab. |

| 25 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
|----|--|
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 21 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 29 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 30 | or/24-29 |
| 31 | and/3,23,30 |

Database(s): EBM Reviews - Cochrane Central Register of Controlled Trials September 2012

FICu_antipyretics_masking_cctr_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp INFANT/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).ti,ab. |
| 3 | exp CHILD/ |
| 4 | (child\$ or toddler\$).ti,ab. |
| 5 | or/1-4 |
| 6 | *INFECTION/ or *COMMUNICABLE DISEASES/ |
| 7 | VIRUS DISEASES/ |
| 8 | exp BACTERIAL INFECTIONS/ |
| 9 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 10 | ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 11 | (infect\$ adj disease?).ti. |
| 12 | or/6-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.ti,ab. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |

| 19 | (sepsis or septic?emi\$).ti,ab. |
|----|--|
| 20 | bacter?emi\$.ti,ab. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.ti,ab. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 30 | py?arth\$.ti,ab. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.ti,ab. |
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 37 | ((upper or lower) adj5 urin\$).ti,ab. |
| 38 | UTI.ti,ab. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 46 | MCLS.ti,ab. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| | |

| 50 | pyrogen\$.ti,ab. |
|--------|--|
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp ANTIPYRETICS/ |
| 54 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 55 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| 56 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| II ^ I | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 58 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| | ACETAMINOPHEN/ |
| 60 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| | IBUPROFEN/ |
| 62 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 63 | or/53-62 |
| 64 | and/5,52,63 |

Database(s): EBM Reviews - Cochrane Database of Systematic Reviews 2005 to September 2012, EBM Reviews - Database of Abstracts of Reviews of Effects 3rd Quarter 2012

FICu_antipyretics_masking_cdsrdare_rerun2_011012

| # | Searches |
|----|---|
| 1 | INFANT.kw. |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw,tx. |
| 3 | CHILD.kw. |
| 4 | (child\$ or toddler\$).tw,tx. |
| 5 | or/1-4 |
| 6 | (INFECTION or COMMUNICABLE DISEASES).kw. |
| 7 | VIRUS DISEASES.kw. |
| 8 | BACTERIAL INFECTIONS.kw. |
| 9 | (CRITICAL ILLNESS or ACUTE DISEASE).kw. |
| 10 | ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj |

| | (infect\$ or ill\$ or disease?)).tw,tx. |
|----|--|
| 11 | (infect\$ adj disease?).ti. |
| 12 | or/6-11 |
| 13 | MENINGITIS, BACTERIAL.kw. |
| 14 | MENINGOENCEPHALITIS.kw. |
| 15 | mening\$.tw,tx. |
| 16 | or/13-15 |
| 17 | SEPSIS.kw. |
| 18 | BACTEREMIA.kw. |
| 19 | (sepsis or septic?emi\$).tw,tx. |
| 20 | bacter?emi\$.tw,tx. |
| 21 | or/17-20 |
| 22 | PNEUMONIA.kw. |
| 23 | pneumon\$.tw,tx. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX.kw. |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw,tx. |
| 27 | or/25-26 |
| 28 | ARTHRITIS, INFECTIOUS.kw. |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw,tx. |
| 30 | py?arth\$.tw,tx. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS.kw. |
| 33 | osteomyelit\$.tw,tx. |
| 34 | or/32-33 |
| 35 | URINARY TRACT INFECTIONS.kw. |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw,tx. |
| 37 | ((upper or lower) adj5 urin\$).tw,tx. |
| 38 | UTI.tw,tx. |
| 39 | CYSTITIS.kw. |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw,tx. |
| | |

| 41 | PYELONEPHRITIS.kw. |
|------|--|
| 42 | (pyelonephr\$ or pyonephr\$).tw,tx. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME.kw. |
| 45 | (mucocutaneous adj3 lymph\$).tw,tx. |
| 46 | MCLS.tw,tx. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw,tx. |
| 48 | or/44-47 |
| 49 | PYROGENS.kw. |
| 50 | pyrogen\$.tw,tx. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | ANTIPYRETICS.kw. |
| 54 | (anti pyretic? or anti?pyretic?).tw,tx. |
| 55 | ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL.kw. |
| 56 | (NSAID? or NAID? or NSAIA? or NSAIM?).tw,tx. |
| | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw,tx. |
| ארוו | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw,tx. |
| 59 | ACETAMINOPHEN.kw. |
| 60 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).tw,tx. |
| 61 | IBUPROFEN.kw. |
| 62 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).tw,tx. |
| 63 | or/53-62 |
| 64 | and/5,52,63 |

Database(s): EBM Reviews - Health Technology Assessment 3rd Quarter 2012

FICu_antipyretics_masking_hta_rerun2_011012

| # | ŧ | Searches |
|---|---|--|
| 1 | | exp INFANT/ |
| 2 | 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies).tw. |

| 3 | exp CHILD/ |
|----|--|
| 4 | (child\$ or toddler\$).tw. |
| 5 | or/1-4 |
| 6 | INFECTION/ or COMMUNICABLE DISEASES/ |
| 7 | VIRUS DISEASES/ |
| 8 | exp BACTERIAL INFECTIONS/ |
| 9 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 10 | ((bacteri\$ or virus or viral or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).tw. |
| 11 | (infect\$ adj disease?).ti. |
| 12 | or/6-11 |
| 13 | exp MENINGITIS, BACTERIAL/ |
| 14 | MENINGOENCEPHALITIS/ |
| 15 | mening\$.tw. |
| 16 | or/13-15 |
| 17 | SEPSIS/ |
| 18 | exp BACTEREMIA/ |
| 19 | (sepsis or septic?emi\$).tw. |
| 20 | bacter?emi\$.tw. |
| 21 | or/17-20 |
| 22 | exp PNEUMONIA/ |
| 23 | pneumon\$.tw. |
| 24 | or/22-23 |
| 25 | ENCEPHALITIS, HERPES SIMPLEX/ |
| 26 | (encephalit\$ adj5 (herpe\$ or HSV)).tw. |
| 27 | or/25-26 |
| 28 | exp ARTHRITIS, INFECTIOUS/ |
| 29 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).tw. |
| 30 | py?arth\$.tw. |
| 31 | or/28-30 |
| 32 | OSTEOMYELITIS/ |
| 33 | osteomyelit\$.tw. |

| _ | |
|----|---|
| 34 | or/32-33 |
| 35 | exp URINARY TRACT INFECTIONS/ |
| 36 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).tw. |
| 37 | ((upper or lower) adj5 urin\$).tw. |
| 38 | UTI.tw. |
| 39 | exp CYSTITIS/ |
| 40 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).tw. |
| 41 | exp PYELONEPHRITIS/ |
| 42 | (pyelonephr\$ or pyonephr\$).tw. |
| 43 | or/35-42 |
| 44 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 45 | (mucocutaneous adj3 lymph\$).tw. |
| 46 | MCLS.tw. |
| 47 | (kawasaki\$ adj (disease? or syndrome?)).tw. |
| 48 | or/44-47 |
| 49 | exp PYROGENS/ |
| 50 | pyrogen\$.tw. |
| 51 | or/49-50 |
| 52 | or/12,16,21,24,27,31,34,43,48,51 |
| 53 | exp ANALGESICS, NON-NARCOTIC/ |
| 54 | (anti pyretic? or anti?pyretic?).tw. |
| 55 | exp ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ |
| 56 | (NSAID? or NAID? or NSAIA? or NSAIM?).tw. |
| 57 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 58 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).tw. |
| 59 | ACETAMINOPHEN/ |
| 60 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).tw. |
| 61 | IBUPROFEN/ |
| 62 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or |

| | orbifen or fenbid).tw. |
|----|------------------------|
| 63 | or/53-62 |
| 64 | and/5,52,63 |

Database(s): Embase 1980 to 2012 Week 39

FICu_antipyretics_masking_embase_rerun2_011012

| # | Searches |
|----|---|
| 1 | exp CHILD/ |
| 2 | (infan\$ or neonat\$ or newborn\$ or baby or babies or child\$ or toddler\$).ti,ab. |
| 3 | or/1-2 |
| 4 | *INFECTION/ or *COMMUNICABLE DISEASE/ |
| 5 | VIRAL INFECTION/ |
| 6 | exp BACTERIAL INFECTION/ |
| 7 | CRITICAL ILLNESS/ or ACUTE DISEASE/ |
| 8 | ((bacteri\$ or viral or virus or streptococc\$ or staphylococc\$ or serious\$ or severe\$ or critical\$ or acute\$) adj (infect\$ or ill\$ or disease?)).ti,ab. |
| 9 | (infect\$ adj disease?).ti. |
| 10 | or/4-9 |
| 11 | BACTERIAL MENINGITIS/ |
| 12 | MENINGOENCEPHALITIS/ |
| 13 | mening\$.ti,ab. |
| 14 | or/11-13 |
| 15 | SEPTICEMIA/ |
| 16 | exp BACTEREMIA/ |
| 17 | (sepsis or septic?emi\$).ti,ab. |
| 18 | bacter?emi\$.ti,ab. |
| 19 | or/15-18 |
| 20 | exp PNEUMONIA/ |
| 21 | pneumon\$.ti,ab. |
| 22 | or/20-21 |
| 23 | HERPES SIMPLEX ENCEPHALITIS/ |
| 24 | (encephalit\$ adj5 (herpe\$ or HSV)).ti,ab. |

| 25 | or/23-24 |
|----|--|
| 26 | exp INFECTIOUS ARTHRITIS/ |
| 27 | (arthrit\$ adj3 (bacteri\$ or septic\$ or infect\$ or suppurat\$ or purulen\$ or pyogen\$)).ti,ab. |
| 28 | py?arth\$.ti,ab. |
| 29 | or/26-28 |
| 30 | exp OSTEOMYELITIS/ |
| 31 | osteomyelit\$.ti,ab. |
| 32 | or/30-31 |
| 33 | exp URINARY TRACT INFECTION/ |
| 34 | ((urin\$ or bladder\$ or genito?urin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urolog\$ or uro gen\$ or uro?gen\$) adj5 infect\$).ti,ab. |
| 35 | ((upper or lower) adj5 urin\$).ti,ab. |
| 36 | UTI.ti,ab. |
| 37 | exp CYSTITIS/ |
| 38 | (cystit\$ or pyocystit\$ or pyelocystit\$ or cystopyelit\$).ti,ab. |
| 39 | exp PYELONEPHRITIS/ |
| 40 | (pyelonephr\$ or pyonephr\$).ti,ab. |
| 41 | or/33-40 |
| 42 | MUCOCUTANEOUS LYMPH NODE SYNDROME/ |
| 43 | (mucocutaneous adj3 lymph\$).ti,ab. |
| 44 | MCLS.ti,ab. |
| 45 | (kawasaki\$ adj (disease? or syndrome?)).ti,ab. |
| 46 | or/42-45 |
| 47 | exp PYROGEN/ |
| 48 | pyrogen\$.ti,ab. |
| 49 | or/47-48 |
| 50 | or/10,14,19,22,25,29,32,41,46,49 |
| 51 | ANTIPYRETIC AGENT/ |
| 52 | (anti pyretic? or anti?pyretic?).ti,ab. |
| 53 | exp NONSTEROID ANTIINFLAMMATORY AGENT/ |
| 54 | (NSAID? or NAID? or NSAIA? or NSAIM?).ti,ab. |
| 55 | ((non steroid\$ or non?steroid\$) adj3 (anti inflammatory or anti?inflammatory or anti rheumatic or |

| | anti?rheumatic) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
|----|--|
| 56 | ((aspirin like or aspirin?like or anti nocicept\$ or anti?nocicept\$) adj3 (agent? or ana?lgesi\$ or drug? or medicine?)).ti,ab. |
| 57 | PARACETAMOL/ |
| 58 | (paracetamol or acetaminophen or alvedon or anadin or calpol or perfalgan or disprol or medinol or hedex or panadol or parapaed or tylenol).ti,ab. |
| 59 | IBUPROFEN/ |
| 60 | (ibuprofen or brufen or calprofen or cuprofen or arthrofen or ebufac or rimafen or feverfen or nurofen or orbifen or fenbid).ti,ab. |
| 61 | or/51-60 |
| 62 | and/3,50,61 |
| 63 | limit 62 to english language |
| 64 | conference abstract.pt. |
| 65 | letter.pt. or LETTER/ |
| 66 | note.pt. |
| 67 | editorial.pt. |
| 68 | CASE REPORT/ or CASE STUDY/ |
| 69 | (letter or comment* or abstracts).ti. |
| 70 | or/64-69 |
| 71 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 72 | 70 not 71 |
| 73 | ANIMAL/ not HUMAN/ |
| 74 | NONHUMAN/ |
| 75 | exp ANIMAL EXPERIMENT/ |
| 76 | exp EXPERIMENTAL ANIMAL/ |
| 77 | ANIMAL MODEL/ |
| 78 | exp RODENT/ |
| 79 | (rat or rats or mouse or mice).ti. |
| 80 | or/72-79 |
| 81 | 63 not 80 |
| | |

2007 Search strategies

FEVER_bacterial_causes_medline_261005

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. exp BACTERIAL INFECTIONS/
- 31. exp BACTERIA/
- 32. bacteri\$.tw.
- 33. eubacteri\$.tw.
- 34. bacillacea\$.tw.
- 35. or/30-34
- 36. and/29,35
- 37. exp GREAT BRITAIN/

- 38. and/36-37
- 39. limit 38 to yr="1992 2005"

FEVER_bacterial_cause_embase_261005

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. exp BACTERIUM/
- 31. BACTERIAL STRAIN/
- 32. exp BACTERIAL INFECTION/
- 33. bacteri\$.tw.
- 34. eubacteri\$.tw.
- 35. bacillacea\$.tw.
- 36. or/30-35

- 37. and/29,36
- 38. UNITED KINGDOM/
- 39. and/37-38
- 40. limit 39 to yr="1992 2006"

FEVER_bacterial_cause_cinahl_261005

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. exp BACTERIAL INFECTIONS/
- 31. exp BACTERIA/
- 32. bacteri\$.tw.
- 33. eubacteri\$.tw.
- 34. bacillacea\$.tw.

- 35. or/30-34
- 36. and/29,35
- 37. exp GREAT BRITAIN/
- 38. and/36-37
- 39. limit 38 to yr="1992 2005"

FEVER_consultation_referral_medline_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/

- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.

- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. "REFERRAL AND CONSULTATION"/
- 82. refer\$.tw.
- 83. consult\$.tw.
- 84. or/81-83
- 85. "ATTITUDE TO HEALTH"/
- 86. DECISION MAKING/
- 87. "HEALTH KNOWLEDGE, ATTITUDES, PRACTICE"/
- 88. or/85-87
- 89. or/84-88
- 90. and/80,89
- 91. animal/ not (human/ or (human/ and animal/))
- 92. 90 not 91

FEVER_consultation_referral_embase_280206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.

- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.

- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. PATIENT REFERRAL/
- 84. refer\$.tw.
- 85. consult\$.tw.
- 86. or/83-85
- 87. ATTITUDE/
- 88. DECISION MAKING/
- 89. or/87-88
- 90. or/86,89
- 91. and/82,90
- 92. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))

93. 91 not 92

FEVER_consultation_referral_cinahl_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35

- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/

- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. "REFERRAL AND CONSULTATION"/
- 82. refer\$.tw.
- 83. consult\$.tw.
- 84. or/81-83
- 85. "ATTITUDE TO HEALTH"/
- 86. DECISION MAKING/
- 87. "HEALTH KNOWLEDGE, ATTITUDES, PRACTICE"/
- 88. or/85-87
- 89. or/84,88
- 90. and/80,89

FEVER_diagnosis_capillary_refill_medline_240406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/

- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.

- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp MICROCIRCULATION/
- 69. CAPILLARIES/
- 70. capillar\$.tw.
- 71. or/68-70
- 72. exp "SENSITIVITY AND SPECIFICITY"/
- 73. (sensitivity or specificity).tw.
- 74. (predictive adj value\$).tw.
- 75. LIKELIHOOD FUNCTIONS/
- 76. (likelihood adj (estimate\$ or ratio\$)).tw.
- 77. exp DIAGNOSTIC ERRORS/
- 78. (false adj (negative\$ or positive\$)).tw.
- 79. "REPRODUCIBILITY OF RESULTS"/
- 80. DIAGNOSIS, DIFFERENTIAL/
- 81. (differential adj diagnos\$).tw.
- 82. or/72-81
- 83. and/17,67,71,82
- 84. animal/ not (human/ or (human/ and animal/))
- 85. 83 not 84

FEVER diagnosis capillary refill embase 240406

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/

- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47
- 49. OSTEOMYELITIS/

- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.
- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/
- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. CAPILLARY FLOW/
- 71. capillar\$.tw.
- 72. or/70-71
- 73. exp "SENSITIVITY AND SPECIFICITY"/
- 74. (sensitivity or specificity).tw.
- 75. (predictive adj value\$).tw.
- 76. STATISTICAL MODEL/
- 77. (likelihood adj (estimate\$ or ratio\$)).tw.
- 78. DIAGNOSTIC ERROR/
- 79. (false adj (negative\$ or positive\$)).tw.
- 80. REPRODUCIBILITY/
- 81. DIFFERENTIAL DIAGNOSIS/
- 82. (differential adj diagnos\$).tw.
- 83. or/73-82
- 84. and/17,69,72,83
- 85. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 86. 84 not 85

FEVER_diagnosis_capillary_refill_cinahl_240406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.

- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. capillar\$.tw.
- 69. and/17,67-68

FEVER_diagnosis_health_economics_medline_100506

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, POSTMATURE/
- 4. ((postmature\$ or postterm\$ or post?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 5. INFANT, NEWBORN/

- 6. neonat\$.tw.
- 7. newborn\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. INFANT, SMALL FOR GESTATIONAL AGE/
- 11. (small adj2 gestational age).tw.
- 12. INFANT, LOW BIRTH WEIGHT/
- 13. INFANT, VERY LOW BIRTH WEIGHT/
- 14. (low adj birth adj weight).tw.
- 15. (low adj birth?weight).tw.
- 16. lbw.tw.
- 17. vlbw.tw.
- 18. (baby or babies).tw.
- 19. CHILD, PRESCHOOL/
- 20. toddler\$.tw.
- 21. exp CHILD/
- 22. child\$.tw.
- 23. ADOLESCENT/
- 24. adolescen\$.tw.
- 25. juvenile\$.tw.
- 26. youth\$.tw.
- 27. teen\$.tw.
- 28. PUBERTY/
- 29. pubert\$.tw.
- 30. pubesc\$.tw.
- 31. MINORS/
- 32. minors.tw.
- 33. or/1-32
- 34. BACTERIAL INFECTIONS/
- 35. (bacteri\$ adj infect\$).tw.
- 36. or/34-35
- 37. exp MENINGITIS, BACTERIAL/
- 38. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 39. meningococc\$.tw.
- 40. or/37-39
- 41. SEPTICEMIA/
- 42. septicemi\$.tw.
- 43. septicaemia\$.tw.

- 44. or/41-43
- 45. BACTEREMIA/
- 46. bacteremi\$.tw.
- 47. bacteraemia\$.tw.
- 48. or/45-47
- 49. exp PNEUMONIA/
- 50. pneumoni\$.tw.
- 51. or/49-50
- 52. HERPES SIMPLEX/
- 53. herpes simplex.tw.
- 54. or/52-53
- 55. exp ARTHRITIS, INFECTIOUS/
- 56. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 57. pyarthrosis.tw.
- 58. pyoarthritis.tw.
- 59. or/55-58
- 60. STAPHYLOCOCCAL INFECTIONS/
- 61. STREPTOCOCCAL INFECTIONS/
- 62. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 63. or/60-62
- 64. OSTEOMYELITIS/
- 65. osteomyeliti\$.tw.
- 66. or/64-65
- 67. exp URINARY TRACT INFECTIONS/
- 68. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 69. UTI.tw.
- 70. ((upper or lower) adj5 urin\$).tw.
- 71. exp CYSTITIS/
- 72. cystitis\$.tw.
- 73. PYELONEPHRITIS/
- 74. pyelonephriti\$.tw.
- 75. pyonephrosi\$.tw.
- 76. pyelocystiti\$.tw.
- 77. or/67-76
- 78. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 79. (mucocutaneous adj2 lymph\$).tw.
- 80. mcls.tw.
- 81. (kawasaki adj (disease or syndrome)).tw.

- 82. or/78-81
- 83. or/36,40,44,48,51,54,59,63,66,77,82
- 84. HEMATOLOGIC TESTS/
- 85. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 86. or/84-85
- 87. exp BLOOD CELL COUNT/
- 88. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 89. leu?ocyte\$.tw.
- 90. or/87-89
- 91. BLOOD SEDIMENTATION/
- 92. ((blood or erythrocyte) adj sedimentation).tw.
- 93. or/91-92
- 94. C-REACTIVE PROTEIN/
- 95. c reactive protein\$.tw.
- 96. CRP.tw.
- 97. or/94-96
- 98. CALCITONIN/
- 99. calcitoni\$.tw.
- 100. PROTEIN PRECURSORS/
- 101. procalcitonin.tw.
- 102. or/98-101
- 103. DIAGNOSTIC TECHNIQUES, UROLOGICAL/
- 104. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 105. or/103-104
- 106. URINALYSIS/
- 107. ((urine or urinary) adj2 (analys\$ or test\$)).tw.
- 108. or/106-107
- 109. REAGENT KITS, DIAGNOSTIC/
- 110. REAGENT STRIPS/
- 111. "INDICATORS AND REAGENTS"/
- 112. (reagent\$ adj (kit\$ or strip\$)).tw.
- 113. (dipstick\$ or dip?stick\$).tw.
- 114. or/109-113
- 115. exp MICROSCOPY/
- 116. microscopy\$.tw.
- 117. (dipslide\$ or dip?slide\$).tw.
- 118. or/115-117
- 119. SPINAL PUNCTURE/
- 120. ((lumbar or spinal) adj puncture\$).tw.

- 121. CEREBROSPINAL FLUID/
- 122. cerebrospinal fluid.tw.
- 123. or/119-122
- 124. X-RAYS/
- 125. x ray\$.tw.
- 126. or/124-125
- 127. exp MICROCIRCULATION/
- 128. CAPILLARIES/
- 129. capillar\$.tw.
- 130. or/127-129
- 131. exp OXIMETRY/
- 132. pulse oximetry.tw.
- 133. or/131-132
- 134. BLOOD GLUCOSE/
- 135. blood glucose.tw.
- 136. or/134-135
- 137. RADIOGRAPHY, THORACIC/
- 138. ((chest or thoracic) adj2 radiograph\$).tw.
- 139. or/137-138
- 140. X-RAYS/
- 141. x ray\$.tw.
- 142. or/140-141
- 143. or/86,90,93,97,102,105,108,114,118,123,126,130,133,136,139,142
- 144. ECONOMICS/
- 145. "COSTS AND COST ANALYSIS"/
- 146. COST ALLOCATION/
- 147. COST-BENEFIT ANALYSIS/
- 148. COST CONTROL/
- 149. COST SAVINGS/
- 150. COST OF ILLNESS/
- 151. COST SHARING/
- 152. HEALTH CARE COSTS/
- 153. DIRECT SERVICE COSTS/
- 154. DRUG COSTS/
- 155. EMPLOYER HEALTH COSTS/
- 156. HOSPITAL COSTS/
- 157. HEALTH RESOURCES/
- 158. "HEALTH SERVICES NEEDS AND DEMAND"/
- 159. HEALTH PRIORITIES/

- 160. HEALTH EXPENDITURES/
- 161. CAPITAL EXPENDITURES/
- 162. FINANCIAL MANAGEMENT/
- 163. FINANCIAL MANAGEMENT, HOSPITAL/
- 164. QUALITY-ADJUSTED LIFE YEARS/
- 165. "DEDUCTIBLES AND COINSURANCE"/
- 166. MEDICAL SAVINGS ACCOUNTS/
- 167. ECONOMICS, HOSPITAL/
- 168. ECONOMICS, MEDICAL/
- 169. ECONOMICS, NURSING/
- 170. ECONOMICS, PHARMACEUTICAL/
- 171. MODELS, ECONOMIC/
- 172. MODELS, ECONOMETRIC/
- 173. RESOURCE ALLOCATION/
- 174. HEALTH CARE RATIONING/
- 175. "FEES AND CHARGES"/
- 176. BUDGETS/
- 177. VALUE OF LIFE/
- 178. (financ\$ or fiscal\$ or funding).tw.
- 179. (QALY\$ or life?year\$).tw.
- 180. (econom\$ or cost\$).tw.
- 181. pharmacoeconomic\$.tw.
- 182. ec.fs.
- 183. or/144-182
- 184. and/33,83,143,183
- 185. animal/ not (human/ or (human/ and animal/))
- 186. 184 not 185

FEVER_diagnosis_health_economics_embase_100506

- 1. PREMATURITY/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. exp NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. NEWBORN PERIOD/
- 7. PERINATAL PERIOD/
- 8. perinatal\$.tw.
- 9. postnatal\$.tw.
- 10. exp INFANT/
- 11. INFANCY/

- 12. BABY/
- 13. infan\$.tw.
- 14. (baby or babies).tw.
- 15. SMALL FOR DATE INFANT/
- 16. (small adj2 (date or "gestational age")).tw.
- 17. lbw.tw.
- 18. vlbw.tw.
- 19. CHILD/
- 20. CHILDHOOD/
- 21. PRESCHOOL CHILD/
- 22. SCHOOL CHILD/
- 23. child\$.tw.
- 24. PREPUBERTY/
- 25. PUBERTY/
- 26. prepube\$.tw.
- 27. pubert\$.tw.
- 28. pubesc\$.tw.
- 29. ADOLESCENCE/
- 30. adolescen\$.tw.
- 31. JUVENILE/
- 32. ADOLESCENT/
- 33. juvenile\$.tw.
- 34. minors.tw.
- 35. youth\$.tw.
- 36. teen\$.tw.
- 37. or/1-36
- 38. BACTERIAL INFECTION/
- 39. (bacteri\$ adj infect\$).tw.
- 40. or/38-39
- 41. BACTERIAL MENINGITIS/
- 42. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 43. meningococc\$.tw.
- 44. or/41-43
- 45. SEPTICEMIA/
- 46. septicemi\$.tw.
- 47. septicaemia\$.tw.
- 48. or/45-47
- 49. BACTEREMIA/

- 50. bacteremi\$.tw.
- 51. bacteraemia\$.tw.
- 52. or/49-51
- 53. exp PNEUMONIA/
- 54. pneumoni\$.tw.
- 55. or/53-54
- 56. HERPES SIMPLEX/
- 57. herpes simplex.tw.
- 58. or/56-57
- 59. BACTERIAL ARTHRITIS/
- 60. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 61. pyarthrosis.tw.
- 62. pyoarthritis.tw.
- 63. or/59-62
- 64. STAPHYLOCOCCAL INFECTION/
- 65. STREPTOCOCCAL INFECTION/
- 66. straphylococc\$.tw.
- 67. streptococc\$.tw.
- 68. or/64-67
- 69. OSTEOMYELITIS/
- 70. osteomyeliti\$.tw.
- 71. or/69-70
- 72. exp URINARY TRACT INFECTION/
- 73. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 74. UTI.tw.
- 75. ((upper or lower) adj5 urin\$).tw.
- 76. exp CYSTITIS/
- 77. cystitis\$.tw.
- 78. or/72-77
- 79. PYELONEPHRITIS/
- 80. pyelonephriti\$.tw.
- 81. pyonephrosi\$.tw.
- 82. pyelocystiti\$.tw.
- 83. or/79-82
- 84. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 85. (mucocutaneous adj2 lymph\$).tw.
- 86. mcls.tw.
- 87. (kawasaki adj (disease or syndrome)).tw.

- 88. or/84-87
- 89. or/40,44,48,52,55,58,63,68,71,78,83,88
- 90. exp BLOOD EXAMINATION/
- 91. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 92. or/90-91
- 93. exp BLOOD CELL COUNT/
- 94. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 95. leu?ocyte\$.tw.
- 96. or/93-95
- 97. ERYTHROCYTE SEDIMENTATION RATE/
- 98. ((blood or erythrocyte) adj sedimentation).tw.
- 99. or/97-98
- 100. C REACTIVE PROTEIN/
- 101. c reactive protein\$.tw.
- 102. CRP.tw.
- 103. or/100-102
- 104. CALCITONIN/
- 105. calcitoni\$.tw.
- 106. PROTEIN PRECURSORS/
- 107. PROCALCITONIN/
- 108. procalcitonin.tw.
- 109. or/104-108
- 110. UROLOGIC EXAMINATION/
- 111. (urolog\$ adj2 exam\$).tw.
- 112. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 113. (urin\$ adj cytology).tw.
- 114. or/110-113
- 115. URINALYSIS/
- 116. ((urine or urinary) adj2 (analys\$ or test\$ or exam\$ or investigat\$ or sample)).tw.
- 117. or/115-116
- 118. ANALYTICAL EQUIPMENT/
- 119. TEST STRIP/
- 120. REAGENT/
- 121. "DYES, REAGENTS, INDICATORS, MARKERS and BUFFERS"/
- 122. (reagent\$ adj (kit\$ or strip\$)).tw.
- 123. test strip.tw.
- 124. (dipstick\$ or dip?stick\$).tw.
- 125. or/118-124
- 126. exp MICROSCOPY/

- 127. microscopy\$.tw.
- 128. (dipslide\$ or dip?slide\$).tw.
- 129. or/126-128
- 130. LUMBAR PUNCTURE/
- 131. ((lumbar or spinal) adj punctur\$).tw.
- 132. CEREBROSPINAL FLUID/
- 133. cerebrospinal fluid.tw.
- 134. or/130-133
- 135. X RAY/
- 136. x ray\$.tw.
- 137. or/135-136
- 138. CAPILLARY FLOW/
- 139. capillar\$.tw.
- 140. or/138-139
- 141. exp OXIMETRY/
- 142. pulse oximetry.tw.
- 143. or/141-142
- 144. BLOOD GLUCOSE MONITORING/
- 145. blood glucose.tw.
- 146. or/144-145
- 147. THORAX RADIOGRAPHY/
- 148. ((chest or thoracic) adj2 radiograph\$).tw.
- 149. or/147-148
- 150. or/92,96,99,103,109,114,117,125,129,134,137,140,143,146,149
- 151. ECONOMICS/
- 152. HEALTH ECONOMICS/
- 153. ECONOMIC EVALUATION/
- 154. COST BENEFIT ANALYSIS/
- 155. COST CONTROL/
- 156. COST EFFECTIVENESS ANALYSIS/
- 157. COST MINIMIZATION ANALYSIS/
- 158. COST OF ILLNESS/
- 159. COST UTILITY ANALYSIS/
- 160. COST/
- 161. HEALTH CARE COST/
- 162. DRUG COST/
- 163. HEALTH CARE FINANCING/
- 164. HOSPITAL COST/
- 165. SOCIOECONOMICS/

- 166. ECONOMIC ASPECT/
- 167. QUALITY-ADJUSTED LIFE YEARS/
- 168. FINANCIAL MANAGEMENT/
- 169. PHARMACOECONOMICS/
- 170. RESOURCE ALLOCATION/
- 171. (financ\$ or fiscal\$ or funding).tw.
- 172. (QALY\$ or life?year\$).tw.
- 173. (econom\$ or cost\$).tw.
- 174. pharmacoeconomic\$.tw.
- 175. or/151-174
- 176. and/37,89,150,175
- 177. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 178. 176 not 177

FEVER_diagnosis_health_economics_cinahl_100506

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. perinatal\$.tw.
- 7. postnatal\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. (baby or babies).tw.
- 11. INFANT, LOW BIRTH WEIGHT/
- 12. INFANT, VERY LOW BIRTH WEIGHT/
- 13. INFANT, SMALL FOR GESTATIONAL AGE/
- 14. (small adj2 (date or "gestational age")).tw.
- 15. lbw.tw.
- 16. vlbw.tw.
- 17. CHILD/
- 18. CHILD, PRESCHOOL/
- 19. SCHOOL CHILD/
- 20. child\$.tw.
- 21. PREPUBERTY/
- 22. PUBERTY/
- 23. prepube\$.tw.
- 24. pubert\$.tw.
- 25. pubesc\$.tw.

- 26. ADOLESCENCE/
- 27. adolescen\$.tw.
- 28. "MINORS (LEGAL)"/
- 29. juvenile\$.tw.
- 30. minors.tw.
- 31. youth\$.tw.
- 32. teen\$.tw.
- 33. or/1-32
- 34. BACTERIAL INFECTIONS/
- 35. (bacteri\$ adj infect\$).tw.
- 36. or/34-35
- 37. exp MENINGITIS, BACTERIAL/
- 38. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 39. meningococc\$.tw.
- 40. or/37-39
- 41. exp SEPSIS/
- 42. septicemi\$.tw.
- 43. septicaemia\$.tw.
- 44. or/41-43
- 45. BACTEREMIA/
- 46. bacteremi\$.tw.
- 47. bacteraemia\$.tw.
- 48. or/45-47
- 49. exp PNEUMONIA/
- 50. pneumoni\$.tw.
- 51. or/49-50
- 52. HERPES SIMPLEX/
- 53. herpes simplex.tw.
- 54. or/52-53
- 55. exp ARTHRITIS, INFECTIOUS/
- 56. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 57. pyarthrosis.tw.
- 58. pyoarthritis.tw.
- 59. or/55-58
- 60. STAPHYLOCOCCAL INFECTIONS/
- 61. STREPTOCOCCAL INFECTIONS/
- 62. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 63. or/60-62

- 64. OSTEOMYELITIS/
- 65. osteomyeliti\$.tw.
- 66. or/64-65
- 67. exp URINARY TRACT INFECTION/
- 68. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 69. UTI.tw.
- 70. ((upper or lower) adj5 urin\$).tw.
- 71. CYSTITIS/
- 72. cystitis\$.tw.
- 73. PYELONEPHRITIS/
- 74. pyelonephriti\$.tw.
- 75. pyonephrosi\$.tw.
- 76. pyelocystiti\$.tw.
- 77. or/67-76
- 78. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 79. (mucocutaneous adj2 lymph\$).tw.
- 80. mcls.tw.
- 81. (kawasaki adj (disease or syndrome)).tw.
- 82. or/78-81
- 83. or/36,40,44,48,51,54,59,63,66,77,82
- 84. HEMATOLOGIC TESTS/
- 85. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 86. or/84-85
- 87. exp BLOOD CELL COUNT/
- 88. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 89. leu?ocyte\$.tw.
- 90. or/87-89
- 91. BLOOD SEDIMENTATION/
- 92. ((blood or erythrocyte) adj sedimentation).tw.
- 93. or/91-92
- 94. C-REACTIVE PROTEIN/
- 95. c reactive protein\$.tw.
- 96. CRP.tw.
- 97. or/94-96
- 98. CALCITONIN/
- 99. calcitoni\$.tw.
- 100. PROTEIN PRECURSORS/
- 101. procalcitonin.tw.

- 102. or/98-101
- 103. DIAGNOSTIC TECHNIQUES, UROLOGICAL/
- 104. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 105. or/103-104
- 106. URINALYSIS/
- 107. ((urine or urinary) adj2 (analys\$ or test\$ or exam\$ or investigat\$ or sample)).tw.
- 108. or/106-107
- 109. "REAGENT KITS, DIAGNOSTIC"/
- 110. REAGENT STRIPS/
- 111. "INDICATORS AND REAGENTS"/
- 112. (reagent\$ adj (kit\$ or strip\$)).tw.
- 113. (dipstick\$ or dip?stick\$).tw.
- 114. or/109-113
- 115. exp MICROSCOPY/
- 116. microscopy\$.tw.
- 117. (dipslide\$ or dip?slide\$).tw.
- 118. or/115-117
- 119. SPINAL PUNCTURE/
- 120. ((lumbar or spinal) adj puncture\$).tw.
- 121. CEREBROSPINAL FLUID/
- 122. cerebrospinal fluid.tw.
- 123. or/119-122
- 124. X-RAYS/
- 125. x ray\$.tw.
- 126. or/124-125
- 127. capillar\$.tw.
- 128. exp OXIMETRY/
- 129. pulse oximetry.tw.
- 130. or/128-129
- 131. BLOOD GLUCOSE/
- 132. blood glucose.tw.
- 133. or/131-132
- 134. RADIOGRAPHY, THORACIC/
- 135. ((chest or thoracic) adj2 radiograph\$).tw.
- 136. or/134-135
- $137. \ or/86, 90, 93, 97, 102, 105, 108, 114, 118, 123, 126-127, 130, 133, 136$
- 138. ECONOMICS/
- 139. "COSTS AND COST ANALYSIS"/
- 140. COST BENEFIT ANALYSIS/

- 141. COST CONTROL/
- 142. COST SAVINGS/
- 143. COST OF ILLNESS/
- 144. HEALTH CARE COSTS/
- 145. ECONOMIC ASPECTS OF ILLNESS/
- 146. ECONOMICS, PHARMACEUTICAL/
- 147. HEALTH CARE FINANCING/
- 148. FINANCIAL MANAGEMENT/
- 149. HOSPITAL COST/
- 150. SOCIOECONOMIC FACTORS/
- 151. HEALTH RESOURCE ALLOCATION/
- 152. (financ\$ or fiscal\$ or funding).tw.
- 153. (QALY\$ or life?year\$).tw.
- 154. (econom\$ or cost\$).tw.
- 155. pharmacoeconomic\$.tw.
- 156. or/138-155
- 157. and/33,83,137,156

FEVER_diagnosis_pulse_oximetry_capillary_glucose_medline_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/

- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.

- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp OXIMETRY/
- 69. pulse oximetry.tw.
- 70. or/68-69
- 71. BLOOD GLUCOSE/
- 72. blood glucose.tw.
- 73. or/71-72
- 74. or/70.73
- 75. exp "SENSITIVITY AND SPECIFICITY"/
- 76. (sensitivity or specificity).tw.
- 77. (predictive adj value\$).tw.
- 78. LIKELIHOOD FUNCTIONS/
- 79. (likelihood adj (estimate\$ or ratio\$)).tw.
- 80. exp DIAGNOSTIC ERRORS/
- 81. (false adj (negative\$ or positive\$)).tw.
- 82. "REPRODUCIBILITY OF RESULTS"/
- 83. DIAGNOSIS, DIFFERENTIAL/
- 84. (differential adj diagnos\$).tw.
- 85. or/75-84
- 86. and/17,67,74,85

FEVER_diagnosis_pulse_oximetry_capillary_glucose_embase_090506

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.

- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47

- 49. OSTEOMYELITIS/
- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.
- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/
- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. exp OXIMETRY/
- 71. pulse oximetry.tw.
- 72. or/70-71
- 73. BLOOD GLUCOSE MONITORING/
- 74. blood glucose.tw.
- 75. or/73-74
- 76. or/72,75
- 77. exp "SENSITIVITY AND SPECIFICITY"/
- 78. (sensitivity or specificity).tw.
- 79. (predictive adj value\$).tw.
- 80. STATISTICAL MODEL/
- 81. (likelihood adj (estimate\$ or ratio\$)).tw.
- 82. DIAGNOSTIC ERROR/
- 83. (false adj (negative\$ or positive\$)).tw.
- 84. REPRODUCIBILITY/
- 85. DIFFERENTIAL DIAGNOSIS/
- 86. (differential adj diagnos\$).tw.

- 87. or/77-86
- 88. and/17,69,76,87
- 89. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 90.88 not 89

FEVER_diagnosis_pulse_oximetry_capillary_glucose_cinahl_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.

- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp OXIMETRY/
- 69. pulse oximetry.tw.
- 70. or/68-69
- 71. BLOOD GLUCOSE/
- 72. blood glucose.tw.

- 73. or/71-72
- 74. or/70,73
- 75. and/17,67,74

FEVER_diagnosis_test_accuracy_medline_150206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.

- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.

- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. HEMATOLOGIC TESTS/
- 82. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 83. or/81-82
- 84. exp BLOOD CELL COUNT/
- 85. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 86. leu?ocyte\$.tw.
- 87. or/84-86
- 88. BLOOD SEDIMENTATION/
- 89. ((blood or erythrocyte) adj sedimentation).tw.
- 90. or/88-89
- 91. C-REACTIVE PROTEIN/
- 92. c reactive protein\$.tw.
- 93. CRP.tw.
- 94. or/91-93
- 95. CALCITONIN/
- 96. calcitoni\$.tw.
- 97. PROTEIN PRECURSORS/
- 98. procalcitonin.tw.
- 99. or/95-98
- 100. DIAGNOSTIC TECHNIQUES, UROLOGICAL/
- 101. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 102. or/100-101
- 103. URINALYSIS/
- 104. ((urine or urinary) adj2 (analys\$ or test\$)).tw.
- 105. or/103-104
- 106. REAGENT KITS, DIAGNOSTIC/
- 107. REAGENT STRIPS/
- 108. "INDICATORS AND REAGENTS"/
- 109. (reagent\$ adj (kit\$ or strip\$)).tw.
- 110. (dipstick\$ or dip?stick\$).tw.
- 111. or/106-110

- 112. exp MICROSCOPY/
- 113. microscopy\$.tw.
- 114. (dipslide\$ or dip?slide\$).tw.
- 115. or/112-114
- 116. SPINAL PUNCTURE/
- 117. ((lumbar or spinal) adj puncture\$).tw.
- 118. CEREBROSPINAL FLUID/
- 119. cerebrospinal fluid.tw.
- 120. or/116-119
- 121. X-RAYS/
- 122. x ray\$.tw.
- 123. or/121-122
- 124. or/83,87,90,94,99,102,105,111,115,120,123
- 125. and/80,124
- 126. exp "SENSITIVITY AND SPECIFICITY"/
- 127. (sensitivity or specificity).tw.
- 128. (predictive adj value\$).tw.
- 129. LIKELIHOOD FUNCTIONS/
- 130. (likelihood adj (estimate\$ or ratio\$)).tw.
- 131. exp DIAGNOSTIC ERRORS/
- 132. (false adj (negative\$ or positive\$)).tw.
- 133. "REPRODUCIBILITY OF RESULTS"/
- 134. DIAGNOSIS, DIFFERENTIAL/
- 135. (differential adj diagnos\$).tw.
- 136. or/126-135
- 137. and/125,136
- 138. animal/ not (human/ or (human/ and animal/))
- 139. 137 not 138

FEVER_diagnosis_test_accuracy_embase_150206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.

Feverish illness in children (appendices)

- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/

- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. exp BLOOD EXAMINATION/
- 84. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 85. or/83-84
- 86. exp BLOOD CELL COUNT/

- 87. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 88. leu?ocyte\$.tw.
- 89. or/86-88
- 90. ERYTHROCYTE SEDIMENTATION RATE/
- 91. ((blood or erythrocyte) adj sedimentation).tw.
- 92. or/90-91
- 93. C REACTIVE PROTEIN/
- 94. c reactive protein\$.tw.
- 95. CRP.tw.
- 96. or/93-95
- 97. CALCITONIN/
- 98. calcitoni\$.tw.
- 99. PROTEIN PRECURSORS/
- 100. PROCALCITONIN/
- 101. procalcitonin.tw.
- 102. or/97-101
- 103. UROLOGIC EXAMINATION/
- 104. (urolog\$ adj2 exam\$).tw.
- 105. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 106. (urin\$ adj cytology).tw.
- 107. or/103-106
- 108. URINALYSIS/
- 109. ((urine or urinary) adj2 (analys\$ or test\$ or exam\$ or investigat\$ or sample)).tw.
- 110. or/108-109
- 111. ANALYTICAL EQUIPMENT/
- 112. TEST STRIP/
- 113. REAGENT/
- 114. "DYES, REAGENTS, INDICATORS, MARKERS and BUFFERS"/
- 115. (reagent\$ adj (kit\$ or strip\$)).tw.
- 116. test strip.tw.
- 117. (dipstick\$ or dip?stick\$).tw.
- 118. or/111-117
- 119. exp MICROSCOPY/
- 120. microscopy\$.tw.
- 121. (dipslide\$ or dip?slide\$).tw.
- 122. or/119-121
- 123. LUMBAR PUNCTURE/
- 124. ((lumbar or spinal) adj punctur\$).tw.
- 125. CEREBROSPINAL FLUID/

- 126. cerebrospinal fluid.tw.
- 127. or/123-126
- 128. X RAY/
- 129. x ray\$.tw.
- 130. or/128-129
- 131. or/85,89,92,96,102,107,110,118,122,127,130
- 132. and/82,131
- 133. exp "SENSITIVITY AND SPECIFICITY"/
- 134. (sensitivity or specificity).tw.
- 135. (predictive adj value\$).tw.
- 136. STATISTICAL MODEL/
- 137. (likelihood adj (estimate\$ or ratio\$)).tw.
- 138. DIAGNOSTIC ERROR/
- 139. (false adj (negative\$ or positive\$)).tw.
- 140. REPRODUCIBILITY/
- 141. DIFFERENTIAL DIAGNOSIS/
- 142. (differential adj diagnos\$).tw.
- 143. or/133-142
- 144. and/132,143
- 145. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 146. 144 not 145

FEVER_diagnosis_test_accuracy_cinahl_150206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16

- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54

- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. HEMATOLOGIC TESTS/
- 82. ((blood or hematolog\$) adj (analys\$ or examin\$ or test\$)).tw.
- 83. or/81-82
- 84. exp BLOOD CELL COUNT/
- 85. ((blood or platelet\$) adj (count\$ or number\$)).tw.
- 86. leu?ocyte\$.tw.
- 87. or/84-86
- 88. BLOOD SEDIMENTATION/
- 89. ((blood or erythrocyte) adj sedimentation).tw.
- 90. or/88-89
- 91. C-REACTIVE PROTEIN/
- 92. c reactive protein\$.tw.
- 93. CRP.tw.

- 94. or/91-93
- 95. CALCITONIN/
- 96. calcitoni\$.tw.
- 97. PROTEIN PRECURSORS/
- 98. procalcitonin.tw.
- 99. or/95-98
- 100. DIAGNOSTIC TECHNIQUES, UROLOGICAL/
- 101. (urolog\$ adj2 (diagnostic\$ or technic\$ or technique\$)).tw.
- 102. or/100-101
- 103. URINALYSIS/
- 104. ((urine or urinary) adj2 (analys\$ or test\$ or exam\$ or investigat\$ or sample)).tw.
- 105. or/103-104
- 106. "REAGENT KITS, DIAGNOSTIC"/
- 107. REAGENT STRIPS/
- 108. "INDICATORS AND REAGENTS"/
- 109. (reagent\$ adj (kit\$ or strip\$)).tw.
- 110. (dipstick\$ or dip?stick\$).tw.
- 111. or/106-110
- 112. exp MICROSCOPY/
- 113. microscopy\$.tw.
- 114. (dipslide\$ or dip?slide\$).tw.
- 115. or/112-114
- 116. SPINAL PUNCTURE/
- 117. ((lumbar or spinal) adj puncture\$).tw.
- 118. CEREBROSPINAL FLUID/
- 119. cerebrospinal fluid.tw.
- 120. or/116-119
- 121. X-RAYS/
- 122. x ray\$.tw.
- 123. or/121-122
- 124. or/83,87,90,94,99,102,105,111,115,120,123
- 125. and/80,124

FEVER_diagnosis_thoracic_radiography_pneumonia_medline_260406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/

- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp PNEUMONIA/
- 19. pneumoni\$.tw.
- 20. or/18-19
- 21. RADIOGRAPHY, THORACIC/
- 22. ((chest or thoracic) adj2 radiograph\$).tw.
- 23. or/21-22
- 24. X-RAYS/
- 25. x ray\$.tw.
- 26. or/24-25
- 27. or/23,26
- 28. exp "SENSITIVITY AND SPECIFICITY"/
- 29. (sensitivity or specificity).tw.
- 30. (predictive adj value\$).tw.
- 31. LIKELIHOOD FUNCTIONS/
- 32. (likelihood adj (estimate\$ or ratio\$)).tw.
- 33. exp DIAGNOSTIC ERRORS/
- 34. (false adj (negative\$ or positive\$)).tw.
- 35. "REPRODUCIBILITY OF RESULTS"/
- 36. DIAGNOSIS, DIFFERENTIAL/
- 37. (differential adj diagnos\$).tw.
- 38. or/28-37
- 39. and/17,20,27,38
- 40. animal/ not (human/ or (human/ and animal/))
- 41. 39 not 40

FEVER_diagnosis_thoracic_radiography_pneumonia_embase_260406

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/

- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp PNEUMONIA/
- 19. pneumoni\$.tw.
- 20. or/18-19
- 21. THORAX RADIOGRAPHY/
- 22. ((chest or thoracic) adj2 radiograph\$).tw.
- 23. or/21-22
- 24. X RAY/
- 25. x ray\$.tw.
- 26. or/24-25
- 27. or/23,26
- 28. exp "SENSITIVITY AND SPECIFICITY"/
- 29. (sensitivity or specificity).tw.
- 30. (predictive adj value\$).tw.
- 31. STATISTICAL MODEL/
- 32. (likelihood adj (estimate\$ or ratio\$)).tw.
- 33. DIAGNOSTIC ERROR/
- 34. (false adj (negative\$ or positive\$)).tw.
- 35. REPRODUCIBILITY/
- 36. DIFFERENTIAL DIAGNOSIS/
- 37. (differential adj diagnos\$).tw.
- 38. or/28-37
- 39. and/17,20,27,38
- 40. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 41. 39 not 40

FEVER_diagnosis_thoracic_radiography_pneumonia_cinahl_260406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp PNEUMONIA/
- 19. pneumoni\$.tw.
- 20. or/18-19
- 21. RADIOGRAPHY, THORACIC/
- 22. ((chest or thoracic) adj2 radiograph\$).tw.
- 23. or/21-22
- 24. X-RAYS/
- 25. x ray\$.tw.
- 26. or/24-25
- 27. or/23,26
- 28. and/17,20,27

FEVER_febrile_convulsions_antipyretics_medline_020506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.

- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ANALGESICS/
- 19. ANALGESICS, NON-NARCOTIC/
- 20. (analges\$ or analget\$ or anodyne\$).tw.
- 21. anti?pyretic\$.tw.
- 22. (antinociceptive adj (agent\$ or drug\$)).tw.
- 23. or/18-22
- 24. ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/
- 25. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 26. NSAID\$.tw.
- 27. or/24-26
- 28. IBUPROFEN/
- 29. ibuprofen\$.tw.
- 30. or/28-29
- 31. ACETAMINOPHEN/
- 32. acetaminophen\$.tw.
- 33. paracetamol\$.tw.
- 34. or/31-33
- 35. or/23,27,30,34
- 36. CRYOTHERAPY/
- 37. cryother\$.tw.
- 38. cryotreatment\$.tw.
- 39. cryoanalgesi\$.tw.
- 40. cyroanalgesi\$.tw.
- 41. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 42. or/36-41
- 43. BATHS/
- 44. bath\$.tw.
- 45. spong\$.tw.
- 46. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 47. or/43-46
- 48. WATER/

- 49. DRINKING/
- 50. FLUID THERAPY/
- 51. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 52. hydrat\$.tw.
- 53. rehydrat\$.tw.
- 54. or/48-53
- 55. CLOTHING/
- 56. ((light\$ or remov\$) adj2 cloth\$).tw.
- 57. or/55-56
- 58. climatotherap\$.tw.
- 59. (climat\$ adj (therap\$ or treat\$)).tw.
- 60. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 61. fan\$.tw.
- 62. or/58-61
- 63. HYPOTHERMIA, INDUCED/
- 64. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 65. (blanket adj treatment\$).tw.
- 66. swaddling.tw.
- 67. or/63-66
- 68. COMBINED MODALITY THERAPY/
- 69. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 70. or/68-69
- 71. or/35,42,47,54,57,62,67,70
- 72. SEIZURES, FEBRILE/
- 73. ((febrile or fever or pyrexial) adj (convulsion\$ or fit\$ or seizure\$)).tw.
- 74. or/72-73
- 75. and/17,71,74
- 76. animal/ not (human/ or (human/ and animal/))
- 77. 75 not 76

FEVER_febrile_convulsions_antipyretics_embase_020506

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/

- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ANALGESIA/
- 19. ANALGESIC AGENT/
- 20. (analges\$ or analget\$ or anodyne\$).tw.
- 21. (antinociceptive adj (agent\$ or drug\$)).tw.
- 22. ANTIPYRETIC AGENT/
- 23. anti?pyretic\$.tw.
- 24. or/18-23
- 25. NONSTEROID ANTIINFLAMMATORY AGENT/
- 26. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 27. NSAID\$.tw.
- 28. or/25-27
- 29. IBUPROFEN/
- 30. ibuprofen\$.tw.
- 31. or/29-30
- 32. PARACETAMOL/
- 33. paracetamol\$.tw.
- 34. acetaminophen\$.tw.
- 35. or/32-34
- 36. or/24,28,31,35
- 37. CRYOTHERAPY/
- 38. cryother\$.tw.
- 39. cryotreatment\$.tw.
- 40. CRYOANESTHESIA/
- 41. cryoanalgesi\$.tw.
- 42. cyroanalgesi\$.tw.
- 43. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 44. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 45. (blanket adj treatment\$).tw.
- 46. swaddling.tw.
- 47. or/37-46

- 48. BATH/
- 49. bath\$.tw.
- 50. spong\$.tw.
- 51. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 52. or/48-51
- 53. WATER/
- 54. FLUID THERAPY/
- 55. FLUID INTAKE/
- 56. FLUID BALANCE/
- 57. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 58. HYDRATION/
- 59. REHYDRATION/
- 60. hydrat\$.tw.
- 61. rehydrat\$.tw.
- 62. or/53-61
- 63. CLOTHING/
- 64. ((light\$ or remov\$) adj2 cloth\$).tw.
- 65. or/63-64
- 66. CLIMATOTHERAPY/
- 67. climatotherap\$.tw.
- 68. (climat\$ adj (therap\$ or treat\$)).tw.
- 69. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 70. fan\$.tw.
- 71. or/66-70
- 72. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 73. or/36,47,52,62,65,71-72
- 74. FEBRILE CONVULSION/
- 75. ((febrile or fever or pyrexial) adj (convulsion\$ or fit\$ or seizure\$)).tw.
- 76. or/74-75
- 77. and/17,73,76
- 78. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 79. 77 not 78

FEVER_febrile_convulsions_antipyretics_cinahl_020506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.

- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ANALGESIA/
- 19. ANALGESICS/
- 20. ANALGESICS, NONNARCOTIC/
- 21. (analges\$ or analget\$ or anodyne\$).tw.
- 22. (antinociceptive adj (agent\$ or drug\$)).tw.
- 23. (anti-pyretic\$ or antipyretic\$).tw.
- 24. or/18-23
- 25. ANTIINFLAMMATORY AGENTS, NON-STEROIDAL/
- 26. ((non-steroid\$ or nonsteroid\$) adj (anti-inflammatory or antiinflammatory) adj (agent\$ or drug\$)).tw.
- 27. NSAID\$.tw.
- 28. or/25-27
- 29. IBUPROFEN/
- 30. ibuprofen\$.tw.
- 31. or/29-30
- 32. ACETAMINOPHEN/
- 33. acetaminophen\$.tw.
- 34. paracetamol\$.tw.
- 35. or/32-34
- 36. or/24,28,31,35
- 37. CRYOTHERAPY/
- 38. cryother\$.tw.
- 39. cryotreatment\$.tw.
- 40. cryoanalgesi\$.tw.
- 41. cyroanalgesi\$.tw.
- 42. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 43. or/37-42

- 44. BATHS/
- 45. bath\$.tw.
- 46. spong\$.tw.
- 47. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 48. or/44-47
- 49. WATER/
- 50. DRINKING BEHAVIOR/
- 51. FLUID THERAPY/
- 52. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 53. hydrat\$.tw.
- 54. rehydrat\$.tw.
- 55. or/49-54
- 56. CLOTHING/
- 57. ((light\$ or remov\$) adj2 cloth\$).tw.
- 58. or/56-57
- 59. climatotherap\$.tw.
- 60. (climat\$ adj (therap\$ or treat\$)).tw.
- 61. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 62. fan\$.tw.
- 63. or/59-62
- 64. HYPOTHERMIA, INDUCED/
- 65. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 66. (blanket adj treatment\$).tw.
- 67. swaddling.tw.
- 68. or/64-67
- 69. COMBINED MODALITY THERAPY/
- 70. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 71. or/69-70
- 72. or/36,43,48,55,58,63,68,71
- 73. CONVULSIONS, FEBRILE/
- 74. ((febrile or fever or pyrexial) adj (convulsion\$ or fit\$ or seizure\$)).tw.
- 75. or/73-74
- 76. and/17,72,75

FEVER_health_economic_filter_medline_021205

- 1. ECONOMICS/
- 2. "COSTS AND COST ANALYSIS"/
- 3. COST ALLOCATION/
- 4. COST-BENEFIT ANALYSIS/

- 5. COST CONTROL/
- 6. COST SAVINGS/
- 7. COST OF ILLNESS/
- 8. COST SHARING/
- 9. HEALTH CARE COSTS/
- 10. DIRECT SERVICE COSTS/
- 11. DRUG COSTS/
- 12. EMPLOYER HEALTH COSTS/
- 13. HOSPITAL COSTS/
- 14. HEALTH RESOURCES/
- 15. "HEALTH SERVICES NEEDS AND DEMAND"/
- 16. HEALTH PRIORITIES/
- 17. HEALTH EXPENDITURES/
- 18. CAPITAL EXPENDITURES/
- 19. FINANCIAL MANAGEMENT/
- 20. FINANCIAL MANAGEMENT, HOSPITAL/
- 21. QUALITY-ADJUSTED LIFE YEARS/
- 22. "DEDUCTIBLES AND COINSURANCE"/
- 23. MEDICAL SAVINGS ACCOUNTS/
- 24. ECONOMICS, HOSPITAL/
- 25. ECONOMICS, MEDICAL/
- 26. ECONOMICS, NURSING/
- 27. ECONOMICS, PHARMACEUTICAL/
- 28. MODELS, ECONOMIC/
- 29. MODELS, ECONOMETRIC/
- 30. RESOURCE ALLOCATION/
- 31. HEALTH CARE RATIONING/
- 32. "FEES AND CHARGES"/
- 33. BUDGETS/
- 34. VALUE OF LIFE/
- 35. (financ\$ or fiscal\$ or funding).tw.
- 36. (QALY\$ or life?year\$).tw.
- 37. (econom\$ or cost\$).tw.
- 38. pharmacoeconomic\$.tw.
- 39. ec.fs.
- 40. or/1-39
- 41. INFANT, PREMATURE/
- 42. INFANT, POSTMATURE/
- 43. INFANT, LOW BIRTH WEIGHT/

- 44. (low adj birth adj weight).tw.
- 45. lbw.tw.
- 46. INFANT, VERY LOW BIRTH WEIGHT/
- 47. vlbw.tw.
- 48. INFANT, NEWBORN/
- 49. neonat\$.tw.
- 50. newborn\$.tw.
- 51. exp INFANT/
- 52. infan\$.tw.
- 53. CHILD, PRESCHOOL/
- 54. (baby or babies).tw.
- 55. (child\$ adj5 pre?school).tw.
- 56. toddler\$.tw.
- 57. or/41-56
- 58. exp FEVER/
- 59. "FEVER OF UNKNOWN ORIGIN"/
- 60. fever\$.tw.
- 61. febril\$.tw.
- 62. hypertherm\$.tw.
- 63. pyrexi\$.tw.
- 64. MALIGNANT HYPERTHERMIA/
- 65. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 66. exp PYROGENS/
- 67. pyrogen\$.tw.
- 68. or/58-67
- 69. and/57,68
- 70. and/40,69
- 71. animal/ not (human/ or (human/ and animal/))
- 72. 70 not 71

FEVER_health_economic_filter_embase_021205

- 1. ECONOMICS/
- 2. HEALTH ECONOMICS/
- 3. ECONOMIC EVALUATION/
- 4. COST BENEFIT ANALYSIS/
- 5. COST CONTROL/
- 6. COST EFFECTIVENESS ANALYSIS/
- 7. COST MINIMIZATION ANALYSIS/
- 8. COST OF ILLNESS/
- 9. COST UTILITY ANALYSIS/

- 10. COST/
- 11. HEALTH CARE COST/
- 12. DRUG COST/
- 13. HEALTH CARE FINANCING/
- 14. HOSPITAL COST/
- 15. SOCIOECONOMICS/
- 16. ECONOMIC ASPECT/
- 17. QUALITY-ADJUSTED LIFE YEARS/
- 18. FINANCIAL MANAGEMENT/
- 19. PHARMACOECONOMICS/
- 20. RESOURCE ALLOCATION/
- 21. (financ\$ or fiscal\$ or funding).tw.
- 22. (QALY\$ or life?year\$).tw.
- 23. (econom\$ or cost\$).tw.
- 24. pharmacoeconomic\$.tw.
- 25. or/1-24
- 26. PREMATURITY/
- 27. POSTMATURITY/
- 28. LOW BIRTH WEIGHT/
- 29. (low adj birth adj weight).tw.
- 30. lbw.tw.
- 31. VERY LOW BIRTH WEIGHT/
- 32. vlbw.tw.
- 33. NEWBORN/
- 34. neonat\$.tw.
- 35. newborn\$.tw.
- 36. exp INFANT/
- 37. infan\$.tw.
- 38. PRESCHOOL CHILD/
- 39. (baby or babies).tw.
- 40. (child\$ adj5 pre?school).tw.
- 41. toddler\$.tw.
- 42. or/26-41
- 43. exp FEVER/
- 44. PYREXIA IDIOPATHICA/
- 45. fever\$.tw.
- 46. febril\$.tw.
- 47. hypertherm\$.tw.
- 48. pyrexi\$.tw.

- 49. MALIGNANT HYPERTHERMIA/
- 50. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 51. exp PYROGEN/
- 52. pyrogen\$.tw.
- 53. or/43-52
- 54. and/42,53
- 55. and/25,54
- 56. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 57. 55 not 56

FEVER_health_economic_filter_cinahl_021205

- 1. ECONOMICS/
- 2. "COSTS AND COST ANALYSIS"/
- 3. COST BENEFIT ANALYSIS/
- 4. COST CONTROL/
- 5. COST SAVINGS/
- 6. COST OF ILLNESS/
- 7. HEALTH CARE COSTS/
- 8. ECONOMIC ASPECTS OF ILLNESS/
- 9. ECONOMICS, PHARMACEUTICAL/
- 10. HEALTH CARE FINANCING/
- 11. FINANCIAL MANAGEMENT/
- 12. HOSPITAL COST/
- 13. SOCIOECONOMIC FACTORS/
- 14. HEALTH RESOURCE ALLOCATION/
- 15. (financ\$ or fiscal\$ or funding).tw.
- 16. (QALY\$ or life?year\$).tw.
- 17. (econom\$ or cost\$).tw.
- 18. pharmacoeconomic\$.tw.
- 19. or/1-18
- 20. INFANT, PREMATURE/
- 21. INFANT, POSTMATURE/
- 22. LOW BIRTH WEIGHT/
- 23. (low adj birth adj weight).tw.
- 24. lbw.tw.
- 25. VERY LOW BIRTH WEIGHT/
- 26. vlbw.tw.
- 27. INFANT, NEWBORN/
- 28. neonat\$.tw.
- 29. newborn\$.tw.

- 30. exp INFANT/
- 31. infan\$.tw.
- 32. PRESCHOOL CHILD/
- 33. (baby or babies).tw.
- 34. (child\$ adj5 pre?school).tw.
- 35. toddler\$.tw.
- 36. or/20-35
- 37. exp FEVER/
- 38. "FEVER OF UNKNOWN ORIGIN"/
- 39. fever\$.tw.
- 40. febril\$.tw.
- 41. hypertherm\$.tw.
- 42. pyrexi\$.tw.
- 43. MALIGNANT HYPERTHERMIA/
- 44. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 45. exp PYROGENS/
- 46. pyrogen\$.tw.
- 47. or/37-46
- 48. and/36,47
- 49. and/19,48

FEVER_heart_monitoring_medline_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/

- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/

- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. HEART RATE/
- 82. exp TACHYCARDIA/
- 83. ((cardiac or heart or pulse) adj (rate\$ or monitor\$)).tw.
- 84. or/81-83
- 85. and/80,84
- 86. animal/ not (human/ or (human/ and animal/))
- 87. 85 not 86

FEVER_heart_monitoring_embase_280206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/

- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43

- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81

- 83. HEART RATE/
- 84. PULSE RATE/
- 85. exp TACHYCARDIA/
- 86. ((cardiac or heart or pulse) adj (rate\$ or monitor\$)).tw.
- 87. or/83-86
- 88. and/82,87
- 89. animal/ not (human/ or (human/ and animal/))
- 90. 88 not 89

FEVER_heart_monitoring_cinahl_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/

- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/

- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. HEART RATE/
- 82. exp TACHYCARDIA/
- 83. ((cardiac or heart or pulse) adj (rate\$ or monitor\$)).tw.
- 84. or/81-83
- 85. and/80,84

FEVER_hospitalisation_medline_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.

- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. PATIENT ADMISSION/
- 31. CHILD, HOSPITALIZED/
- 32. or/30-31
- 33. and/29,32
- 34. animal/ not (human/ or (human/ and animal/))
- 35. 33 not 34

FEVER_hospitalisation_embase_280206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.

- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/

- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. HOSPITAL ADMISSION/
- 84. CHILD HOSPITALIZATION/
- 85. or/83-84
- 86. and/82,85
- 87. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 88. 86 not 87

FEVER_hospitalisation_cinahl_280206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.

- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/

- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. PATIENT ADMISSION/
- 82. CHILD, HOSPITALIZED/
- 83. or/81-82
- 84. and/80,83

FEVER_ibuprofen_paracetamol_adverse_effects_medline_091105

1. INFANT, PREMATURE/

- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANALGESICS/
- 31. ANALGESICS, NON-NARCOTIC/
- 32. (analges\$ or analget\$ or anodyne\$).tw.
- 33. anti?pyretic\$.tw.
- 34. (antinociceptive adj (agent\$ or drug\$)).tw.
- 35. or/30-34
- 36. ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/
- 37. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 38. NSAID\$.tw.
- 39. or/36-38
- 40. IBUPROFEN/

- 41. ibuprofen\$.tw.
- 42. or/40-41
- 43. ACETAMINOPHEN/
- 44. acetaminophen\$.tw.
- 45. paracetamol\$.tw.
- 46. or/43-45
- 47. or/35,39,42,46
- 48. and/29,47
- 49. ANALGESICS, NON-NARCOTIC/ae
- 50. ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/ae
- 51. IBUPROFEN/ae
- 52. ACETAMINOPHEN/ae
- 53. (adverse adj (effect\$ or outcome\$ or react\$)).tw.
- 54. side effect\$.tw.
- 55. or/49-54
- 56. and/48,55
- 57. animal/ not (human/ or (human/ and animal/))
- 58. 56 not 57

FEVER_ibuprofen_paracetamol_adverse_effects_embase_091105

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.

- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANALGESIA/
- 31. ANALGESIC AGENT/
- 32. (analges\$ or analget\$ or anodyne\$).tw.
- 33. (antinociceptive adj (agent\$ or drug\$)).tw.
- 34. ANTIPYRETIC AGENT/
- 35. anti?pyretic\$.tw.
- 36. or/30-35
- 37. NONSTEROID ANTIINFLAMMATORY AGENT/
- 38. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 39. NSAID\$.tw.
- 40. or/37-39
- 41. IBUPROFEN/
- 42. ibuprofen\$.tw.
- 43. or/41-42
- 44. PARACETAMOL/
- 45. paracetamol\$.tw.
- 46. acetaminophen\$.tw.
- 47. or/44-46
- 48. or/36,40,43,47
- 49. and/29,48
- 50. ANALGESIC AGENT/ae
- 51. ANTIPYRETIC AGENT/ae
- 52. NONSTEROID ANTIINFLAMMATORY AGENT/ae
- 53. IBUPROFEN/ae
- 54. PARACETAMOL/ae
- 55. ADVERSE DRUG REACTION/
- 56. (adverse adj (effect\$ or outcome\$ or react\$)).tw.
- 57. side effect\$.tw.
- 58. or/50-57
- 59. and/49,58

FEVER_ibuprofen_paracetamol_adverse_effects_cinahl_091105

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANALGESIA/
- 31. ANALGESICS/
- 32. ANALGESICS, NONNARCOTIC/
- 33. (analges\$ or analget\$ or anodyne\$).tw.
- 34. (antinociceptive adj (agent\$ or drug\$)).tw.
- 35. (anti-pyretic\$ or antipyretic\$).tw.
- 36. or/30-35
- 37. ANTIINFLAMMATORY AGENTS, NON-STEROIDAL/

- 38. ((non-steroid\$ or nonsteroid\$) adj (anti-inflammatory or antiinflammatory) adj (agent\$ or drug\$)).tw.
- 39. NSAID\$.tw.
- 40. or/37-39
- 41. IBUPROFEN/
- 42. ibuprofen\$.tw.
- 43. or/41-42
- 44. ACETAMINOPHEN/
- 45. acetaminophen\$.tw.
- 46. paracetamol\$.tw.
- 47. or/44-46
- 48. or/36,40,43,47
- 49. and/29,48
- 50. ANALGESICS/ae
- 51. ANALGESICS, NONNARCOTIC/ae
- 52. ANTIINFLAMMATORY AGENTS, NON-STEROIDAL/ae
- 53. IBUPROFEN/ae
- 54. ACETAMINOPHEN/ae
- 55. ADVERSE DRUG EVENT/
- 56. (adverse adj (effect\$ or event\$ or outcome\$ or react\$)).tw.
- 57. side effect\$.tw.
- 58. or/50-57
- 59. and/49,58

FEVER_influenza_rsv_medline_150506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.

- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. INFLUENZA, HUMAN/
- 30. influenza.tw.
- 31. flu.tw.
- 32. or/29-31
- 33. RESPIRATORY SYNCYTIAL VIRUSES/
- 34. respiratory syncytial virus\$.tw.
- 35. rsv.tw.
- 36. or/33-35
- 37. and/17,28,32,36
- 38. animal/ not (human/ or (human/ and animal/))
- 39. 37 not 38

FEVER_influenza_rsv_embase_150506

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.

- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. INFLUENZA/
- 30. influenza.tw.
- 31. flu.tw.
- 32. or/29-31
- 33. RESPIRATORY SYNCYTIAL PNEUMOVIRUS/
- 34. respiratory syncytial virus\$.tw.
- 35. rsv.tw.
- 36. or/33-35
- 37. and/17,28,32,36

FEVER_influenza_rsv_cinahl_150506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.

- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. INFLUENZA/
- 30. influenza.tw.
- 31. flu.tw.
- 32. or/29-31
- 33. RESPIRATORY SYNCYTIAL VIRUSES/
- 34. respiratory syncytial virus\$.tw.
- 35. rsv.tw.
- 36. or/33-35
- 37. and/17,28,32,36

FEVER_oxygen_medline_210206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.

- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.

- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. exp ANOXIA/
- 82. anoxi\$.tw.
- 83. hypoxi\$.tw.
- 84. ((oxygen or O2) adj deficien\$).tw.
- 85. or/81-84
- 86. OXYGEN CONSUMPTION/
- 87. (oxygen adj (consumption or saturat\$)).tw.
- 88. or/86-87
- 89. OXIMETRY/
- 90. oximetry.tw.
- 91. or/89-90
- 92. OXYGEN INHALATION THERAPY/

- 93. (oxygen\$ adj (administer or administration or therap\$)).tw.
- 94. or/92-93
- 95. or/85,88,91,94
- 96. and/80,95
- 97. animal/ not (human/ or (human/ and animal/))
- 98. 96 not 97

FEVER_oxygen_embase_210206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31

- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.

- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. exp ANOXIA/
- 84. anoxi\$.tw.
- 85. hypoxi\$.tw.
- 86. ((oxygen or O2) adj deficien\$).tw.
- 87. or/83-86
- 88. OXYGEN THERAPY/
- 89. (oxygen adj (administer or administration or therap\$)).tw.
- 90. or/88-89
- 91. OXYGEN CONSUMPTION/
- 92. (oxygen adj consumption).tw.
- 93. or/91-92
- 94. OXYGEN SATURATION/
- 95. (oxygen adj saturat\$).tw.
- 96. or/94-95
- 97. exp OXIMETRY/
- 98. oximetry.tw.
- 99. or/97-98
- 100. or/87,90,93,96,99
- 101. and/82,100
- 102. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 103. 101 not 102

FEVER_oxygen_cinahl_210206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.

- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.

- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79

- 81. exp ANOXIA/
- 82. anoxi\$.tw.
- 83. hypoxi\$.tw.
- 84. ((oxygen or O2) adj deficien\$).tw.
- 85. or/81-84
- 86. OXYGEN INHALATION THERAPY/
- 87. (oxygen\$ adj (administer or administration or therap\$)).tw.
- 88. or/86-87
- 89. OXYGEN CONSUMPTION/
- 90. (oxygen adj comsumption).tw.
- 91. or/89-90
- 92. OXYGEN SATURATION/
- 93. (oxygen adj saturat\$).tw.
- 94. or/92-93
- 95. OXIMETRY/
- 96. oximetry.tw.
- 97. or/95-96
- 98. or/85,88,91,94,97
- 99. and/80,98

FEVER_patient_observation_medline_210206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/

- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/

- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. MONITORING, PHYSIOLOGIC/
- 82. ((patient\$ or physical\$ or physiologic\$) adj2 (assess\$ or monitor\$)).tw.
- 83. or/81-82
- 84. RISK ASSESSMENT/
- 85. risk\$.tw.
- 86. TIME FACTORS/
- 87. or/84-86
- 88. OBSERVATION/
- 89. observ\$.tw.
- 90. or/88-89
- 91. and/87,90
- 92. or/83,91
- 93. and/80,92
- 94. animal/ not (human/ or (human/ and animal/))
- 95. 93 not 94

FEVER_patient_observation_embase_210206

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/

Feverish illness in children (appendices)

- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74

- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. exp PATIENT MONITORING/
- 84. ((patient\$ or physical\$ or physiologic\$) adj2 (assess\$ or monitor\$)).tw.
- 85. or/83-84
- 86. RISK ASSESSMENT/
- 87. risk\$.tw.
- 88. TIME/
- 89. or/86-88
- 90. CLINICAL OBSERVATION/
- 91. observ\$.tw.
- 92. or/90-91
- 93. and/89,92
- 94. or/85,93
- 95. and/82,94
- 96. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 97. 95 not 96

FEVER_patient_observation_cinahl_210206

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.

- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.

- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. MONITORING, PHYSIOLOGIC/
- 82. ((patient\$ or physical\$ or physiologic\$) adj2 (assess\$ or monitor\$)).tw.
- 83. or/81-82
- 84. RISK ASSESSMENT/
- 85. risk\$.tw.
- 86. TIME FACTORS/
- 87. or/84-86
- 88. OBSERVATION UNITS/
- 89. observ\$.tw.
- 90. or/88-89
- 91. and/87,90
- 92. or/83,91

93. and/80,92

FEVER_perception_medline_010306

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ACUTE DISEASE/
- 19. (acute adj (disease\$ or illness\$)).tw.
- 20. or/18-19
- 21. BACTERIAL INFECTIONS/
- 22. (bacteri\$ adj infect\$).tw.
- 23. or/21-22
- 24. exp MENINGITIS, BACTERIAL/
- 25. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 26. meningococc\$.tw.
- 27. or/24-26
- 28. SEPTICEMIA/
- 29. septicemi\$.tw.
- 30. septicaemia\$.tw.
- 31. or/28-30
- 32. BACTEREMIA/
- 33. bacteremi\$.tw.
- 34. bacteraemia\$.tw.
- 35. or/32-34
- 36. exp PNEUMONIA/

- 37. pneumoni\$.tw.
- 38. or/36-37
- 39. HERPES SIMPLEX/
- 40. herpes simplex.tw.
- 41. or/39-40
- 42. exp ARTHRITIS, INFECTIOUS/
- 43. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 44. pyarthrosis.tw.
- 45. pyoarthritis.tw.
- 46. or/42-45
- 47. STAPHYLOCOCCAL INFECTIONS/
- 48. STREPTOCOCCAL INFECTIONS/
- 49. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 50. or/47-49
- 51. OSTEOMYELITIS/
- 52. osteomyeliti\$.tw.
- 53. or/51-52
- 54. exp URINARY TRACT INFECTIONS/
- 55. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 56. UTI.tw.
- 57. ((upper or lower) adj5 urin\$).tw.
- 58. exp CYSTITIS/
- 59. cystitis\$.tw.
- 60. PYELONEPHRITIS/
- 61. pyelonephriti\$.tw.
- 62. pyonephrosi\$.tw.
- 63. pyelocystiti\$.tw.
- 64. or/54-63
- 65. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 66. (mucocutaneous adj2 lymph\$).tw.
- 67. mcls.tw.
- 68. (kawasaki adj (disease or syndrome)).tw.
- 69. or/65-68
- 70. or/20,23,27,31,35,38,41,46,50,53,64,69
- 71. "ATTITUDE OF HEALTH PERSONNEL"/
- 72. PERCEPTION/
- 73. perception.tw.
- 74. perceive\$.tw.

- 75. or/71-74
- 76. and/17,70,75
- 77. animal/ not (human/ or (human/ and animal/))
- 78. 76 not 77

FEVER_perception_embase_010306

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ACUTE DISEASE/
- 19. (acute adj (disease\$ or illness\$)).tw.
- 20. or/18-19
- 21. BACTERIAL INFECTION/
- 22. (bacteri\$ adj infect\$).tw.
- 23. or/21-22
- 24. BACTERIAL MENINGITIS/
- 25. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 26. meningococc\$.tw.
- 27. or/24-26
- 28. SEPTICEMIA/
- 29. septicemi\$.tw.
- 30. septicaemia\$.tw.
- 31. or/28-30
- 32. BACTEREMIA/
- 33. bacteremi\$.tw.

- 34. bacteraemia\$.tw.
- 35. or/32-34
- 36. exp PNEUMONIA/
- 37. pneumoni\$.tw.
- 38. or/36-37
- 39. HERPES SIMPLEX/
- 40. herpes simplex.tw.
- 41. or/39-40
- 42. BACTERIAL ARTHRITIS/
- 43. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 44. pyarthrosis.tw.
- 45. pyoarthritis.tw.
- 46. or/42-45
- 47. STAPHYLOCOCCAL INFECTION/
- 48. STREPTOCOCCAL INFECTION/
- 49. straphylococc\$.tw.
- 50. streptococc\$.tw.
- 51. or/47-50
- 52. OSTEOMYELITIS/
- 53. osteomyeliti\$.tw.
- 54. or/52-53
- 55. exp URINARY TRACT INFECTION/
- 56. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 57. UTI.tw.
- 58. ((upper or lower) adj5 urin\$).tw.
- 59. exp CYSTITIS/
- 60. cystitis\$.tw.
- 61. or/55-60
- 62. PYELONEPHRITIS/
- 63. pyelonephriti\$.tw.
- 64. pyonephrosi\$.tw.
- 65. pyelocystiti\$.tw.
- 66. or/62-65
- 67. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 68. (mucocutaneous adj2 lymph\$).tw.
- 69. mcls.tw.
- 70. (kawasaki adj (disease or syndrome)).tw.
- 71. or/67-70

- 72. or/20,23,27,31,35,38,41,46,51,54,61,66,71
- 73. "HEALTH PERSONNEL ATTITUDE"/
- 74. PERCEPTION/
- 75. perception.tw.
- 76. perceive\$.tw.
- 77. or/73-76
- 78. and/17,72,77
- 79. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 80. 78 not 79

FEVER_perception_cinahl_010306

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. ACUTE DISEASE/
- 19. (acute adj (disease\$ or illness\$)).tw.
- 20. or/18-19
- 21. BACTERIAL INFECTIONS/
- 22. (bacteri\$ adj infect\$).tw.
- 23. or/21-22
- 24. exp MENINGITIS, BACTERIAL/
- 25. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 26. meningococc\$.tw.
- 27. or/24-26
- 28. exp SEPSIS/

- 29. septicemi\$.tw.
- 30. septicaemia\$.tw.
- 31. or/28-30
- 32. BACTEREMIA/
- 33. bacteremi\$.tw.
- 34. bacteraemia\$.tw.
- 35. or/32-34
- 36. exp PNEUMONIA/
- 37. pneumoni\$.tw.
- 38. or/36-37
- 39. HERPES SIMPLEX/
- 40. herpes simplex.tw.
- 41. or/39-40
- 42. exp ARTHRITIS, INFECTIOUS/
- 43. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 44. pyarthrosis.tw.
- 45. pyoarthritis.tw.
- 46. or/42-45
- 47. STAPHYLOCOCCAL INFECTIONS/
- 48. STREPTOCOCCAL INFECTIONS/
- 49. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 50. or/47-49
- 51. OSTEOMYELITIS/
- 52. osteomyeliti\$.tw.
- 53. or/51-52
- 54. exp URINARY TRACT INFECTION/
- 55. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 56. UTI.tw.
- 57. ((upper or lower) adj5 urin\$).tw.
- 58. CYSTITIS/
- 59. cystitis\$.tw.
- 60. PYELONEPHRITIS/
- 61. pyelonephriti\$.tw.
- 62. pyonephrosi\$.tw.
- 63. pyelocystiti\$.tw.
- 64. or/54-63
- 65. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 66. (mucocutaneous adj2 lymph\$).tw.

- 67. mcls.tw.
- 68. (kawasaki adj (disease or syndrome)).tw.
- 69. or/65-68
- 70. or/20,23,27,31,35,38,41,46,50,53,64,69
- 71. "ATTITUDE OF HEALTH PERSONNEL"/
- 72. PERCEPTION/
- 73. perception.tw.
- 74. perceive\$.tw.
- 75. or/71-74
- 76. and/17,70,75

FEVER_prediction_severity_illness_medline_270905

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27

- 29. and/17,28
- 30. "SEVERITY OF ILLNESS INDEX"/
- 31. (sever\$ adj3 (disease\$ or illness\$ or infect\$)).tw.
- 32 or/30-31
- 33. (temperature\$ adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 34. ((fever\$ or febrile\$ or hypertherm\$ or pyre\$) adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 35. or/33,34
- 36. and/32,35
- 37. and/29,36
- 38. animal/ not (human/ or (human/ and animal/))
- 39. 37 not 38

FEVER_prediction_severity_illness_embase_270905

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.

- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. HOSPITALIZATION/
- 31. (sever\$ adj3 (disease\$ or illness\$ or infect\$)).tw.
- 32. or/30-31
- 33. (temperature\$ adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 34. (fever\$ adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 35. or/33-34
- 36. and/32,35
- 37. and/29,36
- 38. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 39. 37 not 38

FEVER_prediction_severity_illness_cinahl_270905

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.

- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. "SEVERITY OF ILLNESS INDICES"/
- 31. (sever\$ adj3 (disease\$ or illness\$ or infect\$)).tw.
- 32. or/30-31
- 33. (temperature\$ adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 34. (fever\$ adj3 (classif\$ or correlat\$ or degree\$ or height\$ or indicat\$ or magnitude\$ or predict\$ or sever\$ or stratif\$)).tw.
- 35. or/33-34
- 36. and/32,35
- 37. and/29,36

FEVER_procalcitonin_medline_120406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/

- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.

- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. CALCITONIN/
- 69. calcitoni\$.tw.
- 70. PROTEIN PRECURSORS/
- 71. procalcitonin.tw.
- 72. or/68-71
- 73. exp "SENSITIVITY AND SPECIFICITY"/
- 74. (sensitivity or specificity).tw.
- 75. (predictive adj value\$).tw.
- 76. LIKELIHOOD FUNCTIONS/
- 77. (likelihood adj (estimate\$ or ratio\$)).tw.
- 78. exp DIAGNOSTIC ERRORS/
- 79. (false adj (negative\$ or positive\$)).tw.
- 80. "REPRODUCIBILITY OF RESULTS"/
- 81. DIAGNOSIS, DIFFERENTIAL/
- 82. (differential adj diagnos\$).tw.
- 83. or/73-82
- 84. and/17,67,72,83
- 85. animal/ not (human/ or (human/ and animal/))
- 86. 84 not 85

FEVER_procalcitonin_embase_120406

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.

- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47

- 49. OSTEOMYELITIS/
- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.
- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/
- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. CALCITONIN/
- 71. calcitoni\$.tw.
- 72. PROTEIN PRECURSORS/
- 73. PROCALCITONIN/
- 74. procalcitonin.tw.
- 75. or/70-74
- 76. exp "SENSITIVITY AND SPECIFICITY"/
- 77. (sensitivity or specificity).tw.
- 78. (predictive adj value\$).tw.
- 79. STATISTICAL MODEL/
- 80. (likelihood adj (estimate\$ or ratio\$)).tw.
- 81. DIAGNOSTIC ERROR/
- 82. (false adj (negative\$ or positive\$)).tw.
- 83. REPRODUCIBILITY/
- 84. DIFFERENTIAL DIAGNOSIS/
- 85. (differential adj diagnos\$).tw.
- 86. or/76-85

- 87. and/17,69,75,86
- 88. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 89. 87 not 88

FEVER_procalcitonin_cinahl_120406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.

- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. CALCITONIN/
- 69. calcitoni\$.tw.
- 70. PROTEIN PRECURSORS/
- 71. procalcitonin.tw.
- 72. or/68-71

73. and/17,67,72

FEVER_prognosis_medline_251105

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35

- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTIONS/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. exp CYSTITIS/
- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/

- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. exp COHORT STUDIES/
- 82. exp MORTALITY/
- 83. exp MORBIDITY/
- 84. natural history.ti,ab.
- 85. prognos\$.ti,ab.
- 86. course.ti,ab.
- 87. predict\$.ti,ab.
- 88. exp "OUTCOME ASSESSMENT (HEALTH CARE)"/
- 89. outcome\$.ti,ab.
- 90. (inception adj cohort\$).ti,ab.
- 91. DISEASE PROGRESSION/
- 92. exp SURVIVAL ANALYSIS/
- 93. exp PROGNOSIS/
- 94. or/81-93
- 95. and/80,94
- 96. animal/ not (human/ or (human/ and animal/))
- 97. 95 not 96

FEVER_prognosis_embase_251105

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.

- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.

- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69
- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. exp COHORT STUDIES/
- 84. exp MORTALITY/
- 85. exp MORBIDITY/
- 86. natural history.ti,ab.
- 87. prognos\$.ti,ab.
- 88. course.ti,ab.
- 89. predict\$.ti,ab.
- 90. exp "OUTCOME ASSESSMENT (HEALTH CARE)"/
- 91. outcome\$.ti,ab.

- 92. (inception adj cohort\$).ti,ab.
- 93. DISEASE PROGRESSION/
- 94. exp SURVIVAL ANALYSIS/
- 95. exp PROGNOSIS/
- 96. or/83-95
- 97. and/82,96
- 98. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 99. 97 not 98

FEVER_prognosis_cinahl_251105

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTIONS/

- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. exp MENINGITIS, BACTERIAL/
- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. exp SEPSIS/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. exp ARTHRITIS, INFECTIOUS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTIONS/
- 57. STREPTOCOCCAL INFECTIONS/
- 58. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 59. or/56-58
- 60. OSTEOMYELITIS/
- 61. osteomyeliti\$.tw.
- 62. or/60-61
- 63. exp URINARY TRACT INFECTION/
- 64. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 65. UTI.tw.
- 66. ((upper or lower) adj5 urin\$).tw.
- 67. CYSTITIS/

- 68. cystitis\$.tw.
- 69. PYELONEPHRITIS/
- 70. pyelonephriti\$.tw.
- 71. pyonephrosi\$.tw.
- 72. pyelocystiti\$.tw.
- 73. or/63-72
- 74. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 75. (mucocutaneous adj2 lymph\$).tw.
- 76. mcls.tw.
- 77. (kawasaki adj (disease or syndrome)).tw.
- 78. or/74-77
- 79. or/32,36,40,44,47,50,55,59,62,73,78
- 80. and/29,79
- 81. exp COHORT STUDIES/
- 82. exp MORTALITY/
- 83. exp MORBIDITY/
- 84. natural history.ti,ab.
- 85. prognos\$.ti,ab.
- 86. course.ti,ab.
- 87. predict\$.ti,ab.
- 88. OUTCOME ASSESSMENT/
- 89. outcome\$.ti,ab.
- 90. (inception adj cohort\$).ti,ab.
- 91. DISEASE PROGRESSION/
- 92. exp SURVIVAL ANALYSIS/
- 93. exp PROGNOSIS/
- 94. or/81-93
- 95. and/80,94

FEVER_serious_bacterial_infections_epidemiology_medline_101105

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.

- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/

- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. and/17,67
- 69. EPIDEMIOLOGY/
- 70. epidemiolog\$.tw.
- 71. BACTERIAL INFECTIONS/ep
- 72. MENINGITIS, BACTERIAL/ep
- 73. SEPTICEMIA/ep
- 74. BACTEREMIA/ep
- 75. PNEUMONIA/ep
- 76. HERPES SIMPLEX/ep
- 77. ARTHRITIS, INFECTIOUS/ep
- 78. STAPHYLOCOCCAL INFECTIONS/ep
- 79. STREPTOCOCCAL INFECTIONS/ep
- 80. OSTEOMYELITIS/ep
- 81. URINARY TRACT INFECTIONS/ep
- 82. CYSTITIS/ep
- 83. PYELONEPHRITIS/ep
- 84. MUCOCUTANEOUS LYMPH NODE SYNDROME/ep
- 85. or/69-84
- 86. and/68,85

- 87. exp GREAT BRITAIN/
- 88. (britain or england or northern ireland or scotland or united kingdom or wales).tw.
- 89. or/87-88
- 90. and/86,89
- 91. limit 90 to yr="1992 2006"

FEVER_serious_bacterial_infections_epidemiology_embase_101105

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BACTERIAL INFECTION/
- 31. (bacteri\$ adj infect\$).tw.
- 32. or/30-31
- 33. BACTERIAL MENINGITIS/

- 34. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 35. meningococc\$.tw.
- 36. or/33-35
- 37. SEPTICEMIA/
- 38. septicemi\$.tw.
- 39. septicaemia\$.tw.
- 40. or/37-39
- 41. BACTEREMIA/
- 42. bacteremi\$.tw.
- 43. bacteraemia\$.tw.
- 44. or/41-43
- 45. exp PNEUMONIA/
- 46. pneumoni\$.tw.
- 47. or/45-46
- 48. HERPES SIMPLEX/
- 49. herpes simplex.tw.
- 50. or/48-49
- 51. BACTERIAL ARTHRITIS/
- 52. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 53. pyarthrosis.tw.
- 54. pyoarthritis.tw.
- 55. or/51-54
- 56. STAPHYLOCOCCAL INFECTION/
- 57. STREPTOCOCCAL INFECTION/
- 58. straphylococc\$.tw.
- 59. streptococc\$.tw.
- 60. or/56-59
- 61. OSTEOMYELITIS/
- 62. osteomyeliti\$.tw.
- 63. or/61-62
- 64. exp URINARY TRACT INFECTION/
- 65. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 66. UTI.tw.
- 67. ((upper or lower) adj5 urin\$).tw.
- 68. exp CYSTITIS/
- 69. cystitis\$.tw.
- 70. or/64-69

- 71. PYELONEPHRITIS/
- 72. pyelonephriti\$.tw.
- 73. pyonephrosi\$.tw.
- 74. pyelocystiti\$.tw.
- 75. or/71-74
- 76. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 77. (mucocutaneous adj2 lymph\$).tw.
- 78. mcls.tw.
- 79. (kawasaki adj (disease or syndrome)).tw.
- 80. or/76-79
- 81. or/32,36,40,44,47,50,55,60,63,70,75,80
- 82. and/29,81
- 83. EPIDEMIOLOGY/
- 84. epidemiolog\$.tw.
- 85. BACTERIAL INFECTION/ep
- 86. BACTERIAL MENINGITIS/ep
- 87. PNEUMONIA/ep
- 88. HERPES SIMPLEX/ep
- 89. BACTERIAL ARTHRITIS/ep
- 90. STAPHYLOCOCCAL INFECTION/ep
- 91. STREPTOCOCCAL INFECTION/ep
- 92. OSTEOMYELITIS/ep
- 93. URINARY TRACT INFECTION/ep
- 94. CYSTITIS/ep
- 95. PYELONEPHRITIS/ep
- 96. MUCOCUTANEOUS LYMPH NODE SYNDROME/ep
- 97. or/83-96
- 98. and/82,97
- 99. exp UNITED KINGDOM/
- 100. (britain or england or northern ireland or scotland or united kingdom or wales).tw.
- 101. or/99-100
- 102. and/98,101
- 103. limit 102 to yr="1992 2006"

FEVER_serious_bacterial_infections_epidemiology_cinahl_101105

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.

- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42

- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. and/17,67
- 69. EPIDEMIOLOGY/
- 70. epidemiolog\$.tw.
- 71. BACTERIAL INFECTIONS/ep
- 72. MENINGITIS, BACTERIAL/ep
- 73. SEPSIS/ep
- 74. BACTEREMIA/ep
- 75. PNEUMONIA/ep
- 76. HERPES SIMPLEX/ep
- 77. ARTHRITIS, INFECTIOUS/ep
- 78. STAPHYLOCOCCAL INFECTIONS/ep
- 79. STREPTOCOCCAL INFECTIONS/ep
- 80. OSTEOMYELITIS/ep
- 81. URINARY TRACT INFECTION/ep

- 82. CYSTITIS/ep
- 83. PYELONEPHRITIS/ep
- 84. MUCOCUTANEOUS LYMPH NODE SYNDROME/ep
- 85. or/69-84
- 86. and/68,85
- 87. exp GREAT BRITAIN/
- 88. (britain or england or northern ireland or scotland or united kingdom or wales).tw.
- 89. or/87-88
- 90. and/86,89
- 91. limit 90 to yr="1992 2005"

FEVER_severity_of_illness_indices_medline_250106

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.

- 28. or/18-27
- 29. and/17,28
- 30. "SEVERITY OF ILLNESS INDEX"/
- 31. ((illness or severity) adj3 (classif\$ or criteria or index or indice\$ or scale\$)).tw.
- 32. (yale adj2 (observation or scale)).tw.
- 33. (rochester adj2(criteria or scale)).tw.
- 34. RISK ASSESSMENT/
- 35. (risk adj (assess\$ or criteria\$)).tw.
- 36. or/30-35
- 37. and/29,36
- 38. animal/ not (human/ or (human/ and animal/))
- 39. 37 not 38

FEVER_severity_of_illness_indices_embase_250106

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.

- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. HOSPITALIZATION/
- 31. ((illness or severity) adj3 (classif\$ or criteria or index or indice\$ or scale\$)).tw.
- 32. (yale adj2 (observation or scale)).tw.
- 33. (rochester adj (criteria or scale)).tw.
- 34. SCORING SYSTEM/
- 35. RISK ASSESSMENT/
- 36. (risk adj (assess\$ or criteria\$)).tw.
- 37. or/30-36
- 38. and/29,37
- 39. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 40. 38 not 39

FEVER_severity_of_illness_indices_cinahl_250106

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.

- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. "SEVERITY OF ILLNESS INDEX"/
- 31. ((illness or severity) adj3 (classif\$ or criteria or index or indice\$ or scale\$)).tw.
- 32. (yale adj2 (observation or scale)).tw.
- 33. (rochester adj (criteria or scale)).tw.
- 34. RISK ASSESSMENT/
- 35. (risk adj (assess\$ or criteria\$)).tw.
- 36. or/30-35
- 37. and/29,36

FEVER_signs_symptoms_prospective_medline_200306

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.

- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.

- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp "SIGNS AND SYMPTOMS"/
- 69. (sign\$ adj2 symptom\$).tw.
- 70. or/68-69
- 71. COHORT STUDIES/
- 72. LONGITUDINAL STUDIES/
- 73. FOLLOW-UP STUDIES/
- 74. PROSPECTIVE STUDIES/
- 75. ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw.
- 76. or/71-75
- 77. and/17,67,70,76
- 78. animal/ not (human/ or (human/ and animal/))
- 79. 77 not 78
- 80. limit 79 to yr="1985 2006"

 ${\sf FEVER_signs_symptoms_prospective_embase_200306}$

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16

- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47
- 49. OSTEOMYELITIS/
- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.

- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/
- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. exp "PHYSICAL DISEASE BY BODY FUNCTION"/
- 71. (sign\$ adj2 symptom\$).tw.
- 72. or/70-71
- 73. COHORT STUDIES/
- 74. LONGITUDINAL STUDIES/
- 75. FOLLOW-UP STUDIES/
- 76. PROSPECTIVE STUDIES/
- 77. ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw.
- 78. or/73-77
- 79. and/17,69,72,78
- 80. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 81. 79 not 80
- 82. limit 81 to yr="1985 2006"

FEVER_signs_symptoms_prospective_cinahl_200306

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.

- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46

- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp "SIGNS AND SYMPTOMS"/
- 69. (sign\$ adj2 symptom\$).tw.
- 70. or/68-69
- 71. COHORT STUDIES/
- 72. LONGITUDINAL STUDIES/
- 73. FOLLOW-UP STUDIES/
- 74. PROSPECTIVE STUDIES/
- 75. ((cohort\$ or follow-up or follow?up or inciden\$ or longitudinal or prospective) adj1 (stud\$ or research or analys\$)).tw.
- 76. or/71-75
- 77. and/17,67,70,76
- 78. limit 77 to yr="1985 2006"

FEVER_signs_symptoms_retrospective_medline_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.

- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42

- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp "SIGNS AND SYMPTOMS"/
- 69. (sign\$ adj2 symptom\$).tw.
- 70. or/68-69
- 71. RETROSPECTIVE STUDIES/
- 72. retrospective\$.tw.
- 73. or/71-72
- 74. and/17,67,70,73
- 75. animal/ not (human/ or (human/ and animal/))
- 76. 74 not 75
- 77. limit 76 to yr="1985 2006"

FEVER_signs_symptoms_retrospective_embase_090506

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/

- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.

- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47
- 49. OSTEOMYELITIS/
- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.
- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/
- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. exp "PHYSICAL DISEASE BY BODY FUNCTION"/
- 71. (sign\$ adj2 symptom\$).tw.
- 72. or/70-71
- 73. RETROSPECTIVE STUDY/
- 74. retrospective\$.tw.
- 75. or/73-74
- 76. and/17,69,72,75
- 77. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 78. 76 not 77
- 79. limit 78 to yr="1985 2006"

FEVER_signs_symptoms_retrospective_cinahl_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.

- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. exp "SIGNS AND SYMPTOMS"/
- 69. (sign\$ adj2 symptom\$).tw.
- 70. or/68-69
- 71. RETROSPECTIVE DESIGN/
- 72. retrospective\$.tw.
- 73. or/71-72
- 74. and/17,67,70,73
- 75. limit 74 to yr="1985 2006"

FEVER_subjective_diagnosis_medline_050905

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. (carer\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 31. ((maternal\$ or mother\$) adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 32. (parent\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 33. (subjective\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 34. or/30-33
- 35. PALPATION/

- 36. (palpation adj5 (fever\$ or febril\$ or hypertherm\$ or pyrexi\$)).tw.
- 37. ((tactile or touch) adj2 examin\$).tw.
- 38. or/35-37
- 39. or/34,38
- 40. and/29,39
- 41. animal/ not (human/ or (human/ and animal/))
- 42. 40 not 41

FEVER_subjective_diagnosis_embase_060905

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. (carer\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.

- 31. ((maternal\$ or mother\$) adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 32. (parent\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 33. (subjective\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 34. or/30-33
- 35. PALPATATION/
- 36. (palpation adj5 (fever\$ or febril\$ or hypertherm\$ or pyrexi\$)).tw.
- 37. ((tactile or touch) adj2 examin\$).tw.
- 38. or/35-37
- 39. or/34,38
- 40. and/29,39
- 41. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 42. 40 not 41

FEVER_subjective_diagnosis_cinahl_060905

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/

- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17.28
- 30. (carer\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 31. ((maternal\$ or mother\$) adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 32. (parent\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 33. (subjective\$ adj2 (assess\$ or detect\$ or determin\$ or diagnos\$ or evaluat\$ or measur\$ or perceive\$ or perception\$ or presence\$)).tw.
- 34. or/30-33
- 35. PALPATION/
- 36. (palpation adj5 (fever\$ or febril\$ or hypertherm\$ or pyrexi\$)).tw.
- 37. ((tactile or touch) adj2 examin\$).tw.
- 38. or/35-37
- 39. or/34,38
- 40. and/29,39
- 41. animal/ not (human/ or (human/ and animal/))
- 42. 40 not 41

FEVER_temperature_measurement_medline_050805

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16

- 18. BODY TEMPERATURE/
- 19. ((bodies or body\$) adj2 temperature\$).tw.
- 20. ((axillar\$ or forehead\$ or oral\$ or rect\$ or skin\$ or surface\$ or topical\$) adj2 temperature\$).tw.
- 21. or/18-20
- 22. THERMOMETERS/
- 23. THERMOGRAPHY/mt
- 24. thermomet\$.tw.
- 25. thermograph\$.tw.
- 26. ((chemical\$ or crystal\$ or digital\$ or dispos\$ or electr\$ or forehead\$ or infrared\$ or glass\$ or mercury\$ or tympanic\$) adj5 thermomet\$).tw.
- 27. (pulmonary adj2 artery adj5 temperature).tw.
- 28. *TYMPANIC MEMBRANE/
- 29. INFRARED RAYS/du
- 30. or/22-29
- 31. and/21,30
- 32. and/17,31
- 33. animal/ not (human/ or (human/ and animal/))
- 34. 32 not 33

FEVER_temperature_measurement_embase_050805

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BODY TEMPERATURE/
- 19. ((bodies or body\$) adj2 temperature\$).tw.
- 20. ((axillar\$ or forehead\$ or oral\$ or rect\$ or skin\$ or surface\$ or topical\$) adj2 temperature\$).tw.

- 21. or/18-20
- 22. THERMOMETER/
- 23. THERMOGRAPHY/
- 24. thermomet\$.tw.
- 25. thermograph\$.tw.
- 26. ((chemical\$ or crystal\$ or digital\$ or dispos\$ or electr\$ or forehead\$ or infrared\$ or glass\$ or mercury\$ or tympanic\$) adj5 thermomet\$).tw.
- 27. (pulmonary adj2 artery adj5 temperature).tw.
- 28. *EARDRUM/
- 29. INFRARED RADIATION/du
- 30. or/22-29
- 31. and/21,30
- 32. and/17,31
- 33. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 34. 32 not 33

FEVER_temperature_measurement_cinahl_050805

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BODY TEMPERATURE/
- 19. ((bodies or body\$) adj2 temperature\$).tw.
- 20. ((axillar\$ or forehead\$ or oral\$ or rect\$ or skin\$ or surface\$ or topical\$) adj2 temperature\$).tw.
- 21. or/18-20
- 22. THERMOMETER/
- 23. THERMOGRAPHY/

- 24. thermomet\$.tw.
- 25. thermograph\$.tw.
- 26. ((chemical\$ or crystal\$ or digital\$ or dispos\$ or electr\$ or forehead\$ or infrared\$ or glass\$ or mercury\$ or tympanic\$) adj5 thermomet\$).tw.
- 27. (pulmonary adj2 artery adj5 temperature).tw.
- 28. *TYMPANIC MEMBRANE/
- 29. (infrared adj (rays or radiation)).tw.
- 30. or/22-29
- 31. and/21.30
- 32. and/17,31
- 33. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 34. 32 not 33

FEVER_temperature_measurement_tempadot_medline_110506

- 1. tempa?dot.mp.
- 2. tempa dot.mp.
- 3. or/1-2

FEVER_temperature_measurement_tempadot_embase_110506

- 1. tempa?dot.mp.
- 2. tempa dot.mp.
- 3. or/1-2

FEVER_temperature_measurement_tempadot_cinahl_110506

- 1. tempa?dot.mp.
- 2. tempa dot.mp.
- 3. or/1-2

FEVER temperature reduction medline 171005

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.

- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BODY TEMPERATURE/
- 31. BODY TEMPERATURE REGULATION/
- 32. ((temperature or thermal or thermo) adj2 (reduc\$ or regulat\$)).tw.
- 33. thermoregulat\$.tw.
- 34. cool\$.tw.
- 35. heat loss.tw.
- 36. or/30-35
- 37. ANALGESICS/
- 38. ANALGESICS, NON-NARCOTIC/
- 39. (analges\$ or analget\$ or anodyne\$).tw.
- 40. anti?pyretic\$.tw.
- 41. (antinociceptive adj (agent\$ or drug\$)).tw.
- 42. or/37-41
- 43. ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL/
- 44. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 45. NSAID\$.tw.
- 46. or/43-45
- 47. IBUPROFEN/
- 48. ibuprofen\$.tw.
- 49. or/47-48
- 50. ACETAMINOPHEN/
- 51. acetaminophen\$.tw.
- 52. paracetamol\$.tw.
- 53. or/50-52

- 54. or/42,46,49,53
- 55. CRYOTHERAPY/
- 56. cryother\$.tw.
- 57. cryotreatment\$.tw.
- 58. cryoanalgesi\$.tw.
- 59. cyroanalgesi\$.tw.
- 60. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 61. or/55-60
- 62. BATHS/
- 63. bath\$.tw.
- 64. spong\$.tw.
- 65. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 66. or/62-65
- 67. WATER/
- 68. DRINKING/
- 69. FLUID THERAPY/
- 70. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 71. hydrat\$.tw.
- 72. rehydrat\$.tw.
- 73. or/67-72
- 74. CLOTHING/
- 75. ((light\$ or remov\$) adj2 cloth\$).tw.
- 76. or/74-75
- 77. climatotherap\$.tw.
- 78. (climat\$ adj (therap\$ or treat\$)).tw.
- 79. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 80. fan\$.tw.
- 81. or/77-80
- 82. HYPOTHERMIA, INDUCED/
- 83. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 84. (blanket adj treatment\$).tw.
- 85. swaddling.tw.
- 86. or/82-85
- 87. COMBINED MODALITY THERAPY/
- 88. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 89. or/87-88
- 90. or/54,61,66,73,76,81,86,89
- 91. and/36,90

- 92. and/29,91
- 93. animal/ not (human/ or (human/ and animal/))
- 94. 92 not 93

FEVER_temperature_reduction_embase_171005

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BODY TEMPERATURE/
- 31. THERMOREGULATION/
- 32. thermoregulat\$.tw.
- 33. ((temperature or thermal or thermo) adj2 (reduc\$ or regulat\$)).tw.
- 34. or/30-33
- 35. COOLING/

- 36. cool\$.tw.
- 37. heat loss.tw.
- 38. or/35-37
- 39. or/34,38
- 40. ANALGESIA/
- 41. ANALGESIC AGENT/
- 42. (analges\$ or analget\$ or anodyne\$).tw.
- 43. (antinociceptive adj (agent\$ or drug\$)).tw.
- 44. ANTIPYRETIC AGENT/
- 45. anti?pyretic\$.tw.
- 46. or/40-45
- 47. NONSTEROID ANTIINFLAMMATORY AGENT/
- 48. (non?steroid\$ adj anti?inflammatory adj (agent\$ or drug\$)).tw.
- 49. NSAID\$.tw.
- 50. or/47-49
- 51. IBUPROFEN/
- 52. ibuprofen\$.tw.
- 53. or/51-52
- 54. PARACETAMOL/
- 55. paracetamol\$.tw.
- 56. acetaminophen\$.tw.
- 57. or/54-56
- 58. or/46,50,53,57
- 59. CRYOTHERAPY/
- 60. cryother\$.tw.
- 61. cryotreatment\$.tw.
- 62. CRYOANESTHESIA/
- 63. cryoanalgesi\$.tw.
- 64. cyroanalgesi\$.tw.
- 65. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 66. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 67. (blanket adj treatment\$).tw.
- 68. swaddling.tw.
- 69. or/59-68
- 70. BATH/
- 71. bath\$.tw.
- 72. spong\$.tw.
- 73. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 74. or/70-73

- 75. WATER/
- 76. FLUID THERAPY/
- 77. FLUID INTAKE/
- 78. FLUID BALANCE/
- 79. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 80. HYDRATION/
- 81. REHYDRATION/
- 82. hydrat\$.tw.
- 83. rehydrat\$.tw.
- 84. or/75-83
- 85. CLOTHING/
- 86. ((light\$ or remov\$) adj2 cloth\$).tw.
- 87. or/85-86
- 88. CLIMATOTHERAPY/
- 89. climatotherap\$.tw.
- 90. (climat\$ adj (therap\$ or treat\$)).tw.
- 91. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 92. fan\$.tw.
- 93. or/88-92
- 94. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 95. or/58,69,74,84,87,93-94
- 96. and/39,95
- 97. and/29,96
- 98. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 99. 97 not 98

FEVER_temperature_reduction_cinahl_171005

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.

- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. BODY TEMPERATURE/
- 31. BODY TEMPERATURE REGULATION/
- 32. ((temperature or thermal or thermo) adj2 (reduc\$ or regulat\$)).tw.
- 33. thermoregulat\$.tw.
- 34. cool\$.tw.
- 35. heat loss.tw.
- 36. or/30-35
- 37. ANALGESIA/
- 38. ANALGESICS/
- 39. ANALGESICS, NONNARCOTIC/
- 40. (analges\$ or analget\$ or anodyne\$).tw.
- 41. (antinociceptive adj (agent\$ or drug\$)).tw.
- 42. (anti-pyretic\$ or antipyretic\$).tw.
- 43. or/37-42
- 44. ANTIINFLAMMATORY AGENTS, NON-STEROIDAL/
- 45. ((non-steroid\$ or nonsteroid\$) adj (anti-inflammatory or antiinflammatory) adj (agent\$ or drug\$)).tw.
- 46. NSAID\$.tw.
- 47. or/44-46
- 48. IBUPROFEN/
- 49. ibuprofen\$.tw.
- 50. or/48-49

- 51. ACETAMINOPHEN/
- 52. acetaminophen\$.tw.
- 53. paracetamol\$.tw.
- 54. or/51-53
- 55. or/43,47,50,54
- 56. CRYOTHERAPY/
- 57. cryother\$.tw.
- 58. cryotreatment\$.tw.
- 59. cryoanalgesi\$.tw.
- 60. cyroanalgesi\$.tw.
- 61. (cold adj2 (analgesi\$ or an?esthe\$ or therap\$ or treat\$)).tw.
- 62. or/56-61
- 63. BATHS/
- 64. bath\$.tw.
- 65. spong\$.tw.
- 66. ((liquid or spray\$ or water) adj2 (cool\$ or immers\$ or submers\$)).tw.
- 67. or/63-66
- 68. WATER/
- 69. DRINKING BEHAVIOR/
- 70. FLUID THERAPY/
- 71. ((drink\$ or fluid\$ or liquid\$ or water\$) adj2 (balance\$ or consum\$ or equilibrium\$ or intake\$ or therap\$)).tw.
- 72. hydrat\$.tw.
- 73. rehydrat\$.tw.
- 74. or/68-73
- 75. CLOTHING/
- 76. ((light\$ or remov\$) adj2 cloth\$).tw.
- 77. or/75-76
- 78. climatotherap\$.tw.
- 79. (climat\$ adj (therap\$ or treat\$)).tw.
- 80. ((ambient\$ or environment\$ or room\$) adj5 (chill\$ or cold\$ or cool\$ or lower\$ or reduc\$)).tw.
- 81. fan\$.tw.
- 82. or/78-81
- 83. HYPOTHERMIA, INDUCED/
- 84. (hypothermi\$ adj2 (blanket\$ or induce\$)).tw.
- 85. (blanket adj treatment\$).tw.
- 86. swaddling.tw.
- 87. or/83-86
- 88. COMBINED MODALITY THERAPY/

- 89. ((modal\$ or multimodal\$) adj (combin\$ or therap\$ or treat\$)).tw.
- 90. or/88-89
- 91. or/55,62,67,74,77,82,87,90
- 92. and/36,91
- 93. and/29,92

FEVER_treatment_iv_fluids_steroids_aciclovir_medline_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp MENINGITIS, BACTERIAL/
- 19. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 20. meningococc\$.tw.
- 21. or/18-20
- 22. exp SEPSIS/
- 23. sepsis.tw.
- 24. exp SEPTICEMIA/
- 25. septicemi\$.tw.
- 26. septicaemia\$.tw.
- 27. SHOCK, SEPTIC/
- 28. (septic adj shock).tw.
- 29. or/22-28
- 30. ENCEPHALITIS, HERPES SIMPLEX/
- 31. HERPES SIMPLEX/
- 32. herpes simplex.tw.

- 33. or/30-32
- 34. or/21,29,33
- 35. INFUSIONS, INTRAVENOUS/
- 36. INFUSIONS, PARENTERAL/
- 37. (infusion\$ adj2 (intravenous or parenteral)).tw.
- 38. bolus.tw.
- 39. or/35-38
- 40. exp ALBUMINS/
- 41. albumin\$.tw.
- 42. or/40-41
- 43. PLASMA SUBSTITUTES/
- 44. plasma substitut\$.tw.
- 45. ((blood or plasma) adj expander\$).tw.
- 46. crystalloid\$.tw.
- 47. or/43-46
- 48. COLLOIDS/
- 49. colloid\$.tw.
- 50. or/48-49
- 51. SODIUM CHLORIDE/
- 52. saline.tw.
- 53. or/51-52
- 54. ELECTROLYTES/
- 55. electrolyte\$.tw.
- 56. or/54-55
- 57. ISOTONIC SOLUTIONS/
- 58. (isotonic adj solution\$).tw.
- 59. or/57-58
- 60. FLUID THERAPY/
- 61. fluid therapy.tw.
- 62. or/60-61
- 63. or/39,42,47,50,53,56,59,62
- 64. exp ADRENAL CORTEX HORMONES/
- 65. adrenal cortex hormone\$.tw.
- 66. corticoid\$.tw.
- 67. corticosteroid\$.tw.
- 68. or/64-67
- 69. exp DEXAMETHASONE/
- 70. dexamethasone\$.tw.
- 71. or/69-70

- 72. or/68,71
- 73. ACYCLOVIR/
- 74. acyclovir.tw.
- 75. aciclovir.tw.
- 76. or/73-75
- 77. or/63,72,76
- 78. and/17,34,77
- 79. exp TREATMENT OUTCOME/
- 80. (treat\$ adj2 (effect\$ or efficac\$ or fail\$ or outcome\$)).tw.
- 81. or/79,80
- 82. and/78,81
- 83. animal/ not (human/ or (human/ and animal/))
- 84. 82 not 83

FEVER_treatment_iv_fluids_steroids_aciclovir_embase_090506

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL MENINGITIS/
- 19. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 20. meningococc\$.tw.
- 21. or/18-20
- 22. SEPSIS/
- 23. sepsis.tw.
- 24. SEPTICEMIA/

- 25. septicemi\$.tw.
- 26. septicaemia\$.tw.
- 27. SEPTIC SHOCK/
- 28. (septic adj shock).tw.
- 29. or/22-28
- 30. HERPES SIMPLEX ENCEPHALITIS/
- 31. HERPES SIMPLEX/
- 32. herpes simplex.tw.
- 33. or/30-32
- 34. or/21,29,33
- 35. BOLUS INJECTION/
- 36. bolus.tw.
- 37. or/35-36
- 38. ALBUMIN/
- 39. albumin\$.tw.
- 40. or/38-39
- 41. exp PLASMA SUBSTITUTE/
- 42. plasma substitut\$.tw.
- 43. ((blood or plasma) adj expander\$).tw.
- 44. crystalloid\$.tw.
- 45. or/41-44
- 46. COLLOID/
- 47. colloid\$.tw.
- 48. or/46-47
- 49. SODIUM CHLORIDE/
- 50. saline.tw.
- 51. or/49-50
- 52. ELECTROLYTE/
- 53. electrolyte\$.tw.
- 54. or/52-53
- 55. ISOTONIC SOLUTION/
- 56. (isotonic adj solution\$).tw.
- 57. or/55-56
- 58. exp FLUID THERAPY/
- 59. fluid therapy.tw.
- 60. or/58-59
- 61. or/37,40,45,48,51,54,57,60
- 62. exp CORTICOSTEROID/
- 63. corticosteroid\$.tw.

- 64. corticoid\$.tw.
- 65. adrenal cortex hormone\$.tw.
- 66. or/62-65
- 67. DEXAMETHASONE/
- 68. dexamethasone\$.tw.
- 69. or/67-68
- 70. or/66,69
- 71. ACICLOVIR/
- 72. aciclovir.tw.
- 73. acyclovir.tw.
- 74. or/71-73
- 75. or/61,70,74
- 76. and/17,34,75
- 77. exp TREATMENT OUTCOME/
- 78. (treat\$ adj2 (effect\$ or efficac\$ or fail\$ or outcome\$)).tw.
- 79. or/77-78
- 80. and/76,79
- 81. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 82. 80 not 81

FEVER_treatment_iv_fluids_steroids_aciclovir_cinahl_090506

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp MENINGITIS, BACTERIAL/

- 19. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 20. meningococc\$.tw.
- 21. or/18-20
- 22. exp SEPSIS/
- 23. septicemi\$.tw.
- 24. septicaemia\$.tw.
- 25. SHOCK, SEPTIC/
- 26. (septic adj shock).tw.
- 27. or/22-26
- 28. HERPES SIMPLEX/
- 29. herpes simplex.tw.
- 30. or/28-29
- 31. or/21,27,30
- 32. INFUSIONS, INTRAVENOUS/
- 33. INFUSIONS, PARENTERAL/
- 34. (infusion\$ adj2 (intravenous or parenteral)).tw.
- 35. bolus.tw.
- 36. or/32-35
- 37. exp ALBUMINS/
- 38. albumin\$.tw.
- 39. or/37-38
- 40. PLASMA SUBSTITUTES/
- 41. plasma substitut\$.tw.
- 42. ((blood or plasma) adj expander\$).tw.
- 43. crystalloid\$.tw.
- 44. or/40-43
- 45. COLLOIDS/
- 46. colloid\$.tw.
- 47. or/45-46
- 48. SODIUM CHLORIDE/
- 49. saline.tw.
- 50. or/48-49
- 51. ELECTROLYTES/
- 52. electrolyte\$.tw.
- 53. or/51-52
- 54. ISOTONIC SOLUTIONS/
- 55. (isotonic adj solution\$).tw.
- 56. or/54-55

- 57. FLUID THERAPY/
- 58. fluid therapy.tw.
- 59. or/57-58
- 60. or/36,39,44,47,50,53,56,59
- 61. exp ADRENAL CORTEX HORMONES/
- 62. adrenal cortex hormone\$.tw.
- 63. corticoid\$.tw.
- 64. corticosteroid\$.tw.
- 65. or/61-64
- 66. exp DEXAMETHASONE/
- 67. dexamethasone\$.tw.
- 68. or/66-67
- 69. or/65,68
- 70. ACYCLOVIR/
- 71. acyclovir.tw.
- 72. aciclovir.tw.
- 73. or/70-72
- 74. or/60,69,73
- 75. and/17,31,74
- 76. exp TREATMENT OUTCOMES/
- 77. (treat\$ adj2 (effect\$ or efficac\$ or fail\$ or outcome\$)).tw.
- 78. or/76-77
- 79. and/75,78

FEVER_treatment_iv_fluids_steroids_aciclovir_health_economics_medline_11050 6

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, POSTMATURE/
- 4. ((postmature\$ or postterm\$ or post?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 5. INFANT, NEWBORN/
- 6. neonat\$.tw.
- 7. newborn\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. INFANT, SMALL FOR GESTATIONAL AGE/
- 11. (small adj2 gestational age).tw.
- 12. INFANT, LOW BIRTH WEIGHT/
- 13. INFANT, VERY LOW BIRTH WEIGHT/
- 14. (low adj birth adj weight).tw.

- 15. (low adj birth?weight).tw.
- 16. lbw.tw.
- 17. vlbw.tw.
- 18. (baby or babies).tw.
- 19. CHILD, PRESCHOOL/
- 20. toddler\$.tw.
- 21. exp CHILD/
- 22. child\$.tw.
- 23. ADOLESCENT/
- 24. adolescen\$.tw.
- 25. juvenile\$.tw.
- 26. youth\$.tw.
- 27. teen\$.tw.
- 28. PUBERTY/
- 29. pubert\$.tw.
- 30. pubesc\$.tw.
- 31. MINORS/
- 32. minors.tw.
- 33. or/1-32
- 34. exp MENINGITIS, BACTERIAL/
- 35. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 36. meningococc\$.tw.
- 37. or/34-36
- 38. exp SEPSIS/
- 39. sepsis.tw.
- 40. exp SEPTICEMIA/
- 41. septicemi\$.tw.
- 42. septicaemia\$.tw.
- 43. SHOCK, SEPTIC/
- 44. (septic adj shock).tw.
- 45. or/38-44
- 46. ENCEPHALITIS, HERPES SIMPLEX/
- 47. HERPES SIMPLEX/
- 48. herpes simplex.tw.
- 49. or/46-48
- 50. or/37,45,49
- 51. INFUSIONS, INTRAVENOUS/
- 52. INFUSIONS, PARENTERAL/

- 53. (infusion\$ adj2 (intravenous or parenteral)).tw.
- 54. bolus.tw.
- 55. or/51-54
- 56. exp ALBUMINS/
- 57. albumin\$.tw.
- 58. or/56-57
- 59. PLASMA SUBSTITUTES/
- 60. plasma substitut\$.tw.
- 61. ((blood or plasma) adj expander\$).tw.
- 62. crystalloid\$.tw.
- 63. or/59-62
- 64. COLLOIDS/
- 65. colloid\$.tw.
- 66. or/64-65
- 67. SODIUM CHLORIDE/
- 68. saline.tw.
- 69. or/67-68
- 70. ELECTROLYTES/
- 71. electrolyte\$.tw.
- 72. or/70-71
- 73. ISOTONIC SOLUTIONS/
- 74. (isotonic adj solution\$).tw.
- 75. or/73-74
- 76. FLUID THERAPY/
- 77. fluid therapy.tw.
- 78. or/76-77
- 79. or/55,58,63,66,69,72,75,78
- 80. exp ADRENAL CORTEX HORMONES/
- 81. adrenal cortex hormone\$.tw.
- 82. corticoid\$.tw.
- 83. corticosteroid\$.tw.
- 84. or/80-83
- 85. exp DEXAMETHASONE/
- 86. dexamethasone\$.tw.
- 87. or/85-86
- 88. or/84,87
- 89. ACYCLOVIR/
- 90. acyclovir.tw.
- 91. aciclovir.tw.

- 92. or/89-91
- 93. or/79,88,92
- 94. ECONOMICS/
- 95. "COSTS AND COST ANALYSIS"/
- 96. COST ALLOCATION/
- 97. COST-BENEFIT ANALYSIS/
- 98. COST CONTROL/
- 99. COST SAVINGS/
- 100. COST OF ILLNESS/
- 101. COST SHARING/
- 102. HEALTH CARE COSTS/
- 103. DIRECT SERVICE COSTS/
- 104. DRUG COSTS/
- 105. EMPLOYER HEALTH COSTS/
- 106. HOSPITAL COSTS/
- 107. HEALTH RESOURCES/
- 108. "HEALTH SERVICES NEEDS AND DEMAND"/
- 109. HEALTH PRIORITIES/
- 110. HEALTH EXPENDITURES/
- 111. CAPITAL EXPENDITURES/
- 112. FINANCIAL MANAGEMENT/
- 113. FINANCIAL MANAGEMENT, HOSPITAL/
- 114. QUALITY-ADJUSTED LIFE YEARS/
- 115. "DEDUCTIBLES AND COINSURANCE"/
- 116. MEDICAL SAVINGS ACCOUNTS/
- 117. ECONOMICS, HOSPITAL/
- 118. ECONOMICS, MEDICAL/
- 119. ECONOMICS, NURSING/
- 120. ECONOMICS, PHARMACEUTICAL/
- 121. MODELS, ECONOMIC/
- 122. MODELS, ECONOMETRIC/
- 123. RESOURCE ALLOCATION/
- 124. HEALTH CARE RATIONING/
- 125. "FEES AND CHARGES"/
- 126. BUDGETS/
- 127. VALUE OF LIFE/
- 128. (financ\$ or fiscal\$ or funding).tw.
- 129. (QALY\$ or life?year\$).tw.
- 130. (econom\$ or cost\$).tw.

- 131. pharmacoeconomic\$.tw.
- 132. ec.fs.
- 133. or/94-132
- 134. and/33,50,93,133

FEVER_treatment_iv_fluids_steroids_aciclovir_health_economics_embase_11050 6

- 1. PREMATURITY/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. exp NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. NEWBORN PERIOD/
- 7. PERINATAL PERIOD/
- 8. perinatal\$.tw.
- 9. postnatal\$.tw.
- 10. exp INFANT/
- 11. INFANCY/
- 12. BABY/
- 13. infan\$.tw.
- 14. (baby or babies).tw.
- 15. SMALL FOR DATE INFANT/
- 16. (small adj2 (date or "gestational age")).tw.
- 17. lbw.tw.
- 18. vlbw.tw.
- 19. CHILD/
- 20. CHILDHOOD/
- 21. PRESCHOOL CHILD/
- 22. SCHOOL CHILD/
- 23. child\$.tw.
- 24. PREPUBERTY/
- 25. PUBERTY/
- 26. prepube\$.tw.
- 27. pubert\$.tw.
- 28. pubesc\$.tw.
- 29. ADOLESCENCE/
- 30. adolescen\$.tw.
- 31. JUVENILE/
- 32. ADOLESCENT/
- 33. juvenile\$.tw.

- 34. minors.tw.
- 35. youth\$.tw.
- 36. teen\$.tw.
- 37. or/1-36
- 38. BACTERIAL MENINGITIS/
- 39. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 40. meningococc\$.tw.
- 41. or/38-40
- 42. SEPSIS/
- 43. sepsis.tw.
- 44. SEPTICEMIA/
- 45. septicemi\$.tw.
- 46. septicaemia\$.tw.
- 47. SEPTIC SHOCK/
- 48. (septic adj shock).tw.
- 49. or/42-48
- 50. HERPES SIMPLEX ENCEPHALITIS/
- 51. HERPES SIMPLEX/
- 52. herpes simplex.tw.
- 53. or/50-52
- 54. or/41,49,53
- 55. BOLUS INJECTION/
- 56. bolus.tw.
- 57. or/55-56
- 58. ALBUMIN/
- 59. albumin\$.tw.
- 60. or/58-59
- 61. exp PLASMA SUBSTITUTE/
- 62. plasma substitut\$.tw.
- 63. ((blood or plasma) adj expander\$).tw.
- 64. crystalloid\$.tw.
- 65. or/61-64
- 66. COLLOID/
- 67. colloid\$.tw.
- 68. or/66-67
- 69. SODIUM CHLORIDE/
- 70. saline.tw.
- 71. or/69-70

- 72. ELECTROLYTE/
- 73. electrolyte\$.tw.
- 74. or/72-73
- 75. ISOTONIC SOLUTION/
- 76. (isotonic adj solution\$).tw.
- 77. or/75-76
- 78. exp FLUID THERAPY/
- 79. fluid therapy.tw.
- 80. or/78-79
- 81. or/57,60,65,68,71,74,77,80
- 82. exp CORTICOSTEROID/
- 83. corticosteroid\$.tw.
- 84. corticoid\$.tw.
- 85. adrenal cortex hormone\$.tw.
- 86. or/82-85
- 87. DEXAMETHASONE/
- 88. dexamethasone\$.tw.
- 89. or/87-88
- 90. or/86,89
- 91. ACICLOVIR/
- 92. aciclovir.tw.
- 93. acyclovir.tw.
- 94. or/91-93
- 95. or/81,90,94
- 96. ECONOMICS/
- 97. HEALTH ECONOMICS/
- 98. ECONOMIC EVALUATION/
- 99. COST BENEFIT ANALYSIS/
- 100. COST CONTROL/
- 101. COST EFFECTIVENESS ANALYSIS/
- 102. COST MINIMIZATION ANALYSIS/
- 103. COST OF ILLNESS/
- 104. COST UTILITY ANALYSIS/
- 105. COST/
- 106. HEALTH CARE COST/
- 107. DRUG COST/
- 108. HEALTH CARE FINANCING/
- 109. HOSPITAL COST/
- 110. SOCIOECONOMICS/

- 111. ECONOMIC ASPECT/
- 112. QUALITY-ADJUSTED LIFE YEARS/
- 113. FINANCIAL MANAGEMENT/
- 114. PHARMACOECONOMICS/
- 115. RESOURCE ALLOCATION/
- 116. (financ\$ or fiscal\$ or funding).tw.
- 117. (QALY\$ or life?year\$).tw.
- 118. (econom\$ or cost\$).tw.
- 119. pharmacoeconomic\$.tw.
- 120. or/96-119
- 121. and/37,54,95,120

FEVER_treatment_iv_fluids_steroids_aciclovir_health_economics_cinahl_110506

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. perinatal\$.tw.
- 7. postnatal\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. (baby or babies).tw.
- 11. INFANT, LOW BIRTH WEIGHT/
- 12. INFANT, VERY LOW BIRTH WEIGHT/
- 13. INFANT, SMALL FOR GESTATIONAL AGE/
- 14. (small adj2 (date or "gestational age")).tw.
- 15. lbw.tw.
- 16. vlbw.tw.
- 17. CHILD/
- 18. CHILD, PRESCHOOL/
- 19. SCHOOL CHILD/
- 20. child\$.tw.
- 21. PREPUBERTY/
- 22. PUBERTY/
- 23. prepube\$.tw.
- 24. pubert\$.tw.
- 25. pubesc\$.tw.
- 26. ADOLESCENCE/
- 27. adolescen\$.tw.

- 28. "MINORS (LEGAL)"/
- 29. juvenile\$.tw.
- 30. minors.tw.
- 31. youth\$.tw.
- 32. teen\$.tw.
- 33. or/1-32
- 34. exp MENINGITIS, BACTERIAL/
- 35. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 36. meningococc\$.tw.
- 37. or/34-36
- 38. exp SEPSIS/
- 39. septicemi\$.tw.
- 40. septicaemia\$.tw.
- 41. SHOCK, SEPTIC/
- 42. (septic adj shock).tw.
- 43. or/38-42
- 44. HERPES SIMPLEX/
- 45. herpes simplex.tw.
- 46. or/44-45
- 47. or/37,43,46
- 48. INFUSIONS, INTRAVENOUS/
- 49. INFUSIONS, PARENTERAL/
- 50. (infusion\$ adj2 (intravenous or parenteral)).tw.
- 51. bolus.tw.
- 52. or/48-51
- 53. exp ALBUMINS/
- 54. albumin\$.tw.
- 55. or/53-54
- 56. PLASMA SUBSTITUTES/
- 57. plasma substitut\$.tw.
- 58. ((blood or plasma) adj expander\$).tw.
- 59. crystalloid\$.tw.
- 60. or/56-59
- 61. COLLOIDS/
- 62. colloid\$.tw.
- 63. or/61-62
- 64. SODIUM CHLORIDE/
- 65. saline.tw.

- 66. or/64-65
- 67. ELECTROLYTES/
- 68. electrolyte\$.tw.
- 69. or/67-68
- 70. ISOTONIC SOLUTIONS/
- 71. (isotonic adj solution\$).tw.
- 72. or/70-71
- 73. FLUID THERAPY/
- 74. fluid therapy.tw.
- 75. or/73-74
- 76. or/52,55,60,63,66,69,72,75
- 77. exp ADRENAL CORTEX HORMONES/
- 78. adrenal cortex hormone\$.tw.
- 79. corticoid\$.tw.
- 80. corticosteroid\$.tw.
- 81. or/77-80
- 82. exp DEXAMETHASONE/
- 83. dexamethasone\$.tw.
- 84. or/82-83
- 85. or/81,84
- 86. ACYCLOVIR/
- 87. acyclovir.tw.
- 88. aciclovir.tw.
- 89. or/86-88
- 90. or/76,85,89
- 91. ECONOMICS/
- 92. "COSTS AND COST ANALYSIS"/
- 93. COST BENEFIT ANALYSIS/
- 94. COST CONTROL/
- 95. COST SAVINGS/
- 96. COST OF ILLNESS/
- 97. HEALTH CARE COSTS/
- 98. ECONOMIC ASPECTS OF ILLNESS/
- 99. ECONOMICS, PHARMACEUTICAL/
- 100. HEALTH CARE FINANCING/
- 101. FINANCIAL MANAGEMENT/
- 102. HOSPITAL COST/
- 103. SOCIOECONOMIC FACTORS/
- 104. HEALTH RESOURCE ALLOCATION/

- 105. (financ\$ or fiscal\$ or funding).tw.
- 106. (QALY\$ or life?year\$).tw.
- 107. (econom\$ or cost\$).tw.
- 108. pharmacoeconomic\$.tw.
- 109. or/91-108
- 110. and/33,47,90,109

FEVER_treatment_oral_pharmaceutical_empirical_medline_270406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. ANTI-INFECTIVE AGENTS/
- 30. antibiotic\$.tw.
- 31. bacteriocide\$.tw.
- 32. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.

- 33. or/29-32
- 34. PENICILLINS/
- 35. penicillin\$.tw.
- 36. or/33-34
- 37. PENICILLIIN G/
- 38. benzylpenicillin\$.tw.
- 39. or/37-38
- 40. AMOXICILLIN/
- 41. amoxicil\$.tw.
- 42. amoxycil\$.tw.
- 43. amoxil\$.tw.
- 44. or/40-43
- 45. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 46. augmentin\$.tw.
- 47. or/45-46
- 48. AMPICILLIN/
- 49. ampicillin\$.tw.
- 50. penbritin\$.tw.
- 51. or/48-50
- 52. CEFADROXIL/
- 53. cefadroxil\$.tw.
- 54. cephadrox\$.tw.
- 55. or/52-54
- 56. CEPHALEXIN/
- 57. cephalexin\$.tw.
- 58. cefalexin\$.tw.
- 59. cefaclor\$.tw.
- 60. ceporex\$.tw.
- 61. keflex\$.tw.
- 62. or/56-61
- 63. CEFIXIME/
- 64. cefixim\$.tw.
- 65. suprax\$.tw.
- 66. or/63-65
- 67. CEFOTAXIME/
- 68. cefotaxim\$.tw.
- 69. cephotaxim\$.tw.
- 70. claforan\$.tw.
- 71. klaforan\$.tw.

- 72. or/67-71
- 73. CEPHALOSPORINS/
- 74. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 75. cefpirome\$.tw.
- 76. or/73-75
- 77. CEFTIZOXIME/
- 78. cefpodoxim\$.tw.
- 79. ceftizoxim\$.tw.
- 80. orelox\$.tw.
- 81. or/77-80
- 82. CEPHRADINE/
- 83. cefradin\$.tw.
- 84. velosef\$.tw.
- 85. or/82-84
- 86. CEFTAZIDIME/
- 87. ceftazidim\$.tw.
- 88. fortum\$.tw.
- 89. or/86-88
- 90. CEFTRIAXONE/
- 91. ceftriaxon\$.tw.
- 92. rocephin\$.tw.
- 93. or/90-92
- 94. CEFUROXIME/
- 95. cefuroxim\$.tw.
- 96. zinacef\$.tw.
- 97. zinnat\$.tw.
- 98. or/94-97
- 99. GENTAMICINS/
- 100. gentamicin\$.tw.
- 101. cidomycin\$.tw.
- 102. genticin\$.tw.
- 103. or/99-102
- 104. AMIKACIN/
- 105. amikacin\$.tw.
- 106. or/104-105
- 107. AMINOGLYCOSIDES/
- 108. aminoglycoside\$.tw.
- 109. aminoglucoside\$.tw.
- 110. or/107-109

- 111. TOBRAMYCIN/
- 112. tobramycin\$.tw.
- 113. nebcin\$.tw.
- 114. tobi.tw.
- 115. or/111-114
- 116. NETILMICIN/
- 117. netilmicin\$.tw.
- 118. netillin\$.tw.
- 119. or/116-118
- 120. or/33,36,39,44,47,51,55,62,66,72,76,81,85,89,93,98,103,106,110,115,119
- 121. exp ADMINISTRATION, ORAL/
- 122. (administ\$ adj2 (mouth or oral\$)).tw.
- 123. or/121-122
- 124. empiric\$.tw.
- 125. ((blind\$ or early) adj5 treat\$).tw.
- 126. or/124-125
- 127. and/17,28,120,123,126
- 128. animal/ not (human/ or (human/ and animal/))
- 129. 127 not 128

FEVER_treatment_oral_pharmaceutical_empirical_embase_270406

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/

- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. ANTIINFECTIVE AGENT/
- 30. ANTIBIOTIC AGENT/
- 31. antibiotic\$.tw.
- 32. bacteriocide\$.tw.
- 33. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 34. penicillin\$.tw.
- 35. PENICILLIN G/
- 36. benzylpenicillin\$.tw.
- 37. or/29-36
- 38. AMOXICILLIN/
- 39. amoxicil\$.tw.
- 40. amoxycil\$.tw.
- 41. amoxil\$.tw.
- 42. or/38-41
- 43. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 44. augmentin\$.tw.
- 45. or/43-44
- 46. AMPICILLIN/
- 47. ampicillin\$.tw.
- 48. penbritin\$.tw.
- 49. or/46-48
- 50. CEFADROXIL/
- 51. cefadroxil\$.tw.
- 52. cephadrox\$.tw.
- 53. or/50-52
- 54. CEPHALEXIN/
- 55. cephalexin\$.tw.
- 56. cefalexin\$.tw.
- 57. cefaclor\$.tw.
- 58. ceporex\$.tw.

- 59. keflex\$.tw.
- 60. or/54-59
- 61. CEFIXIME/
- 62. cefixim\$.tw.
- 63. suprax\$.tw.
- 64. or/61-63
- 65. CEFOTAXIME/
- 66. cefotaxim\$.tw.
- 67. cephotaxim\$.tw.
- 68. claforan\$.tw.
- 69. klaforan\$.tw.
- 70. or/65-69
- 71. CEPHALOSPORINS/
- 72. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 73. cefpirome\$.tw.
- 74. cefrom\$.tw.
- 75. or/71-74
- 76. CEFTIZOXIME/
- 77. cefpodoxim\$.tw.
- 78. ceftizoxim\$.tw.
- 79. orelox\$.tw.
- 80. or/76-79
- 81. CEPHRADINE/
- 82. cefradin\$.tw.
- 83. velosef\$.tw.
- 84. or/81-83
- 85. CEFTAZIDIME/
- 86. ceftazidim\$.tw.
- 87. fortum\$.tw.
- 88. kefadim\$.tw.
- 89. or/85-88
- 90. CEFTRIAXONE/
- 91. ceftriaxon\$.tw.
- 92. rocephin\$.tw.
- 93. or/90-92
- 94. CEFUROXIME/
- 95. cefuroxim\$.tw.
- 96. zinacef\$.tw.
- 97. zinnat\$.tw.

- 98. or/94-97
- 99. GENTAMICINS/
- 100. gentamicin\$.tw.
- 101. cidomycin\$.tw.
- 102. genticin\$.tw.
- 103. or/99-102
- 104. AMIKACIN/
- 105. amikacin\$.tw.
- 106. AMINOGLYCOSIDE/
- 107. (aminoglycoside\$ or aminoglucoside\$).tw.
- 108. TOBRAMYCIN/
- 109. tobramycin\$.tw.
- 110. TOBRAMYCIN SULPHATE/
- 111. nebcin\$.tw.
- 112. tobi.tw.
- 113. NETILMICIN/
- 114. netilmicin\$.tw.
- 115. netillin\$.tw.
- 116. or/104-115
- 117. or/37,42,45,49,53,60,64,70,75,80,84,89,93,98,103,116
- 118. ORAL DRUG ADMINISTRATION/
- 119. (administ\$ adj2 (mouth or oral\$)).tw.
- 120. or/118-119
- 121. empiric\$.tw.
- 122. ((blind\$ or early) adj5 treat\$).tw.
- 123. or/121-122
- 124. and/17,28,117,120,123
- 125. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 126. 124 not 125

FEVER_treatment_oral_pharmaceutical_empirical_cinahl_270406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- Ibw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.

- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. ANTIINFECTIVE AGENT/
- 30. ANTIBIOTIC AGENT/
- 31. PENICILLINS/
- 32. penicillin\$.tw.
- 33. antibiotic\$.tw.
- 34. bacteriocide\$.tw.
- 35. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 36. or/29-35
- 37. AMOXICILLIN/
- 38. amoxicil\$.tw.
- 39. amoxycil\$.tw.
- 40. amoxil\$.tw.
- 41. or/37-40
- 42. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 43. augmentin\$.tw.
- 44. or/42-43
- 45. AMPICILLIN/
- 46. ampicillin\$.tw.
- 47. penbritin\$.tw.
- 48. or/45-47

- 49. CEFADROXIL/
- 50. cefadroxil\$.tw.
- 51. cephadrox\$.tw.
- 52. or/49-51
- 53. CEPHALEXIN/
- 54. cephalexin\$.tw.
- 55. cefalexin\$.tw.
- 56. cefaclor\$.tw.
- 57. ceporex\$.tw.
- 58. keflex\$.tw.
- 59. or/53-58
- 60. CEFIXIME/
- 61. cefixim\$.tw.
- 62. suprax\$.tw.
- 63. or/60-62
- 64. CEFOTAXIME/
- 65. cefotaxim\$.tw.
- 66. cephotaxim\$.tw.
- 67. claforan\$.tw.
- 68. klaforan\$.tw.
- 69. or/64-68
- 70. CEPHALOSPORINS/
- 71. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 72. cefpirome\$.tw.
- 73. cefrom\$.tw.
- 74. or/70-73
- 75. CEFTIZOXIME/
- 76. cefpodoxim\$.tw.
- 77. ceftizoxim\$.tw.
- 78. orelox\$.tw.
- 79. or/75-78
- 80. CEPHRADINE/
- 81. cefradin\$.tw.
- 82. velosef\$.tw.
- 83. or/80-82
- 84. CEFTAZIDIME/
- 85. ceftazidim\$.tw.
- 86. fortum\$.tw.
- 87. kefadim\$.tw.

- 88. or/84-87
- 89. CEFTRIAXONE/
- 90. ceftriaxon\$.tw.
- 91. rocephin\$.tw.
- 92. or/89-91
- 93. CEFUROXIME/
- 94. cefuroxim\$.tw.
- 95. zinacef\$.tw.
- 96. zinnat\$.tw.
- 97. or/93-96
- 98. GENTAMICINS/
- 99. gentamicin\$.tw.
- 100. cidomycin\$.tw.
- 101. genticin\$.tw.
- 102. or/98-101
- 103. AMIKACIN/
- 104. amikacin\$.tw.
- 105. AMINOGLYCOSIDES/
- 106. (aminoglycoside\$ or aminoglucoside\$).tw.
- 107. TOBRAMYCIN/
- 108. tobramycin\$.tw.
- 109. nebcin\$.tw.
- 110. tobi.tw.
- 111. netilmicin\$.tw.
- 112. or/103-111
- 113. or/36,41,44,48,52,59,63,69,74,79,83,88,92,97,102,112
- 114. exp ADMINISTRATION, ORAL/
- 115. (administ\$ adj2 (mouth or oral\$)).tw.
- 116. or/114-115
- 117. empiric\$.tw.
- 118. ((blind\$ or early) adj5 treat\$).tw.
- 119. or/117-118
- 120. and/17,28,113,116,119

FEVER_treatment_pharmaceutical_empirical_IV_versus_IM_medline_230406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.

- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42

- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTIONS/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. exp CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. ANTI-INFECTIVE AGENTS/
- 69. antibiotic\$.tw.
- 70. bacteriocide\$.tw.
- 71. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 72. or/68-71
- 73. PENICILLINS/
- 74. penicillin\$.tw.
- 75. or/72-73
- 76. PENICILLIIN G/
- 77. benzylpenicillin\$.tw.
- 78. or/76-77
- 79. AMOXICILLIN/
- 80. amoxicil\$.tw.
- 81. amoxycil\$.tw.

- 82. amoxil\$.tw.
- 83. or/79-82
- 84. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 85. augmentin\$.tw.
- 86. or/84-85
- 87. AMPICILLIN/
- 88. ampicillin\$.tw.
- 89. penbritin\$.tw.
- 90. or/87-89
- 91. CEFADROXIL/
- 92. cefadroxil\$.tw.
- 93. cephadrox\$.tw.
- 94. or/91-93
- 95. CEPHALEXIN/
- 96. cephalexin\$.tw.
- 97. cefalexin\$.tw.
- 98. cefaclor\$.tw.
- 99. ceporex\$.tw.
- 100. keflex\$.tw.
- 101. or/95-100
- 102. CEFIXIME/
- 103. cefixim\$.tw.
- 104. suprax\$.tw.
- 105. or/102-104
- 106. CEFOTAXIME/
- 107. cefotaxim\$.tw.
- 108. cephotaxim\$.tw.
- 109. claforan\$.tw.
- 110. klaforan\$.tw.
- 111. or/106-110
- 112. CEPHALOSPORINS/
- 113. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 114. cefpirome\$.tw.
- 115. or/112-114
- 116. CEFTIZOXIME/
- 117. cefpodoxim\$.tw.
- 118. ceftizoxim\$.tw.
- 119. orelox\$.tw.
- 120. or/116-119

- 121. CEPHRADINE/
- 122. cefradin\$.tw.
- 123. velosef\$.tw.
- 124. or/121-123
- 125. CEFTAZIDIME/
- 126. ceftazidim\$.tw.
- 127. fortum\$.tw.
- 128. or/125-127
- 129. CEFTRIAXONE/
- 130. ceftriaxon\$.tw.
- 131. rocephin\$.tw.
- 132. or/129-131
- 133. CEFUROXIME/
- 134. cefuroxim\$.tw.
- 135. zinacef\$.tw.
- 136. zinnat\$.tw.
- 137. or/133-136
- 138. GENTAMICINS/
- 139. gentamicin\$.tw.
- 140. cidomycin\$.tw.
- 141. genticin\$.tw.
- 142. or/138-141
- 143. AMIKACIN/
- 144. amikacin\$.tw.
- 145. or/143-144
- 146. AMINOGLYCOSIDES/
- 147. aminoglycoside\$.tw.
- 148. aminoglucoside\$.tw.
- 149. or/146-148
- 150. TOBRAMYCIN/
- 151. tobramycin\$.tw.
- 152. nebcin\$.tw.
- 153. tobi.tw.
- 154. or/150-153
- 155. NETILMICIN/
- 156. netilmicin\$.tw.
- 157. netillin\$.tw.
- 158. or/155-157
- 159. or/72,75,78,83,86,90,94,101,105,111,115,120,124,128,132,137,142,145,149,154,158

- 160. INJECTIONS, INTRAVENOUS/
- 161. INFUSIONS, INTRAVENOUS/
- 162. ((intravenous\$ or iv) adj (administ\$ or deliver\$ or infus\$ or inject\$)).tw.
- 163. ((infusion or intravenous or iv) adj drip\$).tw.
- 164. or/160-163
- 165. INJECTIONS, INTRAMUSCULAR/
- 166. ((im or intramuscular\$) adj (administ\$ or deliver\$ or inject\$)).tw.
- 167. or/165-166
- 168. parenteral\$.tw.
- 169. or/164,167-168
- 170. and/159,169
- 171. and/17,67,170
- 172. empiric\$.tw.
- 173. ((blind\$ or early) adj5 treat\$).tw.
- 174. ((before or prior) adj5 (admission or admit\$)).tw.
- 175. or/172-174
- 176. and/171,175
- 177. animal/ not (human/ or (human/ and animal/))
- 178, 176 not 177

FEVER_treatment_pharmaceutical_empirical_IV_versus_IM_embase_230406

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTION/
- 19. (bacteri\$ adj infect\$).tw.

- 20. or/18-19
- 21. BACTERIAL MENINGITIS/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. SEPTICEMIA/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.
- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. BACTERIAL ARTHRITIS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTION/
- 45. STREPTOCOCCAL INFECTION/
- 46. straphylococc\$.tw.
- 47. streptococc\$.tw.
- 48. or/44-47
- 49. OSTEOMYELITIS/
- 50. osteomyeliti\$.tw.
- 51. or/49-50
- 52. exp URINARY TRACT INFECTION/
- 53. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 54. UTI.tw.
- 55. ((upper or lower) adj5 urin\$).tw.
- 56. exp CYSTITIS/

- 57. cystitis\$.tw.
- 58. or/52-57
- 59. PYELONEPHRITIS/
- 60. pyelonephriti\$.tw.
- 61. pyonephrosi\$.tw.
- 62. pyelocystiti\$.tw.
- 63. or/59-62
- 64. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 65. (mucocutaneous adj2 lymph\$).tw.
- 66. mcls.tw.
- 67. (kawasaki adj (disease or syndrome)).tw.
- 68. or/64-67
- 69. or/20,24,28,32,35,38,43,48,51,58,63,68
- 70. ANTIINFECTIVE AGENT/
- 71. ANTIBIOTIC AGENT/
- 72. antibiotic\$.tw.
- 73. bacteriocide\$.tw.
- 74. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 75. penicillin\$.tw.
- 76. PENICILLIN G/
- 77. benzylpenicillin\$.tw.
- 78. or/70-77
- 79. AMOXICILLIN/
- 80. amoxicil\$.tw.
- 81. amoxycil\$.tw.
- 82. amoxil\$.tw.
- 83. or/79-82
- 84. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 85. augmentin\$.tw.
- 86. or/84-85
- 87. AMPICILLIN/
- 88. ampicillin\$.tw.
- 89. penbritin\$.tw.
- 90. or/87-89
- 91. CEFADROXIL/
- 92. cefadroxil\$.tw.
- 93. cephadrox\$.tw.
- 94. or/91-93
- 95. CEPHALEXIN/

- 96. cephalexin\$.tw.
- 97. cefalexin\$.tw.
- 98. cefaclor\$.tw.
- 99. ceporex\$.tw.
- 100. keflex\$.tw.
- 101. or/95-100
- 102. CEFIXIME/
- 103. cefixim\$.tw.
- 104. suprax\$.tw.
- 105. or/102-104
- 106. CEFOTAXIME/
- 107. cefotaxim\$.tw.
- 108. cephotaxim\$.tw.
- 109. claforan\$.tw.
- 110. klaforan\$.tw.
- 111. or/106-110
- 112. CEPHALOSPORINS/
- 113. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 114. cefpirome\$.tw.
- 115. cefrom\$.tw.
- 116. or/112-115
- 117. CEFTIZOXIME/
- 118. cefpodoxim\$.tw.
- 119. ceftizoxim\$.tw.
- 120. orelox\$.tw.
- 121. or/117-120
- 122. CEPHRADINE/
- 123. cefradin\$.tw.
- 124. velosef\$.tw.
- 125. or/122-124
- 126. CEFTAZIDIME/
- 127. ceftazidim\$.tw.
- 128. fortum\$.tw.
- 129. kefadim\$.tw.
- 130. or/126-129
- 131. CEFTRIAXONE/
- 132. ceftriaxon\$.tw.
- 133. rocephin\$.tw.
- 134. or/131-133

- 135. CEFUROXIME/
- 136. cefuroxim\$.tw.
- 137. zinacef\$.tw.
- 138. zinnat\$.tw.
- 139. or/135-138
- 140. GENTAMICINS/
- 141. gentamicin\$.tw.
- 142. cidomycin\$.tw.
- 143. genticin\$.tw.
- 144. or/140-143
- 145. AMIKACIN/
- 146. amikacin\$.tw.
- 147. AMINOGLYCOSIDE/
- 148. (aminoglycoside\$ or aminoglucoside\$).tw.
- 149. TOBRAMYCIN/
- 150. tobramycin\$.tw.
- 151. TOBRAMYCIN SULPHATE/
- 152. nebcin\$.tw.
- 153. tobi.tw.
- 154. NETILMICIN/
- 155. netilmicin\$.tw.
- 156. netillin\$.tw.
- 157. or/145-156
- 158. or/78,83,86,90,94,101,105,111,116,121,125,130,134,139,144,157
- 159. INTRAVENOUS DRUG ADMINISTRATION/
- 160. ((intravenous\$ or iv) adj (administ\$ or deliver\$ or infus\$ or inject\$)).tw.
- 161. ((infusion or intravenous or iv) adj drip\$).tw.
- 162. or/159-161
- 163. INTRAMUSCULAR DRUG ADMINISTRATION/
- 164. ((im or intramuscular\$) adj (administ\$ or deliver\$ or inject\$)).tw.
- 165. or/163-164
- 166. parenteral\$.tw.
- 167. or/162,165-166
- 168. and/158,167
- 169. and/17,69,168
- 170. empiric\$.tw.
- 171. ((blind\$ or early) adj5 treat\$).tw.
- 172. ((before or prior) adj5 (admission or admit\$)).tw.
- 173. or/170-172

- 174. and/169,173
- 175. (animal/ or nonhuman/) not (human/ or ((animal/ or nonhuman/) and human/))
- 176. 174 not 175

FEVER_treatment_pharmaceutical_empirical_IV_versus_IM_cinahl_230406

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. BACTERIAL INFECTIONS/
- 19. (bacteri\$ adj infect\$).tw.
- 20. or/18-19
- 21. exp MENINGITIS, BACTERIAL/
- 22. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 23. meningococc\$.tw.
- 24. or/21-23
- 25. exp SEPSIS/
- 26. septicemi\$.tw.
- 27. septicaemia\$.tw.
- 28. or/25-27
- 29. BACTEREMIA/
- 30. bacteremi\$.tw.
- 31. bacteraemia\$.tw.
- 32. or/29-31
- 33. exp PNEUMONIA/
- 34. pneumoni\$.tw.

- 35. or/33-34
- 36. HERPES SIMPLEX/
- 37. herpes simplex.tw.
- 38. or/36-37
- 39. exp ARTHRITIS, INFECTIOUS/
- 40. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 41. pyarthrosis.tw.
- 42. pyoarthritis.tw.
- 43. or/39-42
- 44. STAPHYLOCOCCAL INFECTIONS/
- 45. STREPTOCOCCAL INFECTIONS/
- 46. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 47. or/44-46
- 48. OSTEOMYELITIS/
- 49. osteomyeliti\$.tw.
- 50. or/48-49
- 51. exp URINARY TRACT INFECTION/
- 52. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 53. UTI.tw.
- 54. ((upper or lower) adj5 urin\$).tw.
- 55. CYSTITIS/
- 56. cystitis\$.tw.
- 57. PYELONEPHRITIS/
- 58. pyelonephriti\$.tw.
- 59. pyonephrosi\$.tw.
- 60. pyelocystiti\$.tw.
- 61. or/51-60
- 62. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 63. (mucocutaneous adj2 lymph\$).tw.
- 64. mcls.tw.
- 65. (kawasaki adj (disease or syndrome)).tw.
- 66. or/62-65
- 67. or/20,24,28,32,35,38,43,47,50,61,66
- 68. ANTIINFECTIVE AGENT/
- 69. ANTIBIOTIC AGENT/
- 70. PENICILLINS/
- 71. penicillin\$.tw.
- 72. antibiotic\$.tw.

- 73. bacteriocide\$.tw.
- 74. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 75. or/68-74
- 76. AMOXICILLIN/
- 77. amoxicil\$.tw.
- 78. amoxycil\$.tw.
- 79. amoxil\$.tw.
- 80. or/76-79
- 81. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 82. augmentin\$.tw.
- 83. or/81-82
- 84. AMPICILLIN/
- 85. ampicillin\$.tw.
- 86. penbritin\$.tw.
- 87. or/84-86
- 88. CEFADROXIL/
- 89. cefadroxil\$.tw.
- 90. cephadrox\$.tw.
- 91. or/88-90
- 92. CEPHALEXIN/
- 93. cephalexin\$.tw.
- 94. cefalexin\$.tw.
- 95. cefaclor\$.tw.
- 96. ceporex\$.tw.
- 97. keflex\$.tw.
- 98. or/92-97
- 99. CEFIXIME/
- 100. cefixim\$.tw.
- 101. suprax\$.tw.
- 102. or/99-101
- 103. CEFOTAXIME/
- 104. cefotaxim\$.tw.
- 105. cephotaxim\$.tw.
- 106. claforan\$.tw.
- 107. klaforan\$.tw.
- 108. or/103-107
- 109. CEPHALOSPORINS/
- 110. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 111. cefpirome\$.tw.

- 112. cefrom\$.tw.
- 113. or/109-112
- 114. CEFTIZOXIME/
- 115. cefpodoxim\$.tw.
- 116. ceftizoxim\$.tw.
- 117. orelox\$.tw.
- 118. or/114-117
- 119. CEPHRADINE/
- 120. cefradin\$.tw.
- 121. velosef\$.tw.
- 122. or/119-121
- 123. CEFTAZIDIME/
- 124. ceftazidim\$.tw.
- 125. fortum\$.tw.
- 126. kefadim\$.tw.
- 127. or/123-126
- 128. CEFTRIAXONE/
- 129. ceftriaxon\$.tw.
- 130. rocephin\$.tw.
- 131. or/128-130
- 132. CEFUROXIME/
- 133. cefuroxim\$.tw.
- 134. zinacef\$.tw.
- 135. zinnat\$.tw.
- 136. or/132-135
- 137. GENTAMICINS/
- 138. gentamicin\$.tw.
- 139. cidomycin\$.tw.
- 140. genticin\$.tw.
- 141. or/137-140
- 142. AMIKACIN/
- 143. amikacin\$.tw.
- 144. AMINOGLYCOSIDES/
- 145. (aminoglycoside\$ or aminoglucoside\$).tw.
- 146. TOBRAMYCIN/
- 147. tobramycin\$.tw.
- 148. nebcin\$.tw.
- 149. tobi.tw.
- 150. netilmicin\$.tw.

- 151. or/142-150
- 152. or/75,80,83,87,91,98,102,108,113,118,122,127,131,136,141,151
- 153. INJECTIONS, INTRAVENOUS/
- 154. INFUSIONS, INTRAVENOUS/
- 155. ((intravenous\$ or iv) adj (administ\$ or deliver\$ or infus\$ or inject\$)).tw.
- 156. ((infusion or intravenous or iv) adj drip\$).tw.
- 157. or/153-156
- 158. INJECTIONS, INTRAMUSCULAR/
- 159. ((im or intramuscular\$) adj (administ\$ or deliver\$ or inject\$)).tw.
- 160. or/158-159
- 161. parenteral\$.tw.
- 162. or/157,160-161
- 163. and/152,162
- 164. and/17,67,163
- 165. empiric\$.tw.
- 166. ((blind\$ or early) adj5 treat\$).tw.
- 167. ((before or prior) adj5 (admission or admit\$)).tw.
- 168. or/165-167
- 169. and/164,168

FEVER_treatment_pharmaceuticals_RCT_SR_medline_300306

- 1. INFANT, PREMATURE/
- 2. INFANT, POSTMATURE/
- 3. INFANT, LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. INFANT, VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. CHILD, PRESCHOOL/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/

- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANTI-INFECTIVE AGENTS/
- 31. antibiotic\$.tw.
- 32. bacteriocide\$.tw.
- 33. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 34. or/30-33
- 35. PENICILLINS/
- 36. penicillin\$.tw.
- 37. or/34-35
- 38. PENICILLIIN G/
- 39. benzylpenicillin\$.tw.
- 40. or/38-39
- 41. AMOXICILLIN/
- 42. amoxicil\$.tw.
- 43. amoxycil\$.tw.
- 44. amoxil\$.tw.
- 45. or/41-44
- 46. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 47. augmentin\$.tw.
- 48. or/46-47
- 49. AMPICILLIN/
- 50. ampicillin\$.tw.
- 51. penbritin\$.tw.
- 52. or/49-51
- 53. CEFADROXIL/
- 54. cefadroxil\$.tw.
- 55. cephadrox\$.tw.
- 56. or/53-55
- 57. CEPHALEXIN/
- 58. cephalexin\$.tw.

- 59. cefalexin\$.tw.
- 60. cefaclor\$.tw.
- 61. ceporex\$.tw.
- 62. keflex\$.tw.
- 63. or/57-62
- 64. CEFIXIME/
- 65. cefixim\$.tw.
- 66. suprax\$.tw.
- 67. or/64-66
- 68. CEFOTAXIME/
- 69. cefotaxim\$.tw.
- 70. cephotaxim\$.tw.
- 71. claforan\$.tw.
- 72. klaforan\$.tw.
- 73. or/68-72
- 74. CEPHALOSPORINS/
- 75. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 76. cefpirome\$.tw.
- 77. or/74-76
- 78. CEFTIZOXIME/
- 79. cefpodoxim\$.tw.
- 80. ceftizoxim\$.tw.
- 81. orelox\$.tw.
- 82. or/78-81
- 83. CEPHRADINE/
- 84. cefradin\$.tw.
- 85. velosef\$.tw.
- 86. or/83-85
- 87. CEFTAZIDIME/
- 88. ceftazidim\$.tw.
- 89. fortum\$.tw.
- 90. or/87-89
- 91. CEFTRIAXONE/
- 92. ceftriaxon\$.tw.
- 93. rocephin\$.tw.
- 94. or/91-93
- 95. CEFUROXIME/
- 96. cefuroxim\$.tw.
- 97. zinacef\$.tw.

- 98. zinnat\$.tw.
- 99. or/95-98
- 100. GENTAMICINS/
- 101. gentamicin\$.tw.
- 102. cidomycin\$.tw.
- 103. genticin\$.tw.
- 104. or/100-103
- 105. AMIKACIN/
- 106. amikacin\$.tw.
- 107. or/105-106
- 108. AMINOGLYCOSIDES/
- 109. aminoglycoside\$.tw.
- 110. aminoglucoside\$.tw.
- 111. or/108-110
- 112. TOBRAMYCIN/
- 113. tobramycin\$.tw.
- 114. nebcin\$.tw.
- 115. tobi.tw.
- 116. or/112-115
- 117. NETILMICIN/
- 118. netilmicin\$.tw.
- 119. netillin\$.tw.
- 120. or/117-119
- 121. or/34,37,40,45,48,52,56,63,67,73,77,82,86,90,94,99,104,107,111,116,120
- 122. and/29,121
- 123. randomized controlled trial.pt.
- 124. controlled clinical trial.pt.
- 125. DOUBLE BLIND METHOD/
- 126. SINGLE BLIND METHOD/
- 127. RANDOM ALLOCATION/
- 128. RANDOMIZED CONTROLLED TRIALS/
- 129. or/123-128
- 130. ((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
- 131. clinical trial.pt.
- 132. exp CLINICAL TRIALS/
- 133. (clinic\$ adj5 trial\$).tw,sh.
- 134. PLACEBOS/
- 135. placebo\$.tw,sh.
- 136. random\$.tw,sh.

- 137. or/130-136
- 138. or/129,137
- 139. META ANALYSIS/
- 140. meta analysis.pt.
- 141. (metaanaly\$ or meta-analy\$ or (meta adj analy\$)).tw,sh.
- 142. (systematic\$ adj5 (review\$ or overview\$)).tw,sh.
- 143. (methodologic\$ adj5 (review\$ or overview\$)).tw,sh.
- 144. or/139-143
- 145. review\$.pt.
- 146. (medline or medlars or embase or cinahl or cochrane or psychinfo or psychinfo
- 147. ((hand or manual\$) adj2 search\$).tw.
- 148. (electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw,sh.
- 149. (pooling or pooled or mantel haenszel).tw,sh.
- 150. (peto or dersimonian or der simonian or fixed effect).tw,sh.
- 151. or/146-150
- 152. 145 and 151
- 153. or/144.152
- 154. letter.pt.
- 155. case report.tw.
- 156. comment.pt.
- 157. editorial.pt.
- 158. historical article.pt.
- 159. ANIMAL/ not (HUMAN/ and ANIMAL/)
- 160. or/154-159
- 161, 138 not 160
- 162. 153 not 160
- 163. or/161-162
- 164. and/122,163

FEVER_treatment_pharmaceuticals_RCT_SR_embase_300306

- 1. PREMATURITY/
- 2. POSTMATURITY/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. NEWBORN/

- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. PYREXIA IDIOPATHICA/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGEN/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANTIINFECTIVE AGENT/
- 31. ANTIBIOTIC AGENT/
- 32. antibiotic\$.tw.
- 33. bacteriocide\$.tw.
- 34. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 35. penicillin\$.tw.
- 36. PENICILLIN G/
- 37. benzylpenicillin\$.tw.
- 38. or/30-37
- 39. AMOXICILLIN/
- 40. amoxicil\$.tw.
- 41. amoxycil\$.tw.
- 42. amoxil\$.tw.
- 43. or/39-42
- 44. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 45. augmentin\$.tw.
- 46. or/44-45
- 47. AMPICILLIN/

- 48. ampicillin\$.tw.
- 49. penbritin\$.tw.
- 50. or/47-49
- 51. CEFADROXIL/
- 52. cefadroxil\$.tw.
- 53. cephadrox\$.tw.
- 54. or/51-53
- 55. CEPHALEXIN/
- 56. cephalexin\$.tw.
- 57. cefalexin\$.tw.
- 58. cefaclor\$.tw.
- 59. ceporex\$.tw.
- 60. keflex\$.tw.
- 61. or/55-60
- 62. CEFIXIME/
- 63. cefixim\$.tw.
- 64. suprax\$.tw.
- 65. or/62-64
- 66. CEFOTAXIME/
- 67. cefotaxim\$.tw.
- 68. cephotaxim\$.tw.
- 69. claforan\$.tw.
- 70. klaforan\$.tw.
- 71. or/66-70
- 72. CEPHALOSPORINS/
- 73. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 74. cefpirome\$.tw.
- 75. cefrom\$.tw.
- 76. or/72-75
- 77. CEFTIZOXIME/
- 78. cefpodoxim\$.tw.
- 79. ceftizoxim\$.tw.
- 80. orelox\$.tw.
- 81. or/77-80
- 82. CEPHRADINE/
- 83. cefradin\$.tw.
- 84. velosef\$.tw.
- 85. or/82-84
- 86. CEFTAZIDIME/

- 87. ceftazidim\$.tw.
- 88. fortum\$.tw.
- 89. kefadim\$.tw.
- 90. or/86-89
- 91. CEFTRIAXONE/
- 92. ceftriaxon\$.tw.
- 93. rocephin\$.tw.
- 94. or/91-93
- 95. CEFUROXIME/
- 96. cefuroxim\$.tw.
- 97. zinacef\$.tw.
- 98. zinnat\$.tw.
- 99. or/95-98
- 100. GENTAMICINS/
- 101. gentamicin\$.tw.
- 102. cidomycin\$.tw.
- 103. genticin\$.tw.
- 104. or/100-103
- 105. AMIKACIN/
- 106. amikacin\$.tw.
- 107. AMINOGLYCOSIDE/
- 108. (aminoglycoside\$ or aminoglucoside\$).tw.
- 109. TOBRAMYCIN/
- 110. tobramycin\$.tw.
- 111. TOBRAMYCIN SULPHATE/
- 112. nebcin\$.tw.
- 113. tobi.tw.
- 114. NETILMICIN/
- 115. netilmicin\$.tw.
- 116. netillin\$.tw.
- 117. or/105-116
- 118. or/38,43,46,50,54,61,65,71,76,81,85,90,94,99,104,117
- 119. and/29,118
- 120. CLINICAL TRIALS/
- 121. (clinic\$ adj5 trial\$).ti,ab,sh.
- 122. SINGLE BLIND PROCEDURE/
- 123. DOUBLE BLIND PROCEDURE/
- 124. RANDOM ALLOCATION/
- 125. CROSSOVER PROCEDURE/

- 126. PLACEBO/
- 127. placebo\$.ti,ab,sh.
- 128. random\$.ti,ab,sh.
- 129. RANDOMIZED CONTROLLED TRIALS/
- 130. ((single or double or triple or treble) adj (blind\$ or mask\$)).ti,ab,sh.
- 131. randomi?ed control\$ trial\$.tw.
- 132. or/120-131
- 133. META ANALYSIS/
- 134. ((meta adj analy\$) or metaanalys\$ or meta-analy\$).ti,ab,sh.
- 135. (systematic\$ adj5 (review\$ or overview\$)).ti,sh,ab.
- 136. (methodologic\$ adj5 (review\$ or overview\$)).ti,ab,sh.
- 137. or/133-136
- 138. review.pt.
- 139. (medline or medlars or embase).ab.
- 140. (scisearch or science citation index).ab.
- 141. (psychlit or psyclit or psychinfo or psycinfo or cinahl or cochrane).ab.
- 142. ((hand or manual\$) adj2 search\$).tw.
- 143. (electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
- 144. (pooling or pooled or mantel haenszel).tw.
- 145. (peto or dersimonian or "der simonian" or fixed effect).tw.
- 146. or/139-145
- 147, 138 and 146
- 148. or/137,147
- 149. case study.tw,sh.
- 150. abstract report.tw,sh.
- 151. note.tw,sh.
- 152. short survey.tw,sh.
- 153. letter.tw,sh.
- 154. case report.tw,sh.
- 155. editorial.tw,sh.
- 156. (ANIMAL/ or NONHUMAN/) not (HUMAN/ or ((ANIMAL/ or NONHUMAN/) and HUMAN/))
- 157. or/149-156
- 158. 132 not 157
- 159. 148 not 157
- 160. or/158-159
- 161. and/119,160

FEVER_treatment_pharmaceuticals_RCT_SR_cinahl_300306

1. INFANT, PREMATURE/

- 2. INFANT, POSTMATURE/
- 3. LOW BIRTH WEIGHT/
- 4. (low adj birth adj weight).tw.
- 5. lbw.tw.
- 6. VERY LOW BIRTH WEIGHT/
- 7. vlbw.tw.
- 8. INFANT, NEWBORN/
- 9. neonat\$.tw.
- 10. newborn\$.tw.
- 11. exp INFANT/
- 12. infan\$.tw.
- 13. PRESCHOOL CHILD/
- 14. (baby or babies).tw.
- 15. (child\$ adj5 pre?school).tw.
- 16. toddler\$.tw.
- 17. or/1-16
- 18. exp FEVER/
- 19. "FEVER OF UNKNOWN ORIGIN"/
- 20. fever\$.tw.
- 21. febril\$.tw.
- 22. hypertherm\$.tw.
- 23. pyrexi\$.tw.
- 24. MALIGNANT HYPERTHERMIA/
- 25. (malignan\$ adj3 (hypertherm\$ or hyperpyrex\$)).tw.
- 26. exp PYROGENS/
- 27. pyrogen\$.tw.
- 28. or/18-27
- 29. and/17,28
- 30. ANTIINFECTIVE AGENT/
- 31. ANTIBIOTIC AGENT/
- 32. PENICILLINS/
- 33. penicillin\$.tw.
- 34. antibiotic\$.tw.
- 35. bacteriocide\$.tw.
- 36. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 37. or/30-36
- 38. AMOXICILLIN/
- 39. amoxicil\$.tw.
- 40. amoxycil\$.tw.

- 41. amoxil\$.tw.
- 42. or/38-41
- 43. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 44. augmentin\$.tw.
- 45. or/43-44
- 46. AMPICILLIN/
- 47. ampicillin\$.tw.
- 48. penbritin\$.tw.
- 49. or/46-48
- 50. CEFADROXIL/
- 51. cefadroxil\$.tw.
- 52. cephadrox\$.tw.
- 53. or/50-52
- 54. CEPHALEXIN/
- 55. cephalexin\$.tw.
- 56. cefalexin\$.tw.
- 57. cefaclor\$.tw.
- 58. ceporex\$.tw.
- 59. keflex\$.tw.
- 60. or/54-59
- 61. CEFIXIME/
- 62. cefixim\$.tw.
- 63. suprax\$.tw.
- 64. or/61-63
- 65. CEFOTAXIME/
- 66. cefotaxim\$.tw.
- 67. cephotaxim\$.tw.
- 68. claforan\$.tw.
- 69. klaforan\$.tw.
- 70. or/65-69
- 71. CEPHALOSPORINS/
- 72. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 73. cefpirome\$.tw.
- 74. cefrom\$.tw.
- 75. or/71-74
- 76. CEFTIZOXIME/
- 77. cefpodoxim\$.tw.
- 78. ceftizoxim\$.tw.
- 79. orelox\$.tw.

- 80. or/76-79
- 81. CEPHRADINE/
- 82. cefradin\$.tw.
- 83. velosef\$.tw.
- 84. or/81-83
- 85. CEFTAZIDIME/
- 86. ceftazidim\$.tw.
- 87. fortum\$.tw.
- 88. kefadim\$.tw.
- 89. or/85-88
- 90. CEFTRIAXONE/
- 91. ceftriaxon\$.tw.
- 92. rocephin\$.tw.
- 93. or/90-92
- 94. CEFUROXIME/
- 95. cefuroxim\$.tw.
- 96. zinacef\$.tw.
- 97. zinnat\$.tw.
- 98. or/94-97
- 99. GENTAMICINS/
- 100. gentamicin\$.tw.
- 101. cidomycin\$.tw.
- 102. genticin\$.tw.
- 103. or/99-102
- 104. AMIKACIN/
- 105. amikacin\$.tw.
- 106. AMINOGLYCOSIDES/
- 107. (aminoglycoside\$ or aminoglucoside\$).tw.
- 108. TOBRAMYCIN/
- 109. tobramycin\$.tw.
- 110. nebcin\$.tw.
- 111. tobi.tw.
- 112. netilmicin\$.tw.
- 113. or/104-112
- 114. or/37,42,45,49,53,60,64,70,75,80,84,89,93,98,103,113
- 115. and/29,114
- 116. exp CLINICAL TRIALS/
- 117. (clinic\$ adj5 trial\$).tw,sh.
- 118. clinical trial.pt.

- 119. SINGLE-BLIND STUDIES/
- 120. DOUBLE-BLIND STUDIES/
- 121. TRIPLE-BLIND STUDIES/
- 122. ((single or double or triple or treble) adj5 (blind\$ or mask\$)).tw,sh.
- 123. RANDOM ASSIGNMENT/
- 124. random\$.tw.
- 125. RANDOMIZED CONTROLLED TRIALS/
- 126. randomi?ed control\$ trial\$.tw.
- 127. PLACEBOS/
- 128. placebo\$.tw.
- 129. or/116-128
- 130. META ANALYSIS/
- 131. ((meta adj analy\$) or metaanalys\$ or meta-analy\$).tw.
- 132. SYSTEMATIC REVIEW/
- 133. systematic review\$.pt.
- 134. (systematic\$ adj5 (review\$ or overview\$)).tw.
- 135. LITERATURE REVIEW/
- 136. or/130-135
- 137. ("review" or "review studies" or "review academic" or "review tutorial").ti,ab,sh,pt.
- 138. (medline or medlars or embase or cochrane or scisearch or psychinfo or psychin
- 139. ((hand or manual\$) adj2 search\$).tw.
- 140. (electronic database\$ or bibliographic database\$ or computeri?ed database\$ or online database\$).tw.
- 141. (pooling or pooled or mantel haenszel).tw.
- 142. (peto or dersimonian or "der simonian" or fixed effect).tw.
- 143. or/138-142
- 144. 137 and 143
- 145. or/136,144
- 146. letter.pt,sh.
- 147. commentary.pt,sh.
- 148. editorial.pt,sh.
- 149. manuscripts.pt,sh.
- 150. pamphlets.pt,sh.
- 151. reports.pt,sh.
- 152. newsletters.pt,sh.
- 153. newspapers.pt,sh.
- 154. ANIMALS/ or ANIMAL STUDIES/
- 155. or/146-154

- 156. 129 not 155
- 157, 145 not 155
- 158. or/156-157
- 159. and/115,158

FEVER_treatment_pharmaceuticals_health_economics_medline_150506

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, POSTMATURE/
- 4. ((postmature\$ or postterm\$ or post?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 5. INFANT, NEWBORN/
- 6. neonat\$.tw.
- 7. newborn\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. INFANT, SMALL FOR GESTATIONAL AGE/
- 11. (small adj2 gestational age).tw.
- 12. INFANT, LOW BIRTH WEIGHT/
- 13. INFANT, VERY LOW BIRTH WEIGHT/
- 14. (low adj birth adj weight).tw.
- 15. (low adj birth?weight).tw.
- 16. lbw.tw.
- 17. vlbw.tw.
- 18. (baby or babies).tw.
- 19. CHILD, PRESCHOOL/
- 20. toddler\$.tw.
- 21. exp CHILD/
- 22. child\$.tw.
- 23. ADOLESCENT/
- 24. adolescen\$.tw.
- 25. juvenile\$.tw.
- 26. youth\$.tw.
- 27. teen\$.tw.
- 28. PUBERTY/
- 29. pubert\$.tw.
- 30. pubesc\$.tw.
- 31. MINORS/
- 32. minors.tw.
- 33. or/1-32
- 34. BACTERIAL INFECTIONS/

- 35. (bacteri\$ adj infect\$).tw.
- 36. or/34-35
- 37. exp MENINGITIS, BACTERIAL/
- 38. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 39. meningococc\$.tw.
- 40. or/37-39
- 41. SEPTICEMIA/
- 42. septicemi\$.tw.
- 43. septicaemia\$.tw.
- 44. or/41-43
- 45. BACTEREMIA/
- 46. bacteremi\$.tw.
- 47. bacteraemia\$.tw.
- 48. or/45-47
- 49. exp PNEUMONIA/
- 50. pneumoni\$.tw.
- 51. or/49-50
- 52. HERPES SIMPLEX/
- 53. herpes simplex.tw.
- 54. or/52-53
- 55. exp ARTHRITIS, INFECTIOUS/
- 56. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 57. pyarthrosis.tw.
- 58. pyoarthritis.tw.
- 59. or/55-58
- 60. STAPHYLOCOCCAL INFECTIONS/
- 61. STREPTOCOCCAL INFECTIONS/
- 62. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 63. or/60-62
- 64. OSTEOMYELITIS/
- 65. osteomyeliti\$.tw.
- 66. or/64-65
- 67. exp URINARY TRACT INFECTIONS/
- 68. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 69. UTI.tw.
- 70. ((upper or lower) adj5 urin\$).tw.
- 71. exp CYSTITIS/

- 72. cystitis\$.tw.
- 73. PYELONEPHRITIS/
- 74. pyelonephriti\$.tw.
- 75. pyonephrosi\$.tw.
- 76. pyelocystiti\$.tw.
- 77. or/67-76
- 78. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 79. (mucocutaneous adj2 lymph\$).tw.
- 80. mcls.tw.
- 81. (kawasaki adj (disease or syndrome)).tw.
- 82. or/78-81
- 83. or/36,40,44,48,51,54,59,63,66,77,82
- 84. ANTI-INFECTIVE AGENTS/
- 85. antibiotic\$.tw.
- 86. bacteriocide\$.tw.
- 87. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 88. or/84-87
- 89. PENICILLINS/
- 90. penicillin\$.tw.
- 91. or/88-89
- 92. PENICILLIIN G/
- 93. benzylpenicillin\$.tw.
- 94. or/92-93
- 95. AMOXICILLIN/
- 96. amoxicil\$.tw.
- 97. amoxycil\$.tw.
- 98. amoxil\$.tw.
- 99. or/95-98
- 100. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 101. augmentin\$.tw.
- 102. or/100-101
- 103. AMPICILLIN/
- 104. ampicillin\$.tw.
- 105. penbritin\$.tw.
- 106. or/103-105
- 107. CEFADROXIL/
- 108. cefadroxil\$.tw.
- 109. cephadrox\$.tw.
- 110. or/107-109

- 111. CEPHALEXIN/
- 112. cephalexin\$.tw.
- 113. cefalexin\$.tw.
- 114. cefaclor\$.tw.
- 115. ceporex\$.tw.
- 116. keflex\$.tw.
- 117. or/111-116
- 118. CEFIXIME/
- 119. cefixim\$.tw.
- 120. suprax\$.tw.
- 121. or/118-120
- 122. CEFOTAXIME/
- 123. cefotaxim\$.tw.
- 124. cephotaxim\$.tw.
- 125. claforan\$.tw.
- 126. klaforan\$.tw.
- 127. or/122-126
- 128. CEPHALOSPORINS/
- 129. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 130. cefpirome\$.tw.
- 131. or/128-130
- 132. CEFTIZOXIME/
- 133. cefpodoxim\$.tw.
- 134. ceftizoxim\$.tw.
- 135. orelox\$.tw.
- 136. or/132-135
- 137. CEPHRADINE/
- 138. cefradin\$.tw.
- 139. velosef\$.tw.
- 140. or/137-139
- 141. CEFTAZIDIME/
- 142. ceftazidim\$.tw.
- 143. fortum\$.tw.
- 144. or/141-143
- 145. CEFTRIAXONE/
- 146. ceftriaxon\$.tw.
- 147. rocephin\$.tw.
- 148. or/145-147
- 149. CEFUROXIME/

- 150. cefuroxim\$.tw.
- 151. zinacef\$.tw.
- 152. zinnat\$.tw.
- 153. or/149-152
- 154. GENTAMICINS/
- 155. gentamicin\$.tw.
- 156. cidomycin\$.tw.
- 157. genticin\$.tw.
- 158. or/154-157
- 159. AMIKACIN/
- 160. amikacin\$.tw.
- 161. or/159-160
- 162. AMINOGLYCOSIDES/
- 163. aminoglycoside\$.tw.
- 164. aminoglucoside\$.tw.
- 165. or/162-164
- 166. TOBRAMYCIN/
- 167. tobramycin\$.tw.
- 168. nebcin\$.tw.
- 169. tobi.tw.
- 170. or/166-169
- 171. NETILMICIN/
- 172. netilmicin\$.tw.
- 173. netillin\$.tw.
- 174. or/171-173
- 175. or/88,91,94,99,102,106,110,117,121,127,131,136,140,144,148,153,158,161,165,170,174
- 176. ECONOMICS/
- 177. "COSTS AND COST ANALYSIS"/
- 178. COST ALLOCATION/
- 179. COST-BENEFIT ANALYSIS/
- 180. COST CONTROL/
- 181. COST SAVINGS/
- 182. COST OF ILLNESS/
- 183. COST SHARING/
- 184. HEALTH CARE COSTS/
- 185. DIRECT SERVICE COSTS/
- 186. DRUG COSTS/
- 187. EMPLOYER HEALTH COSTS/
- 188. HOSPITAL COSTS/

- 189. HEALTH RESOURCES/
- 190. "HEALTH SERVICES NEEDS AND DEMAND"/
- 191. HEALTH PRIORITIES/
- 192. HEALTH EXPENDITURES/
- 193. CAPITAL EXPENDITURES/
- 194. FINANCIAL MANAGEMENT/
- 195. FINANCIAL MANAGEMENT, HOSPITAL/
- 196. QUALITY-ADJUSTED LIFE YEARS/
- 197. "DEDUCTIBLES AND COINSURANCE"/
- 198. MEDICAL SAVINGS ACCOUNTS/
- 199. ECONOMICS, HOSPITAL/
- 200. ECONOMICS, MEDICAL/
- 201. ECONOMICS, NURSING/
- 202. ECONOMICS, PHARMACEUTICAL/
- 203. MODELS, ECONOMIC/
- 204. MODELS, ECONOMETRIC/
- 205. RESOURCE ALLOCATION/
- 206. HEALTH CARE RATIONING/
- 207. "FEES AND CHARGES"/
- 208. BUDGETS/
- 209. VALUE OF LIFE/
- 210. (financ\$ or fiscal\$ or funding).tw.
- 211. (QALY\$ or life?year\$).tw.
- 212. (econom\$ or cost\$).tw.
- 213. pharmacoeconomic\$.tw.
- 214. ec.fs.
- 215. or/176-214
- 216. and/33,83,175,215
- 217. animal/ not (human/ or (human/ and animal/))
- 218. 216 not 217

FEVER_treatment_pharmaceuticals_health_economics_embase_150506

- 1. PREMATURITY/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. exp NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. NEWBORN PERIOD/
- 7. PERINATAL PERIOD/
- 8. perinatal\$.tw.

- 9. postnatal\$.tw.
- 10. exp INFANT/
- 11. INFANCY/
- 12. BABY/
- 13. infan\$.tw.
- 14. (baby or babies).tw.
- 15. SMALL FOR DATE INFANT/
- 16. (small adj2 (date or "gestational age")).tw.
- 17. lbw.tw.
- 18. vlbw.tw.
- 19. CHILD/
- 20. CHILDHOOD/
- 21. PRESCHOOL CHILD/
- 22. SCHOOL CHILD/
- 23. child\$.tw.
- 24. PREPUBERTY/
- 25. PUBERTY/
- 26. prepube\$.tw.
- 27. pubert\$.tw.
- 28. pubesc\$.tw.
- 29. ADOLESCENCE/
- 30. adolescen\$.tw.
- 31. JUVENILE/
- 32. ADOLESCENT/
- 33. juvenile\$.tw.
- 34. minors.tw.
- 35. youth\$.tw.
- 36. teen\$.tw.
- 37. or/1-36
- 38. BACTERIAL INFECTION/
- 39. (bacteri\$ adj infect\$).tw.
- 40. or/38-39
- 41. BACTERIAL MENINGITIS/
- 42. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 43. meningococc\$.tw.
- 44. or/41-43
- 45. SEPTICEMIA/
- 46. septicemi\$.tw.

- 47. septicaemia\$.tw.
- 48. or/45-47
- 49. BACTEREMIA/
- 50. bacteremi\$.tw.
- 51. bacteraemia\$.tw.
- 52. or/49-51
- 53. exp PNEUMONIA/
- 54. pneumoni\$.tw.
- 55. or/53-54
- 56. HERPES SIMPLEX/
- 57. herpes simplex.tw.
- 58. or/56-57
- 59. BACTERIAL ARTHRITIS/
- 60. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 61. pyarthrosis.tw.
- 62. pyoarthritis.tw.
- 63. or/59-62
- 64. STAPHYLOCOCCAL INFECTION/
- 65. STREPTOCOCCAL INFECTION/
- 66. straphylococc\$.tw.
- 67. streptococc\$.tw.
- 68. or/64-67
- 69. OSTEOMYELITIS/
- 70. osteomyeliti\$.tw.
- 71. or/69-70
- 72. exp URINARY TRACT INFECTION/
- 73. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 74. UTI.tw.
- 75. ((upper or lower) adj5 urin\$).tw.
- 76. exp CYSTITIS/
- 77. cystitis\$.tw.
- 78. or/72-77
- 79. PYELONEPHRITIS/
- 80. pyelonephriti\$.tw.
- 81. pyonephrosi\$.tw.
- 82. pyelocystiti\$.tw.
- 83. or/79-82
- 84. MUCOCUTANEOUS LYMPH NODE SYNDROME/

- 85. (mucocutaneous adj2 lymph\$).tw.
- 86. mcls.tw.
- 87. (kawasaki adj (disease or syndrome)).tw.
- 88. or/84-87
- 89. or/40,44,48,52,55,58,63,68,71,78,83,88
- 90. ANTIINFECTIVE AGENT/
- 91. ANTIBIOTIC AGENT/
- 92. antibiotic\$.tw.
- 93. bacteriocide\$.tw.
- 94. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 95. penicillin\$.tw.
- 96. PENICILLIN G/
- 97. benzylpenicillin\$.tw.
- 98. or/90-97
- 99. AMOXICILLIN/
- 100. amoxicil\$.tw.
- 101. amoxycil\$.tw.
- 102. amoxil\$.tw.
- 103. or/99-102
- 104. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 105. augmentin\$.tw.
- 106. or/104-105
- 107. AMPICILLIN/
- 108. ampicillin\$.tw.
- 109. penbritin\$.tw.
- 110. or/107-109
- 111. CEFADROXIL/
- 112. cefadroxil\$.tw.
- 113. cephadrox\$.tw.
- 114. or/111-113
- 115. CEPHALEXIN/
- 116. cephalexin\$.tw.
- 117. cefalexin\$.tw.
- 118. cefaclor\$.tw.
- 119. ceporex\$.tw.
- 120. keflex\$.tw.
- 121. or/115-120
- 122. CEFIXIME/
- 123. cefixim\$.tw.

Feverish illness in children (appendices)

- 124. suprax\$.tw.
- 125. or/122-124
- 126. CEFOTAXIME/
- 127. cefotaxim\$.tw.
- 128. cephotaxim\$.tw.
- 129. claforan\$.tw.
- 130. klaforan\$.tw.
- 131. or/126-130
- 132. CEPHALOSPORINS/
- 133. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 134. cefpirome\$.tw.
- 135. cefrom\$.tw.
- 136. or/132-135
- 137. CEFTIZOXIME/
- 138. cefpodoxim\$.tw.
- 139. ceftizoxim\$.tw.
- 140. orelox\$.tw.
- 141. or/137-140
- 142. CEPHRADINE/
- 143. cefradin\$.tw.
- 144. velosef\$.tw.
- 145. or/142-144
- 146. CEFTAZIDIME/
- 147. ceftazidim\$.tw.
- 148. fortum\$.tw.
- 149. kefadim\$.tw.
- 150. or/146-149
- 151. CEFTRIAXONE/
- 152. ceftriaxon\$.tw.
- 153. rocephin\$.tw.
- 154. or/151-153
- 155. CEFUROXIME/
- 156. cefuroxim\$.tw.
- 157. zinacef\$.tw.
- 158. zinnat\$.tw.
- 159. or/155-158
- 160. GENTAMICINS/
- 161. gentamicin\$.tw.
- 162. cidomycin\$.tw.

- 163. genticin\$.tw.
- 164. or/160-163
- 165. AMIKACIN/
- 166. amikacin\$.tw.
- 167. AMINOGLYCOSIDE/
- 168. (aminoglycoside\$ or aminoglucoside\$).tw.
- 169. TOBRAMYCIN/
- 170. tobramycin\$.tw.
- 171. TOBRAMYCIN SULPHATE/
- 172. nebcin\$.tw.
- 173. tobi.tw.
- 174. NETILMICIN/
- 175. netilmicin\$.tw.
- 176. netillin\$.tw.
- 177. or/165-176
- 178. or/98,103,106,110,114,121,125,131,136,141,145,150,154,159,164,177
- 179. ECONOMICS/
- 180. HEALTH ECONOMICS/
- 181. ECONOMIC EVALUATION/
- 182. COST BENEFIT ANALYSIS/
- 183. COST CONTROL/
- 184. COST EFFECTIVENESS ANALYSIS/
- 185. COST MINIMIZATION ANALYSIS/
- 186. COST OF ILLNESS/
- 187. COST UTILITY ANALYSIS/
- 188. COST/
- 189. HEALTH CARE COST/
- 190. DRUG COST/
- 191. HEALTH CARE FINANCING/
- 192. HOSPITAL COST/
- 193. SOCIOECONOMICS/
- 194. ECONOMIC ASPECT/
- 195. QUALITY-ADJUSTED LIFE YEARS/
- 196. FINANCIAL MANAGEMENT/
- 197. PHARMACOECONOMICS/
- 198. RESOURCE ALLOCATION/
- 199. (financ\$ or fiscal\$ or funding).tw.
- 200. (QALY\$ or life?year\$).tw.
- 201. (econom\$ or cost\$).tw.

- 202. pharmacoeconomic\$.tw.
- 203. or/179-202
- 204. and/37,89,178,203
- 205. (ANIMAL/ or NONHUMAN/) not (HUMAN/ or ((ANIMAL/ or NONHUMAN/) and HUMAN/))
- 206. 204 not 205

FEVER_treatment_pharmaceuticals_health_economics_cinahl_150506

- 1. INFANT, PREMATURE/
- 2. ((premature\$ or preterm\$ or pre?term\$) adj (baby or babies or child\$ or infan\$)).tw.
- 3. INFANT, NEWBORN/
- 4. neonat\$.tw.
- 5. newborn\$.tw.
- 6. perinatal\$.tw.
- 7. postnatal\$.tw.
- 8. exp INFANT/
- 9. infan\$.tw.
- 10. (baby or babies).tw.
- 11. INFANT, LOW BIRTH WEIGHT/
- 12. INFANT, VERY LOW BIRTH WEIGHT/
- 13. INFANT, SMALL FOR GESTATIONAL AGE/
- 14. (small adj2 (date or "gestational age")).tw.
- 15. lbw.tw.
- 16. vlbw.tw.
- 17. CHILD/
- 18. CHILD, PRESCHOOL/
- 19. SCHOOL CHILD/
- 20. child\$.tw.
- 21. PREPUBERTY/
- 22. PUBERTY/
- 23. prepube\$.tw.
- 24. pubert\$.tw.
- 25. pubesc\$.tw.
- 26. ADOLESCENCE/
- 27. adolescen\$.tw.
- 28. "MINORS (LEGAL)"/
- 29. juvenile\$.tw.
- 30. minors.tw.
- 31. youth\$.tw.
- 32. teen\$.tw.
- 33. or/1-32

- 34. BACTERIAL INFECTIONS/
- 35. (bacteri\$ adj infect\$).tw.
- 36. or/34-35
- 37. exp MENINGITIS, BACTERIAL/
- 38. (meningitis\$ adj2 (bacteri\$ or coli or escheichia or listeria or pneumococc\$ or purulent\$ or pyrogen\$)).tw.
- 39. meningococc\$.tw.
- 40. or/37-39
- 41. exp SEPSIS/
- 42. septicemi\$.tw.
- 43. septicaemia\$.tw.
- 44. or/41-43
- 45. BACTEREMIA/
- 46. bacteremi\$.tw.
- 47. bacteraemia\$.tw.
- 48. or/45-47
- 49. exp PNEUMONIA/
- 50. pneumoni\$.tw.
- 51. or/49-50
- 52. HERPES SIMPLEX/
- 53. herpes simplex.tw.
- 54. or/52-53
- 55. exp ARTHRITIS, INFECTIOUS/
- 56. (arthriti\$ adj2 (bacteri\$ or infect\$ or purulen\$ or pyogenic\$ or septic\$ or suppurative\$)).tw.
- 57. pyarthrosis.tw.
- 58. pyoarthritis.tw.
- 59. or/55-58
- 60. STAPHYLOCOCCAL INFECTIONS/
- 61. STREPTOCOCCAL INFECTIONS/
- 62. ((straphylococc\$ or streptococc\$) adj infect\$).tw.
- 63. or/60-62
- 64. OSTEOMYELITIS/
- 65. osteomyeliti\$.tw.
- 66. or/64-65
- 67. exp URINARY TRACT INFECTION/
- 68. ((bladder\$ or genitourin\$ or kidney\$ or pyelo\$ or renal\$ or ureter\$ or ureth\$ or urin\$ or urolog\$ or urogen\$) adj5 infect\$).tw.
- 69. UTI.tw.
- 70. ((upper or lower) adj5 urin\$).tw.

- 71. CYSTITIS/
- 72. cystitis\$.tw.
- 73. PYELONEPHRITIS/
- 74. pyelonephriti\$.tw.
- 75. pyonephrosi\$.tw.
- 76. pyelocystiti\$.tw.
- 77. or/67-76
- 78. MUCOCUTANEOUS LYMPH NODE SYNDROME/
- 79. (mucocutaneous adj2 lymph\$).tw.
- 80. mcls.tw.
- 81. (kawasaki adj (disease or syndrome)).tw.
- 82. or/78-81
- 83. or/36,40,44,48,51,54,59,63,66,77,82
- 84. ANTIINFECTIVE AGENT/
- 85. ANTIBIOTIC AGENT/
- 86. PENICILLINS/
- 87. penicillin\$.tw.
- 88. antibiotic\$.tw.
- 89. bacteriocide\$.tw.
- 90. ((antibacterial\$ or antimycobacteria\$ or bacteriocidal\$) adj agent\$).tw.
- 91. or/84-90
- 92. AMOXICILLIN/
- 93. amoxicil\$.tw.
- 94. amoxycil\$.tw.
- 95. amoxil\$.tw.
- 96. or/92-95
- 97. AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION/
- 98. augmentin\$.tw.
- 99. or/97-98
- 100. AMPICILLIN/
- 101. ampicillin\$.tw.
- 102. penbritin\$.tw.
- 103. or/100-102
- 104. CEFADROXIL/
- 105. cefadroxil\$.tw.
- 106. cephadrox\$.tw.
- 107. or/104-106
- 108. CEPHALEXIN/
- 109. cephalexin\$.tw.

- 110. cefalexin\$.tw.
- 111. cefaclor\$.tw.
- 112. ceporex\$.tw.
- 113. keflex\$.tw.
- 114. or/108-113
- 115. CEFIXIME/
- 116. cefixim\$.tw.
- 117. suprax\$.tw.
- 118. or/115-117
- 119. CEFOTAXIME/
- 120. cefotaxim\$.tw.
- 121. cephotaxim\$.tw.
- 122. claforan\$.tw.
- 123. klaforan\$.tw.
- 124. or/119-123
- 125. CEPHALOSPORINS/
- 126. (cephalospor\$ adj2 (acid\$ or antibiotic\$)).tw.
- 127. cefpirome\$.tw.
- 128. cefrom\$.tw.
- 129. or/125-128
- 130. CEFTIZOXIME/
- 131. cefpodoxim\$.tw.
- 132. ceftizoxim\$.tw.
- 133. orelox\$.tw.
- 134. or/130-133
- 135. CEPHRADINE/
- 136. cefradin\$.tw.
- 137. velosef\$.tw.
- 138. or/135-137
- 139. CEFTAZIDIME/
- 140. ceftazidim\$.tw.
- 141. fortum\$.tw.
- 142. kefadim\$.tw.
- 143. or/139-142
- 144. CEFTRIAXONE/
- 145. ceftriaxon\$.tw.
- 146. rocephin\$.tw.
- 147. or/144-146
- 148. CEFUROXIME/

Feverish illness in children (appendices)

- 149. cefuroxim\$.tw.
- 150. zinacef\$.tw.
- 151. zinnat\$.tw.
- 152. or/148-151
- 153. GENTAMICINS/
- 154. gentamicin\$.tw.
- 155. cidomycin\$.tw.
- 156. genticin\$.tw.
- 157. or/153-156
- 158. AMIKACIN/
- 159. amikacin\$.tw.
- 160. AMINOGLYCOSIDES/
- 161. (aminoglycoside\$ or aminoglucoside\$).tw.
- 162. TOBRAMYCIN/
- 163. tobramycin\$.tw.
- 164. nebcin\$.tw.
- 165. tobi.tw.
- 166. netilmicin\$.tw.
- 167. or/158-166
- 168. or/91,96,99,103,107,114,118,124,129,134,138,143,147,152,157,167
- 169. ECONOMICS/
- 170. "COSTS AND COST ANALYSIS"/
- 171. COST BENEFIT ANALYSIS/
- 172. COST CONTROL/
- 173. COST SAVINGS/
- 174. COST OF ILLNESS/
- 175. HEALTH CARE COSTS/
- 176. ECONOMIC ASPECTS OF ILLNESS/
- 177. ECONOMICS, PHARMACEUTICAL/
- 178. HEALTH CARE FINANCING/
- 179. FINANCIAL MANAGEMENT/
- 180. HOSPITAL COST/
- 181. SOCIOECONOMIC FACTORS/
- 182. HEALTH RESOURCE ALLOCATION/
- 183. (financ\$ or fiscal\$ or funding).tw.
- 184. (QALY\$ or life?year\$).tw.
- 185. (econom\$ or cost\$).tw.
- 186. pharmacoeconomic\$.tw.
- 187. or/169-186

188. and/33,83,168,187

Appendix F Summary of identified studies

Chapter 5

Review question

The predictive value of the following symptoms and signs, alone or in combination, as initial indications of serious illness:

- abnormal skin or mucosal colour (for example, pallor or cyanosis)
- · appearing ill to a healthcare professional or parent/carer
- altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing)
- abnormal respiratory rate, pulmonary (lung) crackles and othersounds
- · oxygen desaturation
- dehydration
- prolonged capillary refill time, cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- limb or joint swelling
- unwillingness to bear weight or use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- · focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- status epilepticus (prolonged or continuous fits).

Number of papers identified: 9401 Number of papers weeded out: 8537 Number of papers requested: 211 Number of papers excluded: 142 Number of papers included: 69

Chapter 5

Heart rate

Review question

The predictive value of heart rate, including:

- how heart rate changes with temperature?
- whether heart rate outside the normal range detects serious illness?
- whether heart rate and temperature outside normal range detects serious illness?

Number of papers identified: 193
Number of papers weeded out: 188
Number of papers requested: 5
Number of papers excluded: 0
Number of papers included: 5

Chapter 8

Children 3 months and older

Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

Number of papers identified: 619
Number of papers weeded out: 519
Number of papers requested: 46
Number of papers excluded: 31
Number of papers included: 15

Health economics

Number of papers identified: 17
Number of papers weeded out: 14
Number of papers requested: 1
Number of papers excluded: 1
Number of papers included: 0

Chapter 8

Response to antipyretic medication

Review question

What is the predictive value of the clinical response to paracetamol or NSAIDs?

Number of papers identified: 5372 Number of papers weeded out: 5250 Number of papers requested: 19 Number of papers excluded: 5 Number of papers included: 14

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

Number of papers identified: 1705 Number of papers weeded out: 1699 Number of papers requested: 4 Number of papers excluded: 4 Number of papers included: 0

9.3 Physical and drug interventions

Review question

Effect on fever and associated symptoms of treatment with:

- Paracetamol alone or NSAIDs alone, compared with placebo and with one another
- Alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- Paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone.

Number of papers identified: 1732 Number of papers weeded out: 1636 Number of papers requested: 86 Number of papers excluded: 58 Number of papers included: 28

Appendix G Excluded studies

Chapter 5

Review question

What is the value (as shown by likelihood ratios, sensitivity, specificity, positive predictive value and negative predictive value) of the following symptoms and signs, alone or in combination, as initial indications of serious illness?

- abnormal skin or mucosal colour (for example, pallor or cyanosis)
- · appearing ill to a healthcare professional or parent/carer
- · altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing)
- abnormal respiratory rate, pulmonary (lung) crackles and othersounds
- oxygen desaturation
- dehydration
- · prolonged capillary refill time, cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- limb or joint swelling
- · unwillingness to bear weight or use a limb
- bulging fontanelle
- rash (blanching or non-blanching)
- focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- status epilepticus (prolonged or continuous fits).

Number of papers identified: 9401 Number of papers weeded out: 8537 Number of papers requested: 211 Number of papers excluded: 142 Number of papers included: 69

value of clinical signs and

symptoms alone

| Table G.1 | |
|--|---|
| Bibliographic information | Reason for exclusion |
| Akpede,G.O., Abiodun,P.O., Sykes,R.M., Pattern of infections in children under-six years old presenting with convulsions associated with fever of acute onset in a children's emergency room in Benin City, Nigeria, Journal of Tropical Pediatrics, 39, 11-15, 1993 | Does not compare signs and symptoms in children with and children without serious illness |
| Akpede, G.O., Abiodun, P.O., Sykes, R.M., Acute fevers of unknown origin in young children in the tropics, Journal of Pediatrics, 122, 79-81, 1993 | Compares signs and symptoms in children with and children without malaria - tropical diseases are not included in the current review |
| Al-Eissa, Y.A., Lumbar puncture in the clinical evaluation of children with seizures associated with fever, Pediatric Emergency Care, 11, 347-350, 1995 | Does not compare signs and symptoms in children with and children without serious illness |
| Al-Khathlan, N.A., Jan, M.M., Clinical profile of admitted children with febrile seizures, Neurosciences, 10, 30-33, 2005 | Does not compare signs and symptoms in children with and children without serious illness |
| Al-Rashed,A.M., Bacteremia in febrile children under 3 years of age in an emergency department of a university hospital, Saudi Medical Journal, 29, 229-233, 2008 | Not a predictive or comparative study |
| Anderson, A.B., Desisto, M.J., Marshall, P.C., DeWitt, T.G., Duration of fever prior to onset of a simple febrile seizure: a predictor of significant illness and neurologic course, Pediatric Emergency Care, 5, 12-15, 1989 | Duration of fever reported is duration of fever prior to seizure - not a comparison of interest for this review |
| Anga,G., Barnabas,R., Kaminiel,O., Tefuarani,N., Vince,J., Ripa,P., Riddell,M., Duke,T., The aetiology, clinical presentations and outcome of febrile encephalopathy in children in Papua New Guinea, Annals of Tropical Paediatrics, 30, 109-118, 2010 | Does not review individual symptoms and signs |
| Arguedas, A., Abdelnour, A., Soley, C., Jimenez, E., Jimenez, A.L., Ramcharran, D., Porat, N., Dagan, R., Gray, S., Rodgers, G.L., Prospective epidemiologic surveillance of invasive pneumococcal disease and pneumonia in children in San Jose, Costa Rica, Vaccine, 30, 2342-2348, 2012 | Does not look at symptoms and signs |
| Ariffin,H., Navaratnam,P., Lin,H.P., Surveillance study of bacteraemic episodes in febrile neutropenic children, International Journal of Clinical Practice, 56, 237-240, 2002 | Does not compare signs and symptoms in children with and children without serious illness |
| Barbado, F.J., Vazquez, J.J., Pena, J.M., Seoane, J.G., Arnalich, F., Gil, A., Puig, J.G., Vazquez, J.O., Fever of unknown origin: a survey on 133 patients, Journal of Medicine, 15, 185-192, 1984 | Does not compare signs and symptoms in children with and children without serious illness |
| Belongia,E.A., Irving,S.A., Waring,S.C., Coleman,L.A., Meece,J.K., Vandermause,M., Lindstrom,S., Kempf,D., Shay,D.K., Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections, JAMA, 304, 1091-1098, 2010 | Does not compare those with and without serious illness |
| Berkowitz, C.D., Uchiyama, N., Tully, S.B., Marble, R.D., Spencer, M., Stein, M.T., Orr, D.P., Fever in infants less than two months of age: spectrum of disease and predictors of outcome, Pediatric Emergency Care 1, 128-135, 1985. | Prediction of serious illness included laboratory test results - was not possible to determine predictive value of clinical signs and |

Care, 1, 128-135, 1985

Bilavsky,E., shkenazi-Hoffnung,L., Yarden-Bilavsky,H., Amir,J., Livni,G., A search for the 'Holy Grail' in the evaluation of febrile neonates aged 28 days or less: A prospective study, Scandinavian Journal of Infectious Diseases, 43, 264-268, 2011

Bilavsky,E., Shouval,D.S., Yarden-Bilavsky,H., Fisch,N., Ashkenazi,S., Amir,J., A prospective study of the risk for serious bacterial infections in hospitalized febrile infants with or without bronchiolitis, Pediatric Infectious Disease Journal, 27, 269-270, 2008

Biswas,R., Dhakal,B., Das,R.N., Shetty,K.J., Resolving diagnostic uncertainty in initially poorly localizable fevers: a prospective study, International Journal of Clinical Practice, 58, 26-28, 2004

Blacklock, C; Maydon-White, R; Coad, N; Thompson, M, Which symptoms and clinical features correctly identify serious respiratory infection in children attending a paediatric assessment unit?, Archives of Disease in Childhood, 96, 708-714, 2011

Bohnhorst,B., Lange,M., Bartels,D.B., Bejo,L., Hoy,L., Peter,C., Procalcitonin and valuable clinical symptoms in the early detection of neonatal late-onset bacterial infection, Acta Paediatrica, International Journal of Paediatrics, 101, 19-25, 2012

Bonadio, W.A., The history and physical assessments of the febrile infant, Pediatric Clinics of North America, 45, 65-77, 1998

Bonadio, W.A., Hagen, E., Rucka, J., Shallow, K., Stommel, P., Smith, D., Efficacy of a protocol to distinguish risk of serious bacterial infection in the outpatient evaluation of febrile young infants, Clinical Pediatrics, Clin. Pediatr., 32, 401-404, 1993

Bonadio, W.A., Hennes, H., Smith, D., Ruffing, R., Melzer-Lange, M., Lye, P., Isaacman, D., Reliability of observation variables in distinguishing infectious outcome of febrile young infants, Pediatric Infectious Disease Journal, 12, 111-114, 1993

Bonadio, W.A., Stremski, E., Shallow, K., Clinical characteristics of children with fever and transient neutropenia who experience serious bacterial infections, Pediatric Emergency Care, 5, 163-165, 1989

Bower, J.R., Powell, K.R., Unexplained fever in infants and young children: How to manage, Consultant, 41, 712-715, 2001

Brent, A.J., Lakhanpaul, M., Ninis, N., Levin, M., MacFaul, R., Thompson, M., Evaluation of temperature-pulse centile charts in identifying serious bacterial illness: observational cohort study, Archives of Disease in Childhood, 96, 368-373, 2011

Bressan, S., Andreola, B., Zucchetta, P., Montini, G., Burei, M., Perilongo, G., Da, Dalt L., Procalcitonin as a predictor of renal scarring in infants and young children, Pediatric Nephrology, 24, 1199-1204, 2009

Include laboratory test results - not possible to separate out clinical signs and symptoms

Compares serious bacterial illness in children with and children without bronchiolitis - does not compare signs and symptoms in children with and children without serious illness

Does not compare signs and symptoms in children with and children without serious illness. The included population were older than 14 years.

Not all children were febrile and results were not presented as a subgroup analysis. The grouping of illnesses meant that the comparison relevant to the current review (serious illness vs. no/minor illness) could not be made.

Not all children had fever. No subgroup analysis was available for those that did.

Review with no new data

Looks at the Rochester and Milwalkee protocols, both of which include laboratory findings in their criteria

Scoring system that is not relevant to this review

Does not compare signs and symptoms in children with and children without serious illness

Does not compare symptoms and signs in children with and without serious bacterial illness

Useful data are temperature-pulse centile charts - more relevant to the separate heart rate question

Not a comparison of interest

Bressan,S., Berlese,P., Mion,T., Masiero,S., Cavallaro,A., Da,Dalt L., Bacteremia in feverish children presenting to the emergency department: a retrospective study and literature review, Acta Paediatrica, 101, 271-277, 2012

Does not compare symptoms and signs in children with and children without serious illlness. Excludes children that the current review question is interested in (e.g. those who appear ill, those who are irritable).

Brogan, P.A., Raffles, A., The management of fever and petechiae: making sense of rash decisions, Archives of Disease in Childhood, 83, 506-507, 2000

Includes a laboratory test as part of the predictive model - not possible to examine the predictive value of signs and symptoms alone

Byer,R.L., Bachur,R.G., Clinical deterioration among patients with fever and erythroderma, Pediatrics, 118, 2450-2460, 2006

Does not compare signs and symptoms in children with and children without serious illness

Byington,C.L., Reynolds,C.C., Korgenski,K., Sheng,X., Valentine,K.J., Nelson,R.E., Daly,J.A., Osguthorpe,R.J., James,B., Savitz,L., Pavia,A.T., Clark,E.B., Costs and infant outcomes after implementation of a care process model for febrile infants, Pediatrics, 130, e16-e24, 2012

Not relevant to question

Canadian Agency for Drugs and Technologies in Health., Early identification of sepsis: a review of the evidence for clinical indicators and guidelines for management (Structured abstract), Health Technology Assessment Database, -, 2012

Structured abstract. Full article accessed - excluded as does not compare symptoms and signs for detecting serious illness in children with fever. Not all children had fever, does not compare symptoms and signs in combination with fever.

Carrol,E.D., Newland,P., Riordan,F.A., Thomson,A.P., Curtis,N., Hart,C.A., Procalcitonin as a diagnostic marker of meningococcal disease in children presenting with fever and a rash, Archives of Disease in Childhood, 86, 282-285, 2002

Does not compare clinical signs and symptoms in those with and without serious bacterial illness

Caspe,W.B., Chamudes,O., Louie,B., The evaluation and treatment of the febrile infant, Pediatric Infectious Disease, 2, 131-135, 1983

Uses signs and symptoms to distinguish between viral and bacterial infections, not serious and non-serious illness

Chaturvedi,P., Kishore,M., Modified Glasgow Coma Scale to predict mortality in febrile unconscious children, Indian Journal of Pediatrics, 68, 311-314, 2001

Does not compare signs and symptoms in children with and children without serious illness

Chiappini,E., Principi,N., Longhi,R., Tovo,P.A., Becherucci,P., Bonsignori,F., Esposito,S., Festini,F., Galli,L., Lucchesi,B., Mugelli,A., de,Martino M., Writing Committee of the Italian Pediatric Society Panel for the Management of Fever in Children., Management of fever in children: summary of the Italian Pediatric Society guidelines, Clinical Therapeutics, 31, 1826-1843, 2009

Narrative review with no new data

Chin,R.F., Neville,B.G., Peckham,C., Bedford,H., Wade,A., Scott,R.C., NLSTEPSS Collaborative Group., Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study, Lancet, 368, 222-229, 2006

Does not compare serious illness in children with and without status epilepticus

Chin,R.F., Neville,B.G., Scott,R.C., Meningitis is a common cause of convulsive status epilepticus with fever, Archives of Disease in Childhood, 90, 66-69, 2005

Does not compare signs and symptoms in children with and children without serious illness

Dagan,R., Powell,K.R., Hall,C.B., Menegus,M.A., Identification of infants unlikely to have serious bacterial infection although hospitalized for suspected sepsis, Journal of Pediatrics, 107, 855-860, 1985

Rochester criteria - based on laboratory test results rather than clinical signs and symptoms

Dagan,R., Sofer,S., Phillip,M., Shachak,E., Ambulatory care of febrile infants younger than 2 months of age classified as being at low risk for having serious bacterial infections, Journal of Pediatrics, 112, 355-360, 1988

Laboratory test results rather than clinical signs and symptoms

Deorari,A.K., Chellani,H., Carlin,J.B., Greenwood,P., Prasad,M.S., Satyavani,A., Singh,J., John,R., Taneja,D.K., Paul,P., Meenakshi,M., Kapil,A., Paul,V.K., Weber,M., Clinico-epidemiological profile and predictors of severe illness in young infants (<60 days) reporting to a hospital in North India, Indian Pediatrics, 44, 739-748, 2007

Not all children had fever. Does not link signs and symptoms to the prediction of serious bacterial illness.

Fleming,S., Thompson,M., Stevens,R., Heneghan,C., Pluddemann,A., Maconochie,I., Tarassenko,L., Mant,D., Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: a systematic review of observational studies, Lancet, 377, 1011-1018, 2011

Does not predict serious bacterial infection

Galetto-Lacour, A., Zamora, S.A., Andreola, B., Bressan, S., Lacroix, L., Da, Dalt L., Gervaix, A., Validation of a laboratory risk index score for the identification of severe bacterial infection in children with fever without source, Archives of Disease in Childhood, 95, 968-973, 2010

Laboratory test results not covered by the guideline update

Garcia,S., Mintegi,S., Gomez,B., Barron,J., Pinedo,M., Barcena,N., Martinez,E., Benito,J., Is 15 days an appropriate cut-off age for considering serious bacterial infection in the management of febrile infants?, Pediatric Infectious Disease Journal, 31, 455-458, 2012

Does not use symptoms and signs in the prediction of serious illness

Gorelick,M.H., Shaw,K.N., Murphy,K.O., Baker,M.D., Effect of fever on capillary refill time, Pediatric Emergency Care,Pediatr.Emerg.Care, 13, 305-307, 1997

Not all children had fever. There is not a clear link in the results between fever and CRT.

Grupo de Trabajo sobre el Nino Febril de la Sociedad Espanola de Urgencias de Pediatria., [The young febrile child. Results of a multicenter survey]. [Spanish], Anales Espanoles de Pediatria, 55, 5-10, 2001

Spanish language paper

Gupta, D., Mishra, S., Chaturvedi, P., Fast breathing in the diagnosis of pneumonia--a reassessment, Journal of Tropical Pediatrics, J. Trop. Pediatr., 42, 196-199, 1996

Children did not present with fever

Haj-Hassan,T.A., Thompson,M.J., Mayon-White,R.T., Ninis,N., Harnden,A., Smith,L.F., Perera,R., Mant,D.C., Which early 'red flag' symptoms identify children with meningococcal disease in primary care?, British Journal of General Practice, 61, e97-104, 2011

Not all children had fever. Does not compare signs and symptoms in those with fever.

Hampers,L.C., Spina,L.A., Evaluation and management of pediatric febrile seizures in the emergency department, Emergency Medicine Clinics of North America, 29, 83-93, 2011

Narrative review with no new data

Haq,S.A., Alam,M.N., Hossain,S.M., Ahmed,T., Tahir,M., Value of clinical features in the diagnosis of enteric fever, Bangladesh Medical Research Council Bulletin, 23, 42-46, 1997

All participants were older than 12 years of age. Prediction of enteric/typhoid fever - not a serious illness of interest to the GDG

Henderson,S., A paediatric early warning scoring system for a remote rural area, Nursing Children and Young People, 24, 23-26, 2012

Does not compare symptoms and signs in children with and children without serious illness

Heulitt, M.J., Ablow, R.C., Santos, C.C., O'Shea, T.M., Hilfer, C.L., Febrile infants less than 3 months old: value of chest radiography, Radiology, 167, 135-137, 1988

Hiew,T.M., Tan,A.M., Cheng,H.K., Clinical features and haematological indices of bacterial infections in young infants, Singapore Medical Journal, 33, 125-130, 1992

Huang,G.Y., Ma,X.J., Huang,M., Chen,S.B., Huang,M.R., Gui,Y.H., Ning,S.B., Zhang,T.H., DU,Z.D., Yanagawa,H., Kawasaki,T., Epidemiologic pictures of Kawasaki disease in Shanghai from 1998 through 2002, Journal of Epidemiology, 16, 9-14, 2006

Huppler, A.R., Eickhoff, J.C., Wald, E.R., Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature. [31 refs], Pediatrics, 125, 228-233, 2010

Jaffe, D.M., Fleisher, G.R., Temperature and total white blood cell count as indicators of bacteremia, Pediatrics, 87, 670-674, 1991

Jamuna, R., Srinivasan, S., Harish, B.N., Factors predicting occult bacteremia in young children, Indian Journal of Pediatrics, Indian J. Pediatr., 67, 709-711, 2000

Jaskiewicz, J.A., McCarthy, C.A., Richardson, A.C., White, K.C., Fisher, D.J., Dagan, R., Powell, K.R., Febrile infants at low risk for serious bacterial infection--an appraisal of the Rochester criteria and implications for management. Febrile Infant Collaborative Study Group, Pediatrics, 94, 390-396, 1994

Joshi,BatajooR, Rayamajhi,A., Mahaseth,C., Children with first episode of fever with seizure: Is lumbar puncture necessary?, Journal of the Nepal Medical Association, 47, 109-112, 2008

Joshi, N., Rajeshwari, K., Dubey, A.P., Singh, T., Kaur, R., Clinical spectrum of fever of unknown origin among Indian children. [27 refs], Annals of Tropical Paediatrics, 28, 261-266, 2008

Juntunen, A., Herrgard, E., Mannonen, L., Korppi, M., Linnavuori, K., Vaheri, A., Koskiniemi, M., A major role of viruses in convulsive status epilepticus in children: a prospective study of 22 children, European Journal of Pediatrics, 160, 37-42, 2001

Kao,H.C., Huang,Y.C., Chiu,C.H., Chang,L.Y., Lee,Z.L., Chung,P.W., Kao,F.C., Lin,T.Y., Acute hematogenous osteomyelitis and septic arthritis in children, Journal of Microbiology, Immunology and Infection, 36, 260-265, 2003

Karmarkar, S.A., Aneja, S., Khare, S., Saini, A., Seth, A., Chauhan, B.K., A study of acute febrile encephalopathy with special reference to viral etiology, Indian Journal of Pediatrics, 75, 801-805, 2008

Kennedy,P.G., A retrospective analysis of forty-six cases of herpes simplex encephalitis seen in Glasgow between 1962 and 1985, Quarterly Journal of Medicine,Q.J.Med., 68, 533-540, 1988

Does not compare signs and symptoms in children with and children without serious illness

Not all children had fever. The prediction of signs and symptoms in conjunction with fever is not reported.

All had Kawasaki disease and does not look at fever + signs and symptoms

Only looks at laboratory criteria

White blood cell count and laboratory values rather than clinical symptoms and signs

Did not look at relevant symptoms/signs

Uses Rochester criteria - includes laboratory results rather than clinical signs and symptoms

Reports on 'meningeal signs' - these are not clearly defined and the current review is looking at evidence for individual symptoms and signs

Does not compare signs and symptoms in children with and children without serious illness

Does not compare signs and symptoms in children with and children without serious illness

Children did not present with fever

Does not compare signs and symptoms in children with and children without serious illness

Not all children had fever - this study looks at children with herpes simplex encephalitis rather than at children with fever

Kimia, A., Ben-Joseph, E.P., Rudloe, T., Capraro, A., Sarco, D., Hummel, D., Johnston, P., Harper, M.B., Yield of lumbar puncture among children who present with their first complex febrile seizure, Pediatrics, 126, 62-69, 2010

Does not compare signs and symptoms in children with and children without serious illness

King, C., Evaluation and management of febrile infants in the emergency department, Emergency Medicine Clinics of North America, 21, 89-99, 2003

The review did not present usuable data

King, E.A., Slawson, D.C., Tachypnea as a predictor of pneumonia in febrile children, Journal of Family Practice, 42, 25-, 1996

Brief report of Taylor (1995) "Establishing clinically relevant standards for tachypnea in febrile children younger than 2 years" - full article considered separately for inclusion in the review

Klein-Kremer,A., Goldman,R.D., Return visits to the emergency department among febrile children 3 to 36 months of age, Pediatric Emergency Care, 27, 1126-1129, 2011

Does not compare symptoms and signs in children with and without serious illness

Kocher,M.S., Mandiga,R., Zurakowski,D., Barnewolt,C., Kasser,J.R., Validation of a clinical prediction rule for the differentiation between septic arthritis and transient synovitis of the hip in children, Journal of Bone and Joint Surgery - Series A, 86, 1629-1635, 2004

Not all children presented with fever

Krief,W.I., Levine,D.A., Platt,S.L., Macias,C.G., Dayan,P.S., Zorc,J.J., Feffermann,N., Kuppermann,N., Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics., Influenza virus infection and the risk of serious bacterial infections in young febrile infants, Pediatrics, 124, 30-39, 2009

Compares children with influenza to those without influenza. Does not link clinical signs and symptoms to serious illness

Kuppermann, N., Fleisher, G.R., Jaffe, D.M., Predictors of occult pneumococcal bacteremia in young febrile children, Annals of Emergency Medicine, 31, 679-687, 1998

Does not compare signs and symptoms in children with and children without serious illness

Lacour,A.G., Zamora,S.A., Gervaix,A., A score identifying serious bacterial infections in children with fever without source, Pediatric Infectious Disease Journal, 27, 654-656, 2008

Uses laboratory tests as predictors

Laman,M., Manning,L., Hwaiwhange,I., Vince,J., Aipit,S., Mare,T., Warrel,J., Karunajeewa,H., Siba,P., Mueller,I., Davis,T.M., Lumbar puncture in children from an area of malaria endemicity who present with a febrile seizure, Clinical Infectious Diseases, 51, 534-540, 2010

Compares outcome in children with simple or complex seizures - not a relevant comparison

Leonard, P.A., Beattie, T.F., Is measurement of capillary refill time useful as part of the initial assessment of children?, European Journal of Emergency Medicine, 11, 158-163, 2004

Not all children had fever

Levine,D.A., Platt,S.L., Dayan,P.S., Macias,C.G., Zorc,J.J., Krief,W., Schor,J., Bank,D., Fefferman,N., Shaw,K.N., Kuppermann,N., Multicenter RSV-SBI Study Group of the Pediatric Emergency Medicine Collaborative Research Committee of the American Academy of Pediatrics., Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections, Pediatrics, 113, 1728-1734, 2004

Compares children with respiratory syncytial virus to those without respiratory syncytial virus. Does not link clinical signs and symptoms to serious illness

Lorber, J., Sunderland, R., Lumbar puncture in children with convulsions associated with fever, Lancet, 1, 785-786, 1980

Reported on duration of convulsion - not relevant to this review

Luaces-Cubells, C., Mintegi, S., Garcia-Garcia, J.J., Astobiza, E., Garrido-Romero, R., Velasco-Rodriguez, J., Benito, J., Procalcitonin to detect invasive bacterial infection in non-toxic-appearing infants with fever without apparent source in the emergency department, Pediatric Infectious Disease Journal, 31, 645-647, 2012

Included in PCT vs CRP question. Not relevant to the current review.

Lucero,M.G., Tupasi,T.E., Gomez,M.L., Beltran,G.L., Crisostomo,A.U., Romano,V.V., Rivera,L.M., Respiratory rate greater than 50 per minute as a clinical indicator of pneumonia in Filipino children with cough, Reviews of Infectious Diseases,Rev.Infect.Dis., 12 Suppl 8, S1081-S1083, 1990

Population was did not include Children with fever

Luginbuhl,L.M., Newman,T.B., Pantell,R.H., Finch,S.A., Wasserman,R.C., Office-based treatment and outcomes for febrile infants with clinically diagnosed bronchiolitis, Pediatrics, 122, 947-954, 2008

Compares signs and symptoms for children with and without bronchiolitis - not a serious illness of interest to the GDG

Lumsden, D.E., de la Morandiere, K.P., Best evidence topic report. Rigors in febrile children may be associated with a higher incidence of serious bacterial infection. [1 refs], Emergency Medicine Journal, 24, 663-, 2007

Summary of a study. Original study (Tal, 1997) reviewed separately.

Maayan-Metzger,A., Mazkereth,R., Kuint,J., Fever in healthy asymptomatic newborns during the first days of life, Archives of Disease in Childhood: Fetal and Neonatal Edition, 88, F312-F314, 2003

Compares characteristics of children with and children without fever - prediction of fever rather than serious illness

Machado,B.M., Cardoso,D.M., De,PaulisM, Escobar,A.M.D.U., Gilio,A.E., Fever without source: Evaluation of a guideline, Jornal de Pediatria, 85, 426-432, 2009

The presence of toxaemia was evaluated when the children were not febrile

Mahabee-Gittens,E.M., Grupp-Phelan,J., Brody,A.S., Donnelly,L.F., Bracey,S.E., Duma,E.M., Mallory,M.L., Slap,G.B., Identifying children with pneumonia in the emergency department, Clinical Pediatrics, 44, 427-435, 2005

Not all children had fever. All children had cough.

Manzano,S., Bailey,B., Gervaix,A., Cousineau,J., Delvin,E., Girodias,J.B., Markers for bacterial infection in children with fever without source, Archives of Disease in Childhood, 96, 440-446, 2011

Use of the visual analogue scale not relevant to the current review

Manzano,S., Bailey,B., Girodias,J.B., Galetto-Lacour,A., Cousineau,J., Delvin,E., Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial, American Journal of Emergency Medicine, 28, 647-653, 2010

Does not use signs and symptoms to predict serious illness. Excluded children that were diagnosed with the SBIs of interest (UTI, pneumonia, etc).

Marom,R., Sakran,W., Antonelli,J., Horovitz,Y., Zarfin,Y., Koren,A., Miron,D., Quick identification of febrile neonates with low risk for serious bacterial infection: an observational study, Archives of Disease in Childhood Fetal and Neonatal Edition, 92, F15-F18, 2007

Did not assess individual symptoms/signs. Scoring system not relevant to this review

Massin, M.M., Montesanti, J., Lepage, P., Management of fever without source in young children presenting to an emergency room, Acta Paediatrica, 95, 1446-1450, 2006

Does not compare signs and symptoms in children with and children without serious illness

Mazzi, E., Bartos, A.E., Carlin, J., Weber, M.W., Darmstadt, G.L., Bolivia Clinical Signs Study Group., Clinical signs predicting severe illness in young infants (<60 days) in Bolivia, Journal of Tropical Pediatrics, 56, 307-316, 2010

Not all of the illnesses predicted were serious bacterial illnesses

McCarthy, P.L., Dolan, T.F., Jr., Hyperpyrexia in children. Eight-year emergency room experience, American Journal of Diseases of Children, 130, 849-851, 1976

Does not compare signs and symptoms in children with and children without serious illness

McCarthy,P.L., Lembo,R.M., Fink,H.D., Observation, history, and physical examination in diagnosis of serious illnesses in febrile children <=24 months, Journal of Pediatrics,J.Pediatr., 110, 26-30, 1987

Not looking at individual symptoms and signs. Not a scoring system of interest

Millichap, J.J., Gordon, Millichap J., Methods of investigation and management of infections causing febrile seizures, Pediatric Neurology, 39, 381-386, 2008

Compares infections in complex and simple seizures - does not compare signs and symptoms of children with and children without serious illness

Mintegi,S., Benito,J., Astobiza,E., Capape,S., Gomez,B., Eguireun,A., Well appearing young infants with fever without known source in the emergency department: are lumbar punctures always necessary?, European Journal of Emergency Medicine, 17, 167-169, 2010

Does not compare signs and symptoms in children with and children without serious illness

Mintegi,S., Benito,J., Pijoan,J.I., Maranon,R., Penalba,A., Gonzalez,A., Munoz,G., Luaces,C., Claret,G., Occult pneumonia in infants with high fever without source: a prospective multicenter study, Pediatric Emergency Care, 26, 470-474, 2010

Laboratory test results

Mintegi,S., Gomez,B., Urra,E., Romero,A., Paniagua,N., Lopez,E., Benito,J., Use of urine dipstick evaluating young infants with fever without a source and positive urine culture, Pediatric Infectious Disease Journal, 30, 1103-1105, 2011

Does not compare symptoms and signs in those with and without serious illness

Morley, C.J., Thornton, A.J., Cole, T.J., Fowler, M.A., Hewson, P.H., Symptoms and Signs in Infants Younger Than 6 Months of Age Correlated With the Severity of Their Illness, Pediatrics, 88, 1119-1124, 1991

Fever was not an inclusion criterion in the study. Temperature was not reported as a baseline characteristic or a result.

Mustafa,B., Hani,A.W.A., Chem,Y.K., Mariam,M., Khairul,A.H., Rasid,K.A., Chua,K.B., Epidemiological and clinical features of dengue versus other acute febrile illnesses amongst patients seen at government polyclinics, Medical Journal of Malaysia, 65, 293-298, 2010

Study was unavailable

Nguyen, C.T.E., Clavel, V., Major, P., Hervouet-Zeiber, C., Di, Liddol, Mattimoe, C., Bernard-Bonnin, A.C., Febrile seizures: How do current clinical practices compare with literature guidelines?, Paediatrics and Child Health, 16, 40A, 2011

Abstract only. Does not look at the link between symptoms and signs and serious illness.

Nijman,R.G., Thompson,M., van,Veen M., Perera,R., Moll,H.A., Oostenbrink,R., Derivation and validation of age and temperature specific reference values and centile charts to predict lower respiratory tract infection in children with fever: prospective observational study, BMJ, 345, e4224-, 2012

Does not compare symptoms and signs in children with and children without serious illness

Oostenbrink,R., Moons,K.G., Donders,A.R., Grobbee,D.E., Moll,H.A., Prediction of bacterial meningitis in children with meningeal signs: reduction of lumbar punctures, Acta Paediatrica, 90, 611-617, 2001

Not all children had fever

Oostenbrink,R., Moons,K.G., rksen-Lubsen,A.G., Grobbee,D.E., Moll,H.A., A diagnostic decision rule for management of children with meningeal signs, European Journal of Epidemiology,Eur.J.Epidemiol., 19, 109-116, 2004

Not all children had fever. The study does not look at the presence of fever with other signs and symptoms.

Osborn, L.M., Bolus, R., Temperature and fever in the full-term newborn, Journal of Family Practice, 20, 261-264, 1985

Does not compare signs and symptoms in children with and children without serious illness. Not all children presented with fever

Osman,O., Brown,D., Beattie,T., Midgley,P., Management of febrile children in a paediatric emergency department, Health Bulletin, 60, 33-39, 2002

Not all children had fever. The results for height of temperature were not clearly reported. The age of the children was not reported in the paper.

Otieno,H., Were,E., Ahmed,I., Charo,E., Brent,A., Maitland,K., Are bedside features of shock reproducible between different observers?, Archives of Disease in Childhood,Arch.Dis.Child., 89, 977-979, 2004

Not all children had fever

Pancharoen, C., Chansongsakul, T., Bhattarakosol, P., Causes of fever in children with first febrile seizures: how common are human herpesvirus-6 and dengue virus infections?, Southeast Asian Journal of Tropical Medicine and Public Health, 31, 521-523, 2000

Does not compare signs and symptoms in children with and children without serious illness

Paquette, K., Cheng, M.P., McGillivray, D., Lam, C., Quach, C., Is a lumbar puncture necessary when evaluating febrile infants (30 to 90 days of age) with an abnormal urinalysis?, Pediatric Emergency Care, 27, 1057-1061, 2011

Does not compare symptoms and signs in those with and without serious illness

Pasic,S., Minic,A., Djuric,P., Micic,D., Kuzmanovic,M., Sarjanovic,L., Markovic,M., Fever of unknown origin in 185 paediatric patients: a single-centre experience, Acta Paediatrica, 95, 463-466, 2006

Does not compare signs and symptoms in children with and children without serious illness

Phelps,K.E., Steele,R.W., Fever and stiff neck, Clinical Pediatrics, 51, 193-196, 2012

Case report on one child

Ploin,D., Gillet,Y., Morfin,F., Fouilhoux,A., Billaud,G., Liberas,S., Denis,A., Thouvenot,D., Fritzell,B., Lina,B., Floret,D., Influenza burden in febrile infants and young children in a pediatric emergency department, Pediatric Infectious Disease Journal, 26, 142-147, 2007

Not all children presented with fever. Predicting influenza - not an illness of interest to the GDG

Pluddemann,A., Price,C.P., Thompson,M., Wolstenholme,J., Heneghan,C., Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin, British Journal of General Practice, 61, 139-140, 2011

Review with no new data. Does not compare signs and symptoms in children with and children without serious illness

Pomeroy,S.L., Holmes,S.J., Dodge,P.R., Feigin,R.D., Seizures and other neurologic sequelae of bacterial meningitis in children, New England Journal of Medicine, 323, 1651-1657, 1990

Does not compare signs and symptoms in children with and children without serious illness

Press,S., Association of hyperpyrexia with serious disease in children, Clinical Pediatrics, 33, 19-25, 1994

Does not compare signs and symptoms in children with and children without serious illness

Pusic, M.V., Clinical management of fever in children younger than three years of age, Paediatrics and Child Health, 12, 469-472, 2007

Narrative review with no new data outlines management strategies rather than diagnosis

Ramakrishan, K., Mathew, K.N., Thomas, K., Causes of fever in febrile seizures, Indian Journal of Pediatrics, 49, 367-369, 1982

Does not compare signs and symptoms in children with and children without serious illness

Rampersad, A., Mukundan, D., Fever, Current Opinion in Pediatrics, 21, 139-144, 2009

Review with no new data

Ray, J.G., Screening and active management reduced perinatal complications more than routine care in gestational diabetes, ACP Journal Club, 143, 65-, 2005

Commentary on gestational diabetes

Razak,M., Ismail,M.M., Omar,A., A review of haematogenous osteomyelitis in children in Kuala Lumpur Hospital, Medical Journal of Malaysia, 53 Suppl A, 83-85, 1998

Not all had fever (80%). All children were included because they had haematogenous osteomyelitis.

Redd,S.C., Vreuls,R., Metsing,M., Mohobane,P.H., Patrick,E., Moteetee,M., Clinical signs of pneumonia in children attending a hospital outpatient department in Lesotho, Bulletin of the World Health Organization,Bull.World Health Organ., 72, 113-118, 1994

Children did not present with fever

Richet,H., Casalta,J.P., Thuny,F., Merrien,J., Harle,J.R., Weiller,P.J., Habib,G., Raoult,D., Development and assessment of a new early scoring system using non-specific clinical signs and biological results to identify children and adult patients with a high probability of infective endocarditis on admission, Journal of Antimicrobial Chemotherapy, 62, 1434-1440, 2008

Does not link signs and symptoms to serious bacterial illness. Not all participants had fever.

Riordan, A.F., Marzouk, O., Thomson, A.P., Sills, J.A., Hart, A.C., Prospective validation of the glasgow meningococcal septicaemia prognostic score. Comparison with other scoring methods, European Journal of Pediatrics, Eur. J. Pediatr., 161, 531-537, 2002

Not all children had fever

Ronfani, L., Vilarim, J.N., Dragovich, D., Bacalhau, A.F., Cattaneo, A., Signs of severe bacterial infection in neonates, Journal of Tropical Pediatrics, 45, 48-51, 1999

Not all children had fever. Fever is not reported in conjunction with other signs and symptoms for predicting serious bacterial infection.

Rossi, L.N., Brunelli, G., Duzioni, N., Rossi, G., Lumbar puncture and febrile convulsions, Helvetica Paediatrica Acta, 41, 19-24, 1986

Does not compare signs and symptoms in children with and children without serious illness

Shacham,S., Kozer,E., Bahat,H., Mordish,Y., Goldman,M., Bulging fontanelle in febrile infants: is lumbar puncture mandatory?, Archives of Disease in Childhood, 94, 690-692, 2009

Does not report enough data in comparing those with a serious bacterial infection and those without. Only reports that none of the 'good' or 'excellent' appearance children had bacterial meningitis (does not report how many ill appearing children had bacterial meningitis. Makes a comparison between aseptic meningitis and normal CSF, which is not relevant to the current review). Laboratory test results were not used in all children, and so the study authors suggest caution in a bacterial vs. viral diagnosis.

Shamo'on,H., Hawamdah,A., Haddadin,R., Jmeian,S., Detection of pneumonia among children under six years by clinical evaluation, Eastern Mediterranean Health Journal, 10, 482-487, 2004

Children did not present with fever

Shiva,F., Hashemian,H.R., Febrile seizures: clinical course and diagnostic evaluation, JPMA - Journal of the Pakistan Medical Association, 48, 276-277, 1998

Does not compare signs and symptoms in children with and children without serious illness

Singh,R.R., Chaudhary,S.K., Bhatta,N.K., Khanal,B., Shah,D., Clinical and etiological profile of acute febrile encephalopathy in eastern Nepal, Indian Journal of Pediatrics, 76, 1109-1111, 2009

Does not link clinical signs and symptoms to serious illness

Steiner, M.J., DeWalt, D.A., Byerley, J.S., Is this child dehydrated?, JAMA, 291, 2746-2754, 2004

The included children did not all have fever

Sur, D.K., Bukont, E.L., Evaluating fever of unidentifiable source in young children, American Family Physician, 75, 1805-1811, 2007

Narrative review with no new data

Surpure, J.S., Hyperpyrexia (temperature greater than 40 C) in children, JACEP, 8, 130-133, 1979

Does not compare signs and symptoms in children with and children without serious illness

Thompson,M., Van den,Bruel A., Verbakel,J., Lakhanpaul,M., Haj-Hassan,T., Stevens,R., Moll,H., Buntinx,F., Berger,M., Aertgeerts,B., Oostenbrink,R., Mant,D., Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care, Health Technology Assessment (Winchester, England), 16, 1-100, 2012

Published after the current review was started - individual studies were assessed for inclusion in the current review

Thompson,M., van,denBruelA, Verbakel,J., Lakhanpaul,M., Haj-Hassan,T., Stevens,R., Moll,H., Buntinx,F., Berger,M., Aertgeerts,B., Oostenbrink,R., Mant,D., Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care, Health Technology Assessment, 16, 1-99, 2012

Not all children had fever. The individual studies from this systematic review were reviewed separately for inclusion.

Thompson,M.J., Ninis,N., Perera,R., Mayon-White,R.T., Phillips,C., Bailey,L., Harnden,A., Mant,D., Levin,M.J., Clinical recognition of meningococcal disease in children and adolescents, Lancet, 367, 397-403, 2006

Children did not all present with fever

Tibby,S.M., Hatherill,M., Murdoch,I.A., Capillary refill and coreperipheral temperature gap as indicators of haemodynamic status in paediatric intensive care patients, Archives of Disease in Childhood,Arch.Dis.Child., 80, 163-166, 1999 Not a population of interest

Tseng,C.F., Fu,Y.C., Fu,L.S., Betau,H., Chi,C.S., Clinical spectrum of Kawasaki disease in infants, Chung Hua i Hsueh Tsa Chih - Chinese Medical Journal, 64, 168-173, 2001

All had Kawasaki disease therefore not predictive

Tunkel, A.R., Scheld, W.M., Acute bacterial meningitis, Lancet, 346, 1675-1680, 1995

Narrative review. Not all children had fever.

Van den,Bruel A., Aertgeerts,B., Bruyninckx,R., Aerts,M., Buntinx,F., Signs and symptoms for diagnosis of serious infections in children: a prospective study in primary care, British Journal of General Practice, 57, 538-546, 2007

Does not review individual symptoms and signs

Van den,Bruel A., Bruyninckx,R., Vermeire,E., Aerssens,P., Aertgeerts,B., Buntinx,F., Signs and symptoms in children with a serious infection: a qualitative study, BMC Family Practice, 6, 36-, 2005

Included children are not presenting with fever. Series of case reports. Not a predictive study.

Van den,Bruel A., Haj-Hassan,T., Thompson,M., Buntinx,F., Mant,D., European Research Network on Recognising Serious Infection investigators., Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: a systematic review. [53 refs], Lancet, 375, 834-845, 2010

Review with no meta-analysis. Included studies considered separately for inclusion in the NCC review.

Van, Den Bruel A, Thompson, M.J., Haj-Hassan, T., Stevens, R., Moll, H., Lakhanpaul, M., Mant, D., Diagnostic value of laboratory tests in identifying serious infections in febrile children: Systematic review, BMJ, 342, -, 2011

Uses laboratory test results rather than clinical signs and symptoms

Walsh-Kelly,C., Nelson,D.B., Smith,D.S., Losek,J.D., Melzer-Lange,M., Hennes,H.M., Glaeser,P.W., Clinical predictors of bacterial versus aseptic meningitis in childhood, Annals of Emergency Medicine,Ann.Emerg.Med., 21, 910-914, 1992

Not all children had fever (around 50% in infants and 15% in other children)

Waskerwitz, S., Berkelhamer, J.E., Outpatient bacteremia: clinical findings in children under two years with initial temperatures of 39.5 degrees C or higher, Journal of Pediatrics, 99, 231-233, 1981

Does not look at relevant symptoms or signs

Wilkinson,M., Bulloch,B., Smith,M., Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the postpneumococcal conjugate vaccine era, Academic Emergency Medicine, 16, 220-225, 2009

Wilson, D., Assessing and managing the febrile child, Nurse Practitioner, 20, 59-74, 1995

Yamamoto, L.T., Wigder, H.N., Fligner, D.J., Rauen, M., Dershewitz, R.A., Relationship of bacteremia to antipyretic therapy in febrile children, Pediatric Emergency Care, 3, 223-227, 1987

Yarden-Bilavsky,H., Bilavsky,E., Amir,J., Ashkenazi,S., Livni,G., Serious bacterial infections in neonates with fever by history only versus documented fever, Scandinavian Journal of Infectious Diseases, 42, 812-816, 2010

Yilmaz,H.L., Yildizdas,R.D., Alparslan,N., Ozcan,K., Yaman,A., Kibar,F., Screening tools for bacteraemia in a selected population of febrile children, Annals of the Academy of Medicine, Singapore, 37, 192-199, 2008

Does not compare signs and symptoms in children with and children without serious illness

Review with no new data

Does not compare signs and symptoms in children with and children without serious illness

Compares the incidence of serious illness with documented fever compared to fever by history only not a comparison of interest to the GDG

A white blood cell count of =< 5000/mm3 or =>15000/mm3 was an entry requirement for the study - this review does not look at the use of laboratory tests.

Chapter 5

Heart rate

Review question

The predictive value of heart rate, including:

- how heart rate changes with temperature?
- whether heart rate outside the normal range detects serious illness?
- whether heart rate and temperature outside normal range detects serious illness?

No studies were excluded

Chapter 8

Children 3 months and older

Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

Table G.2

| Study | Reason for exclusion |
|--|---|
| Alnader, M.F., Dasoky, H.A., Al-hamiedeen, N., Is C-reactive protein a valuable marker for severe bacterial infection?, Rawal Medical Journal, 37, 152-154, 2012 | Foral publication process for the paper is unclear. |
| Bhatnagar, S., Beig, F.K., Malik, A., Adenosine deaminase and C-reactive protein in cerebrospinal fluid for differential diagnosis of tubercular meningitis in children, Indian Journal of Clinical Biochemistry, 23, 299-301, 2008 | Includes children with confirmed diagnoses over 5 years of age |
| Bilavsky,E., Yarden-Bilavsky,H., Ashkenazi,S., Amir,J., C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants, Acta Paediatrica, 98, 1776-1780, 2009 | Children are already hospitalised so outside the guideline population |
| Bleeker, S.E., rksen-Lubsen, G., Grobbee, D.E., Donders, A.R.T., Moons, K.G.M., Moll, H.A., Validating and updating a prediction rule for serious bacterial infection in patients with fever without source, Acta Paediatrica, International Journal of Paediatrics, 96, 100-104, 2007 | Prediction rules for SBI using combination of factors. |
| Bressan,S., Andreola,B., Cattelan,F., Zangardi,T., Perilongo,G., Da,Dalt L., Predicting severe bacterial infections in well-appearing febrile neonates: laboratory markers accuracy and duration of fever, Pediatric Infectious Disease Journal, 29, 227-232, 2010 | Does not include PCT test |
| Butbul-Aviel,Y., Koren,A., Halevy,R., Sakran,W., Procalcitonin as a diagnostic aid in osteomyelitis and septic arthritis, Pediatric Emergency Care, 21, 828-832, 2005 | Children presenting with specific systems of arthritis. |
| Centre for Reviews and Dissemination., Accuracy of the procalcitonin test in the diagnosis of occult bacteremia in paediatrics: a systematic review and meta-analysis (;Provisional abstract);, Database of Abstracts of Reviews of Effects, -, 2012 | Review protocol only |
| Chang,W.S., Chiu,N.C., Chi,H., Li,W.C., Huang,F.Y., Comparison of the characteristics of culture-negative versus culture-positive septic arthritis in children, Journal of Microbiology, Immunology and Infection, 38, 189-193, 2005 | Not relevant to the question |
| Chen,C.J., Lo,Y.F., Huang,M.C., Chung,R.L., Tang,R.B., Wu,K.G., A model for predicting risk of serious bacterial infection in febrile infants younger than 3 months of age, Journal of the Chinese Medical Association: JCMA, 72, 521-526, 2009 | Mathematical model no clinical data |
| England,R.J., Crabbe,D.C.G., Delayed diagnosis of appendicitis in children treated with antibiotics, Pediatric Surgery International, 22, 541-545, 2006 | Not relevant to the question |
| Galetto-Lacour, A., Zamora, S.A., Andreola, B., Bressan, S., Lacroix, L., Da, Dalt L., Gervaix, A., Validation of a laboratory risk index score for the identification of severe bacterial infection in children with fever without | It uses the same population as in Andreola 2007. |

source, Archives of Disease in Childhood, 95, 968-973, 2010

Garin, E.H., Olavarria, F., Araya, C., Broussain, M., Barrera, C., Young, L., Diagnostic significance of clinical and laboratory findings to localize site of urinary infection, Pediatric Nephrology, 22, 1002-1006, 2007

Not relevant to the research question

Huang,M.Y., Gupta-Malhotra,M., Huang,J.J., Syu,F.K., Huang,T.Y., Acute-phase reactants and a supplemental diagnostic aid for Kawasaki disease, Pediatric Cardiology, 31, 1209-1213, 2010

Not relevant to the question

Jaksic, E., Bogdanovic, R., Artiko, V., Saranovic, D.S., Petrasinovic, Z., Petrovic, M., Bojic, L., Pavlovic, S., Paripovic, A., Antonovic, O., Lezaic, V.D., Saranovic, D., Petrovic, N., Obradovic, V., Diagnostic role of initial renal cortical scintigraphy in children with the first episode of acute pyelonephritis, Annals of Nuclear Medicine, 25, 37-43, 2011

Not relevant to question

Lacour,A.G., Zamora,S.A., Gervaix,A., A score identifying serious bacterial infections in children with fever without source, Pediatric Infectious Disease Journal, 27, 654-656, 2008

It combines data from Lacour 2001 and Lacour 2003, which are already included in the review

Manzano,S., Bailey,B., Girodias,J.B., Galetto-Lacour,A., Cousineau,J., Delvin,E., Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial, American Journal of Emergency Medicine, 28, 647-653, 2010

Investigates the impact of PCT measurement on antibiotic use

Mintegi,S., Benito,J., Pijoan,J.I., Maranon,R., Penalba,A., Gonzalez,A., Munoz,G., Luaces,C., Claret,G., Occult pneumonia in infants with high fever without source: a prospective multicenter study, Pediatric Emergency Care, 26, 470-474, 2010

Relevant data were not reported

Nahum, E., Livni, G., Schiller, O., Bitan, S., Ashkenazi, S., Dagan, O., Role of C-reactive protein velocity in the diagnosis of early bacterial infections in children after cardiac surgery, Journal of Intensive Care Medicine, 27, 191-196, 2012

Children already in hospital for cardiac surgery so outside the review population. Potential interaction for surgery and other treatments.

Papaevangelou, V., Papassotiriou, I., Sakou, I., Ferentinos, G., Liapi, G., Kyrka, A., Konstantopoulos, A., Evaluation of a quick test for C-reactive protein in a pediatric emergency department, Scandinavian Journal of Clinical and Laboratory Investigation, 66, 717-721, 2006

Methods of measuring CRP not included in review

Peltola, V., Toikka, P., Irjala, K., Mertsola, J., Ruuskanen, O., Discrepancy between total white blood cell counts and serum C-reactive protein levels in febrile children, Scandinavian Journal of Infectious Diseases, 39, 560-565, 2007

Study pre-defined cut-offs to compared WBC and CRP

Reitzenstein, J.E., Yamamoto, L.G., Mavoori, H., Similar erythrocyte sedimentation rate and C-reactive protein sensitivities at the onset of septic arthritis, osteomyelitis, acute rheumatic fever, Pediatric Reports, 2, 32-35, 2010

The study population was an inpatient cohort

Rudensky,B., Sirota,G., Erlichman,M., Yinnon,A.M., Schlesinger,Y., Neutrophil CD64 expression as a diagnostic marker of bacterial infection in febrile children presenting to a hospital emergency department, Pediatric Emergency Care, 24, 745-748, 2008

Not relevant to question

Sanders,S., Barnett,A., Correa-Velez,I., Coulthard,M., Doust,J., Systematic Review of the Diagnostic Accuracy of C-Reactive Protein to Detect Bacterial Infection in Nonhospitalized Infants and Children with Fever, Journal of Pediatrics, 153, 570-574, 2008

Systematic review - relevant individual studies were included

Shin,S.H., Choi,C.W., Lee,J.A., Kim,E.K., Choi,E.H., Kim,H.S., Kim,B.I., Choi,J.H., Risk factors for serious bacterial infection in febrile young infants in a community referral hospital, Journal of Korean Medical Science, 24, 844-848, 2009

The participants had obvious signs of localised infections

Thompson,A., Mannix,R., Bachur,R., Acute pediatric monoarticular arthritis: distinguishing lyme arthritis from other etiologies, Pediatrics, 123, 959-965, 2009

Lyme disease is not endemic in UK

Thompson,M., van,denBruelA, Verbakel,J., Lakhanpaul,M., Haj-Hassan,T., Stevens,R., Moll,H., Buntinx,F., Berger,M., Aertgeerts,B., Oostenbrink,R., Mant,D., Systematic review and validation of prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care, Health Technology Assessment, 16, 1-99, 2012

Individual studies included in our review; review mentioned in text, but not formally reviewed.

Van den,Bruel A., Thompson,M.J., Haj-Hassan,T., Stevens,R., Moll,H., Lakhanpaul,M., Mant,D., Diagnostic value of laboratory tests in identifying serious infections in febrile children: systematic review, BMJ, 342, d3082-, 2011

Papers included in this review already included in our review. Review mentioned in text of our review, but not formally reviewed.

Van, Den Bruel A, Thompson, M.J., Haj-Hassan, T., Stevens, R., Moll, H., Lakhanpaul, M., Mant, D., Diagnostic value of laboratory tests in identifying serious infections in febrile children: Systematic review, BMJ, 342, -, 2011

Systematic review - relevant individual studies have been included

Velasco-Zuniga,R., Trujillo-Wurttele,J.E., Fernandez-Arribas,J.L., Serrano-Carro,B., Campo-Fernandez,N., Puente-Montes,S., Predictive factors of low risk for bacteremia in infants with urinary tract infection, Pediatric Infectious Disease Journal, 31, 642-645, 2012

Not relevant to the question

Verboon-Maciolek,M.A., Thijsen,S.F.T., Hemels,M.A.C., Menses,M., Van,LoonA, Krediet,T.G., Gerards,L.J., Fleer,A., Voorbij,H.A.M., Rijkers,G.T., Inflammatory mediators for the diagnosis and treatment of sepsis in early infancy, Pediatric Research, 59, 457-461, 2006

Potentially biased population

Wander,K., Brindle,E., O'connor,K.A., Sensitivity and specificity of C-reactive protein and alpha(1) -acid glycoprotein for episodes of acute infection among children in kilimanjaro, tanzania, American Journal of Human Biology, 24, 565-568, 2012

abstract), Health Technology Assessment Database, -, 2012

Type of infection could not be confirmed

Health economics

Table G.3

Study

Reason for exclusion

Phillips,R., Wade,R., Myers,L., Hardman,M., Sutton,A., Stewart,L., A systematic review of prognostic serum markers in febrile neutropenic episodes in children and young people undergoing treatment for malignant disease (Protocol for a systematic review) (Structured

Chapter 8

Response to antipyretic medication

Review question

What is the predictive value of the clinical response to paracetamol or NSAIDs?

Table G.4

| Study | Reason for exclusion |
|--|--|
| Kramer,M.S., Naimark,L.E., Roberts-Brauer,R., McDougall,A., Leduc,D.G., Risks and benefits of paracetamol antipyresis in young children with fever of presumed viral origin, Lancet, 337, 591-594, 1991 | Does not report required outcomes |
| Lesko,S.M., O'Brien,K.L., Schwartz,B., Vezina,R., Mitchell,A.A., Invasive group A streptococcal infection and nonsteroidal antiinflammatory drug use among children with primary varicella, Pediatrics, 107, 1108-1115, 2001 | Not relevant to this question, but included in another question. |
| Mackowiak, P.A., Diagnostic implications and clinical consequences of antipyretic therapy, Clinical Infectious Diseases, 31, S230-S233, 2000 | Non-systematic review of evidence |
| McErlean, M.A., Bartfield, J.M., Kennedy, D.A., Gilman, E.A., Stram, R.L., Raccio-Robak, N., Home antipyretic use in children brought to the emergency department, Pediatric Emergency Care, 17, 249-251, 2001 | Does not address study question |
| Richardson,A.C., Roghmann,K.J., White,K.C., Use of clinical observation scales following antipyretic therapy to predict serious illness in febrile children, American Journal of Diseases of Children,Am.J.Dis.Child., 144, 435-, 1990 | Not relevant to question |

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

Table G.5

| Study | Reason for exclusion |
|--|---|
| Hoover,L., AAP reports on the use of antipyretics for fever in children, American Family Physician, 85, 518-519, 2012 | General comment paper; not a review |
| Pereira,G.L., Dagostini,J.M., Dal Pizzol,T.S., Alternating antipyretics in the treatment of fever in children: a systematic review of randomized clinical trials, Jornal de Pediatria, 88, 289-296, 2012 | All papers already included in NCCs own review |
| Section,onClinicalPharmacologyandTherapeutics, Committee,onDrugs, Sullivan,J.E., Farrar,H.C., Fever and antipyretic use in children, Pediatrics, 127, 580-587, 2011 | General literature review; not a systematic review |
| Senel,S., Erkek,N., Karacan,C.D., Comparison of acetaminophen and ketoprofen in febrile children: a single dose randomized clinical trial, Indian Journal of Pediatrics, 79, 213-217, 2012 | Ketoprofen not licenced in the UK and was not included as a treatment for review. |

9.3 Physical and drug interventions

Review question

Effect on fever and associated symptoms of treatment with:

- Paracetamol alone or NSAIDs alone, compared with placebo and with one another
- Alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- Paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone.

Table G.6

| Study | Reason for exclusion |
|---|---|
| Aksoylar,S., Aksit,S., Caglayan,S., Yaprak,I., Bakiler,R., Cetin,F., Evaluation of sponging and antipyretic medication to reduce body temperature in febrile children, Acta Paediatrica Japonica, 39, 215-217, 1997 | Physical methods not included in review |
| Amdekar,Y.K., Desai,R.Z., Antipyretic activity of ibuprofen and paracetamol in children with pyrexia, British Journal of Clinical Practice, 39, 140-143, 1985 | It could not be established if this was a randomised study or not |
| Ashraf,E., Ford,L., Geetha,R., Cooper,S., Safety profile of ibuprofen suspension in young children, Inflammopharmacology, 7, 219-225, 1999 | Included in Southy review |
| Baker MD, Fosarelli PD, Carpenter RO., Childhood fever: correlation of diagnosis with temperature response to acetaminophen., Pediatrics , 80, 315–8, 1987 | Not relevant to question |
| Baker RC, Tiller T, Bausher JC, et al., Severity of disease correlated with fever reduction in febrile infants., Pediatrics , 83, 1016–9, 1989 | Not relevant to question |

Bertin,L., Pons,G., d'Athis,P., Duhamel,J.F., Maudelonde,C., Lasfargues,G., Guillot,M., Marsac,A., Debregeas,B., Olive,G., A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children, Fundamental and Clinical Pharmacology, 10, 387-392, 1996

Main focus is not fever. Outcomes of interest not reported in usable format. Only useful for adverse events and already included in Pierce and Southey systematic reviews.

Brown,R.D., Wilson,J.T., Kearns,G.L., Eichler,V.F., Johnson,V.A., Bertrand,K.M., Single-dose pharmacokinetics of ibuprofen and acetaminophen in febrile children, Journal of Clinical Pharmacology, 32, 231-241, 1992

No outcomes of interest reported

Carley,S., Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Paracetamol or ibuprofen in febrile children. [15 refs], Journal of Accident and Emergency Medicine, 16, 137-139, 1999

Short report review

Catti,A., Monti,T., Treatment of infants with acute upper respiratory tract inflammation. A double-blind comparison between nimesulide and paracetamol suppositories, Clinical Trials Journal, 27, 327-335, 1990

Nimesulide not licenced in the UK

Celebi,S., Hacimustafaoglu,M., Aygun,D., Arisoy,E.S., Karali,Y., Akgoz,S., Citak Kurt,A.N., Seringec,M., Antipyretic effect of ketoprofen, Indian Journal of Pediatrics, 76, 287-291, 2009

Ketoprofen not licenced in UK

Del Vecchio, M.T., Sundel, E.R., Alternating antipyretics: is this an alternative?, Pediatrics, 108, 1236-1237, 2001

Letter to editor

Duhamel, J.F., Le, Gall E., Dalphin, M.L., Payen-Champenois, C., Antipyretic efficacy and safety of a single intravenous administration of 15 mg/kg paracetamol versus 30 mg/kg propacetamol in children with acute fever due to infection, International Journal of Clinical Pharmacology and Therapeutics, 45, 221-229, 2007

Compares types of paracetamol

Gianiorio,P., Zappa,R., Sacco,O., Fregonese,B., Scaricabarozzi,I., Rossi,G.A., Antipyretic and anti-inflammatory efficacy of nimesulide vs paracetamol in the symptomatic treatment of acute respiratory infections in children, Drugs, 46 Suppl 1, 204-207, 1993

Nimesilude not used in UK

Goldstein, L.H., Berlin, M., Berkovitch, M., Kozer, E., Effectiveness of oral vs rectal acetaminophen: a meta-analysis, Archives of Pediatrics and Adolescent Medicine, 162, 1042-1046, 2008

Route of administration

Goyal, P.K., Chandra, J., Unnikrishnan, G., Kumari, S., Passah, S.M., Double blind randomized comparative evaluation of nimesulide and paracetamol as antipyretics, Indian Pediatrics, 35, 519-522, 1998

Nimesulide not licenced in the UK

Hay,A.D., Costelloe,C., Redmond,N.M., Montgomery,A.A., Fletcher,M., Hollinghurst,S., Peters,T.J., Paracetamol plus ibuprofen for the treatment of fever in children (PITCH): randomised controlled trial.[Erratum appears in BMJ. 2009;339:b3295], BMJ, 337, a1302-, 2008

Summary of larger HTA report already included

Heubi, J.E., Barbacci, M.B., Zimmerman, H.J., Therapeutic misadventures with acetaminophen: hepatoxicity after multiple doses in children. [see comment]. [44 refs], Journal of Pediatrics, J. Pediatr., 132, 22-27, 1998

Case study reports.

Hopchet,L., Kulo,A., Rayyan,M., Verbesselt,R., Vanhole,C., de Hoon,J.N., Allegaert,K., Does intravenous paracetamol administration affect body temperature in neonates?, Archives of Disease in Childhood, 96, 301-304, 2011

Only 6 infants with fever assessed.

Houry, D., Ernst, A., Weiss, S., Ledbetter, M., Ketorolac versus acetaminophen for treatment of acute fever in the emergency department, Southern Medical Journal, 92, 1171-1173, 1999

Ketoprofen not recommended in children

Joshi, Y.M., Sovani, V.B., Joshi, V.V., Navrange, J.R., Benakappa, D.G., Shivananda, P., Sankaranarayanan, V.S., Comparative evaluation of the antipyretic efficacy of ibuprofen and paracetamol, Indian Pediatrics, 27, 803-806, 1990

Not an RCT

Kanabar, D., Dale, S., Rawat, M., A review of ibuprofen and acetaminophen use in febrile children and the occurrence of asthmarelated symptoms. [32 refs], Clinical Therapeutics, 29, 2716-2723, 2007

Safety not being examined

Karbasi,S.A., Modares-Mosadegh,M., Golestan,M., Comparison of antipyretic effectiveness of equal doses of rectal and oral acetaminophen in children, Jornal de Pediatria, 86, 228-232, 2010

Route of administration not being examined

Keinanen,S., Hietula,M., Simila,S., Kouvalainen,K., Antipyretic therapy. Comparison of rectal and oral paracetamol, European Journal of Clinical Pharmacology, 12, 77-80, 1977

Compares route of administration rather than treatments.

Khubchandani, R.P., Ghatikar, K.N., Keny, S., Usgaonkar, N.G., Choice of antipyretic in children, Journal of the Association of Physicians of India, 43, 614-616, 1995

Data cannot be extracted on comparisons of interest

Kidon,M.I., Kang,L.W., Chin,C.W., Hoon,L.S., Hugo,V.B., Nonsteroidal anti-inflammatory drug hypersensitivity in preschool children, Allergy, Asthma and Clinical Immunology, 3, 114-122, 2007

General literature review

Kokki, H., Ketoprofen pharmacokinetics, efficacy, and tolerability in pediatric patients, Paediatric Drugs, 12, 313-329, 2010

Ketoprofen not recommended in this age-group.

Kokki,H., Kokki,M., Ketoprofen versus paracetamol (acetaminophen) or ibuprofen in the management of fever: results of two randomized, double-blind, double-dummy, parallel-group, repeated-dose, multicentre, phase III studies in children, Clinical Drug Investigation, 30, 375-386, 2010

Ketoprofen not recommended in children

Lal,A., Gomber,S., Talukdar,B., Antipyretic effects of nimesulide, paracetamol and ibuprofen-paracetamol, Indian Journal of Pediatrics,Indian J.Pediatr., 67, 865-870, 2000

Focus of study was not comparison of interest. Data not reported in usable format.

Leroy,S., Marc,E., Bavoux,F., Treluyer,J.M., Gendrel,D., Breart,G., Pons,G., Chalumeau,M., Hospitalization for severe bacterial infections in children after exposure to NSAIDs: A prospective adverse drug reaction reporting study, Clinical Drug Investigation, 30, 179-185, 2010

Aim of study was unclear.

Lesko, S.M., Mitchell, A.A., An assessment of the safety of pediatric ibuprofen. A practitioner-based randomized clinical trial, JAMA, 273, 929-933, 1995

Included in Southy review

Mackowiak, P.A., Diagnostic implications and clinical consequences of antipyretic therapy, Clinical Infectious Diseases, 31, S230-S233, 2000

Not relevant to question

Magni, A.M., Scheffer, D.K., Bruniera, P., Antipyretic effect of ibuprofen and dipyrone in febrile children, Jornal de Pediatria, 87, 36-42, 2011

Dipyrone not used in UK

Maron, J.J., Ickes, A.C., The antipyretic effectiveness of acetaminophen suppositories versus tablets: a double-blind study, Current Therapeutic Research, Clinical and Experimental, 20, 45-52, 1976

Study examined route of administration.

Marriott,S.C., Stephenson,T.J., Hull,D., Pownall,R., Smith,C.M., Butler,A., A dose ranging study of ibuprofen suspension as an antipyretic, Archives of Disease in Childhood, 66, 1037-1041, 1991

No comparison with placebo or paracetamol

Mayoral, C.E., Marino, R.V., Rosenfeld, W., Greensher, J., Alternating antipyretics: is this an alternative?, Pediatrics, 105, 1009-1012, 2000

Survey of clinicians not an intervention study.

Mazur LJ, Jones TM, Kozinetz CA., Temperature response to acetaminophen and risk of occult bacteremia: a case-control study., J Pediatr, 115, 888â□"91, 1989

Not relevant to question

Meremikwu,Martin M., Oyolta,Angela, Paracetamol versus placebo or physical methods for treating fever in children, Cochrane Database of Systematic Reviews, -, 2010

Has not been edited since 2004. Individual studies will be included in the review.

Nabulsi,M., Is combining or alternating antipyretic therapy more beneficial than monotherapy for febrile children?, BMJ, 340, 92-93, 2010

Comment and literature review

Nabulsi,M., Tamim,H., Sabra,R., Mahfoud,Z., Malaeb,S., Fakih,H., Mikati,M., Equal antipyretic effectiveness of oral and rectal acetaminophen: a randomized controlled trial [ISRCTN11886401], BMC Pediatrics, 5, 35-, 2005

Examines the route of administration

Offringa,M., Newton,R., Prophylactic drug management for febrile convulsions in children, Cochrane Database of Systematic Reviews, -, 2007

Does not address the study question

Pardo, J., Daza, R., Chumbes, O., Loayza, I., Huicho, L., Antipyretic efficacy and tolerability of oral ibuprofen, oral dipyrone and intramuscular dipyrone in children: A randomized controlled trial, Sao Paulo Medical Journal, 124, 135-140, 2006

Dipyrone not used in UK

Perrott,D.A., Piira,T., Goodenough,B., Champion,G.D., Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: A Meta-analysis, Archives of Pediatrics and Adolescent Medicine, 158, 521-526, 2004

Meta-analysis included in 2007 guideline. Individual studies included in 2012 guideline.

Polidori,G., Titti,G., Pieragostini,P., Comito,A., Scaricabarozzi,I., A comparison of nimesulide and paracetamol in the treatment of fever due to inflammatory diseases of the upper respiratory tract in children, Drugs, 46 Suppl 1, 231-233, 1993

Nimesulide banned in UK

Purssell, E., Treating fever in children: paracetamol or ibuprofen?, British Journal of Community Nursing, Br J Community Nurs, 7, 316-320, 2002

Out of date. Individual studies will be included in meta-analysis.

Scolnik,D., Kozer,E., Jacobson,S., Diamond,S., Young,N.L., Comparison of oral versus normal and high-dose rectal acetaminophen in the treatment of febrile children, Pediatrics, 110, 553-556, 2002

Examined route of administration, not comparison of treatments

Sheth, U.K., Gupta, K., Paul, T., Pispati, P.K., Measurement of antipyretic activity of ibuprofen and paracetamol in children, Journal of Clinical Pharmacology, 20, 672-675, 1980

Figures not presented in a format that could be be used in analysis

Simila,S., Kouvalainen,K., Keinanen,S., Oral antipyretic therapy, Scandinavian Journal of Rheumatology, 5, 81-83, 1976

Not an RCT - no evidence of randomisation

Strengell,T., Uhari,M., Tarkka,R., Uusimaa,J., Alen,R., Lautala,P., Rantala,H., Antipyretic agents for preventing recurrences of febrile seizures: randomized controlled trial, Archives of Pediatrics and Adolescent Medicine, 163, 799-804, 2009

Diclofenac used in all groups, so cannot isolate effect of other treatments.

Torrey SB, Henretig F, Fleisher G, et al., Temperature response to antipyretic therapy in children: relationship to occult bacteremia., Am J Emerg Med, 3, 190â□"2, 1985

Not relevant to question

Ugazio, A.G., Guarnaccia, S., Berardi, M., Renzetti, I., Clinical and pharmacokinetic study of nimesulide in children, Drugs, 46 Suppl 1, 215-218, 1993

Nimsulide not used in UK

utret-Leca,E., souda-Grimaldi,L., Maurage,C., Jonville-Bera,A.P., Upper gastrointestinal complications associated with NSAIDs in children, Therapie, 62, 173-176, 2007

Vernon,S., Bacon,C., Weightman,D., Rectal paracetamol in small Examines the route of children with fever, Archives of Disease in Childhood, 54, 469-470, 1979 administration

Walson, P.D., Jones, J., Chesney, R., Rodarte, A., Antipyretic efficacy and tolerability of a single intravenous dose of the acetaminophen prodrug propacetamol in children: a randomized, double-blind, placebocontrolled trial, Clinical Therapeutics, 28, 762-769, 2006

Compares types of paracetamol

Weisse, M.E., Miller, G., Brien, J.H., Fever response to acetaminophen in viral vs. bacterial infections, Pediatric Infectious Disease Journal, 6, 1091-1094, 1987

Not relevant to question

Case reports

Wilson, J.T., Helms, R., Pickering, B.D., Donahue, L., Brown, R.D., Acetaminophen controlled-release sprinkles versus acetaminophen immediate-release elixir in febrile children, Journal of Clinical Pharmacology, 40, 360-369, 2000

Examines the route of administration

Yaffe,S.J., Comparative efficacy of aspirin and acetaminophen in the reduction of fever in children, Archives of Internal Medicine, 141, 286-292, 1981

Non-systematic literature review.

Yamamoto LT, Wigder HN, Fligner DJ, et al., Relationship of bacteremia to antipyretic therapy in febrile children, Pediatr Emerg Care, 3, 223â □ "7, 1987

Not relevant to question

Yoon, J.S., Jeong, D.C., Oh, J.W., Lee, K.Y., Lee, H.S., Koh, Y.Y., Kim, J.T., Kang, J.H., Lee, J.S., The effects and safety of dexibuprofen compared with ibuprofen in febrile children caused by upper respiratory tract infection, British Journal of Clinical Pharmacology, 66, 854-860, 2008

Dexiprofen not used in UK

Appendix H Evidence tables

The evidence tables are presented in a separate file

Appendix I GRADE profiles

These are the complete GRADE profiles which accompany the abbreviated versions in the full guideline. These include details of the quality assessment and additional footnoted information which accompanies the main findings. The GRADE findings (evidence profiles) are presented with the same table numbers as the abbreviated tables in the main text of the full guideline to assist cross-referencing.

Chapter 5

Review question

What is the value (as shown by likelihood ratios, sensitivity, specificity, positive predictive value and negative predictive value) of the following symptoms and signs, alone or in combination, as initial indications of serious illness?

- abnormal skin or mucosal colour (for example, pallor or cyanosis)
- appearing ill to a healthcare professional or parent/carer
- altered responsiveness or cry
- altered breathing (for example, nasal flaring, grunting, chest indrawing)
- · abnormal respiratory rate, pulmonary (lung) crackles and othersounds
- oxygen desaturation
- dehydration
- · prolonged capillary refill time, cold hands and feet
- poor feeding
- persistent fever (5 days or more)
- height of fever
- limb or joint swelling
- · unwillingness to bear weight or use a limb

- bulging fontanelle
- rash (blanching or non-blanching)
- focal neurological signs
- focal seizures
- new lumps
- neck stiffness
- vomiting
- status epilepticus (prolonged or continuous fits).

Table I5.3 GRADE profile for evaluation of colour

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|---------------------------------|---------------|---------------|---------------|--------|
| Colour (cy | anotic or p | ale or flushed | /mottled) | | | | | | | | | | | |
| For detect | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 36 (20 to 53) ^a | 40 (31 to 49) ^a | 16 (8 to 24) ^a | 67 (55 to 78) ^a | 0.6 (0.4 to 1.0) ^a | 1.6 (1.1 to 2.3) | Low | Prospe ctive | Very serious ^{b, c} | NA | No serious | No serious | Yes d, |
| For detect | ing urinary tı | ract infection | 1 | | | | l | I | | | | | | |
| 1 (Newma n, 2002) | 1666 | 9 (5 to 14) ^a | 92 (90 to 93) ^a | 11 (6 to 16) ^a | 90 (89 to 92) ^a | 1.1 (0.7 to 1.8) ^a | 1.0 (0.9 to 1.0) | Low | Prospe ctive | Very serious ^{b, f} | NA | No serious | No serious | Yes d, |

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all children received the same test to confirm serious infection

^c Some results were uninterpretable, indeterminable or intermediate test results

^d Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

Table I5.4 GRADE profile for evaluation of social cues

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|---------------------------------|---------------|---------------|---------------|-------------------------|
| Decreased | d social inte | eraction | | | | | | | | | | | | |
| For detecti | ing urinary tı | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 24 (17 to 30) ^a | 74 (71 to 76) ^a | 9 (6 to 11) ^a | 90 (88 to 92) ^a | 0.9 (0.7 to 1.2) ^a | 1.0 (0.9 to 1.1) | Low | Prospe ctive | Very serious ^{b, c} | NA | No serious | No serious | Yes ^{d,} |

e Included children were aged 2 weeks to 1 year old. Children were included if they had a rectal temperature greater than or equal to 38°C. The study was conducted in a paediatric emergency ward of a hospital in the Netherlands. Children were self-referred or referred by a GP.

^f The study authors report that not all eligible infants were enrolled

⁹ Included children were less than 3 months old. Infants were included if they had auxiliary, rectal or tympanic temperatures equal to or greater than 38°C in the office or in the previous 24 hours at home. The study was based in a GP's office in the USA.

^a Calculated by the NCC-WCH based on results reported in the study

^b The study authors report that not all eligible infants were enrolled

^c It is not clear whether all participants received the same test to confirm serious illness

^d Included children were less than 3 months old. Included infants had auxiliary, rectal or tympanic temperatures equal to or greater than 38°C in the office or in the previous 24 hours at home. The study was based in a GP's office in the USA.

^e Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

Table 15.5 GRADE profile for evaluation of 'appears ill to a healthcare professional'

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|----------|-----------------|--|---------------|---------------|---------------|-------------------------|
| At least m | ildly unwell | (includes mile | dly unwell, mode | rately unwell, a | nd very unwell |) | | | | | | | | |
| For detecti | ng urinary tr | act infection, pr | neumonia or bacte | eraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 74 (72 to 77) ^a | 42 (41 to 43) ^a | 9 (9 to 10) ^a | 95 (95 to 96) a | 1.3 (1.2 to 1.3) ^a | 0.6 (0.5 to 0.7) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes e, f, g, h |
| At least m | oderately il | l or moderatel | y unwell (include | es moderately il | l/unwell and ve | ry ill/unwell) | | | | | | | | |
| For detecti | ng serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 58 (41 to 74) ^a | 70 (61 to 78) ^a | 37 (24 to 51) | 84 (76 to 92) | 1.9 (1.3 to 2.9) a | 0.6 (0.4 to 0.9) ^a | Low | Prospe ctive | Very seriou s ^{c, i} | NA | No serious | No serious | Yes ^{f, j} |
| For detecti | ing urinary tr | act infection, p | neumonia or bacto | eraemia | | | <u> </u> | <u> </u> | <u> </u> | | <u>I</u> | <u> </u> | <u>I</u> | |
| 1 (Craig, 2010) | 12807 | 22 (20 to 25) ^a | 92 (91 to 92) ^a | 17 (15 to 19) | 94 (93 to 94) | 2.7 (2.4 to 3.0) ^a | 0.8 (0.8 to 0.9) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes e, f, g, h |
| For detecti | ing urinary tr | act infection | | | | | | | I | | l . | | l . | |
| 1 (Newma n, 2002) | 1666 | 38 (30 to 45) a | 65 (62 to 67) ^a | 10 (8 to 13) ^a | 91 (89 to 92) | 1.1 (0.9 to 1.3) ^a | 1.0 (0.8 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes ^e |
| For detecti | ing occult int | ections | | | | | - | | - | • | | • | | |
| 1 (Pantell, 2004) | 3066 | NC | NC | NC | NC | NC | NC | Low | Prospe ctive | Very seriou s ^{c, k, l} | NA | No serious | NA | Yes f, h, m, n |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|---|--|--|----------|-------------------|--|---------------|---------------|---------------|-------------------------|
| Not well-a | ppearing | | | | | | | | | | | | | |
| For detecti | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Gomez, 2010) | 1018 | 26 (8 to 44) ^a | 96 (95 to 97) ^a | 13 (3 to 22) ^a | 98 (97 to 99) ^a | 6.2 (2.9 to 13.1) | 0.8 (0.6 to 1.0) | Very low | Retrosp ective | Very seriou s ^{c, d, o} | NA | No serious | No serious | Yes h, p, q |
| Appears u | inwell | | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Nijuman , 2012) | 1255 | 1 (0 to 4) ^a | 97 (96 to 98) ^a | 6 (0 to 15) ^a | 89 (88 to 91) | 0.6 (0.1 to 2.5) ^a | 1.0 (1.0 to 1.0) ^a | Very low | Prospe ctive | Very seriou s c, d, o, l | NA | Serious r | No serious | Yes h, |
| Poor appe | earance | | | | | | | | | | | | | |
| For detecti | ing serious t | pacterial infection | on | | | | | | | | | | | |
| 1 (Chen, 2009) | 135 | 35 (19 to 51) ^a | 82 (75 to 90) ^a | 40 (22 to 58) | 79 (71 to 87) | 2.0 (1.1 to 3.6) ^a | 0.8 (0.6 to 1.0) ^a | Very low | Retrosp ective | Very seriou s b, c, d, o, I | NA | No serious | No serious | Yes h, |
| III appeara | ance | | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (McCarth y, 1985) | 103 | 54 (35 to 73) ^a | 90 (83 to 96) ^a | 64 (44 to 84) | 85 (77 to 93) | 5.2 (2.5 to 10.9) ^a | 0.5 (0.3 to 0.8) ^a | Very low | Prospe ctive | Very seriou s ^{b, c, l} | NA | No serious | Serious | Yes h, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|---|--|--|----------|---|--|---------------|---------------|---------------|----------------------|
| For detecti | ing invasive | bacterial diseas | se | | | | | | | | | | | |
| 1 (Baker, 1989) | 190 | 47 (21 to 72) ^a | 90 (80 to 99) ^a | 64 (35 to 92) ^a | 81 (70 to 93) ^a | 4.6 (1.6 to 13.3) | 0.6 (0.4 to 1.0) | Very low | Prospe ctive | Very seriou s ^{I, o} | NA | Serious w | Serious | Yes f, h, x |
| For detecti | ing serious i | nvasive bactera | nemia | | | | | | 1 | | | | | |
| 1 (Mandl, 1997) | 411 | 100 (60 to 100) | 88 (86 to 91) | 11 (1 to 23) | 100 (97 to 100) | 8.6 (6.6 to 11.2) | NC | Very low | Prospe ctive and retrosp ective | Very seriou s ^{b, l, o,} y | NA | Serious z | Serious | Yes f, h, aa, ab |
| For detecti | ing serious k | pacterial infection | on | | | | | | 1 | | | | | |
| 1 (Schwart z, 2009) | 449 | 21 (12 to 29) ^a | 90 (87 to 93) ^a | 33 (20 to 45) | 82 (79 to 86) | 2.0 (1.2 to 3.4) ^a | 0.9 (0.8 to 1.0) ^a | Very low | Retrosp ective | Very seriou s c, d, I, | NA | No serious | No serious | Yes h, |
| 1 (Shin, 2009) | 221 | 37 (22 to 51) ^a | 69 (62 to 76) ^a | 22 (12 to 32) | 82 (76 to 88) | 1.2 (0.7 to 1.9) ^a | 0.9 (0.7 to 1.2) ^a | Low | Prospe ctive | Very seriou s d, l, o | NA | No serious | No serious | Yes h, |
| For detecti | ing urinary tı | ract infection | • | <u>'</u> | . | . | • | • | • | | | • | | |
| 1 (Shaw, 1998) | 2411 | 49 (38 to 60) ^a | 72 (71 to 74) ^a | 6 (4 to 7) ^a | 98 (97 to 98) ^a | 1.8 (1.4 to 2.2) ^a | 0.7 (0.6 to 0.9) | Low | Prospe ctive | Very seriou s ^{f, l} | NA | No serious | No serious | Yes h, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|---------|-----------------|--|---------------|---------------|---------------|-------------------------|
| Very ill or | very unwel | I appearance | | | | | | | | | | | | |
| For detecti | ing urinary ti | ract infection, p | neumonia or bact | eraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 3 (2 to 3) ^a | 100 (100 to 100) ^a | 45 (33 to 58) ^a | 93 (93 to 93) ^a | 10.6 (6.5 to 17.3) | 1.0 (1.0 to 1.0) | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes e, f, g, h |
| For detecti | ing urinary ti | ract infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 4 (1 to 7) ^a | 97 (97 to 98) ^a | 14 (4 to 24) ^a | 90 (89 to 92) ^a | 1.5 (0.6 to 3.4) ^a | 13.6 (3.5 to 23.8) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes ^e |
| For detecti | ing occult in | fections | | | | | | | | | | | | ı |
| 1 (Pantell (2004) | 3066 | NC | NC | NC | NC | NC | NC | Low | Prospe ctive | Very seriou s ^{c, k, I} | NA | No serious | NA | Yes f, h, m, af |
| Severely i | II | | 1 | | | 1 | | | | | L | | | |
| For detecti | ing serious l | bacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 33 (17 to 49) ^a | 90 (85 to 96) ^a | 52 (31 to 73) ^a | 81 (74 to 88) ^a | 3.5 (1.6 to 7.5) ^a | 0.7 (0.6 to 0.9) | Low | Prospe ctive | Very seriou s ^{c, i} | NA | No serious | No serious | Yes ^{f, j} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|----------|-------------------|---------------------------------------|---------------|---------------|--------------------------|--------------------------------|
| Toxicity | | | | | | | | | | | | | | |
| For detecti | ing meningiti | is | | | | | | | | | | | | |
| 1 (Ghotbi, 2009) | 254 | 33 (7 to 60) | 97 (94 to 99) ^a | 33 (7 to 60) ^a | 97 (94 to 99) a | 10.1 (3.5 to 28.8) ^a | 0.7 (0.5 to 1.0) ^a | Very low | Prospe ctive | Very seriou s d, l, | NA | No serious | Serious _{ah} | Yes ^{f,} h, aa, ai |
| Suspiciou | s physical f | findings | | | | | | | | | | | | |
| For detecti | ing meningiti | is | | | | | | | | | | | | |
| 1 (Joffe, 1983) | 241 | 23 (16 to 30) ^a | 97 (94 to 100) | 91 (81 to 100) ^a | 52 (45 to 59) a | 8.5 (2.7 to 27.2) ^a | 0.8 (0.7 to 0.9) ^a | Very low | Retrosp ective | Very seriou s b, c, o, l, aj | NA | Serious ak | No serious | Yes ^{h,} aa, al |

NC Not calculable

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^c It is not clear whether all children received the same test to confirm serious infection

^d It is not clear whether the test to confirm serious infection was independent of the signs and symptoms

^e Included children were less than 5 years old. Included children had a measured axillary temperature of greater than or equal to 38°C; parental report of a temperature of greater than or equal to 38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. The study was undertaken in a hospital in Australia.

f Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

⁹ Results are reported per illness rather than per child – some children were included more than once for different illnesses

^h It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

¹ Some results were uninterpretable, indeterminable or intermediate test results

^j Included children were between 2 weeks and 1 year old. Included children had a rectal temperature equal to or greater than 38°C. This study took place in a paediatric emergency ward of a hospital in the Netherlands. Children were self referred or referred by a GP.

k It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

It is unclear whether the results of the test used to confirm serious illness were interpreted without knowledge of the signs or symptoms

m Included children were 3 months old or younger. Included children had a temperature of 38°C or greater either at home or in the clinician's office. Undertaken in a GP's office in the USA.

ⁿ Results reported in the paper: adjusted OR 1.79 (0.95 to 3.38), *P* = 0.07. Data on diagnostic accuracy or that would allow diagnostic accuracy data to be calculated was not reported in the study.

^o It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

P Included children aged less than 90 days. Included temperatures greater or equal to 38°C at home or at presentation. Undertaken in a paediatric emergency department in Spain.

^q Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated

Included children up to 16 years old (83% of children were 5 years and under)

s Included children aged 1 month to 16 years. Included children with a temperature of 38.5°C or higher, recent high fever, or fever as a reason for referral. Undertaken in the emergency department of a children's hospital in the Netherlands.

^t Included children aged under 3 months. Included children had a rectal temperature of 38°C or higher. The study was undertaken in a hospital in Taiwan.

^u The difference between the lower and upper confidence intervals is 40% or greater for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value

^v Included children aged 24 months and younger. Included children had a temperature of 38.3°C or higher. The study was undertaken in an emergency room in the USA.

w Included children were aged 3 months to 15 years (54% of children were younger than 2 years)

x Included children aged 3 months to 15 years. Included children with a presence or history of fever greater than 38°C. It took place in a hospital medical centre in the USA

^y Is it not clearly reported how many children were enrolled retrospectively and how many were enrolled prospectively into the study

² Included children up to and including 18 years of age (58% of children were aged between 3 and 36 months)

aa It was unclear whether the period between the reference test and the signs and symptoms being recorded was short enough to be reasonably sure that the illness did not resolve before the reference test was undertaken

ab Included children up to 18 years of age. Included children with a temperature equal to or greater than 38°C. It was undertaken in a hospital setting in the USA.

ac Included children were neonates (not defined). Included children with a rectal temperature of 38°C or higher. Undertaken in a paediatric emergency room in Israel.

ad Included children were under 3 months old. Included children had an axillary temperature of 38°C or higher. The study was undertaken in a hospital in South Korea.

ae Included boys younger than 1 year and girls younger than 2 years. Included children with a temperature equal to or greater than 38.3°C. It took place in the emergency department in the USA.

^{af} Results reported in the paper: adjusted OR 8.90 (3.34 to 23.69), *P* < 0.001. Data on diagnostic accuracy or that would allow diagnostic accuracy data to be calculated was not reported in the study.

^{ag} The selection criteria for the children included in the study were not clearly described

ah The difference between the upper and lower confidence intervals is 40% or greater for one, two or three of sensitivity, specificity, positive predictive value or negative predictive value

^{ai} Included children 6 months to 5 years. Fever was not defined. The study was undertaken in the paediatric ward of a hospital in Iran.

all tis unclear whether the spectrum of children included in the study was representative of those who would be seen in practice

^{ak} Included children up to the age of 6 years

al Included children between 6 months and 6 years. Fever was not defined. The study was undertaken in two hospitals in the USA.

Table I5.6 GRADE profile for evaluation of awake

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|---|--|--|-------------|-------------------|--|---------------|---------------------------|---------------------------|---------------------------|
| Drowsy or | n history or | examination | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (Hewson , 2000) | 313 | 51 (40 to 61) ^a | 84 (79 to 89) ^a | 55 (44 to 66) | 82 (77 to 87) a | 3.2 (2.2 to 4.6) b | 0.6 (0.5 to 0.7) b | Low | Prospe ctive | Very serious ^{c, d,} e | NA | No seriou ^s | No seriou ^s | Yes f, g, h |
| Increased | sleepiness | | | | | | | | | | | | | |
| For detecti | ing urinary tı | ract infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 34 (26 to 41) ^b | 74 (71 to 76) ^b | 12 (9 to 15) ^b | 91 (90 to 93) | 1.3 (1.0 to 1.6) b | 0.9 (0.8 to 1.0) b | Low | Prospe ctive | Very serious i | NA | No serious | No seriou ^s | Yes ^{g,} |
| Drowsines | ss | | | | | | | | 1 | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Ghotbi, 2009) | 254 | 25 (1 to 50) | 100 (100 to 100) ^b | 100 (100 to 100) ^b | 96 (94 to 99) | NC ^b | 0.8 (0.5 to 1.0) b | Very low | Prospe ctive | Very serious e, I | NA | No serious | Serious m | Yes ^{g,} h, n |
| 1 (Offringa, 1992) | 92 | 25 (1 to 50) | 74 (64 to 84) ^b | 14 (0 to 29) ^b | 85 (76 to 94) | 1.0 (0.3 to 2.8) ^b | 1.0 (0.7 to 1.4) ^b | Very low | Retrosp ective | Very serious ^{c, d,} e, i, l, o | NA | Serious p | Serious m | Yes ^{g,} h, q |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|---|--|--|-------------|-------------------|---|---------------|--------------|--------------|------------------------------|
| Drowsines | ss at home | | | | | | | | | | | | | |
| For detecti | ing meningiti | is | | | | | | | | | | | | |
| 1 (Offringa, 1992) | 92 | 30 (12 to 49) ^b | 94 (89 to100) | 64 (35 to 92) | 80 (72 to 89) | 5.3 (1.7 to 16.3) ^b | 0.7 (0.6 to 1.0) b | Very low | Retrosp ective | Very serious ^{c, d,} e, j, l, o, | NA | Serious p | Serious m | Yes ^{g,} h, q |
| Postictal of | drowsiness | | | | | | | | | | | | | |
| For detecti | ing meningiti | is | | | | | | | | | | | | |
| 1 (Batra, 2011) | 199 | 60 (17 to 100) ^b | 96 (93 to 99) ^b | 27 (1 to 54) ^b | 99 (97 to 100) ^b | 14.6 (5.4 to 39.0) b | 0.4 (0.1 to 1.2) b | Very low | Retrosp ective | Very serious ^{c, d,} e, j, I | NA | Serious | Serious m | Yes ^{g,} h, r, s |

^a Confidence intervals calculated by the NCC-WCH based on results reported in the study

^b Calculated by the NCC-WCH based on results reported in the study

^c Not all of the children received the same test to confirm serious illness

^d It is not clear if the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious infection

e It is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms

^f Fever was not defined. Included children aged 1 to 26 weeks. This study took place in an emergency department in Australia.

⁹ Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

h It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

ilt is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^j The study authors report that not all eligible infants were enrolled

^k Included axillary, rectal or tympanic temperature of 38°C or greater at presentation or 24 hours previously. Included children aged 3 months or younger. Study was undertaken at GP's offices in Australia.

It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

^m The confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%

ⁿ Fever was not defined. Included children aged 6 months to 5 years. Study undertaken in the paediatric ward of a hospital in Iran

^o It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

Table I5.7 GRADE profile for evaluation of decreased activity

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|--------------|-----------------|---------------------------------|---------------|---------------|---------------|-------------------------|
| Decreased | dactivity | | | | | | | | | | | | | |
| For detecti | ing urinary tı | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 17 (12 to 23) ^a | 82 (80 to 84) ^a | 9 (6 to 12) ^a | 90 (89 to 92) | 0.9 (0.7 to 1.3) ^a | 1.0 (0.9 to 1.1) ^a | Low | Prospe ctive | Very serious ^{b, c} | NA | No serious | No serious | Yes d, |
| Decreased | d activity le | vel during exa | mination | | | | | | | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Crain, 1982) | 175 | NC | NC | NC | NC | NC | NC | Mode rate | Prospe ctive | Serious ^f | NA | No serious | NA | Yes ^{e,} |
| Looking a | round the r | oom (moderat | ely impaired) | | | | | | | | | | | |
| For detecti | ing serious k | acterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 21 (7 to 35) | 69 (60 to 78) ^a | 18 (6 to 30) ^a | 73 (64 to 82) | 0.7 (0.3 to 1.4) ^a | 1.1 (0.9 to 1.4) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes ^{e,} |

^p Included children aged from 3 months to 6 years

^q Fever was not defined. Included children aged 3 months to 6 years. Study was undertaken in the emergency room of a hospital Netherlands

^r Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated

^s Fever was not defined. Included children aged 6 to 18 months. Study undertaken in a paediatric casualty ward in India

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|---------|-----------------|---------------------------------|---------------|---------------|---------------|----------------------|
| Looking a | round the r | oom (severely | impaired) | | | | | | | | | | | |
| For detect | ing serious l | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 30 (15 to 46) ^a | 92 (87 to 97) ^a | 56 (33 to 79) | 81 (73 to 88) | 3.9 (1.7 to 9.0) ^a | 0.8 (0.6 to 1.0) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes ^{e,} |
| Moving ar | ms and leg | s spontaneous | sly (moderately i | mpaired) | | | | | | | | | | |
| For detect | ing serious l | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 27 (12 to 42) ^a | 78 (70 to 86) ^a | 28 (13 to 44) | 77 (69 to 85) | 1.2 (0.6 to 2.4) ^a | 0.9 (0.7 to 1.2) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes ^{e,} |
| Moving ar | ms and leg | s spontaneous | sly (severely imp | aired) | | | | | | | | | | |
| For detect | ing serious l | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 24 (10 to 39) ^a | 96 (93 to 100) | 67 (40 to 93) | 80 (73 to 87) | 6.4 (2.0 to 19.8) ^a | 0.8 (0.6 to 1.0) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes e, |
| Reaching | for objects | (moderately in | mpaired) | <u> </u> | | | | | | | | | | _ |
| For detect | ing serious l | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 15 (3 to 27) | 77 (69 to 85) ^a | 17 (3 to 31) ^a | 74 (66 to 83) | 0.7 (0.3 to 1.6) ^a | 1.1 (0.9 to 1.3) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes ^{e,} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|-------------|-----------------|----------------------------------|---------------|---------------|---------------|---------------------------|
| Reaching | for objects | (severely impa | aired) | | | | | | | | | | | |
| For detect | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 30 (15 to 46) ^a | 90 (85 to 96) ^a | 50 (28 to 72) | 81 (73 to 88) | 3.2 (1.5 to 7.0) ^a | 0.8 (0.6 to 1.0) ^a | Low | Prospe ctive | Very serious ^{f, h} | NA | No serious | No serious | Yes ^{e,} |
| Lethargy | | | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Shin, 2009) | 221 | 17 (6 to 29) | 72 (65 to 79) ^a | 13 (4 to 22) ^a | 78 (72 to 85) | 0.6 (0.3 to 1.2) ^a | 1.2 (1.0 to 1.4) ^a | Low | Prospe ctive | Very serious ^{j, k,} | NA | No serious | No serious | Yes ^{m,} |
| For detecti | ing meningit | is | | | | | | | 1 | | | | | |
| 1 (Ghotbi, 2009) | 254 | 42 (14 to 70) ^a | 95 (92 to 97) ^a | 28 (7 to 48) ^a | 97 (95 to 99) a | 7.8 (3.3 to 18.2) ^a | 0.6 (0.4 to 1.0) ^a | Very low | Prospe ctive | Very serious ^{j, o} | NA | No serious | Serious p | Yes e, m, q |
| For detecti | ing bacterae | emia | | | | • | 1 | · | • | • | 1 | • | • | |
| 1 (Crocker, 1985) | 201 | 14 (1 to 27) | 78 (72 to 84) ^a | 10 (1 to 18) ^a | 85 (79 to 90) | 0.7 (0.3 to 1.7) ^a | 1.1 (0.9 to 1.3) ^a | Low | Prospe ctive | Very serious f, k | NA | No serious | No serious | Yes ^{e,} j, p, r |

^a Calculated by the NCC-WCH based on results reported in the study

^b The authors report that not all eligible infants were enrolled in the study

^c It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

d Included children aged 3 months or younger. Included axillary, rectal or tympanic temperature of 38°C or greater at presentation or 24 hours previously. Study was undertaken at GP's offices in Australia.

^e Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

Table I5.8 GRADE profile for evaluation of no smile and/or abnormal cry

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------|--|--|---|---|--|--|---------|-----------------|---------------------------------|---------------|---------------|---------------|----------------|
| Cry | | | | | | | | | | | | | | |
| For detecti | ing serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Craig, 2010) | 15781 | 43 (40 to 45) ^a | 68 (67 to 68) ^a | 9 (9 to 10) ^a | 94 (93 to 94) | 1.3 (1.2 to 1.4) ^a | 0.9 (0.8 to 0.9) ^a | Low | Prospe ctive | Very serious ^{b, c} | NA | No serious | No serious | Yes d, e, f |
| For detecti | ing bacterae | mia | | | | | | | l | | | l | | |
| 1 (Crain, 1982) | 175 | NR ^k | NR ^k | NR ^k | NR ^k | NR ^k | NR ^k | Low | Prospe ctive | Very serious ^{g, h} | NA | No serious | NA | Yes d, |

f It is not clear whether all children received the same test to confirm serious infection

⁹ Included children 8 weeks old and younger. Included temperatures of 38°C and greater. The study was undertaken in a paediatric emergency room in the USA.

^h Some results were uninterpretable, indeterminable or intermediate test results

¹ Included children aged 2 week to 1 year old. Included temperatures of 38°C or greater. Undertaken in a paediatric emergency ward of a hospital in the Netherlands. Self referred or referred by general practitioner.

it is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms

k It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

It is unclear whether the test to confirm serious illness is independent of the child's symptoms and signs

m It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

ⁿ Included children aged less than 3 months. Included axillary temperature of 38°C or higher. Undertaken in outpatients clinic in South Korea.

[°] It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

^P The confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%

^q Included children aged 6 months to 5 years. Fever not defined. Undertaken in a paediatric ward of a hospital in Iran.

Included children aged 6 months to 2 years. Included temperature of 39.4°C and higher. Undertaken in an emergency department of a hospital in the USA.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|---|--|--|---------|-----------------|--|---------------|---------------|-------------|-------------------------|
| Abnormal | cry | | | | | | | | | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Pantell, 2004) | 3066 | NR ¹ | NR ¹ | NR ¹ | NR ¹ | NR ¹ | NR ¹ | Low | Prospe ctive | Very serious ^{b, c,} g, h | NA | No serious | NA | Yes d, e, j |

NR Not reported

^a Calculated by the NCC-WCH based on results reported in the study

^b Not all of the children were tested for the presence of a serious illness

^c Not all of the children received the same test to confirm serious illness

d It was unclear whether the period between noting the child's signs and symptoms and the tests to confirm serious illness was short enough to be reasonably sure that the illness did not change or resolve

e It is unclear whether the same data was available when the test results were interpreted would be available when the test is used in practice

f Included children were under 5 years. Children were included if they had an axillary temperature/parental report of a temperature ≥ 38°C. The study was conducted in the emergency department of a hospital in Australia. Results are reported per illness rather than per child – some children were included more than once for different illnesses.

⁹ Selection criteria for inclusion into the study were not clearly described

h It is unclear whether the results of the test to confirm serious illness was undertaken without knowledge of the child's signs and symptoms

included children were 8 weeks old or younger. Included temperatures were a rectal temperature of 38°C or greater. Undertaken in a paediatric emergency room of a hospital in USA.

¹ Included children were 3 months old or younger. Included temperatures were 38°C or greater at home or in the clinician's office. Undertaken in GP's office in the USA.

^k Text in the study paper stated that crying is not significantly associated with bacteraemia

¹ Adjusted OR 2.23 (95% CI 1.16 to 4.29), *P* < 0.02

Table I5.9 GRADE profile for evaluation of irritability

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-------------------|---|---------------|---------------|---------------|-------------------------|
| Irritability | | | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Shin, 2009) | 221 | 34 (20 to 49) ^a | 63 (56 to 70) ^a | 18 (10 to 27) | 80 (73 to 87) | 0.9 (0.6 to 1.5) ^a | 1.0 (0.8 to 1.3) ^a | Low | Prospe ctive | Very serious b, c, | NA | No serious | No serious | Yes ^{e,} |
| For detecti | ing bacterae | mia | | | | | | | <u> </u> | | | | | |
| 1 (Crain, 1982) | 175 | NR ^g | NR ^g | NR ^g | NR ^g | NR ^g | NR ^g | Low | Prospe ctive | Very serious ^{a, b} | NA | No serious | NA | Yes e, |
| 1 (Crocker, 1985) | 201 | 64 (47 to 82) ^j | 55 (48 to 62) ^j | 19 (11 to 27) | 91 (85 to 96) | 1.4 (1.0 to 2.0) j | 0.7 (0.4 to 1.1) ^j | Low | Prospe ctive | Very serious ^{c, k,} | NA | No serious | No serious | Yes e, |
| For detecti | ing urinary tr | ract infection | | | | | | | <u> </u> | | | | | |
| 1 (Morris, 2007) | 98 | NR ⁿ | NR ⁿ | NR ⁿ | NR ⁿ | NR ⁿ | NR ⁿ | Low | Prospe ctive | Very serious ^{a, d,} | NA | No serious | NA | Yes e, h, o, p |
| For detecti | ing meningiti | is | | | | | | ı | • | | | | | |
| 1 (Ghotbi, 2009) | 254 | 58 (30 to 86) ^j | 86 (82 to 90) ^j | 17 (6 to 29) ^j | 98 (96 to 100) ^j | 4.2 (2.3 to 7.3) j | 0.5 (0.2 to 0.9) ^j | Low | Prospe ctive | Very serious ^{a, c,} | NA | No serious | Serious q | Yes e, h, o, r |
| For detecti | ing viral mer | ningitis or non-s | pecific meningitis | L | | L | L | 1 | | L | L | ı | L | |
| 1 (Gomez, 2012) | 309 | 24 (15 to 32) ^j | 78 (72 to 84) ^j | 34 (23 to 45) ^j | 68 (62 to 74) ^j | 1.1 (0.7 to 1.7) i | 1.0 (0.9 to 1.1) ^j | | Retrosp ective | Very serious ^{b, c,} _{d, k} | NA | No serious | No serious | Yes e, |

Table I5.10 GRADE profile for evaluation of decreased consciousness/coma

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|--|---------------|---------------|--------------|-------------------------|
| Decreased | d conscious | sness | | | | | | | | | | | | |
| For detecti | ing serious b | acterial infection | on | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 3 (1 to 6) ^a | 91 (84 to 99) ^a | 55 (25 to 84) | 24 (18 to 30) | 0.4 (0.1 to 1.3) ^a | 1.1 (1.0 to 1.1) ^a | Very low | Retrosp ective | Very serious ^{b, c,} d, e, f, g | NA | No serious | Serious h | Yes ^{i, j} |

^a The selection criteria for including children in the study were not clearly described

b It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's signs and symptoms

^c It is not clear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

^d It is not clear whether the test to confirm serious illness was independent of the child's signs and symptoms

elt is not clear whether the same clinical data were available as would be available in practice

function of the function of th

⁹ Text in the paper stated that irritability is not significantly associated with bacteraemia

h It is not clear if the period of time between assessing the child's signs and symptoms and performing the test to confirm serious illness is short enough

included children aged 8 weeks old and younger. Included children with rectal temperatures of 38°C and higher. The study was undertaken in a paediatric emergency room in the USA.

^j Calculated by the NCC-WCH based on results reported in the study

^k It is not clear whether all children received the same test to confirm serious illness

¹ It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's signs and symptoms

m Included children aged 6 months to 2 years. Included children with temperatures of 39.4°C and higher. Undertaken in an emergency department of a hospital in the USA.

ⁿ Text in the paper stated that irritability is not predictive of urinary tract infection

^o The sign or symptom was not described in enough detail to allow another clinician to make the same diagnosis

P Included children less than 36 months. Included children with an axillary temperature greater than 37.2°C. The study was undertaken in the children's outpatients department in a hospital in Papua New Guinea.

^q The difference between the lower and upper confidence intervals is greater than 40% for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value

Included children aged 6 months to 5 years. Fever was not defined. The study was undertaken in the paediatric ward of a hospital in Iran.

s Included children aged younger than 90 days. Included children with a temperature of 38.0°C or greater at home or upon arrival at the ED. Undertaken in a paediatric emergency department in Spain.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|--------------------------|--------------------------|--|--|---|--|--|--|--------------|-------------------|---|---------------|---------------|---------------|----------|
| Coma | | | | | | | | | | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Ghotbi, 2009) | 254 | 8 (0 to 24) ^a | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 96 (93 to 98) | NC | 0.9 (0.8 to 1.1) ^a | Mode rate | Prospe ctive | Serious ^k | NA | No serious | No serious | Yes i, i |
| 1 (Offringa, 1992) | 92 | 26 (8 to 44) | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 80 (72 to 89) | NC | 0.7 (0.6 to 0.9) ^a | Very low | Retrosp ective | Very serious ^{b, c,} d, e, f, g, m | NA | Serious | No serious | Yes i, |
| Unrousab | le coma | | | | | | | | | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Akpede, 1992) | 522 | 22 (5 to 40) | 94 (92 to 96) ^a | 15 (3 to 27) ^a | 97 (95 to 98) | 3.9 (1.7 to 9.1) ^a | 0.8 (0.7 to 1.0) ^a | Low | Prospe ctive | Serious ^{b, f,} | NA | Serious | No serious | Yes i, |

NC Not calculable

^a Calculated by the NCC-WCH based on data reported in the study

^b It is unclear whether the children who were included in the study were representative of those that will receive the test in practice

^c It is unclear whether the test used to confirm serious illness would classify the illness correctly

^d It is unclear whether all of the children received the same test to confirm serious illness

e It is unclear whether the test to confirm serious illness was independent of the signs and symptoms

f It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

⁹ It is unclear whether the results of the test to confirm serious illness were interpreted without knowledge of the signs and symptoms

^h The confidence intervals were 40% or greater for one, two or three of sensitivity, specificity, positive predictive value or negative predictive value

ilt is unclear whether the same clinical data were available when the test results were interpreted as would be available when the test is used in practice

¹ Included children aged 1 to 36 months. Fever was not defined. Undertaken at two children's hospitals in the Netherlands.

^k The selection criteria were not clearly described

Table I5.11 GRADE profile for evaluation of restlessness

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|-------------|-----------------|--|---------------|--------------|---------------|-------------------------|
| Restlessn | ess | | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (Nademi, 2001) | 141 | 76 (62 to 88) | 43 (33 to 52) | 35 (25 to 45) | 81 (70 to 91) | 1.3 (1.0 to 1.7) ^a | 0.6 (0.3 to 1.0) ^a | Very low | Prospe ctive | Very serious ^{b, c,} d, e | NA | Serious f | No serious | Yes ^{g,} |

Included children were aged from 6 months to 5 years. Temperature was not used as an inclusion criterion, but children were those hospitalised after a fever associated seizure. Undertaken in the paediatric department of a hospital in Iran.

m It is unclear whether the whole sample (or a random selection of the sample) received the test to confirm serious illness

ⁿ Children were included that were 6 years old

^o Not enough detail was reported on the test to confirm serious illness for it to be replicated by a different healthcare professional

P Included children were 3 months to 6 years old. Temperature was not used as an inclusion criterion, but children had had a first episode of seizure associated with fever. Undertaken in the emergency room of two hospitals in the Netherlands.

^q Included children were 1 month to 6 years old. Included rectal temperatures of 38°C or higher. Children had had convulsions associated with fever and had a fever duration of less than 7 days. Undertaken in a paediatric emergency department in Nigeria.

^a Calculated by the NCC based on data reported in the study

b It is unclear whether all children received the same reference test

^c It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

^d It is unclear whether the results of test to confirm serious illness were interpreted without knowledge of the signs and symptoms

e Not enough detail on the definition of the sign or symptom was provided to allow another healthcare professional to make the same diagnosis

^f Included children up to 16 years old (mean age was 3.3 years)

⁹ It is unclear whether the same clinical data would be available when the test results were interpreted as would be available when the test is used in practice

h Included children from 8 days to 16 years old. Included those with a temperature of 38°C or higher. Undertaken in the paediatric assessment unit of two hospitals in England.

Table 15.12 GRADE profile for evaluation of tachypnoea

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|--|---------------|---------------|---------------|-------------------------|
| Tachypne | a | | | | | | | | | | | | | |
| For detecti | ing pneumor | nia | | | | | | | | | | | | |
| 1 (Taylor, 1995) | 572 | 74 (70 to 77) | 77 (77 to 80) | 20 (17 to 23) | 97 (96 to 99) | 3.2 (2.5 to 4.0) ^a | 0.3 (0.2 to 0.6) ^a | Low | Prospe ctive | Very serious ^{b, c,} d, e | NA | No serious | No serious | Yes f, |
| Elevated r | espiratory i | rate | | | | | | | | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 11 (3 to 19) | 85 (84 to 86) ^a | 1 (0 to 1) ^a | 100 (99 to 100) ^a | 0.7 (0.4 to 1.5) ^a | 1.0 (1.0 to 1.1) ^a | Low | Prospe ctive | Very serious ^{c, d,} | NA | No serious | No serious | Yes f, i, j, k |

^a Calculated by the NCC-WCH based on results reported in the study

^b It was not clear if the reference standard was likely to classify the target condition correctly

^c It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^d It is not clear whether all children received the same test to confirm serious infection

e It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

flt is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

⁹ Included children were less than 2 years old. Included children had a temperature of 38°C or greater. Study undertaken in the emergency department of a children's hospital in the USA.

^h It is not clear whether the test to confirm serious infection was independent of the signs and symptoms

¹ Included children were less than 5 years old. Included children had a measured axillary temperature of greater than or equal to 38°C; parental report of a temperature of greater than or equal to 38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever (10th revision of the international classification of diseases, Australian modification codes R50, R50.0, R50.1, R50.9 and R56.0), as determined by a triage nurse. The study was undertaken in a hospital in Australia.

¹ Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

k Results are reported per illness rather than per child – some children were included more than once for different illnesses

Table I5.13 GRADE profile for evaluation of crackles

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|---|---------------|---------------|---------------|-------------------------|
| Chest cra | ckles | | | | | | | | | | | | | |
| For detect | ing pneumoi | nia, urinary trac | t infection and ba | cteraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 19 (17 to 22) ^a | 93 (92 to 93) ^a | 17 (15 to 19) | 1 (1 to 1) ^a | 2.6 (2.3 to 2.9) ^a | 0.9 (0.8 to 0.9) ^a | Low | Prospe ctive | Very serious ^{b, c,} | NA | No serious | No serious | Yes e, |
| Abnormal | chest sour | nds | | | | | | | | | | | | |
| For detect | ing pneumoi | nia, urinary trac | t infection and ba | cteraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 29 (27 to 32) ^a | 85 (85 to 86) ^a | 13 (12 to 15) | 94 (94 to 94) | 2.0 (1.8 to 2.2) ^a | 0.8 (0.8 to 0.9) ^a | Low | Prospe ctive | Very serious b, c, | NA | No serious | No serious | Yes e, |
| Crepitatio | ns | | | | | | | | | | | | | |
| For detect | ing serious k | pacterial illness | | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 2 (0 to 5) ^a | 93 (87 to 100) | 50 (15 to 85) | 24 (19 to 30) | 0.3 (0.1 to 1.3) ^a | 1.0 (1.0 to 1.1) ^a | Very low | Retrosp ective | Very serious ^{c, d,} h, i, j | NA | Serious k | No serious | Yes ^{g,} |

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^c It is not clear whether all children received the same test to confirm serious infection

^d It is unclear whether the results of the test used to confirm serious illness were interpreted without knowledge of the signs or symptoms

^e Included children were less than 5 years old. Included children had a measured auxiliary temperature of greater than or equal to 38°C; parental report of a temperature of greater than or equal to 38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever (10th revision of the international classification of diseases, Australian modification codes R50, R50.0, R50.1, R50.9 and R56.0), as determined by a triage nurse. The study was undertaken in a hospital in Australia.

f Results are reported per illness rather than per child – some children were included more than once for different illnesses

⁹ It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

Table I5.14 GRADE profile for evaluation of respiratory symptoms

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|-------------------------------|---------------|---------------|---------------|-------------------------|
| Respirato | ry distress | | | | | | | | | | | | | |
| For detecti | ing urinary tr | ract infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 3066 | 4 (1 to 8) ^a | 92 (90 to 93) ^a | 5 (1 to 9) ^a | 90 (88 to 91) | 0.5 (0.2 to 1.1) ^a | 1.0 (1.0 to 1.1) ^a | Mode rate | Prospe ctive | Serious ^b | NA | No serious | No serious | Yes c, |
| Breathing | difficulty | | | | | | | | | | | | | |
| For detecti | ing pneumor | nia, urinary trac | t infection, or bac | teraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 26 (23 to 28) ^a | 87 (87 to 88) ^a | 13 (12 to 15) | 94 (93 to 94) | 2.0 (1.8 to 2.2) ^a | 0.9 (0.8 to 0.9) ^a | Mode rate | Prospe ctive | Serious b, e, f | NA | No serious | No serious | Yes c, |
| Breathing | difficulty o | r chest wall re | cession | | | | | | | | | | | |
| For detecti | ing serious ii | llness | | | | | | | | | | | | |
| 1 (Hewson , 2000) | 313 | NR/NC | 65 (NR/NC) | 41 (NR/NC) | 82 (NR/NC) | NR/NC | NR/NC | Mode rate | Prospe ctive | Serious ^{e,} h, i | NA | No serious | No serious | Yes ^{c,} |

^h It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

ⁱ It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

¹ It is not clear whether the test to confirm serious infection was independent of the signs and symptoms

^k Included children from 8 days to 16 years of age (mean: 3.3 years)

¹ Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated

m Included temperatures of 38°C or greater. Included children aged 1 to 36 months. Undertaken in the emergency department of two hospitals in the Netherlands.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|--|---------------|---------------|---------------|----------------------|
| Shortness | of breath | | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Njiman, 2012) | 1255 | 27 (20 to 35) ^a | 88 (86 to 90) ^a | 21 (15 to 27) | 91 (90 to 93) | 2.2 (1.6 to 3.1) ^a | 0.8 (0.7 to 0.9) ^a | Very low | Prospe ctive | Very serious ^{e, f,} h, i | NA | Serious k | No serious | Yes c, |
| Respirato | ry symptom | ns | | | | | | | | | | | | |
| For detecti | ing pneumor | nia, urinary trac | t infection, or bac | teraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 70 (67 to 72) ^a | 28 (27 to 28) ^a | 7 (7 to 7) ^a | 92 (91 to 93) | 1.0 (0.9 to 1.0) ^a | 1.1 (1.0 to 1.2) a | Mode rate | Prospe ctive | Serious b, e, f | NA | No serious | No serious | Yes c, |

NR/NC Not reported/not calculable

^a Results calculated by the NCC-WCH based on results reported in the study

b It is not clear if the whole sample of children (or a random sample) received a test to confirm serious illness

^c It is not clear whether the same clinical data were available when the test results were interpreted as would be available in practice

^d Included children were aged 3 months or younger. Included those with an auxiliary, rectal or tympanic temperature of 38°C or higher at presentation or in the 24 hours prior to presentation. Undertaken in GPs offices in the USA.

e It is not clear whether all children received the same test to confirm serious illness

f It is not clear whether the test to confirm serious illness was independent of the clinical signs and symptoms

^g Included children were under 5 years old. Included those with one or more of the following elements: a measured auxiliary temperature of 38°C or higher; parental report of a temperature of 38°C or higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in the emergency department of a children's hospital in Australia.

h It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness.

ilt is unclear whether the results of the test to confirm serious illness were interpreted without knowledge of the signs and symptoms

¹ Includes children aged 1 to 26 weeks. Temperature was not an inclusion criterion, but the results reported here are for a subgroup of febrile infants. Undertaken in the emergency department of one children's hospital and the emergency departments of two general hospitals in Australia.

^k Included children aged up to 16 years (83% were 5 years or younger)

Table I5.15 GRADE profile for evaluation of nasal symptoms

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|--------------|-------------------|--|---------------|---------------|---------------|-------------------------|
| Purulent n | nasal discha | arge | | | | | | | | | | | | |
| For detecti | ing serious b | acterial illness | | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 20 (14 to 26) ^a | 53 (41 to 66) ^a | 56 (44 to 69) | 18 (13 to 24) | 0.4 (0.3 to 0.7) ^a | 1.5 (1.2 to 1.9) ^a | Very low | Retrosp ective | Very serious ^{b, c,} d, e, f, g | NA | No serious | No serious | Yes h, |
| Upper res | piratory tra | ct infection or | runny nose | | | | | | | | | | | |
| For detecti | ing urinary tı | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 5 (2 to 8) ^a | 90 (88 to 91) ^a | 5 (2 to 8) ^a | 90 (88 to 91) | 0.5 (0.2 to 1.0) ^a | 1.1 (1.0 to 1.1) ^a | Mode rate | Prospe ctive | Serious ^j | NA | No serious | No serious | Yes i, |
| Mild uppe | r respirator | y tract infection | n symptoms | | | | | | | | | | | |
| For detecti | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Shin, 2009) | 221 | 5 (0 to 11) ^a | 72 (65 to 79) ^a | 4 (0 to 9) ^a | 76 (69 to 82) | 0.2 (0.0 to 0.7) a | 1.3 (1.2 to 1.5) ^a | Low | Prospe ctive | Very serious ^{e, f,} g | NA | No serious | No serious | Yes ^{i, I} |

¹ Included children aged 1 month to 16 years. Included those with a temperature of 38.5°C or higher, recent high fever or fever as a reason for referral. Undertaken in the emergency department of a children's hospital in the Netherlands.

^m Not enough detail regarding the measurement of the sign or symptom was provided to allow another healthcare provider to repeat the measurement

^a Calculated by the NCC-WCH based on results reported in the study

^b It is unclear whether the spectrum of children is representative of those who will receive the test in practice

[°] It is unclear whether the test to confirm serious illness is likely to confirm serious illness

^d It is unclear whether all of the children received the same test to confirm serious illness

^e It is unclear whether the test to confirm serious illness is independent of the clinical signs and symptoms

Table I5.16 GRADE profile for evaluation of wheeze

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|-------------|---------------|---------------|---------------|-------------------------|
| Audible w | heeze | | | | | | | | | | | | | |
| For detecti | ing pneumoi | nia, urinary trac | t infection, or bac | teraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 8 (7 to 10) ^a | 94 (93 to 94) ^a | 9 (7 to 11) ^a | 93 (92 to 93) | 1.3 (1.1 to 1.6) ^a | 1.0 (1.0 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, | NA | No serious | No serious | Yes ^{e,} |
| Stridor | | | | | | | | | | | | | | |
| For detecti | ing pneumor | nia, urinary trac | t infection, or bac | teraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 1 (1 to 2) ^a | 98 (98 to 98) ^a | 5 (2 to 7) ^a | 93 (92 to 93) | 0.6 (0.4 to 1.1) ^a | 1.0 (1.0 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, | NA | No serious | No serious | Yes ^{e,} |

f It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

⁹ It is unclear whether the results of the test to confirm serious illness were interpreted without knowledge of the signs and symptoms

h Included children aged between 1 and 36 months. Temperature was not specified as an inclusion criterion, but only those with 'acute fever' were included. Undertaken in a children's hospital in the Netherlands.

ilt is not clear whether the same clinical data were available when the test results were interpreted as would be available in practice

¹ It is not clear if the whole sample of children (or a random sample) received a test to confirm serious illness

^k Included children were aged 3 months or younger. Included those with an auxiliary, rectal or tympanic temperature of 38°C or higher at presentation or in the 24 hours prior to presentation. Undertaken in GPs offices in the USA.

¹ Included children aged less than 3 months. Included those with an axillary temperature of 38°C or higher. Undertaken in an outpatients clinic in South Korea.

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all of the children or a random sample of the children were given a test to confirm serious illness

^c It is not clear whether all children received the same test to confirm serious illness

^d It is not clear whether the test to confirm serious illness was independent of the clinical signs and symptoms

e It is not clear whether the clinical data available when the test results were interpreted are what would be available when the test is used in practice

Table I5.17 GRADE profile for evaluation of chest findings/abnormal chest sounds

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--|--------------------------|--|--|---|--|--|--|--------------|-----------------|----------------------|---------------|---------------|---------------|-------------------------|
| Abnormal chest sounds | | | | | | | | | | | | | | |
| For detecting pneumonia, urinary tract infection, or bacteraemia | | | | | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 8 (7 to 10) ^a | 94 (93 to 94) ^a | 9 (7 to 11) ^a | 93 (92 to 93) | 1.3 (1.1 to 1.6) ^a | 1.0 (1.0 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, | NA | No serious | No serious | Yes ^{e,} |
| Chest find | lings | | | | | | | | | | | | | |
| For detecting urinary tract infection | | | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 2 (0 to 4) | 95 (94 to 96) | 4 (0 to 8) | 90 (89 to 92) | 0.4 (0.1 to 1.2) | 1.0 (1.0 to 1.1) | Mode rate | Prospe ctive | Serious ^b | NA | No serious | No serious | Yes ^{e,} g, h |

Included children aged under 5 years. Included those with one or more of the following elements: a measured auxiliary temperature of 38°C or higher; parental report of a temperature of 38°C or higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in a children's emergency department of a hospital in Australia.

^a Calculated by the NCC-WCH based on results reported in the study

b It is not clear whether all of the children or a random sample of the children were given a test to confirm serious illness

^c It is not clear whether all children received the same test to confirm serious illness

^d It is not clear whether the test to confirm serious illness was independent of the clinical signs and symptoms

e It is not clear whether the clinical data available when the test results were interpreted are what would be available when the test is used in practice

function in Included children aged under 5 years. Included those with one or more of the following elements: a measured auxiliary temperature of 38°C or higher; parental report of a temperature of 38°C or higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in a children's emergency department of a hospital in Australia.

⁹ Not enough detail was provided on the measurement of the sign or symptom so that another healthcare professional could make the same diagnosis

h Included children were aged 3 months or younger. Included those with an auxiliary, rectal or tympanic temperature of 38°C or higher at presentation or in the 24 hours prior to presentation. Undertaken in GPs offices in the USA.

Table I5.18 GRADE profile for evaluation of cough

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|-------------------------------------|--|--|---|--|--|--|--------------|-----------------|--|---------------|---------------|---------------|-------------------------|
| Cough | | | | | | | | | | | | | | |
| For detecti | ing pneumor | nia, urinary trac | t infection, or bac | eraemia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 58 (55 to 61) ^a | 46 (46 to 47) ^a | 8 (7 to 8) ^a | 93 (93 to 94) | 1.1 (1.0 to 1.1) ^a | 0.9 (0.9 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, | NA | No serious | No serious | Yes ^{e,} |
| For detecti | ing urinary tr | ract infection | 1 | | | 1 | | | • | | | | | |
| 1 (Newma n, 2002) | 1666 | 1 (0 to 2) ^a | 98 (98 to 99) ^a | 4 (0 to 11) ^a | 90 (89 to 92) | 0.4 (0.1 to 2.7) ^a | 1.0 (1.0 to 1.0) ^a | Mode rate | Prospe ctive | Serious ^b | NA | No serious | No serious | Yes ^{e,} |
| For detecti | For detecting meningococcal disease | | | | | | | | | | | | | • |
| 1 (Nielsen, 2001) | 208 | 15 (4 to 27) | 63 (55 to 70) ^a | 9 (2 to 15) ^a | 76 (69 to 83) a | 0.4 (0.2 to 0.9) a | 1.3 (1.1 to 1.6) ^a | Very low | Prospe ctive | Very serious ^{b, c,} d, h, i, j | NA | Serious k | No serious | Yes e, |

^a Calculated by the NCC-WCH based on results reported in the study

b It is not clear whether all of the children or a random sample of the children were given a test to confirm serious illness

^c It is not clear whether all children received the same test to confirm serious illness

^d It is not clear whether the test to confirm serious illness was independent of the clinical signs and symptoms

e It is not clear whether the clinical data available when the test results were interpreted are what would be available when the test is used in practice

f Included children aged under 5 years. Included those with one or more of the following elements: a measured auxiliary temperature of 38°C or higher; parental report of a temperature of 38°C or higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in a children's emergency department of a hospital in Australia.

⁹ Included children were aged 3 months or younger. Included those with an auxiliary, rectal or tympanic temperature of 38°C or higher at presentation or in the 24 hours prior to presentation. Undertaken in GPs' offices in the USA.

^h It is not clear whether the spectrum of children was representative of those who would receive the test in practice

ilt is not clear whether the clinical signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

it is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the clinical signs and symptoms

Table I5.19 GRADE profile for evaluation of poor feeding

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|-------------------------------|--|--|---|--|--|--|-------------|-------------------|--|---------------|---------------|---------------|-------------------------|
| Poor intak | (e | | | | | | | | | | | | | |
| For detecting serious bacterial infection | | | | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 36 (29 to 44) ^a | 74 (63 to 85) ^a | 81 (72 to 90) | 28 (21 to 35) a | 1.4 (0.9 to 2.3) ^a | 0.9 (0.7 to 1.0) ^a | Very low | Retrosp ective | Very serious ^{b, c,} d, e, f, g | NA | No serious | No serious | Yes h, |
| Poor feedi | Poor feeding Poor feeding | | | | | | | | | | | | | |
| For detecti | For detecting serious disease | | | | | | | | | | | | | |
| 1 (Nademi, 2001) | 141 | 78 (65 to 90) | 43 (33 to 52) | 36 (25 to 45) | 83 (72 to 92) | 1.4 (1.1 to 1.7) ^a | 0.5 (0.3 to 0.9) ^a | Very low | Prospe ctive | Very serious ^{d, e,} f, g | NA | Serious k | No serious | Yes h, i, l, m |
| For detecti | ing serious k | pacterial infection | on | 1 | | | | | • | | | | | • |
| 1 (Shin, 2009) | 221 | 27 (13 to 40) ^a | 63 (56 to 70) ^a | 15 (7 to 23) ^a | 78 (71 to 85) | 0.7 (0.4 to 1.2) ^a | 1.2 (0.9 to 1.4) ^a | Low | Prospe ctive | Very serious ^{e, f,} | NA | No serious | No serious | Yes i, |
| Decreased | d feeding | | | | | | | | 1 | | · | l | | |
| For detecti | ing urinary tı | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 37 (29 to 44) ^a | 63 (60 to 65) ^a | 9 (7 to 12) ^a | 90 (88 to 92) a | 1.0 (0.8 to 1.2) ^a | 1.0 (0.9 to 1.1) ^a | Low | Prospe ctive | Very serious ^{o, p} | NA | No serious | No serious | Yes h, |

^k Included children aged up to 16 years old

Included children aged from 1 month to 16 years. Included those with a rectal temperature above 38°C at some time within 24 hours before inclusion. Undertaken in a hospital in Denmark.

^a Calculated by the NCC-WCH based on results reported in the study

^b It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

^c It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

^d Not all of the children received the same test to confirm serious illness

^e It is not clear if the child's signs and symptoms formed part of the test for serious illness

f It is not clear if the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious infection

⁹ It is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms

^h Not enough detail was provided in the study paper to allow the sign or symptom to be detected by a different clinician

ilt is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

¹ Included children aged 1 to 36 months. Included temperatures equal to or greater than 38°C.Undertaken in the emergency department of two children's hospitals in the Netherlands.

^k Included children from 8 days to 16 years of age (mean: 3.3 years)

¹ Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated

m Included children aged 8 days to 16 years. Included temperature of 38°C or greater. Study undertaken in a paediatric assessment unit of a hospital in the UK.

ⁿ Included children aged less than 3 months. Included those with an axillary temperature of 38°C or higher. Undertaken in an outpatients clinic in South Korea.

[°] The study authors report that not all eligible infants were enrolled

P It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^q Included children were less than 3 months old. Included infants had auxiliary, rectal or tympanic temperatures equal to or greater than 38°C in the office or in the previous 24 hours at home. The study was based in a GP's office in the USA.

Table 15.20 GRADE profile for evaluation of capillary refill time

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--|--------------------------|--|--|---|--|--|--|---------|-----------------|----------------------------------|---------------|---------------|---------------|-------------------------|
| Capillary r | efill time of | 2 to 3 second | ls | | | | | | | | | | | |
| For detecting pneumonia, urinary tract infection and bacteraemia | | | | | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 10 (8 to 11) | 96 (96 to 96) ^a | 17 (14 to 19) | 93 (93 to 94) | 2.6 (2.1 to 3.1) ^a | 0.9 (0.9 to 1.0) ^a | Low | Prospe ctive | Very serious ^{b, c,} | NA | No serious | No serious | Yes ^{e,} |
| Capillary r | efill time of | > 3 seconds | | | | | | | | | | | | |
| For detecting pneumonia, urinary tract infection and bacteraemia | | | | | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 1 (1 to 2) ^a | 100 (100 to 100) ^a | 35 (22 to 49) | 93 (92 to 93) a | 7.0 (3.9 to 12.7) ^a | 1.0 (1.0 to 1.0) ^a | Low | Prospe ctive | Very serious ^{b, c,} | NA | No serious | No serious | Yes e, |

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^c Not all of the children received the same test to confirm serious illness

^d It is not clear whether the test to confirm serious infection was independent of the signs and symptoms

^e Included children were less than 5 years old. Included children had a measured auxiliary temperature of greater than or equal to 38°C; parental report of a temperature of greater than or equal to 38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever (10th revision of the international classification of diseases, Australian modification codes R50, R50.0, R50.1, R50.9 and R56.0), as determined by a triage nurse. The study was undertaken in a hospital in Australia.

f Results are reported per illness rather than per child – some children were included more than once for different illnesses

⁹ It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

Table I5.21 GRADE profile for evaluation of reduced urine output

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|--|--|---|---|--|--|-------------|-------------------|--|---------------|---------------|---------------|-------------------------|
| Reduced | urine outpu | t | | | | | | | | | | | | |
| For detecting urinary tract infection | | | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 17 (11 to 23) ^a | 86 (85 to 88) ^a | 12 (8 to16) ^a | 91 (89 to 92) | 1.2 (0.8 to 1.8) ^a | 1.0 (0.9 to 1.0) ^a | Low | Prospe ctive | Very serious ^{b, c,} | NA | No serious | No serious | Yes e, f, g, h |
| Poor mict | urition | | | | | | | | | | | | | |
| For detecting serious bacterial infection | | | | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 33 (26 to 40) ^a | 79 (69 to 90) ^a | 83 (74 to 92) | 28 (22 to 35) | 1.6 (0.9 to 2.8) ^a | 0.8 (0.7 to 1.0) ^a | Very low | Retrosp ective | Very serious ^{c, d,} i, j | NA | No serious | No serious | Yes ^{e,} g, k |

^a Calculated by NCC-WCH based on results reported in the study

^b Selection criteria for inclusion in the study were not clearly described

^c Not all of the children (or a random sample of the children) received a test to confirm serious illness

^d Not all children received the same test to confirm serious illness

e It is unclear whether the period between noting a child's signs and symptoms and performing the test to confirm serious illness was short enough to be reasonably sure that the target condition did not change between the two tests

f Not enough details were provided on the signs and symptoms to ensure the findings could be replicated by another healthcare professional

⁹ It is not clear whether the same clinical data available when the test results were interpreted would be available when the test is used in practice

h Included children were 3 months or younger. Infants were included if they had an axillary, rectal or tympanic temperature ≥38°C in the office or in the previous 24 hours at home. The study was conducted in GPs' offices in the USA.

it is unclear whether the child's signs and symptoms were interpreted without knowledge of the results of the test to confirm serious illness

ilt is unclear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's signs and symptoms

^k Not enough detail on the test used to confirm serious illness was reported in the study

Table I5.22 GRADE profile for evaluation of duration of fever

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|---------------------------|--|--|---|--|--|--|-------------|-------------------|---|---------------|---------------|---------------|-------------------------|
| Fever dura | Fever duration > 12 hours | | | | | | | | | | | | | |
| For detecting serious bacterial infection | | | | | | | | | | | | | | |
| 1 (Pratt, 2007) | 119 | 44 (22 to 67) ^a | 19 (15 to 22) ^a | 2 (1 to 3) ^a | 90 (85 to 96) a | 0.5 (0.3 to 0.9) ^a | 3.0 (1.9 to 4.7) ^a | Very low | Prospe ctive | Very serious ^{b, c,} | NA | No serious | Serious e | Yes f, |
| For detecti | ng bacterae | mia | | | | | | | | | | | | |
| 1 (Haddon, 1999) | 534 | 65 (42 to 87) ^a | 38 (29 to 48) ^a | 15 (7 to 23) ^a | 87 (77 to 97) | 1.0 (0.7 to 1.5) ^a | 0.9 (0.5 to 1.8) ^a | Very low | Prospe ctive | Very serious ^{d, i,} _{j, k} | NA | No serious | Serious e | Yes f, I |
| Fever dura | ation <u>></u> 24 h | ours | | | | | | | | | | | | |
| For detecti | ng urinary tr | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 19 (13 to 25) ^a | 90 (89 to 92) ^a | 17 (11 to 22) | 91 (90 to 93) | 1.9 (1.3 to 2.7) ^a | 0.9 (0.8 to 1.0) ^a | Low | Prospe ctive | Very serious ^{b, c,} m, n | NA | No serious | No serious | Yes f, g, o |
| For detecti | ng bacterae | mia | l | | | <u> </u> | | I | | | | I. | I. | |
| 1 (Teach, 1997) | 6619 | 60 (53 to 67) ^a | 28 (27 to 30) ^a | 2 (2.00 to 3) ^a | 96 (95 to 97) | 0.8 (0.7 to 0.9) a | 1.4 (1.2 to 1.7) ^a | Very low | Retrosp ective | Very serious ^{d, i,} | NA | No serious | No serious | Yes ^{g,} |
| Fever dura | Fever duration >24 hours | | | | | | | | | | | | | |
| For detecti | ng serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Andreol a, 2007) | 408 | 52 (42 to 62) ^a | 31 (26 to 36) ^a | 18 (14 to 23) | 69 (61 to 76) | 0.8 (0.6 to 0.9) ^a | 1.5 (1.2 to 2.0) ^a | Low | Prospe ctive | Very serious ^{d, i,} | NA | No serious | No serious | Yes ^{g, t} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|--|--|--|--|-------------|-------------------|--|---------------|---------------|---------------|-----------------------------|
| Fever dura | ation > 2 da | ys | | | | | | | <u>'</u> | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Teach, 1997) | 6619 | 18 (12 to 23) a | 74 (73 to 75) ^a | 2 (1 to 3) ^a | 97 (96 to 97) | 0.7 (0.5 to 0.9) a | 1.1 (1.0 to 1.2) ^a | Very low | Retrosp ective | Very serious d, i, p, q | NA | No serious | No serious | Yes ^{g,} |
| Fever dura | ation > 48 h | ours | | | | | | | _ | | | | | |
| For detect | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Berger, 1996) | 138 | 39 (23 to 56) ^a | 82 (75 to 89) ^a | 41 (24 to 58) | 81 (74 to 89) | 2.2 (1.2 to 3.9) ^a | 0.7 (0.6 to 1.0) ^a | Low | Prospe ctive | Very serious ^{b, c,} d, i | NA | No serious | No serious | Yes f, g, u |
| 1 (Trautner , 2006) | 103 | NR/NC ^v | NR/NC ^v | NR/NC ^v | NR/NC ^v | NR/NC ^v | NR/NC V | Low | Prospe ctive | Serious d, i, | NA | Serious w | NA | Yes ^{g,} x, y |
| Fever dura | ation <u>></u> 72 h | ours | | | | | | | | | | | | |
| For detecti | ing urinary ti | ract infection | | | | | | | | | | | | |
| 1 (Salleeh, 2010) | 818 | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | Very low | Prospe ctive | Very serious ^{c, d,} , aa | NA | Serious ab | NA | Yes ^{g,} ac, ad |
| Fever dura | ation > 3 da | ys | | | | | | | | | | | | |
| For detect | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Factor, 2001) | 669 | 25 (21 to 30) ^a | 85 (81 to 89) ^a | 69 (61 to 76) | 47 (42 to 51) | 1.7 (1.2 to 2.3) ^a | 0.9 (0.8 to 0.9) ^a | Low | Prospe ctive | Very serious ^{c, d,} i, s, ae | NA | No serious | No serious | Yes ^{g,} |

NC Not calculable

NR Not reported

^a Calculated by the NCC-WCH based on results reported in the study

b It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^c It is not clear whether all children received the same test to confirm serious infection

d It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

e The difference between the highest and lowest confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%

f It was unclear whether the period between the reference test and the signs and symptoms being recorded was short enough to be reasonably sure that the illness did not resolve before the reference test was undertaken

⁹ It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

h Included children were 1 to 36 months old. Included children had a temperature equal to or greater than 39°C (reported or documented). The study was conducted in a hospital in USA.

ilt is unclear whether the results of the test used to confirm serious illness were interpreted without knowledge of the signs or symptoms

¹Uninterpretable, indeterminate or intermediate test results were reported for some children

^k Withdrawals from the study were not explained

Included children were 3 to 36 months old. Included children had a temperature equal to or greater than 39°C recorded in the emergency department. The study was based in the emergency department of a hospital in Australia.

^m The selection criteria were not clearly described

ⁿ Some eligible infants were not enrolled

o Included children were less than or equal 3 months. Included infants had an auxiliary, rectal or tympanic temperature greater than or equal to 38 degrees in the office or at home. The study was based In GPs offices in USA.

P Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated

⁹ Study authors report that it is possible the duration of fever data is not accurate as it was reliant on the caregivers' recall of the day on which the fever began

Included children were 3 to 36 months old with an initial recorded temperature of greater than or equal to 39°C. The subjects were part of a multicenter trial conduced in USA.

^s It is not clear whether the test to confirm serious infection was independent of the signs and symptoms

^t Included children aged less than 3 years. Included those with fever, although fever was not defined. Undertaken in an emergency department in Italy.

^u Included children were 2 weeks to 1 year old with a temperature greater than or equal to 38°C. The study was based in the paediatric emergency ward of a hospital in the Netherlands.

^vOR 1.04 (95% CI 0.35 to 3.12)

w Included children up to 18 years old

x Included children less than 18 years old with a temperature greater than or equal to 41.1°C. The study was conducted in a paediatric emergency department in USA.

^y Results reported in the study: OR 1.04 (0.35 to 3.12) (compared to duration < 24 hours). Data on diagnostic accuracy or data that would allow diagnostic accuracy data to be calculated was not reported.

^z RR 1.6 (95% 1.2 to 2.1), P = 0.002

aa It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

ab This study reported on bag urinalysis results rather than urinary tract infection specifically

^{ac} Included children were 3 to 36 months with a temperature greater than or equal to 38°C recorded in the emergency department or by parental report. The study was based in a paediatric emergency department in Canada.

Table I5.23 GRADE profile for comparison of duration of fever

| Number | Duration of fever | | Effect | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|------------------------------------|----------------------------------|----------------------------------|-----------|----------|-------------------|-------------|---------------|--------------|-------------|------------------|
| of studies | With SBI (Mean) | Without SBI (Mean) | P value | | | | | | | considerations |
| Duration o | of fever | | | | | | | | | |
| For detecti | ing serious bacterial infection | on | | | | | | | | |
| 1 (Hsiao, 2006) | 26.5 hours (SD 41.5) | 18.6 hours (SD 21.7) | P < 0.001 | High | Prospecti ve | No serious | NA | No serious | NA | Yes ^a |
| 1 (Bleeker, 2007) | 2.5 days (SD 2.6) | 2.6 days (SD 2.3) | NR | High | Prospecti ve | No serious | NA | No serious | NA | Yes ^b |
| 1 (Lacour, 2001) | Median 27 hours (range 2 to 140) | Median 24 hours (range 2 to 140) | P=0.02 | High | Prospecti ve | No serious | NA | No serious | NA | Yes ^c |
| 1 (Galetto- Lacour, 2003) | Median 48 hours (range 6 to 140) | Median 24 hours (range 1 to 140) | P=0.026 | High | Prospecti ve | No serious | NA | No serious | NA | Yes ^c |
| 1 (Olacireg ui, 2009) | 18.62 hours (SD 35.8) | 13.81 hours (SD 26) | P=0.26 | Moderate | Retrospe ctive | No serious | NA | No serious | NA | Yes ^d |
| 1 (Bleeker, 2001) | 2.6 days (SD 2.2) | 3.2 days (SD 2.8) | P < 0.15 | Moderate | Retrospe ctive | No serious | NA | No serious | NA | Yes ^e |

^{ad} Results reported in the study: RR 1.6 (1.2 to 2.1), p =0.002 (compared to duration < 2 days). Data on diagnostic accuracy or data that would allow diagnostic accuracy data to be calculated was not reported.

ae It is unclear whether the spectrum of participants is representative of those that will present for assessment in practice

^{af} Included children aged 2 to 59 months. Included those with an axillary temperature of 38°C or more. Undertaken in an outpatient department and emergency room in Bangladesh.

| Number | Duration of fever | | Effect | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------------|--------------------------------|-------------------|----------|-------------------|----------------------|---------------|----------------------|-------------|------------------|
| of studies | With SBI (Mean) | Without SBI (Mean) | P value | | | | | | | considerations |
| 1 (Fouzas, 2010) | Median 14 hours (IQR 6 to 29) | Median 14 hours (IQR 6 to 27) | P = 0.49 | Moderate | Retrospe ctive | No serious | NA | No serious | NA | Yes ^f |
| For detection | ing meningococcal disease | | | | | | | | | |
| 1 (Nielsen, 2001) | Median 21 hours (IQR/range NR) | Median 24 hours (IQR/range NR) | P not significant | Low | Prospecti ve | Serious ^g | NA | Serious ^h | NA | Yes ⁱ |

IQR Interquartile range, NA Not applicable, NR Not reported, SD standard deviation

a Included children were 57 to 180 days old (2 to 6 months) with a rectal temperature of greater than 37.9°C. The study was based in a children's hospital in USA.

^b Included children were 1 to 36 months with a temperature greater than or equal to 38°C. The study was based in 2 paediatric teaching hospitals in the Netherlands.

^c Included children were 7 days to 36 months with a rectal temperature greater than 38°C. The study was conducted in the emergency department of a children's hospital in Switzerland.

^d Included children were 4 to 90 days old with a rectal temperature greater than 38°C. The study was based in an emergency department in Spain.

e Included children were 1 to 36 months. Included children had acute fever without apparent source (cut off not defined). The study was based in 2 paediatric teaching hospitals in the Netherlands.

f Included children were 29 to 89 days with a rectal temperature greater than 38°C. The study was based in a tertiary care paediatric unit in Greece.

⁹ 10 of the 39 cases of meningococcal disease were probable rather than confirmed.

^h Included children up to 16 years old

¹ Included children were greater than 1 month and less than 16 years with a rectal temperature greater than 38°C at some time within the 24 hours before inclusion. The study was conducted in the paediatric department of a hospital in Denmark.

Table I5.24 GRADE profile for evaluation of height of fever in children younger than 3 months

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------|--------------------------|--|--|---|--|--|--|--------------|-------------------|-------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | <u>></u> 38.0°C | | | | | | | | | | | | | |
| For detecting | serious bact | erial infection | | | | | | | | | | | | |
| 1 (Stanley, 2005) | 5279 | 100 (100 to 100) ^a | 0 (0 to 0) ^a | 9 (8 to 10) ^a | NC | 1.0 (1.0 to 1.0) ^a | NC | Very low | Retrosp ective | Very serious b, c, d | NA | No serious | No serious | Yes ^{e,} |
| For detecting | sepsis | | | | | | | | | | | I | | ı |
| 1 (Weber, 2003) | 3303 | NR/NC ^g | NR/NC ^g | NR/NC ^g | NR/NC ^g | NR/NC ^g | NR/NC ^g | Low | Prospe ctive | Very serious b, c, d, h | NA | No serious | NA | Yes ^{e,} |
| For detecting | meningitis | | | | | | | | | | | | | |
| 1 (Weber, 2003) | 3303 | NR/NC ^j | NR/NC ^j | NR/NC ^j | NR/NC ^j | NR/NC ^j | NR/NC ^j | Low | Prospe ctive | Very serious b, c, d, h | NA | No serious | NA | Yes ^{e,} |
| Temperature | > 39.0°C | | | | | | | | | | | | | |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Zorc, 2005) | 1025 | 37 (27 to 47) ^a | 81 (78 to 83) ^a | 16 (11 to 21) | 93 (91 to 95) a | 2.0 (1.4 to 2.6) ^a | 0.8 (0.7 to 0.9) ^a | Mode rate | Prospe ctive | Serious c, d, k | NA | No serious | No serious | Yes e, |
| Temperature | ≥ 39.5°C | | | | | | | | | | | | | |
| For detecting | serious bact | erial infection | | | | | | | | | | | | |
| 1 (Zarkesh, 2011) | 202 | 24 (10 to 37) ^a | 76 (70 to 83) ^a | 19 (8 to 30) ^a | 81 (75 to 87) | 1.0 (0.5 to 1.9) ^a | 1.0 (0.8 to 1.2) a | Low | Retrosp ective | Serious b, d, h | NA | No serious | No serious | Yes e, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|----------------------------|---------------|---------------|---------------|-------------------------|
| For detecting | occult bacte | raemia, urinary | tract infection, or | bacteraemia | | | | | | | | | | |
| 1 (Gomez, 2010) | 1018 | 26 (8 to 44) | 91 (89 to 93) ^a | 6 (1 to 11) ^a | 98 (97 to 99) | 2.8 (1.4 to 5.8) ^a | 0.8 (0.6 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, d | NA | No serious | No serious | Yes e, |
| Temperature | ≥ 40.0°C | | | | | | | | | | | | | |
| For detecting | bacterial me | ningitis, bactera | aemia, urinary trad | ct infection, or sa | almonella enteriti | S | | | | | | | | |
| 1 (Bonadio, 1994) | 356 | 21 (7 to 35) | 96 (94 to 98) ^a | 35 (14 to 56) | 92 (89 to 95) | 5.3 (2.3 to 12.3) ^a | 0.8 (0.7 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, d | NA | No serious | No serious | Yes ^{e,} |
| Temperature | > 40.0°C | | | | | | | | | | | | | |
| For detecting | serious bact | erial infection | | | | | | | | | | | | |
| 1 (Stanley, 2005) | 5279 | 7 (5 to 10) ^a | 99 (99 to 99) ^a | 38 (28 to 48) | 91 (91 to 92) | 6.1 (4.1 to 9.3) ^a | 0.9 (0.9 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, d | NA | No serious | No serious | Yes ^{e,} |

NA Not applicable, NC Not calculable, NR/NC Not reported/Not calculable

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all children received the same test to confirm serious infection

^c It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

d It is unclear whether the results of the test used to confirm serious illness were interpreted without knowledge of the signs or symptoms

e It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

function Included children aged under 3 months. Included those with a temperature of 38°C or higher. Undertaken in a paediatric emergency department in the USA.

⁹ OR 3.6 (95% CI 2.6 to 5.1)

^h It is unclear whether the results of the test to confirm serious illness included the assessment of symptoms and signs

ⁱ Included children aged 0 to 59 days. Temperature was not an inclusion criterion. Undertaken in hospitals and outpatient clinics in Ethiopia, The Gambia, Papua New Guinea, and Phillipines

^j OR 11.8 (95% CI 5.7 to 24.6)

^k One third of eligible infants were not enrolled - missed infants had a lower rate of urinary tract infection than enrolled infants

Table I5.25 GRADE profile for evaluation of height of fever in all ages up to 5 years, including those less than 3 months

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|-------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | ≥ 37.4°C | | | | | | | | | | | | | |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Shettigar, 2011) | 334 | 100 (100 to 100) ^a | 0 (0 to 0) ^a | 8 (5 to 11) ^a | NC | 1.0 (1.0 to 1.0) ^a | NC | Mode rate | Prospe ctive | Serious b, c | NA | No serious | No serious | Yes d, |
| Temperature | ≥ 37.5°C | | | | | | | | | | | | | |
| For detecting | serious bac | terial infection | | | | | | | | | | | | |
| 1 (Brent, 2011) | 1716 | 61 (49 to 72) | 65 (62 to 67) | 7 (5 to 9) | 2 (2 to 3) | 1.7 (0.7 to 4.5) | 0.6 (0.2 to 1.6) | Very low | Prospe ctive | Very serious b, c, f | NA | Serious g | No serious | Yes ^h |
| For detecting | malaria or n | neningitis | | I | | | | | I | | | <u> </u> | I | |
| 1 (Owusu- Ofori, 2004) | 608 | 75 (67 to 83) ^a | 21 (8 to 34) ^a | 74 (66 to 82) | 22 (8 to 35) ^a | 0.9 (0.8 to 1.1) ^a | 1.2 (0.6 to 2.4) ^a | Low | Prospe ctive | Serious b, c, i | NA | Serious g | No serious | Yes d, |
| For detecting | serious illne | SS | 1 | 1 | | I | | | l | | | | l | |
| 1 (Yeboah- Antwi, 2008) | 685 | NR/NC k | NR/NC k | NR/NC k | NR/NC k | NR/NC k | NR/NC k | Low | Prospe ctive | Very serious b, c, f, I | NA | No serious | NA | Yes d, m, n, o |

Results reported in the study: OR 7.4 (95% CI 3.0 to 18.5). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.

m Included children aged 60 days or younger. Included those with a temperature of 38°C or higher. Undertaken in eight paediatric emergency departments in the USA.

ⁿ Includes children aged 28 days or younger. Included those with a rectal temperature of 38.5°C or higher measured in the emergency room. Undertaken in a hospital in Iran.

o Included children aged under 90 days. Included those with a temperature of 38°C or higher at home or at presentation. Undertaken in an emergency department in Spain.

P Includes children aged 8 to 12 weeks. Included those with a temperature of 38°C of higher. Undertaken in the emergency department of a children's hospital in the USA.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|-------------------------------|---------------|---------------|---------------|-------------------------|
| 1 (Yeboah- Antwi, 2008) | 685 | NR/NC ^p | NR/NC ^p | NR/NC ^p | NR/NC ^p | NR/NC ^p | NR/NC ^p | Low | Prospe ctive | Very serious b, c, f, I | NA | No serious | NA | Yes d, m, n, q |
| 1 (Yeboah- Antwi, 2008) | 685 | NR/NC ^r | NR/NC ^r | NR/NC ^r | NR/NC ^r | NR/NC ^r | NR/NC ^r | Low | Prospe ctive | Very serious b, c, f, I | NA | No serious | NA | Yes d, m, n, s |
| For detecting | severe illnes | ss requiring hos | pitalisation | | | | | | | | | | | |
| 1 (YICSSG, 2008) | 8889 | NR/NC t | NR/NC ^t | NR/NC ^t | NR/NC ^t | NR/NC ^t | NR/NC ^t | Low | Prospe ctive | Very serious b, c, f, u | NA | No serious | NA | Yes d, |
| 1 (YICSSG, 2008) | 8889 | NR/NC * | NR/NC * | NR/NC ^x | NR/NC ^x | NR/NC ^x | NR/NC ^x | Low | Prospe ctive | Very serious b, c, f, u | NA | No serious | NA | Yes d, |
| 1 (YICSSG, 2008) | 8889 | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | NR/NC ^z | Low | Prospe ctive | Very serious b, c, f, u | NA | No serious | NA | Yes d, v, aa |
| Temperature | > 37.5°C | | | L | | | | | | | | | | |
| For detecting | meningitis | | | | | | | | | | | | | |
| 1 (Wells, 2001) | 218 | 79 (63 to 95) | 55 (48 to 62) | 18 (11 to 25) | 95 (88 to 100) | 1.7 (1.3 to 2.3) ^a | 0.4 (0.2 to 0.8) ^a | Low | Prospe ctive | Serious b, c, f, i | NA | Serious g | No serious | Yes d, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------|--------------------------|--|--|---|--|--|--|--------------|-------------------|--------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | <u>></u> 38.0°C | | | | | | | L | | <u> </u> | | | <u> </u> | |
| For detecting | oneumonia, | urinary tract in | fection or bacterae | emia | | | | | | | | | | |
| 1 (Craig, 2010) | 12807 | 85 (83 to 87) ^a | 22 (22 to 23) ^a | 8 (7 to 8) ^a | 95 (94 to 96) | 1.1 (1.1 to 1.1) ^a | 0.7 (0.6 to 0.8) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | urinary tract | infection | I | | I | | | l | | ľ | | | | ı |
| 1 (Newman, 2002) | 1666 | 100 (100 to 100) ^a | 0 (0 to 0) ^a | 10 (8 to 11) ^a | NC | 1.0 (1.0 to 1.0) ^a | NC | Mode rate | Prospe ctive | Serious | NA | No serious | No serious | Yes d, |
| For detecting | bacteraemia | or bacterial me | eningitis | 1 | | | | ľ | | | • | 1 | | , |
| 1 (Pantell, 2004) | 3066 | 90 (83 to 98) ^a | 29 (28 to 31) ^a | 3 (2 to 3) ^a | 99 (99 to 100) ^a | 1.3 (1.2 to 1.4) ^a | 0.3 (0.2 to 0.7) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes ^{d,} |
| For detecting | serious bact | terial infection | | | | | | | | | | I | | 1 |
| 1 (Stanley, 2005) | 5279 | 100 (100 to 100) ^a | 0 (0 to 0) ^a | 9 (8 to 10) ^a | NC | 1.0 (1.0 to 1.0) ^a | NC | Very low | Retrosp ective | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | sepsis | 1 | 1 | 1 | 1 | | | I. | l | L | L | ı | L | 1 |
| 1 (Weber, 2003) | 3303 | NR/NC ^{ah} | NR/NC ^{ah} | NR/NC ^{ah} | NR/NC ^{ah} | NR/NC ^{ah} | NR/NC ^{ah} | Low | Prospe ctive | Very serious b, c, f, ai | NA | No serious | NA | Yes ^{d,} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|--------------------------------|---------------|---------------|---------------|-------------------------|
| For detecting | meningitis | | | | | | | | | • | | • | • | |
| 1 (Weber, 2003) | 3303 | NR/NC ak | NR/NC ak | NR/NC ak | NR/NC ak | NR/NC ^{ak} | NR/NC ak | Low | Prospe ctive | Very serious b, c, f, ai | NA | No serious | NA | Yes ^{d,} |
| Temperature | ≥ 38.4°C | | | | | | | | | | | | | |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Shettigar, 2011) | 334 | 78 (62 to 93) | 41 (36 to 47) | 10 (6 to 15) | 95 (92 to 99) | 1.3 (1.1 to 1.6) | 0.5 (0.3 to 1.1) | Mode rate | Prospe ctive | Serious b, c | NA | No serious | No serious | Yes d, |
| Temperature | <u>></u> 38.5°C | | | | | | | | | | | | | |
| For detecting | serious bact | terial infection | | | | | | | | | | | | |
| 1 (Brent, 2011) | 1716 | 38 (27 to 50) | 85 (83 to 86) | 9 (6 to 13) | 97 (96 to 98) | 2.5 (1.1 to 5.7) | 0.7 (0.3 to 1.7) | Very low | Prospe ctive | Very serious b, c, f | NA | Serious g | No serious | Yes h |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Newman, 2002) | 1666 | 77 (71 to 84) ^a | 38 (35 to 40) ^a | 12 (10 to 14) | 94 (92 to 96) | 1.2 (1.1 to 1.4) ^a | 0.6 (0.5 to 0.8) ^a | Mode rate | Prospe ctive | Serious ad | NA | No serious | No serious | Yes ^{d,} |
| For detecting | bacteraemia | or bacterial me | eningitis | | • | | . | 1 | 1 | • | | • | | ' |
| 1 (Pantell, 2004) | 3066 | 61 (48 to 73) ^a | 69 (67 to 71) ^a | 4 (3 to 5) ^a | 99 (98 to 99) a | 2.0 (1.6 to 2.4) ^a | 0.6 (0.4 to 0.8) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|--------------|-----------------|----------------------------|---------------|--------------------------|---------------|-------------------------|
| Temperature | > 38.5°C | | | | | | | | | | | | | |
| For detecting | meningitis | | | | | | | | | | | | | |
| 1 (Wells, 2001) | 218 | 58 (39 to 78) | 81 (75 to 86) | 27 (15 to 40) | 94 (88 to 100) | 3.1 (2.0 to 4.8) ^a | 0.5 (0.3 to 0.8) ^a | Low | Prospe ctive | Serious b, c, f, i | NA | Serious g | No serious | Yes ^{d,} |
| Temperature | <u>></u> 39.0°C | | | | | | | | | | | | | |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Shaw, 1998) | 2411 | 79 (70 to 88) ^a | 33 (31 to 35) ^a | 9 (3 to 5) ^a | 98 (97 to 99) | 1.2 (1.0 to 1.3) ^a | 0.6 (0.4 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, c | NA | No serious | No serious | Yes d, |
| 1 (Newman, 2002) | 1666 | 40 (32 to 47) ^a | 74 (72 to 76) ^a | 14 (11 to 17) | 92 (90 to 94) | 1.5 (1.2 to 1.9) ^a | 0.8 (0.7 to 0.9) | Mode rate | Prospe ctive | Serious ad | NA | No serious | No serious | Yes d, |
| For detecting | serious infed | ction | | | | | | l | | | | | | |
| 1 (Thompson, 2009) | 700 | 27 (22 to 32) | 87 (84 to 91) | 41 (30 to 51) | 82 (78 to 85) | 2.1 (1.5 to 2.9) | 0.8 (0.8 to 0.9) | Low | Prospe ctive | Serious c | NA | Serious _{am} | No serious | Yes d, |
| For detecting | oneumonia, | urinary tract in | fection or bacterae | emia | | | | ľ | | | | | | |
| 1 (Craig, 2010) | 12807 | 54 (51 to 57) ^a | 58 (58 to 59) ^a | 9 (9 to 10) ^a | 94 (94 to 95) | 1.3 (1.2 to 1.4) ^a | 0.8 (0.7 to 0.8) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | bacteraemia | or bacterial me | eningitis | <u> </u> | | | | I | | | | | | ı |
| 1 (Pantell, 2004) | 3066 | 16 (7 to 26) | 90 (88 to 91) ^a | 3 (1 to 5) ^a | 98 (97 to 99) a | 1.6 (0.9 to 2.8) ^a | 0.9 (0.8 to 1.0) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-----------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|-----------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | > 39.0°C | | | | | | | | | | | <u>'</u> | | |
| For detecting | serious dise | ase | | | | | | | | | | | | |
| 1 (Nademi, 2001) | 141 | 14 (3 to 25) | 82 (74 to 89) | 25 (7 to 42) | 70 (61 to 78) | 0.8 (0.3 to 1.9) ^a | 1.0 (0.9 to 1.2) ^a | Very low | Prospe ctive | Very serious b, c, f | NA | Serious am | No serious | Yes d, |
| For detecting | bacteraemia | or bacterial me | eningitis | | | | | | | | | I | | 1 |
| 1 (Pantell, 2004) | 3066 | 43 (31 to 55) ^a | 81 (79 to 82) ^a | 4 (3 to 6) ^a | 99 (98 to 99) a | 2.2 (1.7 to 3.0) ^a | 0.7 (0.6 to 0.9) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | urinary tract | infection | | | | | | l | I. | I. | | 1 | l | |
| 1 (Zorc, 2005) | 1025 | 37 (27 to 47) ^a | 81 (78 to 83) ^a | 16 (11 to 21) | 93 (91 to 95) | 2.0 (1.4 to 2.6) ^a | 0.8 (0.7 to 0.9) ^a | Mode rate | Prospe ctive | Serious b, c, ap | NA | No serious | No serious | Yes d, o, aq |
| Temperature | <u>></u> 39.1°C | | | | | | | | | | | | | |
| For detecting | pneumonia, | urinary tract in | fection, meningitis | , or bacteraemia | | | | | | | | | | |
| 1 (Rudinsky, 2009) | 985 | 83 (75 to 88) | 18 (16 to 21) | 13 (11 to 15) | 88 (83 to 92) | 1.0 (0.9 to 1.1) | 0.9 (0.6 to 1.4) | Low | Prospe ctive | Very serious b, c, f, u, ar | NA | No serious | No serious | Yes ^{d,} |
| For detecting | bacteraemia | , bacterial men | ingitis, urinary tra | ct infection, or pr | neumonia | | ' | 1 | | | | | | • |
| 1 (Alpert, 1990) | 152 | 100 (100 to 100) ^a | 0 (0 to 0) ^a | 14 (9 to 18) ^a | NC | 1.0 (1.0 to 1.0) ^a | NC | Very low | Retrosp ective | Very serious b, c, f, ar | NA | No serious | No serious | Yes d, at, au |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-----------------------|--------------------------|--|--|---|--|--|--|--------------|-------------------|-----------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | > 39.3°C | | | | | | | | <u>'</u> | <u>'</u> | | <u>'</u> | <u>'</u> | |
| For detecting | urinary tract | infection | | | | | | | | | | | | |
| 1 (Shettigar, 2011) | 334 | 33 (16 to 51) ^a | 85 (81 to 89) ^a | 16 (6 to 26) ^a | 93 (91 to 96) | 2.2 (1.2 to 3.9) ^a | 0.8 (0.6 to 1.0) ^a | Mode rate | Prospe ctive | Serious b, c | NA | No serious | No serious | Yes d, |
| Temperature | ≥ 39.4°C | | | | | | | | | | | | | |
| For detecting | pneumonia, | urinary tract in | fection, meningitis | , or bacteraemia | 1 | | | | | | | | | |
| 1 (Rudinsky, 2009) | 985 | 67 (59 to 75) | 36 (33 to 39) | 14 (11 to 16) | 88 (85 to 91) | 1.1 (0.9 to 1.2) | 0.9 (0.7 to 1.2) | Low | Prospe ctive | Very serious b, c, f, u, ar | NA | No serious | No serious | Yes d, |
| Temperature | ≥ 39.5°C | | | | | | | | | L | | L | L | |
| For detecting | serious bact | terial infection | | | | | | | | | | | | |
| 1 (Zarkesh, 2011) | 202 | 24 (10 to 37) ^a | 76 (70 to 83) ^a | 19 (8 to 30) ^a | 81 (75 to 87) | 1.0 (0.5 to 1.9) ^a | 1.0 (0.8 to 1.2) ^a | Low | Retrosp ective | Serious c, f, ai | NA | No serious | No serious | Yes d, |
| For detecting | occult bacte | raemia, urinary | tract infection, or | bacteraemia | 1 | 1 | 1 | • | | 1 | | • | | ľ |
| 1 (Gomez, 2010) | 1018 | 26 (8 to 44) | 91 (89 to 93) ^a | 6 (1 to 11) ^a | 98 (97 to 99) a | 2.8 (1.4 to 5.8) ^a | 0.8 (0.6 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | urinary tract | infection | 1 | | • | • | | 1 | • | • | 1 | • | • | 1 |
| 1 (Newman, 2002) | 1666 | 19 (13 to 25) ^a | 92 (91 to 94) ^a | 21 (15 to 28) | 91 (90 to 93) | 2.5 (1.8 to 3.6) ^a | 0.9 (0.8 to 0.9) ^a | Mode rate | Prospe ctive | Serious ad | NA | No serious | No serious | Yes d, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-----------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|-----------------------------------|---------------|---------------|---------------|-------------------------|
| For detecting | bacteraemia | or bacterial me | eningitis | | | | | | | | | | | |
| 1 (Pantell, 2004) | 3066 | NR/NC ^{ax} | NR/NC ax | NR/NC ax | NR/NC ^{ax} | NR/NC ax | NR/NC ax | Low | Prospe ctive | Very serious b, c, f | NA | No serious | NA | Yes d, af, ay |
| Temperature | > 39.5°C | | | | | | | | | | | | | |
| For detecting | serious dise | ase | | | | | | | | | | | | |
| 1 (Nademi, 2001) | 141 | 7 (0 to 15) | 93 (87 to 98) | 30 (1 to 58) | 71 (63 to 78) | 1.0 (0.3 to 3.8) ^a | 1.0 (0.9 to 1.1) ^a | Very low | Prospe ctive | Very serious b, c, f | NA | Serious am | No serious | Yes d, |
| Temperature | ≥ 40.0°C | | | | | | | <u> </u> | | | | | | |
| For detecting | bacterial me | ningitis, bacter | aemia, urinary tra | ct infection, or sa | almonella enteriti | ·s | | | | | | | | |
| 1 (Bonadio, 1994) | 356 | 21 (7 to 35) | 96 (94 to 98) ^a | 35 (14 to 56) | 92 (89 to 95) a | 5.3 (2.3 to 12.3) ^a | 0.8 (0.7 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| For detecting | pneumonia, | urinary tract in | l fection, meningitis | , or bacteraemia | | | | <u> </u> | | | | | I | I |
| 1 (Rudinsky, 2009) | 985 | 29 (22 to 38) | 70 (67 to 73) | 13 (9 to 16) ^a | 87 (84 to 89) | 1.0 (0.8 to 1.3) | 1.0 (0.9 to 1.1) | Low | Prospe ctive | Very serious b, c, f, u, ar | NA | No serious | No serious | Yes d, |
| For detecting | pneumonia, | urinary tract in | fection, or bactera | emia | | | ı | 1 | | | | | | |
| 1 (Craig, 2010) | 12807 | 15 (13 to 17) ^a | 89 (89 to 90) ^a | 10 (8 to 11) ^a | 93 (93 to 94) a | 1.4 (1.2 to 1.6) ^a | 1.0 (0.9 to 1.0) ^a | Low | Prospe ctive | Very serious b, c, f | NA | No serious | No serious | Yes d, ac |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------|--------------------------|--|--|---|--|--|--|-------------|-------------------|--------------------------------|---------------|---------------|---------------|-------------------------|
| Temperature | > 40.0°C | | | | | | | | | | | <u>'</u> | | |
| For detecting | serious bact | erial infection | | | | | | | | | | | | |
| 1 (Stanley, 2005) | 5279 | 7 (5 to 10) ^a | 99 (99 to 99) ^a | 38 (28 to 48) | 91 (91 to 92) | 6.1 (4.1 to 9.3) ^a | 0.9 (0.9 to 1.0) ^a | Very low | Retrosp ective | Very serious b, c, f | NA | No serious | No serious | Yes d, |
| Temperature | <u>></u> 40.1°C | | | | | | | | | | | | | |
| For detecting | bacteraemia | , bacterial men | ingitis, urinary tra | ct infection, or pr | neumonia | | | | | | | | | |
| 1 (Alpert, 1990) | 152 | 71 (55 to 87) ^a | 34 (27 to 41) ^a | 14 (9 to 20) ^a | 88 (81 to 95) | 1.1 (0.8 to 1.4) ^a | 0.9 (0.5 to 1.5) ^a | Very low | Retrosp ective | Very serious b, c, f, ar | NA | No serious | No serious | Yes d, at, au |
| Temperature | ≥ 41.1°C | | | | | | | | | | | | | |
| For detecting | bacteraemia | , bacterial men | ingitis, urinary tra | ct infection, or pr | neumonia | | | | | | | | | |
| 1 (Alpert, 1990) | 152 | 45 (28 to 63) ^a | 69 (62 to 75) ^a | 18 (10 to 27) | 89 (84 to 94) | 1.4 (0.9 to 2.2) ^a | 0.8 (0.6 to 1.1) ^a | Very low | Retrosp ective | Very serious b, c, f, ar | NA | No serious | No serious | Yes d, at, au |

NA Not applicable, NR/NC Not reported/Not calculable

^a Calculated by the NCC-WCH based on results reported in the study

^b It is unclear whether the signs and symptoms were interpreted without knowledge of the results of the test to confirm serious infection

^c It is unclear whether the results of the test used to confirm serious illness were interpreted without knowledge of the signs or symptoms

d It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

e Included children aged under 5 years. Included those with an axillary temperature of 37.4°C or greater within 24 hours of admission. Undertaken in a hospital in India.

^f It is not clear whether all children received the same test to confirm serious infection

^g Included children aged up to 15 years old

^h Included children aged 1 month to 15 years old. Temperature was not specified as an inclusion criterion. Undertaken in an emergency department of a hospital in the UK.

ilt is unclear whether the spectrum of children included in the study were representative of those who will be assessed in practice

¹Included children aged 3 months to 15 years. Temperature was not specified as an inclusion criterion. Undertaken in a hospital in Ghana.

- ^k OR 7.4 (95% CI 3.0 to 18.5)
- ¹ It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected
- m Not enough detail was provided in the study paper to allow the test used to confirm serious illness to be replicated
- ⁿ Included children aged younger than 2 months. Temperature was not specified as an inclusion criterion. Undertaken in a hospital in Ghana.
- ^o Results reported in the study: OR 7.4 (95% CI 3.0 to 18.5). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ^pOR 11.1 (95% CI 5.2 to 24.1)
- ^q Results reported in the study: OR 11.1 (95% CI 5.2 to 24.1). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ^r OR 7.4 (95% CI 2.8 to 19.5)
- s Results reported in the study: OR 7.4 (95% CI 2.8 to 19.5). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ^tOR 4.7 (95% CI 2.8 to 8.0)
- ^u Uninterpretable, indeterminate or intermediate test results were reported for some children
- ^v Included children aged younger than 60 days. Temperature was not specified as an inclusion criterion. Undertaken in hospitals and outpatient clinics in Bangladesh, Bolivia, Ghana, India, Pakistan and South Africa.
- w Results reported in the study: OR 4.7 (2.8 to 8.0). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ^x OR 7.5 (95% CI 5.0 to 11.4)
- Y Results reported in the study: OR 7.5 (5.0 to 11.4). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ^z OR 3.4 (95% CI 2.4 to 4.9)
- aa Results reported in the study: OR 3.4 (2.4 to 4.9) (P < 0.0001). Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.
- ab Included children aged up to 15 years old with a non-blanching rash. Temperature was not specified as an inclusion criterion. Undertaken in an accident and emergency department in the UK.
- ac Included children aged under 5 years. 'Febrile illness' was defined as any illness with one or more of the following: a measured axillary temperature of ≥ 38°C; parental report of a temperature of ≥38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in an emergency department in Australia.
- ad It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection
- ^{ae} Included children aged 3 months or younger. Included those with an auxiliary, rectal or tympanic temperature of 38°C at presentation or in previous 24 hours at home. Undertaken in GPs offices in the USA.
- af Included children 3 months or younger. Included those with a temperature of 38°C or higher either at home or in the clinicians office. Undertake in GPs offices in the USA.
- ag Included children aged under 3 months. Included those with a temperature of 38°C or higher. Undertaken in a paediatric emergency department in the USA.
- ^{ah} OR 3.6 (95% CI 2.6 to 5.1)
- ai It is unclear whether the test to confirm serious illness was independent of the symptoms and signs
- ^{aj} Included children were aged 0 to 59 days. Temperature was not specified as an inclusion criterion. Undertaken in hospitals and outpatient clinics in Ethiopia, The Gambia, Papua New Guinea, and Philippines
- ^{ak} OR 11.8 (95% CI 5.7 to 24.6)
- al Includes boys under 1 year of age and girls under 2 years. Includes those with a temperature of 38.3°C or higher. Undertaken in an emergency department in the USA. Ak Included children up to 16 years old
- am Includes children aged up to 16 years
- an Includes children aged between 3 months and 16 years. Temperature was not specified as an inclusion criterion. Undertaken in a paediatric assessment unit of a hospital in the UK.
- ^{ao} Includes children aged 8 days to 16 years. Includes those with a temperature of 38°C or higher. Undertaken in a hospital in the UK.

Feverish illness in children (appendices)

Table I5.26 GRADE profile for comparison of height of fever in children with and without serious illness – all ages up to 5 years

| Number | Height of fever | | Effect | | | | cy | ω. | _ | on |
|------------------------------------|---------------------------------|-------------------------------|---------------------------|---------|-----------------|-------------------|---------------|---------------|-------------|------------------------|
| of studies | With SBI (Degrees C, mean) | Without SBI (Degrees C, mean) | P value | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Height of t | fever | | | | | | | | | |
| For detecti | ing serious bacterial infection | | | | | | | | | |
| 1 (Baskin, 1992) | 39.0 (SD 0.6) | 38.9 (SD 0.6) | P = 0.01 | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^a |
| 1 (Galetto- Lacour, 2003) | Median 39.4 (38.3 to 41) | Median 39.5 (38 to 40.8) | P value 'not significant' | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^b |
| 1 (Hsiao, 2006) | 38.4 (SD 0.8) | 38.5 (SD 1.0) | P = 0.178 | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^c |

ap One third of eligible infants were not enrolled - missed infants had a lower rate of urinary tract infection than enrolled infants

aq Included children aged 60 days or younger. Included those with a temperature of 38°C or higher. Undertaken in eight paediatric emergency departments in the USA.

^{ar} The selection criteria were not clearly described

as Includes children aged less than 3 months. Includes temperature of 100.4°F or higher at home or at presentation. Undertaken in an emergency departments in the USA.

at It was unclear whether the period between the reference test and the signs and symptoms being recorded was short enough to be reasonably sure that the illness did not resolve before the reference test was undertaken

au Includes children aged 3 to 36 months. Includes temperatures of 41.1°C or higher. Undertaken in an emergency department of a children's hospital in the USA.

^{av} Includes children aged 28 days or younger. Included those with a rectal temperature of 38.5°C or higher measured in the emergency room. Undertaken in a hospital in Iran.

aw Included children aged under 90 days. Included those with a temperature of 38°C or higher at home or at presentation. Undertaken in an emergency department in Spain.

^{ax} Adjusted OR 3.61 (95% CI 1.40 to 9.25)

ay Results reported in the study: adjusted OR 3.61 (1.40 to 9.25), P = 0.02. Data on diagnostic accuracy, or data that would allow diagnostic accuracy data to be calculated, was not reported.

az Includes children aged 8 to 12 weeks. Included those with a temperature of 38°C of higher. Undertaken in the emergency department of a children's hospital in the USA.

| Number | Height of fever | | Effect | | | | > | | | <u>_</u> |
|-----------------------------|--------------------------------|--------------------------------|---------------------------|----------|---|--------------------------|---------------|---------------|-------------|------------------------|
| of studies | With SBI (Degrees C, mean) | Without SBI (Degrees C, mean) | P value | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Lacour, 2001) | 39.1 (SD 0.2) | 39.0 (SD 0.1) | P value 'not significant' | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^d |
| 1 (Shin, 2009) | 38.7 (SD 0.5) | 38.6 (SD 0.4) | P = 0.34 | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^e |
| 1 (Andreol a, 2007) | 39.2 (SD 0.8) | 39.0 (SD 0.8) | P = 0.004 | Moderate | Prospe ctive | Serio us ^f | NA | No serious | NA | Yes ^g |
| 1 (Fouzas, 2010) | Median 38.5 (IQR 38.1 to 39.0) | Median 38.5 (IQR 38.1 to 38.8) | P = 0.22 | Moderate | Retrosp ective | No seriou s | NA | No serious | NA | Yes ^h |
| 1 (Nijman, 2011) | Median 39.3 (IQR 38.6 to 39.8) | Median 38.9 (IQR 38.1 to 39.6) | P < 0.000 | Moderate | Prospe ctive | No seriou s | NA | Serious | NA | Yes ^j |
| 1 (Olacireg ui, 2009) | 38.23 (SD 0.82) | 38.23 (SD 0.64) | P = 0.58 | Moderate | Retrosp ective | No seriou s | NA | No serious | NA | Yes ^k |
| 1 (Maniaci, 2008) | 38.9 (SD 0.72) | 38.6 (SD 0.45) | P=0.003 | Low | Prospe ctive and retrosp ective | Serio us ¹ | NA | No serious | NA | Yes ^m |
| 1 (Nguyen, 1984) | 39.9 (SD 0.96) | 39.1 (SD 3.0) | P > 0.2 | Low | Retrosp ective | No seriou s | NA | Serious | NA | Yes ° |

| Number | Height of fever | | Effect | | | | <u>خ</u> | | | E |
|----------------------------|------------------------------------|------------------------------------|---------------------------|----------|-------------------|--------------------------|---------------|---------------|-------------|------------------------|
| of studies | With SBI (Degrees C, mean) | Without SBI (Degrees C, mean) | P value | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| For detecti | ing bacteraemia | | | | | | | | | |
| 1 (Crocker, 1985) | 40.0 (SD 0.4) | 40.1 (SD 0.3) | P value 'not significant' | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^p |
| 1 (Haddon, 1999) | 39.7 (SD 0.39) | 39.7 (SD 0.55) | P = 0.91 | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^q |
| 1 (Singhi, 1992) | 38.8 (SD 0.3) | 38.8 (SD 0.15) | NR | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^r |
| 1 (Singhi, 1992) | 38.7 (SD 0.2) | 38.8 (SD 0.15) | NR | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^r |
| 1 (Teach, 1997) | 40.0 (SD 0.61) | 39.8 (SD 0.55) | P < 0.001 | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes ^s |
| 1 (Stathaki s, 2007) | 39.0 (SD 0.9) | 38.8 (SD 1.0) | P = 0.80 | Moderate | Retrosp ective | No seriou s | NA | No serious | NA | Yes ^t |
| For detecti | ing meningococcal disease | | | • | • | • | | • | | |
| 1 (Nielsen, 2001) | Median 40 (IQR/range not reported) | Median 39 (IQR/range not reported) | P < 0.01 | High | Prospe ctive | Serio us ^u | NA | Serious | NA | Yes ^v |

| Number | Height of fever | | Effect | | | | cy. | | | n |
|---------------------------|---|-------------------------------|----------|----------|-----------------|--------------------------|---------------|---------------|-------------|-----------------------|
| of studies | With SBI (Degrees C, mean) | Without SBI (Degrees C, mean) | P value | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideratio |
| For detecti | ing pneumonia, urinary tract infection, | meningitis, or bacteraemia | | • | • | | • | | • | • |
| 1 (Rudinsk y, 2009) | 103.3F (SD 1.2) | 103.2F (SD 1.2) | P = 0.26 | Moderate | Prospe ctive | Serio us ^w | NA | No serious | NA | Yes ^x |
| For detecti | ing urinary tract infection | | | | | | | | | |
| 1 (Singhi, 1992) | 38.8 (SD 0.1) | 38.8 (SD 0.15) | NR | High | Prospe ctive | No seriou s | NA | No serious | NA | Yes |

NA Not applicable, NR Not reported, SD standard deviation

^a Includes children aged between 28 and 90 days old. Includes those with a rectal temperature of 38°C or higher at presentation, or a parental history of an equivalent rectal temperature. Undertaken in an emergency department in the USA.

b Includes children aged from 7 days to 36 months. Includes those with a temperature of 38°C or higher. Undertaken in a hospital in Switzerland.

^c Includes children aged between 2 and 6 months old. Includes those with a rectal temperature higher than 37.9°C. Undertaken in the emergency departments of a children's hospital in the USA.

Includes children aged from 7 days to 36 months. Includes those with a rectal temperature higher than 38°C. Undertaken in a hospital in Switzerland.

^e Includes children aged less than 3 months. Includes those with an axillary temperature of 38°C or higher. Undertaken in a hospital in South Korea.

^f Not all children had blood culture performed to confirm serious illness

⁹ Includes children aged less than 3 years. Includes children with a fever, although fever was not defined. Undertaken in a hospital in Italy.

h Includes children aged 29 to 89 days old. Includes those with a rectal temperature higher than 38°C. Undertaken in a tertiary care paediatric unit in Greece.

ⁱChildren were aged up to 16 years old

^j Included children aged 1 month to 16 years old. Included those with a temperature higher than 38.5°C, a recent high fever or fever as a reason for referral. Undertaken in the emergency department of a children's hospital in the Netherlands.

k Includes children aged between 4 and 90 days old. Includes those with a rectal temperature greater than 38°C.Undertaken in an emergency department in Spain.

¹ It is not clearly reported how many children were retrospectively recruited

m Includes children aged 90 days or younger. Includes those with a temperature of 38°C or higher. Undertaken in a hospital in the USA.

ⁿ Includes children up to 16.5 years old (mean 33.9 months)

o Includes children aged between 1 month and 16.5 years with fever and petechiae (fever not defined). Undertaken in a medical centre in the USA.

P Includes children aged between 6 months and 2 years. Includes those with a rectal temperature of 39.4°C. Undertaken in a hospital in the USA.

⁹ Includes children aged between 3 and 36 months. Includes those with a temperature by tympanic thermometry of 39°C or higher. Undertaken in an emergency department in Australia.

Table I5.27 GRADE profile for evaluation of bulging fontanelle

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|---|---------------|---------------|---------------|---------------------|
| Bulging fo | ontanelle | | | | | | | | | | | | | |
| For detect | ing serious b | pacterial illness | | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 5 (2 to 9) ^a | 90 (82 to 97) ^a | 60 (35 to 85) a | 24 (18 to 30) | 0.5 (0.2 to 1.4) ^a | 1.1 (1.0 to 1.2) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e, f, g | NA | No serious | Serious h | Yes ^{i, j} |
| For detect | ing meningit | is | I | | | | | I | | | | | ľ | |
| 1 (Ghotbi, 2009) | 254 | 8 (0 to 24) ^a | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 96 (93 to 98) | NC | 0.9 (0.8 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{b, g} | NA | No serious | No serious | Yes i, |
| For detect | ing pneumoi | nia, urinary trac | t infection, or bac | teraemia | | | | | | • | | | | |
| 1 (Craig, 2010) | 12807 | 1 (0 to 1) ^a | 100 (100 to 100) ^a | 19 (7 to 31) ^a | 93 (92 to 93) a | 3.0 (1.4 to 6.5) ^a | 1.0 (1.0 to 1.0) ^a | Low | Prospe ctive | Very seriou s d, l, m | NA | No serious | No serious | Yes i, |

Includes children aged between 1 month and 3 years. Includes those with an axillary temperature of higher than 38.5°C or a rectal temperature of 39°C or higher. Excluded those whose fever had lasted for 3 days or more. Undertaken at a hospital in India.

s Included children aged from 90 days to 36 months old. Included those with an initially recorded temperature of 39°C or higher. Undertaken as part of a multicentre study in the USA.

^t Includes children aged 3 to 36 months old. Includes those with a core temperature of 38°C or above measured by tympanic thermometer. Undertaken in a paediatric emergency department in Australia.

^u 10 of the 39 cases of meningococcal disease were probable rather than confirmed

^v Includes children aged from 1 month to 16 years. Includes those with a rectal temperature above 38°C at presentation or in the 24 hours prior to presentation. Undertaken at a hospital in Denmark.

The study authors report possible errors in the data from incomplete medical records. They also report that it is possible that the case definition of pneumonia overestimated the number of cases of pneumonia.

x Includes children aged less than 3 months. Includes those with a temperature of 100.4F or higher at home or at presentation. Undertaken in an emergency department in the USA.

NA Not applicable, NC Not calculable

Table I5.28 GRADE profile for evaluation of neck stiffness

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|---|---------------|---------------|---------------|-------------------------|
| Nuchal rig | gidity | | | | | | | | | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Ghotbi, 2009) | 254 | 8 (0 to 24) ^a | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 96 (93 to 98) | NC | 0.9 (0.8 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{b, c} | NA | No serious | No serious | Yes d, |
| 1 (Offringa, 1992) | 92 | 48 (27 to 68) ^a | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 85 (77 to 93) | NC | 0.5 (0.4 to 0.8) a | Very low | Retrosp ective | Very seriou s b, c, f, g, h, i | NA | Serious j | Serious k | Yes d, |

^a Calculated by the NCC-WCH based on results reported in the study

b It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

^c It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

^d Not all of the children received the same test to confirm serious illness

e It is not clear if the child's signs and symptoms formed part of the test to confirm serious illness

f It is not clear if the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious infection

⁹ It is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms

^h The difference between the lower and upper confidence intervals is greater than 40% for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value

ilt is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

¹ Includes children aged 1 to 36 months. Includes temperatures equal to or greater than 38°C. Undertaken in the emergency department of two children's hospitals in the Netherlands

k Included children aged 6 months to 5 years. Fever was not defined, included children with seizure associated with fever. Undertaken in the paediatric department of a hospital in Iran.

It is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

m It is not clear if the test to confirm serious illness was independent of the child's signs and symptoms

ⁿ Included children were less than 5 years old. Included children had a measured axillary temperature of greater than or equal to 38°C; parental report of a temperature of greater than or equal to 38°C measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever (10th revision of the international classification of diseases, Australian modification codes R50, R50.0, R50.1, R50.9 and R56.0), as determined by a triage nurse. The study was undertaken in a hospital in Australia.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|---|---------------|--------------|---------------|--------|
| For detecti | ing meningo | coccal disease | | | | | | | | | | | | |
| 1 (Nielsen, 2001) | 208 | 41 (26 to 56) ^a | 97 (94 to 100) | 76 (58 to 94) | 88 (83 to 92) | 13.9 (5.4 to 35.6) ^a | 0.6 (0.5 to 0.8) ^a | Very low | Prospe ctive | Very seriou s b, c, g, h, i, m | NA | Serious | No serious | Yes d, |

NA Not applicable

NC Not calculable

^a Calculated by the NCC-WCH based on results reported in the study

b It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice

^c It is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms

^d It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study

e Included children aged 6 months to 5 years. Fever not defined, seizures associated with fever. Undertaken in the paediatric department of a hospital in Iran

f It is unclear whether the test used to confirm serious illness was likely to confirm the serious illness being detected

⁹ Not all of the children received the same test to confirm serious illness

h It is not clear if the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious infection

it is not clear whether the whole sample (or a random selection of the sample) were tested to confirm serious infection

^j Includes children aged from 3 months to 6 years

^k The confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%

Includes children aged 3 months to 6 years. Fever not defined, seizure associated with fever. Undertaken in the emergency department of two hospitals in the Netherlands.

m It is not clear if the child's signs and symptoms formed part of the test to confirm serious illness

ⁿ Includes children aged from 1 month to 16 years

[°] Includes children aged from 1 month to 16 years. Includes temperature greater than 38°Csome time within the 24 hours prior to inclusion. Children had skin haemorrhages. Undertaken in five paediatric departments in hospitals in Denmark.

Table I5.29 GRADE profile for evaluation of focal seizures

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|---|--|----------|-------------------|--|---------------|--------------|--------------|-------------------------|
| Focal seiz | ures | | | | | | | | | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Akpede, 1992) | 522 | 41 (20 to 61) ^a | 92 (90 to 94) ^a | 18 (8 to 29) ^a | 97 (96 to 99) | 5.1 (2.9 to 9.2) a | 0.6 (0.5 to 0.9) ^a | Very low | Prospe ctive | Very seriou s ^{b, c, d} | NA | Serious e | Serious f | Yes ^{g, h} |
| 1 (Joffe, 1983) | 241 | 38 (12 to 65) i | 91 (87 to 95) ⁱ | 20 (4 to 34) ⁱ | 96 (94 to 99) | 4.2 (1.9 to 9.3) ^a | 0.7 (0.4 to 1.0) ^a | Very low | Retrosp ective | Very seriou s ^{b, c, d} | NA | Serious j | Serious f | Yes ^{f, k} |

NA Not applicable

^a Calculated by the NCC-WCH based on results reported in the study.

b It is unclear whether the spectrum of children in the study is representative of those who will present to a healthcare professional in practice.

^c It is not clear if the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious infection.

^d It is not clear if the results of the test used to confirm serious infection were interpreted without knowledge of the child's signs and symptoms.

^e included children aged from 1 month to 6 years old.

^f The confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%.

⁹ It is unclear whether all of the data that would be available when signs and symptoms are interpreted in practice were available in the study.

h Included children aged 1 month to 6 years. Included temperatures 38°C or greater, convulsions associated with fever. Undertaken in the children's emergency room of a hospital in Nigeria.

¹ Confidence intervals were calculated by the NCC-WCH based on results reported in the study.

^j Included children from 6 months to 6 years old.

k Included children aged 6 months to 6 years. Fever not defined, seizure associated with fever. Undertaken in the emergency room of a hospital in the USA.

Table I5.30 GRADE profile for evaluation of non-blanching rash

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|-----------------|---|--|---------------|---------------|---------------------------------------|------------------------------|
| Rash | | | | | | | | | | | | | | |
| For detecti | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Nijman, 2011) | 1255 | 3 (0 to 6) ^a | 97 (96 to 98) ^a | 12 (1 to 23) ^a | 90 (88 to 91) | 1.1 (0.4 to 3.1) ^a | 1.0 (1.0 to 1.0) ^a | Very serious | Prospe ctive | Very seriou s b, c, d, e | NA | Serious f | No serious | Yes ^g |
| For detecti | ing pneumoi | nia, UTI or bact | teraemia | | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 12 (10 to 14) ^a | 82 (81 to 83) ^a | 5 (4 to 6) ^a | 92 (92 to 93) ^a | 0.7 (0.6 to 0.8) ^a | 1.1 (1.1 to 1.1) | Low | Prospe ctive | Very seriou s ^{b, c, h} | NA | No serious | No serious | Yes ^{g, i} |
| Purpura | | | <u>l</u> | | | | | | | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 Mandl (1997) | 411 | 83 (40 to 99) | 97 (95 to 98) | 31 (5 to 57) | 99 (99 to 100) | 28.1 (14.5 to 54.5) | 0.2 (0.0 to 1.0) | Very low | Prospe ctive and retrosp ective | Very seriou s ^{b, c, d,} e, h, j | NA | Serious k | Serious | Yes ^{g,} m, n, o |
| Petechiae | | <u>'</u> | ' | <u>'</u> | <u></u> | <u>'</u> | _ | | | | · | | · · · · · · · · · · · · · · · · · · · | |
| For detecti | ing serious d | disease | | | | | | | | | | | | |
| 1 (Nademi, 2001) | 141 | 29 (15 to 43) | 98 (95 to 100) | 86 (67 to 100) | 77 (69 to 84) | 8.9 (2.6 to 30.4) | 0.8 (0.6 to 0.9) | Very low | Prospe ctive | Very seriou s ^{b, d, e} | NA | Serious f | No serious | Yes ^{g,} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|----------|---------------------------------|--|---------------|--------------|---------------|------------------------------|
| | ing invasive | | T | T | <u> </u> | 1 | T | T | 1 | 1 | | 1 | ı | - |
| 1 (Baker, 1989) | 190 | (15 to 65) ^a | 89 (80 to 98) ^a | 55 (25 to 84) ^a | 82 (71 to 92) ^a | 3.6 (1.3 to 10.1) | 0.7 (0.4 to 1.0) | Very low | Prospe ctive | Very seriou s ^{c, d, e,} j | NA | Serious f | Serious | Yes ^{g,} |
| For detecti | ing meningiti | is | L | | | L | L | L | I | I | L | | L | |
| 1 (Offringa, 1992) | 401 | 13 (0 to 27) ^a | 100 (100 to 100) ^a | 100 (100 to 100) | 78 (69 to 86) ^a | NC | 0.9 (0.7 to 1.0) | Very low | Retrosp ective | Very seriou s ^{b, c, d,} e, h, j | NA | Serious | No serious | Yes ^{n,} |
| Purpura a | nd petechia | ie | | | | | | | | | | 1 | | |
| For detecti | ing serious ii | nvasive bactera | aemia | | | | | | | | | | | |
| 1 Mandl (1997) | 411 | 83 (54 to 100) ^a | 97 (95 to 99) ^a | 31 (9 to 54) ^a | 100 (99 to 100) ^a | 28.5 (14.4 to 56.4) ^a | 0.2 (0.0 to 1.0) ^a | Very low | Prospe ctive and retrosp ective | Very seriou s b, c, d, e, h, j | NA | Serious k | Serious | Yes ^{g,} m, n, o |
| More than | 20 skin ha | emorrhages | | | | | | | | | | • | | |
| For detecti | ing meningo | coccal disease | | | | | | | | | | | | |
| 1 (Nielsen, 2001) | 208 | 74 (61 to 88) ^a | 49 (42 to 57) ^a | 25 (17 to 33) ^a | 89 (83 to 96) ^a | 1.5 (1.2 to 1.9) ^a | 0.5 (0.3 to 0.9) | Very low | Prospe ctive | Very seriou s ^{b, c, d,} e, h, j | NA | Serious f | No serious | Yes ^{g, t} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|--|---------------|--------------|---------------|-------------------------|
| Maximum | diameter of | f haemorrhage | es greater than 1 | mm | | | | | | | | | | |
| For detecti | ing meningo | coccal disease | | | | | | | | | | | | |
| 1 (Nielsen, 2001) | 208 | 95 (88 to 100) | 78 (72 to 84) ^a | 50 (39 to 61) ^a | 99 (96 to 100) ^a | 4.3 (3.2 to 5.8) ^a | 0.1 (0.0 to 0.3) | Very low | Prospe ctive | Very seriou s ^{b, c, d,} e, h, j | NA | Serious f | No serious | Yes ^{g, t} |
| Maximum | diameter of | f haemorrhage | es greater than 2 | mm | | | | | | | | | | |
| For detect | ing meningo | coccal disease | | | | | | | | | | | | |
| 1 (Nielsen, 2001) | 208 | 74 (61 to 88) ^a | 92 (88 to 96) ^a | 67 (53 to 81) ^a | 94 (90 to 98) ^a | 9.0 (5.3 to 15.3) | 0.3 (0.2 to 0.5) | Very low | Prospe ctive | Very seriou s ^{b, c, d,} e, h, j | NA | Serious f | No serious | Yes ^{g, t} |

NA Not applicable

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all of the children received the same test to confirm serious illness

^c It is not clear whether the test to confirm serious illness was independent of the symptoms and signs

^d It is unclear whether the symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

e It is unclear whether the results of the test to confirm serious illness were interpreted without knowledge of the symptoms or signs

f Included children up to 16 years old

⁹ It is not clear whether the same clinical data were available as would be when the test is used in practice

h It is not clear whether all of the children (or a random selection of the children) received a test to confirm serious illness

Included children under 5 years of age. Included those with an axillary temperature of 38°C or higher; a parental report of a temperature of 38°Cor higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in the emergency department of a children's hospital in Australia

¹ It is unclear whether the spectrum of children included was representative of those that would be seen in practice

k Included children up to 18 years old

¹ The difference between the upper and lower confidence intervals for one, two, or three of sensitivity, specificity, positive predictive value or negative predictive value was 40% or greater

m It is unclear whether the period of time between assessing the child's symptoms and signs and using a test to confirm serious illness was short enough

Table I5.31 GRADE profile for evaluation of diarrhoea

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|--------------------------------------|---------------|---------------|---------------|-------------------------|
| Diarrhoea | | | | | | | | | | | | | | |
| For detecti | ing serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Craig, 2010) | 15781 | 21 (19 to 24) ^a | 74 (73 to 75) ^a | 6 (5 to 7) ^a | 92 (92 to 93) a | 0.8 (0.7 to 0.9) ^a | 1.1 (1.0 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{b, c} | NA | No serious | No serious | Yes d, e, f |
| 1 (Berger, 1996) | 138 | 55 (38 to 72) ^a | 20 (12 to 28) ^a | 18 (10 to 25) ^a | 58 (42 to 74) ^a | 0.7 (0.5 to 0.9) ^a | 2.3 (1.3 to 3.9) ^a | Low | Prospe ctive | Very seriou s b, c, g, h | NA | No serious | No serious | Yes d, e, i |
| For detecti | ing urinary tr | ract infection | | | | 1 | | ı | | • | | • | | • |
| 1 (Morris, 2007) | 98 | NC ^j | NC ^j | NC ^j | NC ^j | NC ^j | NC ^j | Low | Prospe ctive | Very seriou s c, g, h, k, I | NA | No serious | NA | Yes d, e, m, n |

ⁿ Not enough detail regarding the test for serious illness was provided to allow another clinician to repeat the test

o Included children aged 18 years and younger. Included those with a temperature of 38°C or higher. Undertaken in the emergency department of a paediatric hospital in the USA.

P Included children aged up to 16 years old. Included those with a temperature of 38°C or higher. Undertaken in the paediatric assessment unit of two hospitals in the UK.

q Included children up to 15 years old. Included those with a temperature higher than 38°C.Undertaken in a children's hospital medical centre in the USA.

^r Included children up to 6 years old

s Included children from 3 months to 6 years old. Fever was not defined, included children had had a seizure associated with fever. Undertaken in the emergency room of a hospital in the Netherlands.

^t Included children aged 1 month to 16 years. Included those with a fever higher than 38°C.Undertaken in a hospital in Denmark.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------|--|--|---|--|--|--|----------|-----------------|--|---------------|---------------|---------------|-------------------------|
| 1 (Trautner , 2006) | 103 | NC ° | NC ° | NC ° | NC ° | NC ° | NC ° | Very low | Prospe ctive | Very seriou s c, g, h, p | NA | Serious q | NA | Yes d, e, m, r |
| Diarrhoea | and vomiti | ng | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Nijman, 2011) | 1255 | 6 (2 to 10) ^a | 91 (89 to 92) ^a | 7 (2 to 12) ^a | 89 (87 to 91) | 0.6 (0.3 to 1.3) ^a | 1.0 (1.0 to 1.1) ^a | Very low | Prospe ctive | Very seriou s c, g, h, l | NA | Serious s | No serious | Yes ^{e, t} |
| Mild gastr | ointestinal | symptoms | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Shin, 2009) | 221 | 15 (4 to 25) | 89 (84 to 94) ^a | 24 (7 to 41) ^a | 81 (76 to 87) | 1.3 (0.6 to 3.1) ^a | 1.0 (0.8 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{g, h, I} | NA | No serious | No serious | Yes ^{e,} |

NC Non-calculable

^a Calculated by the NCC-WCH based on results reported in the study.

^b It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness.

^c It is not clear whether all of the children received the same test to confirm serious illness.

d It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough.

e It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice.

f Included children were under 5 years. Children were included if they had an axillary temperature/parental report of a temperature of 38°C or higher. The study was conducted in the emergency department of a hospital in Australia. Results are reported per illness rather than per child – some children were included more than once for different illnesses.

⁹ It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness.

h It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

Table I5.32 GRADE profile for evaluation of vomiting

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|--|---------------|---------------|---------------|-------------------------|
| Vomiting | | | | | | | | | | | | | | |
| For detect | ing serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Bleeker, 2007) | 381 | 49 (40 to 59) ^a | 69 (64 to 75) ^a | 36 (28 to 44) | 80 (75 to 85) | 1.6 (1.2 to 2.1) ^a | 0.7 (0.6 to 0.9) ^a | Low | Prospe ctive | Very seriou s ^{b, c,} d, e | NA | No serious | No serious | Yes f, g, h, i |
| 1 (Bleeker, 2001) | 231 | 37 (30 to 44) ^a | 43 (30 to 56) ^a | 66 (57 to 75) | 19 (12 to 25) | 0.7 (0.5 to 0.9) ^a | 1.5 (1.1 to 2.0) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e | NA | No serious | No serious | Yes f, g, h, j |

¹ Included children were between 2 weeks and 1 years old with a rectal temperature of 38°C or higher. The study was undertaken in the paediatric emergency room of a hospital in the Netherlands.

¹ Text in the paper stated that diarrhoea is not predictive of urinary tract infection

^k The selection criteria used to recruit children into the study were not clearly described

¹ It is not clear whether the test to confirm serious illness was independent of the child's symptoms and signs

^m Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

ⁿ Included children less than 36 months. Included those with an axillary temperature higher than 37.2°C. The study was undertaken in the Children's Outpatients Department in a hospital in Papua New Guinea

[°] The paper reported: OR 3.93 (95% CI 1.27 to 12.19)

PIt is not clear whether the spectrum of included participants in the study was representative of the children that would be assessed in practice

^q Included children were less than 18 years old. 84.5% were 3 - 35 months and 15.5% were 36 months or younger.

Included children were less than 18 years old with a rectal temperature of 41.1°C or higher. The study was undertaken in the paediatric emergency department of a hospital in USA.

^s Included children aged 1 month to 16 years. Included those with a temperature of 38.5°C or higher, a recent high fever, or fever as a reason for referral. Conducted in the emergency department of a children's hospital in the Netherlands.

^t Included children up to 16 years old (83% of children were five years old or younger)

^u Included children aged less than 3 months. Included those with axillary temperature of 38°C or higher. Undertaken in an outpatients clinic in South Korea.

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|---|---------------|---------------|---------------|-------------------------|
| For detecti | ing serious o | | | | | | | | _ | | | | | |
| 1 (Nademi, 2001) | 141 | 59 (43 to 73) | 60 (50 to 69) | 38 (25 to 49) | 78 (68 to 87) | 1.5 (1.0 to 2.1) ^a | 0.7 (0.5 to 1.0) ^a | Very low | Prospe ctive | Very seriou s b, c, d, e, k, l | NA | Serious m | No serious | Yes f, g, h, n |
| For detecti | ing bacterial | illness | | | | | | | • | | 1 | | | • |
| 1 (Trautner , 2006) | 103 | NR ° | NR ° | NR ° | NR ° | NR ° | NR ° | Very low | Prospe ctive | Very seriou s b, c, d, I | NA | Serious p | NA | Yes f, g, q, r |
| For detecti | ing urinary ti | ract infection | | | | | | | • | 1 | • | | | • |
| 1 (Morris, 2007) | 98 | NR ^s | NR ^s | NR ^s | NR ^s | NR ^{\$} | NR ^s | Low | Prospe ctive | Very seriou s b, c, d, k, t | NA | No serious | NA | Yes f, g, q, u |
| 1 (Rabasa Al, 2009) | 145 | 60 (39 to 81) ^a | 60 (51 to 69) ^a | 19 (10 to 29) | 90 (84 to 97) | 1.5 (1.0 to 2.3) ^a | 0.7 (0.4 to 1.2) ^a | Low | Prospe ctive | Very seriou s b, c, d, e | NA | No serious | Serious | Yes g, |
| For detecti | ing meningit | is | <u> </u> | <u> </u> | <u> </u> | 1 | <u> </u> | <u> </u> | 1 | Г | ı | _1 | 1 | 1 |
| 1 (Ghotbi, 2009) | 254 | 67 (40 to 93) ^a | 100 (100 to 100) ^a | 100 (100 to 100) ^a | 98 (97 to 100) ^a | NC | 0.3 (0.1 to 0.7) ^a | Very low | Prospe ctive | Very seriou s ^{c, d, t} | NA | No serious | Serious | Yes f, g, q, w |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|---|---------------|---------------|---------------|-------------------------|
| 1 (Offringa, 1992) | 92 | 48 (27 to 68) ^a | 81 (72 to 90) ^a | 46 (26 to 66) | 82 (73 to 91) | 2.5 (1.3 to 4.9) ^a | 0.6 (0.4 to 1.0) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e, l, t | NA | Serious × | Serious | Yes f, |
| For detecti | ing meningo | coccal disease | | | | | | | | | | | | |
| 1 (Nielsen, 2001) | 208 | 44 (28 to 59) ^a | 60 (52 to 67) ^a | 20 (12 to 29) a | 82 (75 to 89) a | 1.1 (0.7 to 1.6) ^a | 0.9 (0.7 to 1.3) ^a | Very low | Prospe ctive | Very seriou s b, c, d, e, l | NA | Serious | No serious | Yes ^{g,} |
| Increased | vomiting | | | | | | | | | | | | | |
| For detecti | ing urinary tr | act infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 15 (9 to 20) | 82 (80 to 84) ^a | 8 (5 to 11) ^a | 90 (88 to 92) | 0.8 (0.6 to 1.2) ^a | 1.0 (1.0 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{b, e, t} | NA | No serious | No serious | Yes f, g, q, ab |
| Diarrhoea | and vomiti | ng | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Nijman, 2011) | 1255 | 6 (2 to 10) ^a | 91 (89 to 92) ^a | 7 (2 to 12) ^a | 89 (87 to 91) | 0.6 (0.3 to 1.3) ^a | 1.0 (1.0 to 1.1) ^a | Very low | Prospe ctive | Very seriou s b, c, d, k | NA | Serious ac | No serious | Yes ^{g,} ad |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|--|---------------|---------------|---------------|-------------------------|
| Mild gastr | ointestinal | symptoms | | | | | | | | | | | | |
| For detect | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Shin, 2009) | 221 | 15 (4 to 25) | 89 (84 to 94) ^a | 24 (7 to 41) ^a | 81 (76 to 87) | 1.3 (0.6 to 3.1) a | 1.0 (0.8 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes ^{g,} |

NR Not reported

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all of the children received the same test to confirm serious illness

^c It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

^d It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

e It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

f It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

⁹ It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

^h Not enough detail regarding the test to confirm serious illness was provided to allow another clinician to replicate the results

¹ Included children 1 to 36 months with acute fever without apparent source. The study was undertaken in two hospitals in the Netherlands.

¹ Included children 1 to 36 months with acute fever without apparent source. The study was undertaken in two hospitals in the Netherlands.

k It is not clear whether the test to confirm serious illness was independent of the child's symptoms and signs

It is not clear whether the spectrum of included participants in the study was representative of the children that would be assessed in practice

^m Included children from 8 days to 16 years old

ⁿ Included children 8 days to 16 years with a temperature of 38°C or higher. The study was undertaken in two hospitals in the UK.

[°] The paper reported: OR 0.76 (95% CI 0.26 to 2.18)

^p Included children less than 18 years

^q Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

Included children were less than 18 years old with a rectal temperature of 41.1°C or higher. The study was undertaken in the paediatric emergency department of a hospital in USA.

^sThe text in the paper stated that vomiting is not predictive of urinary tract infection

^t The selection criteria used to recruit children into the study were not clearly described

^u Included children less than 36 months. Included axillary temperatures higher than 37.2°C. The study was undertaken in the Children's Outpatients Department in a hospital in Papua New Guinea.

Included children 1 month to 60 months (5 years) with an axillary temperature of 37.5°C or higher. The study was undertaken in the paediatric department of a hospital in Nigeria.

w Included children 6 months to 5 years. Fever was not defined. The study was undertaken in the paediatric ward of a hospital in Iran.

Table I5.33 GRADE profile for evaluation of abdominal pain

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality <mark></mark> | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|-----------------------|-----------------|--------------------------------------|---------------|---------------|---------------|---------------------------|
| Abdomina | al pain | | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (Nijman, 2011) | 1255 | 5 (1 to 8) ^a | 97 (95 to 98) ^a | 13 (3 to 23) ^a | 90 (88 to 91) | 1.3 (0.6 to 3.1) ^a | 1.0 (1.0 to 1.0) ^a | Very low | Prospe ctive | Very seriou s b, c, d, e | NA | Serious f | No serious | Yes ^{g,} |
| For detecti | ing urinary tı | ract infection | | | | | | | | | | | | |
| 1 (Morris, 2007) | 98 | NR ⁱ | NR ⁱ | NR ⁱ | NR ⁱ | NR ⁱ | NR ⁱ | Low | Prospe ctive | Very seriou s b, c, d, e, j | NA | No serious | NA | Yes ^{g,} k, l, m |

NR Not reported

^{*} Included children up to the age of 6

^y Included children 3 months to 6 years with first episode of seizure associated with fever (fever not defined). The study was undertaken in two hospitals in the Netherlands.

^z Included children older than 1 month and younger than 16 years old

aa Included children greater than 1 month and less than 16 years with rectal temperature above 38°C. The study was undertaken in 5 paediatric departments in Denmark.

ab Included children 3 months or younger with an axillary, rectal or tympanic temperatures of 38°C or higher. The study was undertaken in GP offices in USA.

^{ac} Included children up to the age of 16 (83% of children were aged 5 years or younger)

ad Included children aged 1 month to 16 years. Included those with a temperature of 38.5°C or higher, or a history of fever, or fever as a reason for referral. Undertaken in the emergency department of a paediatric hospital in the Netherlands.

^{ae} Included children aged less than 3 months. Included those with axillary temperature of 38°C or higher. Undertaken in an outpatients clinic in South Korea.

^a Calculated by the NCC-WCH based on data reported in the study

^b It is not clear whether all of the children received the same test to confirm serious illness

^c It is not clear whether the test to confirm serious illness was independent of the child's symptoms and signs

^d It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

Feverish illness in children (appendices)

Table I5.34 GRADE profile for evaluation of crying on micturition/dysuria

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|-----------------------------------|---------------|---------------|---------------|-------------------------|
| Crying on | micturition | /dysuria | | | | | | | | | | | | |
| For detect | ing urinary ti | ract infection | | | | | | | | | | | | |
| 1 (Rabasa Al, 2009) | 145 | 10 (0 to 23) | 86 (79 to 92) ^a | 10 (0 to 23) ^a | 86 (79 to 92) | 0.7 (0.2 to 2.8) ^a | 1.1 (0.9 to 1.2) ^a | Low | Propse ctive | Very seriou s b, c, d, e | NA | No serious | No serious | Yes f, g, h |

^a Calculated by the NCC-WCH based on results reported in the study

e It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

f Included children up to the age of 16 years

⁹ It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

h Included children aged less than 36 months. Included axillary temperatures higher than 37.2°C. The study was undertaken in the Children's Outpatient Department of a hospital in Papua New Guinea.

¹ The text in the paper stated that abdominal pain is not predictive or urinary tract infection

¹ The selection criteria used to recruit children into the study were not clearly described

k It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

¹ Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

m Included children with a fever of 38.5°C or higher, a recent high fever, or fever as a reason for referral. Included children aged 1 month to 16 years. Undertaken in the emergency department of a children's hospital in the Netherlands.

b It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^c It is not clear whether all of the children received the same test to confirm serious illness

^d It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

e It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

f Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

⁹ It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

h Included children aged 1 month to 60 months (5 years) old with an axillary temperature of 37.5°C or higher. The study was undertaken in the paediatric department of a hospital in Nigeria.

Table 15.35 GRADE profile for evaluation of headache

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|--|---------------|---------------|--------------|----------------|
| Headache | • | | | | | | | | | | | | | |
| For detect | ing meningit | is | | | | | | | | | | | | |
| 1 (Ghotbi, 2009) | 254 | 17 (0 to 38) | 100 (99 to | 67 (13 to 100) ^a | 96 (94 to 98) | 40.3 (3.9 to 414.3) ^a | 0.8 (0.6 to 1.1) ^a | Very low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | Serious e | Yes f, g, h, i |

^a Calculated by the NCC-WCH based on results reported in the study

^b The selection criteria used to recruit children into the study were not clearly described

^c It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

^d It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^e The difference between the upper and lower confidence intervals is 40% or greater for 1,2, or 3 of sensitivity, specificity, PPV and NPV

f It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

⁹ Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

h It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

¹Included children 6 months to 5 years. Fever was not defined. The study was undertaken in the paediatric ward of a hospital in Iran.

Table I5.36 GRADE profile for evaluation of conjunctivitis

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|----------------------------|---------------|---------------|---------------|-------------------------|
| Conjuncti | vitis | | | | | | | | | | | | | |
| For detect | ing urinary tı | ract infection | | | | | | | | | | | | |
| 1 (Newma n, 2002) | 1666 | 1 (1 to 2) ^a | 99 (99 to 100) | 7 (6 to 21) ^a | 90 (89 to 92) | 0.7 (0.1 to 5.5) ^a | 1.0 (1.0 to 1.0) ^a | Low | Prosp ective | Very serious b, c, d | NA | No serious | No serious | Yes e, |

^a Calculated by the NCC-WCH based on results reported in the study

^bThe selection criteria used to recruit children into the study were not clearly described

^c It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^d It is not clear whether all of the children received the same test to confirm serious illness

e It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

^f Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

g It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

^h Included children 3 months or younger with axillary, rectal or tympanic temperatures of 38°C or higher. The study was undertaken in GP offices in USA.

Table I5.37 GRADE profile for evaluation of poor peripheral circulation

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidenc e interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|---|----------|-----------------------|-------------------------------|---------------|---------------|---------------|-------------------------|
| Poor perip | oheral circu | lation | | | | | | | | | | | | |
| For detect | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 11 (6 to 16) | 78 (69 to 88) ^a | 59 (42 to 76) | 23 (17 to 28) | 0.5 (0.3 to 0.9) ^a | 1.1 (1.0 to 1.3) ^a | Very low | Retro specti ve | Very serious b, c, d, e | NA | No serious | No serious | Yes f, g, h, i |

^a Calculated by the NCC-WCH based on results reported in the study

b It is not clear whether all of the children (or a random selection of the children) received a test to confirm serious illness

^c It is not clear whether all the children received the same test to confirm serious illness

^d It is not clear whether the clinical symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

e It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the clinical symptoms and signs

^f It is not clear whether the period of time between assessing the symptoms and signs and performing the test to confirm serious illness was short enough

⁹ Not enough detail was provided regarding the test to confirm serious illness to allow it to be performed by another clinician

h It is not clear whether the same clinical data that was available when the test results were interpreted would be available in practice

¹ Included children 1 to 36 months with acute fever without apparent source. The study was undertaken in two hospitals in the Netherlands.

Table 15.38 GRADE profile for evaluation of bulging abdomen

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|-----------------------------------|---------------|---------------|--------------|------------------------------|
| Bulging a | bdomen | | | | | | | | | | | | | |
| For detect | ing serious b | acterial infection | on | | | | | | | | | | | |
| 1 (Bleeker, 2001) | 231 | 6 (2 to 9) ^a | 88 (80 to 96) ^a | 59 (35 to 82) | 24 (18 to 30) | 0.5 (0.2 to 1.2) ^a | 1.1 (1.0 to 1.2) ^a | Very low | Retrosp ective | Very seriou s b. c. d. e | NA | No serious | Serious f | Yes ^{g,} h, i, j |

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^c It is not clear whether all of the children received the same test to confirm serious illness

^d It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

e It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^f The difference between the upper and lower confidence intervals is 40% or greater for 1,2, or 3 of sensitivity, specificity, PPV and NPV

⁹ It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

h Not enough detail regarding the test to confirm serious illness was provided to allow another clinician to replicate the results

¹ It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

¹ Included children 1 to 36 months with acute fever without apparent source. The study was undertaken in two hospitals in the Netherlands.

Table I5.39 GRADE profile for evaluation of paresis or paralysis

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality <mark></mark> | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|-----------------------|-------------------|---|---------------|--------------|--------------|-------------------------|
| Paresis or | paralysis | | | | | | | | | | | | | |
| For detecti | ing meningiti | is | | | | | | | | | | | | |
| 1 (Offringa, 1992) | 92 | 30 (12 to 49) ^a | 91 (85 to 98) ^a | 54 (27 to 81) | 80 (71 to 89) | 3.5 (1.3 to 9.4) ^a | 0.8 (0.6 to 1.0) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e, f, g | NA | Serious h | Serious i | Yes ^{j,} |

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether the spectrum of included participants in the study was representative of the children that would be assessed in practice

^c The selection criteria used to recruit children into the study were not clearly described

^d It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^e It is not clear whether all of the children received the same test to confirm serious illness

f It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

⁹ It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^h Included children up to the age of 6

¹The difference between the upper and lower confidence intervals is 40% or greater for 1,2, or 3 of sensitivity, specificity, PPV and NPV

it is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

k It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

Included children 3 months to 6 years with first episode of seizure associated with fever (fever not defined). The study was undertaken in two hospitals in the Netherlands.

Table I5.40 GRADE profile for evaluation of abnormal neurological findings

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|---|---------------|---------------|---------------|-------------------------|
| | ing meningit | _ | | | | | | | | | | | | |
| 1 (Joffe, 1983) | 241 | 92 (78 to 100) ^a | 84 (79 to 89) ^a | 25 (13 to 37) | 99 (98 to 100) ^a | 5.8 (4.2 to 8.2) ^a | 0.1 (0.0 to 0.6) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e, f | NA | Serious g | No serious | Yes h, |
| 1 (Offringa, 1992) | 92 | 64 (44 to 84) ^a | 91 (88 to 94) ^a | 35 (20 to 50) | 97 (95 to 99) | 7.0 (4.3 to 11.4) ^a | 0.4 (0.2 to 0.7) ^a | Very low | Retrosp ective | Very seriou s b, c, d, e, f, k | NA | Serious g | Serious | Yes h, |
| Neurologi | cal deficit | | | | | | | | | | | | | |
| For detecti | ing meningit | is | | | | | | | | | | | | |
| 1 (Batra, 2011) | 199 | 80 (45 to 100) ^a | 99 (98 to 100) a | 80 (45 to 100) ^a | 99 (98 to 100) ^a | 155.2 (20.9 to 1150.8) ^a | 0.2 (0.0 to 1.2) ^a | Very low | Retrosp ective | Very seriou s c, d, e, f, n | NA | No serious | Serious I | Yes h, |

^a Calculated by the NCC-WCH based on data reported in the study

b It is not clear whether the spectrum of included participants in the study was representative of the children that would be assessed in practice

^c It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^d It is not clear whether all of the children received the same test to confirm serious illness

e It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

f It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^g Included children up to the age of 6

h It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

ilt is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

Table I5.41 GRADE profile for evaluation of impression of tone

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|-------------------------------------|---------------|---------------|-------------|-------------------------|
| Impressio | n of tone | | | | | | | | | | | | | |
| For detecti | ing bacterae | emia | | | | | | | | | | | | |
| 1 (Crain, 1982) | 175 | NR ^a | NR ^a | NR ^a | NR ^a | NR ^a | NR ^a | Low | Prospe ctive | Very seriou s ^{b, c} | NA | No serious | NA | Yes d, e, f |

^a Text in the paper stated that impression of tone is not significantly associated with bacteraemia

¹ Included children between 6 months and 6 years. Fever was not defined. The study was undertaken in two hospitals in the USA.

^k The selection criteria used to recruit children into the study were not clearly described

¹ The difference between the highest and lowest confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and/or negative predictive value are greater than 40%

m Included children 3 months to 6 years with first episode of seizure associated with fever (fever not defined). The study was undertaken in two hospitals in the Netherlands.

ⁿ It is not clear whether the test to confirm serious illness was independent of the child's symptoms and signs

o Included children aged 6-18 months presenting with a first episode of seizure with fever. Fever not defined. The study was undertaken in the paediatric casualty ward of a hospital in India.

b It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^c The selection criteria used to recruit children into the study were not clearly described

^d It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

e It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

f Included children 8 weeks old and younger. Included rectal temperatures of 38°C and greater. The study was undertaken in a paediatric emergency room in the USA.

Table I5.42 GRADE profile for evaluation of tenderness on examination

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|--|---------------|---------------|---------------|-------------------------|
| Tenderne | ss on exam | ination | | | | | | | | | | | | |
| For detect | ing urinary tı | act infection | | | | | | | | | | | | |
| 1 (Shaw, 1998) | 2411 | 5 (0 to 10) ^a | 99 (98 to 99) ^a | 13 (1 to 26) ^a | 97 (96 to 98) | 4.5 (1.6 to 12.5) ^a | 1.0 (0.9 to 1.0) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes ^{e,} |

^a Calculated by the NCC-WCH based on data reported in the study

b It is not clear whether the spectrum of included participants in the study was representative of the children that would be assessed in practice

^c It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

d It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^e Not enough detail was provided to allow the child's symptom or sign to be assessed by a different clinician

f It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

g Included boys younger than 1 year and girls younger than 2 years. Included children with a temperature of 38.3°C or higher. It took place in an emergency department in the USA

Table I5.43 GRADE profile for evaluation of urinary symptoms

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|-------------------------------------|---------------|---------------|---------------|-------------------------|
| Urinary sy | mptoms | | | | | | | | | | | | | |
| For detecti | ing serious l | pacterial infection | on | | | | | | | | | | | |
| 1 (Craig, 2010) | 15781 | 5 (4 to 6) ^a | 98 (98 to 98) ^a | 17 (13 to 21) | 93 (93 to 93) | 2.7 (2.0 to 3.6) ^a | 1.0 (1.0 to 1.0) ^a | Low | Prospe ctive | Very seriou s ^{b, c} | NA | No serious | No serious | Yes d, e, f |
| 1 (Nijman, 2011) | 1255 | 8 (4 to 13) ^a | 99 (98 to 99) ^a | 41 (22 to 59) | 90 (89 to 92) | 5.9 (2.8 to 12.4) ^a | 0.9 (0.9 to 1.0) ^a | | Prospe ctive | Very seriou s c, g, h, i | NA | Serious j | No serious | Yes ^{e,} |

^a Calculated by the NCC-WCH based on data reported in the study

^b It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^c It is not clear whether all of the children received the same test to confirm serious illness

d It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

e It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

function Included children were under 5 years. Children were included if they had an axillary temperature or parental report of a temperature of 38°C or higher. The study was conducted in the emergency department of a hospital in Australia. Results are reported per illness rather than per child – some children were included more than once for different illnesses.

⁹ It is not clear if the test to confirm serious illness was independent of the child's symptoms and signs

^h It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the test to confirm serious illness

ilt is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

¹Included children up to the age of 16 years old

k Included children aged 1 month to 16 years. Included children with a temperature of 38.5°C or higher, a recent history of fever, or fever as a reason for referral. Undertaken in the emergency department of a children's hospital in the Netherlands.

Table I5.44 GRADE profile for evaluation of abnormal ear, nose and throat signs

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|-------------------------------------|---------------|---------------|---------------|-------------------------|
| Abnormal | ear, nose a | and throat sign | ıs | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Craig, 2010) | 15781 | 42 (39 to 45) ^a | 45 (44 to 46) ^a | 6 (5 to 6) ^a | 91 (90 to 92) | 0.8 (0.7 to 0.8) ^a | 1.3 (1.2 to 1.4) ^a | Low | Prospe ctive | Very seriou s ^{b, c} | NA | No serious | No serious | Yes d, e, f |
| Ear proble | ems | | | | | | | | | | | | | |
| Serious ba | ncterial infec | tion | | | | | | | | | | | | |
| 1 (Nijman, 2011) | 1255 | 4 (1 to 7) ^a | 99 (98 to 99) ^a | 17 (3 to 31) ^a | 94 (93 to 95) a | 3.2 (1.2 to 8.3) ^a | 1.0 (0.9 to 1.0) ^a | Very low | Prospe ctive | Very seriou s c, g, h, i | NA | Serious j | No serious | Yes ^{e,} |

^a Calculated by the NCC-WCH based on data reported in the study

b It is not clear whether all of the children (or a random sample of the children) received the test to confirm serious illness

^c It is not clear whether all of the children received the same test to confirm serious illness

d It is not clear whether the period of time between assessing the child's symptoms and signs and administering the test to confirm serious illness was short enough

e It is not clear whether the same clinical data were available during the study as would be available when the test is used in practice

function function for the function of a temperature ≥ 38°C. The study was conducted in the emergency department of a hospital in Australia. Results are reported per illness rather than per child – some children were included more than once for different illnesses.

⁹ It is not clear whether the test to confirm serious illness was independent of the child's symptoms and signs

h It is not clear whether the child's symptoms and signs were interpreted without knowledge of the results of the tests to confirm serious illness

ilt is not clear whether the results of the tests to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

included children aged up to 16 years

k Included children aged one month to 16 years. Included those with a temperature of 38.5°C or higher, recent high fever or fever as a reason for referral. Undertake in the emergency department of a children's hospital in the Netherlands.

Table I5.45 GRADE profile for evaluation of rigor and/or chills

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------------|--------------------------|--|--|---|--|--|--|----------|-----------------|--|---------------|--------------|---------------|-------------------------|
| Rigors | | | | | | | | | | | | | | |
| For detect | ing confirme | d or presumed | bacterial illness | | | | | | | | | | | |
| 1 (Tal, 1997) | 434 | 28 (23 to 34) ^a | 83 (78 to 89) ^a | 67 (78 to 95) | 49 (44 to 55) | 1.7 (1.2 to 2.5) ^a | 0.9 (0.8 to 1.0) ^a | Very low | Prospe ctive | Very seriou s ^{b, c, d} | NA | Serious e | No serious | Yes f, |

NA Not applicable

^a Calculated by the NCC-WCH based on results reported in the study

^b It is not clear whether all children received the same test to confirm serious infection

^c It is not clear whether the symptoms and signs were interpreted without knowledge of the results of the test for detecting serious illness

^d It is not clear whether the results of the test for serious illness were interpreted without knowledge of the symptoms and signs

^e Included children aged up to 16 years old

function Included children were aged 6 months to 16 years old. Children were included if they had a rectal temperature greater than or equal to 38.5°C and were admitted to hospital. The study was conducted in a hospital in Israel.

g It is not clear whether the same clinical data were available when the results of the test for serious illness were interpreted as would be available in practice

Table I5.46 GRADE profile for evaluation of Yale Observation Scale

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|--|---------------|---------------|---------------|----------------------|
| Score of 3 | or 4 | | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (McCarth y, 1981) | 312 | 67 (45 to 88) ^a | 79 (74 to 84) ^a | 19 (9 to 29) ^a | 97 (95 to 99) | 3.2 (2.1 to 4.8) ^a | 0.4 (0.2 to 0.8) ^a | Very low | Retrosp ective | Very seriou s ^{b, c, d} | NA | No serious | No serious | Yes ^{e,} |
| 1 (McCarth y, 1981) | 312 | 56 (33 to 79) ^a | 89 (85 to 93) ^a | 27 (13 to 41) | 96 (94 to 99) | 5.0 (2.9 to 8.7) ^a | 0.5 (0.3 to 0.8) ^a | Very low | Retrosp ective | Very seriou s ^{b, c, d} | NA | No serious | Serious | Yes ^{e,} |
| 1 (McCarth y, 1981) | 312 | 72 (52 to 93) ^a | 79 (74 to 84) ^a | 20 (10 to 30) | 97 (95 to 100) ^a | 3.5 (2.4 to 5.0) ^a | 0.4 (0.2 to 0.7) ^a | Very low | Retrosp ective | Very seriou s ^{b, c, d} | NA | No serious | Serious | Yes ^{e,} |
| Score of 4 | or 5 | | | | | | | | - | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Haddon, 1999) | 534 | 6 (0 to 16) ^a | 95 (92 to 97) ^a | 5 (0 to 15) ^a | 95 (93 to 97) | 1.0 (0.1 to 7.4) ^a | 1.0 (0.9 to 1.1) ^a | Low | Prospe ctive | Very seriou s ^{c, d} | NA | No serious | No serious | Ye s f, |
| Score of 5 | , 6, or 7 | | | | | | | | | | | | | |
| For detecti | ing bacterial | illness or pneu | monia | | | | | | | | | | | |
| 1 (McCarth y, 1980) | 219 | 60 (35 to 85) ^a | 76 (70 to 82) ^a | 16 (6 to 25) ^a | 96 (93 to 99) a | 2.5 (1.5 to 4.0) ^a | 0.5 (0.3 to 1.0) ^a | Very low | Prospe ctive | Very seriou s b, c, d, e | NA | No serious | Serious h | Yes ^{f, j} |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|--|---------------|---------------|---------------|-------------------------|
| 1 (McCarth y, 1980) | 219 | 27 (4 to 49) | 94 (91 to 97) ^a | 25 (4 to 46) ^a | 95 (91 to 98) | 4.5 (1.7 to 12.4) ^a | 0.8 (0.6 to 1.1) ^a | Very low | Prospe ctive | Very seriou s b, c, d, e | NA | No serious | Serious h | Yes ^{f, j} |
| Score > 6 | | | | | | | | | | | | | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Teach, 1995) | 6680 | 29 (22 to 35) ^m | 83 (82 to 83) ^m | 5 (3 to 6) ^m | 97 (97 to 98) | 1.6 (1.3 to 2.1) ^a | 0.9 (0.8 to 0.9) ^a | Very low | Retrosp ective | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes f, I |
| Score > 8 | | | | | | | | | 1 | | | 1 | | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Teach, 1995) | 6680 | 17 (11 to 22) ^m | 92 (91. to 93) | 6 (4 to 8) ^m | 97 (97 to 98) | 2.0 (1.5 to 2.8) ^a | 0.9 (0.9 to 1.0) ^a | Very low | Retrosp ective | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes f, I |
| 1 (Bang, 2009) | 219 | 97 (79 to 99) | 66 (55 to 72) | 52 (43 to 62) | 98 (93 to 100) | 2.8 (2.2 to 3.5) | 0.1 (0.0 to 0.2) | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes f, |
| Score > 9 | | | | | | | | | 1 | | | 1 | | |
| For detecti | ing serious k | pacterial infection | on | | | | | | | | | | | |
| 1 (Thayyil, 2005) | 72 | 13 (0 to 35) | 33 (21 to 44) ^a | 2 (0 to 7) ^a | 75 (59 to 91) | 0.2 (0.0 to 1.2) ^a | 2.7 (1.7 to 4.1) ^a | Low | Prospe ctive | Very seriou s ^{b, d, k} | NA | No serious | No serious | Yes f, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|--|---------------|---------------|---------------|----------------------|
| Score of > | 10 | | | | | | | | | | | | | |
| For detecti | ing serious ii | llness (including | g aseptic meningit | is) | | | | | | | | | | |
| 1 (Baker, 1990) | 126 | 46 (30 to 62) ^m | 80 (71 to 88) ^m | 49 (32 to 65) | 78 (70 to 87) | 2.3 (1.3 to 3.9) ^a | 0.7 (0.5 to 0.9) ^a | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes ^{f,} |
| For detecti | ing serious b | acterial infectio | on | | | | | | | | | | | |
| 1 (Galetto- Lacour, 2003) | 110 | 23 (5 to 54) | 82 (67 to 92) | 32 (12 to 51) | 75 (66 to 84) | 1.3 (0.6 to 2.9) ^m | 0.9 (0.8 to 1.2) ^m | Very low | Prospe ctive | Very seriou s ^{b, d, k} | NA | No serious | Serious h | Yes ^{f,} |
| 1 (Andreol a, 2007) | 408 | 38 (28 to 48) ^m | 68 (63 to 73) ^m | 26 (19 to 34) | 79 (74 to 83) | 1.2 (0.9 to 1.6) ^m | 0.9 (0.8 to 1.1) ^m | Low | Prospe ctive | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes f, |
| For detecti | ing bacterae | mia | | | | | | | | | | l | l | |
| 1 (Teach, 1995) | 6680 | 5 (2 to 8) ^m | 97 (96 to 97) ^m | 5 (2 to 7) ^m | 97 (97 to 98) | 1.6 (0.9 to 3.0) ^a | 1.0 (0.9 to 1.0) ^a | Very low | Retrosp ective | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes ^{f, I} |
| 1 (Bang, 2009) | 219 | 88 (71 to 93) | 84 (73 to 87) | 68 (56 to 78) | 95 (89 to 98) | 5.4 (3.7 to 7.9) | 0.1 (0.1 to 0.3) | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes f, |
| For detecti | ing bacterial | disease | | | | | | | | | | | | |
| 1 (Baker, 1990) | 126 | 33 (7 to 60) | 73 (65 to 81) ^m | 11 (1 to 22) ^m | 91 (85 to 97) | 1.2 (0.5 to 2.9) ^a | 0.9 (0.6 to 1.4) ^a | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes f, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|----------|-------------------|--|---------------|---------------|---------------|-------------------------|
| For detecti | ing urinary ti | ract infection | | | | | | | | | | | | |
| 1 (Zorc, 1995) | 1025 | 4 (0 to 9) ^a | 93 (91 to 94) ^a | 6 (0 to 11) ^a | 91 (89 to 93) | 0.6 (0.2 to 1.6) ^a | 1.0 (1.0 to 1.1) ^a | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes f, |
| Score of 1 | 0 to 16 | | | | | | | | | | | | | |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Andreol a, 2007) | 408 | 43 (33 to 53) ^a | 74 (69 to 79) ^a | 33 (24 to 41) | 81 (77 to 86) | 1.6 (1.2 to 2.2) a | 0.8 (0.6 to 0.9) ^a | Low | Prospe ctive | Very seriou s c, d, k | NA | No serious | No serious | Yes ^{f,} |
| Score of 1 | 1 to 15 | | | | | | | ı | | | | | L | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (McCarth y, 1982) | 312 | 31 (16 to 46) ^a | 84 (79 to 89) ^a | 26 (13 to 39) | 87 (82 to 2) ^a | 1.9 (1.1 to 3.4) ^a | 0.8 (0.7 to 1.0) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d,} k | NA | No serious | No serious | Yes ^{f, j} |
| Score > 12 | 2 | | | | | L | L | | | | | <u> </u> | L | |
| For detecti | ing bacterae | mia | | | | | | | | | | | | |
| 1 (Teach, 1995) | 6680 | 1 (0 to 2) ^m | 99 (99 to 99) ^m | 1 (0 to 4) ^m | 97. (97 to 97) | 0.4 (0.1 to 3.2) ^a | 1.0 (1.0 to 1.0) ^a | Very low | Retrosp ective | Very seriou s ^{c, d, k} | NA | No serious | No serious | Yes f, I |
| 1 (Bang, 2009) | 219 | 48 (27 to 56) | 91 (67 to 90) | 68 (52 to 82) | 82 (75 to 87) | 5.5 (3.0 to 9.8) | 0.6 (0.4 to 0.7) | Moderate | Prospe ctive | Serio us ^{d, k} | NA | No serious | No serious | Yes f, |

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------|--------------------------|--|--|---|--|--|--|---------|-----------------|---|---------------|---------------|---------------|-------------------------|
| Score of ≥ | <u>.</u> 16 | | | | | | | | | | | | | |
| For detecti | ing serious i | llness | | | | | | | | | | | | |
| 1 (McCarth y, 1982) | 312 | 33 (18 to 49) ^a | 99 (98 to 100) a | 92 (78 to 100) ^a | 89 (85 to 93) a | 64.7 (8.7 to 482.0) ^a | 0.7 (0.5 to 0.8) ^a | Low | Prospe ctive | Very seriou s ^{b, c, d,} | NA | No serious | No serious | Yes ^{f, j} |
| For detecti | ing serious b | pacterial infection | on | | | | | | | | | | | |
| 1 (Andreol a, 2007) | 408 | 9 (3 to 14) ^a | 98 (96 to 99) ^a | 53 (28 to 79) | 78 (74 to 82) | 3.8 (1.4 to 10.3) ^a | 0.9 (0.9 to 1.0) ^a | Low | Prospe ctive | Very seriou s c, d, k | NA | No serious | No serious | Yes ^{f,} |

NA Not applicable

^a Calculated by the NCC-WCH from results reported in the study

^b Not all children received the same test to confirm serious illness

^c It is not clear whether the test to confirm serious illness was independent of the child's signs and symptoms

d It is not clear whether the results of the test to confirm serious illness were interpreted without knowledge of the child's symptoms and signs

^e Not enough detail was provided to allow the test to confirm serious illness to be replicated by another healthcare professional

f It is not clear if the same data were available when interpreting the test results as would be available in practice

⁹ Included children aged 24 months or less. Included temperatures of 38.3°C or higher. Undertaken in an emergency room of a hospital in the USA.

h The difference between the upper and lower confidence intervals for one, two or three of sensitivity, specificity, positive predictive value and negative predictive value is 40% or greater

included children aged 3 to 36 months. Included temperatures of 39°C of higher by tympanic thermometry. Undertaken in an emergency department in Australia.

¹ Included children aged 24 months or younger. Included temperatures of 38.3°C of higher. Undertaken in the emergency room of a hospital in the USA.

k It is not clear whether the child's signs and symptoms were interpreted without knowledge of the results of the test used to confirm serious illness

Included children aged 90 days to 36 months. Included temperatures of 39°C or higher. Undertaken at a hospital in the USA.

^m Confidence intervals calculated by the NCC-WCH from data reported in the study

ⁿ Included children aged 3 to 36 months. Included temperature greater than 38°C.Undertaken in a paediatric ward of a hospital in India.

o Included children aged 1 to 36 months. Included temperatures higher than 39°C. Undertaken in a hospital in the UK.

P Included children aged 29 to 56 days. Included temperatures greater than 38.2°C.Undertaken at the emergency department of a children's hospital in the USA.

^q Included children aged 7 days to 36 months. Included temperatures of 38°C or higher. Undertaken at a referral centre in Switzerland.

Table I5.47 GRADE profile for comparison of Yale Observation Scores

| Number of | Duration of feve | Duration of fever | | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|---------------------|------------------------|---------------------------|----------|---------|-------------|-------------|---------------|--------------|-------------|------------------|
| studies | With SBI (Mean, SD) | Without SBI (Mean, SD) | P value | | | | | | | considerations |
| Yale Observa | tion Score | | | | | | | | | |
| For detecting | serious bacterial ir | nfection | | | | | | | | |
| 1 (Hsiao, 2006) | 9.4 (SD 4.6) | 8.1 (SD 3.6) | P < 0.05 | High | Prospective | No serious | NA | No serious | NA | Yes ^a |
| For detecting | bacteraemia | | | | | | | | | |
| 1 (Haddon, 1999) | 7.0 (SD 1.5) | 7.4 (SD 1.9) | P = 0.45 | High | Prospective | No serious | NA | No serious | NA | Yes ^b |

NA Not applicable

^r Included children aged less than 3 years. Included those with a fever, although fever was not defined. Undertaken in an emergency department in Italy.

^s Included children aged 60 days or younger. Included temperatures of 38°C or higher. Undertaken in 8 paediatric emergency departments in the USA.

a Includes children aged 2 to 6 months old. Includes those with a rectal temperature higher than 37.9°C. Undertaken in the emergency department of a hospital in the USA.

^b Includes children aged 90 days to 36 months. Includes those with temperatures of 39°C of higher. Undertaken at a hospital in the USA.

Chapter 5

Heart rate

Review question

The predictive value of heart rate, including:

- how heart rate changes with temperature?
- whether heart rate outside the normal range detects serious illness?
- whether heart rate and temperature outside normal range detects serious illness?

Table I5.51 Summary of study quality for change in heart rate with change in body temperature

| Number of studies | Number of children | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------------|--|----------|---------------------|----------------------------|---------------|----------------------|-------------|----------------------|
| Change in heart rate (with inc | reasing body temperature) | | | | | | | |
| 1 study (Davies 2009) | 21,033 ^a | Very low | Observational study | Very serious b, | None | Serious ^d | None | None |
| Change in heart rate (with inc | reasing body temperature) ^e | | | L | | | | |
| 1 study (Thompson 2009) | 1,589 ^f | Low | Observational study | Serious i | None | Serious d | None | None |
| Change in heart rate (with inc | reasing body temperature) | | | | l | | | 1 |
| 1 study (Hanna 2004) | 490 ⁹ | Very low | Observational study | Very serious ^{h,} | None | None | None | None |

^a The data were analysed using a quantile regression and a statistical model developed a best fit equation:

Expected parameter value = (Temperature (°C) \times **a**)+ (Age (months) \times **b**)+ (Age² (months²) \times **c**)+ constant

The temperature multiplier \mathbf{a} , has a mean increase of 10.52 beat per minute (bpm) through the centile, resulting in a heart rate increase of approximately 10 bpm with each 1°C increment in temperature

^b Retrospective study

^c Measurement bias likely due to variation in pulse and temperature assessments

^d This study includes children older than 5 years of age

Table 15.53 Evidence profile for the distribution of age specific heart rate data by centile group for 1,360 children presenting at a paediatric emergency department with suspected serious bacterial infection for the detection of serious illness

| Number of studies | Number of childr | en | Effect | | | | | > | | | ns |
|------------------------------|--------------------|-------------------------------|--|--|-------------|-----------------------------------|----------------------|---------------|----------------------|----------------------|-------------------------|
| | Total | Children with SBI | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Detection of serious | illness using hear | t rate above 97 th | centile | | | | | | | | |
| 1 study (Brent et al., 2011) | 28 | 1 | OR 1.51 (95% CI 0.19 to 12.0) | - | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |
| Detection of serious | illness using hear | t rate above 90 th | centile | | | | | | | | |
| 1 study (Brent et al., 2011) | 91 | 10 | OR 5.04 (95% CI 2.14 to 11.9) | - | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Detection of serious | illness using hear | t rate above 75 th | centile | | | | | l | | | |
| 1 study (Brent et al., 2011) | 199 | 12 | OR 2.62 (95% CI 1.19 to 5.79) | - | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Detection of serious | illness using hear | t rate above 50 th | centile | | | | | | | | |
| 1 study (Brent et al., 2011) | 324 | 14 | OR 1.85 (95% CI 0.87 to 3.93) | - | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |

^e Centiles charts of heart rate plotted against temperature in febrile children were produced. The incremental increases of heart rate for each increment in 1 °C of temperature are showed in appendices x.x table x. Heart rate was negatively correlated with age (r = -0.62) and positively correlated with temperature (r = 0.49). This study showed that, in the study population, the heart rate increases by 9.9 to14.1 bpm with each 1°C increment in temperature.

[†] Children were not truly representative of a primary care population due to problems with recruiting. Recruitment was not systematic, the proportion of children consulting out-of-hours care was high, and the researcher set the minimum recruitment targets for each age–temperature combination.

⁹ Mean increase in pulse rate per 1°C increase in temperature was calculated using linear regression analysis of the relation between pulse rate and temperature. The authors report that for every 1°C rise in body temperature, the resting heart rate rose by 9.6 bpm.

^h Restricted data on the clinical status of the patients from which to determine the exclusion criteria.

¹ Impossible to control the baseline variation between children when evaluating the effect of temperature on pulse rate.

| Number of studies | Number of childr | en | Effect | | | | | <u>~</u> | | | ns |
|------------------------------|--------------------|----------------------|--|--|---------|-----------------------------------|----------------------|--------------|----------------------|-------------|------------------------|
| | Total | Children with SBI | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistenc | Indirectness | Imprecision | Other consideration |
| Detection of serious | illness using hear | t rate below equa | al 50 th centile | | | | | | | | |
| 1 study (Brent et al., 2011) | 586 | 14 | OR 1.00 (Ref) | - | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Tachycardia | | | | | | | | | | | |
| 1 study (Brent et al., 2011) | 514 | 34 | OR 2.90 (95% CI 1.60 to 5.26) | - | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |

OR odds ratios; SBI serious bacterial infection.

Table I5.54 Evidence profile for the Sensitivity, specificity, positive and negative likelihood ratios for significant bacterial infection of cut-offs defined by pulse centiles in 1,360 children presenting at a paediatric emergency department with suspected serious bacterial infection for the detection of serious illness

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------|--------------------|--|--|---|--|---------|--|----------------------|---------------|----------------------|-------------|-------------------------|
| Detection of ser | ious illness us | ing heart rate ab | ove 97 th centile | | | | | | | | | |
| 1 (Brent 2011) | 1360 | 2.0 (0.04 to 10.4) | 97.7 (96.7 to 98.5) | 2.7 (2.2 to 3.4) | 0.96 (0.76 to 1.2) | Low | Observational cohort study (Retrospective) | Serious ^a | NA | Serious ^b | None | None |

^a No definition of SBI

^bThis study includes children older than 5 years of age

^{°95%} confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both no effect and appreciable harm

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------|--------------------|--|--|---|--|---------|--|----------------------|---------------|----------------------|-------------|-------------------------|
| Detection of ser | ious illness us | sing heart rate ab | ove 90 th centile | | | | | | | | | |
| 1 (Brent 2011) | 1360 | 21.6 (11.3 to 35.3) | 90.8 (89.0 to 92.4) | 2.4 (1.6 to 3.7) | 0.86 (0.57 to 1.3) | Low | Observational cohort study (Retrospective) | Serious ^a | NA | Serious ^b | None | None |
| Detection of ser | ious illness us | sing heart rate ab | ove 75 th centile | | | | | | | | | |
| 1 (Brent 2011) | 1360 | 45.1 (31.1 to 59.7) | 75.7 (73.1 to 78.1) | 1.7 (0.84 to 3.3) | 0.78 (0.40 to 1.5) | Low | Observational cohort study (Retrospective) | Serious ^a | NA | Serious ^b | None | None |
| Detection of ser | ious illness us | sing heart rate ab | ove 50 th centile | | | | | | | | | |
| 1 (Brent 2011) | 1360 | 72.5 (58.3 to 84.1) | 48.6 (45.7 to 51.5) | 1.3 (0.58 to 3.1) | 0.64 (0.28 to 1.5) | Low | Observational cohort study (Retrospective) | Serious ^a | NA | Serious ^b | None | None |
| Tachycardia | | • | | | • | L | | L | 1 | 1 | | 1 |
| 1 study (Brent et al., 2011) | 1360 | 66.7 (52.1 to 79.2) | 59.2 (56.3 to 62.0) | 1.5 (0.67 to 3.4) | 0.65 (0.29 to 1.46) | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |

^a Lack of clear definition of SBI

^bThis study includes children older than 5 years of age

Table I5.55 Evidence profile for the sensitivity of cut-offs defined by heart rate centiles for detecting children with meningococcal septicaemia of various degrees of severity in 325 children presenting to hospital with meningitis

| Number of studies | Total number of children | Sensitivity (95% confidence interval) | (95% confidence interval) | | | ons | stency | iness | sion | Other considerations |
|---------------------------------|--------------------------|---|---|---------|-----------------------------------|------------|---------------|---------------------------------|-------------|-------------------------|
| | | All children with meningococcal septicaemia | Children with severe disease on admission | Quality | Design | Limitation | Inconsistency | Indirectness | Imprecision | Other |
| Detection of se | rious illness using he | art rate above 97 th centile | | | 1 | 1 | 1 | | | |
| 1 study (Brent et al., 2011) | 325 | 11.0 (7.7 to 15.1) | 17.9 (10.2 to 28.3) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a, b} | None | None |
| Detection of se | rious illness using he | art above 90 th centile | | | | | 1 | | | |
| 1 study (Brent et al., 2011) | 325 | 27.8 (22.8 to 33.2) | 38.5 (27.7 to 50.2) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a, b} | None | None |
| Detection of se | rious illness using he | art rate above 75 th centile | | | | | 1 | | | |
| 1 study (Brent et al., 2011) | 325 | 49. (43.4 to 55.0) | 61.5 (49.8 to 72.3) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a, b} | None | None |
| Detection of se | rious illness using he | art rate above 50 th centile | | | | 1 | | | l | |
| 1 study (Brent et al., 2011) | 325 | 73.9 (68.5 to 78.8) | 84.6 (74.7 to 91.8) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a, b} | None | None |
| Detection of se | rious illness using he | art rate below 50 th centile | | | | | • | | | |
| 1 study (Brent et al., 2011) | 325 | 26.1 (21.2 to 31.5) | 15.4 (8.2 to 25.3) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a, b} | None | None |

^a The study includes only children with meningococcal disease. Therefore, the researchers were unable to assess the specificity of centile cut-offs in identifying children presenting with meningococcal disease.

^bThis study includes children older than 5 years of age

Table I5.56 GRADE findings for evaluation of elevated heart rate

| Number of | Number of children | Number of children | | Effect | | | | cy. | | | ns |
|-------------------|--------------------|-----------------------------------|---|--|---------|-------------|----------------------|--------------|----------------------|-------------|-------------------------|
| | Total | Children with SBI | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistenc | Indirectness | Imprecision | Other considerations |
| Tachycardia | | | | | | | | | | | |
| Thompson, 2009 | 691 | 191 of 307 compared to 160 of 384 | 2.3 (1.7 to 3.1) | - | Low | Prospective | Serious ^a | NA | Serious ^b | None | No |

^a All the children did not have the same tests

Table I5.57 GRADE findings for evaluation of elevated heart rate

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-------------------|--------------------|--|--|---|--|--|--|---------|---------------------|----------------------|---------------|----------------------|-------------|-------------------------|
| Elevated heart | rate" | | | | | | | | | | | | | |
| For detecting pn | eumonia, urinary | tract infection, | , or bacteraemi | ia | | | | | | | | | | |
| 1 (Craig, 2010) | 12,807 | 58 (55 to 61) | 58 (57 to 59) | 10 (9 to 10) | 95 (94 to 95) | 1.4 (1.3 to 1.5) | 0.7 (0.7 to 0.8) | Low | Pros pecti ve | Serious b, c, d | NA | Serious [†] | None | Yes e, g |
| Thompson, 2009 | 691 | 62 (57 to 68) | 58 (53 to 63) | NR | NR | 1.5 (1.3 to 1.7) | 0.7 (0.6 to 0.8) | Low | Pros pecti ve | Serious ^c | NA | Serious ^f | None | No |

NA Not applicable, NR Not reported

^b Study included children aged up to 16 years.

^a Calculated by the NCC-WCH based on results reported in the study

Table I5.59 Evidence profile for the distribution of age specific heart rate temperature data by centile group for 1,360 children presenting at a paediatric emergency department with suspected serious bacterial infection for the detection of serious illness

| Number of | Number of childs | ren | Effect | | | | | | | | |
|------------------------------|---------------------|----------------------|--|--|-------------|-----------------------------------|----------------------|---------------|----------------------|----------------------|-------------------------|
| Detection of serious i | Total | Children with SBI | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Detection of serio | us illness using he | art rate and temper | erature above 97 th cen | tile | | | | | | | |
| 1 study (Brent et al., 2011) | 135 | 7 | OR 1.84 (95% CI 0.72 to 4.71) | - | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |
| Detection of serio | us illness using he | art rate and tempe | erature above 90 th cen | tile | | | | | | | |
| 1 study (Brent et al., 2011) | 110 | 4 | OR 1.19 (95% CI 0.38 to 3.73) | - | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |
| Detection of serio | us illness using he | art rate and temper | erature above 75 th cen | tile | | | | | | | |
| 1 study (Brent et al., 2011) | 227 | 11 | OR 1.67 (95% CI 0.73 to 3.79) | - | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |

b It is not clear whether all of the children or a random sample of the children were given a test to confirm serious illness

^c It is not clear whether all children received the same test to confirm serious illness

^d It is not clear whether the test to confirm serious illness was independent of the clinical signs and symptoms

e It is not clear whether the clinical data available when the test results were interpreted are what would be available when the test is used in practice

Included children aged under 5 years. Included those with one or more of the following elements: a measured auxiliary temperature of 38C or higher; parental report of a temperature of 38C or higher measured at home within the previous 24 hours; a parental report that the child 'felt hot' in the previous 24 hours; or a presenting problem related to fever as determined by a triage nurse. Undertaken in a children's emergency department of a hospital in Australia.

⁹ Not enough detail was provided regarding the measurement of the sign or symptom to allow another healthcare professional to make the same diagnosis

h Based on figures: Age (years) and recommended upper limit of normal for FEVER study (source): 0 = 160 (WHO); 1 = 150 (WHO); 2 = 150 (WHO); 3 = 140 (WHO); 4 = 130 (Wallis); 5 = 120 (Wallis). From: 1) Wallis et al, Arch. Dis. Child. 2005;90;1117-1121. 2) WHO. Pocket Book of Hospital Care for Children: Guidelines for the management of common illnesses with limited resources. 2005, page 232

| Number of | Number of child | ren | Effect | | | | | | | | " |
|------------------------------|---------------------|----------------------|--|--|-------------|-----------------------------------|----------------------|---------------|----------------------|----------------------|-------------------------|
| | Total | Children with SBI | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Detection of serio | us illness using he | eart rate and temper | erature above 50 th cen | tile | • | | | • | | | |
| 1 study (Brent et al., 2011) | 316 | 16 | OR 1.75 (95% CI 0.83 to 3.69) | | Very low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | Serious ^c | None |
| Detection of serio | us illness using he | eart rate and tempe | erature below equal 50 |) th centile | | | | | | 1 | |
| 1 study (Brent et al., 2011) | 439 | 13 | OR 1.00 (NR) | | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |

OR odds ratios; NR not reported; SBI serious bacterial infection.

Table I5.60 Evidence profile reporting the sensitivity, specificity, positive and negative likelihood ratio for significant bacterial infection of cut-offs defined by heart rate and body temperature for 1,360 children presenting at a paediatric emergency department with suspected serious bacterial infection

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------------|--------------------|--|--|---|---|---------|-----------------------------------|----------------------|---------------|----------------------|-------------|-------------------------|
| Detection of | serious illne | ss using heart ra | te and temperatu | ire above 97 th cent | ile | | | | | | | |
| 1 study (Brent et al., 2011) | 1360 | 13.7 (5.7 to 26.3) | 89.4 (87.5 to 91.1) | 1.4 (0.69 to 2.7) | 0.96 (0.48 to 1.9 | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |

^a No definition of SBI

^bThis study includes children older than 5 years of age

^{°95%} confidence interval (or alternative estimate of precision) around the pooled or best estimate of effect includes both no effect and appreciable harm

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------------|--------------------|--|--|---|---|---------|-----------------------------------|----------------------|---------------|----------------------|-------------|----------------------|
| 1 study (Brent et al., 2011) | 1360 | 21.6 (11.3 to 35.3) | 80.0 (77.6 to 82.3) | re above 90 th cent | 0.96 (0.63 to 1.5) | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Detection of | serious illne | ss using heart ra | te and temperatu | re above 75 th cent | tile | | | | | • | | |
| 1 study (Brent et al., 2011) | 1360 | 43.1 (29.3 to 57.8) | 61.7 (58.8 to 64.5) | 1.2 (0.58 to 2.3) | 0.90 (0.45 to 1.8) | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Detection of | serious illne | ss using heart ra | te and temperatu | re above 50 th cent | tile | • | | | | | | |
| 1 study (Brent et al., 2011) | 1360 | 74.5 (60.4 to 85.7) | 36.2 (33.4 to 39.0) | 1 (0.50 to 2.6) | 0.75 (0.33 to 1.7) | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |
| Tachycardia | | | | | | | 1 | | | , | 1 | |
| 1 study (Brent et al., 2011) | 1360 | 66.7 (52.1 to 79.2) | 59.2 (56.3 to 62.0) | 1.5 (0.67 to 3.4) | 0.65 (0.29 to 1.46) | Low | Cross-sectional prospective study | Serious ^a | NA | Serious ^b | None | None |

^a No definition of SBI

^bThis study includes children older than 5 years of age

Table I5.61 Evidence profile for the sensitivity of cut-offs defined by heart rate and body temperature centiles and tachycardia for detecting children with meningococcal septicaemia of various degrees of severity in 325 children presenting to hospital with meningitis

| Number of studies | Total number of children | Sensitivity (95% confidence interval) | | | | ons | stency | ness | sion | ration |
|------------------------------------|--------------------------------|---|---|---------|-----------------------------------|-------------|---------------|-------------------------------|-------------|------------------------|
| | | All children with meningococcal septicaemia | Children with severe disease on admission | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Detection of | serious illnes | s using heart rate and temperate | ure above 97 th centile | | | | | | | |
| 1 study (Brent et al., 2011) | 325 | 23.6 (18.5 to 29.3) | 33.3 (22.9 to 45.2) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a,} | None | None |
| Detection of | serious illnes | s using heart rate and temperate | ure above 90 th centile | | | | | | | |
| 1 study (Brent et al., 2011) | 325 | 37.8 (31.8 to 44.1) | 50.7 (38.9 to 62.4) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a,} | None | None |
| Detection of | serious illnes | s using heart rate and temperate | ure above 75 th centile | | | | | | | |
| 1 study (Brent et al., 2011) | 325 | 55.5 (49.2 to 61.7) | 62.7 (50.7 to 73.6) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a,} | None | None |
| Detection of | serious illnes | s using heart rate and temperate | ure above 50 th centile | | | | | | | |
| 1 study (Brent et al., 2011) | 325 | 70.1 (64.0 to 75.6) | 74.7 (63.3 to 84.0) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a,} | None | None |
| Detection of | serious illnes | s using heart rate and temperate | ure below 50 th centile | • | | | , | • | | |
| 1 study (Brent et al., 2011) | 325 | 29.9 (24.4 to 36.0) | 25.3 (16.0 to 36.7) | Low | Cross-sectional prospective study | None | NA | Very serious ^{a,} | None | None |

^a The study includes only children with meningococcal disease. Therefore, the researchers were unable to assess the specificity of centile cut-offs in identifying children presenting with meningococcal disease.

^bThis study includes children older than 5 years of age

Chapter 8

Children 3 months and older

Review question

What is the predictive value of procalcitonin compared to C-reactive protein for detecting serious illness in fever without apparent source in children under 5?

 Table I8.1 GRADE findings for comparison of different procalcitonin thresholds

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------------|--------------------------|---|---|---|---|--|--|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|-------------------------|
| Bacteremi | a, pyelonep | hriitis, pneum | onia, meningi | tis, sepsis, bone | infections. Pro | evalence = 23% | | | | | | | | |
| 0.5 ng/ml | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 73.4 (63 to 82) | 76 (71 to 81) | 48 (40 to 56) ^a | 91 (87, 94) ^a | 3.1 (2.5, 3.9) ^b | 0.4 (0.2, 0.5) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |
| 1 ng/ml | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 64 (53 to 74) | 90 (86 to 93) | 65 (55 to 75) ^a | 89 (85, 93) ^a | 6.2 (4.4, 9.0) ^b | 0.4 (0.3, 0.5) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |
| 2 ng/ml | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 48 (38 to 58) | 97 (94 to 98) | 80 (70 to 91) ^a | 86 (82 to 90) ^a | 13.6 (7.4 to 25.3) ^b | 0.5 (0.4 to 0.7) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|------------------------------------|--------------------------|---|---|---|---|--|--|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|-------------------------|
| Fever < 8h | nours | | | | | | | | | | | | | |
| 1 ng/ml | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 45 | 86 (Not reported) | 100 (Not reported) | Not reported | Not reported | Not reported | Not reported | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |
| Bacteraen | nia, pyelone | phritis, lobar p | oulmonary cor | ndensation. Pre | valence = 22.6° | % | | | | | | 1 | | |
| 0.9 ng/ml | | | | | | | | | | | | | | |
| 1 (Lacour et al, 2001) | N = 124 | 93 (77 to 99) | 78 (69 to 86) | 55 (41 to 70) ^a | 97 (94 to 101) ^a | 4.2 (2.9 to 6.3) ^b | 0.1 (0.0 to 0.3) ^b | Low | Prospe ctive Observ ational | Serio us ^f | - | None | None | Yes ^g |
| < 12 month | hs of age | I. | | | l | 1 | 1 | .1 | .1 | l | | 1 | | |
| 1 (Lacour et al, 2001) | N = 80 | 94 (Not reported) | 87 (Not reported) | 68 (Not reported) | 98 (Not reported) | Not reported | Not reported | Very low | Prospe ctive Observ ational | Very seriou s ^h | - | - | None | Yes ^g |
| > 12 | 2 months of a | age | | | | | | | | | | | | |
| 1 (Lacour et al, 2001) | N = 44 | 90 (Not reported) | 62 (Not reported) | 41 (Not reported) | 96 (Not reported) | Not reported | Not reported | Very low | Prospe ctive Observ ational | Very seriou s ^h | - | - | None | Yes ^g |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--|--------------------------|---|---|---|---|--|--|---------|--|--------------------------|---------------|--------------|-------------|-------------------------|
| Bacteremi | a, pyelonep | hritis, pneumo | onia, mastoidi | tis and retropha | ryngeal absces | ss. Prevalence = | 29% | | | | | | | |
| 0.5 ng/ml | | | | | | | | | | | | | | |
| 1 (Galetto- Lacour et al, 2003) | N = 99 | 93 (77 to 99) | 74 (62 to 84) | 60 (46, 74) ^a | 96 (91, 101) ^a | 3.6 (2.4, 5.5) ^a | 0.1 (0.0 to 0.4) | Low | Prospe ctive Observ ational | Serio us ⁱ | - | None | None | Yes ^j |
| Bacteremi | a, meningiti | s, sepsis, UTI | pneumonia, | gastroenteritis, | cellulitis. Preva | lence = 23.6% | | | | | | | | |
| ≥0.5 ng/ml | 1 | | | | | | | | | | | | | |
| 1 (Olacireg ui et al, 2009) | N = 347 | 63 (52 to 74) | 87 (83 to 91) | 59 (48 to 70) | 89 (85 to 93) | 4.8 (3.5 to 7.0) ^b | 0.4 (0.3 to 0.5) ^b | Low | Retrosp ective Observ ational | Serio us ^k | - | None | None | Yes ^I |
| Bacteremi | ia, UTI and b | acteremia/UT | . Prevalence | = 13% | | | | | | | | | | |
| 0.13 ng/ml | 1 | | | | | | | | | | | | | |
| 1 (Maniaci et al, 2008) | N = 234 | 97 (81 to 100) | 30 (24 to 38) | 17 (11 to 23) | 98 (90 to 100) | 1.4 (1.2 to 1.6) | 0.1 (0.0 to 0.8) | Low | Prospe ctive cohort | Serio us ^m | - | None | None | No |
| Bacteremi | ia, UTI, bacto | eremia/UTI, ba | cterial pneum | onia. Prevalenc | e = 18% | | | • | • | | • | • | • | |
| 0.12 ng/ml | | | | | | | | | | | | | | |
| 1 (Maniaci et al, 2008) | N = 234 | 95 (83 to 99) | 26 (20 to 32) | 22 (16 to 28) | 96 (85 to 99) | 1.3 (1.1 to 1.4) | 0.2 (0.1 to 0.7) | Low | Prospe ctive cohort | Serio us ^m | - | None | None | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-----------------------------------|--------------------------|---|---|---|---|--|--|-------------|--------------------------------------|----------------------------------|---------------|--------------|--------------|-------------------------|
| Bacteremi | a, UTI, pneu | monia and me | eningitis. Prev | alence = 16% | | | | | | | | | | |
| > 0.2 ng/m | I | | | | | | | | | | | | | |
| 1 (Manzan o et al, 2011) | N = 328 | 85 (74 to 92) | 70 (68 to 71) | 36 (31 to 39) | 96 (93 to 98) | 2.8 (2.3 to 3.2) | 0.2 (0.1 to 0.4) | Low | Prospe ctive observ ational | Serio us ⁿ | - | None | None | Yes° |
| Children w | vith normal | urine analysis | only | | | | | | | | | | | |
| > 0.2 ng/m | I | | | | | | | | | | | | | |
| 1 (Manzan o et al, 2011) | N = 262 | 88 (54 to 98) | 71 (69 to 71) | 9 (5 to 10) | 99 (98 to 100) | 3.0 (1.8 to 3.3) | 0.2 (0.0 to 0.7) | Low | Prospe ctive observ ational | Serio us ⁿ | - | None | None | Yes° |
| Bacterial p | oneumonia, | meningitis, se | pticaemia and | d pyelonephritis | . Prevalence = | 1.1% | | L | | | | L | L | |
| > 500 ng/m | nl (> 0.5 ng/l) | | | | | | | | | | | | | |
| 1 (Thayyil et al, 2005) | N = 72 | 88 (65 to 110) ^b | 50 (38 to 62) ^b | 18 (6 to 30)2 | 97 (91 to 103) ^b | 1.8 (1.2 to 2.5) ^b | 0.3 (0.0 to 1.6) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^p | - | None | Serious q | Yes ^r |
| > 2000 ng/ | /ml (> 2 ng/l) | • | • | | • | | | • | • | • | | • | • | |
| 1 (Thayyil et al, 2005) | N = 72 | 50 (15 to 85) ^b | 86 (77 to 94) ^b | 31 (6 to 56) ^b | 93 (87 to 100) ^b | 3.6 (1.4 to 8.9) ^b | 0.6 (0.3 to 1.2) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^p | - | None | Serious q | Yes ^r |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|---|---|---|---|--|--|---------|--|--------------------------|---------------|--------------|-------------|-------------------------|
| Bacteremi | a/sepsis. Pr | evalence = 0. | 6% | | | | | | | | | | | |
| > 0.5 ng/m | I | | | | | | | | | | | | | |
| 1 (Olacireg ui et al, 2009) | N = 347 | 86 (58 to100) | 93 (90 to 96) | 35 (19 to 51) | 99 (98 to100) | 12.3 (Not reported) | 0.2 (Not reported) | Low | Retrosp ective Observ ational | Serio us ^k | - | None | None | Yes ^I |
| Bacteremi | a. Prevalenc | ce = 3.2% | | | | | | | | | | | | |
| ≥ 2 ng/ml (. | ± IC 95%) | | | | | | | | | | | | | |
| 1 (Guen et al, 2007) | N = 215 | 57.1 ±0.37 | 86.4±0.05 | 13.8 ±0.26 | 98.1 ±0.06 | 4.19 | 0.49 | Low | Prospe ctive observ ational | Serio us ^s | - | None | None | No |
| Invasive b | acterial infe | ctions: Bacter | ial meningitis | , Occult bactere | mia & Sepis. P | revalence = 1.7% | 0 | | | | | | | |
| ≥ 0.5 ng/m | L | | | | | | | | | | | | | |
| 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.87 (0.60 to 0.98) | 0.83 (0.81 to 0.86) | 0.09 (0.05 to 0.14) ^a | 1.00 (0.99 to 1.00) ^a | 5.15 (4.04 to 6.66) ^a | 0.16 (0.04 to 0.58) ^a | Low | Prospe ctive observ ational | Serio us ^t | - | Serious | None | No |
| ≥ 0.9 ng/m | L | I | | | | | | I. | 1 | l . | | | | |
| 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.87 (0.60 to 0.98) | 0.91 (0.88 to 0.92) | 0.14 (0.08 to 0.23) ^a | 1.00 (0.99 to 1.00) ^a | 9.13 (6.84 to 12.18) | 0.15 (0.04 to 0.54) ^a | Low | Prospe ctive observ ational | Serio us ^t | - | Serious u | None | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|---|---|---|---|--|--|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|-------------------------|
| ≥ 1 ng/mL | T | | | | | | | T | T | | T | T | | |
| 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.73 (0.45 to 0.92) | 0.92 (0.89 to 0.93) | 0.14 (0.07 to 0.23) ^a | 0.99 (0.99 to 1.00) ^a | 8.72 (5.97 to 12.73) ^a | 0.29 (0.13to 0.67) ^a | Low | Prospe ctive observ ational | Serio us ^t | - | Serious | None | No |
| ≥ 2 ng/mL | | | | | | | | | | | | | | |
| 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.60 (0.32 to 0.84) | 0.95 (0.94 to 0.97) | 0.19 (0.09 to 0.33) ^a | 0.99 (0.98 to 1.00) ^a | 12.80 (7.65 to 21.41) ^a | 0.42 (0.23 to 0.78) ^a | Low | Prospe ctive observ ational | Serio us ^t | - | Serious | None | No |
| Serious ba | acterial infed | ctions: Bacteri | al meningitis, | Occult bactere | mia & UTI. Prev | alence = 8.3% | | | | | | | | |
| ≥ 0.2 ng/mi | L | | | | | | | | | | | | | |
| 1 (Woelker et al, 2012) | N = 155 | 1.0 (0.72 to 1.0) | 0.41 (0.33 to 0.49) | 0.13 (0.08 to 0.22) ^a | 1.0 (0.92 to 1.0) ^a | 1.69 (1.47 to 1.94) ^a | NC | Very low | Prospe ctive observ ational | Very seriou s ^v | - | Serious w | None | No |
| ≥ 0.26 ng/n | nL | | | | | | | | | | | | | |
| 1 (Woelker et al, 2012) | N = 155 | 0.92 (0.62 to 1.0) | 0.64 (0.55 to 0.72) | 0.19 (0.11 to 0.31) ^a | 0.99 (0.93 to 1.0) ^a | 2.57 (1.96 to 3.37) ^a | 0.12 (0.02 to 0.80 | Very low | Prospe ctive observ ational | Very seriou s ^v | - | Serious w | None | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specificity (95% confidenc e interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|----------------------------------|--------------------------|---|---|---|---|--|--|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|-------------------------|
| ≥ 0.3 ng/m | L | | | | | | | | | | | | | |
| 1 (Woelker et al, 2012) | N = 155 | 0.85 (0.54 to 0.97) | 0.64 (0.55 to 0.72) | 0.19 (0.10 0.32) ^a | 0.98 (0.92 to 1.0) ^a | 2.56 (1.84 to 3.55) ^a | 0.23 (0.06 to 0.83) ^a | Very low | Prospe ctive observ ational | Very seriou s ^v | - | Serious w | None | No |

^a Estimates and confidence intervals were calculated by the NCC-WCH technical team.

^b Confidence intervals were calculated by the NCC-WCH technical team.

^c All participants did not receive the same reference standard; Toxic appearing children were given a full sepsis work up while well appearing children were given tests if the fulfilled certain criteria. Apart from the chest X- ray, it is not clear whether any other test (reference or index) was interpreted in a blinded manner.

^d Indirectness of population: Toxic appearing children were included in the study.

^e There was no significant difference when the AUC data for PCT and CRP were compared (*P* = 0.75). A subgroup analysis by age and duration of evolution of fever also showed no difference when PCT and CRP were compared. The authors concluded that PCT and CRP are both valuable markers for prediction of SBI but PCT seems to be a more accurate at the beginning of an infection whereas CRP if properly employed may be a better test in emergency settings because of its overall better sensitivity and feasibility.(Andreola 2007)

¹ It is not clear whether there was blinding in interpreting all reference (except the chest x-ray) and/or index tests.

⁹ About 7% of children with SBI had PCT concentration below the cut off level (0.9 ng/ml). The authors concluded that PCT offers only a modest advantage over CRP.

^h It is not clear whether there was blinding in interpreting all reference (except the chest x-ray) and/or index tests. Confidence intervals were not reported and not calculable by the NCC technical team (Lacour 2001)

Participants did not receive the same reference tests; non-toxic appearing children received individualised tests according to certain clinical/laboratory criteria.

¹The authors concluded that PCT seems to have a slight advantage over CRP because of its earlier increase after stimulation and a better negative predictive value. (Lacour 2003)

^k Retrospective study design

¹ The reference tests were not performed in a small percentage of the infants included in the study (Olacirequi)

^m Participants received tests depending on what condition was suggested by physical examination or clinical history. (Maniaci)

ⁿ Not all markers were available in every patient as some were missing in 15% (56/384) of the children included in the RCT.

^o The authors concluded that CRP, PCT, WBC and ANC had similar diagnostic properties to detect an SBI in the study population (Manzano)

^p The execution of the reference standard was not described in sufficient detail. It is not clear whether the index test results were interpreted without knowledge of the results of the index test. Blood cultures (gold standard) in the study population was done only when other markers of infection were positive which could have introduced bias into the analysis (Thayyil)

^qWide confidence interval (≥20% around the point estimate).

The authors conclude that while the elevation of all the inflammatory markers makes SBI very likely in fever without localising signs, normal procalcitonin does not exclude SBI in this population (Thayyil)

s It is not clear whether there was blinding in interpreting any of the reference and/or index tests (Guen)

 Table I8.2 GRADE findings for comparison of different C-Reactive Protein thresholds

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other |
|------------------------------------|--------------------------|---|--|---|---|--|---|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|------------------|
| Bacteremi | a, pyelonep | hritis, pneum | onia, menin | ngitis, bone infe | ctions, sepsis. | Prevalence = 23% | | | | | | | | |
| 20 mg/l | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 88 (80 to 94) | 61 (55 to 66) | 40 (34 to 47) ^a | 95 (91 to 98) ^a | 2.3 (1.9 to 2.6) ^b | 0.2 (0.1 to 0.3) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |
| 40 mg/l | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 71 (61 to 80) | 81 (76 to 85) | 53 (44 to 66) ^a | 90 (87 to 94) ^a | 3.8 (2.9 to 4.9) ^b | 0.4 (0.3 to 0.5) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |
| 80 mg/l | | | | | | | | | | | | | | |
| 1 (Andreol a et al, 2007) | N = 408 | 46 (36 to 57) | 95 (92 to 97) | 72 (60 to 83) ^a | 85 (82 to 89) ^a | 8.7 (5.1 to 14.1) ^b | 0.6 (0.5 to 0.7) ^b | Very Low | Prospe ctive Observ ational | Very seriou s ^c | - | Serious d | None | Yes ^e |

^t Children with UTI included as possible invasive illness, but unclear how they were included in the analysis.

^u Only included children who appeared non-toxic. All children seen in emergency department

^v Potential selection bias due to number of eligible children 'missed', only 19% of eligible children recruited. Did not compare CRP and PCT..

^w Only included children who appeared well. All children seen in an emergency department.

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--|--------------------------|---|--|---|---|--|---|-------------|--------------------------------------|----------------------------------|---------------|--------------|-------------|-------------------------|
| Bacteraem | nia, pyelone | phritis, lobar | pulmonary | condensation. | Prevalence = 22 | 2.6% | | | | | | | | |
| 40 mg/l | | | | | | | | | | | | | | |
| 1 (Lacour et al, 2001) | N = 124 | 89 (72 to 98) | 75 (65 to 83) | 96 (92 to 100) ^a | 51 (37 to 65) ^a | 3.6 (2.5 to 5.2) ^b | 0.1 (0.0 to 0.4) ^b | Low | Prospe ctive Observ ational | Serio us ^f | - | None | None | Yes ^g |
| < 12 month | ns of age | | | | | | | | | | | | | |
| 1 (Lacour et al, 2001) | N = 80 | 94 (Not reported) | 84 (Not reported) | 63 (Not reported) | 98 (Not reported) | Not reported | Not reported | Very low | Prospe ctive Observ ational | Very seriou s ^h | - | None | None | Yes |
| > 12 month | ns of age | | | | | | | • | | • | | | | |
| 1 (Lacour et al, 2001) | N = 80 | 80 (Not reported) | 59 (Not reported) | 91 (Not reported) | 36 (Not reported) | Not reported | Not reported | Very low | Prospe ctive Observ ational | Very seriou s ^h | - | None | None | Yes |
| Bacteremi | a, pyelonep | hritis, pneum | onia, menin | gitis and deep | abscess. Preva | lence = 29% | | | | | | | | |
| 40 mg/l | | | | | | | | | | | | | | |
| 1 (Galetto- Lacour et al, 2003) | N = 99 | 79 (65 to 94) | 79 (69 to 88) | 61 (45 to 76) ^d | 90 (83 to 98) ^d | 3.7 (2.3 to 6.0) ^e | 0.3 (0.1 to 0.5) ^e | Low | Prospe ctive Observ ational | Serio us ⁱ | - | None | None | Yes ^j |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------------------|--------------------------|---|--|---|---|--|---|---------|--|--------------------------|---------------|--------------|-------------|-------------------------|
| Bacteremi | ia, meningit | is, sepsis, UT | I, pneumoni | a, gastroenteri | tis, cellulitis. Pı | revalence = 23.6% | | | | | | | | |
| ≥ 20mg/l | | | | | | | | | | | | | | |
| 1 (Olacireg ui et al, 2009) | N = 347 | 64 (54 to 74) | 84 (80 to 88) | 55 (45 to 65) | 88 (84 to 92) | 4.0 (2.9 to 5.5) ^b | 0.4 (0.3 to 0.6) ^b | Low | Retrosp ective Observ ational | Serio us ^k | - | None | None | Yes ^l |
| ≥ 30mg/l | | | | | | | | | | | | | | |
| 1 (Olacireg ui et al, 2009) | N = 347 | 59 (48 to 70) | 89 (85 to 93) | 63 (52 to 74) | 83 (87 to 91) | 5.4 (3.6 to 7.9) ^b | 0.5 (0.4 to 0.6) ^b | Low | Retrosp ective Observ ational | Serio us ^k | - | None | None | Yes |
| Bacteremi | ia, UTI, pne | umonia and m | eningitis. P | revalence = 16° | % | | | | | | | | | |
| > 17.7mg/l | 1 | | | | | | | | | | | | | |
| 1 (Manzan o et al, 2011) | N = 328 | 94 (96 to 98) | 69 (67 to 69) | 37 (34 to 39) | 98 (96 to 100) | 3.0 (2.6 to 3.2) | 0.1 (0.0 to 0.2) | Low | Prospe ctive observ ational | Serio us ^m | - | None | None | Yes ⁿ |
| Children w | vith normal | urine analysis | sonly | | | | | | | | | | | |
| > 17.7mg/l | 1 | | | | | | | | | | | | | |
| 1 (Manzan o et al, 2011) | N = 262 | 88 (54 to 98) | 70 (69 to 70) | 8 (5 to 9) | 99 (98 to 100) | 2.9 (2.4 to 3.5) | 0.2 (0.1 to 0.4) | Low | Prospe ctive observ ational | Serio us ^m | - | None | None | Yes ⁿ |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|---|--|---|---|--|---|-------------|--|-------------------------------------|---------------|--------------|--------------|-------------------------|
| Bacterial pneumonia, meningitis, septicaemia and pyelonephritis. Prevalence = 11.1% | | | | | | | | | | | | | | |
| > 50 mg/l | | | | | | | | | | | | | | |
| 1 (Thayyil et al, 2005) | N = 72 | 75 (45 to 105) ^b | 69 (57 to 80) ^b | 23 (7 to 39) ^b | 96 (90 to 102) ^b | 2.4 (1.4 4.1) ^b | 0.4 (0.1 to 1.2) ^b | Very Low | Prospe ctive Observ ational | Very seriou s° | - | None | Serious p | Yes ^q |
| Bacteremia/sepsis. Prevalence = 0.6% | | | | | | | | | | | | | | |
| > 30 mg/l | | | | | | | | | | | | | | |
| 1 (Olacireg ui et al, 2009) | N = 347 | 56 (32 to 80)* | 74 (69 to 79) | 10 (4 to 16) | 95 (97 to 99) | 2.2 (Not reported) | 0.6 (Not reported) | Very Low | Retrosp ective Observ ational | Serio us ^k | - | None | Serious p | Yes |
| Bacteremi | a. Prevalen | ce = 3.2% | | | | | | | | | | | | |
| ≥ 40 mg/l (. | ± IC 95%) | | | | | | | | | | | | | |
| 1 (Guen et al, 2007) | N = 215 | 42.8±0.37 | 64.8±0.0 7 | 3.8±0.22 | 97.2±0.06 | 1.21 | 0.88 | Low | Prospe ctive observ ational | Serio us ^r | - | None | None | No |
| Bacteraen | nia, urinary | tract infection | n. Prevalenc | e = 10.3% | | | | | | | | | | |
| > 2 mg/l | | | | | | | | | | | | | | |
| 1 (Hsiao et al, 2006) | N = 387 | 100 (89 to 100) | 29 (24 to 34) | 74 (69 to 79) | 26 (22 to 31) | 1.4 (1.3 to 1.5) | - | Very Low | Prospe ctive observ ational | Very seriou s ^{s, t} | - | Serious u | None | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--------------------------------|--------------------------|---|--|---|---|--|---|--------------|--|-------------------------------------|---------------|--------------|--------------|-------------------------|
| > 5.2 mg/l | | | | | | | | | | | | | | |
| 1 (Hsiao et al, 2006) | N = 387 | 84 (70 to 94) | 54 (49 to 60) | 50 (45 to 55) | 50 (45 to 55) | 1.9 (1.6 to 2.3) | 0.27 (0.13 to 0.57) | Very Low | Prospe ctive observ ational | Very seriou s ^{s, t} | - | Serious | None | No |
| > 9.8 mg/l | | | | | | | | | | | | | | |
| 1 (Hsiao et al, 2006) | N = 387 | 51 (31 to 67) | 80 (76 to 84) | 23 (16 to 34) | 77 (72 to 81) | 2.6 (1.8 to 3.8) | 0.6 (0.4 to 0.8) | Very Low | Prospe ctive observ ational | Very seriou s ^{s, t} | - | Serious | None | No |
| Pneumoni | ia, urinary tı | ract infection, | bacteraemi | a, meningitis, o | ellulitis, septic | arthritis, osteomye | litis, otitis media, b | acterial | gastroente | eritis. Pro | evalence= | 23.9% | | |
| > 20 mg/l | | | | | | | | | | | | | | |
| 1 (Berger et al, 1996) | N = 138 | 83.3 (70.0- 96.7 | 67.0 (57.7- 76.4) | 43.9 (31.0- 56.7) | 92.9 (86.8- 98.9) | 2.53 (1.82-3.50) | 0.25 (0.11-0.56) | Mode rate | Prospe ctive observ ational | None | - | None | None | No |
| Occult bac | cteremia, ba | cterial menin | gitis, UTI. P | revalence = 0.9 | % | | | | | | | | | |
| 20 g/l | | | | | | | | | | | | | | |
| 1 (Gomez et al, 2010) | N = 1018 | 73.9 (53.5 to 87.5) | 74.8 (72 to 77.5) | 3 (1 to 5) | 100 (99 to 100) | 3.1 (2.1 to 4.5) | 0.3 (0.1 to 1.0) | Very low | Retrosp ective observ ational | Serio us ^v | - | Serious w | Serious x | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|---|--|---|---|--|---|-------------|--|--------------------------|---------------|--------------|-----------------|----------------------|
| 70 g/l | | | | | | | | | | | | | | |
| 1 (Gomez et al, 2010) | N = 1018 | 69.6 (49.1 to 89.4) | 93.8 (92.1 to 95.1) | 9 (2 to 15) | 99.3 (98.5 to 99.6) | 10.7 (6.3 to 18.0) | 0.4 (0.1 to 0.9) | Very low | Retrosp ective observ ational | Serio us ^v | - | Serious w | Serious × | No |
| Occult bacteremia, UTI, Pneumonia. Prevalence = 14.3% | | | | | | | | | | | | | | |
| 3 mg/dl | | | | | | | | | | | | | | |
| 1 (Pratt et al, 2007) | N = 119 | 88 (62 to 98) | 68 (58 to 76) | 0.31 (19 to 46) | 97 (89 to 100) | 2.7 91.96 to 3.80) | 0.17 (0.05 to 0.64) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Very serious | Yes ^{af} |
| 5 mg/dl | | | | | | | | | | | | | | |
| 1 (Pratt et al, 2007) | N = 119 | 71 (44 to 89) | 84 (75 to 100) | 43 (25 to 63) | 94 (87 to 98) | 4.5 (2.6 to 7.8) | 0.35 (0.17 to 0.73) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious | Very serious | Yes ^{af} |
| 7 mg/dl | • | | | • | • | | | • | • | | | | | |
| 1 (Pratt et al, 2007) | N = 119 | 59 (33 to 81) | 87 (79 to 93) | 43 (24 to 65) | 93 (85 to 97) | 4.6 (2.4 to 8.8) | 0.47 (0.27 to 0.83) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Very serious | Yes ^{af} |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|-----------------------------|--------------------------|---|--|---|---|--|---|-------------|--------------------------------------|--------------------------|---------------|-------------------------|-----------------|----------------------|
| 3 mg/dl < 1 | 2 hours | | | | | | | • | | | • | | | |
| 1 (Pratt et al, 2007) | N = 45 | 67 (24 to 94) | 74 (58 to 86) | 28 (5 to 52) | 94 (85 to 102) | 2.6 (1 to 5.2) | 0.4 (0.1 to 1.4) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Very serious | No |
| 5 mg/dl | | | | | | | | • | | | | | | |
| 1 (Pratt et al, 2007) | N = 45 | 50 (14 to 86) | 92 (78 to 98) | 50 (10 to 90) | 92 (84 to 101) | 6.5 (1.7 to 22.3) | 0.5 (0.2 to 1.2) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Very serious | No |
| 7 mg/dl | | | | | | | | | • | ı | 1 | | | |
| 1 (Pratt et al, 2007) | N = 45 | 33 (6 to 76) | 97 (85 to 100) | 67 (13 to 120) | 90 (82 to 99) | 13 (1.8 to 88.4) | 0.7 (0.4 to 1.2) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious ^z | Very serious | No |
| 3 mg/dl > 1 | 2 hours | | | | | | | ı | | ı | | | | |
| 1 (Pratt et al, 2007) | N = 74 | 100 (72 to 100) | 63 (50 to 75) | 32 (17 to 48) | 100 (98 to 101) | 2.7 (1.7 to 3.8) | 0.0 (0.0 to 6.8) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Serious ab | No |
| 5 mg/dl | | | | | | | | 1 | ı | 1 | ı | | | 1 |
| 1 (Pratt et al, 2007) | N = 74 | 82 (48 to 97) | 79 (67 to 88) | 41 (20 to 61) | 96 (91 to 101) | 4 (2.1 to 6.9) | 0.2 (0.1 to 0.8) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious z | Serious ab | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---|--------------------------|---|--|---|---|--|---|--------------|--------------------------------------|---------------------------|---------------|---------------|---------------|----------------------|
| 7 mg/dl | | | | | | | | | | | | | | |
| 1 (Pratt et al, 2007) | N = 74 | 73 (40 to 93) | 81 (69 to 89) | 40 (19 to 61) | 94 (88 to 101) | 3.8 (1.9 to 7) | 0.3 (0.1 to 0.9) | Very Low | Prospe ctive observ ational | Serio us ^Y | - | Serious | Serious ab | No |
| Occult bac | cteremia, U | ΓΙ, Pneumonia | . Prevalenc | e = 11.3% | | | | I | L | | L | | | |
| 4.4 mg/dl | | | | | | | | | | | | | | |
| 1 (Isaacma n et al, 2002) | N = 256 | 63 (43 to 82) | 81 (76 to 87) | 30 (18 to 43) | 94 (91 to 98) | 3.3 (2.2 to 4.8) | 0.5 (0.3 to 0.7) | Low | Prospe ctive observ ational | Serio us ^{ac} | - | None | Serious ad | No |
| Occult bac | cteremia, U | ΓΙ, Pneumonia | . Prevalenc | e = 18% | | | | | | | | | | |
| 7 mg/dl | | | | | | | | | | | | | | |
| 1 (Pulliam et al, 2001) | N = 77 | 79 (49 to 94.2) | 91 (79.8 to 96) | 65 (38.3 to 85.8) | 95 (86.1 to 99) | 8.3 (3.8 to 27.3) | 0.2 (0.1 to 0.6) | Mode rate | Prospe ctive observ ational | None | - | None | Serious ae | No |
| Invasive b | acterial infe | ections: Bacte | rial meningi | itis, occult bact | eremia & sepis | . Prevalence = 1.7% | | | | | | | | |
| ≥ 20 mg/L | | | | | | | | | | | | | | |
| 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.80 (0.52 to 0.96) | 0.66 (0.63 to 0.69) | 0.04 (0.02 to 0.07) ^a | 0.99 (0.98 to 1.00) ^a | 2.36 (1.80 to 3.09) | 0.30 (0.11 to 0.83) ^a | Low | Prospe ctive observ ational | Serio us ^{ag} | None | Serious ah | None | No |

| Number of studies | Number of children | Sensitivity (95% confidenc e interval) | Specifici ty (95% confiden ce interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|--|--------------------------|---|--|---|---|--|---|---------|--------------------------------------|---------------------------|---------------|---------------|-------------|-------------------------|
| ≥ 40 mg/L 1 (Luaces- Cubells et al, 2012) | N = 868 | 0.47 (0.21 to 0.73) | 0.83 (0.80 to 0.85) | 0.05 (0.02 to 0.10) ^a | 0.99 (0.98 to 0.99) ^a | 2.72 (1.55 to 4.76) | 0.64 (0.40 to 1.03) ^a | Low | Prospe ctive observ ational | Serio us ^{ag} | None | Serious ah | None | No |
| ≥ 80 mg/L 1 (Luaces- Cubells et al, | N = 868 | 0.33 (0.12 to 0.62) | 0.95 (0.93 to 0.96) | 0.10 (0.04 to 0.23) ^a | 0.99 (0.98 to 0.99) ^a | 6.45 (2.98 to 13.97) ^a | 0.70 (0.49 to 1.01) ^a | Low | Prospe ctive observ ational | Serio us ^{ag} | None | Serious ah | None | No |
| 2012) ≥ 91 mg/L 1 (Luaces- Cubells | N = 868 | 0.33 (0.12 to 0.62) | 0.96 (0.94 to 0.97) | 0.13 (0.05 to 0.28) ^a | 0.99 (0.98 to 0.99) ^a | 8.16 (3.71 to 17.93) ^a | 0.70 (0.49 to 0.99) ^a | Low | Prospe ctive observ | Serio us ^{ag} | None | Serious ah | None | No |
| et al, 2012) | | | | | | | | | ational | | | | | |

^a Estimates and confidence intervals were calculated by the NCC-WCH technical team.

^b Confidence intervals were calculated by the NCC-WCH technical team.

^c All participants did not receive the same reference standard; Toxic appearing children were given a full sepsis work up while well appearing children were given tests if the fulfilled certain criteria. Apart from the chest X- ray, it is not clear whether any other test (reference or index) was interpreted in a blinded manner.

^d Indirectness of population: Toxic appearing children were included in the study.

^e There was no significant difference when the AUC data for PCT and CRP were compared (*P* = 0.75). A subgroup analysis by age and duration of evolution of fever also showed no difference when PCT and CRP were compared. The authors concluded that PCT and CRP are both valuable markers for prediction of SBI but PCT seems to be a more accurate at the beginning of an infection whereas CRP if properly employed may be a better test in emergency settings because of its overall better sensitivity and feasibility.(Andreola 2007)

flt is not clear whether there was blinding in interpreting all reference (except the chest x-ray) and/or index tests.

⁹ About 7% of children with SBI had PCT concentration below the cut off level (0.9 ng/ml). The authors concluded that PCT offers only a modest advantage over CRP.

Feverish illness in children (appendices)

- h It is not clear whether there was blinding in interpreting all reference (except the chest x-ray) and/or index tests. Confidence intervals were not reported and not calculable by the NCC technical team (Lacour 2001)
- Participants did not receive the same reference tests; non-toxic appearing children received individualised tests according to certain clinical/laboratory criteria.
- ¹The authors concluded that PCT seems to have a slight advantage over CRP because of its earlier increase after stimulation and a better negative predictive value. (Lacour 2003)
- ^k Retrospective study design
- The reference tests were not performed in a small percentage of the infants included in the study (Olaciregui)
- ^m Not all markers were available in every patient as some were missing in 15% (56/384) of the children included in the RCT.
- ⁿ The authors concluded that CRP, PCT, WBC and ANC had similar diagnostic properties to detect an SBI in the study population (Manzano)
- ^o The execution of the reference standard was not described in sufficient detail. It is not clear whether the index test results were interpreted without knowledge of the results of the index test. Blood cultures (gold standard) in the study population was done only when other markers of infection were positive which could have introduced bias into the analysis (Thayyil)
- ^p Wide confidence interval (≥20% around the point estimate).
- ^qThe authors conclude that while the elevation of all the inflammatory markers makes SBI very likely in fever without localising signs, normal procalcitonin does not exclude SBI in this population (Thayyil)
- ^r It is not clear whether there was blinding in interpreting any of the reference and/or index tests (Guen)
- ^s Subjects did not all receive tests
- ^t Gold standards not described in detail
- ^u Children with symptoms of specific conditions included
- ^v Retrospective study design is liable to bias
- w Low prevalence is unlikely to be representative of clinical situations in which use of CRP is considered
- * Imprecision of 40% across two of four outcomes
- Y Not all subjects had reference tests
- ^z Study examining sub-groups of children presenting <12 hours or >12 hours after becoming febrile.
- ^{aa} Imprecision greater than 40% across all outcomes (Pratt < 12 hours)
- ^{ab} Imprecision of 40% across two of four outcomes (Pratt > 12 hours)
- ac Blinding of assessment of specified
- ^{ad} Imprecision greater than 40% across all outcomes
- ^{ae} Imprecision greater than 40% across all outcomes
- ^{af} Reviewer calculated from sub-groups (Pratt)
- ^{ag} Children with UTI included as possible invasive illness, but unclear how they were included in the analysis.
- ^{ah}Only included children who appeared non-toxic. All children seen in emergency department

Table 18.3 GRADE findings for combined PCT and CRP tests

| Number of studies | Number of children | Sensitivity (95% confidence interval) | Specificity (95% confidence interval) | Positive predictive value (95% confidence interval) | Negative predictive value (95% confidence interval) | Positive likelihood ratio (95% confidence interval) | Negative likelihood ratio (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
|---------------------------------|--------------------------|--|--|---|---|--|--|---------|--|--------------------------|---------------|--------------|-------------|----------------------|
| Bacteraen | nia, pyelone | ephritis, lobar p | oulmonary con | densation. Pre | valence = 22.6 | 5% | | | | | | | | |
| PCT 0.9 n | g/ml or CRP | 40 mg/l | | | | | | | | | | | | |
| 1 (Lacour et al, 2001) | N = 124 | 96 (82 to 100) | 67 (56 to 76) | 46 (33 to 58) ^a | 98 (95 to 101) ^a | 2.9 (2.2 to 3.9) ^b | 0.1 (0.0 to 0.4) ^b | Low | Prosp ective Obser vation al | Seriou s ^c | - | None | None | Yes ^d |
| Bacterem | ia. Prevalen | ce = 3.2% | | | | | | | | | | | | |
| PCT ≥ 2ng | g/ml and/or C | RP ≥ 40mg/l | | | | | | | | | | | | |
| 1 (Guen et al, 2007) | N = 215 | 71.4 ±0.33 | 61.4±0.07 | 6.5 ±0.37 | 98.2 ±0.06 | 1.85 | 0.46 | Low | Prosp ective observ ational | Seriou s ^e | - | None | None | No |

^a Estimates and confidence intervals were calculated by the NCC-WCH technical team.

^b Confidence intervals were calculated by the NCC-WCH technical team.

^c It is not clear whether there was blinding in interpreting all reference (except the chest x-ray) and/or index tests.

^d About 7% of children with SBI had PCT concentration below the cut off level (0.9 ng/ml). The authors concluded that PCT offers only a modest advantage over CRP (Lacour)

^e It is not clear whether there was blinding in interpreting any of the reference and/or index tests (Guen)

Response to antipyretic medication

Review question

What is the predictive value of the clinical response to paracetamol or NSAIDs?

Table I8.7 GRADE findings of response to antipyretics by children with bacterial or non-bacterial illnesses.

| Number | Number of children | | Effect | | | | | | | | |
|-----------------------------|------------------------------------|-------------------------------------|---|--------------------------|-------------|---------------------------|-------------------------------|---------------|----------------------|-------------|-------------------------|
| of studies | Serious disease (Δ °C, (SD), n) | Not serious disease (Δ °C, (SD), n) | Relative (95% confidence interval (CL)) (MD and Standardise MD) (95% confidence interval) | Absolute mean difference | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Final symp | ptoms score – Yale O | bservation Score | | | | | | | | | |
| Baker et al, 1989 | 7.5, (± 1.4), n = 15 | 7.7, (± 2.2), n = 135 | 0.2 (NS) | - | Very low | Prospec tive cohort | Serious _{a,b} | - | Serious ^c | None | None |
| Change in | symptoms - Yale Ob | servation Score | | | | | | | | | |
| Baker et al, 1989 | -3.8 (± 3.2), n = 15 | -1.6 (± 2.5), n = 135 | 2.2 (P < 0.001) | - | Very low | Prospec tive cohort | Very serious | - | Serious ^c | None | None c |
| Change in | temperature°C between | een serious and non-seri | ous disease | | | | | | 1 | | |
| Torrey et al, 1984 | -1.32, - , n = 16 | -1.05, - , n = 239 | 0.27 (P = 0.14) | - | Very low | Prospec tive cohort | Very serious a, b ,d | - | None | None | Some e, f, g |
| Baker et al, 1989 | -1.7, (± 0.8), n = 15 | -1.6, (± 0.6), n = 135 | SMD -0.16 (-0.69, to +0.37) | - | Very low | Prospec tive cohort | Very serious a,b | - | Serious ^c | None | Some f |
| Yamamo to et al, 1987 | -1.606 (± 0.722), n = 17 | -1.639 (± 0.705), N = 216 | SMD 0.05 (-0.45 to +0.54) | - | Very low | Prospec tive cohort | Very serious a, d, h, i | - | None | None | Some |

| Number | Number of children | | Effect | | | | | | | | |
|---------------------------|------------------------------------|-------------------------------------|--|--------------------------|-------------|---------------------------|----------------------------|---------------|-------------------------------|-------------|-------------------------|
| of studies | Serious disease (∆ °C, (SD), n) | Not serious disease (Δ °C, (SD), n) | Relative (95% confidence interval (CL)) (MD and Standardise MD) (95% confidence interval) | Absolute mean difference | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mazur et al, 1989 | -1.0 (± 0.6), N = 34 | -1.5 (± 0.5), N = 68 | SMD 0.92 (0.49 to 1.36) | - | Very low | Retrosp ective | Very serious a, j | - | None | None | Some f, k |
| Weisse et al, 1987 | 1.48°F, -, n = 17 | 1.16°F, -, 1n = 6 | 0.32°F (p = 0.37)° | - | Very low | Prospec tive cohort | Serious | - | Very serious ^{m,} | None | Some e, f |
| Baker et al, 1987 | 1.3 (± 0.8), n = 62 | 1.0 (± 0.6), n = 234 | SMD -0.46 (-0.75 to -0.18) $P < 0.01$ against all groups° | - | Very low | Prospec tive cohort | Very serious I, n, o | - | Very Serious m, c | None | Some e, f |
| Mazur et al, 1994 | -1.0, (± 0.6, n = 34 | -1.2, (± 0.6), n = 450 | SMD -0.33 (-0.68 to +0.02) | - | Very low | Retrosp ective | Very serious a, j | - | None | None | Some f, k |
| Bonadio et al, 1993 | -1.40, -, n = 59 | -1.44, -, n = 59 | 0.04 (NS)° | - | Very low | Retrosp ective | Very serious a, j | - | Serious ^c | None | Some e, f |
| Final temp | erature (°C) between | serious and non-serious | disease | | | | | | | | |
| Torrey et al, 1984 | 38.8, - , n = 16 | 38.8, - , n = 239 | (P = 0.46)° | - | Very low | Prospec tive cohort | Very serious | - | None | None | Some e, f, g |
| Baker et al, 1989 | 38.5 (SD ± 0.6), n = 15 | 38.4 (SD ± 0.6), n = 135 | (NS)° SMD 0.17 (-0.37 to +0.70) | - | Very | Prospec tive cohort | Very serious | - | Serious ^c | None | Some |

| Number | Number of children | | Effect | | | | | | | | |
|-----------------------------|---------------------------------|-------------------------------------|--|--------------------------|-------------|---------------------------|------------------------------------|---------------|-------------------------|-------------|-------------------------|
| of studies | Serious disease (Δ °C, (SD), n) | Not serious disease (Δ °C, (SD), n) | Relative (95% confidence interval (CL)) (MD and Standardise MD) (95% confidence interval) | Absolute mean difference | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Change in | febrile state | | | | | | | | | | |
| Yamamo to et al, 1987 | 15 of 17 | 180 of 216 | RR 1.06 (0.88 to 1.27) | - | Very low | Prospec tive cohort | Very serious a, d, h, i | - | None | None | Some f |
| Mazur et al, 1989 | 18 of 34 | 62 of 68 | Univariate OR = 9.2 (95% CI 2.7 to 32.0)° Multivariate OR = 9.4 (95% CI 2.6 to 34.2)° | - | Very low | Retrosp ective | Very serious a, j | - | None | None | Some f, k |
| Weisse et al, 1987 | 4 of 35 | 10 of 65 | RR 0.74 (0.25 to 2.20) | - | Very low | Prospec tive cohort | Serious | - | Very Serious m, c | None | Some e, f |
| Mazur et al, 1994 | 18 of 34 | 335 of 450 | RR 0.71 (0.52, 0.98) Univariate OR = 2.6 (95% CI 1.3 to 5.2)° Multivariate OR = 3.4 (95% CI 1.6 to 7.3)° | - | Very low | Retrosp ective | Very serious ^{a,} j | - | None | None | Some f, k |

NS, OR, RR, SD SMD

^a No blinding

^b Different measurement times between patients

^c Other groups defined in study but not included in table. Baker 1989 – meningitis (-1.3 (SD ± 0.8) Weisse, 1987 - symptoms of viral illness or bacterial illness Baker, 1987 - Group A B-hemolytic streptococcus pharyngitis, non-cultured gastroenteritis, Pneumonia, Otis media, Viral syndrome. Bonadio, 1993 - Bacterial meningitis (mean -1.06°C)

^d Different antipyretics given (paracetamol or aspirin)

^e Poor reporting of results. Data no reported for calculation.

f Different definitions of fever – Torry >38.9°C, Baker 1989 >39.4°C, Yamamoto, 1987 ≥ 40°C, Mazur, 1989 ≥ 38.9°C, Weisse, 1987 ≥ 39.8C, Baker, 1987 Rectal temperature > 38.4°C, Mazur, 1994 ≥ 38.9°C, Bonadio, 1993 ≥ 39.0°C rectal temperature.

^g Different conditions being compared. – Torrey Occult bacteremia vs non-bacterial illness, Baker 1989 + bacteremia vs – bacteremia culture, Yamamoto, 1987 + bacteremia vs – bacteremia vs – bacteremia vs – bacteremia culture, Weisse, 1987 + bacteremia vs + viral culture, Baker, 1987 Bacterial vs. non-bacterial, Mazur, 1994 + bacteremia vs – bacteremia culture, Bonadio, 1993 Isolated bacteremia vs non-bacterial illness.

^h Timing of 2nd temperature measurement not defined

ⁱSample size calculation not reported

^j Retrospective design

^kSame cases used but control populations different.

¹Not all children had reference tests. Diagnosis were not based on single 'gold' standard reference test.

^m Included children outside specified age range

ⁿ Reference tests not described in enough detail to repeat

[°] Subjects were not required to stay for completion of study.

Chapter 9 Antipyretic interventions

9.1 Effects of body temperature reduction

Review question

Whether reducing fever with paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) affects the course of the disease?

Table 19.1 GRADE findings for outcome of disease in children after antipyretics.

| Number | Number of children | | Effect | | | | | | | | |
|--------------------------------------|-------------------------|-----------------------------|--|--|-------------|--|-------------|---------------|----------------------|-------------|-------------------------|
| of studies | Antipyretic | No treatment | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Cases of c | complicated pneumo | nia vs. uncomplicated pne | eumonia using ibuprofen | | | | | | | | |
| 1 (Byington et al., 2002) | Ibuprofen | No treatment | Adjusted OR 4.0 (2.5 to 6.5), <i>P</i> < 0.001 ^a | - | Very low | Retrosp ective observ ational | None | - | Serious ^b | None | Yes ^c |
| 1 (Francois et al., 2010) | Ibuprofen | No treatment | Adjusted OR 2.57 (1.51 to 4.35), <i>P</i> < 0.001 ^a | - | Very low | Retrosp ective observ ational | None | - | Serious ^b | None | Yes ^c |
| Primary va | aricella with skin or s | soft tissue complications u | using paracetamol | | | | | | | | |
| 1 (Mikaelof f et al., 2007) | Paracetamol | No treatment | Adjusted RR 4.9 (2.1 to 11.4) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | None | Yes ^c |
| 1 (Mikaelof f et al., 2007) | Paracetamol | No treatment | Adjusted RR 1.5 (1.0 to 2.2) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | None | Yes ^c |

| Number | Number of children | | Effect | | | | | | | | |
|------------------------------|--|--------------------------|--|--|-------------|--------------------------------------|-------------|---------------|----------------------|----------------------|-------------------------|
| of studies | Antipyretic | No treatment | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Dubos et al., 2008) | Paracetamol | No treatment | Adjusted OR 4.8 (1.6 to 14.4), $P = 0.005^a$ | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | None | Yes ^c |
| Risk of an | y invasive group A st | reptococcal infection us | ing ibuprofen or paracetamo | l | | | | | | | |
| 1 (Lesko et al., 2001) | Any Ibuprofen during illness | No ibuprofen | OR 3.9, (1.3 to 12) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | None | Yes ^d |
| 1 (Lesko et al., 2001) | Any Acetaminophen during illness | No acetaminophen | OR 1.2, (0.50 to 3.0) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | Serious ^e | Yes ^d |
| 1 (Lesko et al., 2001) | Ibuprofen only | No medication | Matched OR 1.5 (0.58 to 11) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | Serious ^e | Yes ^d |
| 1 (Lesko et al., 2001) | Acetaminophen only | No medication | Matched OR 0.98 (0.43 to 2.2) ^a , Adjusted OR 0.94 (0.34 to 2.6) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | Serious ^e | Yes ^d |
| 1 (Lesko et al., 2001) | Acetaminophen and ibuprofen | Neither | Matched OR 5.0 (1.6 to 16) ^a Adjusted OR 5.6 (1.2 to 25) ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | Serious ^e | Yes ^d |

| Number | Number of children | | Effect | | | | | | | | |
|-------------------------------------|--------------------------------------|--------------------------|--|--|-------------|--------------------------------------|--------------|---------------|----------------------|----------------------|-------------------------|
| of studies | Antipyretic | No treatment | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Time to to | tal scabbing using p | paracetamol | | | | | | | | | |
| 1 (Doran et al., 1988) | 6.7 days (SD 2.3) | 5.6 days (SD 2.5) | P < 0.05 ^a | - | Very low | RCT | Serious g | - | Serious ^b | Serious ^f | No |
| Time to las | st new vesicle using | paracetamol | | | | | | | | | |
| 1 (Doran et al., 1988) | 3.9 days (SD 1.4) | 4.1 days (SD 1.2) | P = 0.64 ^a | - | Very low | RCT | Serious g | - | Serious ^b | Serious ^f | No |
| Time to to | tal healing using pa | racetamol | | | | - | | | | | |
| 1 (Doran et al., 1988) | 16.1 (SD 5.6) | 16.2 (SD 5.8) | $P = 0.45^{a}$ | - | Very low | RCT | Serious g | - | Serious ^b | Serious ^f | No |
| Number of | f paracetamol doses | used by parents | | | | | | | | | |
| 1 (Sugimur a et al., 1994) | Complicated pneumonia 2.52 (SD 0.80) | Pneumonia 1.37 (SD 0.72) | P < 0.001 ^a | - | Very low | Prospe ctive observ ational | None | - | Serious ^b | None | Yes ^c |

Note: Observational studies are set at low quality unless they have design aspects that increase this.

^a As reported by authors

b Included children aged over 5 (Sugimura- Aged 6 to 15; Byington up to 19; Francois up to age of 15; Mikaeloff – all ages; Dubos – aged up to 16; Doran aged 1 to 12; Lesko age up to 19)

^cCausal pathway is unclear – not established that antipyretics caused or were an effect of illness.

^d Casual relationship examined by restricting cases to those who received antipyretics in 7 days before emergence of GAS infection.

e Crosses 0 and ± 0.25

^f Small sample size (n < 100) so results sensitive to change.

^g Investigators were not blinded and method of allocation is unclear.

9.3 Physical and drug interventions

Review question

Effect on fever and associated symptoms of treatment with:

- Paracetamol alone or NSAIDs alone, compared with placebo and with one another
- Alternating paracetamol and NSAIDs, compared with placebo, either drug alone, and taking both at the same time
- Paracetamol and NSAIDs taken at the same time, compared with placebo, and either drug alone and either drug alone.

Table 19.2 GRADE findings for paracetamol vs. placebo

| Number | Number of children | | Effect* | | | | | > | | | ns |
|--------------------------------|------------------------|-----------------------|---|--|---------|--------|----------------------------------|---------------|-------------------|-------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Quality of | Life at 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Quality of | Life at > 2 to 5 hours | | | | | | | | | | |
| At 4 hours | | | | | | | | | | | |
| Comfort 1 (Gupta et al, 2007) | 19 of 103 ^a | 9 of 107 ^b | RR 2.19 (1.04, 4.62) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Activity 1 (Gupta et al, 2007) | 29 of 103 ^a | 4 of 107 ^b | RR 7.53 (2.74, 20.67) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |

| Number | Number of child | ren | Effect [*] | | | | | | | | SI |
|---------------------------------|------------------------|------------------------|---|--|---------|--------|----------------------------------|---------------|-------------------|-------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Alertness 1 (Gupta et al, 2007) | 22 of 103 ^a | 4 of 107 ^b | RR 5.71 (2.04, 16.01) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Mood 1 (Gupta et al, 2007) | 1 of 103 ^a | 3 of 107 ^b | RR 3.81 (1.09, 13.26) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Appetite 1 (Gupta et al, 2007) | 7 of 103 ^a | 1 of 107 ^b | RR 7.27 (0.91, 58.08) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Quality of | life at > 5 to 24 ho | urs | | | | | | | | | |
| At 6 hours | | | | | | | | | | | |
| Comfort 1 (Gupta et al, 2007) | 38 of 103 ^a | 8 of 107 ^b | RR 4.93 (2.42 to 10.06) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Activity 1 (Gupta et al, 2007) | 62 of 103 ^a | 17 of 107 ^b | RR 3.79 (2.38 to 6.02) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |

| Number | Number of children | | | Effect* | | | | | > | | | ડા |
|--|--|----------------------------------|----------|---|--|---------|--------|----------------------------------|---------------|-------------------|-----------------|-------------------------|
| of studies | Paracetamol | Placebo | | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Alertness 1 (Gupta et al, 2007) | 60 of 103 ^a | 22 of 107 ^b | | RR 2.83 (1.89, 4.26) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Mood 1 (Gupta et al, 2007) | 37 of 103 ^a | 13 of 107 ^b | | RR 2.96 (1.67 to 5.23) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Appetite (Gupta et al, 2007) | 21 of 103 ^a | 1 of 103 ^b | | RR 21.00 (2.88 to 153.23) | - | Low | RCT | Very seriou s ^c | - | None ^d | None | None |
| Discomfor | t > 24 hours | | | | | | - | | | | | |
| No data | | | | | | | | | | | | |
| Mean temp | perature at 1 to 2 hou | irs | | | | | | | | | | |
| 1 hour | | | | | | | | | | | | |
| 1 (Walson et al., 1989a) | 101.2°F (SD 0.9), n = 31° | 102.1°F (n = 33 ^b | SD 0.9), | SMD -0.99 (-1.51 to -0.47) | - | Low | RCT | None f, g, h | - | Serious d | None | None |
| 1 (Gupta et al., 2007) | 38.4°C (SD 1.0), n = 101 ^a | 38.7°C (S | SD 0.9), | SMD -0.31 (-0.59 to -0.04) | - | Low | RCT | None | - | None ^d | Very Serious | None |

| Number | Number of children | | Effect [*] | | | | | _ | | | SI |
|-------------------------------------|--|---|---|--|----------|--------|------------------------------|---------------|-------------------|-----------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Kauffma n et al., 1992) | 38.2°C (SD 0.5657), n = 8 ^e | 38.8°C (SD 0.6), n = 9 ^b | SMD -0.97 (-2.00 to +0.05) | - | Very Low | RCT | None g | - | Serious d | Very Serious | None |
| 2 hours | | | | | | | | | | | |
| 1 (Walson et al., 1989a) | 100.3°F (SD 0.9), n = 31° | 101.8°F (SD 1.3), n = 33 ^b | SMD -1.32 (-1.86 to -0.77) | - | Low | RCT | Serio us ^{f, g,} | - | Serious d | None | None |
| 1 (Gupta et al., 2007) | 38.0°C (SD 0.8), n = 101 a | 38.6°C (SD 0.9), n = 102 ^b | SMD -0.70 (-0.99 to -0.42) | - | Low | RCT | None | - | None ^d | Very Serious | None |
| 1 (Kauffma n et al., 1992) | 37.7°C (SD 0.6), n = 8° | 39.0°C (SD 0.56), n = 9 ^b | SMD -2.13 (-3.39 to -0.88) | - | Very Low | RCT | None g | - | Serious d | Very Serious | None |
| Mean in te | mperature at > 2 to 5 | hours | | | | | | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Walson et al, 1989a) | 100.1°F (SD 1.0), n = 31° | 101.7°F (SD 1.4), n = 33 ^b | SMD -1.29 (-1.83, -0.75) | - | Very Low | RCT | None f, g, h | - | Serious d | None | None |
| 1 (Gupta et al, 2007) | 37.8°C (SD 0.8), n = 101 ^a | 38.55°C (SD 1.0), n = 102 ^b | SMD -0.82 (-1.11 to -0.54) | - | Low | RCT | None | - | None ^d | Very serious | None |

| Number | Number of children | | Effect [*] | | | | | > | | | SI |
|---------------------------------------|--|--|---|--|----------|--------|-----------------------------------|---------------|-------------------|-----------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Kauffma n, et al, , 1992) | 37.7°C (SD 0.8485), n = 8° | 39.2 °C (SD 0.9), n = 9 ^b | SMD -1.62 (-2.76 to -0.49) | - | Very Low | RCT | None g | - | Serious d | Very Serious | None |
| 4 hours | | | | | | | | | | | • |
| 1 (Walson et al, 1989a) | 100.3°F (SD 1.3), n = 31° | 101.6°F (SD 1.5), n = 33 ^b | SMD -0.91 (-1.43 to -0.40) | - | Low | RCT | Serio us ^{f, g,} h | - | Serious d | None | None |
| 1 (Gupta et al, 2007) | 37.6°C (SD 0.8), n = 101 a | 38.5°C (SD 1.0), n = 102 ^b | SMD -0.99 (-1.28 to -0.70) | - | Low | RCT | None | - | None ^d | Very Serious | None |
| 1 (Kauffma n, et al, 1992) | 37.8°C (SD 0.8485), n = 8° | 39.4 °C (SD 0.6), n = 9 ^b | SMD -2.09 (-3.33 to -0.85) | - | Very Low | RCT | None ef | - | Serious b | Very Serious | None |
| 5 hours | | | | | | | | | | | |
| 1 (Walson et al, 1989a) | 100.5°F (SD 1.3), n = 31° | 101.3°F (SD 1.6), n = 33 ^b | SMD -0.54 (-1.04 to -0.04) | - | Low | RCT | Serio us ^{f, g,} h | - | Serious d | None | None |
| 1 (Gupta et al, 2007) | 37.6°C (SD 0.7), n = 101 ^a | 38.4°C (SD 0.9), n = 102 ^b | SMD -0.99 (-1.28 to -0.70) | - | Low | RCT | None | - | None ^d | Very Serious | None |

| Number | Number of children | | Effect [*] | | | | | | | | S |
|-------------------------------------|---|--|---|--|----------|--------|--|---------------|-------------------|-----------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Kauffma n, et al, 1992) | 38.1°C (SD 0.5657), n = 8° | 39.4°C (SD 0.9), n = 9 ^b | SMD -1.62 (-2.76 to -0.48) | - | Very Low | RCT | None g | - | Serious d | Very Serious | None |
| Mean in te | mperature at > 5 to 2 | 4 hours | | | | | | | | | |
| 6 hours | | I | | T | Т. | | T | 1 | T | | |
| 1 (Walson et al, 1989a) | 100.8°F (SD 1.9), n = n = 31° | 101.2°F (SD 1.5), n = 33 ^b | SMD -0.23 (-0.72 to 0.26) | - | Low | RCT | None f, g | - | Serious d | Serious j | None |
| 1 (Gupta et al, 2007) | 37.7°C (SD 0.7), n = 101 a | 38.3°C (SD 1.0), n = 102 ^b | SMD -0.69 (-0.98 to -0.41) | - | Low | RCT | None | - | None ^d | Very Serious | None |
| 1 (Kauffma n, et al, 1992) | 38.5°C (SD 1.1314), n = 8 ^e | 39.3°C (SD 0.6), n = 9 ^b | SMD -0.85 (-1.86 to +0.15) | - | Very Low | RCT | None ef | - | Serious d | Very Serious | None |
| 8 hours | | | | | | • | • | | | | |
| 1 (Walson et al, 1989a) | 101.6°F (SD 1.8), n =31° | 101.2°F (SD 1.7), n = 33 ^b | SMD 0.23 (-0.27 to +0.72) | - | Very Low | RCT | Very seriou s ^{f, g, h} | - | Serious d | Serious j | None |
| 1 (Kauffma n, et al, 1992) | 38.8°C (SD 0.8485), n = 8° | 39.2°C (SD0.6), n = 9 ^b | SMD -0.52 (-1.50 to +0.45) | - | Very Low | RCT | None g | - | Serious d | Very Serious | None |

| No data No data Mean change temperature at 1 to 2 hours 2 hours 1 (Gupta et al., 2007) None detail, n = 101 a n = 102 b (SD 24.4), n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a n = 101 a n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a n = 101 a (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a (SD 33.3), n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a (SD 33.3), n = 102 b (SD 33.3), SMD 1.35 (+1.66 to et al., 2007) None detail, n = 101 a (SD 33.3), n = 102 b (SD 33.3), n = 102 b (SD 33.3), None detail, n = 101 a (SD 33.3), n = 102 b (SD 33.3), n = | Effect* | | | | | | | | | _ | | | St |
|--|-------------|-----|------|----|-----------------|---------|--------|---|-------------|---------------|-------------------|-------------|-------------------------|
| No data Mean change temperature at 1 to 2 hours | (95% confid | ce | ļ | | (95% confidence | Quality | Design | | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean change temperature at 1 to 2 hours 2 hours 1 (Gupta et al, 2007) None N | - | | | | | | | | | | | | |
| 2 hours 1 (Gupta et al, 2007) RCT None None | | | | | | | | | | | | | |
| 1 (Gupta et al, 2007) | | | | | | | | | | | | | |
| Real change temperature at > 2 to 5 hours High RCT None | | | | | | | | | | | | | |
| 4 hours 1 (Gupta et al, 2007) 85.4% (SD 22.4), n = 101 a n = 102b 45.5% (SD 34.1), smD 1.38 (+1.68 to - hours High RCT None - None n = 102b None - None n = 102b Mean change temperature at > 5 to 24 hours 6 hours 1 (Gupta et al, 2007) 87.6% (SD 18.6), n = 101a 51.0% (SD 33.3), smD 1.35 (+1.66 to +1.04) - High RCT None - None n = 102b None - None n = 102b | • | (+1 | 1.24 | to | - | High | RC | Т | None | - | None ^d | None | None |
| 1 (Gupta et al, n = 101 a | | | | | | | | | | | | | |
| et al, n = 101 a n = 102b + 1.07) Mean change temperature at > 5 to 24 hours 6 hours 1 (Gupta et al, 2007) | | | | | | | | | | | | | |
| 6 hours 1 (Gupta al, 2007) ST.0% (SD 33.3), SMD 1.35 (+1.66 to +1.04) High RCT None - None None - | , · | (+1 | 1.68 | to | - | High | RC | Т | None | - | None ^d | None | None |
| 1 (Gupta et al, 2007) 87.6% (SD 18.6), 51.0% (SD 33.3), SMD 1.35 (+1.66 to +1.04) - High RCT None - None ^d | | | | | | | | | | | | | |
| et al, $n = 101^a$ $n = 102^b$ $+1.04$) | | | | | | | | | | | | | |
| | | 6 t | to | | - | High | RC | Т | None | - | None ^d | None | None |
| Mean change temperature at > 24 hours | | | | | | | | | | | | | |
| No data | | | | | | | | | | | | | |
| Afebrile at 1 to 2 hours | | | | | | | | | | | | | |
| No data | | | | | | | | | | | | | |

| Number | Number of children | 1 | Effect [*] | | | | | > | | | su |
|------------------------------------|--------------------------------|--------------------------------|---|--|---------|----------|-------------------------------------|---------------|--------------|-------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Afebrile at | t > 2 to 5 hours | | | | | <u>'</u> | | | • | | |
| No data | | | | | | | | | | | |
| Afebrile at | t > 5 to 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Afebrile at | t > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Temperati | ure Area Under the C | urve | | | | | | | | | |
| 0 to 8 hour | rs | | | | | | | | | | |
| 1 (Kauffma n et al, 1992) | 328 (-356 to 686) ^e | - 67 (-629 to 120 ^b | P < 0.01 | - | Low | RCT | Serio us ^{g, h} | - | Serious d | _ k | Yes |
| 1 (Walson, et al,1989) | 365.0 ^e | 166.5 ^b | P < 0.05 | - | Low | RCT | Serio us ^{f, g,} | - | Serious d | _ k | Yes ^m |
| 0 to 6 hour | rs | • | • | • | I | 1 | | | 1 | | <u>.</u> |
| 1 (Wilson, et al,1991) | 6.72 (± 0.58) ⁿ | 11.70 (0.83) ^b | - | - | Low | RCT | Very seriou s ^{h, o} | - | Serious d | _ k | Yes |

| Number | Number of children | 1 | Effect* | | | | | | | | ω |
|---|----------------------|---------------------------|---|--|----------|----------------------------------|--------------------------------------|---------------|-------------------|-------------|-------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Adverse e | vents | | | | 1 | | | | | | |
| 5 (Southey et al., 2009; Brewer et al., 1968; Gupta et al., 2007; Kauffman et al., 1992; and Walson et al., 1989) | 23 of 385 | 12 of 371 | RR 1.81 (0.94 to 3.50) | - | Very low | Meta- analysi s of RCTs | Serio us ^p | None | Serious | Serious | None |
| Long-term | effects of paracetar | mol – Asthma | | | | | | | | | |
| 1 (Beasley et al., 2008) | NR | NR | RR 1.46 (1.36 to 1.56) | - | Very low | Observ ational | Very Serio us ^{q,r,s} | - | None ^d | None | None |
| Long-term | effects of paracetar | nol – Rhinoconjunctivitis | | | | | | | | | |
| 1 (Beasley et al., 2008) | NR | NR | RR 1.48 (1.38 to 1.60) | - | Very low | Observ ational | Very Serio us ^{q,r,s} | - | None ^d | None | None |

| Number | Number of children | | Effect [*] | | | | | cy | | | ns |
|-----------------------------------|----------------------|--------------|---|--|----------|-------------------|--------------------------------------|--------------|-------------------|-------------|------------------------|
| of studies | Paracetamol | Placebo | Relative risk (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistenc | Indirectness | Imprecision | Other consideration |
| Long-term | effects of paracetan | nol – Eczema | | | | | | | | | |
| 1 (Beasley et al., 2008) | NR | NR | RR 1.35 (1.26 to 1.45) | - | Very low | Observ ational | Very Serio us ^{q,r,s} | - | None ^d | None | None |

NR Not reported

^a15 mg/kg paracetamol repeated at 6 hours

^b Placebo

^c Outcome measure was not based on a validated questionnaire and was the subjective assessment of the clinician.

^d Children aged more than 5 years included in study (Gupta – up to 6; Walson – up to 11; Kauffman – up to 12, Brewer – up to 14; Wilson up to 12)

e 10mg/kg paracetamol single dose

^fChildren recruited from three sources, including newspaper advert.

^g Method of randomisation and allocation not described in detail

^h Small sample size (<100)

ⁱ Figures taken from graph, so likely to have measurement error.

^j Wide confidence intervals (CI > 0.5 around SMD)

k Imprecision could not be calculated

¹ AUC of percentage decrease of temperature (from baseline to normal 37°C) vs. time

^m AUC of percentage decrease of temperature (from baseline to 98.6°F) vs. time

ⁿ 120 mgm/ 5ml

[°] Study not blinded

^p Different definitions of treatment regimens used

^q Observational study design starts at low

^r Causal pathway and confounding of underlying conditions

^sTreatment regimen unknown.

Relative and absolute differences are calculated by the NCC technical team based on the data presented in the papers. When this data is unavailable the authors reported figures may be used.

Table 19.3 GRADE findings for ibuprofen vs. placebo

| Number | Number of children | | Effect ^a | | | | | > | | | ns. |
|---------------|--|------------------|---------------------------------------|--|---------|--------|-------------|---------------|--------------|-------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt at 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 5 to 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean cha | nge temperature at 1 | to 2 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean cha | nge in temperature a | t > 2 to 5 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean cha | change in temperature at > 5 to 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean cha | change in temperature at > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |

| Number | Number of children | | | Effect ^a | | | | | > | | | St |
|----------------------------------|--|------------------------|-------|---------------------------------------|--|----------|--------|-----------------------------------|---------------|--------------|-------------|----------------------|
| of studies | Intervention | Control | | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean tem | perature at 1 to 2 hou | rs | | | | | 1 | _ | | | | |
| 1 hour | | | | | | | | | | | | |
| 1 (Walson et al., 1989) | 100.9°F (SD 1.0), n = 29 ^b | 102.1°F (SD n = 33° | 0.9), | SMD -1.25 (-1.80 to -0.70) | - | Moderate | RCT | Serio us ^{d, e,} | - | Serious g | None | None |
| 1 (Walson et al., 1989) | 100.8°F (SD 0.9), n = 25 ^h | 102.1°F (SD n = 33° | 0.9), | SMD -1.43 (-2.01 to -0.84) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |
| 2 hours | | | | | | • | | | | | | • |
| 1 (Walson et al., 1989) | 99.8°F (SD 1.1), n = 29 ^b | 101.8°F (SD n = 33° | 1.3), | SMD -1.63 (-2.21 to -1.05) | - | Moderate | RCT | Serio us ^{d, e,} | - | Serious g | None | No |
| 1 (Walson et al, 1989) | 99.5°F (SD 0.7), n = 25 ⁹ | 101.8°F (SD n = 33° | 1.3), | SMD -2.09 (-2.75 to -1.44) | - | Moderate | RCT | Serio us ^{d, e,} | - | Serious g | None | No |
| Mean tem | perature at > 2 to 5 ho | ours | | | | | | | | | | |
| 3 hours | | | | | | | | | | | | |
| 1 (Walson et a.l, 1989) | 99.5°F (SD 1.3), n = 29 ^b | 101.7°F (SD n = 33° | 1.4), | SMD -1.60 (-2.18 to -1.03) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |

| Number | Number of ch | ildren | | Effect ^a | | | | | > | | | Su |
|----------------------------------|-----------------------------------|--------|------------------------------|---------------------------------------|--|----------|--------|-----------------------------------|---------------|--------------|-------------|-------------------------|
| of studies | Intervention | | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Walson et al, 1989) | 99.3°F (SD n = 25 ^h | 0.7), | 101.7°F (SD 1.4), n = 33° | SMD -2.05 (-2.70 to -1.41) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |
| 4 hours | | | | | | 1 | | ı | | | | |
| 1 (Walson et al., 1989) | 99.5°F (SD n = 29 ^b | 1.6) | 101.6°F (SD 1.5) n = 33 | SMD -1.34 (-1.90 to -0.78) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |
| 1 (Walson et al, 1989) | 99.2°F (SD n = 25 ⁹ | 1.2) | 101.6°F (SD 1.5) n = 33 | SMD -1.72 (-2.33 to -1.10) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |
| 5 hours | | | | | | • | • | | | • | | |
| 1 (Walson et al., 1989) | 99.8°F (SD n = 29 ^b | 1.9) | 101.3°F (SD 1.6) n = 33 | SMD -0.85 (-1.37 to -0.33) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |
| 1 (Walson et al., 1989) | 99.3°F (SD n = 25 ⁹ | 1.7 | 101.3°F (SD 1.6 n = 33° | SMD -1.20 (-1.77 to -0.63) | - | Moderate | RCT | Serio us ^{d, e,} f | - | Serious g | None | No |

| Number | Number of children | | Effect ^a | | | | | > | | | SI |
|----------------------------------|---|-----------------------------|---------------------------------------|--|----------|--------|-----------------------------------|---------------|--------------|--------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean temp | perature at > 5 to 24 | hours | | | | | | | _ | | |
| 6 hours | | | | | | | | | | | |
| 1 (Walson et al, 1989) | 100.2°F (SD 2.2) n = 29 ^b | 101.2°F (SD 1.5) n = 33° | SMD -0.53 (-1.04 to -0.02) | - | Moderate | RCT | Serio us ^{d, e,} | - | Serious g | None | No |
| 1 (Walson et al., 1989) | 99.7°F (SD 1.9) n = 25 ^h | 101.2°F (SD 1.5) n = 33° | SMD -0.88 (-1.42 to -0.33) | - | Moderate | RCT | Serio us ^{d, e,} | - | Serious g | None | No |
| 7 hours | l | | | | | | ' | | 1 | | 1 |
| 1 (Walson et al., 1989) | 101.2°F (SD 2.0) n = 29 ^b | 101.2°F (SD 1.7) n = 33 | SMD 0.00 (-0.50 to +0.50) | - | Low | RCT | Serio us ^{d, e,} | - | Serious g | Serious i | No |
| 1 (Walson et al., 1989) | 100.6°F (SD 2.2) n = 25 ^h | 101.2°F (SD 1.7) n = 33 | SMD -0.31 (-0.83 to +0.22) | - | Low | RCT | Serio us ^{d, e,} f | - | Serious g | Serious | No |
| Mean temp | perature at > 24 hour | s | | | | | | L | 1 | | |
| No data | | | | | | | | | | | |
| Afebrile at | t 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |

| Number | Number of children | า | Effect ^a | | | | | > | | | SL |
|-------------------------------------|-------------------------------|---------------------|---------------------------------------|--|---------|--------|-----------------------------------|---------------|--------------|----------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Afebrile a | t > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Afebrile a | t > 5 to 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Afebrile a | t > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Temperate | ure Area Under the C | Curve | | | | | | | | | |
| 0 to 8 hou | | | | 1 | | | _ | | _ | | |
| 1 (Kauffma n et al., 1992) | 730 (576 to 839) ^j | -67 (-629 to 120) ° | P < 0.01 | - | Low | RCT | Serio us ^{e,f} | - | Serious g | _ ^K | Yes ^l |
| 1 (Kauffma n et al., 1992) | 590 (160 to 875) ^h | -67 (-629 to 120 ° | P < 0.01 | - | Low | RCT | Serio us ^{e,f} | - | Serious g | _ k | Yes ^l |
| 1 (Walson et al., 1989) | 460.9 ^b | 139.0° | P < 0.05 | - | Low | RCT | None d, e, f | - | Serious g | _ k | Yes ^m |
| 1 (Walson et al., 1989) | 510.8 ^h | 139.0 ° | P < 0.05 | - | Low | RCT | Serio us ^{d, e,} f | - | Serious g | _ k | Yes ^m |

| Number | Number of children | 1 | Effect ^a | | | | | > | | | SI |
|---|--------------------------|----------------|---------------------------------------|--|---------|-----------------------|--------------------------|---------------|--------------|----------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 0 to 6 hour | rs – Change in temper | rature | | | | | | | | | |
| 1 (Wilson et al., 1991) | 7.09 (0.58) ^b | 11.70 (0.83) ° | | - | Low | RCT | Serio us ^f | - | Serious g | _ k | Yes |
| 1 (Wilson et al, 1991) | 4.91 (0.47) ^h | 11.70 (0.83) ° | | - | Low | RCT | Serio us ^f | - | Serious g | _ ^k | Yes |
| Adverse e | vents | | | | | | | | | | |
| 4 (Southey et al., 2009; Kauffma n et al.,1992; Walson et al., 1989a; and | 55 of 357 | 27 of 294 | RR 1.67 (1.12, 2.48) | - | Low | Meta- analysi s | Serio us ⁿ | None | Serious g | None | None |
| Wilson et al., 1991) | | | | | | | | | | | |

NR Not reported

^a Relative and absolute differences are calculated by the NCC technical team based on the data presented in the papers. When this data is unavailable the authors reported figures may be used.

^b Dose of 5 mg/kg

^c Placebo

^d Children recruited from three sources, including newspaper advert

^e Method of randomisation and allocation not explained in detail

Table 19.4 GRADE findings for paracetamol vs. ibuprofen

| Number | Number of children | | Effect | | | | | 5 | | | <u>_</u> |
|--|---|--------------------------------------|--|--|---------|--------|----------------------------|---------------|--------------|-------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Discomfo | rt at 1 to 2 hours | | | | | | • | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 2 to 5 hours | | | | | | | | | | |
| 4 hours | | | | | | | | | | | |
| GBC- score 1 (Autret et al., 1997) | 0.8 (SD 1), n = 116 ^a | 0.6 (SD 0.9), n = 113 ^b | NS ° | - | Low | RCT | Very seriou s d,e,f, | - | None | None | None |
| GBC- VAS 1 (Autret et al., 1997) | 27.8 (SD 29.5), n = 114 ^a | 18.3 (SD 26.5), n = 108 ^b | SMD 0.34 (0.07, 0.60) | - | Low | RCT | Very seriou s d,e,f, | - | None | None | None |

f Small sample size (< 100 in total)

⁹ Children aged more than 5 years included in study (Gupta – up to 6; Walson – up to 11; Kauffman – up to 12; Wilson up to 12)

^h Dose of 10 mg/kg ibuprofen

ⁱWide confidence intervals (CI > 0.5 around SMD)

^j7.5 mg/kg ibuprofen

k Imprecision could not be calculated

¹ AUC of percentage decrease of temperature (from baseline to normal 37°C) vs. time

^m AUC of percentage decrease of temperature (from baseline to 98.6°F) vs. time

ⁿ Different definitions of treatment regimens used

| Number | Number of children | | Effect | | | | | χ | | | Ē |
|--|---|--------------------------------------|--|--|----------|--------|--|---------------|--------------|--------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| CHEOPs discomfo rt 1 (Autret et al., 1997) | 2.2 (SD 0.9), n = 114 ^a | 2.5 (1.0), n = 108 ^b | NS ° | - | Low | RCT | Very seriou s d,e,f, g | - | None | None | None |
| Overal efficacy 1 (Figueras Nadal et al., 2002) | 64 of 94 ^h | 61 of 93 ⁱ | RR 1.04 (0.85 to 1.27) | - | Very low | RCT | Very seriou s ^{d,j, k} | - | Serious | Serious m | None |
| | rt at > 5 to 24 hours | ı | | ı | | | | | | | |
| 6 hours | | | | | | | | | | | |
| GBC- score 1 (Autret et al, 1997) | 0.8 (SD 1.0), n = 114 ^a | 0.5 (SD 1.0), n = 112 ^b | NS ° | - | Low | RCT | Very seriou s ^{d,e,f,g} | - | None | None | None |
| GBC- VAS 1 (Autret et al, 1997) | 26.7 (SD 30.6), n = 112 ^a | 15.9 (SD 31.1), n = 107 ^b | SMD 0.35 (+0.08 to +0.62) | - | Low | RCT | Very seriou s ^{d,e,f,g} | - | None | None | None |

| Number | Number of children | Number of children | | Effect [*] | | | | <u>خ</u> | | | Ē |
|---|--|----------------------------------|--|--|---------|--------|-----------------------------|---------------|--------------|-------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| CHEOPs discomfo rt 1 (Autret et al., 1997) | 2.3 (SD 0.9), n = 112 ^a | 2.5 (SD 1), n = 107 ^b | NS ° | - | Low | RCT | Very seriou s d,e,f,g | - | None | None | None |
| Discomfor | rt > 24 hours | | | | | | | | | | |
| Day 1 | | | | | | | | | | | |
| NCCPC stress test 1 (Sarrell et al, | 11.48 (SD 2.58), n = 155 ⁿ | 11.77 (SD 2.64), n = 154° | SMD -0.11 (-0.33 to +0.11) | - | High | RCT | None p | - | None | None | Yes ^q |
| 2006) | | | | | | | | | | | |
| Day 2 | | | | | | | | | | | |
| NCCPC stress test | 8.83 (SD 2.67) n = 155 ⁿ | 8.87 (SD 2.54) n = 154° | SMD 0.02 (-0.24 to +0.21) | - | High | RCT | None p | - | None | None | Yes ^q |
| 1 (Sarrell et al., 2006) | | | | | | | | | | | |

| Number | Number of children | | Effect [*] | | | | | <u>خ</u> | | | Ē |
|---|--|--|--|--|----------|--------|-----------------------------------|---------------|--------------|-----------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Day 3 | | | | | | | | | | | |
| NCCPC stress test | 7.96 (SD 2.71), n = 155 ⁿ | 7.66 (SD 2.96) n = 154° | SMD 0.11 (-0.12 to +0.33) | - | High | RCT | None p | - | None | None | Yes ^q |
| 1 (Sarrell et al., 2006) | | | | | | | | | | | |
| Mean cha | nge temperature at 1 | to 2 hours | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Autret et al., 1997) | -0.97°C (SD 0.58) n = 114 ^a | -0.90°C (SD 0.56) n = 114 ^b | SMD -0.12 (-0.38 to +0.14) | - | Low | RCT | Very seriou s d,e,f | - | None | None | None |
| 1 (Wong et al., 2001) | -1.00°C (SD 0.65), n = 185 ^r | -1.05°C (SD 0.70), n = 191 ^s | SMD 0.07 (-0.13 to +0.28) | - | Moderate | RCT | Serio us ^{d, k} | | None | None | None |
| 1 (Erlewyn- Lajeunes se et al., 2006) | -0.92°C (95% CI 0.70 to 1.14), n = 35 ⁿ | -0.95°C (95% CI 0.72 to 1.17), n = 37 ^t | SMD 0.04 (-0.42 to +0.51) | - | Low | RCT | Serio us ^{d, e,} u | - | Serious | None | None |
| 1 (Wilson et al., 1991) | -0.8°C (SD 0.3279), n = 43 ⁿ | -0.8°C (SD 0.3606), n = 52° | SMD 0.04 (-0.42 to +0.51) | - | Very low | RCT | None d, u | - | Serious I | Very serious | None |

| Number | Number of children | | Effect [*] | | | | | > | | | ٦ |
|------------------------------|--|---|--|--|----------|--------|-----------------------------|---------------|--------------|-----------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Wilson et al, 1991) | -0.8°C (SD 0.3428), n = 47 w | -0.8°C (SD 0.3606), n = 52° | SMD 0.00 (-0.40 to +0.40) | - | Very low | RCT | None d, u | - | Serious | Very serious | None |
| 1.5 hours | | | | | | | | | | | |
| 1 (Wong et al., 2001) | -1.33°C (SD 0.66), n = 185 ^r | -1.33°C (SD 0.68) n = 191 ^s | SMD 0.00 (-0.20 to +0.20) | - | Moderate | RCT | Serio us ^{d, k} | - | None | None | None |
| 2 hours | | | | | | • | | | | | |
| 1 (Wong et al., 2001) | -1.56°C (SD 0.72), n = 185 ^r | -1.55°C (SD 0.68) n = 191° | SMD: -0.01 (-0.22 to +0.19) | - | Moderate | RCT | Serio us ^{d, k} | - | None | None | None |
| 1 (Wilson et al, 1991) | -1.2°C (SD 0.6557), n = 43 ⁿ | -1.2°C (SD 0.7211), n = 52° | SMD 0.00 (-0.40 to +0.40) | - | Very low | RCT | None d, u | - | Serious | Very serious | None |
| 1 (Wilson et al., 1991) | -1.2°C (SD 0.6856), n = 47 w | -1.2°C (SD 0.7211), n = 52° | SMD 0.00 (-0.39 to +0.39) | - | Very low | RCT | None d, u | - | Serious | Very serious | None |
| Mean char | nge in temperature at | > 2 to 5 hours | | | · | | • | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Wong et al, 2001) | -1.58°C (SD 0.81), n = 185 ^r | -1.52°C (SD 0.79) n = 191 s | SMD -0.07 (-0.28 to +0.13) | - | Moderate | RCT | Serio us ^{d, k} | - | None | None | None |
| 1 (Wilson et al., 1991) | -1.5°C (SD 0.6856), n = 47 ⁿ | -1.4°C (SD 0.7211), n = 52° | -0.14 (-0.54 to +0.25) | - | Very low | RCT | None d, u | - | Serious | Very serious | None |

| Number | Number of children | | Effect [*] | | | | | 5. | | | ء |
|------------------------------------|--|--|--|--|----------|--------|-----------------------------|---------------|--------------|-----------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Wilson et al., 1991) | -1.4°C (SD 0.6557), n = 43 ^w | -1.4°C (SD 0.7211), n = 52 ⁰ | 0.00 (-0.40 to +0.40) | 1 | Very low | RCT | None d, u | - | Serious | Very serious | None |
| 4 hours | | | | | | | | | | | |
| 1 (Autret et al., 1997) | -1.42°C (SD 0.85) n = 112 ^a | -1.04°C (SD 0.85) n = 110 ^b | SMD -0.45 (-0.71 to -0.18) | - | Very low | RCT | Very seriou s d,e,f | - | None | None | None |
| 1 (Wilson et al., 1991) | -1.6°C (SD 0.6856), n = 47 ⁿ | -1.3°C (SD 1.4422), n = 52° | SMD -0.26 (-0.66 to +0.14) | | Very low | RCT | None d, u | - | Serious | Very serious | None |
| 1 (Wilson et al., 1991) | -1.2°C (SD 0.6557), n = 43 ^w | -1.3°C (SD 1.4422), n = 52° | SMD 0.09 (-0.32 to +0.49) | - | Very low | RCT | None d, u | - | Serious | Very serious | None |
| 1 (Ulukol et al., 1999) | -1.86°C (SD 0.74) n = 30 ^w | -1.29°C (SD 0.71) n = 30 ^b | SMD 0.78 (+0.25 to+1.30) | - | Low | RCT | Serio us' d,e,f, u | - | Serious | None | None |
| 1 (Autret et al., 1994) | -1.32°C (SD 1.00), n = 77 ^a | -1.02°C (SD 1.05), n = 74 ^b | SMD -0.29 (-0.61 to +0.03) | - | Low | RCT | Serio us ^{d,e} | - | None | Serious | None |
| 1 (McIntyre et al., 1996) | -1.80°C (SD -), n = 76 ^x | -1.6°C (SD -), n = 74 ^y | P = 0.39 | - | Moderate | RCT | Serio us ^{d, e} | - | Serious | _Z | None |

| Number | Number of children | | Effect | | | | | . | | | _ |
|-------------------------------|--|--|--|--|----------|--------|---------------------------------------|---------------|------------------------------|--------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Nadal et al., 2002) | -1.30°C (SD 1.1), n = 94 ^{aa} | -1.20°C (SD 0.96), n = 93 ^{ab} | SMD -0.10 (-0.38 to +0.19) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | None | None |
| 1 (Wong, 2001) | -1.44°C (SD 0.98), n = 185 ^r | -1.47°C (SD 0.91), n = 191 ^s | SMD 0.03 (-0.17 to +0.23) | - | Moderate | RCT | Serio us ^{d, k} | - | None | None | None |
| 5 hours | | | | | | | | | | | |
| 1 (Wong et al., 2001) | -1.35°C (SD 1.06), n = 185 ' | -1.34°C (SD 1.05) ^j n = 191 ^s | SMD -0.01 (-0.21 to +0.19) | - | Moderate | RCT | Serio us ^{d, k} | - | None ^{II} | None | None |
| 1 (Wilson et al., 1991) | -1.4°C (SD 0.6856), n = 47 ⁿ | -1.0°C (SD 1.4422), n = 52° | SMD -0.35 (-0.74 to +0.05) | - | Very low | RCT | None d, u | - | Very serious ^l | Serious v | None |
| 1 (Wilson et al., 1991) | -1.1 °C (SD0.6557), n = 43 ^w | -1.0°C (SD 1.4422), n = 52° | SMD -0.09 (-0.49 to +0.32) | - | Very low | RCT | None d, u | - | Very serious ^l | Serious v | None |
| Mean chai | nge in temperature at | > 5 to 24 hours | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Autret et al., 1997) | -1.19°C (SD 0.94), n = 108 ^a | -0.88°C (SD 0.85), n = 108 ^b | SMD -0.34 (-0.61 to -0.08) | - | Low | RCT | Very seriou s d,e,f | - | None | None | None |
| 1 (Wong et al., 2001 | -1.24°C (SD 1.08), n = 185 ' | -1.20°C (SD 1.09) n = 191° | SMD -0.04 (-0.24 to +0.17) | - | Moderate | RCT | Serio us ^{d, k} | - | None | None | None |

| Number | Number of children | | Effect [*] | | | | | 25 | | | Ē |
|---|--|---|--|--|----------|--------|--------------------------|---------------|------------------------------|------------------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Wilson et al, 1991) | -1.1°C (SD 0.6557), n = 43 ⁿ | -0.9°C (SD 1.4422), n = 52° | SMD -0.17 (-0.58 to +0.23) | - | Very low | RCT | None d, u | - | Very serious ^l | Serious v | None |
| 1 (Wilson et al., 1991) | -1.2°C (SD 0.6856), n = 47 ^w | -0.9°C (SD 1.4422), n = 52° | SMD -0.26 (-0.66 to +0.14) | - | Very low | RCT | None d, u | - | Very serious ^l | Serious v | None |
| Mean cha | nge in temperature at | > 24 hours | | | | | | | | | |
| No studies | found | | | | | | | | | | |
| Mean tem | perature at 1 to 2 hou | irs | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Kauffma n et al., 1992) | 38.0°C (SD 0.6928), n = 12 ^a | 38.2°C (SD 0.5657), n = 8 ^b | SMD -0.30 (-1.20 to +0.60) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| 1 (Kauffma n et al., 1992) | 37.9°C (SD 0.4243), n = 8 ^w | 38.2°C (SD 0.5657), n = 8 ^b | SMD -0.57 (-1.57 to +0.44) | - | Very low | RCT | None d, u | - | Serious | Very serious _{v,ac} | None |
| 1 (Vauzelle - Kervroda n et al., 1997) | 38.4°C (SD 0.6) n = 60 ^a | 38.3°C (SD 0.6), n = 56 ^b | SMD: 0.17 (-0.20 to +0.53) | - | Low | RCT | Serio us ^d | - | Serious | Serious | None |

| Number | Number of children | | Effect [*] | | | | | > : | | | Ē |
|---|---|--|--|--|----------|--------|---------------------------------------|---------------|--------------|--------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Erlewyn- Lajeunes se et al., 2006) | 37.81°C (SD 0.69), n = 35 ⁿ | 37.98°C (SD 0.47), n = 37 ^t | SMD: -0.29 (-0.75 to +0.18) | - | Low | RCT | Serio us ^{d e, u} | - | Serious | Serious m | None |
| 1 (Walson et al., 1989) | 100.9°F (SD 1), n = 29 ⁿ | 102.1°F (SD 0.9), n = 31 ^b | SMD -0.31 (-0.82 to +0.20) | - | Low | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Walson et al., 1989) | 100.8°F (SD 0.9) n = 25 w | 102.1°F (SD 0.9), n = 31 ^b | SMD -0.44 (-0.97 to +0.10) | - | Low | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Nadal et al., 2002) | 37.93°C (SD 0.72), n = 100 ^{aa} | 38.06°C (SD 0.72), n = 99 ab | SMD -0.18 (-0.46 to +0.10) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | None | None |
| 1.5 hours | | | | | | | | | | | |
| 1 (Nadal et al., 2002) 1.5 hr | 37.61°C (SD 0.73), n = 100 ^{aa} | 37.78°C (SD 0.70), n = 99 ^{ab} | SMD -0.24 (-0.52 to +0.04) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | Serious m | None |
| 2 hours | | | | | • | | | | | | |
| 1 (Nadal et al., 2002) | 37.50°C(SD 0.74) n = 100 ^{aa} | 37.67°C (SD 0.78), n = 99 ^{ab} | SMD -0.22 (-0.50 to +0.06) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | Serious m | None |

| Number | Number of children | | Effect [*] | | | | | <u></u> | | | |
|---|---|---|--|--|----------|--------|--------------------------|---------------|-----------------|--------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Van Esch et al., 1995) | 37.60°C (SD 0.6025), n = 30 ⁿ | 37.96°C (SD 0.9155), n = 29 ^b | SMD -0.46 (-0.98 to +0.06) | - | Very low | RCT | None d, u | - | Very serious | Serious m | None |
| 1 (Vauzelle - Kervroda n et al., 1997) | 37.9°C (SD 0.7), n = 58 ^w | 37.9°C (SD 0.7), n = 55 ^b | SMD 0.00 (-0.37 to +0.37) | - | Low | RCT | Serio us ^d | - | Serious | Serious m | None |
| 1 (Walson et al., 1989) | 99.8°F (SD 1.1), n = 29 ⁿ | 101.8°F (SD 0.9), n = 31 ^b | SMD -0.49 (-1.01 to +0.02) | - | Low | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Walson et al., 1989) | 99.5°F (SD 0.7) n = 25 ^w | 101.8°F (SD 0.9), n = 31 ^b | SMD -0.97 (-1.52 to -0.41) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Kauffma n, et al., 1992) | 37.3°C (SD 0.5196), n = 12 ^a | 37.7 °C (SD 0.6), n = 8 ^b | SMD -0.69 (-1.62 to +0.23) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| 1 (Kauffma n et al., 1992) | 37.2°C (SD 0.2828), n = 8 ^w | 37.7 °C (SD 0.6), n = 8 ^b | SMD -1.01 (-2.07 to +0.05) | - | Low | RCT | None d, u | - | Serious | Very serious v, ac | None |

| Number | Number of children | | Effect [*] | | | | | <u> </u> | | | Ē |
|---|---|--|--|--|----------|--------|---------------------------------------|---------------|--------------|--------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Autret- Leca et al., 2007 | 37.4 °C (SD 0.75), n = 151 w | 37.4°C (SD 0.8), n = 150 ^{ah} | SMD 0.00 (-0.23 to +0.23) | - | Very low | RCT | None d | | Serious | Very serious | None |
| Mean temp | perature at > 2 to 5 ho | ours | | | | | | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Walson et al., 1989) | 99.5°F (SD 1.0), n = 29 ⁿ | 101.7°F (SD 1.0), n = 31 ^b | SMD -0.51 (-1.03 to 0.00) | - | Low | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Walson et al., 1989) | 99.3°F (0.7), n = 25 | 101.7 °F (SD 1.0),n = 31 ^b | SMD -0.90 (-1.45 to -0.34) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Vauzelle - Kervroda n et al., 1997) | 37.6°C (SD 0.7), n = 58 ^w | 37.8°C (SD 0.7), n = 56 ^b | SMD -0.28 (-0.65 to +0.09) | - | Very Low | RCT | Serio us ^d | - | Serious | Serious | None |
| 1 (Nadal et al., 2002) | 37.57°C (SD 0.92), n = 100 ^{aa} | 37.78°C (SD 0.92), n = 99 ^{ab} | SMD -0.23 (-0.51 to +0.05) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | Serious | None |
| 1 (Kauffma n et al., 1992) | 36.9°C (SD 0.6928), n = 12 ^a | 37.7°C (SD 0.8485), n = 8 ^b | SMD -1.01 (-1.97 to -0.05) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |

| Number | Number of children | | Effect [*] | | | | | >; | | | Ē |
|---|---|---|--|--|----------|--------|---------------------------------------|---------------|-----------------------|-------------------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Kauffma n et al., 1992) | 36.7°C (SD 0.2828), n = 8 ^w | 37.7°C (SD 0.8485), n = 8 ^b | SMD -1.49 (-2.64 to -0.35) | - | Very low | RCT | None d, u | - | Serious | Very serious _{v, ac} | None |
| Autret- Leca et al., 2007 | 37.3°C (SD 0.75), n = 151 w | 37.3°C (SD 0.75), n = 150 ^{ah} | SMD 0.00 (-0.23 to +0.23) | - | Very low | RCT | None d | - | Serious | Very serious | None |
| 4 hours | | | | | • | | | | | | |
| 1 (Van Esch et al., 1995) | 37.38°C (SD 1.0022), n = 31 ⁿ | 37.95°C (SD 1.2806), n = 31 ^b | SMD -0.49 (-1.00 to +0.02) | - | Very low | RCT | None d, u | - | Very serious af | Serious m | None |
| 1 (Vauzelle - Kervroda n et al., 1997) | 37.6°C (SD 0.8), n = 58 ^w | 37.8°C (SD 0.8), n = 55 ^b | SMD -0.25 (-0.62 to +0.12) | - | Very Low | RCT | Serio us ^d | - | Serious | Serious m | None |
| 1 (Nadal et al, 2002) | 37.82°C (SD 1.05), n = 100 ^{aa} | 37.97°C (SD 1.02), n = 99 ab | SMD -0.14 (-0.42 to +0.13) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | None | None |
| 1 (Walson et al., 1989) | 99.5°F (SD 1.6), n = 29 ⁿ | 101.6°F (SD 1.3), n = 31 ^b | SMD -0.54 (-1.06 to -0.03) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |

| Number | Number of children | | Effect [*] | | | | | > | | | _ |
|--|--|---|--|--|----------|--------|------------------|---------------|--------------|--------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Walson et al.,, 1989) | 99.2°F (SD 1.2), n = 25 ^w | 101.6°F (SD 1.3), n = 31 ^b | SMD -0.86 (-1.42 to -0.31) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Kauffma n et al., 1992) | 36.9°C (SD 0.6928), n = 12 ^a | 37.8°C (SD 0.8485), n = 8 ^b | SMD -1.14 (-2.12 to -0.16) | - | Very low | RCT | None d, u | | Serious | Very serious v, ac | None |
| 1 (Kauffma n et al., 1992) | 36.7°C (SD 0.2828), n = 8 ^a | 37.8°C (SD 0.8485), n = 8 ^w | SMD -1.64 (-2.82 to -0.47) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| 1. (Autret- Leca et al., 20070 | 37.4°C (SD 0.9), n = 151 w | 37.4°C (SD 1.0), n = 150 ^{ag} | SMD 0.00 (-0.23 to +0.23) | | Very low | RCT | None d | | Serious | Very serious | None |
| 5 hours | 1 | | | | _ | 1 | | | | | |
| 1 (Walson et al., 1989) | 99.8°F (SD 1.9) ,n = 29 ⁿ | 101.3°F (SD 1.3), n = 31 ^b | SMD -0.43 (-0.94 to +0.09) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Walson et al., 1989) | 99.3°F (SD 1.7) n = 25 ^w | 101.3°F (SD 1.3) n = 31 ^b | SMD -0.79 (-1.34 to -0.25) | - | Moderate | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |

| Number | Number of children | | Effect [*] | | | | | <u></u> | | | |
|---|---|---|--|--|----------|--------|---------------------------------------|---------------|-----------------------|--------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Nadal et al., 2002) | 37.88°C (SD 1.07), n = 100 ^{aa} | 37.85°C (SD 0.87), n = 99 ^{ab} | SMD 0.03 (-0.25 to +0.31) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | None | None |
| 1 (Kauffma n et al., 1992) | 37.0°C (SD 0.6928), n = 12 ^a | 38.1°C (SD 0.5657), n = 8 ^b | SMD -1.63 (-2.69 to -0.57) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| 1 (Kauffma n et al., 1992) | 36.9°C (SD 0.5657), n = 8 w | 38.1°C (SD 0.5657), n = 8 ^b | SMD -2.01 (-3.27 to -0.74) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| Autret- Leca et al., 2007 | 37.4°C (SD 0.9), n = 151 w | 37.6°C (SD 1.0), n = 150 ^{ag} | SMD -0.21 (-0.44 to +0.02) | - | Very low | RCT | None d | - | Serious | Very serious | None |
| 6 hours | | | | | | • | | | | | |
| 1 (Vauzelle - Kervroda n et al., 1997) | 38°C (SD 0.8), n = 56 ^w | 38°C (SD 0.8), n = 55 ^b | SMD 0.00 (-0.37 to +0.37) | - | Low | RCT | Serio us ^d | - | Serious | Serious m | None |
| 1 (Van Esch et al, 1995) | 37.82°C (SD 1.2828), n = 34 ⁿ | 38.23°C (SD 1.3015), n = 35 ^b | SMD -0.31 (-0.79 to +0.16) | - | Very low | RCT | None d, v | - | Very serious af | Serious m | Yes ^{ag} |

| Number | Number of children | | Effect [*] | | | | | > ; | | | Ē |
|-------------------------------------|---|--|--|--|----------|--------|---------------------------------------|---------------|--------------|-------------------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Nadal et al., 2002) | 37.87°C (SD 0.96), n = 100 ^{aa} | 38.10°C (SD 0.97), n = 99 ^{ab} | SMD -0.24 (-0.52 to +0.04) | - | Very low | RCT | Very seriou s ^{d,h, k} | - | Serious | Serious m | None |
| 1 (Walson et al., 1989) | 100.2°F (SD 2.2),n = 29 ⁿ | 101.2°F (SD 1.9), n = 31 ^b | SMD -0.29 (-0.80 to +0.22) | | Low | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Walson et al., 1989) | 99.7°F (SD 1.9) , n = 25 ^w | 101.2°F (SD 1.9), n = 31 ^b | SMD -0.57 (-1.11 to -0.03) | - | Low | RCT | None d, ad, u | - | Serious | Serious m | Yes ^{ae} |
| 1 (Kauffma n et al., 1992) | 37.3°C (SD 0.6928), n = 12 ^a | 38.5°C (SD 1.1314), n = 8 ^b | SMD -1.29 (-2.29 to -0.29) | - | Very low | RCT | None d, u | - | Serious | Very serious _{v, ac} | None |
| 1 (Kauffma n et al., 1992) | 37.2°C (SD 0.5657), n = 8 ^w | 38.5°C (SD 1.1314), n = 8 ^b | SMD -1.37 (-2.50 to -0.25) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| Autret- Leca et al., 2007 | 37.5°C (SD 0.9), n = 151 w | 37.7°C (SD 1.0), n = 150 ^{ah} | SMD -0.21 (-0.44 to +0.02) | - | Very low | RCT | None d | - | Serious | Very serious | None |
| 8 hours | | | | | 1 | I. | | | ı | | |
| 1 (Nadal et al., 2002) | 38.00°C (SD 1.33), n = 100 ^{aa} | 38.20°C (SD 0.84), n = 99 ^{ab} | SMD -0.18 (-0.46 to +0.10) | - | Very low | RCT | Very seriou s d,h, k | - | Serious | None | None |

| Number | Number of children | | Effect [*] | | | | | <u>ج</u> | | | _ |
|--|---|---|--|--|----------|--------|------------------|---------------|-----------------------|--------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Walson et al., 1989) | 101.2°F (SD 2.0), n = 29 ⁿ | 101.2°F (SD 1.8), n = 31 ^b | SMD -0.21 (-0.72 to +0.30) | - | Low | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Walson et al., 1989) | 100.6°F (SD 2.2) n = 25 w | 101.2°F (SD 1.8), n = 31 ^b | SMD -0.50 (-1.03 to +0.04) | - | Low | RCT | None d, ad, u | - | Serious | Serious | Yes ^{ae} |
| 1 (Kauffma n et al., 1992) | 37.7°C (SD 0.8485), n = 8 ^a | 38.8°C (SD 0.8485), n = 8 ^b | SMD -1.23 (-2.32 to -0.13) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| 1 (Kauffma n et al., 1992) | 37.9°C (SD 1.3856), n = 12 w | 38.8°C (SD 0.8485), n = 8 ^b | SMD -0.72 (-1.64 to +0.21) | - | Very low | RCT | None d, u | - | Serious | Very serious v, ac | None |
| Autret- Leca et al, 2007 | 37.6°C (SD 0.9), n = 151 w | 37.6°C (SD 0.95), n = 150 ^{ah} | SMD 0.00 (-0.23 to +0.23) | - | Very low | RCT | None d | - | Serious | Very serious | None |
| 12 hours | | | | | • | | | | | | |
| 1 (Van Esch et al., 1995) 12 hr | 37.87°C (SD 1.3576), n = 32 ⁿ | 37.88°C (SD 1.1241), n = 35 ^b | SMD -0.01 (-0.49 to +0.47) ^b | - | Low | RCT | None d, u | - | Very serious af | Serious m | None |

| Number | Number of children | | Effect [*] | | | | | ÷. | | | ء |
|---------------------------------|---|---|--|--|----------|--------|-----------------------------|---------------|-------------------|-------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 24 hours | | | | | • | | | | | | |
| 1 (Van Esch et al., 1995) | 37.92°C (SD 1.1432), n = 27 ⁿ | 38.18°C (SD 1.2638), n = 33 ^b | SMD -0.21 (-0.72 to +0.30) | - | Very low | RCT | None d, u | - | Very serious | Serious | None |
| 1 (Sarrell et al., 2006) | 40.60°C (SD 1.46)n = 155 ⁿ | 40.55°C (SD 1.31), n = 154° | SMD 0.04 (-0.19 to +0.26) | - | High | RCT | None p | - | None | None | Yes ^q |
| Mean temp | perature at > 24 hours | S | | | | | | | • | | |
| Day 2 | | | | | | | | | | | |
| 1 (Sarrell et al., 2006) | 39.66°C (SD 1.48), n = 155 ⁿ | 39.74°C (SD 1.37), n = 154° | SMD -0.06 (-0.28 to +0.17) | - | High | RCT | None p | - | None | None | Yes ^q |
| Day 3 | | | | | | 1 | | L | l | I. | |
| 1 (Sarrell et al., 2006) | 39.64°C (SD 1.46), n = 155 ⁿ | 39.34°C (SD 1.19) n = 154° | SMD 0.22 (0.00 to +0.45) | - | High | RCT | None p | - | None | None | Yes ^q |
| Afebrile at | 1 to 2 hours | | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Autret et al., 1997) | 33 of 116 ^a | 25 of 113 ^b | RR 1.29 (0.82, 2.02) | - | Low | RCT | Very seriou s d,e,f | - | None | None | None |
| 2 hours | | | | | | | | | | | |
| 1 (Wong et al., 2001) | 145 of 185 ^r | 130 of 191 ^s | RR 1.15 (1.02, 1.30) | - | Moderate | RCT | Serio us ^{d, k} | - | None ^t | None | Yes ^{ah} |

| Number | Number of child | ren | Effect [*] | | | | | <u>,</u> | | | _ |
|--|------------------------|------------------------|--|--|----------|--------|--------------------------------------|---------------|-----------------------|-------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Van Esch et al, 1995) | 27 of 30 ⁿ | 22 of 29 ^b | RR 1.19 (0.94, 1.50)) ^b | - | Very low | RCT | None d, v | - | Very serious | Serious | None |
| Afebrile at | t > 2 to 5 hours | | | | | | | | | | |
| 4 hours | | | | | | | | | | | |
| 1 (Autret et al., 1997) | 69 of 116 ^a | 45 of 113 ^b | RR 1.49 (1.14, 1.96) | - | Low | RCT | Very seriou s d,e,f | - | None | None | None |
| 1 (Van Esch et al., 1995) | 26 of 30 ⁿ | 22 of 29 ^b | RR 1.18 (0.90, 1.55) | - | Very low | RCT | None d, v | - | Very serious af | Serious | None |
| 1 (Vauzelle - Kervroed an et al., 1997) | 56 of 58 ^w | 53 of 55 ^b | RR 1.00 (0.93, 1.08) | - | Moderate | RCT | Serio us ^d | - | Serious | Serious | Yes ^{ai} |
| Afebrile at | t > 5 to 24 hours | | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Autret et al., 1997) | 43 of 116 ^a | 40 of 113 ^b | RR 1.05 (0.74, 1.48) | - | Low | RCT | Very seriou s ^{d,e,f} | - | None | None | None |

| Number | Number of children | | Effect* | | | | | ج | | | - |
|-------------------------------------|-------------------------------|--------------------------------|--|--|----------|--------|--------------|---------------|-----------------------|-------------------------------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 1 (Van Esch et al., 1995) | 20 of 34 ⁿ | 18 of 35 ^b | RR 1.14 (0.75, 1.75) | - | Very low | RCT | None d, u | - | Very serious af | Serious m | None |
| 12 hours | | | | | | | | | | | |
| 1 (Van Esch et al., 1995) | 21 of 34 ⁿ | 24 of 35 ^b | RR 0.96 (0.68, 1.34) | - | Very low | RCT | None d, u | - | Very serious af | Serious | None |
| 24 hours | | • | | | 1 | | 1 | | | | |
| 1 (Van Esch et al., 1995) | 20 of 34 ⁿ | 20 of 35 ^b | RR 1.22 (0.86, 1.74) | - | Very low | RCT | None d, u | - | Very serious | Serious m | None |
| Afebrile at | > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Temperatu | ire AUC | | | | | | | | | | |
| 0 to 8 hour | rs | | | | | | | | | | |
| 1 (Kauffma n et al., 1992) | 730 (576 to 839) ^a | 328 (-356 to 686) ^b | P = 0.05 | - | Very low | RCT | None d, u | - | Serious | Very serious v ac | Yes ^{aj} |
| 1 (Kauffma n et al., 1992) | 590 (160 to 875) w | 328 (-356 to 686) ^b | P = 0.05 | - | Very low | RCT | None d, u | - | Serious | Very serious _{v, ac} | Yes ^{aj} |

| Number | Number of children | | Effect [*] | | | | | <u>></u> | | | Ē |
|----------------------------------|---|--------------------------|--|--|----------|--------|------------------|---------------|------------------------------|--------------|--------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 0 to 6 hour | rs | | | | | • | | • | • | | • |
| 1 (Wilson et al., 1991) | 7.09 (SEM 0.58), n = 43 ⁿ | 6.72 (SEM 0.58), n = 51° | NS | - | Very Low | RCT | None d, u | - | Very serious ^l | Serious v | Yes ^{aj} |
| 1 (Wilson et al., 1991) | 4.91 (SEM 0.47), n = 47 w | 6.72 (SEM 0.58), n = 51° | NS | - | Very low | RCT | None d, u | - | Very serious ^l | Serious v | Yes ^{aj} |
| 0 to 8 hour | | | | | | | | | | | |
| 1 (Walson et al., 1989) | 460.9 ⁿ | 365.0 ^b | NS | - | Low | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 1 (Walson et al., 1989) | 510.9 ^w | 365.0 ^b | P < 0.05 | - | Low | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 0 to 6 hour | rs – total temperature o | hange per hour | | 1 | • | | | | J | | |
| 1 (Walson et al., 1992) | 297 ⁿ | 377 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 1 (Walson et al., 1992) | 385 ^w | 377 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} am |

| Number | Number of child | ren | Effect [*] | | | | | <u>></u> | | | _ |
|----------------------------------|----------------------|----------------------|--|--|----------|--------|------------------|---------------|--------------|-------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 0 to 12 hou | urs – total temperat | ture change per hour | | | | | | | | | |
| 1 (Walson et al., 1992) | 689 ⁿ | 938 ^y | P < 0.05 | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 1 (Walson et al., 1992) | 929 ^w | 938 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 0 to 24 hou | urs – total temperat | ture change per hour | • | | | | • | • | • | | |
| 1 (Walson et al., 1992) | 1572 ⁿ | 2100 ^b | P < 0.05 | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 1 (Walson et al., 1992) | 1995 ^w | 2100 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 0 to 48 hou | urs – total temperat | ture change per hour | | | l . | | | ı | | <u> </u> | |
| 1 (Walson et al, 1992) | 3286 ⁿ | 4400 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |
| 1 (Walson et al, 1992) | 3933 ^w | 4400 ^b | NS | - | Moderate | RCT | None d, ad, u | - | Serious | None | Yes ^{ae,} |

| Number | Number of children | | Effect [*] | | | | | > | | | Ē |
|---|---------------------|----------------|--|--|----------|---|---------------------------|--------------------------|--------------|-----------------|------------------------|
| of studies | Ibuprofen | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Adverse e | vents | | | | | | | | | | |
| 5 (Southey et al., 2009; Pierce et al, 2010; Kauffma n et al., 1992; Sarrell et al., 2006; Walson et al., 1989) | 2962 of 21,843 | 1469 of 11,678 | RR 1.04 (0.98 to 1.10) | - | Very low | Meta- analysi s + addition al RCTs | Serio us ^{am} | Serious _{ak} | Serious | None | None |
| Discontinu | uation of treatment | | | | | | | | | | |
| 1 (Southey et al., 2009) | 5 of 257 | 5 of 226 | RR 0.54 (0.17 to 1.71) | - | Very low | Meta- analysi s of RCTs | Serio us ^{am} | Serious an | Serious | Very serious | None |

NR Not reported

NC Non-calculable

NS Not significant at p < 0.05

Relative and absolute differences are calculated by the NCC technical team based on the data presented in the papers. When this data is unavailable the authors reported figures may be used.

^a Ibuprofen at 7.5 mg/kg

^b Paracetamol at 10 mg/kg

^cNot presented in correct format for analysis of categorical data

^d Method of randomisation and/or blinding not described in detail

- e Blinding of allocation not used
- f Unclear whether groups were comparable for missing data
- ^g Study used a non-validated scoring system
- ^h 6.67 mg/kg of Ibuprofen
- i 10.65 mg/kg of paracetamol
- ¹Investigators not blinded to allocation
- ^k High dropout rate: Nadal 140 of 187 patients did not complete study; Wong 25% withdrawal rate
- Included children aged more than 5 (Nadal = 12; Wong Included children up to 6 years; Ulukol up to 14 years; McIntyre up to aged 12; Kaufmann up to 12; Vauzelle up to 12; Erlewyn; Autret-Leca 12)
- ^m Confidence intervals cross 0 and ± 0.25 effect size
- ⁿ 5 mg/kg of Ibuprofen
- ° 12.5 mg/kg of paracetamol
- ^p Allocation could be determined by different regimens
- ^q Daily temperature was recorded by parents instead of trained clinicians
- ^r At 5mg/kg for initial temp <39.2°C and 10mg/kg for initial temp ≥39.2°C
- \$ 12 mg/kg of paracetamol. The dose of paracetamol was adjusted according to each patient's age following package insert instructions and averaged 12mg/kg
- ^t 15.3 mg/kg paracetamol
- ^u Small sample size (n < 100)
- ^v Data measured from graph so measurement error.
- w 10 mg/kg lbuprofen
- ^x At 20mg/kg in 24 hours
- y At 50mg/kg in 24 hours
- ^z Not calculated
- ^{aa} 6.67 mg/kg of Ibuprofen
- ^{ab} 10.65 mg/kg of paracetamol
- ac RR includes 0 and both \pm 0.25; SMD crosses both \pm 0.5
- ^{ad} Recruited children via newspaper advert
- ae Commercially funded
- ^{af} Children with febrile seizures
- ^{ag} A crossover analysis comparing the study drugs was performed on 22 children with a second episode of fever.
- ^{ah} 1.96h paracetamol; 2.16h ibuprofen
- ai 3.84h paracetamol; 3.79h ibuprofen
- ^{aj} AUC of percentage decrease of temperature (from baseline to normal 37°C) vs. time
- ^{ak} Studies had different treatment regimens, including multidose.
- ^{al} AUC of percentage decrease of temperature (from baseline to 98.6°F) vs time
- am Data from two meta-analysis combined. Methodological issues with underlying RCTs, especially in relation to blinding and allocation concealment.
- ^{an} Included studies had methodological issues, especially relating to blinding and allocation concealment.

Table 19.5 GRADE findings for paracetamol vs. paracetamol and ibuprofen combined

| Number | Number of childr | en | Effect | | | | | _ | | | SI |
|----------------------|-----------------------|-----------------------|---------------------------------------|---------------------------------------|---------|--------|--------------------------|---------------|-------------------|----------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt at 1 to 2 hours | | | | - | | | 1 | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 5 to 24 hours | s | | | | | | | | | |
| 24 hours | | | | | | | | | | | |
| Discomfo rt | 29 of 50 ^a | 22 of 52 ^b | RR 1.37 (0.92 to 2.04) | - | Low | RCT | Serio us ^c | - | None ^d | Serious e | None |
| 1 (Hay et al., 2009) | | | | | | | | | | | |
| Activity | 23 of 48 ^a | 20 of 50 ^b | RR 1.20 (0.76 to 1.88) | - | Very | RCT | Serio | - | None ^d | Serious | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^c | | | | |
| Appetite | 14 of 48 ^a | 10 of 48 ^b | RR 1.40 (0.69 to 2.84) | - | Very | RCT | Serio | - | None ^d | Very | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^c | | | serious ^f | |
| Sleep | 20 of 52 ^a | 17 of 46 ^b | RR 1.04 (0.62 to 1.73) | - | Very | RCT | Serio | - | None ^d | Very · f | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^c | | | serious | |

| Number | Number of child | dren | Effect | | | | | _ | | | SI |
|---|-----------------------|-----------------------|---------------------------------------|---------------------------------------|--------------|--------|--------------------------|---------------|-------------------|------------------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt > 24 hours | | | | | | • | | | | |
| 48 hours | | | | | | | | | | | |
| Discomfo rt 1 (Hay et al., 2009) | 36 of 52 ^a | 34 of 52 ^b | RR 1.06 (0.81 to 1.38) | - | Low | RCT | Serio us ^c | - | None ^d | Serious e | |
| Activity 1 (Hay et al., 2009) | 28 of 52 ^a | 31 of 52 ^b | RR 0.90 (0.65 to 1.26) | - | Very low | RCT | Serio us ^c | - | None ^d | Very serious ^f | |
| Appetite 1 (Hay et al., 2009) | 21 of 51 ^a | 21 of 51 ^b | RR 1.00 (0.63 to 1.59) | - | Very low | RCT | Serio us ^c | - | None ^d | Very serious ^f | |
| Sleep 1 (Hay et al., 2009) | 25 of 52 ^a | 27 of 52 ^b | RR 0.93 (0.63 to 1.36) | - | Very low | RCT | Serio us ^c | - | None ^d | Very serious ^f | |
| Day 5 | 1 | l | | | II. | | | I. | | l | |
| Discomfo rt 1 (Hay et al., 2009) | 38 of 50 ^a | 43 of 49 ^b | RR 0.87 (0.72 to 1.04) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | |
| Activity 1 (Hay et al., 2009) | 37 of 51 ^a | 44 of 49 ^b | RR 0.81 (0.67 to 0.98) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | |

| Number | Number of children | | Effect | | | | | _ | | | SI | |
|---|--|--|---------------------------------------|---------------------------------------|--------------|--------|----------------------------|---------------|-------------------|--------------|-------------------------|--|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations | |
| Appetite 1 (Hay et al., 2009) | 32 of 52 ^a | 29 of 50 ^b | RR 1.06 (0.77 to 1.46) | - | Low | RCT | Serio us ^c | - | None ^d | Serious e | | |
| S <i>leep</i> 1 (Hay et al., 2009) | 27 of 51 ^a | 31 of 50 ^b | RR 0.85 (0.61 to 1.20) | - | Low | RCT | Serio us ^c | - | None ^d | Serious e | | |
| Mean char | nge temperature at 1 | to 2 hours | | | | | | | | | | |
| 1 hour | | | | | | | | | | | | |
| 1 (Erlewyn- Lajeunes se, 2006) | -1.22 (0.95 to 1.50), n = 36 ^g | -0.95 (0.72 to 1.17), n = 37 ^h | RR 0.36 (-0.10 to 0.82) | - | Mode rate | RCT | Serio us ^{i,j} | - | Serious d | Serious e | None | |
| Mean char | nge in temperature at | > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | | |
| Mean char | nge in temperature at | > 5 to 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | | |
| Mean char | lean change in temperature at > 24 hours | | | | | | | | | | | |
| No data | | | | | | | | | | | | |

| Number | Number of children | | Effect | | | | | > | | | SI |
|--|---|---|--|---------------------------------------|--------------|----------|----------------------------|---------------|-------------------|-------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean temp | perature at 1 to 2 hou | rs | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Erlewyn- Lajeunes se, et al., 2006) | 37.59°C (SD 0.61), n = 36 ⁹ | 37.98°C (SD 0.47), n = 37 ^h | RR -0.71 (-1.18 to -0.24) Adjusted 0.35C (0.10 to 0.6), <i>P</i> = 0.028. | - | Mode rate | RCT | Serio us ^{i,j} | - | Serious d | None | None |
| Mean temp | perature at > 2 to 5 ho | ours | | | | | | | | | |
| No data | | | | | | | | • | • | • | |
| Mean tem | perature at > 5 to 24 h | nours | | | | | | | | | |
| 1 (Hay et al., 2009) | 36.6°C (SD 1.01), n = 52 ^a | 36.4°C (SD 0.89), n = 52 ^b | SMD 0.21 (-0.18 to +0.59) | - | Low | RCT | Serio us ^c | - | None ^d | Serious | |
| Mean temp | perature at > 24 hours | S | | | | | | | | | |
| 1 (Hay et al., 2009) | 36.0°C (SD 0.66), n = 52 ^a | 36.2°C (SD 0.93), n = 52 ^b | SMD -0.25 (-0.63 to +0.14) | - | Low | RCT | Serio us ^c | - | None ^d | Serious | |
| Afebrile at | 1 to 2 hours | | | | | | | | | | |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 33 of 52 ^b | RR 1.42 (1.14 to 1.78) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | Yes ^k |
| Afebrile at | > 2 to 5 hours | | | | | <u> </u> | | ı | 1 | | ı |
| 1 (Hay et al., 2009) | 51 of 52 ^a | 37 of 52 ^b | RR 1.38 (1.15 to 1.65) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | Yes ^k |

| Number | Number of children | | Effect | | | | | _ | | | St |
|----------------------|------------------------------|-------------------------------|--|---------------------------------------|--------------|----------|--------------------------|---------------|-------------------|--------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Afebrile at | > 5 to 24 hours | | | | 1 | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 39 of 52 ^b | RR 1.21 (1.01 to 1.44) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | Yes ^k |
| 8 hours | | | | | -1 | | <u> </u> | | | <u> </u> | <u> </u> |
| 1 (Hay et al., 2009) | 45 of 52 ^a | 42 of 52 ^b | RR 1.07 (0.90 to 1.27) | - | Mode rate | RCT | Serio us ^c | - | None ^d | Serious e | Yes ^k |
| 12 hours | | <u> </u> | | | 11 | | | | | | |
| 1 (Hay et al., 2009) | 49 of 52 ^a | 39 of 52 ^b | RR 1.26 (1.06 to 1.49) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | Yes ^k |
| Afebrile at | > 24 hours | | | | | <u> </u> | | | | <u> </u> | |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 46 of 52 ^b | RR 1.02 (0.90 to 1.17) | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | Yes ^k |
| Time with | out fever | | | | | • | | • | <u> </u> | • | |
| 0 to 4 hour | 'S | | | | | | | | | | |
| 1 (Hay et al., 2009) | 116.2 (SD 65.0) ^a | 171.1 (SD 40.8) ^b | Adjusted mean difference 55.3 (33.1 to 77.5), $P < 0.001$ | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | None |
| 24 hours | 1 | ı | | 1 | | 1 | 1 | 1 | l . | | |
| 1 (Hay et al., 2009) | 1217.4 (SD 237.6) | 940.3 (SD 362.9) ^b | Adjusted mean difference 4.4 (2.4 to 6.3), <i>P</i> < 0.001 | - | Mode rate | RCT | Serio us ^c | - | None ^d | None | None |

| Number | | | Effect | | | | | > | | | ns |
|----------------------|-----------------------|-----------------------|---------------------------------------|---------------------------------------|---------|--------|--------------------------|---------------|-------------------|----------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Adverse e | events | | | | | | | | | | |
| Diarrhoea | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 12 of 52 ^a | 10 of 52 ^b | RR 1.20 (0.57 to 2.53) | - | Low | RCT | Serio us ^c | - | None ^d | Very Serious e | None |
| Vomiting | l | 1 | 1 | | 1 | l | I | | I. | I. | |
| 1 (Hay et al., 2009) | 2 of 52 ^a | 6 of 52 ^b | RR 0.33 (0.07 to 1.58) | - | Low | RCT | Serio us ^c | - | None ^d | Very Serious e | None |

NR Not reported

NC Non-calculable

^a Hay - 15mg/kg paracetamol + 10mg/kg ibuprofen

^b15 mg/kg paracetamol

^cRequired sample size not achieved and blinding may not have been achieved

^d Children aged more than 5 included in the study (Hay up to 6)

e RR includes 0 and ± 0.25

fRR includes 0 and both ± 0.25

g15mg/kg + 5 mg/kg

h 15mg/kg paracetamol

Allocation of treatment not blinded

^j Small sample size (n < 100)

^k Afebrile =< 37.2

Table 19.6 GRADE findings for paracetamol vs. paracetamol and ibuprofen alternating

| Number | Number of children | Í | Effect | | | | | > | | | ns . |
|------------------------------------|---|--|---------------------------------------|---------------------------------------|---------|--------|-------------------|---------------|--------------|-------------|-------------------------|
| of studies | Alternating | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfor | rt at 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfor | rt at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfor | rt at > 5 to 24 hours | | | | | | | | | | |
| Day 1 | | | | | • | | | | | | |
| 1 (Sarrell, et al., 2006) | 9.26 (SD 2.49), n = 155 ^a | 11.77 (SD 2.64), n = 154 ^b | SMD -0.98 (-1.21 to -0.74) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Discomfor | rt > 24 hours | | | | | | | | | | |
| Day 2 | | | | | | _ | | | | | |
| 1 (Sarrell et al., 2006) | 5.09 (SD 2.78), n = 155 ^a | 8.87 (SD 2.54), n = 154 ^b | SMD -1.42 (-1.67 to -1.17) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Day 3 | | | | | | | | | | | |
| 1 (Sarrell et al., 2006) | 4.18 (SD 2.74), n = 155 ^a | 7.66 (SD 2.96), n = 154 ^b | SMD -1.22 (-1.46 to -0.97) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Mean chai | nge temperature at 1 | to 2 hours | | | • | • | | | | | |
| No data | | | | | | | | | | | |

| Number | Number of children | | | Effect | | | | | > | | | SI |
|---|--|-----------------------------------|----------|---------------------------------------|---------------------------------------|-------------|--------|---|---------------|-------------------|-----------------|-------------------------|
| of studies | Alternating | Paracetamo | | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean chai | nge in temperature at | > 2 to 5 hours | 5 | | | _ | | | | <u>'</u> | <u>'</u> | |
| No data | | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 5 to 24 hou | rs | | | | | | | | | |
| No data | | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | | |
| Mean temp | perature at 1 to 2 hou | rs | | | | | | | | | | |
| 1 (Pashap our et al., 2009) 2 hours | 38.8°C (SD 0.59), n = 35° | 38.8°C (S n = 35 ^f | D 0.47), | SMD 0.00 (-0.47 to +0.47) | - | Low | RCT | Very seriou s ^{g, h, i,} j, k | None | None | None | None |
| Mean tem | perature at > 2 to 5 ho | ours | | | | | | | | | 1 | |
| 3 hours | | | | | | | | | | | | |
| 1 (Kramer et al., 2008) 3 hours | 37.7°C (SD 0.6224), n = 19 ^l | 37.7°C (SI n = 19 ^f | 0.415), | SMD 0.00 (-0.64 to +0.64) | - | Very low | RCT | Serio us ^k | None | None ^m | Very serious | None |
| 4 hours | 1 | 1 | | <u> </u> | <u> </u> | 1 | 1 | | ı | 1 | 1 | <u> </u> |
| 1 (Pashap our et al., 2009) | 38.4°C (SD 0.34), n = 35° | 38.5°C (S n = 35 ^f | SD 0.3), | SMD -0.31 (-0.78 to +0.16) | - | Very low | RCT | Very seriou s ^{g, h, i,} j, k | None | None | Serious | None |

| Number | Number of children | | Effect | | | | | > | | | SI |
|--------------------------------------|--|--|---------------------------------------|---------------------------------------|--------------|--------|---|---------------|-------------------|-----------------|-------------------------|
| of studies | Alternating | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 1 (Kramer et al., 2008) | 37.4°C (SD 0.8299), n = 19 ¹ | 38.0°C (SD 1.0374), n = 19 ^f | SMD -0.63 (-1.28 to +0.03) | - | Very low | RCT | Serio us ^k | None | None ^m | Serious ° | None |
| 5 hours | | | | | • | | • | | | | |
| 1 (Pashap our et al., 2009) | 38.0°C (SD 0.47), n = 35 ^e | 38.2°C (SD 0.38), n = 35 ^f | SMD -0.46 (-0.94 to +0.01) | - | Very low | RCT | Very seriou s ^{g, h, l,} j, k | None | None | Serious | None |
| 1 (Kramer et al., 2008) | 37.1°C (SD 0.6224), n = 19 ¹ | 37.9°C (SD 0.8299), n = 19 ^f | SMD -1.07 (-1.75 to -0.38) | - | Very low | RCT | Serio us ^k | None | None ^m | None | None |
| Mean temp | perature at > 5 to 24 h | nours | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Kramer et al., 2008) | 37.4°C (SD 0.8299), n = 19 ^l | 37.5°C (SD 0.8299), n = 19 ^f | SMD -0.12 (-0.75 to +0.52) | - | | RCT | Serio us ^k | None | None ^m | Very serious | None |
| 7 hours | | | | | 1 | | 1 | | • | • | |
| 1 (Pashap our et al., 2009) | 38.0°C (SD 0.48), n = 35 ^e | 38.2°C (SD 0.57), n = 35 ^f | SMD -0.38 (-0.85 to +0.10) | - | Mode rate | RCT | Very seriou s ^{g, h, i,} j, k | None | None | Serious ° | None |

| Number | Number of children | | | Effect | | | | | \ \ | | | J.S |
|--------------------------------------|--|-------------------------------------|--------|---------------------------------------|---------------------------------------|--------------|--------|---|---------------|--------------|-------------|-------------------------|
| of studies | Alternating | Paracetamol | | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 8 hours | | | | | | • | | | | | | |
| 1 (Pashap our et al., 2009) | 37.7°C (SD 0.46), n = 35° | 38.0°C (SD n = 35 ^f | 0.52), | SMD -0.60 (-1.08 to -0.12) | - | Mode rate | RCT | Very seriou s ^{g, h, i,} j, k | None | None | None | None |
| Mean temp | perature at > 24 hours | 5 | | | | | | | | | | |
| Day 1 | | | | | | | • | • | • | • | | • |
| 1 (Sarrell et al., 2006) | 39.64°C (SD 1.17), n = 155 ^a | 40.55°C (SD n = 155 ^b | 1.31), | SMD -0.73 (-0.96 to -0.50) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Day 2 | | ı | | | 1 | | | <u>'</u> | | | 1 | |
| 1 (Sarrell et al., 2006) | 38.78°C (SD 0.87), n = 155°a | 39.74°C (SD n = 155 ^b | 1.37), | SMD -0.83 (-1.07 to -0.60) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Day 3 | | I | | | | | | | | | | |
| 1 (Sarrell et al., 2006) | 38.54°C (SD 0.74), n = 155 ^a | 39.34°C (SD n = 155 ^b | 1.19), | SMD -0.81 (-1.04 to -0.57) | - | High | RCT | None ^c | None | None | None | Yes ^d |
| Afebrile at | 1 to 2 hours | | | | | | | • | | | | |
| No data | | | | | | | | | | | | |
| Afebrile at | > 2 to 5 hours | | | | | | | | | | | |
| No data | | | | | | | | | | | | |
| Afebrile at | t > 5 to 24 hours | | | | | | | | | | | |
| No data | | | | | | | | | | | | |

| Number | Number of children | | Effect | | | | | . | | | ns |
|---------------|--------------------|-------------|---------------------------------------|---------------------------------------|---------|--------|-------------|--------------|--------------|-------------|-----------------------|
| of studies | Alternating | Paracetamol | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistenc | Indirectness | Imprecision | Other consideratio |

Afebrile at > 24 hours

No data

Temperature AUC

No data

Adverse events

No reported

NR Not reported

- ^a Alternating acetaminophen (12.5 mg/kg) with ibuprofen (5 mg/kg) every 4 hours
- ^b Acetaminophen (12.5 mg/kg) every 6 hours
- ^c Allocation could be determined by different regimens
- ^d Daily temperature was recorded by parents instead of trained clinicians
- ^e Alternating ibuprofen (10 mg/kg) with acetaminophen (15 mg/kg) every 4 hours
- ^f Acetaminophen (15 mg/kg) every 4 hours
- g Allocation not blinded
- ^h Methodology not explained in detail
- ¹Reporting schedule unclear why 2, 4, 5, 7, and 8 hours; are 1, 3, & 6 unreported?
- ^j Missing data not reported
- k Small sample size (n<100)
- ¹ Alternating acetaminophen (15 mg/kg) with ibuprofen (10 mg/kg) with) every 3 hours
- m Included children aged more than 5
- ⁿRR includes 0 and both ± 0.25; SMD crosses both ± 0.5
- $^{\circ}$ RR includes 0 and \pm 0.25; SMD \pm 0.5

Table 19.7 GRADE findings for ibuprofen vs. paracetamol and ibuprofen combined

| Number | Number of children | | Effect | | | | | | | | |
|----------------------|-----------------------|-----------------------|------------------------------------|---------------------------------------|---------|--------|--------------------------|---------------|-------------------|----------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt at 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 5 to 24 hours | | | | | | | | | | |
| 24 hours | | | | | | | | | | | |
| Discomfo rt | 29 of 50 ^a | 36 of 52 ^b | RR 0.84 (0.62 to 1.13) | - | Low | RCT | Serio us ^c | None | None ^d | None | None |
| 1 (Hay et al., 2009) | | | | | | | | | | | |
| Activity | 23 of 48 ^a | 20 of 34 ^b | RR 0.81 (0.54 to 1.22) | - | Very | RCT | Serio | None | None ^d | None | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^{c,e} | | | | |
| Appetite | 14 of 48 ^a | 14 of 52 ^b | RR 1.08 (0.58 to 2.03) | - | Very | RCT | Serio | None | None ^d | Very | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^c | | | serious ^f | |
| Sleep | 20 of 52 ^a | 13 of 26 ^b | RR 0.77 (0.46 to 1.29) | - | Very | RCT | Serio | None | None ^d | Very | None |
| 1 (Hay et al., 2009) | | | | | low | | us ^{c,e} | | | serious ^f | |

| Number | Number of child | ren | Effect | | | | | | | | |
|------------------------------------|-----------------------|-----------------------|---|---------------------------------------|--------------|--------|--------------------------|---------------|-------------------|------------------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt > 24 hours | | | | • | | | | | | |
| 48 hours | | | | | | | | | | | |
| Comfort 1 (Hay et al., 2009) | 36 of 52 ^a | 37 of 52 ^b | RR 0.97 (0.76 to 1.25) Adjusted OR 0.89 (0.32 to 2.43) | - | Modera te | RCT | Serio us ^c | None | None ^d | Serious g | None |
| Activity 1 (Hay et al., 2009) | 28 of 52 ^a | 37 of 51 ^b | RR 0.74 (0.55 to 1.00) | - | Modera te | RCT | Serio us ^c | None | None ^d | Serious g | None |
| Appetite 1 (Hay et al., 2009) | 21 of 51 ^a | 22 of 50 ^b | RR 0.94 (0.59 to 1.47) | - | Very low | RCT | Serio us ^c | None | None ^d | Very serious ^f | None |
| Sleep 1 (Hay et al., 2009) | 25 of 52 ^a | 31 of 51 ^b | RR 0.79 (0.55 to 1.13) | - | Low | RCT | Serio us ^c | None | None ^d | Serious g | None |
| Day 5 | • | I | | | · I | ı | | 1 | _ L | - L | 1 |
| Comfort 1 (Hay et al., 2009) | 38 of 50 ^a | 38 of 47 ^b | RR 0.94 (0.76 to 1.16) | - | Modera te | RCT | Serio us ^c | None | None ^d | None | None |
| Activity 1 (Hay et al., 2009) | 37 of 51 ^a | 39 of 46 ^b | RR 0.86 (0.69 to 1.05) | - | Low | RCT | Serio us ^c | None | None ^d | Serious g | None |

| Number | Number of children | | Effect | | | | | | | | |
|---|---|--|---------------------------------------|---------------------------------------|--------------|--------|-----------------------------|---------------|-------------------|------------------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Appetite 1 (Hay et al., 2009) | 32 of 52 ^a | 29 of 49 ^b | RR 1.04 (0.76 to 1.43) | - | Low | RCT | Serio us ^c | None | None ^d | Serious g | None |
| Sleep 1 (Hay et al., 2009) | 27 of 51 ^a | 25 of 50 ^b | RR 1.06 (0.72 to 1.55) | - | Low | RCT | Serio us ^c | None | None ^d | Very serious ^f | None |
| Mean char | nge temperature at 1 to | o 2 hours | | | | | | | L | | |
| 1 hour | | | | | | | | | | | |
| 1 (Erlewyn- Lajeunes se et al., 2006) | -1.22 (0.95 to 1.50) n = 36 ^h | -0.92 (0.70 to 1.14), n = 35 ⁱ | SMD -0.33 (-0.80 to +0.13) | - | Modera te | RCT | Serio us ^{j, k} | None | Serious d | Very serious ^f | None |
| Mean char | nge in temperature at | > 2 to 5 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean char | nge in temperature at : | > 5 to 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean char | nge in temperature at : | > 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |

| Number | Number of children | | Effect | | | | | | | | |
|---|---|---|--|---------------------------------------|--|--------|---------------------------------------|---------------|-------------------|--------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean tem | perature at 1 to 2 hour | s | | | <u>. </u> | | | | <u>'</u> | | |
| 1 hour | | | | | | | | | | | |
| 1 (Erlewyn- Lajeunes se et al., 2006) | 37.59°C (SD 0.61) h | 37.81°C (SD 0.69) [†] | SMD -0.33 (-0.80 to +0.13) Adjusted MD = 0.25C (-0.01 to 0.50), p = 0.166 | - | Modera te | RCT | Serio us ^{j, k,} | None | Serious d | Serious g | None |
| 1 (Paul et al., 2010) | 37.4°C (SD 0.5), n = 20 ¹ | 37.6°C (SD 0.5n = 20 ^m | SMD -0.39 (-1.02 to +0.23) | - | | RCT | Very seriou s ^{k,n, o} | None | None ^d | Serious g | None |
| 2 hours | | | | | _ | | | | | | |
| 1 (Paul et al., 2010) | 37.0°C (SD 0.5), n = 20 ¹ | 37.1°C (SD 0.4), n = 20 ^m | SMD -0.22 (-0.84 to +0.41) | - | | RCT | Very seriou s ^{k,n, o} | None | None ^d | Serious g | None |
| Mean tem | perature at > 2 to 5 hor | urs | | | | | | | 1 | | |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.4), n = 20 ¹ | 37.2°C (SD 0.6), n = 20 ^m | SMD -0.58 (-1.21 to +0.06) | - | | RCT | Very seriou s ^{k,n, o} | None | None ^d | Serious g | None |
| 4 hours | L | L | ı | ı | · L | 1 | | 1 | 1 | 1 | ı |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.3), n = 20 ^l | 37.5°C (SD 1.1), n = 20 ^m | SMD -0.73 (-1.37 to -0.09) | - | | RCT | Very seriou s ^{k,n, o} | None | None ^d | None | None |

| Number | Number of children | | Effect | | | | | | | | |
|-----------------------------|--|--|---------------------------------------|---------------------------------------|--------------|--------|---------------------------------------|---------------|-------------------|--------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 5 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.5), n = 20 ^l | 38.0°C (SD 1.1), n = 20 ^m | SMD -1.26 (-1.95 to -0.58) | - | | RCT | Very seriou s ^{k,n, o} | None | None ^d | None | None |
| Mean temp | perature at > 5 to 24 ho | ours | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 37.2°C (SD 0.6), n = 20 ^l | 38.5°C (SD 1.5), n = 20 ^m | SMD -1.12 (-1.79 to -0.44) | - | | RCT | Very seriou s ^{k,n, o} | - | None ^d | None | None |
| 24 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 36.6°C (SD 1.01), n = 52 _a | 36.4°C (SD 0.85), n = 52 ^b | SMD 0.21 (-0.17 to +0.60) | - | Modera te | RCT | Serio us ^c | - | None ^d | Serious g | None |
| Mean temp | perature at > 24 hours | | | | | L | | | | L | |
| 1 (Hay et al., 2009) | 36.0°C (SD 0.66), n = 52 ^a | 36.1°C (SD 0.78), n = 52 ^b | SMD -0.14 (-0.52 to +0.25) | - | Modera te | RCT | Serio us ^c | - | None ^d | Serious g | None |
| Afebrile at | 1 to 2 hours | | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 18 of 20 ^l | 16 of 20 ^m | RR 1.13 (0.86 to 1.46) | - | Very low | RCT | Very seriou s ^{k,n, o} | - | None ^d | Serious g | None |

| Number | Number of child | ren | Effect | | | | | | | | |
|-----------------------------|-----------------------|-----------------------|---------------------------------------|---------------------------------------|--------------|--------|---------------------------------------|---------------|-------------------|--------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 2 hours | | | | | | | | | • | | • |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 44 of 52 ^b | SMD 1.07 (+0.92 to +1.24) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| 1 (Paul et al., 2010) | 20 of 20 ^l | 19 of 20 ^m | RR 1.05 (0.92 to 1.20) | - | Low | RCT | Very seriou s ^{k,n, o} | - | None ^d | None | None |
| Afebrile at | t > 2 to 5 hours | 1 | | | 1 | | | | <u>'</u> | | |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 20 of 20 ^l | 18 of 20 ^m | RR 1.11 (0.93 to1.31) | - | Very low | RCT | Very seriou s ^{k,n, o} | - | None ^d | Serious g | None |
| 4 hours | | | • | | 1 | | • | • | • | • | • |
| 1 (Hay et al., 2009) | 51 of 52 ^l | 44 of 52 ^m | RR 1.16 (1.03 to 1.31) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| 1 (Paul et al., 2010) | 20 of 20 ^l | 14 of 20 ^m | RR 1.41 (1.05 to 1.90) | - | Low | RCT | Very seriou s ^{k,n, o} | - | None ^d | None | None |
| 5 hours | • | • | • | • | | • | Į. | | | 1 | |
| 1 (Paul et al., 2010) | 20 of 20 ^l | 12 of 20 ^m | RR 1.64 (1.15 to 2.35) | - | Low | RCT | Very seriou s ^{k,n, o} | - | None ^d | None | None |

| Number | Number of child | ren | Effect | | | | | | | | |
|------------------------------------|-----------------------|-----------------------|--|---------------------------------------|--------------|--------|---------------------------------------|---------------|-------------------|-------------|----------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Afebrile at | > 5 to 24 hours | | | | | | | | - | | |
| 6 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 37 of 52 ^b | RR 1.27 (1.05 to 1.54) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| 1 (Paul et al., 2010) | 19 of 20 ¹ | 10 of 20 ^m | RR 1.90 (1.21 to 2.98) | - | Low | RCT | Very seriou s ^{k,n, o} | - | None ^d | None | None |
| 8 hours | I | . | | | | 1 | | | | 1 | -1 |
| 1 (Hay et al., 2009) 8 hours | 45 of 52 ^a | 46 of 52 ^b | RR 0.98 (0.85 to 1.13) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| 12 hours | | 1 | | | | | I | | - | | |
| 1 (Hay et al., 2009) | 49 of 52 | 47 of 52 | RR 1.04 (0.93 to 1.17) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| Afebrile at | > 24 hours | | | | | | | | | | |
| 24 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 47 of 52 ^a | 45 of 52 ^b | RR 1.04 (0.91 to 1.20) | - | Modera te | RCT | Serio us ^c | - | None ^d | None | None |
| Time with | out fever | | | | | | | | | | |
| 4 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 171.1 (40.8) | 156.0 (57.6) | adjusted mean difference 16. (-7.0 to 39.4), p = 0.2 | 2 - | Modera te | RCT | Serio us ^c | - | None ^d | - | None |

| Number | Number of children | | Effect | | | | | | | | |
|----------------------|--------------------|----------------|--|---------------------------------------|--------------|--------|--------------------------|---------------|-------------------|------------------------------|-------------------------|
| of studies | Combined | Mono | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 24 hours | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 1217.4 (237.6) | 1055.2 (329.7) | adjusted mean difference 2.5 (0.6 to 4.4), p = 0.008 | - | Modera te | RCT | Serio us ^c | - | None ^d | - | None |
| Adverse ev | vents | | | | | | | | | | |
| Diarrhoea | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 12 of 52 | 9 of 52 | RR 0.75 (0.35 to 1.63) | - | Very low | RCT | Serio us ^c | - | None ^d | Very serious ^f | |
| Vomiting | | | | | | | | | | | |
| 1 (Hay et al., 2009) | 2 of 52 | 3 of 52 | RR 1.50 (0.26 to 8.61) | - | Very low | RCT | Serio us ^c | - | None ^d | Very serious ^f | |

NR Not reported

NC Non-calculable

^a Hay - 15mg/kg paracetamol + 10mg/kg ibuprofen

^b10 mg/kg ibuprofen

^cRequired sample size not achieved and blinding may not have been achieved

^d Children aged more than 5 included in the study (Hay up to 6; Erlewyn up to 10; Paul up to 8)

^e High level of missing data for ibuprofen group

^fRR includes 0 and both ± 0.25; SMD crosses both ± 0.5

g RR includes 0 and ± 0.25; SMD crosses ± 0.5

h 15mg/kg + 5 mg/kg

ⁱ5 mg/kg ibuprofen

^j Allocation of treatment not blinded

^k Small sample size (n < 100)

¹10 mg/kg Ibuprofen and 15 mg/kg acetaminophen single dose

^m 10 mg/kg Ibuprofen single dose

ⁿBlinding of allocation not used

[°] Children included in the study more than once

Table 9.8 GRADE findings for ibuprofen vs. paracetamol and ibuprofen alternating

| Number | Number of children | | Effect | | | | | > | | | su |
|--------------------------------|---|--|--|--|---------|--------|-------------------|---------------|--------------|-------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Discomfo | rt at 1 to 2 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 5 to 24 hours | | | | | | | | | | |
| Day 1 | | | | | | | | | | | |
| NCCPC score | 9.26 (SD 2.49), n = 155 ^a | 11.48 (SD 2.58), n = 155 ^b | SMD -0.87 (-1.11 to -0.64) | - | | RCT | None ^c | - | None | None | Yes ^d |
| 1 (Sarrell | | | | | | | | | | | |
| et al., 2006) | | | | | | | | | | | |
| Discomfo | rt > 24 hours | | | | | | | | | | |
| Day 2 | | | | | | | | | | | |
| NCCPC score | 5.09 (SD 2.78), n = 155 ^a | 8.83 (SD 2.67), n = 155 ^b | SMD -1.37 (-1.62 to -1.12) | - | High | RCT | None ^c | - | None | None | Yes ^d |
| 1 (Sarrell et al., 2006) | | | | | | | | | | | |

| Number | Number of children | | Effect | | | | | > | | | SI |
|--------------------------------|---|--------------------------------------|--|--|----------|--------|------------------------------|---------------|--------------|------------------------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Day 3 | | | | | - | | | | • | • | |
| NCCPC score | 4.18 (SD 2.74), n = 155 ^a | 7.96 (SD 2.71), n = 155 ^b | SMD -1.38 (-1.63 to -1.14) | - | High | RCT | None ^c | - | None | None | Yes ^d |
| 1 (Sarrell et al., 2006) | | | | | | | | | | | |
| Mean chai | nge temperature at 1 | to 2 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 2 to 5 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 5 to 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean temp | perature at 1 to 2 hou | rs | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 37.6°C (SD 0.4), n = 20° | 37.6°C (SD 0.5), n = 20 ^f | SMD 0.00 (-0.62 to +0.62) | - | Very low | RCT | Serio us ^{g,h,i} | - | None | Very serious ^j | None |
| 2 hours | | | | | | | | | | | |
| 1 (Paul et al.,2010) | 37.2°C (SD 0.3), n = 20° | 37.1°C (SD 0.4), n = 20 ^f | SMD 0.28 (-0.35 to +0.90) | - | Very low | RCT | Serio us ^{g,h,i} | - | None | Serious k | None |

| Number | Number of children | | Effect | | | | | > | | | SL |
|-----------------------------------|---|---|--|--|----------|--------|------------------------------|---------------|--------------|--------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean tem | perature at > 2 to 5 h | ours | | | | | | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al.,2010) | 36.9°C (SD 0.4), n = 20° | 37.2°C (SD 0.6), n = 20 ^f | SMD -0.58 (-1.21 to +0.06) | - | Low | RCT | Serio us ^{g,h,i} | - | None | Serious k | None |
| 4 hours | | | | | • | | | | • | | • |
| 1 (Nabulsi et al., 2006) | 37.5°C (SD 0.7), n = 37 ^l | 37.7°C (SD 0.9), n = 33 ^m | SMD -0.25 (-0.72 to +0.22) | - | Very low | RCT | Serio us ^g | - | Serious | Serious k | None |
| 1 (Paul et al.,2010) | 36.9°C (SD 0.3), n = 20° | 37.5°C (SD 1.1), n = 20 ^f | SMD -0.73 (-1.37 to -0.09) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |
| 5 hours | | | | | • | | | | • | | • |
| 1 (Paul et al.,2010) | 36.8°C (SD 0.3), n = 20° | 38.0°C (SD 1.1), n = 20 ^f | SMD -1.46 (-2.16 to -0.75) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |
| Mean temp | perature at > 5 to 24 l | nours | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Paul et al.,2010) | 36.9°C (SD 0.3), n = 20° | 38.5°C (SD 1.5), n = 20 ^f | SMD -1.45 (-2.15 to -0.75) | - | Low | RCT | Serio us ^{g,h,i} | - | None | Serious k | None |

| Number | Number of children | | Effect | | | | | _ | | | SI |
|--------------------------------|--|--|--|--|----------|----------|------------------------------|---------------|--------------|------------------------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Mean tem | perature at > 24 hours | s | | | | | | | | | |
| Day 1 | | | | | | • | 1 | | • | 1 | |
| 1 (Sarrell et al., 2006) | 39.64°C (SD 1.17), n = 155°a | 40.6°C (SD 1.46(), n = 155 ^b | SMD -0.72 (-0.95 to -0.49) | - | High | RCT | None ^c | - | None | None | Yes ^d |
| Day 2 | | | | | | • | | | • | | |
| 1 (Sarrell et al., 2006) | 38.78°C (SD 0.87), n = 155 ^a | 39.66°C (SD 1.48), n = 155 ^b | SMD -0.72 (-0.95 to -0.49) | - | High | RCT | None ^c | - | None | None | Yes ^d |
| Day 3 | | | | | | <u> </u> | | <u> </u> | <u> </u> | | I |
| 1 (Sarrell et al., 2006) | 38.54°C (SD 0.74), n =155°a | 39.64°C (SD 1.46), n = 155 ^b | SMD -0.95 (-1.18 to -0.71) | - | High | RCT | None ^c | - | None | None | Yes ^d |
| Afebrile a | t 1 to 2 hours | | | | | · | | | l | | |
| 1 hour | | | | | | | | | | | |
| 1 (Paul et al.,2010) | 16 of 20 ^e | 16 of 20 ^f | RR 1.00 (0.73, to1.36) | - | Very low | RCT | Serio us ^{g,h,i} | - | None | Very serious ^j | None |
| 2 hours | 1 | 1 | 1 | 1 | 1 | 1 | | ı | <u>.</u> | | 1 |
| 1 (Paul et al., 2010) | 20 of 20 ^e | 19 of 20 ^f | RR 1.05 (0.92 to 1.20) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |

| Number | Number of childr | en | Effect | | | | | > | | | SI |
|-----------------------------------|-----------------------|-----------------------|--|--|----------|--------|------------------------------|---------------|--------------|--------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| Afebrile at | t > 2 to 5 hours | | | | | • | • | | • | | • |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 20 of 20 ^e | 18 of 20 ^f | RR 1.11 (0.93 to 1.31) | - | Low | RCT | Serio us ^{g,h,i} | - | None | Serious k | None |
| 4 hours | | · | • | | | | • | | | | |
| 1 (Paul et al., 2010) | 20 of 20 ^e | 14 of 20 ^f | RR 1.41 (1.05 to 1.90) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |
| 5 hours | | | | • | | • | 1 | • | • | | • |
| 1 (Paul 2010) | 20 of 20 ^e | 12 of 20 ^f | RR 1.64 (1.15 to 2.35) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |
| Afebrile at | t > 5 to 24 hours | | | | | | | | | L | |
| 6 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 20 of 36 ^e | 10 of 33 ^f | RR 1.95 (1.27 to 3.01) | - | Moderate | RCT | Serio us ^{g,h,i} | - | None | None | None |
| 1 (Nabulsi et al., 2006) | 30 of 36 ^l | 19 of 33 ^m | RR 1.62 (1.25 to 2.11) | - | Low | RCT | Serio us ^g | - | Serious | None | None |

| Number | Number of child | ren | Effect | | | | | > | | | SL |
|-----------------------------------|-----------------------|-----------------------|--|--|----------|--------|--------------------------|---------------|--------------|-----------------|-------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other considerations |
| 7 hours | | - | | | <u>'</u> | | | | | | |
| 1 (Nabulsi et al., 2006) | 31 of 36 ^l | 14 of 33 ^m | RR 2.03 (1.34 to 3.08) | - | Low | RCT | Serio us ^g | - | Serious | None | None |
| 8 hours | | · | | · | | | | | | | |
| 1 (Nabulsi et al., 2006) | 29 of 36 ¹ | 11 of 33 ^m | RR 2.42 (1.45 to 4.02) | - | Low | RCT | Serio us ^g | - | Serious | None | None |
| Afebrile at | t > 24 hours | <u>.</u> | <u>.</u> | · | · | | | | | | |
| No data | | | | | | | | | | | |
| Temperatu | ure AUC | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Adverse e | vents | | | | | | | | | | |
| Diarrhoea | | | | | | | | | | | |
| 1 Nabulsi et al., 2006 | 5 of 37 ^l | 6 of 37 ^m | RR 0.83 (0.28 to 2.49) | - | Very low | RCT | Serio us ⁹ | - | Serious | Very Serious | None |

NR Not reported

^a Alternating acetaminophen (12.5 mg/kg) with ibuprofen (5 mg/kg) every 4 hours

^b Ibuprofen (5 mg/kg) every 6 hours

^c Allocation could be determined by different regimens

^d Daily temperature was recorded by parents instead of trained clinicians

^e 10 mg/kg Ibuprofen and 15 mg/kg acetaminophen single dose

| | | • | ol and ibuprofen combined vs. par | acetamor and ibuproferr after | laurig | | | | | | |
|---------------|-----------------------|---------|--|--|---------|--------|-------------|---------------|--------------|-------------|------------------------|
| Number | Number of childr | en | Effect | | | | | 5 | | | <u> </u> |
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Discomfo | rt at 1 to 2 hours | | · | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | ort at > 2 to 5 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt at > 5 to 24 hours | S | | | | | | | | | |
| No data | | | | | | | | | | | |
| Discomfo | rt > 24 hours | | | | | | | | | | |
| No data | | | | | | | | | | | |

Mean change temperature at 1 to 2 hours

No data

Mean change in temperature at > 2 to 5 hours

No data

f 10 mg/kg Ibuprofen single dose

^g Small sample size (n < 100)

^h Blinding of allocation not used

ⁱ Children included in the study more than once

 $^{^{\}rm j}$ RR includes 0 and both ± 0.25; SMD crosses both ± 0.5

^k RR includes 0 and ± 0.25; SMD crosses ± 0.5

¹Ibuprofen 10mg/kg, followed by acetaminophen 15mg/kg at 4h

^m Ibuprofen 10mg/kg, followed by placebo at 4h

ⁿ Includes children age more than 5 (Nabulsi – up to 14 years)

| Number | Number of children | | Effect | | | | | <u>ئ</u> | | | Ę |
|-----------------------------|---|--------------------------------------|--|--|---------|--------|------------------------------|---------------|--------------|--------------|------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Mean chai | nge in temperature at | > 5 to 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean chai | nge in temperature at | > 24 hours | | | | | | | | | |
| No data | | | | | | | | | | | |
| Mean tem | perature at 1 to 2 hou | irs | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 37.4°C (SD 0.5), n = 20 ^a | 37.6°C (SD 0.4), n = 20 ^b | SMD -0.43 (-1.06 to +0.19) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious f | None |
| 2 hours | | | L | L | | | | | | | |
| 1 (Paul et al., 2010) | 37.0°C (SD 0.5), n = 20 ^a | 37.2°C (SD 0.3), n = 20 ^b | SMD -0.48 (-1.10 to +0.15) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious f | None |
| Mean tem | perature at > 2 to 5 h | ours | | | | | | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.4), n = 20 ^a | 36.9°C (SD 0.4), n = 20 ^b | SMD 0.00 (-0.62 to +0.62) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious g | None |
| 4 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.3), n = 20 ^a | 36.9°C (SD 0.3), n = 20 ^b | SMD 0.00 (-0.62 to +0.62) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious g | None |

| Number | Number of children | | Effect | | | | | cy | | | u. |
|-----------------------------|---|--------------------------------------|--|--|----------|--------|------------------------------|---------------|--------------|--------------|------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| 5 hours | | | | | | | • | | | | |
| 1 (Paul et al., 2010) | 36.9°C (SD 0.5), n = 20 ^a | 36.8°C (SD 0.3), n = 20 ^b | SMD 0.24 (-0.38 to +0.86) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious g | None |
| Mean temp | perature at > 5 to 24 h | nours | | | | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 37.2°C (SD 0.6), n = 20 ^a | 36.9°C (SD 0.3), n = 20 ^b | SMD 0.62 (-0.02 to +1.26) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious g | None |
| Mean temp | perature at > 24 hours | S | | | | | | | | | |
| No data | | | | | | | | | | | |
| Afebrile at | 1 to 2 hours | | | | | | | | | | |
| 1 hour | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 18 of 20 ^a | 16 of 20 ^b | RR 1.13 (0.86 to 1.46) | - | Low | RCT | Serio us ^{c,d,e} | - | None | Serious g | None |
| 2 hours | | | | | , | ı | ı | | | | |
| 1 (Paul et al., 2010) | 20 of 20 ^a | 20 of 20 ^b | RR 1.00 (0.91 to 1.10) | - | Moderate | RCT | Serio us ^{c,d,e} | - | None | None | None |

| Number | Number of childre | n | Effect | | | | | <u>ج</u> | | | Ē |
|-----------------------------|-----------------------|-----------------------|--|--|----------|--------|------------------------------|---------------|--------------|-------------|------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsistency | Indirectness | Imprecision | Other consideration |
| Afebrile at | > 2 to 5 hours | | , | | | | • | | | | |
| 3 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 20 of 20 ^a | 20 of 20 ^b | RR 1.00 (0.91 to 1.10) | - | Moderate | RCT | Serio us ^{c,d,e} | - | None | None | None |
| 4 hours | | · | | • | | | | | | | • |
| 1 (Paul et al., 2010) | 20 of 20 ^a | 20 of 20 ^b | RR 1.00 (0.91 to 1.10) | - | Moderate | RCT | Serio us ^{c,d,e} | - | None | None | None |
| 5 hours | | - | | 1 | | | 1 | | II. | | .1 |
| 1 (Paul et al., 2010) | 20 of 20 ^a | 20 of 20 ^b | RR 1.00 (0.91 to 1.10) | - | Moderate | RCT | Serio us ^{c,d,e} | - | None | None | None |
| Afebrile at | > 5 to 24 hours | | · | | · | | | | | | |
| 6 hours | | | | | | | | | | | |
| 1 (Paul et al., 2010) | 19 of 20 ^a | 20 of 20 ^b | RR 0.95 (0.83 to 1.09) | - | Moderate | RCT | Serio us ^{c,d,e} | - | None | None | None |
| Afebrile at | > 24 hours | | | | | | | | | • | |
| No data | | | | | | | | | | | |
| Temperatu | ire AUC | | | | | | | | | | |
| No data | | | | | | | | | | | |

| Number | Number of children | | Effect | | | | | СУ | S | _ | uo |
|---------------|--------------------|---------|--|--|---------|--------|-------------|-------------|-------------|-------------|------------------------|
| of studies | Intervention | Control | Relative (95% confidence interval) | Absolute (95% confidence interval) | Quality | Design | Limitations | Inconsisten | Indirectnes | Imprecision | Other consideration |

Adverse events

No data

NR Not reported

^a 10 mg/kg Ibuprofen and 15 mg/kg acetaminophen single dose

^b 10 mg/kg lbuprofen single dose

^c Small sample size (n < 100)

^dBlinding of allocation not used

^e Children included in the study more than once

^fRR includes 0 and ± 0.25; SMD crosses ± 0.5

 $^{^{9}}$ RR includes 0 and both ± 0.25; SMD crosses both ± 0.5

Appendix J Deleted material from 2007 version

Priorities in the clinical assessment of feverish illness in children

4.make appropriate management decisions based upon the results of the assessment.

Traffic light system

The GDG decided to highlight graphically the non-specific features of illness severity and the specific symptoms and signs of serious illnesses in a 'traffic light' table. The 'red' features are the most worrying, followed by the 'amber' features, and the 'green' features are the most reassuring.

The traffic light table has been developed from many different sources. To ensure the recommendations follow in a logical sequence, the table is provided here *before* the evidence and translations. These are provided in Sections 5.5 and 5.6 of this chapter and the reader is advised to refer back to the table whenever it is mentioned.

Table 5.2 Traffic light system for identifying risk of serious illness. Children with fever and any of the symptoms or signs in the 'red' column should be recognised as being at high risk. Similarly, children with fever and any of the symptoms or signs in the 'amber' column and none in the 'red' column should be recognised as being at intermediate risk. Children with symptoms and signs in the 'green' column and none in the 'amber' or 'red' columns are at low risk. The management of children with fever should be directed by the level of risk

| | Green – low risk | Amber – intermediate risk | Red – high risk |
|-------------|--|--|--|
| Colour | Normal colour of skin, lips and tongue | Pallor reported by parent/carer | Pale/mottled/ashen/blue |
| Activity | Responds normally to social cues Content/smiles Stays awake or awakens quickly Strong normal cry/not crying | Not responding normally to social cues Wakes only with prolonged stimulation Decreased activity No smile | No response to social cues Appears ill to a healthcare professional Does not wake or if roused does not stay awake Weak, high-pitched or continuous cry |
| Respiratory | • | Nasal flaring Tachypnoea: RR > 50 breaths/minute, age 6–12 months RR > 40 breaths/minutes, age > 12 months Oxygen saturation ≤ 95% in air Crackles | Grunting Tachypnoea: RR > 60 breaths/minute Moderate or severe chest indrawing |

| | Green – low risk | Amber – intermediate risk | Red - high risk |
|-----------|---|--|--|
| Hydration | Normal skin and eyesMoist mucous membranes | Dry mucous membranes Poor feeding in infants CRT ≥ 3 seconds Reduced urine output | Reduced skin turgor |
| Other | None of the amber or red symptoms or signs | Fever for ≥ 5 days | Age 0–3 months, temperature ≥ 38°C Age 3–6 months, temperature ≥ 39°C |
| | | Swelling of a limb or joint Non-weight bearing/not using an extremity | Non-blanching rash Bulging fontanelle Neck stiffness Status epilepticus Focal neurological signs Focal seizures |
| | | A new lump > 2 cm | Bile-stained vomiting |

CRT = capillary refill time; RR = respiratory rate.

Non-specific symptoms and signs of serious illness

Evidence was sought for symptoms and signs associated with fever which would predict wellness or serious illness in young children. These symptoms and signs could be non-specific for any feverish illness or be particular to a specific underlying disease. Some features were looked for individually. These included heart rate, capillary refill time (CRT), blood pressure, respiratory rate (RR), height and duration of fever and the assessment of dehydration.

General symptoms and signs of serious illness

Review question

In children with fever, what symptoms or combination of symptoms are associated with serious illness or mortality?

Are there any scoring systems that use symptoms of children with fever to predict the risk of serious illness?

In children with fever, what signs or combination of symptoms and signs are associated with serious illness or mortality?

Are there any scoring systems that use symptoms and signs in children with fever to predict the risk of serious illness? How accurate are they?

In children with fever, what symptoms and signs are associated with self-limiting illness?

In view of the number of different healthcare locations in which the initial assessment can take place, studies that looked just at symptoms alone were reviewed (to assist the remote assessor) and studies that used symptoms and signs were reviewed (to assist the face-to-face assessor).

To determine which clinical features in feverish children are associated with serious illness and which are associated with a non-serious illness, studies looking at children with a variety of symptoms and signs on presentation and followed up to end diagnosis or outcome were sought (prospective cohort studies).

Scoring systems have been developed to try to distinguish seriously ill children from those who have a minor self-limiting illness, based on a combination of objective symptoms and signs. Studies determining the accuracy of these scoring systems were also sought.

Individual symptoms

Four EL $2+^{93-96}$ and one EL $2-^{97}$ prospective cohort studies were found that reported on the relationship between individual symptoms and the likely presence of serious illness. The studies

varied widely in terms of setting (for example, primary and secondary care, developed countries and resource-poor countries), methods of analysis, the ages of children included (0–18 years with different exclusion criteria), symptoms described, definitions and prevalence of serious illness. Due to the methodological and hence statistical heterogeneity, it was inappropriate to perform a meta-analysis.

The symptoms in children aged less than 6 months that were associated with serious illness in one or more papers were drowsiness (RR 7.6), ⁹³ decreased activity (RR 5.8), ⁹³ pale on history (RR 4.4), ⁹³ poor feeding (less than half normal amount) (RR 4.4, ⁹³ OR 2.9–6.0 ⁹⁸), decreased wet nappies (< 4 in 24 hours) (RR 4.1) ⁹³ and bile-stained vomiting (RR 5.1). ⁹³ The RR was calculated based on the reported positive predictive values (PPVs) and negative predictive values (NPVs).

Individual symptoms and signs

Six EL $2+^{93-96,98,99}$ and one EL $2-^{97}$ prospective studies describing the signs and symptoms associated with serious bacterial infection (SBI) were found. There is methodological heterogeneity among the studies. For example, the setting varied from developed countries such as Australia⁹³ to aggregated data from resource-poor settings. Moreover, the age of children included varied from < 2 months⁹⁸ to 3 months to 15 years. The list of signs strongly associated with SBI were:

- being drowsy^{93,98}
- moderate/severe chest recession^{93,98,99}
- respiratory rate > 60 breaths/minute^{97–99}
- nasal flaring⁹⁸
- grunting⁹⁸
- crackles⁹⁸
- $lump > 2 cm^{93}$
- being pale⁹³
- not looking well⁹⁹
- bulging fontanelle.⁹⁸

Scoring systems of combinations of symptoms and signs

When searching for scoring systems using combinations of signs and symptoms, only prospective cohort studies recruiting children with fever without apparent source (FWS) were included.

Seven EL $2+^{100-104,106,107}$ and one EL $2-^{105}$ prospective studies were found covering two scoring systems for febrile infants, which used clinical features of patients alone: Yale Observation Scale (YOS, see Table $4.2)^{100-105}$ and the Young Infant Observation Scale (YIOS). 106,107 Other scoring systems (Rochester 96,108,109 and Philadelphia96) use laboratory values as part of the scale and were therefore not included in this section. There is heterogeneity among the studies as the setting varied from developed countries such as the USA to resource-poor settings such as India, and the age of children included ranged from 0–2 months 106 to 3–36 months. 105

Neither the YOS nor YIOS alone could reliably detect serious illness in infants without missing many cases. The YOS did improve the detection of serious illness in infants when combined with a physician-taken history and examination (sensitivity and NPV improved from 86% to 89–93% and from 85–97% to 96–98%, respectively). All the validation studies found that a low YOS score is associated with well infants. From the validation study of the YOS, 101 in children aged 3 months to 3 years with a score of 6, the NPV is 97.4% for occult bacteraemia.

The symptoms and signs in the YOS associated with being well are:

- strong cry/no cry
- content
- pink
- eyes not sunken/skin normal (hydration)
- if awake stays awake, if asleep is easily roused

· smiles.

When deriving the YOS scoring system, the following symptoms and signs were correlated with serious illness: 100,102

- · weak/high-pitched
- continuous cry
- unable to rouse
- pale/mottled/blue
- sunken eyes/doughy skin
- no smile.

Evidence summary

Individual symptoms and individual symptoms and signs

The evidence from prospective cohort studies demonstrates a number of individual symptoms (i.e. drowsiness, decreased activity, poor feeding, pale, reduced urine output, bile-stained vomiting) and signs (i.e. being drowsy, moderate/severe chest recession, respiratory rate > 60 breaths/minute, nasal flaring, grunting, crackles, lump > 2 cm, being pale, not looking well, bulging fontanelle) that are associated with serious illness in infants and young children. Most of the evidence is limited to data relating to infants less than 6 months in a secondary care setting. In isolation, none of these symptoms or signs are reliably associated with serious illness.

Scoring systems of combinations of symptoms and signs

Scoring more than 10 using the YOS scoring system after a history and examination may help identify other infants and children at high risk of serious illness.

A YOS of 6 with a well-appearing child makes the presence of a serious illness very unlikely. However, the development of features of serious illness including the symptoms listed on the YOS should prompt further evaluation.

In isolation, none of these symptoms are strongly associated with serious illness. A child identified as 'ill' when assessed by an experienced healthcare professional is likely to have an SBI. To ensure that children with serious illness are recognized early, many children without serious illness will need to be examined.

Health economics profile

The GDG did not identify any issues where cost-effectiveness issues were a priority for this clinical question.

GDG translation

Individual symptoms and individual symptoms and signs

Prospective cohort studies of children with fever have identified a number of symptoms and signs that are predictive of serious illness. Much of the most reliable data relates to infants up to the age of 6 months. The GDG decided that it was reasonable based on clinical experience to extrapolate the symptoms and signs to older children and use them as part of the assessment of older children with a feverish illness. The GDG is aware that there is currently a large prospective study being conducted in Australia on the predictive values of symptoms and signs in febrile children of all ages. In the UK, a project is in development on the recognition of acute illness in children (Dr R MacFaul, personal communication). It is hoped that the results of these studies will inform future guidance on the assessment of the risk of serious illness in children with feverish illness.

Scoring systems of combinations of symptoms and signs

The features used in the YOS associated with serious illness are validated and show good correlation with those children who go on to develop serious illness in children aged 3 months to 3 years. The GDG felt that these features can be extrapolated for use on children up to the age of 5 years, based on clinical experience and extrapolated to the UK population.

'Traffic light' system

The GDG attempted to summarise the results of risk stratification from the prospective cohort studies and scoring studies in a 'traffic light' system. From the scoring studies, those symptoms and signs that scored only 1 on the YOS were designated 'green'. Those individual symptoms and signs that scored 5 in the YOS were designated 'red', as a child with only one 'red' symptom and all other 'green' symptoms (i.e. scoring 10 in the YOS) was at significant risk of serious illness. Those symptoms and signs that scored 3 in the YOS were designated 'amber', because while a child with a combination of 'amber' symptoms or signs was at significant risk of serious illness, a child with only one 'amber' feature was not at significant risk of serious illness.

From the prospective cohort studies, the GDG assigned 'red', 'amber' or 'green' status to additional symptoms and signs based on their associated risk of serious illness and on clinical experience.

Common physiological measurements and their predictive values of serious illness

Several other signs were looked for specifically as it was felt they were possible markers of serious illness. These included heart rate, capillary refill time (CRT), blood pressure and respiratory rate.

Heart rate

Narrative summary


No evidence was found that provided 'normal values' for heart rate in the population of children under 5 years old. There is one EL 2+ study¹¹¹ that compared heart rate in children under 1 year with their body temperature. This study found that for every 1°C rise in body temperature, the resting heart rate rose by 9.6 beats/minute (Figure 5.1). The GDG is aware that there is an ongoing UK study to determine normal values for resting heart rate in children with fever aged 3 months to 12 years.

There are unvalidated tables of normal resting heart-rate values in young infants and children without fever which are widely taught (Figure 5.2).

Evidence summary

There is a lack of evidence regarding heart rate as a marker of serious illness. Despite this, the GDG felt that heart rate is a potentially important marker of serious illness. The Delphi panel was used to decide whether heart rate should be part of the routine assessment of a child with a fever, because a raised heart rate can be a sign of serious illness, particularly septic shock.

Figure 5.1 Heart rate rise with rising temperature in children less than 1 year old; adapted with permission from Hanna and Greenes ¹¹¹



Delphi statement

'Healthcare professionals examining children with fever must measure and record heart rate as part of their routine assessment.'

| 1 to 3 | 4 to 6 | 7 to 9 | Don't know | Missing | Total | Median |
|--------|---------|----------|------------|---------|-------|--------|
| 2 (4%) | 8 (15%) | 39 (75%) | 3 (6%) | 1 | 52 | 9 |

Seventy-five percent of the Delphi panel agreed with this statement in round 1 (consensus achieved).

'Healthcare professionals should refer a child for specialist paediatric (children's) care if the resting heart rate is above the expected range for a feverish child.'

| 1 to 3 | 4 to 6 | 7 to 9 | Don't know | Missing | Total | Median | |
|--------|----------|----------|------------|---------|-------|--------|--|
| 2 (4%) | 15 (30%) | 33 (65%) | 1 (2%) | 1 (2%) | 51 | 7 | |

This statement did not reach consensus despite adaptations made to the original statement after round 1.


GDG translation

Heart rate was not placed in the 'traffic light' system (see below) as the Delphi panel did not agree that heart rate *per se* should be used as a basis for referral to specialist care. The statement 'healthcare professionals examining children with fever must measure and record heart rate as part of their routine assessment' was adapted and combined with the statement about the physiological parameters that should be documented as part of the assessment (see the end of Respiratory rate Section 4.5.2.4). The GDG felt it important to make healthcare professionals aware of the significance of a raised heart rate particularly in septic shock (see the recommendations at the end of Respiratory ratesection Section 4.5.2.4).

The GDG felt that basic physiological parameters in children should be backed up by a better weight of evidence. The GDG is aware that one research project on the predictive value of heart rate and

other vital signs in children with fever is currently in progress in the UK (Drs R MacFaul and M Thompson, personal communications) but it is likely that larger studies will be needed to produce definitive results. The GDG therefore recommends that studies are performed to confirm normal ranges for heart rate at various body temperatures and to determine whether children with heart rates outside these ranges are at higher risk of serious illness.

Figure 5.2 Widely quoted values for paediatric heart rates at various ages (left diagonals; right diagonals²⁸⁹) and the heart rates of children with minor blunt trauma at various ages (vertical lines¹¹²)



Capillary refill time

Narrative summary

Five studies were found investigating the prognostic value of the capillary refill time (CRT) with three EL 2+ prospective studies 113-115 and one EL 2- retrospective study which included children in ICU post-resuscitation, which was excluded owing to the lack of relevance. In addition, there is one EL 2+ SR 117 for signs and symptoms of dehydration which included CRT. Overall, the studies were conducted in a range of settings varying from primary care to intensive care in the UK, 113 the USA 114 and Kenya 115 with different baselines which made meta-analysing inappropriate.

The SR¹¹⁷ showed that prolonged CRT had sensitivity of 0.60 (95% CI 0.29 to 0.91) and specificity of 0.85 (95% CI 0.72 to 0.98) of detecting 5% dehydration, which made CRT the most specific sign of dehydration. The results from prospective cohort studies showed that there was no significant association of CRT of 3 seconds with meningococcal disease, other significant bacterial illness or white blood cell count (WBC) (statistics not provided). In one prospective cohort study, the receiver operating characteristic (ROC) curve showed that the best performance was obtained when a CRT of 3 seconds was taken to be 'prolonged'; furthermore, a prolonged CRT (> 3 seconds) was associated with a more urgent triage category, the administration of fluid bolus and the length of hospital stay (all P.< 0.05). Moreover, children with dehydration had prolonged CRT of 2 seconds, with a sensitivity of only 44% for predicting a fluid deficiency of < 5% or more of body weight (other statistics not provided). Overall agreement for CRT was moderate (k = 0.42), and was better for normal values (= 1 second) (k = 0.48) and clearly abnormal values (= 4 seconds) (k = 0.49).

Furthermore, in a search of the specific signs and symptoms of meningococcal disease, CRT was found to be indicative (the OR of CRT > 3 seconds of having meningococcal disease is 29.4 (95% CI 9.4 to 92.6) 118 in children with a petechial rash. In another SR 117 that included four trials investigating the usefulness of prolonged CRT to indicated dehydration, the findings showed that the pooled sensitivity of prolonged CRT (defined differently in different studies) was 0.60 (95% CI 0.29 to 0.91), with a specificity of 0.85 (95% CI 0.72 to 0.98), for detecting 5% dehydration.

Evidence summary

The authors used different cut-offs of CRT and it appeared that CRT of 2 seconds was a weak predictor of dehydration and serious illness while a CRT = 3 seconds is associated with dehydration and significant illness (e.g. meningococcal disease) in children.

GDG translation

The GDG noted that CRT is quick to carry out and exhibits moderate reproducibility. A statement about measuring CRT was combined with the statement about the physiological parameters which should be documented as part of the assessment (see the end of Respiratory rate Section 4.5.2.4). The GDG considered that a CRT of = 3 seconds was an 'amber' sign (see the recommendations at the end of Respiratory ratesection Section 4.5.2.4).

Respiratory rate

Evidence summary

Refer to Sections 4.5.1 (General symptoms and signs of serious illness), 4.5.4 (,Assessment of dehydration), and 4.6.6 (,Pneumonia) ,for evidence relating to respiratory rate.

GDG translation

An abnormal respiratory rate has been shown to be a non-specific marker of serious illness, a specific feature of pneumonia and required for the assessment of dehydration. The GDG felt that respiratory rate is therefore an important physiological parameter which needs to be assessed by healthcare professionals. A statement about measuring respiratory rate was combined with the statement about the physiological parameters which should be documented as part of the assessment (see below).

Height and duration of fever and its predictive value of serious illness

When a child with a febrile illness is being assessed, healthcare professionals often ask about the degree and duration of fever. The reason for these questions is that it is often assumed that these variables can be used to help differentiate serious bacterial illnesses from less serious self-limiting viral infections. Regarding the height of recorded fever, it is often thought that there is a higher risk of serious illness with increasing body temperature. Regarding duration of fever, it is sometimes thought that an SBI is more likely with increasing duration of fever. This is on the grounds that viral illnesses will usually resolve spontaneously over a shorter period of time. There is also a converse view that children with serious illness will present to healthcare professionals earlier in the illness because they may have other features that lead parents and carers to suspect the child is seriously unwell.

Height of fever

Review question

Can the height of body temperature in a young child with fever be used to predict the risk of serious illness or mortality?

Narrative evidence

The literature search was restricted to prospective cohort studies because this would yield the highest quality evidence (EL 2). Twelve prospective cohort studies, $^{93,95,98,99,120-127}$ of which three were EL 2-, 124,125,127 were found that reported on the relationship between height of fever and the outcome in terms of serious illness. The studies varied widely in terms of setting (e.g. hospital emergency department or paediatric assessment units in different countries such as Australia, 93 the UK¹²¹ or the USA, and Puerto Rico¹²⁰), ages of children included (e.g. < 28 days¹²⁷ to 3–36 months¹²⁸), definition of fever (e.g. rectal temperature = 38°C or rectal temperature = 39°C) and outcomes measured. There was also wide variation in the methods of analysis. For these reasons it was not possible or appropriate to pool the data.

Several large EL 2+ studies reported a higher relative risk of SBI with increasing body temperature, with body temperatures = 39°C in particular being associated with a higher risk. Other studies did not report this association. The sensitivity of a high body temperature to detect SBI is low. With one exception, the sensitivity of a temperature = 39°C to detect SBI was between 10% and 32%. In developed countries the sensitivity of a temperature = 39°C to detect SBI was between 10% and 14%. The PPV of a temperature = 39°C varied between 4% and 40% in developed countries.

Evidence summary

Twelve prospective cohort studies (nine EL 2+ and three EL 2-) that reported on the relationship between height of fever and the outcome in terms of serious illness were found.

Several large EL 2+ studies reported a higher relative risk of SBI with increasing body temperature, with body temperatures = 39°C in particular being associated with a higher risk. Other EL 2+ studies did not report this association.

Health economics

The GDG did not identify any issues that required a cost-effectiveness analysis for this clinical question.

GDG translation

The GDG noted that most large EL 2+ studies suggest that the risk of serious illness increases with height of fever in young children. Body temperatures = 39°C in particular were usually associated with a higher relative risk of SBI. The strongest associations were reported in studies involving children aged less than 6 months. However, the sensitivity and PPV of temperatures=39°C were low, which suggests that most cases of serious illness would be missed if height of body temperature was used in isolation to identify children with serious illness. Furthermore, the GDG noted that other features of a child with feverish illness, such as his or her age or an 'ill appearance' were often more predictive.

The GDG concluded that healthcare professionals should be aware that there is an association between height of body temperature and risk of SBI. However, this association is not sufficiently robust to recommend immediate action or referral based on body temperature alone. An exception was made for children aged under 6 months with body temperature = 39°C because the evidence was strongest for this age group.

In addition, the GDG noted that children aged under 3 months with fever are generally at a higher risk of serious illness (see Section 8.3). The incidence of serious illness in this group, for instance, is over ten times higher than that in older children. The clinical studies that provide the evidence for this age group used a body temperature=38°C as the definition of fever. The GDG therefore decided that children aged under 3 months with a body temperature=38°C should also be included in the recommendation about risk of serious illness.

Duration of fever and its predictive value of serious illness

Review question

Can the duration of fever in a febrile young child be used to predict the risk of serious illness or mortality?

Narrative evidence

Three EL 2+ prospective studies 126,129,130 that looked at the duration of fever as a risk factor for SBIs in general were found. One of them129 reported that a duration of fever > 48 hours had an odds ratio of 3.85 (95% CI 1.11 to 13.3) for predicting serious illness. This relationship just reached statistical significance as an independent predictor of SBI. Another prospective cohort study 126 reported that duration of fever was longer in infants with SBIs (26.5 ± 41.5 hours) than those without (18.6 ± 21.7 hours) (P < 0.01). Furthermore, in comparison with < 24 hours, duration of fever > 48 hours had an odds ratio of 1.04 (95% CI 0.35 to 3.12) of having SBIs. 130 Of the other two EL 2 studies, one reported that children with SBI had statistically significant longer duration of fever while the other did not.

Two EL 2+ prospective studies 122,123 were also found that looked at the incidence of (predominantly occult) bacteraemia in relation to duration of fever in children with temperature = 39°C. Both studies reported a higher relative risk of bacteraemia with a shorter duration of fever (RR 1.5^{122} to 4.6^{123}). The PPVs of a short duration of fever were 4% and 10%. 122,123

Evidence summary

It was noted that there was a weak association between duration of fever and risk of serious illness from the three studies that looked at SBI in general. There was also an apparently converse association between duration of fever and risk of one particular SBI, namely bacteraemia.

Health economics

The GDG did not identify any issues that required a cost-effectiveness analysis for this clinical question.

GDG translation

The GDG noted a weak association between duration of fever and risk of serious illness from the five studies that looked at SBI in general. They also noted an apparently converse association between duration of fever and risk of one particular SBI, namely bacteraemia. The GDG concluded that the evidence was equivocal and relatively weak in both directions. They concluded that, on the basis of existing evidence, duration of fever could not usefully be included in the list of features that may be used to help predict serious illness.

The GDG was aware that longer durations of fever than those reported in the studies above may be associated with certain serious illnesses. In particular, the GDG noted that a fever lasting 5 days or more is one of the diagnostic criteria for Kawasaki disease. For this reason, it was decided to include a fever lasting 5 days or more as one of the 'amber' features in the traffic light system. A recommendation on the diagnosis of Kawasaki Disease is included in Section 5.6.

Table 5.4 Summary table for symptoms and signs suggestive of specific diseases

| Diagnosis to be considered | Symptoms and signs in conjunction with fever | | | |
|-----------------------------|--|--|--|--|
| Meningococcal disease | Non-blanching rash, particularly with one or more of the following: | | | |
| | an ill-looking child lesions larger than 2 mm in diameter (purpura) capillary refill time of ≥ 3 seconds neck stiffness | | | |
| Meningitis | Neck stiffness | | | |
| | Bulging fontanelle | | | |
| | Decreased level of consciousness | | | |
| | Convulsive status epilepticus | | | |
| Herpes simplex encephalitis | Focal neurological signs | | | |
| | Focal seizures | | | |
| | Decreased level of consciousness | | | |
| Pneumonia | Tachypnoea (RR > 60 breaths/minute, age 0–5 months; RR > 50 breaths/minute, age 6–12 months; RR > 40 breaths/minute, age > 12 months) | | | |
| | Crackles in the chest | | | |
| | Nasal flaring | | | |
| | Chest indrawing | | | |
| | Cyanosis | | | |
| | Oxygen saturations ≤ 95% | | | |
| Urinary tract infection | Vomiting | | | |
| | Poor feeding | | | |
| | Lethargy | | | |
| | Irritability | | | |
| | Abdominal pain or tenderness | | | |
| | Urinary frequency or dysuria | | | |
| | | | | |

Offensive urine or haematuria

Septic arthritis Swelling of a limb or joint

Not using an extremity

Non-weight bearing

Kawasaki disease Fever for more than 5 days and at least four of the following:

bilateral conjunctival injection

- change in mucous membranes
- change in the extremities
- polymorphous rash
- cervical lymphadenopathy

RR =respiratory rate.

Number Research recommendation

Meningococcal disease

There is a need for a prospective study to assess the prognostic value of symptoms such as limb pain and cold hands and feet that have been identified as possible early markers of meningococcal disease.

Management by the -paediatric specialist

Children less than 3 months old

An EL 1+ SR comprising six studies165 which examined whether procalcitonin (PCT) was a useful marker of SBI in neonates and children was also found. A significant increase in serum PCT concentration during sepsis was found in both term neonates and a heterogeneous group of preterm neonates. However, PCT lacked specificity compared with C-reactive protein (CRP) as an early marker in the diagnosis of SBI. The performance characteristics of CRP as a marker of SBI varied as different cut-off levels were used in the various studies.

C-reactive protein

A heterogeneous group of 11 EL II prospective cohort studies ^{166–174,178} evaluating CRP was identified. Age ranges for these studies were birth to 16 years, but only three EL II studies contained data on children older than 36 months. ^{166,172,174} Conditions studied were SBI, MCD, bacterial meningitis, bacteraemia, OBI and bacterial pneumonia. The cut-off value for CRP varied from 27.5 to 70 mg/litre. Table 8.1 shows sensitivities, specificities and relative risks for CRP values in identifying serious illness or discriminating non-serious from serious illness for each study.

Two other EL II studies^{170,171}looked at differences in CRP depending on the timing of the sample from the onset of symptoms. There was no significant difference in sensitivity or specificity between those CRP values collected more than 12 hours after the onset of feverish illness compared with those collected less than 12 hours after onset.¹⁷⁰ Slightly lower sensitivity (61.3% versus 63.5%) and specificity (80% versus 84.2%) was reported for CRP in infants when taken less than 12 hours after the onset of symptoms, but this was at a lower cut-off value of 19 mg/litre.¹⁷⁰ Furthermore, the study which evaluated the differences in CRP performance at greater than and less than 12 months old was examined. At a CRP cut-off value of 40 mg/litre, for children less than 12 months old, sensitivity and specificity were reported to be 94% and 84%, respectively (RR 31.5), whereas for those greater than 12 months old, sensitivity and specificity were reported as 80% and 59%, respectively (RR 4.0).

This study also demonstrated increased post-test probability of SBI with increasing CRP (10% at CRP < 40 mg/litre versus 86% at CRP > 100 mg/litre).

Table 8.1 Summary of sensitivity, specificity and relative risk of included studies evaluating CRP

| Study | CRP cut-off (mg/litre) | Sensitivity (%) | Specificity (%) | Relative risk |
|------------------------------------|---------------------------|-----------------|-----------------|---------------|
| Galetto- Lacour ^{178a} | 40 | 79 | 79 | 6.1 |
| Galetto- Lacour ^{178a} | 40 | 89 | 75 | 12.75 |
| Carrol ¹⁶⁶ | 30 | 81 | 89 | 3.79 |
| Thayyil ¹⁶⁷ | 50 | 75 | 68.7 | 5.23 |
| Kohli ¹⁶⁸ | 40 | 95 | 86 | 33.5 |
| Pulliam ¹⁶⁹ | 70 | 79 | 91 | 13 |
| Isaacman ¹⁷⁰ | 44 | 63 | 81 | 5.0 |
| Fernandez ¹⁷¹ | 27.5 | 63.5 | 84.2 | 1.97 |
| Gendrel ¹⁷² | 20 | 73 | 88 | 5.43 |
| Lembo ¹⁷³ | 10 | 80 | 55 | 2.3 |
| Moulin ^{174b} | 60 | 69.8 | 52 | 1.94 |
| Moulin ^{174b} | 20 | 88.4 | 40 | 2.14 |

^aGaletto-Lacour *et al.* produced two papers from the same data set

Procalcitonin

An EL 1+ SR¹⁶⁵ looking at 46 articles which evaluated the role of PCT as an early marker of infection in neonates and young children was identified. Neonatal studies regarding the investigation of children less than 3 months of age are discussed in Section 7.3 of this chapter. The findings of the SR against each clinical condition are summarised below.

Health economics

An economic evaluation was undertaken to assess the cost-effectiveness of CRP versus PCT to investigate the presence of SBI in children without apparent source (Appendix D). Health economic evaluation was required since PCT is not routinely used. All other diagnostic tests are offered on the NHS and are part of the usual package of tests for children over 3 months where SBI is suspected. The results indicated that under certain assumptions CRP is both less costly and more effective than PCT in correctly diagnosing and ruling out SBI in children with FWS. However, the results were sensitive to the prevalence of SBI. CRP no longer dominated PCT when the prevalence of SBI was over 27%, keeping all the other baseline assumptions constant. However, given the lack of robust evidence underpinning these baseline assumptions, the analysis cannot support the replacement of CRP with PCT at present. The GDG has recommended more research on the performance characteristics of CRP and PCT in children with feverish illness of uncertain cause.

Response to antipyretic medication

It has been suggested that response to antipyretic medication may help differentiate serious from non-serious illness in febrile children. This could occur in two ways:

- a decrease in fever
- improved clinical appearance.

Decrease in fever after antipyretics

Some healthcare professionals think that a decrease in fever with antipyretic therapy indicates a lower likelihood of SBI. It is also assumed that a lack of response to antipyretic therapy makes an SBI more likely. In contrast to this, other healthcare professionals fear that giving antipyretics to reduce fever in febrile children may make the detection of serious illness more difficult as the high fever of bacterial

^bMoulin *et al.* performed analysis at two CRP cut-off values

illness is 'masked' by antipyretics. Evidence about fever response to antipyretics in children with both serious and non-serious illness would be useful to help in the assessment of these children.

Improved clinical appearance after antipyretics

Antipyretics may also improve the child's general condition. Many healthcare professionals feel that clinical review of a febrile child 1–2 hours after they have been given antipyretics improves the ability to differentiate between serious and non-serious illness. The antipyretic and analgesic effect of antipyretics may lead to the improvement of features which may suggest serious illness (e.g. irritability, tachycardia, etc). If this improvement in features occurred only in those with non-serious illness, this would help to identify these children. However, if this improvement also occurred in children with serious illness, then these children may not have their illness identified correctly.

Evidence about improved clinical appearance after antipyretics would be useful to help in the assessment of children and would also be relevant to the use of observation in febrile children.

Review question

In a child with fever, does a failure to respond to antipyretics increase the likelihood of a serious illness?

Sub-question

Conversely, does a reduction in body temperature in response to antipyretics increase the likelihood of a self-limiting illness?

Narrative evidence

Five EL 2+ prospective cohort studies $^{162,184-187}$ and one EL 4 conference abstract, 188 which was judged to be important for inclusion, investigating the relationship between a reduction of body temperature due to antipyretics and the likelihood of serious illness were identified. Four of these 162,184,185,187,188 were conducted in the USA and one in Japan. 186 All these studies were hospital cohorts with different dosages and type of antipyretics (paracetamol 15 mg/kg 184,185 or 10 mg/kg of paracetamol or aspirin 162,185,186), different ages of children included (3–24 months, 162,185,186 8 weeks to 6 years 187 or < 24 months 188), different definitions of fever and different methods of measuring body temperature. The evidence suggests that a change in temperature 1–2 hours after antipyretics does not help identify children with serious illness. However, assessment with YOS 1 hour after antipyretics seems more specific. The mean repeat YOS was 13.7 in children with serious illness compared with 10.0 in the children without serious illness (P = 0.004). 189

Evidence summary

The results from prospective cohort studies showed that a change in temperature 1–2 hours after antipyretics does not help identify children with serious illness. However, children with serious illness generally appear more ill than those without serious illness after antipyretics.

GDG translation

Some healthcare professionals think that a decrease in temperature after antipyretics makes an SBI less likely. The GDG concluded that this is not supported by evidence. Children with YOS > 10 mostly have 'amber' or 'red' features. The GDG found some evidence that if these children are reassessed after antipyretics, the features may have resolved in those without serious illness. Reassessment after antipyretics may help differentiate those with and without serious illness but the GDG recognised that more research could usefully be undertaken on this subject.

Antipyretic interventions Physical and drug interventions

Drug interventions

Narrative evidence

Two EL 1+ reviews^{210,214} and four EL 1+ RCTs^{215–218} comparing paracetamol and ibuprofen were found. Paracetamol and ibuprofen were both shown to be effective at reducing fever in children.^{210,214,215,217,218} Both reviews^{210,214} demonstrated that ibuprofen had a more pronounced and/or longer lasting effect on fever compared with paracetamol. However, in many of those studies paracetamol was used in doses below those currently recommended in the UK.

Adverse effects of antipyretic drugs

One EL 1+ meta-analysis²¹⁰ which compared patients receiving single doses of paracetamol or ibuprofen was found. Despite the widespread use of ibuprofen and paracetamol, adverse events were rare. No evidence was found to suggest a difference in the risk of either minor or major harm between the two drugs. However, there have been reports of serious suspected adverse reactions even at therapeutic doses for both drugs. ^{4,219} There is greater experience with the use of paracetamol but ibuprofen use is increasing and different adverse effect profiles may emerge.

Delphi consensus

There is a lack of evidence regarding indications for when children should be given antipyretic drugs. The GDG therefore decided to use the Delphi survey to provide information for these questions. After two rounds of Delphi the results below were obtained.

Delphi statement 8.1

Antipyretic drugs should be given to all children with fever.

| 1 to 3 | 4 to 6 | 7 to 9 | Don't now | Missing | Total | Median |
|----------|----------|----------|-----------|---------|-------|--------|
| 10 (19%) | 11 (21%) | 29 (56%) | 2 (4%) | | 52 | 7 |

After two rounds of Delphi this question failed to reach consensus and this statement was not therefore included in the draft version of the guideline. The second question to answer was Statement 8.2 of the Delphi consensus.

Delphi statement 8.2

Antipyretic drugs should be offered to children who are miserable with fever because they may make them feel better.

| 1 to 3 | 4 to 6 | 7 to 9 | Don't now | Missing | Total | Median |
|--------|---------|----------|-----------|---------|-------|--------|
| 3 (6%) | 5 (10%) | 43 (83%) | 1 (2%) | | 52 | 8 |

This reached agreement by consensus of 83% of respondents after round 2 and is therefore included as a recommendation in the guideline.

Evidence summary

Paracetamol and ibuprofen are both effective antipyretics. Physical methods of temperature reduction offer little additional benefit and cause crying and shivering in some children. There is no evidence of a significant difference in the incidence of adverse events between the two drugs. On current evidence both drugs are equally effective but paracetamol has a longer established safety record.

There is no evidence for any specific indications for the administration of antipyretics. Care should, however, be taken with all drugs, including antipyretics if given in combination with other drugs, or if the child is suffering other complications or conditions such as dehydration. Delphi consensus provided strong agreement that antipyretic drugs should be offered to children who are miserable with fever because they may make them feel better, but not that they should be given to all children with fever.

Health economics

Since no evidence of difference in the effectiveness of paracetamol and ibuprofen was identified, decisions on which should be used in the NHS should be based on individual prices available to trusts at the time of purchase.

GDG translation

Ibuprofen and paracetamol are widely used as antipyretic drugs. Although adverse effects and toxicities are possible with their use, paediatric formulations are safe in most children. Healthcare professionals and others involved in the supply of these drugs should ensure that parents understand how to administer them safely.

Despite their common use, there is no evidence regarding the indications for the administration of antipyretic drugs. Consequently, the GDG included questions on this in the Delphi survey. The results of this partly confirmed the lack of evidence, with no consensus on the statement that antipyretic drugs should be given to all children with fever. However, there was strong support for the statement that antipyretics should be offered to children who are miserable with fever because they may make them feel better. In response to stakeholder comments that antipyretics should not be given just because a child has a fever, the GDG decided to revisit the question as to whether all children with fever should be given antipyretics. The GDG achieved consensus among themselves that children with fever do not necessarily need to be given antipyretic agents, especially in light of the following recommendation that children who are miserable with fever may benefit from treatment. Because of the uncertainties about the benefits of antipyretic agents and their indications, the GDG recommended that more research should be conducted on the topic.

Because both drugs are safe and effective, no recommendation can be made about which should be used. The health economic analysis suggests that decisions on which should be used in the NHS should be based upon individual prices available to trusts at the time of purchase.

Research recommendation

Research recommendation on drug interventions for reducing temperature

Efficacy and cost-effectiveness studies are required which measure symptom relief associated with fever relief.

Combining pharmacological treatments

Paracetamol and ibuprofen, the drugs most commonly used to treat fever, are often used together by healthcare professionals, parents and patients, either in combination or alternately.²²⁰

Narrative evidence

Two EL 1- RCTs^{221,222} investigating the combination of antipyretic drug therapies and one EL 1+ RCT²²³ and one EL 1- RCT²²² investigating the alternation of antipyretic drug therapies were found.

Combination treatment

One EL 1- RCT 221 from the UK examined the administration of paracetamol, ibuprofen or both. It has to be noted that this study had no blinding and small numbers (n = 37, 35, 36) in each arm. A statistically significant difference between the combination and paracetamol groups was found, but this was only 0.35°C and was not considered to be clinically significant. Follow-up of the majority of patients was only for 1 hour and therefore failed to detect any delayed differences. A second EL 1-RCT222 from India with small patient numbers (n = 80) showed that ibuprofen combined with paracetamol and nimesulide and paracetamol had almost identical antipyretic effects. No marked adverse effects were detected. Statistical data were not reported.

Neither study was of sufficient methodological quality to provide reliable evidence on the combined use of paracetamol and ibuprofen, which is therefore not recommended.

Alternating treatment

 $\label{eq:two-RCTs-222,223} \textbf{were found which examined the use of alternating regimens of antipyretic agents}.$

One EL 1+ RCT 223 from Israel assigned children to receive either paracetamol or ibuprofen or to receive alternating paracetamol and ibuprofen for 3 days. The group given the alternating regimen was characterised by a lower mean temperature, more rapid reduction of fever, receiving less antipyretic medication, less stress, and less absenteeism from day care as compared with the other groups; all of the differences were statistically significant (P < 0.05). However, the study involved the use of a double dose loading dose, used low paracetamol maintenance doses and relied on parental temperature measurement and documentation at home. The second EL 1- RCT 224 from Lebanon randomly allocated patients into one of two treatment groups: an intervention group where a single oral dose of ibuprofen was administered at baseline followed by a single oral dose of paracetamol

4 hours later; and a control group where a similar dose of ibuprofen was administered initially, followed by placebo 4 hours later. Those in the intervention group were significantly more likely than those in the control group to become afebrile at 6, 7 and 8 hours (P < 0.05). The two groups had similar maximum decline in temperature. No serious adverse reactions were observed. Although these results suggest the superiority of the combined alternating regimen, the findings need to be confirmed in larger trials, since the study had small numbers in each arm and failed to achieve its calculated sample size.

Evidence summary

Current limited evidence from a small number of RCTs suggests that combination treatment offers no advantage over single drug therapy and would not lead to clinically significant further reduction of body temperature. There is also inadequate evidence to demonstrate the safety of combination treatment. An individual case report has highlighted potential interactions between these drugs. More methodologically sound studies are therefore required to investigate the use of antipyretic combination treatment before recommendations can be made.

There is some limited evidence to suggest that alternating ibuprofen and paracetamol treatment is superior to monotherapy, although the safety of this treatment has not been studied.

GDG translation

The GDG recognises that combinations of paracetamol and ibuprofen, or regimens alternating the two drugs, are in common use by healthcare professionals and families. There is insufficient evidence to support or refute these practices. The potential for adverse drug reactions of the two used together is not known. Theoretical interactions are recognised and reliable safety data do not exist. Furthermore, each drug is known to be effective as a single agent and the potential for confusion and drug administration errors is increased by using more than one drug.

The studies examining administering paracetamol and ibuprofen at the same time have demonstrated no benefit above giving either agent alone, but these had low patient numbers. The two studies which have claimed benefit from an alternating regimen of ibuprofen and paracetamol do not provide sufficient evidence to support such a recommendation. The GDG is aware that an HTA study is currently examining the use of combined regimens of paracetamol and ibuprofen and will report in 2009.

The GDG noted that, from the evidence, antipyretic agents do not appear to be effective in the prevention of febrile convulsions. There is very limited evidence regarding the effect of paracetamol on activity and other areas contained within the clinical question, which showed inconsistent effects.

Research recommendation

Research recommendation on combining pharmacological treatment to reduce temperature

The GDG recommends that a study is conducted on the effectiveness and safety of alternating doses of paracetamol and ibuprofen in reducing fever in children who remain febrile after the first antipyretic.

Effects of body temperature reduction

In addition to the underlying illness, fever may be accompanied by a number of unpleasant symptoms including pain, reduced eating and drinking, and reduced activity. In some cases, for example pain, this is likely to be the result of the illness causing the fever. However, in other cases it is not always clear whether these are the direct result of the fever, or of the underlying illness, or a combination of the two. The GDG therefore considered the use of antipyretic interventions in the treatment of these symptoms.

Because fever is a normal response to infection, some studies have been undertaken to look at the effect of the treatment of fever on specific conditions, including malaria, chickenpox and various viral infections. These showed that antipyresis does appear to slow recovery, and makes little

difference to some aspects of wellbeing, although the clinical significance of these findings is marginal. As these studies were undertaken on patients who had a diagnosis, these fell outside of the scope of this guideline, and are not discussed further.

A particular concern of many parents about fever in children is that it may cause fits, or febrile convulsions. ²⁰⁶These are common in young children, and are very rarely associated with epilepsy or other problems in later life. ²³⁰ Because antipyretics reduce temperature, there is a theoretical rationale for their use in the prevention of febrile convulsions.

Review question

Does the use of antipyretic interventions in children with fever serve a benefit or harm in terms of any of the following:

- time to recovery
- wellbeing
- activity
- · eating and drinking
- prevention of febrile convulsions?

We did not find any evidence against other interventions.

Narrative evidence

Although there are some studies looking at the effect of pharmacological antipyresis on recovery from specific conditions such as chickenpox and malaria, and viral conditions, these fell outside of the scope of this guideline.

Research regarding the use of antipyretics in the prevention and treatment of febrile convulsions is limited. One EL 1+ review²³¹ that was judged to be adequate for inclusion owing to its clinical relevance, after obtaining methodological details from the author, and one EL 1+ SR²³² examining the use of antipyretic drugs as prophylaxis against febrile convulsions were found.

The first231 investigated the hypothesis that paracetamol and ibuprofen, used prophylactically, will reduce the incidence of febrile convulsions across a wide variety of conditions. It found no evidence that the prophylactic use of antipyretics has any effect in reducing the incidence of febrile convulsions. The second review²³² assessed 12 studies of the effects of paracetamol for treating children in relation to fever clearance time, febrile convulsions and resolution of associated symptoms. It also found no evidence that the use of prophylactic paracetamol influenced the risk of febrile convulsions.

An EL 1+ double-blind RCT²²⁸ analysing ²²⁵ datasets was also identified, which found that there was no significant difference in mean duration of fever (34.7 hours versus 36.1 hours, P not given) or of other symptoms (72.9 hours versus 71.7 hours). Children treated with paracetamol were more likely to be rated as having at least a 1-category improvement in activity (P = 0.005) and alertness (P = 0.036).

Evidence summary

Limited evidence was found regarding the use of antipyretic medications in the promotion of well-being, activity, eating and drinking, and no evidence of cost-effectiveness. One study suggested that parents could identify some improvement in activity and alertness after the administration of paracetamol, but not in mood, comfort, appetite or fluid intake. There is no evidence that the use of antipyretic agents reduces the incidence of febrile convulsions. (EL 1)

GDG translation

The GDG noted that, from the evidence, antipyretic agents do not appear to be effective in the prevention of febrile convulsions. There is very limited evidence regarding the effect of paracetamol on activity or other areas contained within the clinical question, which showed inconsistent effects.

Appendix K Proposed changes to original recommendations

In the 2013 guideline the term meningitis has been replaced with bacterial meningitis, where appropriate.

| Recommendation [2007] | Replaced with | Reason for change/ deletion |
|---|--|---|
| The oral and rectal routes should not routinely be used to measure the body temperature of children aged 0–5 years. | Do not routinely use the oral and rectal routes to measure the body temperature of children aged 0–5 years. [2007] | The wording of the recommendation was changed to make it an active statement. |
| In infants under the age of 4 weeks, body temperature with an electronic thermometer in the axilla | In infants under the age of 4 weeks, measure body temperature with an electronic thermometer in the axilla. [2007] | The wording of the recommendation was changed to make it an active statement. |
| In children aged 4 weeks to 5 years, healthcare professionals should measure body temperature by one of the following methods: • electronic thermometer in the axilla • chemical dot thermometer in the axilla • infra-red tympanic thermometer. | In children aged 4 weeks to 5 years, measure body temperature by one of the following methods: • electronic thermometer in the axilla • chemical dot thermometer in the axilla • infra-red tympanic | The wording of the recommendation was changed to make it an active statement. |

thermometer. [2007]

Children with the following symptoms or signs should be recognised as being in a high-risk group for serious illness:

- unable to rouse or if roused does not stay awake
- · weak, high-pitched or continuous cry
- pale/mottled/blue/ashen
- reduced skin turgor
- · bile-stained vomiting
- · moderate or severe chest indrawing
- respiratory rate greater than 60 breaths/minute
- grunting
- bulging fontanelle
- appearing ill to a healthcare professional.

Recognise that children with any of the following symptoms or signs are in a high-risk group for serious illness:

- pale/mottled/ashen/blue skin, lips or tongue
- no response to social cues*
- appearing ill to a healthcare professional
- does not wake or if roused does not stay awake
- weak, high-pitched o continuous cry
- grunting
- respiratory rate greater than 60 breaths per minute
- moderate or severe chest indrawing
- reduced skin turgor. [new 2013]

'Bile-stained vomiting' was removed from the traffic liaht system because it was incorrectly included in 2007 the system, and no evidence was found to support inclusion in the recom mendation.

The order of the bullet points in the recommendation have been changed to reflect the order in the Traffic light system.

Children with any of the following symptoms should be recognised as being in at least an intermediate-risk group for serious illness:

- wakes only with prolonged stimulation
- · decreased activity
- poor feeding in infants
- not responding normally to social cues/no smile
- dry mucous membranes
- reduced urine output
- a new lump larger than 2 cm
- pallor reported by parent or carer
- nasal flaring.

Recognise that children with any of the following symptoms or signs are in at least an intermediate-risk group for serious illness:

- pallor of skin, lips or tongue reported by parent or carer
- not responding normally to social cues
- no smile
- wakes only with prolonged stimulation
- decreased activity
- · nasal flaring
- dry mucous membranes
- poor feeding in infants
- reduced urine output
- rigors. [new 2013]

'New lump > 2cm' was removed from the traffic light system because it was incorrectly included in 2007 the system, and no evidence was found to support inclusion in the recommendation.

The order of the bullet points in the

A child's response to social interaction with a parent or healthcare professional, such as response to their name, smiling and/or giggling.

recommendation have been changed to reflect the order in the Traffic light system.

Children who have all of the following features, and none of the high or intermediate risk features, should be recognised as being in a low-risk group for serious illness:

- strong cry or not crying
- · content/smiles
- · stays awake
- · normal colour of skin, lips and tongue
- normal skin and eyes
- moist mucous membranes
- normal response to social cues.

Recognise that children who have all of the following features, and none of the high- or intermediaterisk features, are in a low-risk group for serious illness:

- normal colour of skin, lips and tongue
- responds normally to social cues[†]
- content/smiles
- stays awake awakens or quickly
- strong normal cry or not crying
- normal skin and eyes
- · moist mucous membranes. [new 2013]

The wording of the recommendation was changed to make it an active statement.

Healthcare professionals examining children Removed with fever, should be aware that a raised heart rate can be a sign of serious illness, particularly septic shock.

This recommendation was superseded by a new recommendation on tachycardia

Healthcare professionals should measure and record temperature, heart rate, respiratory rate and capillary refill time as part of the routine assessment of a child with fever.

Measure and record temperature, heart rate, respiratory rate and capillary refill time as part of the routine assessment of a child with fever. [2007]

The wording the recommendation was changed to make it an active statement.

A capillary refill time of 3 seconds or longer should be recognised as an intermediate-risk group marker for serious illness (amber sign).

Recognise that a capillary refill time of 3 seconds or longer is an intermediate-risk group marker for serious illness ('amber' sign) [2013]

The wording the of recommendation was changed to

[†] A child's response to social interaction with a parent or healthcare professional, such as response to their name, smiling and/or giggling.

make it an active statement.

Healthcare professionals should measure the blood pressure of children with fever if the heart rate or capillary refill time is abnormal and the facilities to measure blood pressure are available.

Measure the blood pressure of children with fever if the heart rate or capillary refill time is abnormal and the facilities to measure blood pressure are available. [2007]

The wording of the recommendation was changed to make it an active statement.

Children with fever should be assessed for signs of dehydration. Healthcare professionals should look for:

- prolonged capillary refill time
- abnormal skin turgor
- · abnormal respiratory pattern
- weak pulse
- · cool extremities.

Assess children with fever for signs of dehydration. Look for:prolonged capillary refill time

- abnormal skin turgor
- abnormal respiratory pattern
- weak pulse
- cool extremities. [2007]

The wording of the recommendation was changed to make it an active statement.

Healthcare professionals should ILook for a source of fever and check for the presence of symptoms and signs that are associated with specific diseases (see table 2)

Look for a source of fever and check for the presence of symptoms and signs that are associated with specific diseases (see table 5.66). [2007]

The wording of the recommendation was changed to make it an active statement.

Meningococcal disease should be considered in any child with fever and a non-blanching rash, particularly if any of the following features are present:

- an ill-looking child
- lesions larger than 2 mm in diameter (purpura)
- a capillary refill time of 3 seconds or longer
- neck stiffness.

Consider meningococcal disease in any child with fever and a non-blanching rash, particularly if any of the following features are present^{‡:}

- an ill-looking child
- lesions larger than 2 mm in diameter (purpura)
- a capillary refill time of 3 seconds or longer
- neck stiffness. [2007]

The wording of the recommendation was changed to make it an active statement.

Meningitis should be considered in a child with fever and any of the following features:

- neck stiffness
- · bulging fontanelle
- decreased level of consciousness
- convulsive status epilepticus.

Consider bacterial meningitis in a child with fever and any of the following features:‡

- neck stiffness
- bulging fontanelle
- decreased level of

The wording of the recommendation was changed to make it an active

[‡] See <u>Bacterial meningitis and meningococcal septicaemia</u>. NICE clinical guideline 102 (2010).

consciousness

• convulsive status epilepticus. [2007]

statement.

Healthcare professionals should be aware that classic signs of meningitis (neck stiffness, bulging fontanelle, high-pitched cry) are often absent in infants with bacterial meningitis.

Be aware that classic signs of meningitis (neck stiffness, bulging fontanelle, high-pitched cry) are often absent in infants with bacterial meningitis. § [2007]

The wording of the recommendation was changed to make it an active statement.

Herpes simplex encephalitis should be considered in children with fever and any of the following features:

- · focal neurological signs
- focal seizures
- decreased level of consciousness.

Consider herpes simplex encephalitis in children with fever and any of the following features:

- · focal neurological signs
- · focal seizures
- decreased level of consciousness. [2007]

The wording of the recommendation was changed to make it an active statement.

Pneumonia should be considered in children with fever and any of the following signs :

- tachypnoea (respiratory rate greater than 60 breaths per minute, age 0–5 months; greater than 50 breaths per minute, age 6– 12 months; greater than 40 breaths per minute, age older than 12 months)
- · crackles in the chest
- nasal flaring
- chest indrawing
- cyanosis
- oxygen saturation of 95% or less when breathing air.

Consider pneumonia in children with fever and any of the following signs:

- tachypnoea (respiratory rate greater than 60 breaths per minute, age 0–5 months; greater than 50 breaths per minute, age 6–12 months; greater than 40 breaths per minute, age older than 12 months)
- · crackles in the chest
- nasal flaring
- · chest indrawing
- cyanosis
- oxygen saturation of 95% or less when breathing air. [2007]

The wording of the recommendation was changed to make it an

active

statement.

Urinary tract infection should be considered in any child younger than 3 months with fever.**

Consider urinary tract infection in any child younger than 3 months with fever. [2007]

The wording of the recommendation was changed to make it an active statement.

Septic arthritis/osteomyelitis should be Consider septic The wording

See <u>Urinary tract infection in children</u>, NICE clinical guideline 54 (2007).

[§] See <u>Bacterial meningitis and meningococcal septicaemia</u>. NICE clinical guideline 102 (2010).

considered in children with fever and any of the following signs:

- swelling of a limb or joint
- not using an extremity
- non-weight bearing.

Kawasaki disease should be considered in children with fever that has lasted longer than 5 days and who have 4 of the following 5 features:

- bilateral conjunctival injection
- change in mucous membranes in the upper respiratory tract (for example, injected pharynx, dry cracked lips or strawberry tongue)
- change in the extremities (for example, oedema, erythema or desquamation)
- polymorphous rash
- cervical lymphadenopathy

Healthcare professionals should be aware that, in rare cases, incomplete/atypical Kawasaki disease may be diagnosed with fewer features.

When assessing a child with feverish illness, healthcare professionals should enquire about recent travel abroad and should consider the possibility of imported infections according to the region visited.

arthritis/osteomyelitis in children with fever and any of the following signs:

- swelling of a limb or joint
- not using an extremity
- non-weight bearing. [2007]

of the recommendation was changed to make it an active statement.

The wording

recommend-

changed to

make it an

statement.

the

was

of

ation

active

Consider Kawasaki disease in children with fever that has lasted longer than 5 days and who have 4 of the following 5 features:

- bilateral conjunctival injection
- change in mucous membranes in the upper respiratory tract (for example, injected pharynx, dry cracked lips or strawberry tongue)
- change in the extremities (for example, oedema, erythema or desquamation)
- polymorphous rash

[2007]

· cervical lymphadenopathy.

Be aware that, in rare cases, incomplete/atypical Kawasaki disease may be diagnosed with fewer features. [2007]

When assessing a child with feverish illness, enquire about recent travel abroad and consider the possibility of imported infections according to the region visited.

The wording of the recommendation was changed to make it an active statement.

Table 1 Traffic light system for identifying risk of serious illness Children with fever and any of the symptoms or signs in the red column should be recognised as being at high risk. Similarly, children with fever and any of the symptoms or signs in the amber column and none in the red column should be recognised as being at intermediate risk. Children with symptoms and signs in the green column and none in the amber or red column are at low risk. The management of children with fever should be directed by the level of risk.

Green - low Amber – intermediate risk Red - high risk risk Colour Normal Pallor reported by Pale/mottled/ashen/blue colour of parent/carer skin, lips and tongue Responds Activity Not responding normally to No response to social cues normally to social cues Appears ill to a healthcare Wakes only with prolonged social cues professional Content/s stimulation Does not wake or if roused miles Decreased activity does not stay awake No smile • Weak, high-pitched or Stays awake or continuous cry awakens quickly Strong normal cry/not crying Respirat Nasal flaring Grunting Tachypnoea:RR > 50 breat ory Tachypnoea:RR > 60 brea hs/minute, age 6ths/minute 12 monthsRR > 40 breaths • Moderate or severe chest /minutes, age > 12 months indrawing Oxygen saturation ≤ 95% in air Crackles Normal Dry mucous membranes Hydratio Reduced skin turgor skin and · Poor feeding in infants • CRT ≥ 3 seconds eyes • Reduced urine output Moist mucous membrane Other None of Fever for ≥ 5 days • Age 0-3 months, the amber temperature ≥ 38°C or red Age 3–6 months, symptoms temperature ≥ 39°C or signs Swelling of a limb or joint Non-blanching rash Non-weight bearing/not Bulging fontanelle using an extremity Neck stiffness Status epilepticus Focal neurological signs Focal seizures • A new lump > 2 cm Bile-stained vomiting

The existing 2007 traffic light was amended to reflect the findings of a full update review of all symptoms and signs of fever.

Table 1 replaced by: **table 5.2** (chapter 1- guideline summary, section 1.5 and chaper 5- clinical assessment of the child with fever, section 5.3)

 $\textbf{Table 2} \ \, \textbf{Summary table for symptoms and signs suggestive of specific diseases (Table 2 in [2007] guideline)}$

| Diagnosis to be | Symptoms and signs in conjunction with favor | | | |
|----------------------------|--|--|--|--|
| Diagnosis to be considered | Symptoms and signs in conjunction with fever | | | |
| Meningococcal disease | Non-blanching rash, particularly with one or more of the following: | | | |
| | an ill-looking child lesions larger than 2 mm in diameter (purpura) capillary refill time of ≥ 3 seconds neck stiffness | | | |
| Meningitis | Neck stiffness | | | |
| | Bulging fontanelle | | | |
| | Decreased level of consciousness | | | |
| | Convulsive status epilepticus | | | |
| Herpes simplex | Focal neurological signs | | | |
| encephalitis | Focal seizures | | | |
| | Decreased level of consciousness | | | |
| Pneumonia | Tachypnoea (RR > 60 breaths/minute, age 0–5 months; RR > 50 breaths/minute, age 6–12 months; RR > 40 breaths/minute, age > 12 months) | | | |
| | Crackles in the chest | | | |
| | Nasal flaring | | | |
| | Chest indrawing | | | |
| | Cyanosis | | | |
| | Oxygen saturation ≤ 95% | | | |
| Urinary tract infection | Vomiting | | | |
| | Poor feeding | | | |
| | Lethargy | | | |
| | Irritability | | | |
| | Abdominal pain or tenderness | | | |
| | Urinary frequency or dysuria | | | |
| | Offensive urine or haematuria | | | |
| Septic arthritis | Swelling of a limb or joint | | | |
| | Not using an extremity | | | |
| | Non-weight bearing | | | |
| Kawasaki disease | Fever for more than 5 days and at least four of the following: | | | |
| | bilateral conjunctival injection change in mucous membranes change in the extremities polymorphous rash cervical lymphadenopathy | | | |

Offensive urine and haematuria were removed from the list because they are rarely seen in clinical practice.

Table 2 replaced by: **table 5.66** (chapter 1 – guideline summary, section 1.5 and chaper 5 – clinical assessment of the child with fever, section 5.5)

Children with 'green' features and none of the 'amber' or 'red' features can be managed at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see chapter 9).

Children with 'green' features and none of the 'amber' or 'red' features can be cared for at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see chapter 10). [2007]

The wording of the recommendation was changed to make it an active statement.

If any 'amber' features are present and no diagnosis has been reached, healthcare professionals should provide parents or carers with a 'safety net' or refer to specialist paediatric care for further assessment. The safety net should be 1 or more of the following:

- providing the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed (see chapter 9)
- arranging further follow-up at a specified time and place
- liaising with other healthcare professionals, including out-of-hours providers, to ensure direct access for the child if further assessment is required. [2007

If any 'amber' features are present and no diagnosis has been reached, provide parents or carers with a 'safety net' or refer to specialist paediatric care for further assessment. The safety net should be 1 or more of the following:

- providing the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed (see chapter 10)
- arranging further follow-up at a specified time and place
- liaising with other healthcare professionals, including out-ofhours providers, to ensure direct access for the child if further assessment is required.
 [2007]

The wording of the recommendation was changed to make it an active statement.

Urine should be tested on children with fever as recommended in 'Urinary tract infection in children' (NICE clinical guideline 54). [2007]

Test urine in children with fever as recommended in 'Urinary tract infection in children' (NICE clinical guideline 54). [2007]

The wording of the recommendation was changed to make it an active statement.

Oral antibiotics should not be prescribed to children with fever without apparent source. [2007]

Do not prescribe oral antibiotics to children with fever without apparent source. [2007]

The wording of the recommendation was changed to make it an active statement.

Children with suspected meningococcal disease should be given parenteral antibiotics at the earliest opportunity (either benzylpenicillin or a third-generation cephalosporin). ††.

Give parenteral antibiotics to children with suspected meningococcal disease at the earliest opportunity (either benzylpenicillin thirdor а generation cephalosporin). †† [2007]

The wording of the recommendation was changed to make it an active statement.

Lumbar puncture should be performed on the following children (unless contraindicated):

- infants younger than 1 month
- all infants aged 1–3 months who appear unwell
- infants aged 1–3 months with a white blood cell count (WBC) less than 5 x 10⁹/litre or greater than 15 x 10⁹/litre. [2007]

Perform lumbar puncture in the following children with fever (unless contraindicated):

- infants younger than 1 month
- all infants aged 1–3 months who appear unwell
- infants aged 1–3 months with a white blood cell count (WBC) less than 5 x 10⁹/litre or greater than 15 x 10⁹/litre. [2007, amended 2013]

The wording of the recommendation was changed to make it an active statement.

When indicated, a lumbar puncture should be performed without delay and, whenever possible, before the administration of antibiotics. [2007]

When indicated, perform a lumbar puncture without delay and, whenever possible, before the administration of antibiotics. [2007]

The wording of the recommendation was changed to make it an active statement.

Parenteral antibiotics should be given to:

- infants younger than 1 month
- all infants aged 1–3 months who appear unwell
- infants aged 1–3 months with WBC less than 5 x 10⁹/litre or greater than 15 x 10⁹/litre. [2007]

Give parenteral antibiotics to:

- infants younger than 1 month with fever
- all infants aged 1–3 months with fever who appear unwell
- infants aged 1–3 months with WBC less than 5 x 10⁹/litre or greater than 15 x 10⁹/litre. [2007, amended 2013]

The wording of the recommendation was changed to make it an active statement.

Children with fever without apparent source presenting to paediatric specialists with one or more 'red' features should have the following investigations performed:

- · full blood count
- blood culture
- · C-reactive protein

Perform the following investigations in children with fever without apparent source who present to paediatric specialists with one or more 'red' features:

- full blood count
- blood culture
- C-reactive protein

The wording of the recommendation was changed to make it an active statement.

^{††} See <u>Bacterial meningitis and meningococcal septicaemia,</u> NICE clinical guideline 102 (2010).

• urine testing for urinary tract infection.

• urine testing for urinary tract infection. ‡‡ [2013]

Routine blood tests and chest X-rays should not be performed on children with fever who have no features of serious illness (that is, the 'green' group). Do not routinely perform blood tests and chest X-rays in children with fever who have no features of serious illness (that is, the 'green' group). [2007, amended 2013] The wording of the recommendation was changed to make it an active statement.

When a child has been given antipyretics:

- healthcare professionals should not rely on a decrease or lack of decrease in temperature after 1–2 hours to differentiate between serious and non-serious illness
- children in hospital with 'amber' or 'red' features should be reassessed after 1— 2 hours.

When a child has been given antipyretics, do not rely on a decrease or lack of decrease in temperature at 1–2 hours to differentiate between serious and non-serious illness. Nevertheless, in order to detect possible clinical deterioration, all children in hospital with 'amber' or 'red' features should still be reassessed after 1–2 hours. [new 2013]

The recommendation was revised for style and clarity.

Children with fever presenting to specialist paediatric care or an emergency department should be given immediate parenteral antibiotics if they are:

- shocked
- unrousable
- showing signs of meningococcal disease.

Give immediate parenteral antibiotics to children with fever presenting to specialist paediatric care or an emergency department if they are:

- shocked
- unrousable
- showing signs of meningococcal disease. [2007]

The wording of the recommendation was changed to make it an active statement.

Children with fever and symptoms and signs suggestive of herpes simplex encephalitis should be given intravenous aciclovir.

Give intravenous aciclovir to children with fever and symptoms and signs suggestive of herpes simplex encephalitis (see recommendation 26). [2007]

The wording of the recommendation was changed to make it an active statement.

Healthcare professionals should refer to local treatment guidelines when rates of bacterial antibiotic resistance are significant.

Refer to local treatment guidelines when rates of bacterial antibiotic resistance are significant. [2007]

The wording of the recommendation was changed to make it an active

^{‡‡} See <u>Urinary tract infection in children</u>, NICE clinical guideline 54.

statement.

In addition to the child's clinical condition, healthcare professionals should consider the following factors when deciding whether to admit a child with fever to hospital:

- social and family circumstances
- other illnesses that affect the child or other family members
- parental anxiety and instinct (based on their knowledge of their child)
- contacts with other people who have serious infectious diseases
- recent travel abroad to tropical/subtropical areas, or areas with a high risk of endemic infectious disease
- when the parent or carer's concern for their child's current illness has caused them to seek healthcare advice repeatedly
- where the family has experienced a previous serious illness or death due to feverish illness which has increased their anxiety levels
- when a feverish illness has no obvious cause, but the child remains ill longer than expected for a self-limiting illness.

In addition to the child's clinical condition, consider the following factors when deciding whether to admit a child with fever to hospital:

- social and family circumstances
- other illnesses that affect the child or other family members
- parental anxiety and instinct (based on their knowledge of their child)
- contacts with other people who have serious infectious diseases
- recent travel abroad to tropical/subtropical areas, or areas with a high risk of endemic infectious disease
- when the parent or carer's concern for their child's current illness has caused them to seek healthcare advice repeatedly
- where the family has experienced a previous serious illness or death due to feverish illness which has increased their anxiety levels
- when a feverish illness has no obvious cause, but the child remains ill longer than expected for a self-limiting illness. [2007]

If it is decided that a child does not need to be admitted to hospital, but no diagnosis has been reached, a safety net should be provided for parents and carers if any 'red' or 'amber' prefeatures are present. The safety net should be 1 or more of the following:

- providing the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed (see chapter 9)
- arranging further follow-up at a specified time and place
- liaising with other healthcare professionals, including out-of-hours providers, to ensure direct access for the child if further assessment is required.

If it is decided that a child does not need to be admitted to hospital, but no diagnosis has been reached, provide a safety net for parents and carers if any 'red' or 'amber' features are present. The safety net should be 1 or more of the following:

- providing the parent or carer with verbal and/or written information on warning symptoms and how further healthcare can be accessed (see section 10.2)
- arranging further follow-up at a specified time and place
- liaising with other healthcare professionals, including out-ofhours providers, to ensure

The wording of the recommendation was changed to make it an active statement.

The wording of the recommendation was changed to make it an active statement.

direct access for the child if further assessment is required. [2007]

Children with 'green' features and none of the 'amber' or 'red' features can be can be managed at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see chapter 9).

Children with 'green' features and none of the 'amber' or 'red' features can be cared for at home with appropriate advice for parents and carers, including advice on when to seek further attention from the healthcare services (see chapter 10). [2007, amended 2013]

The wording of the recommendation was changed to make it an active statement.

Children with suspected meningococcal disease should be given parenteral antibiotics at the earliest opportunity (either benzylpenicillin or a third-generation cephalosporin). [2007]

Give parenteral antibiotics to children with suspected meningococcal disease at the earliest opportunity (either benzylpenicillin or a thirdgeneration cephalosporin). [2007]

The wording of the recommendation was changed to make it an active statement.

Either paracetamol or ibuprofen can be used to reduce temperature in children with fever.

Consider using either paracetamol or ibuprofen in children with fever who appear distressed. [new 2013]

The wording the recommendation was changed to make it an active statement. The recommendation was separated to improve clarity.

The use of antipyretic agents should be considered in children with fever who appear distressed or unwell. Antipyretic agents should not routinely be used with the sole aim of reducing body temperature in children with fever who are otherwise well. The views and wishes of parents and carers should be taken into consideration.

Do not use antipyretic agents with the sole aim of reducing body temperature in children with fever. [new 2013]

The wording the of recommendation was changed to make it an active statement. The recommendation was separated to improve clarity.

Paracetamol and ibuprofen should not be administered at the same time to children with fever.

(Recommendation [1.6.1.5] in [2007] guideline)

Paracetamol and ibuprofen should not routinely be given alternately to children with fever. However, use of the alternative drug may be considered if the child does not respond to the first agent. Two recommendations were merged in the following recommendation:

When using paracetamol or ibuprofen in children with fever:

- continue only as long as the child appears distressed
- consider changing to the other agent if the child's distress is not alleviated
- do not give both agents simultaneously
- only consider alternating these agents if the distress persists or recurs before the next dose is due. [new 2013]

Two recommendations were merged to improve clarity. The wording of the recommendation was changed to make it an active statement.

Parents or carers should be advised to manage their child's temperature as described in chapter 8. [2007] Advise parents or carers to manage their child's temperature as described in chapter 9. [2007] The wording of the recommendation was changed to make it an active statement.

Parents or carers looking after a feverish child at home should be advised:

- to offer the child regular fluids (where a baby or child is breastfed the most appropriate fluid is breast milk)
- how to detect signs of dehydration by looking for the following features:
 - o sunken fontanelle
 - dry mouth
 - o sunken eyes
 - absence of tears
 - poor overall appearance
- to encourage their child to drink more fluids and consider seeking further advice if they detect signs of dehydration
- · how to identify a non-blanching rash
- to check their child during the night
- to keep their child away from nursery or school while the child's fever persists but to notify the school or nursery of the illness

Advise parents or carers looking after a feverish child at home:

- to offer the child regular fluids (where a baby or child is breastfed the most appropriate fluid is breast milk)
- how to detect signs of dehydration by looking for the following features:
 - o sunken fontanelle
 - o dry mouth
 - o sunken eyes
 - o absence of tears
 - poor overall appearance
- to encourage their child to drink more fluids and consider seeking further advice if they detect signs of dehydration
- how to identify a non-blanching rash
- to check their child during the night
- to keep their child away from nursery or school while the child's fever persists but to notify the school or nursery of the illness. [2007]

The wording of the recommendation was changed to make it an active statement.

Appendix L The formal consensus survey

Background

NICE clinical guidelines are typically based on a review of evidence from published literature, ideally from large, well-conducted studies. The methods used to develop these guidelines are explicit and transparent. They include literature search, assessment and synthesis of evidence and the final judgements made by the Guideline Development Group (GDG) to reach final decisions. While the use of formal consensus methods in NICE guideline is not customary, there are circumstances when they may be warranted, in the absence of robust evidence. This process is separate from the stakeholder consultation of the draft guideline.

A core objective of this guideline on feverish illness in children was to provide practical recommendations for the clinical assessment of children (aged 0–5 years) presenting with a feverish illness, including risk stratification. An extensive review of the literature revealed major deficiencies with the evidence to answer some of the key clinical questions. The main problems were the poor quality of the studies retrieved (small, poorly conducted studies, or incomplete reporting) and generalisability (studies were often conducted in very different settings from the NHS). Moreover, there was recognition that opinions diverged considerably in these areas among clinicians and parents.

Against this background, the GDG decided to use a formal consensus approach with a larger external group of consultees on selected questions. Formal consensus methods are used increasingly in combination with the best available evidence to develop clinical practice guidelines. The purpose of the consensus was to obtain the opinions of an external multidisciplinary group to assist the GDG in making reliable recommendations in areas where evidence was deficient.

Methods

Choosing the consensus method

The GDG chose a modified Delphi method.²³⁸ Delphi is one of the most widely used formal consensus techniques for obtaining opinions from groups of experts and stakeholders.²³⁹ It involves sending participants questionnaires and asking them for their views. The responses are collated and sent back to participants in a summary form allowing them to revise their original opinion in light of the group feedback.^{240,241} This process is repeated several times, with the aim of obtaining consensus. The GDG used a two-round postal/e-mail survey.

Defining the project plan

A plan protocol was designed initially that incorporated all stages and details of the work, including the consensus method to be used, recruitment of participants, data collection and analysis. Importantly, the GDG agreed the ground rules they would use for analysing the results and for formulating the recommendations based on the results from the survey. These are presented in box M.1.

A timetable was drawn up early in the process to ensure the work could be carried out during the timeline of the guideline development. The Royal College of Paediatrics and Child Health and the Patient and Public Involvement Programme (PPIP) unit at NICE confirmed that the consensus work did not require ethical approval.

Box L.1 Ground rules agreed by the GDG for making recommendations from survey results

- The results of the group ratings will be presented to the GDG, together with comments.
- Whenever appropriate the GDG will aim to formulate a recommendation for each statement. The statements will be worded in a way that can be directly translated into recommendations.
- The GDG will explicitly state the basis for its decision using the 'translation' template currently used with other recommendations for which there is evidence.
- Statements for which 75% or more of the ratings fall in the 7 to 9 range will be classified as agreement and the GDG will use the statement as a basis for making a recommendation.
- Statements for which 75% or more of the ratings fall in the 1 to 3 range will be classified as disagreement. The GDG will usually make a negative recommendation (e.g. does not recommend). In certain circumstances the GDG may decide to make a research recommendation or discard the statement. The decision not to make a negative recommendation will need to be agreed unanimously by the GDG and it will need to be justified.
- In all other cases, the GDG will discard the statement. Exceptionally, it may decide to make a recommendation, depending on the degree of variation in the ratings for that statement. Again, this decision will need to be justified and agreed unanimously by the GDG.
- In cases where there is agreement in the rating group but the GDG considers there are grounds to discard the results, the GDG reserves the right to use its own opinion in making the recommendation. This will need to be agreed unanimously by the GDG. In such cases, the GDG will explain in detail the reasons why it rejected the results.

Selecting clinical questions for formal consensus

A systematic search for the evidence was conducted on all clinical questions and relevant published studies were assessed. On examining the evidence the GDG identified a number of questions/issues for which they did not think they could competently make recommendations based on the published studies, or on their collective experience. These questions are listed in box X.2.

The following criteria were used for selecting the questions:

- there was no appropriate published evidence to answer the question
- there was some evidence but the GDG failed to reach consensus among themselves as to what the recommendation should be.
- the GDG did not think the question could be answered by standard quantitative studies
- the GDG was concerned that the evidence found was not applicable or acceptable to practice in England and Wales.

Developing the statements

The statements focused on issues that were commonly seen in practice and were clinically important both for health professionals and for parents/carers. They were generated for each selected question based on the literature review using the following steps:

- a member of the topic group with the help of the systematic reviewer drafted a background summary describing what was known about the issue, based on available evidence and known current practice as agreed by the GDG
- the summary was presented to the GDG, together with a draft statement for discussion
- the GDG finalised the statement.

The statements were worded as recommendations to ensure that the final guideline recommendations reflected the results from the consensus.

Piloting the statements

The draft statements, background and instructions were piloted for clarity and readability with ten people, including members from another GDG, parents and colleagues at the National Collaborating Centre for Women's and Children's Health. They were asked to read through all the documentation and to provide any feedback on potential improvements. Seven responses were received. On the whole, respondents felt the statements and background were clear. There were comments relating to

presentation and ratings for some statements. Based on these suggestions some of the sections were re-ordered, the wording was clarified when relevant and the rating scale for two sets of statements was modified. A member of the Patient and Public Involvement Programme (PPIP) unit at NICE checked the final wording to ensure it was understandable for parents and carers.

Box L.2 Ground rules agreed by the GDG for making recommendations from survey results

Question 2

How accurate are the different types of thermometer in the measurement of body temperature in young children and how do they compare in their ability to detect fever?

Question 3

How accurate are the readings of temperature from different sites of the body in young children and how do these sites compare in the ability to detect fever?

Question 12

In a child with fever what are the benefits, if any, of a period of observation on an assessment facility?

Question 21

Does the use of antipyretic interventions in children with fever serve a benefit or harm in terms of any of the following:

- · time to recovery
- wellbeing
- activity
- · eating and drinking
- · prevention of febrile convulsions?

Question 22

In children with fever at home following a clinical encounter, what indications should direct the parents or carers to seek further advice?

Need to consider:

- height of temperature
- length of temperature
- colour
- drowsiness
- rash
- · poor feeding
- fluid intake
- · reduction in urine output
- altered consciousness
- rigors
- · parental anxiety/instinct
- · inconsolable crying
- irritability.

Question 23

What advice should be given to parents for further management of a febrile child?

Need to consider:

- hydration
- · feeding
- · frequency of temperature monitoring
- · methods of cooling
- · when to attend nursery or school.

Question 24

What factors other than the child's clinical condition should be considered when deciding to admit a child with fever to hospital?

Need to consider:

- social
- comorbidity
- parental wishes and instinct
- • distance from home
- · time of day
- · contacts with other serious illness
- recent travel abroad.

Selecting participants

Number of participants

There is little evidence about the effect the number of participants has on the reliability or validity of consensus. This depends on the purpose of the study and the diversity of the targeted population.235 It was aimed to obtain at least 50 ratings for each statement with a response rate of at 80%. This was based on the assumption that if 75 people were invited to take part at least 65 would agree.

Inviting and recruiting participants

The purpose of the consensus was to seek the opinions of an external multidisciplinary group including the health professionals and patients/carers /parents who are directly involved with or are affected by the issue covered. Three key groups were identified: professionals from primary care including NHS Direct, professionals from secondary care, and parents/carers. It was aimed to obtain 25 nominations in each of the three groups.

Key professional and patient organisations registered as stakeholders were asked to nominate potential participants. Sure Start was approached separately to identify parents from disadvantaged backgrounds. In addition, a message was posted on the NICE website inviting parents to participate.

A letter of invitation was sent to each nominee, together with a document explaining the background to the survey, its aim, and the task involved, including timing and deadlines. An example of a background summary and statement was provided as illustration. Nominees were asked to respond within 2 weeks. They were requested to sign a letter of confidentiality before participating. table L.1 shows the number of nominations received and the numbers who responded.

Rating

The GDG generated 35 statements for consensus. A pack containing a covering letter, the statements/background and response document, an instruction sheet and background notes was sent to each of the 61 people who had agreed to take part. Respondents were asked to indicate their agreement with each statement using a scale of 1–9 (1 being strongly disagree, 9 being strongly agree). For statements 2.1 and 5.2, participants were asked to indicate which optimum time they preferred. A 'Don't know' box and space for comments were provided. The ratings were done independently. box L.3 shows an example of a statement sent for the first round. For the full list see Annex A.1 on the accompanying CD-ROM.

For each round, participants were given 2 weeks to return their ratings. Most documents were sent by e-mail. A self-addressed labelled envelope was included for postal respondents. The participants were contacted after a week to remind them about the deadline.

Data analysis and presentation to the GDG

Results were analysed using Stata (version 8). In addition to the agreed ground rules (e.g. 75% or more of ratings 7 to 9 = agreement, 75% or more 1 to 3 = disagreement), the median score was calculated for each statement as a measure of central tendency classified as agreement (7 to 9), disagreement (1 to 3), or uncertainty (4 to 6). For statements 2.1 and 5.2 there was agreement if 75% of the ratings were in one of the response categories.

The results were presented to the GDG. For each statement, the results included the median, distribution of ratings for each of the three categories and the comments. All the information was anonymised. Statements for which there was no agreement (according to the ground rules) were

discussed. When appropriate, the GDG reworded the background and/or statement, using the participants' comments as a guide.

The statements were sent for a second round of rating. The results from the first round described above were included without the comments but participants were able to obtain them on request. The participants were asked to consult their first round ratings and to compare them with their second rating.

Table L.1 Nominations to and acceptance of participation in the Delphi survey

| Group/profession | Organisation | Number of nominations received | Number who accepted |
|-------------------------------------|---|--------------------------------|---------------------------|
| Paediatrician | Royal College of Paediatrics and Child | 6 | 6 |
| Paediatrician (A&E) | Health | | |
| Paediatrician (infectious diseases) | | | |
| A&E consultant | College of Emergency Medicine | 2 | 2 |
| Paediatric nurse, A&E nurse | Royal College of Nursing | 20 | 20 |
| Parent/carer | Stakeholder and NICE website (through PPIP) | 2 | 2 |
| | Sure Start | | |
| General practitioner | Royal College of General Practitioners | 33(25 selected) | 15 |
| Practice nurse | Primary care trusts | 9 | 6 |
| Out-of-hours provider | Primary care trusts | 2 | 1 |
| Community pharmacist | Royal Pharmaceutical Society | 1 | 1 |
| NHS Direct | NHS Direct | 6 | 5 |
| Total | | 79 | 61 |

Results

Round 1

Fifty-seven participants (93%) completed their ratings but only 53 returns were used in the analysis as four were received too late. There were 32 missing responses (2%) out of a total of 1855 and 79 (4%) 'Don't know'. table L.2 shows the distribution of ratings. The ratings for each statement are shown in Annex A.1 on the accompanying CD-ROM together with the comments. There was agreement with 12 out of the 35 statements and disagreement with three (on rectal thermometers). For statement 2.1, 43 (83%) of the ratings fell into the 2 hours category. This was accepted as agreement. For the remaining 20 statements there was a range of response across the three categories. Statement 8.1 had agreement (75% in the 7 to 9 category). However, the GDG decided to reword the first two statements in Section 8 in the light of comments made by the participants and also because they realised that the original statements could not be used to make unambiguous recommendations. Therefore statement 8.1 was included in the second round, taking the number of statements for rerating up to 21. In general, the comments indicated that several statements/background needed clarifying or to be made more specific.

Box L.3 Example of a statement sent for first round consensus

Background

Most of the care of feverish children takes place at home and is provided by parents or other carers. Some parents/carers will seek initial advice from healthcare professionals. Most of these children will recover without problems. In some cases, however, their condition may change or fail to improve. Parents need to know when to seek further help and may require further advice about the best way to care for their child.

Statement 3.1

Following contact with a healthcare professional, parents/carers who are looking after their feverish child at home should seek further advice if:

a) the child suffers a fit

Table L.2 Distribution of ratings and median for all statements after round 1

| Statement | Rating car | tegory | | Resp | | | |
|-----------|------------|----------|----------|---------------|---------|-------|--------|
| | 1 to 3 | 4 to 6 | 7 to 9 | Don't know | Missing | Total | Median |
| 1.1 | 0 | 1 (2%) | 48 (96%) | 1 (2%) | 3 | 50 | 9 |
| 1.2 | 0 | 6 (12%) | 42 (84%) | 2 (4%) | 3 | 50 | 8.5 |
| 1.3 | 8 (16%) | 17 (33%) | 24 (47%) | 2 (4%) | 2 | 51 | 7 |
| 1.4 | 2 (4%) | 11 (22%) | 35 (70%) | 2(4%) | 3 | 50 | 8 |
| 1.5 | 1 (2%) | 5 (10%) | 43 (81%) | 1 (2%) | 3 | 50 | 8.5 |
| 3.1a | 0 | 0 | 52 (98%) | 1 (2%) | | 53 | 9 |
| 3.1b | 0 | 2(4%) | 50 (94%) | 1 (2%) | | 53 | 8 |
| 3.1c | 0 | 9 (17%) | 43 (81%) | 1 (2%) | | 53 | 8 |
| 3.1d | 4 (8%) | 14 (27%) | 33 (63%) | 1 (2%) | 1 | 52 | 7 |
| 3.1e | 1 (2%) | 0 | 50 (96%) | 1 (2%) | 1 | 52 | 9 |
| 3.1f | 1 (2%) | 5 (9%) | 46 (87%) | 1 (2%) | | 53 | 9 |
| 4.1 | 2 (4%) | 8 (15%) | 39 (75%) | 3 (6%) | 1 | 52 | 9 |
| 4.2 | 7 (14%) | 14 (28%) | 21 (42%) | 8 (16%) | 3 | 50 | 7 |
| 5.1 | 4 (8%) | 10 (19%) | 36 (69%) | 2 (4%) | 1 | 52 | 8 |
| 6.a | 7 (13%) | 20 (38%) | 25 (47%) | 1 (2%) | | 53 | 6 |
| 6.b | 2 (4%) | 17 (32%) | 32 (60%) | 2 (4%) | | 53 | 7 |
| 6.c | 1 (2%) | 14 (26%) | 37 (70%) | 1 (2%) | | 52 | 8 |
| 6.d | 6 (12%) | 23 (44%) | 22 (42%) | 1 (2%) | 1 | 53 | 6 |
| 6.e | 13 (25%) | 22 (42%) | 17 (32%) | 1 (2%) | | 53 | 6 |
| 6.f | 12 (23%) | 20 (38%) | 20 (38%) | 1 (2%) | | 53 | 6 |
| 6.g | 4 (8%) | 17 (32%) | 28 (53%) | 4 (8%) | | 53 | 7 |
| 6.h | 7 (13%) | 12 (23%) | 32 (60%) | 2 (4%) | | 53 | 7 |
| 6.i | 7 (13%) | 15 (28%) | 30 (57%) | 1 (2%) | | 53 | 7 |
| 6.j | 2 (4%) | 13 (25%) | 37 (70%) | 1 (2%) | | 53 | 8 |
| 6.k | 2 (4%) | 13 (25%) | 36 (70%) | 1 (2%) | 1 | 52 | 7 |

| Statement | Rating car | tegory | Responses | | | | |
|-----------|------------|----------|-----------|---------------|---------------|-------|--------|
| | 1 to 3 | 4 to 6 | 7 to 9 | Don't know | Missing | Total | Median |
| 7.1 | 8 (15%) | 6 (12%) | 29 (56%) | 9 (17%) | 1 | 52 | 8 |
| 7.2 | 2 (4%) | 4 (8%) | 44 (85%) | 2 (4%) | 1 | 52 | 9 |
| 7.3 | 45 (87%) | 3 (6%) | 3 (6%) | 1 (2%) | 1 | 52 | 1 |
| 7.4 | 46 (88%) | 4 (8%) | 1 (2%) | 1 (2%) | 1 | 52 | 1 |
| 7.5 | 47 (92%) | 3 (6%) | 0 | 1 (2%) | 1 | 51 | 1 |
| 8.1 | 3 (6%) | 10 (20%) | 39 (75%) | 0 | 1 | 52 | 8 |
| 8.2 | 12 (23%) | 18 (35%) | 20 (38%) | 2 (4%) | 1 | 52 | 5.5 |
| 8.3 | 2 (4%) | 18 (35%) | 28 (55%) | 3 (6%) | 2 | 51 | 7 |
| | 2 hours | 6 hours | 12 hours | 24 hours | Don't know | Total | Median |
| 2.1 | 43 (83%) | 5 (10%) | 1 (2%) | 0 | 3 (6%) | 52 | 2 |
| | 2 hours | 4 hours | 6 hours | 12 hours | Don't know | Total | Median |
| 5.2 | 2 (4%) | 7 (13%) | 19 (37%) | 10 (19%) | 14 (27%) | 52 | 6 |

Statement for which there was no agreement

Statement for which there was disagreement

Round 2

Fifty-three (93%) of the 57 participants completed the task. There were three missing responses out of 1325. There were 26 'Don't know' responses, 12 of which were for statement 5.2, about the period of observation in hospital. table L.3 shows the distribution of ratings. The ratings for each statement are shown in Annex A.2 on the accompanying CD-ROM together with the comments. There remained 10 statements for which agreement could not be reached.

Formulating the recommendations

The GDG discussed all the statements again after the two consensus rounds. They removed nine of the ten statements with no agreement. In addition,, statement 5.2 was discarded because there was a high degree of uncertainty about the optimum time around the period of observation for assessment in hospital to help differentiate minor from serious illness. This was illustrated in the comments (see Annex A.1 on the accompanying CD-ROM). Box L.4 shows the 25 statements that were retained as recommendations. In most cases, the statement was reproduced exactly as a recommendation. While there was consensus agreement for statement 3.1d, the GDG unanimously decided to remove it because evidence was found after the consensus survey that duration of fever at 48 hours is not a sufficiently important sign to prompt review. However, the recommendation on seeking advice at 5 days, statement 3.1e, was retained because fever of this duration is unusual and Kawasaki disease and other serious causes of prolonged fever should be considered at this stage. An explanatory text was added to statement 4.1 (in italics) after comments suggested the statement needed qualifying ('Healthcare professionals examining children with fever must measure and record heart rate as part of their routine assessment because a raised heart rate can be a sign of serious illness particularly septic shock.'). Statement 6.a, for which there was no agreement, was retained by unanimous consensus in the GDG. The GDG slightly modified the wording of statement 8.2 as comments indicated the message should be more specific. The three statements on rectal thermometers (7.3, 7.4 and 7.5) for which there was disagreement were retained because the GDG considered there was a sufficiently important need for guidance on their use. To reflect the strength of disagreement from the consensus they reworded the statements negatively.

Table L.3 Distribution of ratings and median for statements after round 2

| Statement | Rating category | | | | Responses | | |
|-----------|-----------------|----------|----------|------------|------------|-------|--------|
| | 1 to 3 | 4 to 6 | 7 to 9 | Don't know | Missing | Total | Median |
| 1.3 | 9 (18%) | 10 (20%) | 32 (63%) | | 1 | 51 | 7 |
| 1.4 | 1 (2%) | 5 (10%) | 45 (88%) | | 1 | 51 | 8 |
| 3.1d | 2(4%) | 9 (17%) | 40 (77%) | 1 (2%) | | 52 | 7 |
| 4.2 | 2 (4%) | 15 (30%) | 33 (65%) | 1 (2%) | 1 | 51 | 7 |
| 5.1 | 0 | 6 (12%) | 44 (85%) | 2 (4%) | | 52 | 8 |
| 6.a | 2 (4%) | 17 (33%) | 33 (64%) | | | 52 | 7 |
| 6.b | 1 (2%) | 10 (19%) | 41 (79%) | | | 52 | 7.5 |
| 6.c | 2 (4%) | 7 (13%) | 43 (83%) | | | 52 | 8 |
| 6.d | 7 (13%) | 22 (42%) | 23 (44%) | | | 52 | 6 |
| 6.e | 12 (23%) | 24 (46%) | 16 (31%) | | | 52 | 6 |
| 6.f | 14 (27%) | 16 (31%) | 22 (42%) | | | 52 | 8 |
| 6.g | 1 (2%) | 8 (15%) | 42 (81%) | 1 (2%) | | 52 | 8 |
| 6.h | 1 (2%) | 2 (4%) | 48 (92%) | | | 51 | 8 |
| 6.i | 2 (11%) | 11 (22%) | 38 (75%) | | | 51 | 8 |
| 6.j | 1 (2%) | 9 (17%) | 42 (81%) | | | 52 | 8 |
| 6.k | 2 (4%) | 9 (17%) | 41 (79%) | | | 52 | 8 |
| 7.1 | 11 (21%) | 8 (15%) | 28 (54%) | 5 (10%) | | 52 | 7 |
| 8.1 | 10 (19%) | 11 (21%) | 29 (56%) | 2 (4%) | | 52 | 7 |
| 8.2 | 3 (6%) | 5 (10%) | 43 (83%) | 1 (2%) | | 52 | 8 |
| 8.3 | 2 (4%) | 15 (29%) | 34 (65%) | 1 (2%) | | 52 | 7 |
| | 2 hours | 4 hours | 6 hours | 12 hours | Don't know | Total | Median |
| 5.2 | 1 (2%) | 3 (6%) | 26 (50%) | 10 (19%) | 12 (23%) | 52 | 6 |

Statement with no agreement

The final 25 statements were incorporated as recommendations in the guideline.

Box L.4 Statements retained for recommendations after two rounds of Delphi consensus

1. Care at home

Parents/carers looking after a feverish child at home should be advised:

- to offer the child regular fluids (where a baby or child is breastfed the most appropriate fluid is breast milk)
- how to detect signs of dehydration
- · to check their child during the night
- to keep their child away from nursery or school while the child's fever persists and to notify the school or the nursery of the illness.

2. Assessment by telephone

An urgent face-to-face assessment means that the child should be seen within 2 hours.

3. When to seek medical help

Following contact with a healthcare professional, parents/carers who are looking after their feverish child at

home should seek further advice if:

- · the child suffers a fit
- the parent/carer feels that child is less well than when they previously sought advice
- the parent/carer is more worried than when they previously sought advice
- the fever has not settled after 5 days
- the parent/carer is very distressed or unable to cope with their child's illness.

4. Face-to-face assessment

Healthcare professionals examining children with fever must measure and record heart rate as part of their routine assessment because a raised heart rate can be a sign of serious illness, particularly septic shock.

5. Observation in hospital

A period of observation in hospital (with or without investigations) as part of an assessment can help differentiate minor from serious bacterial illness (such as meningitis or pneumonia) in a young child who has a fever without obvious cause.

6. Other factors for admitting a feverish child to hospital

Healthcare professionals should consider the following factors, as well as the child's clinical condition, when deciding whether to admit a child with fever to hospital:

- social and family circumstances
- other illnesses suffered by the child or other family members
- parental anxiety and instinct (based on their knowledge of their child)
- contacts with other people who have serious infectious diseases
- recent travel abroad to tropical/subtropical areas, or areas with a high risk of endemic infectious disease
- when the parent or carer's concern for their child's current illness has caused them to seek help repeatedly
- where the family has experienced a previous serious illness or death due to feverish illness which has increased their anxiety levels
- when a feverish illness has no obvious cause, but the child remains ill longer than expected for a self-limiting illness.

7. Thermometers

Healthcare professionals should not routinely use the oral route to measure body temperature in children under the age of 5 years.

Healthcare professionals should not routinely use electronic thermometers by the rectal route to measure body temperature in children aged 0–3 months.

Healthcare professionals should not routinely use electronic thermometers by the rectal route to measure body temperature in children aged 3 months to 2 years.

Healthcare professionals should not routinely use electronic thermometers by the rectal route to measure body temperature in children aged 2–5 years.

8. Cooling methods

Antipyretic drugs should be offered to children who are miserable with fever because they may make them feel better.

Acknowledgements

We would like to thank the following individuals for their valuable contribution to the consensus survey: Julie Allison, Mrs Gemma Annett, Krysia Askew, Karen Bell, Sandra Billham, Lorraine Bowden, Beverley Boyd, Hilary Campbell, Dr Bernie Carter, Rupa Chilvers, Robert Cole, Elizabeth Corrigan, Diane Crawford, Elaine Edwards, Christine English, Dr Saul Faust, Julie Flaherty, Jean Firth, Dr Rosie Hague, Sarah Harbour, David Harris, Dr Alastair Hay, Dr Paul Jackson, Marcia Johnson, Dr Duncan Keeley, Chris Lawrence, Jo Lewitt, Michaela Littlewood, Vivien Maiden, Dr Clifford Mann, Dr Omnia Marzouk, Jackie Mastrantone, Jane Mathias, Jenny Medcalf, Heather Motion, Karen Moyse, Caroline O'Callaghan, Catherine O'Hara, Cath O'Kane, Aileen Parke, Sally Parkinson, Nazima Pathan, Dr Iain Phillips, Louise Prime, Dr Anna Riddell, Adele Secombe, Diane

Scott, Julie Simmons, Mary Stanley, Mike Stephenson, John Thain, Dr Matthew Thompson, Miss Clarissa Trengare, Alison Twycross, Eileen Wardhaugh, Miriam Wardle, Dr Mark Whiting, June Wilcock, Bobbie Lloyd from the Centre for Clinical Practice at NICE for her diligent help with the administration of the survey and communication with the participants, Rosie Crossley for her administrative help, Jane Cowl from the Patient and Public Involvement Programme (PPIP) unit at NICE for her valuable assistance with the wording of the background and statements and for her helpful suggestions, the stakeholder organisations and Sure Start for nominating the parents participants, and individuals who piloted the statements.